(lp0
(dp1
S'line'
p2
S'Our results demonstrated that hsa-miR-483-5p, hsa-miR-675, hsa-miR-139-3p, hsa-miR-598, hsa-miR-625 and hsa-miR-187 could serve as prognostic and predictive markers for survival of BDC patients and could potentially be provided as targets for future therapy.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I104
sS'uniprot'
p8
S''
p9
sS'lengthInChars'
p10
I11
sS'name'
p11
Vhsa-miR-187
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I75
sg8
g9
sg10
I11
sg11
Vhsa-miR-598
p15
sg13
I1
sa(dp16
g7
I46
sg8
g9
sg10
I11
sg11
Vhsa-miR-675
p17
sg13
I1
sa(dp18
g7
I30
sg8
g9
sg10
I14
sg11
Vhsa-miR-483-5p
p19
sg13
I1
sa(dp20
g7
I88
sg8
g9
sg10
I11
sg11
Vhsa-miR-625
p21
sg13
I1
sa(dp22
g7
I59
sg8
g9
sg10
I14
sg11
Vhsa-miR-139-3p
p23
sg13
I1
sasS'diseases'
p24
(lp25
(dp26
g7
I30
sS'cui'
p27
VC0393754
p28
sg10
I3
sg11
Vhsa
p29
sg13
I1
sa(dp30
g7
I30
sg27
VC0393754
p31
sg10
I3
sg11
Vhsa
p32
sg13
I1
sa(dp33
g7
I30
sg27
VC0393754
p34
sg10
I3
sg11
Vhsa
p35
sg13
I1
sa(dp36
g7
I181
sg27
VC1266044
p37
sg10
I3
sg11
VBDC
p38
sg13
I1
sa(dp39
g7
I30
sg27
VC0393754
p40
sg10
I3
sg11
Vhsa
p41
sg13
I1
sa(dp42
g7
I30
sg27
VC0393754
p43
sg10
I3
sg11
Vhsa
p44
sg13
I1
sa(dp45
g7
I30
sg27
VC0393754
p46
sg10
I3
sg11
Vhsa
p47
sg13
I1
sasa(dp48
g2
S'Targeting the centromeres of chromosomes 3, 7, 17 (CEP3, 7, 17) and the 9p21-locus (LSI9p21) for diagnosing bladder cancer (BC) is time- and cost-intensive and requires a manual investigation of the sample by a well-trained investigator thus overall limiting its use in clinical diagnostics and large-scaled epidemiological studies.\n'
p49
sg4
(lp50
sg24
(lp51
(dp52
g7
I108
sg27
VC0699885
p53
sg10
I14
sg11
Vbladder cancer
p54
sg13
I2
sa(dp55
g7
I124
sg27
VC0699885
p56
sg10
I2
sg11
VBC
p57
sg13
I1
sasa(dp58
g2
S'Ossification of the ligamentum flavum (OLF) causing compressive cervical myelopathy or radiculopathy is rare.\n'
p59
sg4
(lp60
sg24
(lp61
(dp62
g7
I87
sg27
VC0700594
p63
sg10
I13
sg11
Vradiculopathy
p64
sg13
I1
sa(dp65
g7
I64
sg27
VC0149645
p66
sg10
I19
sg11
Vcervical myelopathy
p67
sg13
I2
sasa(dp68
g2
S'However, thoracic OLF rarely causes radiculopathy.\n'
p69
sg4
(lp70
sg24
(lp71
(dp72
g7
I36
sg27
VC0700594
p73
sg10
I13
sg11
Vradiculopathy
p74
sg13
I1
sa(dp75
g7
I9
sg27
VC0729233
p76
sg10
I8
sg11
Vthoracic
p77
sg13
I1
sasa(dp78
g2
S'We report a rare case of thoracic radiculopathy caused by OLF.\n'
p79
sg4
(lp80
sg24
(lp81
(dp82
g7
I25
sg27
VC0154737
p83
sg10
I22
sg11
Vthoracic radiculopathy
p84
sg13
I2
sasa(dp85
g2
S'Thoracic radiculopathy caused by OLF was suspected.\n'
p86
sg4
(lp87
sg24
(lp88
(dp89
g7
I0
sg27
VC0154737
p90
sg10
I22
sg11
VThoracic radiculopathy
p91
sg13
I2
sasa(dp92
g2
S'Thoracic OLF rarely causes radiculopathy, but it should be considered as a differential diagnosis of thoracic radicular pain.\n'
p93
sg4
(lp94
sg24
(lp95
(dp96
g7
I101
sg27
VC0729233
p97
sg10
I8
sg11
Vthoracic
p98
sg13
I1
sa(dp99
g7
I0
sg27
VC0729233
p100
sg10
I8
sg11
VThoracic
p101
sg13
I1
sa(dp102
g7
I27
sg27
VC0700594
p103
sg10
I13
sg11
Vradiculopathy
p104
sg13
I1
sa(dp105
g7
I110
sg27
VC0278147
p106
sg10
I14
sg11
Vradicular pain
p107
sg13
I2
sasa(dp108
g2
S'OLF should be kept in mind if a patient presents with radiculopathy, particularly in the cervical region, for which surgical intervention is contemplated.\n'
p109
sg4
(lp110
(dp111
g7
I0
sg8
g9
sg10
I3
sg11
VOLF
p112
sg13
I1
sasg24
(lp113
(dp114
g7
I54
sg27
VC0700594
p115
sg10
I13
sg11
Vradiculopathy
p116
sg13
I1
sasa(dp117
g2
S'Radiculopathy resulting from ossification of the ligamentum flavum (OLF) is extremely rare and concerns only intercostal neuralgias.\n'
p118
sg4
(lp119
sg24
(lp120
(dp121
g7
I121
sg27
VC0027796
p122
sg10
I10
sg11
Vneuralgias
p123
sg13
I1
sa(dp124
g7
I0
sg27
VC0700594
p125
sg10
I13
sg11
VRadiculopathy
p126
sg13
I1
sasa(dp127
g2
S'We describe a 37-year-old Caucasian woman with a lumbar radiculopathy revealing an OLF.\n'
p128
sg4
(lp129
sg24
(lp130
(dp131
g7
I49
sg27
VC1263855
p132
sg10
I20
sg11
Vlumbar radiculopathy
p133
sg13
I2
sasa(dp134
g2
S'Pancreatitis was induced in C57Bl/6 wild-type (control), cathepsin B-knockout, and cathepsin L-knockout mice by partial pancreatic duct ligation with supramaximal caerulein injection, or by repetitive supramaximal caerulein injections alone.\n'
p135
sg4
(lp136
(dp137
g7
I57
sg8
VP07858
p138
sg10
I11
sg11
Vcathepsin B
p139
sg13
I2
sa(dp140
g7
I83
sg8
VP07711
p141
sg10
I11
sg11
Vcathepsin L
p142
sg13
I2
sasg24
(lp143
(dp144
g7
I0
sg27
VC0030305
p145
sg10
I12
sg11
VPancreatitis
p146
sg13
I1
sasa(dp147
g2
S'Trypsinogen became activated in macrophages cultured with purified trypsinogen or co-cultured with pancreatic acini and in pancreata of mice with pancreatitis; trypsinogen activation required macrophage endocytosis and expression and activity of cathepsin B, and was sensitive to pH.\n'
p148
sg4
(lp149
(dp150
g7
I67
sg8
VP07478
p151
sg10
I11
sg11
Vtrypsinogen
p152
sg13
I1
sa(dp153
g7
I246
sg8
VP07858
p154
sg10
I11
sg11
Vcathepsin B
p155
sg13
I2
sa(dp156
g7
I67
sg8
VP07478
p157
sg10
I11
sg11
Vtrypsinogen
p158
sg13
I1
sa(dp159
g7
I0
sg8
VP07478
p160
sg10
I11
sg11
VTrypsinogen
p161
sg13
I1
sasg24
(lp162
(dp163
g7
I146
sg27
VC0030305
p164
sg10
I12
sg11
Vpancreatitis
p165
sg13
I1
sasa(dp166
g2
S'Activation of trypsinogen in macrophages resulted in translocation of NF-kB and production of inflammatory cytokines; mice without trypsinogen activation (cathepsin B-knockout mice) in macrophages developed less severe pancreatitis compared with control mice.\n'
p167
sg4
(lp168
(dp169
g7
I131
sg8
VP07478
p170
sg10
I22
sg11
Vtrypsinogen activation
p171
sg13
I2
sa(dp172
g7
I14
sg8
VP07478
p173
sg10
I11
sg11
Vtrypsinogen
p174
sg13
I1
sa(dp175
g7
I155
sg8
VP07858
p176
sg10
I11
sg11
Vcathepsin B
p177
sg13
I2
sasg24
(lp178
(dp179
g7
I53
sg27
VC0040715
p180
sg10
I13
sg11
Vtranslocation
p181
sg13
I1
sa(dp182
g7
I219
sg27
VC0030305
p183
sg10
I12
sg11
Vpancreatitis
p184
sg13
I1
sasa(dp185
g2
S'Transfer of macrophage from control mice to cathepsin B-knockout mice increased the severity of pancreatitis.\n'
p186
sg4
(lp187
(dp188
g7
I44
sg8
VP07858
p189
sg10
I11
sg11
Vcathepsin B
p190
sg13
I2
sasg24
(lp191
(dp192
g7
I96
sg27
VC0030305
p193
sg10
I12
sg11
Vpancreatitis
p194
sg13
I1
sasa(dp195
g2
S'Experimental studies in acute pancreatitis (AP) suggest a strong association of acinar cell injury with cathepsin B-dependent intracellular activation of trypsin.\n'
p196
sg4
(lp197
(dp198
g7
I154
sg8
VP35030
p199
sg10
I7
sg11
Vtrypsin
p200
sg13
I1
sasg24
(lp201
(dp202
g7
I44
sg27
VC0001339
p203
sg10
I2
sg11
VAP
p204
sg13
I1
sa(dp205
g7
I87
sg27
VC0599732
p206
sg10
I11
sg11
Vcell injury
p207
sg13
I2
sa(dp208
g7
I24
sg27
VC0001339
p209
sg10
I18
sg11
Vacute pancreatitis
p210
sg13
I2
sasa(dp211
g2
S'Pancreas, lung, and serum was harvested up to 48 h after pancreatitis induction and used for histopathology, amylase, lipase, cathepsin B, trypsin, and elastase activity measurements, myeloperoxidase (MPO) content and cytokine concentrations.\n'
p212
sg4
(lp213
(dp214
g7
I126
sg8
VP07858
p215
sg10
I11
sg11
Vcathepsin B
p216
sg13
I2
sa(dp217
g7
I152
sg8
VP30740
p218
sg10
I8
sg11
Velastase
p219
sg13
I1
sa(dp220
g7
I184
sg8
VP05164
p221
sg10
I15
sg11
Vmyeloperoxidase
p222
sg13
I1
sa(dp223
g7
I118
sg8
VP04118
p224
sg10
I6
sg11
Vlipase
p225
sg13
I1
sa(dp226
g7
I201
sg8
VP05164
p227
sg10
I3
sg11
VMPO
p228
sg13
I1
sa(dp229
g7
I109
sg8
VP04746
p230
sg10
I7
sg11
Vamylase
p231
sg13
I1
sa(dp232
g7
I139
sg8
VP35030
p233
sg10
I7
sg11
Vtrypsin
p234
sg13
I1
sasg24
(lp235
(dp236
g7
I57
sg27
VC0030305
p237
sg10
I12
sg11
Vpancreatitis
p238
sg13
I1
sasa(dp239
g2
S'In taurocholate-pancreatitis AZD8309 reduced cathepsin B activity and MPO.\n'
p240
sg4
(lp241
(dp242
g7
I45
sg8
VP07858
p243
sg10
I11
sg11
Vcathepsin B
p244
sg13
I2
sa(dp245
g7
I70
sg8
VP05164
p246
sg10
I3
sg11
VMPO
p247
sg13
I1
sasg24
(lp248
(dp249
g7
I16
sg27
VC0030305
p250
sg10
I12
sg11
Vpancreatitis
p251
sg13
I1
sasa(dp252
g2
S'The lysosomal hydrolase cathepsin B (CTSB) is a known activator of trypsinogen, and its deletion reduces disease severity in experimental pancreatitis.\n'
p253
sg4
(lp254
(dp255
g7
I4
sg8
VP07858
p256
sg10
I31
sg11
Vlysosomal hydrolase cathepsin B
p257
sg13
I4
sa(dp258
g7
I37
sg8
VP07858
p259
sg10
I4
sg11
VCTSB
p260
sg13
I1
sa(dp261
g7
I67
sg8
VP07478
p262
sg10
I11
sg11
Vtrypsinogen
p263
sg13
I1
sasg24
(lp264
(dp265
g7
I138
sg27
VC0030305
p266
sg10
I12
sg11
Vpancreatitis
p267
sg13
I1
sasa(dp268
g2
S'In summary, CTSB in pancreatitis undergoes activation in a secretory, vesicular, and acidic compartment where it activates trypsinogen.\n'
p269
sg4
(lp270
(dp271
g7
I123
sg8
VP07478
p272
sg10
I11
sg11
Vtrypsinogen
p273
sg13
I1
sasg24
(lp274
(dp275
g7
I20
sg27
VC0030305
p276
sg10
I12
sg11
Vpancreatitis
p277
sg13
I1
sasa(dp278
g2
S'C3F was also significantly increased in 20 chronic renal failure (CRF) patients as compared to 196 controls; this would support the existence of functional differences between C3F and C3S alleles.\n'
p279
sg4
(lp280
(dp281
g7
I0
sg8
g9
sg10
I3
sg11
VC3F
p282
sg13
I1
sa(dp283
g7
I0
sg8
g9
sg10
I3
sg11
VC3F
p284
sg13
I1
sasg24
(lp285
(dp286
g7
I66
sg27
VC0022661
p287
sg10
I3
sg11
VCRF
p288
sg13
I1
sa(dp289
g7
I43
sg27
VC0022661
p290
sg10
I21
sg11
Vchronic renal failure
p291
sg13
I3
sasa(dp292
g2
S'Ectopic expression of Fgfr2c, a gene implicated in craniosynostosis in mice and humans, and that of Runx2 was detected within the affected sutures of Bcl11b(-/-) mice.\n'
p293
sg4
(lp294
(dp295
g7
I150
sg8
g9
sg10
I11
sg11
VBcl11b(-/-)
p296
sg13
I1
sa(dp297
g7
I100
sg8
g9
sg10
I5
sg11
VRunx2
p298
sg13
I1
sasg24
(lp299
(dp300
g7
I51
sg27
VC0010278
p301
sg10
I16
sg11
Vcraniosynostosis
p302
sg13
I1
sasa(dp303
g2
S'These data suggest that ectopic expression of Fgfr2c in the sutural mesenchyme, without concomitant changes in the expression of FGF ligands, appears to induce the RUNX2-dependent osteogenic program and craniosynostosis in Bcl11b(-/-) mice.\n'
p304
sg4
(lp305
(dp306
g7
I223
sg8
g9
sg10
I11
sg11
VBcl11b(-/-)
p307
sg13
I1
sa(dp308
g7
I129
sg8
g9
sg10
I11
sg11
VFGF ligands
p309
sg13
I2
sa(dp310
g7
I164
sg8
g9
sg10
I5
sg11
VRUNX2
p311
sg13
I1
sasg24
(lp312
(dp313
g7
I203
sg27
VC0010278
p314
sg10
I16
sg11
Vcraniosynostosis
p315
sg13
I1
sasa(dp316
g2
S'(2) An analysis of all published HLA data for patients of European origin indicated a weak association of pernicious anemia with HLA-B7.\n'
p317
sg4
(lp318
(dp319
g7
I129
sg8
VP30486
p320
sg10
I6
sg11
VHLA-B7
p321
sg13
I1
sa(dp322
g7
I33
sg8
VP30486
p323
sg10
I3
sg11
VHLA
p324
sg13
I1
sasg24
(lp325
(dp326
g7
I106
sg27
VC0002892
p327
sg10
I17
sg11
Vpernicious anemia
p328
sg13
I2
sasa(dp329
g2
S'Specifically, studies have demonstrated miR-221/-222 function as oncogenes, and promote PCa cell proliferation and the development of castration-resistant prostate cancer (CRPC).\n'
p330
sg4
(lp331
sg24
(lp332
(dp333
g7
I88
sg27
VC0268398
p334
sg10
I3
sg11
VPCa
p335
sg13
I1
sa(dp336
g7
I155
sg27
VC0600139
p337
sg10
I15
sg11
Vprostate cancer
p338
sg13
I2
sa(dp339
g7
I97
sg27
VC0334094
p340
sg10
I13
sg11
Vproliferation
p341
sg13
I1
sasa(dp342
g2
S'SOCS3 was found significantly declined, while microRNA-221 (miR-221) obviously up-regulated in bladder cancer tissue.\n'
p343
sg4
(lp344
(dp345
g7
I0
sg8
g9
sg10
I5
sg11
VSOCS3
p346
sg13
I1
sasg24
(lp347
(dp348
g7
I95
sg27
VC0699885
p349
sg10
I14
sg11
Vbladder cancer
p350
sg13
I2
sasa(dp351
g2
S'This study investigated the role of miR-221 in regulating SOCS3/JAK-STAT3 signaling pathway and bladder cancer cell proliferation and apoptosis.\n'
p352
sg4
(lp353
(dp354
g7
I68
sg8
VP40763
p355
sg10
I5
sg11
VSTAT3
p356
sg13
I1
sa(dp357
g7
I58
sg8
g9
sg10
I5
sg11
VSOCS3
p358
sg13
I1
sa(dp359
g7
I36
sg8
g9
sg10
I7
sg11
VmiR-221
p360
sg13
I1
sasg24
(lp361
(dp362
g7
I96
sg27
VC0699885
p363
sg10
I14
sg11
Vbladder cancer
p364
sg13
I2
sa(dp365
g7
I116
sg27
VC0334094
p366
sg10
I13
sg11
Vproliferation
p367
sg13
I1
sasa(dp368
g2
S'Bladder cancer tumor tissue and para-carcinoma tissue were collected from patients to test miR-221 and SOCS3 expressions.\n'
p369
sg4
(lp370
(dp371
g7
I91
sg8
g9
sg10
I7
sg11
VmiR-221
p372
sg13
I1
sa(dp373
g7
I103
sg8
g9
sg10
I5
sg11
VSOCS3
p374
sg13
I1
sasg24
(lp375
(dp376
g7
I0
sg27
VC0699885
p377
sg10
I14
sg11
VBladder cancer
p378
sg13
I2
sa(dp379
g7
I15
sg27
VC0027651
p380
sg10
I5
sg11
Vtumor
p381
sg13
I1
sa(dp382
g7
I37
sg27
VC0007097
p383
sg10
I9
sg11
Vcarcinoma
p384
sg13
I1
sasa(dp385
g2
S'MiR-221 significantly increased, while SOCS3 obviously reduced in bladder cancer tissue compared with para-carcinoma tissue.\n'
p386
sg4
(lp387
(dp388
g7
I0
sg8
g9
sg10
I7
sg11
VMiR-221
p389
sg13
I1
sa(dp390
g7
I39
sg8
g9
sg10
I5
sg11
VSOCS3
p391
sg13
I1
sasg24
(lp392
(dp393
g7
I107
sg27
VC0007097
p394
sg10
I9
sg11
Vcarcinoma
p395
sg13
I1
sa(dp396
g7
I66
sg27
VC0699885
p397
sg10
I14
sg11
Vbladder cancer
p398
sg13
I2
sasa(dp399
g2
S'MiR-221 elevated, while SOCS3 reduced in bladder cancer tissue.\n'
p400
sg4
(lp401
(dp402
g7
I0
sg8
g9
sg10
I29
sg11
VMiR-221 elevated, while SOCS3
p403
sg13
I4
sasg24
(lp404
(dp405
g7
I41
sg27
VC0699885
p406
sg10
I14
sg11
Vbladder cancer
p407
sg13
I2
sasa(dp408
g2
S'As miR-221 targets several regulators of the PI3K-AKT-mTOR pathway and a link between this pathway and CD44 has been previously shown in prostate cancer, we considered miR-221 regulation of CD44 may be through this pathway.\n'
p409
sg4
(lp410
(dp411
g7
I54
sg8
VP42345
p412
sg10
I4
sg11
VmTOR
p413
sg13
I1
sa(dp414
g7
I50
sg8
g9
sg10
I3
sg11
VAKT
p415
sg13
I1
sa(dp416
g7
I45
sg8
VP42336
p417
sg10
I4
sg11
VPI3K
p418
sg13
I1
sasg24
(lp419
(dp420
g7
I137
sg27
VC0600139
p421
sg10
I15
sg11
Vprostate cancer
p422
sg13
I2
sasa(dp423
g2
S'The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy.\n'
p424
sg4
(lp425
(dp426
g7
I249
sg8
VP55786
p427
sg10
I9
sg11
Vserum PSA
p428
sg13
I2
sa(dp429
g7
I190
sg8
g9
sg10
I7
sg11
VmiR-221
p430
sg13
I1
sa(dp431
g7
I65
sg8
VP11308
p432
sg10
I3
sg11
VERG
p433
sg13
I1
sa(dp434
g7
I162
sg8
VP78358
p435
sg10
I4
sg11
VPCA3
p436
sg13
I1
sa(dp437
g7
I129
sg8
VP55786
p438
sg10
I3
sg11
VPSA
p439
sg13
I1
sa(dp440
g7
I89
sg8
VP07288
p441
sg10
I38
sg11
Vtumor tissue prostate-specific antigen
p442
sg13
I4
sa(dp443
g7
I135
sg8
VP78358
p444
sg10
I25
sg11
Vprostate cancer antigen 3
p445
sg13
I4
sa(dp446
g7
I178
sg8
g9
sg10
I7
sg11
VmiR-26a
p447
sg13
I1
sa(dp448
g7
I57
sg8
g9
sg10
I7
sg11
VTMPRSS2
p449
sg13
I1
sa(dp450
g7
I169
sg8
g9
sg10
I7
sg11
VmiR-23b
p451
sg13
I1
sasg24
(lp452
(dp453
g7
I280
sg27
VC0268398
p454
sg10
I3
sg11
VPCa
p455
sg13
I1
sa(dp456
g7
I89
sg27
VC0027651
p457
sg10
I5
sg11
Vtumor
p458
sg13
I1
sa(dp459
g7
I284
sg27
VC1458156
p460
sg10
I10
sg11
Vrecurrence
p461
sg13
I1
sa(dp462
g7
I135
sg27
VC0600139
p463
sg10
I15
sg11
Vprostate cancer
p464
sg13
I2
sa(dp465
g7
I129
sg27
VC1519176
p466
sg10
I3
sg11
VPSA
p467
sg13
I1
sa(dp468
g7
I102
sg27
VC1519176
p469
sg10
I25
sg11
Vprostate-specific antigen
p470
sg13
I2
sa(dp471
g7
I129
sg27
VC1519176
p472
sg10
I3
sg11
VPSA
p473
sg13
I1
sasa(dp474
g2
S"2', 5'-Oligoadenylate synthetase-lilke (OASL) protein is an atypical oligoadenylate synthetase (OAS) family member, which possesses antiviral activity but lacks 2', 5'-oligoadenylate synthetase activity.\n"
p475
sg4
(lp476
(dp477
g7
I40
sg8
g9
sg10
I4
sg11
VOASL
p478
sg13
I1
sa(dp479
g7
I40
sg8
g9
sg10
I3
sg11
VOAS
p480
sg13
I1
sasg24
(lp481
(dp482
g7
I122
sg27
VC0850310
p483
sg10
I9
sg11
Vpossesses
p484
sg13
I1
sa(dp485
g7
I40
sg27
VC0599973
p486
sg10
I3
sg11
VOAS
p487
sg13
I1
sasa(dp488
g2
S'Here, a novel variant of porcine OASL (pOASL2) was identified through RT-PCR amplification.\n'
p489
sg4
(lp490
(dp491
g7
I25
sg8
g9
sg10
I12
sg11
Vporcine OASL
p492
sg13
I2
sasg24
(lp493
(dp494
g7
I77
sg27
VC1705759
p495
sg10
I13
sg11
Vamplification
p496
sg13
I1
sasa(dp497
g2
S'This gene is distinguishable from the previously described wild-type porcine OASL (pOASL1).\n'
p498
sg4
(lp499
(dp500
g7
I59
sg8
g9
sg10
I22
sg11
Vwild-type porcine OASL
p501
sg13
I3
sasg24
(lp502
sa(dp503
g2
S'The gene appears to be derived from a truncation of exon 4 plus 8 nucleotides of exon 5 with a premature termination, measuring only 633 bp in length, although its position corresponds to that of pOASL1.\n'
p504
sg4
(lp505
sg24
(lp506
(dp507
g7
I38
sg27
VC1706395
p508
sg10
I10
sg11
Vtruncation
p509
sg13
I1
sasa(dp510
g2
S'Given this novel gene appears to be a variant of pOASL, we assayed for antiviral activity of the protein.\n'
p511
sg4
(lp512
sg24
(lp513
sa(dp514
g2
S'We demonstrated that pOASL2 could inhibit Japanese encephalitis virus (JEV) proliferation as well as pOASL1 in a transient overexpression assay of pOASL1 and pOASL2 in PK-15 and Vero cells.\n'
p515
sg4
(lp516
sg24
(lp517
(dp518
g7
I76
sg27
VC0334094
p519
sg10
I13
sg11
Vproliferation
p520
sg13
I1
sa(dp521
g7
I42
sg27
VC0014057
p522
sg10
I21
sg11
VJapanese encephalitis
p523
sg13
I2
sasa(dp524
g2
S'In addition to JEV, pOASL1 and pOASL2 also decreased the proliferations of Porcine reproductive and respiratory syndrome virus (PRRSV) and vesicular stomatitis virus (VSV), but did not exhibit antiviral activity against pseudorabies virus (PRV).\n'
p525
sg4
(lp526
sg24
(lp527
(dp528
g7
I75
sg27
VC0376538
p529
sg10
I45
sg11
VPorcine reproductive and respiratory syndrome
p530
sg13
I5
sa(dp531
g7
I220
sg27
VC0032463
p532
sg10
I18
sg11
Vpseudorabies virus
p533
sg13
I2
sa(dp534
g7
I139
sg27
VC0266999
p535
sg10
I20
sg11
Vvesicular stomatitis
p536
sg13
I2
sa(dp537
g7
I240
sg27
VC0032463
p538
sg10
I3
sg11
VPRV
p539
sg13
I1
sa(dp540
g7
I57
sg27
VC0334094
p541
sg10
I14
sg11
Vproliferations
p542
sg13
I1
sasa(dp543
g2
S"Structural analysis showed that the pOASL2 gene retained only the first three exons at the 5'-.\n"
p544
sg4
(lp545
sg24
(lp546
sa(dp547
g2
S"To investigate the role of the AlfaN4 helix in pOASL in antiviral responses like that in hOASL, we mutated key residues in the anchor domain of the AlfaN4 helix in pOASL2, based on the domain's location in hOASL.\n"
p548
sg4
(lp549
sg24
(lp550
sa(dp551
g2
S'However, the antiviral activity of pOASL2 was not affected.\n'
p552
sg4
(lp553
sg24
(lp554
sa(dp555
g2
S'Thus, the AlfaN4 helix of pOASL likely does not play a significant role in its antiviral activity.\n'
p556
sg4
(lp557
sg24
(lp558
sa(dp559
g2
S'In conclusion, pOASL2 acts as a new splice isoform of pOASL that plays a role in resistance to infection of several kinds of RNA viruses.\n'
p560
sg4
(lp561
sg24
(lp562
(dp563
g7
I95
sg27
VC0009450
p564
sg10
I9
sg11
Vinfection
p565
sg13
I1
sasa(dp566
g2
S'Only 5 genes were significantly up-regulated in MS patients vs control subjects; namely TNF-AIP6, IL-1RA, OASL, CLC and DOCK4 (p &lt; 0.05).\n'
p567
sg4
(lp568
(dp569
g7
I88
sg8
VP01375
p570
sg10
I8
sg11
VTNF-AIP6
p571
sg13
I1
sa(dp572
g7
I120
sg8
g9
sg10
I5
sg11
VDOCK4
p573
sg13
I1
sa(dp574
g7
I106
sg8
g9
sg10
I4
sg11
VOASL
p575
sg13
I1
sa(dp576
g7
I112
sg8
g9
sg10
I3
sg11
VCLC
p577
sg13
I1
sa(dp578
g7
I98
sg8
VP18510
p579
sg10
I6
sg11
VIL-1RA
p580
sg13
I1
sasg24
(lp581
sa(dp582
g2
S'Analysis of the effector molecules of the up-regulated genes revealed that 83 MS patients had positive serum level of OASL, 87 MS patients had positive serum levels of IL-1RA, and none of the 88 MS patients showed detectable serum levels of TNF-AIP6, CLC or DOCK4.\n'
p583
sg4
(lp584
(dp585
g7
I258
sg8
g9
sg10
I5
sg11
VDOCK4
p586
sg13
I1
sa(dp587
g7
I168
sg8
VP18510
p588
sg10
I6
sg11
VIL-1RA
p589
sg13
I1
sa(dp590
g7
I241
sg8
VP01375
p591
sg10
I3
sg11
VTNF
p592
sg13
I1
sa(dp593
g7
I251
sg8
g9
sg10
I3
sg11
VCLC
p594
sg13
I1
sasg24
(lp595
sa(dp596
g2
S'OASL and IL-1RA genes were strongly expressed in MS patients and that their effector molecules may be considered as biomarkers associated with the inflammatory process of the disease and possibly treatment response.\n'
p597
sg4
(lp598
(dp599
g7
I0
sg8
g9
sg10
I4
sg11
VOASL
p600
sg13
I1
sa(dp601
g7
I9
sg8
VP18510
p602
sg10
I12
sg11
VIL-1RA genes
p603
sg13
I2
sasg24
(lp604
sa(dp605
g2
S'However, IRF1, IFNK and viral restriction factors (IFIT1, 2, 3, 5, OASL, CD74, RTP4) were up-regulated.\n'
p606
sg4
(lp607
(dp608
g7
I73
sg8
VP04233
p609
sg10
I4
sg11
VCD74
p610
sg13
I1
sa(dp611
g7
I51
sg8
VP09914
p612
sg10
I5
sg11
VIFIT1
p613
sg13
I1
sa(dp614
g7
I9
sg8
VP10914
p615
sg10
I4
sg11
VIRF1
p616
sg13
I1
sa(dp617
g7
I79
sg8
g9
sg10
I4
sg11
VRTP4
p618
sg13
I1
sa(dp619
g7
I67
sg8
g9
sg10
I4
sg11
VOASL
p620
sg13
I1
sa(dp621
g7
I24
sg8
VP19883
p622
sg10
I25
sg11
Vviral restriction factors
p623
sg13
I3
sa(dp624
g7
I15
sg8
g9
sg10
I4
sg11
VIFNK
p625
sg13
I1
sasg24
(lp626
sa(dp627
g2
S"The signature's genes are: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 (IL16), 2',5'-Oligoadenylate Synthetase Like (OASL), and Adhesion G Protein Coupled Receptor E5 (ADGRE5).\n"
p628
sg4
(lp629
(dp630
g7
I127
sg8
g9
sg10
I4
sg11
VOASL
p631
sg13
I1
sa(dp632
g7
I66
sg8
g9
sg10
I14
sg11
VInterleukin 16
p633
sg13
I2
sa(dp634
g7
I89
sg8
g9
sg10
I36
sg11
V2',5'-Oligoadenylate Synthetase Like
p635
sg13
I3
sa(dp636
g7
I82
sg8
g9
sg10
I4
sg11
VIL16
p637
sg13
I1
sa(dp638
g7
I27
sg8
g9
sg10
I29
sg11
VInterferon Stimulated Gene 15
p639
sg13
I4
sa(dp640
g7
I58
sg8
VP05161
p641
sg10
I5
sg11
VISG15
p642
sg13
I1
sasg24
(lp643
(dp644
g7
I138
sg27
VC0001511
p645
sg10
I8
sg11
VAdhesion
p646
sg13
I1
sasa(dp647
g2
S"Previous work has identified that following viral infection, type I IFN signaling induces the production of the 2'-5'-oligoadenylate synthetase (OAS) family, which include OAS1, OAS2, OAS3, and OAS-like (OASL) protein.\n"
p648
sg4
(lp649
(dp650
g7
I68
sg8
VP01562
p651
sg10
I3
sg11
VIFN
p652
sg13
I1
sa(dp653
g7
I194
sg8
g9
sg10
I8
sg11
VOAS-like
p654
sg13
I1
sa(dp655
g7
I112
sg8
g9
sg10
I31
sg11
V2'-5'-oligoadenylate synthetase
p656
sg13
I2
sa(dp657
g7
I204
sg8
g9
sg10
I4
sg11
VOASL
p658
sg13
I1
sa(dp659
g7
I184
sg8
g9
sg10
I4
sg11
VOAS3
p660
sg13
I1
sa(dp661
g7
I178
sg8
VP29728
p662
sg10
I4
sg11
VOAS2
p663
sg13
I1
sa(dp664
g7
I145
sg8
g9
sg10
I3
sg11
VOAS
p665
sg13
I1
sasg24
(lp666
(dp667
g7
I145
sg27
VC0599973
p668
sg10
I3
sg11
VOAS
p669
sg13
I1
sa(dp670
g7
I112
sg27
VC0599973
p671
sg10
I31
sg11
V2'-5'-oligoadenylate synthetase
p672
sg13
I2
sa(dp673
g7
I145
sg27
VC0599973
p674
sg10
I3
sg11
VOAS
p675
sg13
I1
sa(dp676
g7
I44
sg27
VC0042769
p677
sg10
I15
sg11
Vviral infection
p678
sg13
I2
sasa(dp679
g2
S'OASL was identified to be strongly induced following viral infection through engaging the RNA sensor RIG-I and increasing signaling through this pathway to enhance the anti-viral type I IFN response.\n'
p680
sg4
(lp681
(dp682
g7
I0
sg8
g9
sg10
I4
sg11
VOASL
p683
sg13
I1
sa(dp684
g7
I101
sg8
g9
sg10
I5
sg11
VRIG-I
p685
sg13
I1
sa(dp686
g7
I186
sg8
VP01562
p687
sg10
I3
sg11
VIFN
p688
sg13
I1
sasg24
(lp689
(dp690
g7
I53
sg27
VC0042769
p691
sg10
I15
sg11
Vviral infection
p692
sg13
I2
sasa(dp693
g2
S'Surprisingly, infection with viral dsDNA revealed an IFN inhibitory role and therefore pro-viral function of OASL through the inhibition of the cGAS cytosolic DNA sensing mechanism.\n'
p694
sg4
(lp695
(dp696
g7
I53
sg8
VP01562
p697
sg10
I3
sg11
VIFN
p698
sg13
I1
sa(dp699
g7
I109
sg8
g9
sg10
I4
sg11
VOASL
p700
sg13
I1
sasg24
(lp701
(dp702
g7
I14
sg27
VC0009450
p703
sg10
I9
sg11
Vinfection
p704
sg13
I1
sasa(dp705
g2
S'Intracellular bacteria are able to activate the cytosolic DNA sensing pathway, however the role of OASL during bacterial infection is largely unknown.\n'
p706
sg4
(lp707
(dp708
g7
I99
sg8
g9
sg10
I4
sg11
VOASL
p709
sg13
I1
sasg24
(lp710
(dp711
g7
I111
sg27
VC0004623
p712
sg10
I19
sg11
Vbacterial infection
p713
sg13
I2
sasa(dp714
g2
S'Vacuolar pathogenic microbes such as mycobacteria induce OASL early post infection, where it functions in a prosurvival fashion by inhibiting autophagic mechanisms and antimicrobial peptide expression.\n'
p715
sg4
(lp716
(dp717
g7
I57
sg8
g9
sg10
I4
sg11
VOASL
p718
sg13
I1
sasg24
(lp719
(dp720
g7
I73
sg27
VC0009450
p721
sg10
I9
sg11
Vinfection
p722
sg13
I1
sasa(dp723
g2
S'This suggests an underestimated role of OASL in the innate immune response to infection with a variety of pathogens and points to OASL-associated modulation of the type I IFN response.\n'
p724
sg4
(lp725
(dp726
g7
I40
sg8
g9
sg10
I4
sg11
VOASL
p727
sg13
I1
sa(dp728
g7
I40
sg8
g9
sg10
I4
sg11
VOASL
p729
sg13
I1
sa(dp730
g7
I164
sg8
VP01562
p731
sg10
I10
sg11
Vtype I IFN
p732
sg13
I3
sasg24
(lp733
(dp734
g7
I78
sg27
VC0009450
p735
sg10
I9
sg11
Vinfection
p736
sg13
I1
sa(dp737
g7
I52
sg27
VC1155265
p738
sg10
I22
sg11
Vinnate immune response
p739
sg13
I3
sasa(dp740
g2
S'OASL may therefore play a critical role in defining the outcome of infection.\n'
p741
sg4
(lp742
(dp743
g7
I0
sg8
g9
sg10
I4
sg11
VOASL
p744
sg13
I1
sasg24
(lp745
(dp746
g7
I67
sg27
VC0009450
p747
sg10
I9
sg11
Vinfection
p748
sg13
I1
sasa(dp749
g2
S'We earlier nominated 16 genes (IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2) as predictors of response to remission induction therapy against MPA.\n'
p750
sg4
(lp751
(dp752
g7
I120
sg8
VP59665
p753
sg10
I5
sg11
VDEFA1
p754
sg13
I1
sa(dp755
g7
I31
sg8
g9
sg10
I4
sg11
VIRF7
p756
sg13
I1
sa(dp757
g7
I57
sg8
g9
sg10
I3
sg11
VCLC
p758
sg13
I1
sa(dp759
g7
I83
sg8
VP32246
p760
sg10
I4
sg11
VCCR1
p761
sg13
I1
sa(dp762
g7
I144
sg8
g9
sg10
I6
sg11
VCOL9A2
p763
sg13
I1
sa(dp764
g7
I112
sg8
g9
sg10
I6
sg11
VPLSCR1
p765
sg13
I1
sa(dp766
g7
I133
sg8
VP12838
p767
sg10
I5
sg11
VDEFA4
p768
sg13
I1
sa(dp769
g7
I103
sg8
g9
sg10
I7
sg11
VBIRC4BP
p770
sg13
I1
sa(dp771
g7
I126
sg8
VP59665
p772
sg10
I5
sg11
VDEFA3
p773
sg13
I1
sa(dp774
g7
I76
sg8
g9
sg10
I5
sg11
VHERC5
p775
sg13
I1
sa(dp776
g7
I37
sg8
VP09914
p777
sg10
I5
sg11
VIFIT1
p778
sg13
I1
sa(dp779
g7
I51
sg8
g9
sg10
I4
sg11
VOASL
p780
sg13
I1
sa(dp781
g7
I44
sg8
g9
sg10
I5
sg11
VIFIT5
p782
sg13
I1
sa(dp783
g7
I69
sg8
VP28065
p784
sg10
I5
sg11
VPSMB9
p785
sg13
I1
sa(dp786
g7
I62
sg8
VP32455
p787
sg10
I5
sg11
VGBP-1
p788
sg13
I1
sa(dp789
g7
I95
sg8
g9
sg10
I6
sg11
VMS4A4A
p790
sg13
I1
sasg24
(lp791
(dp792
g7
I181
sg27
VC0687702
p793
sg10
I9
sg11
Vremission
p794
sg13
I1
sasa(dp795
g2
S"The 2'5'-oligoadenylate synthetase (OAS) is an interferon (IFN)-induced protein that plays an important role in the antiviral action of IFN, with OAS3 being one of the four OAS classes (OAS1, OAS2, OAS3, OASL).\n"
p796
sg4
(lp797
(dp798
g7
I146
sg8
g9
sg10
I4
sg11
VOAS3
p799
sg13
I1
sa(dp800
g7
I4
sg8
g9
sg10
I30
sg11
V2'5'-oligoadenylate synthetase
p801
sg13
I2
sa(dp802
g7
I47
sg8
VP01563
p803
sg10
I10
sg11
Vinterferon
p804
sg13
I1
sa(dp805
g7
I59
sg8
VP01562
p806
sg10
I3
sg11
VIFN
p807
sg13
I1
sa(dp808
g7
I146
sg8
g9
sg10
I4
sg11
VOAS3
p809
sg13
I1
sa(dp810
g7
I204
sg8
g9
sg10
I4
sg11
VOASL
p811
sg13
I1
sa(dp812
g7
I36
sg8
g9
sg10
I3
sg11
VOAS
p813
sg13
I1
sa(dp814
g7
I192
sg8
VP29728
p815
sg10
I4
sg11
VOAS2
p816
sg13
I1
sa(dp817
g7
I59
sg8
VP01562
p818
sg10
I3
sg11
VIFN
p819
sg13
I1
sa(dp820
g7
I36
sg8
g9
sg10
I3
sg11
VOAS
p821
sg13
I1
sasg24
(lp822
(dp823
g7
I36
sg27
VC0599973
p824
sg10
I3
sg11
VOAS
p825
sg13
I1
sa(dp826
g7
I4
sg27
VC0599973
p827
sg10
I30
sg11
V2'5'-oligoadenylate synthetase
p828
sg13
I2
sa(dp829
g7
I36
sg27
VC0599973
p830
sg10
I3
sg11
VOAS
p831
sg13
I1
sasa(dp832
g2
S'In a pooled analysis of 105 candidate genes and two genome-wide association studies, we observed associations of single nucleotide polymorphisms from nine genes (EIF2AK2, IFNAR2, ITPA, MBL2, MX1, OASL, SPP1, TGFB1, TNK2) with response to interferon-based therapy.\n'
p833
sg4
(lp834
(dp835
g7
I191
sg8
VP20591
p836
sg10
I3
sg11
VMX1
p837
sg13
I1
sa(dp838
g7
I196
sg8
g9
sg10
I4
sg11
VOASL
p839
sg13
I1
sa(dp840
g7
I208
sg8
VP01137
p841
sg10
I5
sg11
VTGFB1
p842
sg13
I1
sa(dp843
g7
I202
sg8
VP10451
p844
sg10
I4
sg11
VSPP1
p845
sg13
I1
sa(dp846
g7
I215
sg8
g9
sg10
I4
sg11
VTNK2
p847
sg13
I1
sa(dp848
g7
I162
sg8
VP19525
p849
sg10
I7
sg11
VEIF2AK2
p850
sg13
I1
sa(dp851
g7
I185
sg8
VP11226
p852
sg10
I4
sg11
VMBL2
p853
sg13
I1
sa(dp854
g7
I179
sg8
g9
sg10
I4
sg11
VITPA
p855
sg13
I1
sa(dp856
g7
I171
sg8
VP48551
p857
sg10
I6
sg11
VIFNAR2
p858
sg13
I1
sa(dp859
g7
I238
sg8
VP01563
p860
sg10
I10
sg11
Vinterferon
p861
sg13
I1
sasg24
(lp862
sa(dp863
g2
S'Single nucleotide polymorphisms in the OAS1 (rs1131476), OAS2 (rs1293747), OAS3 (rs2072136), OASL (rs10849829) and IL28B (rs12979860, rs12980275 and rs8099917) genes were studied to examine their associations with responses to IFN treatment in paediatric patients.\n'
p864
sg4
(lp865
(dp866
g7
I93
sg8
g9
sg10
I17
sg11
VOASL (rs10849829)
p867
sg13
I2
sa(dp868
g7
I57
sg8
VP29728
p869
sg10
I4
sg11
VOAS2
p870
sg13
I1
sa(dp871
g7
I75
sg8
g9
sg10
I4
sg11
VOAS3
p872
sg13
I1
sa(dp873
g7
I227
sg8
VP01562
p874
sg10
I3
sg11
VIFN
p875
sg13
I1
sa(dp876
g7
I115
sg8
g9
sg10
I5
sg11
VIL28B
p877
sg13
I1
sasg24
(lp878
sa(dp879
g2
S'The association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group (P = 0.033) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group (P = 0.044, OR = 0.26, 95%CI: 0.07-0.88).\n'
p880
sg4
(lp881
(dp882
g7
I151
sg8
g9
sg10
I15
sg11
VOASL rs10849829
p883
sg13
I2
sa(dp884
g7
I63
sg8
g9
sg10
I16
sg11
VIL28B rs12979860
p885
sg13
I2
sasg24
(lp886
sa(dp887
g2
S'The aim of the present study was to evaluate agreement between three pairs formed by one of three mania scales (Young Mania Rating Scale [YMRS], Bech-Rafaelsen Mania Scale [BRMS], or the Clinician-Administered Rating Scale for Mania [CARS-M]) and a single depression scale (21-item Hamilton Depression Rating Scale [21-HAM-D]) for evaluation of response to mood stabilizers in patients with mixed bipolar disorder.\n'
p888
sg4
(lp889
sg24
(lp890
(dp891
g7
I118
sg27
VC0338831
p892
sg10
I5
sg11
VMania
p893
sg13
I1
sa(dp894
g7
I118
sg27
VC0338831
p895
sg10
I5
sg11
VMania
p896
sg13
I1
sa(dp897
g7
I391
sg27
VC2937260
p898
sg10
I22
sg11
Vmixed bipolar disorder
p899
sg13
I3
sa(dp900
g7
I319
sg27
VC0030481
p901
sg10
I3
sg11
VHAM
p902
sg13
I1
sa(dp903
g7
I256
sg27
VC0011581
p904
sg10
I10
sg11
Vdepression
p905
sg13
I1
sa(dp906
g7
I291
sg27
VC0011581
p907
sg10
I10
sg11
VDepression
p908
sg13
I1
sa(dp909
g7
I98
sg27
VC0338831
p910
sg10
I5
sg11
Vmania
p911
sg13
I1
sa(dp912
g7
I118
sg27
VC0338831
p913
sg10
I5
sg11
VMania
p914
sg13
I1
sasa(dp915
g2
S'The present study suggests that any one of the three tested mania rating scales (YMRS, BRMS, and CARS-M) can be combined with the 21-HAM-D to assess treatment response in patients with mixed bipolar disorder.\n'
p916
sg4
(lp917
(dp918
g7
I97
sg8
VP49589
p919
sg10
I6
sg11
VCARS-M
p920
sg13
I1
sasg24
(lp921
(dp922
g7
I133
sg27
VC0030481
p923
sg10
I3
sg11
VHAM
p924
sg13
I1
sa(dp925
g7
I60
sg27
VC0338831
p926
sg10
I5
sg11
Vmania
p927
sg13
I1
sa(dp928
g7
I185
sg27
VC2937260
p929
sg10
I22
sg11
Vmixed bipolar disorder
p930
sg13
I3
sasa(dp931
g2
S'Older adults and patients with dementia often have disrupted circadian activity rhythms (CARs).\n'
p932
sg4
(lp933
sg24
(lp934
(dp935
g7
I31
sg27
VC0497327
p936
sg10
I8
sg11
Vdementia
p937
sg13
I1
sasa(dp938
g2
S'Clinically, decreased levels of cGAS are associated with poor prognosis for patients with breast cancer harbouring high levels of miR-25/93.\n'
p939
sg4
(lp940
(dp941
g7
I130
sg8
g9
sg10
I6
sg11
VmiR-25
p942
sg13
I1
sa(dp943
g7
I32
sg8
VP10645
p944
sg10
I4
sg11
VcGAS
p945
sg13
I1
sasg24
(lp946
(dp947
g7
I90
sg27
VC0678222
p948
sg10
I13
sg11
Vbreast cancer
p949
sg13
I2
sasa(dp950
g2
S'In our analysis, we found that increased expression of 12 mature miRNAs-hsa-miR-320a, hsa-miR-361-5p, hsa-miR-103a-3p, hsa-miR-21-5p, hsa-miR-374b-5p, hsa-miR-140-3p, hsa-miR-25-3p, hsa-miR-651-5p, hsa-miR-200c-3p, hsa-miR-30a-5p, hsa-miR-30c-5p, and hsa-let-7i-5p -each predicted improved breast cancer survival.\n'
p951
sg4
(lp952
(dp953
g7
I134
sg8
g9
sg10
I15
sg11
Vhsa-miR-374b-5p
p954
sg13
I1
sa(dp955
g7
I151
sg8
g9
sg10
I14
sg11
Vhsa-miR-140-3p
p956
sg13
I1
sa(dp957
g7
I86
sg8
g9
sg10
I14
sg11
Vhsa-miR-361-5p
p958
sg13
I1
sa(dp959
g7
I182
sg8
g9
sg10
I14
sg11
Vhsa-miR-651-5p
p960
sg13
I1
sa(dp961
g7
I215
sg8
g9
sg10
I14
sg11
Vhsa-miR-30a-5p
p962
sg13
I1
sa(dp963
g7
I102
sg8
g9
sg10
I15
sg11
Vhsa-miR-103a-3p
p964
sg13
I1
sa(dp965
g7
I198
sg8
g9
sg10
I15
sg11
Vhsa-miR-200c-3p
p966
sg13
I1
sa(dp967
g7
I119
sg8
g9
sg10
I13
sg11
Vhsa-miR-21-5p
p968
sg13
I1
sa(dp969
g7
I65
sg8
g9
sg10
I3
sg11
VmiR
p970
sg13
I1
sa(dp971
g7
I251
sg8
g9
sg10
I13
sg11
Vhsa-let-7i-5p
p972
sg13
I1
sa(dp973
g7
I231
sg8
g9
sg10
I14
sg11
Vhsa-miR-30c-5p
p974
sg13
I1
sa(dp975
g7
I167
sg8
g9
sg10
I13
sg11
Vhsa-miR-25-3p
p976
sg13
I1
sa(dp977
g7
I72
sg8
g9
sg10
I3
sg11
Vhsa
p978
sg13
I1
sasg24
(lp979
(dp980
g7
I72
sg27
VC0393754
p981
sg10
I3
sg11
Vhsa
p982
sg13
I1
sa(dp983
g7
I72
sg27
VC0393754
p984
sg10
I3
sg11
Vhsa
p985
sg13
I1
sa(dp986
g7
I72
sg27
VC0393754
p987
sg10
I3
sg11
Vhsa
p988
sg13
I1
sa(dp989
g7
I72
sg27
VC0393754
p990
sg10
I3
sg11
Vhsa
p991
sg13
I1
sa(dp992
g7
I290
sg27
VC0678222
p993
sg10
I13
sg11
Vbreast cancer
p994
sg13
I2
sa(dp995
g7
I72
sg27
VC0393754
p996
sg10
I3
sg11
Vhsa
p997
sg13
I1
sa(dp998
g7
I72
sg27
VC0393754
p999
sg10
I3
sg11
Vhsa
p1000
sg13
I1
sa(dp1001
g7
I72
sg27
VC0393754
p1002
sg10
I3
sg11
Vhsa
p1003
sg13
I1
sa(dp1004
g7
I72
sg27
VC0393754
p1005
sg10
I3
sg11
Vhsa
p1006
sg13
I1
sa(dp1007
g7
I72
sg27
VC0393754
p1008
sg10
I3
sg11
Vhsa
p1009
sg13
I1
sa(dp1010
g7
I72
sg27
VC0393754
p1011
sg10
I3
sg11
Vhsa
p1012
sg13
I1
sa(dp1013
g7
I72
sg27
VC0393754
p1014
sg10
I3
sg11
Vhsa
p1015
sg13
I1
sa(dp1016
g7
I72
sg27
VC0393754
p1017
sg10
I3
sg11
Vhsa
p1018
sg13
I1
sasa(dp1019
g2
S'Here, we report a novel function of isoliquiritigenin (ISL) as a natural inhibitor of autophagy-related miR-25 in killing drug-resistant breast cancer cells.\n'
p1020
sg4
(lp1021
(dp1022
g7
I104
sg8
g9
sg10
I6
sg11
VmiR-25
p1023
sg13
I1
sasg24
(lp1024
(dp1025
g7
I137
sg27
VC0678222
p1026
sg10
I13
sg11
Vbreast cancer
p1027
sg13
I2
sasa(dp1028
g2
S'Overall, our results not only indicate that ISL acts as a natural autophagy inducer to increase breast cancer chemosensitivity, but also reveal that miR-25 functions as a novel regulator of autophagy by targeting ULK1.\n'
p1029
sg4
(lp1030
(dp1031
g7
I149
sg8
g9
sg10
I6
sg11
VmiR-25
p1032
sg13
I1
sa(dp1033
g7
I213
sg8
g9
sg10
I4
sg11
VULK1
p1034
sg13
I1
sa(dp1035
g7
I44
sg8
g9
sg10
I3
sg11
VISL
p1036
sg13
I1
sasg24
(lp1037
(dp1038
g7
I96
sg27
VC0678222
p1039
sg10
I13
sg11
Vbreast cancer
p1040
sg13
I2
sasa(dp1041
g2
S'Expression of a panel of seven microRNAs (hsa-miR-34a, hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, hsa-miR-326, and hsa-miR-375) and seven target genes ( E2F3, PI3KCA, TOM34, WNT5A, PDCD4, DFFA, and EGFR) in 43 glioblastoma multiforme specimens were profiled compared to non-cancer tissues via quantitative reverse transcription-polymerase chain reaction.\n'
p1042
sg4
(lp1043
(dp1044
g7
I67
sg8
g9
sg10
I10
sg11
Vhsa-miR-17
p1045
sg13
I1
sa(dp1046
g7
I42
sg8
g9
sg10
I3
sg11
Vhsa
p1047
sg13
I1
sa(dp1048
g7
I194
sg8
g9
sg10
I14
sg11
VDFFA, and EGFR
p1049
sg13
I3
sa(dp1050
g7
I46
sg8
g9
sg10
I3
sg11
VmiR
p1051
sg13
I1
sa(dp1052
g7
I91
sg8
g9
sg10
I11
sg11
Vhsa-miR-221
p1053
sg13
I1
sa(dp1054
g7
I187
sg8
g9
sg10
I5
sg11
VPDCD4
p1055
sg13
I1
sa(dp1056
g7
I180
sg8
VP41221
p1057
sg10
I5
sg11
VWNT5A
p1058
sg13
I1
sa(dp1059
g7
I55
sg8
g9
sg10
I10
sg11
Vhsa-miR-16
p1060
sg13
I1
sa(dp1061
g7
I42
sg8
g9
sg10
I3
sg11
Vhsa
p1062
sg13
I1
sa(dp1063
g7
I104
sg8
g9
sg10
I11
sg11
Vhsa-miR-326
p1064
sg13
I1
sa(dp1065
g7
I42
sg8
g9
sg10
I3
sg11
Vhsa
p1066
sg13
I1
sa(dp1067
g7
I173
sg8
g9
sg10
I5
sg11
VTOM34
p1068
sg13
I1
sa(dp1069
g7
I159
sg8
g9
sg10
I4
sg11
VE2F3
p1070
sg13
I1
sasg24
(lp1071
(dp1072
g7
I42
sg27
VC0393754
p1073
sg10
I3
sg11
Vhsa
p1074
sg13
I1
sa(dp1075
g7
I280
sg27
VC0006826
p1076
sg10
I6
sg11
Vcancer
p1077
sg13
I1
sa(dp1078
g7
I42
sg27
VC0393754
p1079
sg10
I3
sg11
Vhsa
p1080
sg13
I1
sa(dp1081
g7
I216
sg27
VC1621958
p1082
sg10
I23
sg11
Vglioblastoma multiforme
p1083
sg13
I2
sa(dp1084
g7
I42
sg27
VC0393754
p1085
sg10
I3
sg11
Vhsa
p1086
sg13
I1
sa(dp1087
g7
I42
sg27
VC0393754
p1088
sg10
I3
sg11
Vhsa
p1089
sg13
I1
sa(dp1090
g7
I42
sg27
VC0393754
p1091
sg10
I3
sg11
Vhsa
p1092
sg13
I1
sa(dp1093
g7
I42
sg27
VC0393754
p1094
sg10
I3
sg11
Vhsa
p1095
sg13
I1
sa(dp1096
g7
I42
sg27
VC0393754
p1097
sg10
I3
sg11
Vhsa
p1098
sg13
I1
sasa(dp1099
g2
S'The present study examined whether it could be possible to quantify the expression of TOMM34 and RNF43 in colorectal cancer and liver metastasis samples prepared from paraffin blocks.\n'
p1100
sg4
(lp1101
(dp1102
g7
I97
sg8
g9
sg10
I5
sg11
VRNF43
p1103
sg13
I1
sa(dp1104
g7
I86
sg8
g9
sg10
I6
sg11
VTOMM34
p1105
sg13
I1
sasg24
(lp1106
(dp1107
g7
I106
sg27
VC1527249
p1108
sg10
I17
sg11
Vcolorectal cancer
p1109
sg13
I2
sa(dp1110
g7
I128
sg27
VC0494165
p1111
sg10
I16
sg11
Vliver metastasis
p1112
sg13
I2
sasa(dp1113
g2
S'Quantification of TOMM34 and RNF43 gene expression in several-year-old paraffin-embedded colorectal cancer specimens was possible by qPCR using the Universal ProbeLibrary.\n'
p1114
sg4
(lp1115
(dp1116
g7
I18
sg8
g9
sg10
I6
sg11
VTOMM34
p1117
sg13
I1
sa(dp1118
g7
I29
sg8
g9
sg10
I10
sg11
VRNF43 gene
p1119
sg13
I2
sasg24
(lp1120
(dp1121
g7
I89
sg27
VC1527249
p1122
sg10
I17
sg11
Vcolorectal cancer
p1123
sg13
I2
sasa(dp1124
g2
S"The mRNA levels of seven TAAs, Wilms' tumor gene (WT1), kinetochore associated-2 (KNTC2), cell division cycle associated-1 (CDCA1), M phase phosphoprotein-1 (MPHOSPH1), DEP domain-containing 1 (DEPDC1), 34-kDa translocase of the outer mitochondrial membrane (TOMM34) and ring finger protein-43 (RNF43), were analyzed using quantitative real-time reverse transcription-polymerase chain reaction, and their relationships with clinicopathological factors and the cell cycle were analyzed.\n"
p1125
sg4
(lp1126
(dp1127
g7
I82
sg8
g9
sg10
I5
sg11
VKNTC2
p1128
sg13
I1
sa(dp1129
g7
I203
sg8
g9
sg10
I63
sg11
V34-kDa translocase of the outer mitochondrial membrane (TOMM34)
p1130
sg13
I8
sa(dp1131
g7
I132
sg8
g9
sg10
I24
sg11
VM phase phosphoprotein-1
p1132
sg13
I3
sa(dp1133
g7
I169
sg8
g9
sg10
I23
sg11
VDEP domain-containing 1
p1134
sg13
I3
sa(dp1135
g7
I271
sg8
VP62877
p1136
sg10
I22
sg11
Vring finger protein-43
p1137
sg13
I3
sa(dp1138
g7
I194
sg8
g9
sg10
I6
sg11
VDEPDC1
p1139
sg13
I1
sa(dp1140
g7
I295
sg8
g9
sg10
I5
sg11
VRNF43
p1141
sg13
I1
sa(dp1142
g7
I158
sg8
g9
sg10
I8
sg11
VMPHOSPH1
p1143
sg13
I1
sa(dp1144
g7
I31
sg8
g9
sg10
I49
sg11
VWilms' tumor gene (WT1), kinetochore associated-2
p1145
sg13
I6
sasg24
(lp1146
(dp1147
g7
I31
sg27
VC0027708
p1148
sg10
I12
sg11
VWilms' tumor
p1149
sg13
I2
sa(dp1150
g7
I50
sg27
VC0027708
p1151
sg10
I3
sg11
VWT1
p1152
sg13
I1
sasa(dp1153
g2
S'These antigenic peptides were derived from 5 proteins identified as cancer-testis antigens(ring finger protein 43 [RNF43], translocase of outer mitochondrial membrane 34[TOMM34], maternal embryonic leucine zipper kinase[MELK], forkhead box M1[FOXM1], and holliday junction recognition protein[HJURP])and 2 vascular endothelial growth factor receptors(VEGFR1 and VEGFR2).\n'
p1154
sg4
(lp1155
(dp1156
g7
I255
sg8
g9
sg10
I37
sg11
Vholliday junction recognition protein
p1157
sg13
I4
sa(dp1158
g7
I293
sg8
g9
sg10
I5
sg11
VHJURP
p1159
sg13
I1
sa(dp1160
g7
I240
sg8
g9
sg10
I9
sg11
VM1[FOXM1]
p1161
sg13
I1
sa(dp1162
g7
I351
sg8
VP17948
p1163
sg10
I6
sg11
VVEGFR1
p1164
sg13
I1
sa(dp1165
g7
I306
sg8
g9
sg10
I44
sg11
Vvascular endothelial growth factor receptors
p1166
sg13
I5
sa(dp1167
g7
I220
sg8
g9
sg10
I4
sg11
VMELK
p1168
sg13
I1
sa(dp1169
g7
I362
sg8
VP35968
p1170
sg10
I6
sg11
VVEGFR2
p1171
sg13
I1
sa(dp1172
g7
I91
sg8
g9
sg10
I22
sg11
Vring finger protein 43
p1173
sg13
I4
sa(dp1174
g7
I179
sg8
VP30740
p1175
sg10
I40
sg11
Vmaternal embryonic leucine zipper kinase
p1176
sg13
I5
sa(dp1177
g7
I68
sg8
VP15735
p1178
sg10
I22
sg11
Vcancer-testis antigens
p1179
sg13
I2
sasg24
(lp1180
(dp1181
g7
I68
sg27
VC0006826
p1182
sg10
I6
sg11
Vcancer
p1183
sg13
I1
sasa(dp1184
g2
S'To evaluate the safety of combination vaccine treatment of multiple peptides, phase I clinical trial was conducted for patients with advanced colorectal cancer using five novel HLA-A*2402-restricted peptides, three peptides derived from oncoantigens, ring finger protein 43 (RNF43), 34 kDa-translocase of the outer mitochondrial membrane (TOMM34), and insulin-like growth factor-II mRNA binding protein 3 (KOC1), and the remaining two from angiogenesis factors, vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.\n'
p1185
sg4
(lp1186
(dp1187
g7
I406
sg8
g9
sg10
I4
sg11
VKOC1
p1188
sg13
I1
sa(dp1189
g7
I251
sg8
g9
sg10
I22
sg11
Vring finger protein 43
p1190
sg13
I4
sa(dp1191
g7
I352
sg8
VP01308
p1192
sg10
I52
sg11
Vinsulin-like growth factor-II mRNA binding protein 3
p1193
sg13
I7
sa(dp1194
g7
I339
sg8
g9
sg10
I6
sg11
VTOMM34
p1195
sg13
I1
sa(dp1196
g7
I509
sg8
VP17948
p1197
sg10
I6
sg11
VVEGFR1
p1198
sg13
I1
sa(dp1199
g7
I177
sg8
VP30447
p1200
sg10
I10
sg11
VHLA-A*2402
p1201
sg13
I1
sa(dp1202
g7
I462
sg8
VP17948
p1203
sg10
I45
sg11
Vvascular endothelial growth factor receptor 1
p1204
sg13
I6
sa(dp1205
g7
I275
sg8
g9
sg10
I5
sg11
VRNF43
p1206
sg13
I1
sa(dp1207
g7
I521
sg8
VP35968
p1208
sg10
I6
sg11
VVEGFR2
p1209
sg13
I1
sasg24
(lp1210
(dp1211
g7
I142
sg27
VC1527249
p1212
sg10
I17
sg11
Vcolorectal cancer
p1213
sg13
I2
sasa(dp1214
g2
S'These antigenic peptides were derived from 2 different cancer-testis antigens, ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34( TOMM34).\n'
p1215
sg4
(lp1216
(dp1217
g7
I114
sg8
g9
sg10
I46
sg11
Vtranslocase of outer mitochondrial membrane 34
p1218
sg13
I6
sa(dp1219
g7
I55
sg8
VP15735
p1220
sg10
I22
sg11
Vcancer-testis antigens
p1221
sg13
I2
sa(dp1222
g7
I79
sg8
g9
sg10
I22
sg11
Vring finger protein 43
p1223
sg13
I4
sa(dp1224
g7
I103
sg8
g9
sg10
I5
sg11
VRNF43
p1225
sg13
I1
sa(dp1226
g7
I162
sg8
g9
sg10
I6
sg11
VTOMM34
p1227
sg13
I1
sasg24
(lp1228
(dp1229
g7
I55
sg27
VC0006826
p1230
sg10
I6
sg11
Vcancer
p1231
sg13
I1
sasa(dp1232
g2
S'We conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer.\n'
p1233
sg4
(lp1234
(dp1235
g7
I69
sg8
g9
sg10
I5
sg11
VRNF43
p1236
sg13
I1
sa(dp1237
g7
I33
sg8
VP31749
p1238
sg10
I34
sg11
Vcolorectal cancer-specific peptide
p1239
sg13
I3
sa(dp1240
g7
I76
sg8
g9
sg10
I6
sg11
VTOMM34
p1241
sg13
I1
sasg24
(lp1242
(dp1243
g7
I168
sg27
VC0854750
p1244
sg10
I27
sg11
Vrecurrent colorectal cancer
p1245
sg13
I3
sa(dp1246
g7
I33
sg27
VC1527249
p1247
sg10
I17
sg11
Vcolorectal cancer
p1248
sg13
I2
sasa(dp1249
g2
S'We started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.\n'
p1250
sg4
(lp1251
(dp1252
g7
I164
sg8
g9
sg10
I37
sg11
Vholliday junction recognition protein
p1253
sg13
I4
sa(dp1254
g7
I82
sg8
g9
sg10
I31
sg11
Vforkhead box protein M1 [FOXM1]
p1255
sg13
I5
sa(dp1256
g7
I157
sg8
g9
sg10
I4
sg11
VMELK
p1257
sg13
I1
sa(dp1258
g7
I202
sg8
g9
sg10
I5
sg11
VHJURP
p1259
sg13
I1
sa(dp1260
g7
I210
sg8
VP17948
p1261
sg10
I65
sg11
Vvascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2
p1262
sg13
I8
sa(dp1263
g7
I67
sg8
g9
sg10
I5
sg11
VRNF43
p1264
sg13
I1
sa(dp1265
g7
I74
sg8
g9
sg10
I6
sg11
VTOMM34
p1266
sg13
I1
sa(dp1267
g7
I115
sg8
VP30740
p1268
sg10
I40
sg11
Vmaternal embryonic leucine zipper kinase
p1269
sg13
I5
sasg24
(lp1270
(dp1271
g7
I310
sg27
VC0854750
p1272
sg10
I27
sg11
Vrecurrent colorectal cancer
p1273
sg13
I3
sasa(dp1274
g2
S'Recently, analysis of tumor antigens using micro-arrays has revealed upregulation             of cancer-testis antigens RNF43 and TOMM34 and vascular endothelial growth factor             receptors VEGFR1 and VEGFR2 in colorectal cancer.\n'
p1275
sg4
(lp1276
(dp1277
g7
I130
sg8
g9
sg10
I6
sg11
VTOMM34
p1278
sg13
I1
sa(dp1279
g7
I120
sg8
g9
sg10
I5
sg11
VRNF43
p1280
sg13
I1
sa(dp1281
g7
I141
sg8
VP17948
p1282
sg10
I74
sg11
Vvascular endothelial growth factor             receptors VEGFR1 and VEGFR2
p1283
sg13
I20
sasg24
(lp1284
(dp1285
g7
I97
sg27
VC0006826
p1286
sg10
I6
sg11
Vcancer
p1287
sg13
I1
sa(dp1288
g7
I22
sg27
VC0027651
p1289
sg10
I5
sg11
Vtumor
p1290
sg13
I1
sa(dp1291
g7
I219
sg27
VC1527249
p1292
sg10
I17
sg11
Vcolorectal cancer
p1293
sg13
I2
sasa(dp1294
g2
S'Our aim was to analyze the dynamic modulation, determined by ADT, of the expression of selected genes involved in the pathogenesis and progression of prostate cancer (TMPRSS2:ERG, WNT11, SPINK1, CHGA, AR, and SPDEF) using real-time polymerase chain reaction in a series of 59 surgical samples of prostate carcinomas, including 37 cases preoperatively treated with ADT and 22 untreated cases, and in 43 corresponding biopsies.\n'
p1295
sg4
(lp1296
(dp1297
g7
I187
sg8
VP00995
p1298
sg10
I6
sg11
VSPINK1
p1299
sg13
I1
sa(dp1300
g7
I209
sg8
g9
sg10
I5
sg11
VSPDEF
p1301
sg13
I1
sa(dp1302
g7
I175
sg8
VP11308
p1303
sg10
I3
sg11
VERG
p1304
sg13
I1
sa(dp1305
g7
I195
sg8
VP10645
p1306
sg10
I4
sg11
VCHGA
p1307
sg13
I1
sa(dp1308
g7
I180
sg8
g9
sg10
I5
sg11
VWNT11
p1309
sg13
I1
sasg24
(lp1310
(dp1311
g7
I305
sg27
VC0007097
p1312
sg10
I10
sg11
Vcarcinomas
p1313
sg13
I1
sa(dp1314
g7
I118
sg27
VC0699748
p1315
sg10
I12
sg11
Vpathogenesis
p1316
sg13
I1
sa(dp1317
g7
I135
sg27
VC1739135
p1318
sg10
I30
sg11
Vprogression of prostate cancer
p1319
sg13
I4
sasa(dp1320
g2
S'However, Wnt-11 expression in cervical cancer has not been well investigated.\n'
p1321
sg4
(lp1322
sg24
(lp1323
(dp1324
g7
I30
sg27
VC0302592
p1325
sg10
I15
sg11
Vcervical cancer
p1326
sg13
I2
sasa(dp1327
g2
S'Wnt-11 and HR-HPV E6 expression increased in a manner that corresponded with the progression of cervical cancer and was significantly correlated with the International Federation of Gynecology and Obstetrics cancer stage, lymph node metastasis, tumor size, and HPV infection.\n'
p1328
sg4
(lp1329
sg24
(lp1330
(dp1331
g7
I96
sg27
VC0302592
p1332
sg10
I15
sg11
Vcervical cancer
p1333
sg13
I2
sa(dp1334
g7
I245
sg27
VC0027651
p1335
sg10
I5
sg11
Vtumor
p1336
sg13
I1
sa(dp1337
g7
I222
sg27
VC0686619
p1338
sg10
I21
sg11
Vlymph node metastasis
p1339
sg13
I3
sa(dp1340
g7
I105
sg27
VC0006826
p1341
sg10
I6
sg11
Vcancer
p1342
sg13
I1
sa(dp1343
g7
I265
sg27
VC0009450
p1344
sg10
I9
sg11
Vinfection
p1345
sg13
I1
sasa(dp1346
g2
S'Wnt-11 protein expression was positively associated with HR-HPV E6 protein expression in all 78 cervical cancer samples (P &lt; 0.001).\n'
p1347
sg4
(lp1348
sg24
(lp1349
(dp1350
g7
I96
sg27
VC0302592
p1351
sg10
I15
sg11
Vcervical cancer
p1352
sg13
I2
sasa(dp1353
g2
S'Furthermore, Wnt-11 was positively associated with P-JNK1 expression and promoted cervical cancer cell proliferation and invasion.\n'
p1354
sg4
(lp1355
(dp1356
g7
I53
sg8
VP45983
p1357
sg10
I4
sg11
VJNK1
p1358
sg13
I1
sasg24
(lp1359
(dp1360
g7
I103
sg27
VC0334094
p1361
sg10
I13
sg11
Vproliferation
p1362
sg13
I1
sa(dp1363
g7
I121
sg27
VC2699153
p1364
sg10
I8
sg11
Vinvasion
p1365
sg13
I1
sa(dp1366
g7
I82
sg27
VC0302592
p1367
sg10
I15
sg11
Vcervical cancer
p1368
sg13
I2
sasa(dp1369
g2
S'These observations suggest that the increased Wnt-11 expression observed in cervical cancer cells may lead to the phosphorylation and activation of JNK-1 and significantly promote tumor cell proliferation and cell migration/invasion through activation of the Wnt/JNK pathway.\n'
p1370
sg4
(lp1371
(dp1372
g7
I148
sg8
VP53779
p1373
sg10
I5
sg11
VJNK-1
p1374
sg13
I1
sa(dp1375
g7
I148
sg8
VP53779
p1376
sg10
I3
sg11
VJNK
p1377
sg13
I1
sasg24
(lp1378
(dp1379
g7
I191
sg27
VC0334094
p1380
sg10
I13
sg11
Vproliferation
p1381
sg13
I1
sa(dp1382
g7
I180
sg27
VC0027651
p1383
sg10
I5
sg11
Vtumor
p1384
sg13
I1
sa(dp1385
g7
I76
sg27
VC0302592
p1386
sg10
I15
sg11
Vcervical cancer
p1387
sg13
I2
sa(dp1388
g7
I224
sg27
VC2699153
p1389
sg10
I8
sg11
Vinvasion
p1390
sg13
I1
sasa(dp1391
g2
S'Consequently, Wnt-11 may serve as a novel target for cervical cancer therapy.\n'
p1392
sg4
(lp1393
sg24
(lp1394
(dp1395
g7
I53
sg27
VC0302592
p1396
sg10
I15
sg11
Vcervical cancer
p1397
sg13
I2
sasa(dp1398
g2
S'In this study, we aimed to explore the association among gene variants of five cytokines, tumor necrosis factor alpha (TNF-Alfa), transforming growth factor beta-1 (TGF-Beta1), interferon gamma (IFN-Gamma), interleukin-6 (IL-6), and interleukin-10 (IL-10), and clinical parameters and prognosis in patients with multiple myeloma (MM) treated with novel therapeutic drugs in Turkish population for the first time except TNF-Alfa.\n'
p1399
sg4
(lp1400
(dp1401
g7
I249
sg8
VP22301
p1402
sg10
I5
sg11
VIL-10
p1403
sg13
I1
sa(dp1404
g7
I207
sg8
VP05231
p1405
sg10
I13
sg11
Vinterleukin-6
p1406
sg13
I1
sa(dp1407
g7
I130
sg8
VP01137
p1408
sg10
I33
sg11
Vtransforming growth factor beta-1
p1409
sg13
I4
sa(dp1410
g7
I119
sg8
VP01375
p1411
sg10
I8
sg11
VTNF-Alfa
p1412
sg13
I1
sa(dp1413
g7
I90
sg8
VP01375
p1414
sg10
I27
sg11
Vtumor necrosis factor alpha
p1415
sg13
I4
sa(dp1416
g7
I165
sg8
VP01137
p1417
sg10
I9
sg11
VTGF-Beta1
p1418
sg13
I1
sa(dp1419
g7
I195
sg8
VP01579
p1420
sg10
I9
sg11
VIFN-Gamma
p1421
sg13
I1
sa(dp1422
g7
I177
sg8
VP01579
p1423
sg10
I16
sg11
Vinterferon gamma
p1424
sg13
I2
sa(dp1425
g7
I222
sg8
VP05231
p1426
sg10
I4
sg11
VIL-6
p1427
sg13
I1
sa(dp1428
g7
I233
sg8
VP22301
p1429
sg10
I14
sg11
Vinterleukin-10
p1430
sg13
I1
sasg24
(lp1431
(dp1432
g7
I312
sg27
VC0026764
p1433
sg10
I16
sg11
Vmultiple myeloma
p1434
sg13
I2
sa(dp1435
g7
I90
sg27
VC0333516
p1436
sg10
I14
sg11
Vtumor necrosis
p1437
sg13
I2
sasa(dp1438
g2
S'Using absolute value of log2 fold-change &gt; 2 or extremely small P value (10-20) as a criterion, we identified nine significant genes (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, NPPA, NPPB, PDK4, PLA2G2A) in LVH, also found in published data set for ischemic and dilated cardiomyopathy in heart failure.\n'
p1439
sg4
(lp1440
(dp1441
g7
I166
sg8
g9
sg10
I4
sg11
VMYL7
p1442
sg13
I1
sa(dp1443
g7
I159
sg8
VP30711
p1444
sg10
I5
sg11
VGSTT1
p1445
sg13
I1
sa(dp1446
g7
I137
sg8
VP69905
p1447
sg10
I4
sg11
VHBA1
p1448
sg13
I1
sa(dp1449
g7
I143
sg8
VP02042
p1450
sg10
I3
sg11
VHBB
p1451
sg13
I1
sa(dp1452
g7
I172
sg8
VP01160
p1453
sg10
I4
sg11
VNPPA
p1454
sg13
I1
sa(dp1455
g7
I178
sg8
VP16860
p1456
sg10
I4
sg11
VNPPB
p1457
sg13
I1
sa(dp1458
g7
I148
sg8
g9
sg10
I9
sg11
VHIST1H2AC
p1459
sg13
I1
sa(dp1460
g7
I184
sg8
g9
sg10
I4
sg11
VPDK4
p1461
sg13
I1
sa(dp1462
g7
I190
sg8
VP14555
p1463
sg10
I7
sg11
VPLA2G2A
p1464
sg13
I1
sasg24
(lp1465
(dp1466
g7
I257
sg27
VC0007193
p1467
sg10
I22
sg11
Vdilated cardiomyopathy
p1468
sg13
I2
sa(dp1469
g7
I202
sg27
VC0149721
p1470
sg10
I3
sg11
VLVH
p1471
sg13
I1
sa(dp1472
g7
I283
sg27
VC0018802
p1473
sg10
I13
sg11
Vheart failure
p1474
sg13
I2
sasa(dp1475
g2
S"Tolerized cow's milk protein (CMP)-sensitive atopic dermatitis had, in particular, decreased kappa-casein-specific IgG(1) levels, compared with clinically reactive patients.\n"
p1476
sg4
(lp1477
(dp1478
g7
I93
sg8
VP07498
p1479
sg10
I28
sg11
Vkappa-casein-specific IgG(1)
p1480
sg13
I2
sasg24
(lp1481
(dp1482
g7
I45
sg27
VC0011615
p1483
sg10
I17
sg11
Vatopic dermatitis
p1484
sg13
I2
sasa(dp1485
g2
S'Tolerised patients, particularly those with atopic dermatitis, had decreased responses to kappa-casein which were restored after Treg depletion.\n'
p1486
sg4
(lp1487
(dp1488
g7
I90
sg8
VP07498
p1489
sg10
I12
sg11
Vkappa-casein
p1490
sg13
I1
sasg24
(lp1491
(dp1492
g7
I44
sg27
VC0011615
p1493
sg10
I17
sg11
Vatopic dermatitis
p1494
sg13
I2
sasa(dp1495
g2
S'A markedly decreased proliferative response to kappa-casein in tolerised IgE-mediated CMA patients with atopic dermatitis, which was abrogated by Treg depletion, suggested a role for kappa-casein in tolerance induction.\n'
p1496
sg4
(lp1497
(dp1498
g7
I47
sg8
VP07498
p1499
sg10
I12
sg11
Vkappa-casein
p1500
sg13
I1
sa(dp1501
g7
I73
sg8
VP01854
p1502
sg10
I3
sg11
VIgE
p1503
sg13
I1
sa(dp1504
g7
I47
sg8
VP07498
p1505
sg10
I12
sg11
Vkappa-casein
p1506
sg13
I1
sasg24
(lp1507
(dp1508
g7
I21
sg27
VC0334094
p1509
sg10
I13
sg11
Vproliferative
p1510
sg13
I1
sa(dp1511
g7
I73
sg27
VC0270850
p1512
sg10
I3
sg11
VIgE
p1513
sg13
I1
sa(dp1514
g7
I104
sg27
VC0011615
p1515
sg10
I17
sg11
Vatopic dermatitis
p1516
sg13
I2
sa(dp1517
g7
I199
sg27
VC0020963
p1518
sg10
I9
sg11
Vtolerance
p1519
sg13
I1
sasa(dp1520
g2
S'In order to investigate the role of food antigen-specific T cells circulating in the blood of patients with food allergy, we compared T cell response to three casein components (alpha s-, beta- and, kappa-casein) with specificities of IgG and IgE binding to the casein components in four milk-allergic patients (P1-4) with atopic dermatitis.\n'
p1521
sg4
(lp1522
(dp1523
g7
I243
sg8
VP01854
p1524
sg10
I3
sg11
VIgE
p1525
sg13
I1
sasg24
(lp1526
(dp1527
g7
I323
sg27
VC0011615
p1528
sg10
I17
sg11
Vatopic dermatitis
p1529
sg13
I2
sa(dp1530
g7
I108
sg27
VC0016470
p1531
sg10
I12
sg11
Vfood allergy
p1532
sg13
I2
sa(dp1533
g7
I243
sg27
VC0270850
p1534
sg10
I3
sg11
VIgE
p1535
sg13
I1
sasa(dp1536
g2
S'Studies have identified that PKM2 is related to the development of glucose intolerance and insulin resistance in rodents and humans.\n'
p1537
sg4
(lp1538
(dp1539
g7
I91
sg8
VP01308
p1540
sg10
I7
sg11
Vinsulin
p1541
sg13
I1
sasg24
(lp1542
(dp1543
g7
I91
sg27
VC0021655
p1544
sg10
I18
sg11
Vinsulin resistance
p1545
sg13
I2
sa(dp1546
g7
I67
sg27
VC0271650
p1547
sg10
I19
sg11
Vglucose intolerance
p1548
sg13
I2
sasa(dp1549
g2
S'Mechanistically, we showed that hyperglycemia and diabetes decreased PKM2 tetramer formation and activity by sulfenylation in mouse glomeruli and cultured podocytes.\n'
p1550
sg4
(lp1551
sg24
(lp1552
(dp1553
g7
I50
sg27
VC0011849
p1554
sg10
I8
sg11
Vdiabetes
p1555
sg13
I1
sa(dp1556
g7
I32
sg27
VC0020456
p1557
sg10
I13
sg11
Vhyperglycemia
p1558
sg13
I1
sasa(dp1559
g2
S'Podocyte-specific Pkm2-knockout (KO) mice with diabetes developed worse albuminuria and glomerular pathology.\n'
p1560
sg4
(lp1561
sg24
(lp1562
(dp1563
g7
I47
sg27
VC0011849
p1564
sg10
I8
sg11
Vdiabetes
p1565
sg13
I1
sa(dp1566
g7
I99
sg27
VC0677042
p1567
sg10
I9
sg11
Vpathology
p1568
sg13
I1
sasa(dp1569
g2
S'Conversely, we found that pharmacological activation of PKM2 by a small-molecule PKM2 activator, TEPP-46, reversed hyperglycemia-induced elevation in toxic glucose metabolites and mitochondrial dysfunction, partially by increasing glycolytic flux and PGC-1Alfa mRNA in cultured podocytes.\n'
p1570
sg4
(lp1571
(dp1572
g7
I251
sg8
VP20142
p1573
sg10
I14
sg11
VPGC-1Alfa mRNA
p1574
sg13
I2
sa(dp1575
g7
I97
sg8
g9
sg10
I7
sg11
VTEPP-46
p1576
sg13
I1
sa(dp1577
g7
I66
sg8
VP05154
p1578
sg10
I29
sg11
Vsmall-molecule PKM2 activator
p1579
sg13
I3
sasg24
(lp1580
(dp1581
g7
I115
sg27
VC0020456
p1582
sg10
I13
sg11
Vhyperglycemia
p1583
sg13
I1
sasa(dp1584
g2
S'To identify the miR-155 targets relevant for B-cell lymphoma, we performed RNA immunoprecipitation of Argonaute 2 in Hodgkin lymphoma (HL) cells upon miR-155 inhibition and in BL cells upon ectopic expression of miR-155.\n'
p1585
sg4
(lp1586
(dp1587
g7
I16
sg8
g9
sg10
I7
sg11
VmiR-155
p1588
sg13
I1
sasg24
(lp1589
(dp1590
g7
I117
sg27
VC0019829
p1591
sg10
I16
sg11
VHodgkin lymphoma
p1592
sg13
I2
sa(dp1593
g7
I45
sg27
VC0079731
p1594
sg10
I15
sg11
VB-cell lymphoma
p1595
sg13
I2
sa(dp1596
g7
I135
sg27
VC0019829
p1597
sg10
I2
sg11
VHL
p1598
sg13
I1
sasa(dp1599
g2
S'Further research suggested that METTL13 negatively regulates cell proliferation in bladder cancer and reinstates G1/S checkpoint via the coordinated downregulation of CDK6, CDK4 and CCND1, decreased phosphorylation of Rb and subsequent delayed cell cycle progression.\n'
p1600
sg4
(lp1601
(dp1602
g7
I182
sg8
VP24385
p1603
sg10
I5
sg11
VCCND1
p1604
sg13
I1
sa(dp1605
g7
I173
sg8
VP11802
p1606
sg10
I4
sg11
VCDK4
p1607
sg13
I1
sa(dp1608
g7
I167
sg8
g9
sg10
I4
sg11
VCDK6
p1609
sg13
I1
sasg24
(lp1610
(dp1611
g7
I66
sg27
VC0334094
p1612
sg10
I13
sg11
Vproliferation
p1613
sg13
I1
sa(dp1614
g7
I83
sg27
VC0699885
p1615
sg10
I14
sg11
Vbladder cancer
p1616
sg13
I2
sasa(dp1617
g2
S'miR-29c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating CDK6.\n'
p1618
sg4
(lp1619
(dp1620
g7
I103
sg8
g9
sg10
I4
sg11
VCDK6
p1621
sg13
I1
sa(dp1622
g7
I0
sg8
g9
sg10
I7
sg11
VmiR-29c
p1623
sg13
I1
sasg24
(lp1624
(dp1625
g7
I67
sg27
VC0699885
p1626
sg10
I14
sg11
Vbladder cancer
p1627
sg13
I2
sa(dp1628
g7
I55
sg27
VC2699153
p1629
sg10
I8
sg11
Vinvasion
p1630
sg13
I1
sa(dp1631
g7
I26
sg27
VC0334094
p1632
sg10
I13
sg11
Vproliferation
p1633
sg13
I1
sasa(dp1634
g2
S'p34cdc2, collapsin response mediator protein 4 (CRMP4), doublecortin (DCX), HuD, and NeuN expression was assessed in tuber (n = 16) and subependymal giant cell astrocytoma (SEGA; n = 6) specimens in tuberous sclerosis complex to define the developmental phenotype and lineage of giant cells (CGs) in these lesions.\n'
p1635
sg4
(lp1636
(dp1637
g7
I85
sg8
g9
sg10
I4
sg11
VNeuN
p1638
sg13
I1
sa(dp1639
g7
I48
sg8
g9
sg10
I5
sg11
VCRMP4
p1640
sg13
I1
sa(dp1641
g7
I70
sg8
g9
sg10
I3
sg11
VDCX
p1642
sg13
I1
sa(dp1643
g7
I9
sg8
g9
sg10
I37
sg11
Vcollapsin response mediator protein 4
p1644
sg13
I5
sa(dp1645
g7
I76
sg8
VP26378
p1646
sg10
I3
sg11
VHuD
p1647
sg13
I1
sa(dp1648
g7
I0
sg8
VP06493
p1649
sg10
I7
sg11
Vp34cdc2
p1650
sg13
I1
sa(dp1651
g7
I56
sg8
g9
sg10
I12
sg11
Vdoublecortin
p1652
sg13
I1
sasg24
(lp1653
(dp1654
g7
I199
sg27
VC0041341
p1655
sg10
I26
sg11
Vtuberous sclerosis complex
p1656
sg13
I3
sa(dp1657
g7
I136
sg27
VC0205768
p1658
sg10
I35
sg11
Vsubependymal giant cell astrocytoma
p1659
sg13
I4
sa(dp1660
g7
I149
sg27
VC0017547
p1661
sg10
I5
sg11
Vgiant
p1662
sg13
I1
sa(dp1663
g7
I173
sg27
VC0205768
p1664
sg10
I4
sg11
VSEGA
p1665
sg13
I1
sasa(dp1666
g2
S'First, logistic regression analysis in two human prostate gene expression datasets revealed that expression levels of five genes (CXCL14, ITGAX, LPCAT2, RNASEH2A, and ZNF322) were positively correlated with aggressive prostate cancer and two genes (CCL19 and HIST1H1A) were protective for aggressive prostate cancer.\n'
p1667
sg4
(lp1668
(dp1669
g7
I153
sg8
g9
sg10
I8
sg11
VRNASEH2A
p1670
sg13
I1
sa(dp1671
g7
I130
sg8
g9
sg10
I6
sg11
VCXCL14
p1672
sg13
I1
sa(dp1673
g7
I167
sg8
g9
sg10
I6
sg11
VZNF322
p1674
sg13
I1
sa(dp1675
g7
I138
sg8
VP20702
p1676
sg10
I5
sg11
VITGAX
p1677
sg13
I1
sa(dp1678
g7
I145
sg8
g9
sg10
I6
sg11
VLPCAT2
p1679
sg13
I1
sa(dp1680
g7
I259
sg8
g9
sg10
I8
sg11
VHIST1H1A
p1681
sg13
I1
sa(dp1682
g7
I249
sg8
g9
sg10
I5
sg11
VCCL19
p1683
sg13
I1
sasg24
(lp1684
(dp1685
g7
I218
sg27
VC0600139
p1686
sg10
I15
sg11
Vprostate cancer
p1687
sg13
I2
sa(dp1688
g7
I207
sg27
VC0001807
p1689
sg10
I10
sg11
Vaggressive
p1690
sg13
I1
sa(dp1691
g7
I218
sg27
VC0600139
p1692
sg10
I15
sg11
Vprostate cancer
p1693
sg13
I2
sa(dp1694
g7
I207
sg27
VC0001807
p1695
sg10
I10
sg11
Vaggressive
p1696
sg13
I1
sasa(dp1697
g2
S'Second generation H1 antihistamines (H1A) are currently recommended as first choice medications for allergic rhinitis and rhinoconjunctivitis.\n'
p1698
sg4
(lp1699
(dp1700
g7
I18
sg8
VP08620
p1701
sg10
I17
sg11
VH1 antihistamines
p1702
sg13
I2
sa(dp1703
g7
I37
sg8
g9
sg10
I3
sg11
VH1A
p1704
sg13
I1
sasg24
(lp1705
(dp1706
g7
I122
sg27
VC0861155
p1707
sg10
I19
sg11
Vrhinoconjunctivitis
p1708
sg13
I1
sa(dp1709
g7
I100
sg27
VC2607914
p1710
sg10
I17
sg11
Vallergic rhinitis
p1711
sg13
I2
sasa(dp1712
g2
S'Consecutive patients suffering from allergic rhinitis or rhinoconjunctivitis were included and followed prospectively for 30 days from the prescription of a second generation H1A in monotherapy.\n'
p1713
sg4
(lp1714
(dp1715
g7
I175
sg8
g9
sg10
I3
sg11
VH1A
p1716
sg13
I1
sasg24
(lp1717
(dp1718
g7
I57
sg27
VC0861155
p1719
sg10
I19
sg11
Vrhinoconjunctivitis
p1720
sg13
I1
sa(dp1721
g7
I21
sg27
VC0683278
p1722
sg10
I9
sg11
Vsuffering
p1723
sg13
I1
sa(dp1724
g7
I36
sg27
VC2607914
p1725
sg10
I17
sg11
Vallergic rhinitis
p1726
sg13
I2
sasa(dp1727
g2
S'Antibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade.\n'
p1728
sg4
(lp1729
(dp1730
g7
I143
sg8
VP16401
p1731
sg10
I3
sg11
VH1b
p1732
sg13
I1
sasg24
(lp1733
(dp1734
g7
I34
sg27
VC0021400
p1735
sg10
I9
sg11
Vinfluenza
p1736
sg13
I1
sasa(dp1737
g2
S'We have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells.\n'
p1738
sg4
(lp1739
(dp1740
g7
I22
sg8
VP32243
p1741
sg10
I4
sg11
VOTX2
p1742
sg13
I1
sa(dp1743
g7
I163
sg8
g9
sg10
I5
sg11
VMertk
p1744
sg13
I1
sasg24
(lp1745
(dp1746
g7
I119
sg27
VC0035334
p1747
sg10
I20
sg11
Vretinitis pigmentosa
p1748
sg13
I2
sasa(dp1749
g2
S'Transplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.\n'
p1750
sg4
(lp1751
(dp1752
g7
I19
sg8
VP32243
p1753
sg10
I4
sg11
VOTX2
p1754
sg13
I1
sasg24
(lp1755
(dp1756
g7
I88
sg27
VC0035309
p1757
sg10
I16
sg11
Vretinal diseases
p1758
sg13
I2
sa(dp1759
g7
I151
sg27
VC0242383
p1760
sg10
I32
sg11
Vage-related macular degeneration
p1761
sg13
I3
sasa(dp1762
g2
S'Therapeutic restoration of OTX2 expression might help revive RPE and visual function in retinal diseases such as AMD.\n'
p1763
sg4
(lp1764
(dp1765
g7
I27
sg8
VP32243
p1766
sg10
I4
sg11
VOTX2
p1767
sg13
I1
sasg24
(lp1768
(dp1769
g7
I88
sg27
VC0035309
p1770
sg10
I16
sg11
Vretinal diseases
p1771
sg13
I2
sa(dp1772
g7
I113
sg27
VC0242383
p1773
sg10
I3
sg11
VAMD
p1774
sg13
I1
sasa(dp1775
g2
S'The retinal disease resembles conditional mice models that show slow photoreceptor degeneration secondary to loss of Otx2 function in the adult RPE.\n'
p1776
sg4
(lp1777
(dp1778
g7
I117
sg8
VP32243
p1779
sg10
I4
sg11
VOtx2
p1780
sg13
I1
sasg24
(lp1781
(dp1782
g7
I83
sg27
VC0043020
p1783
sg10
I22
sg11
Vdegeneration secondary
p1784
sg13
I2
sa(dp1785
g7
I4
sg27
VC0035309
p1786
sg10
I15
sg11
Vretinal disease
p1787
sg13
I2
sa(dp1788
g7
I69
sg27
VC1998028
p1789
sg10
I26
sg11
Vphotoreceptor degeneration
p1790
sg13
I2
sasa(dp1791
g2
S'When the beads were coated with amelogenin gene splice products (A+4 or A-4), the expression of osteo-chondrogenic markers (RP59, Sox9, or BSP) was also observed.\n'
p1792
sg4
(lp1793
(dp1794
g7
I32
sg8
g9
sg10
I31
sg11
Vamelogenin gene splice products
p1795
sg13
I4
sa(dp1796
g7
I130
sg8
VP48436
p1797
sg10
I4
sg11
VSox9
p1798
sg13
I1
sasg24
(lp1799
(dp1800
g7
I124
sg27
VC3151227
p1801
sg10
I4
sg11
VRP59
p1802
sg13
I1
sasa(dp1803
g2
S'This study has provided evidence that the regulation of the SVCT2 transporter plays an important role not only in T1D osteoporosis but also in other oxidative stress-related musculoskeletal complications.\n'
p1804
sg4
(lp1805
(dp1806
g7
I60
sg8
g9
sg10
I17
sg11
VSVCT2 transporter
p1807
sg13
I2
sasg24
(lp1808
(dp1809
g7
I118
sg27
VC0029456
p1810
sg10
I12
sg11
Vosteoporosis
p1811
sg13
I1
sa(dp1812
g7
I149
sg27
VC0242606
p1813
sg10
I16
sg11
Voxidative stress
p1814
sg13
I2
sasa(dp1815
g2
S'Autosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness.\n'
p1816
sg4
(lp1817
(dp1818
g7
I20
sg8
VP54868
p1819
sg10
I16
sg11
VHMG-CoA synthase
p1820
sg13
I2
sasg24
(lp1821
(dp1822
g7
I90
sg27
VC0020615
p1823
sg10
I12
sg11
Vhypoglycemia
p1824
sg13
I1
sa(dp1825
g7
I104
sg27
VC0042963
p1826
sg10
I8
sg11
Vvomiting
p1827
sg13
I1
sa(dp1828
g7
I128
sg27
VC0019209
p1829
sg10
I12
sg11
Vhepatomegaly
p1830
sg13
I1
sa(dp1831
g7
I24
sg27
VC2678439
p1832
sg10
I3
sg11
VCoA
p1833
sg13
I1
sa(dp1834
g7
I114
sg27
VC0023380
p1835
sg10
I8
sg11
Vlethargy
p1836
sg13
I1
sasa(dp1837
g2
S'Most frequent disease presentation in our patients was characterized with early and prominent oromandibular dystonia (OMD), followed by severe generalized dystonia and early loss of mobility within the first five years of prolonged disease duration (18.7 +/- 10.0 years).\n'
p1838
sg4
(lp1839
sg24
(lp1840
(dp1841
g7
I94
sg27
VC2242577
p1842
sg10
I22
sg11
Voromandibular dystonia
p1843
sg13
I2
sa(dp1844
g7
I118
sg27
VC3150833
p1845
sg10
I3
sg11
VOMD
p1846
sg13
I1
sa(dp1847
g7
I143
sg27
VC1848954
p1848
sg10
I20
sg11
Vgeneralized dystonia
p1849
sg13
I2
sasa(dp1850
g2
S'Eight out of 9 patients reached 7 significant clinical milestones (OMD, generalized dystonia, dysarthria, dysphagia, postural instability, gait difficulties, ADL dependency) in the first 4.6 years of disease course.\n'
p1851
sg4
(lp1852
sg24
(lp1853
(dp1854
g7
I72
sg27
VC1848954
p1855
sg10
I20
sg11
Vgeneralized dystonia
p1856
sg13
I2
sa(dp1857
g7
I139
sg27
VC0575081
p1858
sg10
I17
sg11
Vgait difficulties
p1859
sg13
I2
sa(dp1860
g7
I67
sg27
VC3150833
p1861
sg10
I3
sg11
VOMD
p1862
sg13
I1
sa(dp1863
g7
I106
sg27
VC0011168
p1864
sg10
I9
sg11
Vdysphagia
p1865
sg13
I1
sa(dp1866
g7
I94
sg27
VC0013362
p1867
sg10
I10
sg11
Vdysarthria
p1868
sg13
I1
sasa(dp1869
g2
S'A smoothelin-deficient mouse model may help to establish the role of smoothelin-A in intestinal contraction and provide a model for myogenic chronic intestinal pseudo-obstruction.\n'
p1870
sg4
(lp1871
sg24
(lp1872
(dp1873
g7
I96
sg27
VC1140999
p1874
sg10
I11
sg11
Vcontraction
p1875
sg13
I1
sa(dp1876
g7
I141
sg27
VC0238062
p1877
sg10
I37
sg11
Vchronic intestinal pseudo-obstruction
p1878
sg13
I3
sasa(dp1879
g2
S'The pathology of mice lacking smoothelin-A is reminiscent of that seen in patients with chronic intestinal pseudo-obstruction.\n'
p1880
sg4
(lp1881
sg24
(lp1882
(dp1883
g7
I4
sg27
VC0677042
p1884
sg10
I9
sg11
Vpathology
p1885
sg13
I1
sa(dp1886
g7
I88
sg27
VC0238062
p1887
sg10
I37
sg11
Vchronic intestinal pseudo-obstruction
p1888
sg13
I3
sasa(dp1889
g2
S'Hereditary tyrosinemia type 1 (HT1) is characterized by severe progressive liver disease and renal tubular dysfunction.\n'
p1890
sg4
(lp1891
sg24
(lp1892
(dp1893
g7
I0
sg27
VC0268483
p1894
sg10
I22
sg11
VHereditary tyrosinemia
p1895
sg13
I2
sa(dp1896
g7
I93
sg27
VC0151747
p1897
sg10
I25
sg11
Vrenal tubular dysfunction
p1898
sg13
I3
sa(dp1899
g7
I75
sg27
VC0023895
p1900
sg10
I13
sg11
Vliver disease
p1901
sg13
I2
sasa(dp1902
g2
S'If left untreated this deficiency of functional FAH leads to a buildup of toxic metabolites that can cause liver disease, kidney dysfunction and high mortality.\n'
p1903
sg4
(lp1904
(dp1905
g7
I48
sg8
VP16930
p1906
sg10
I3
sg11
VFAH
p1907
sg13
I1
sasg24
(lp1908
(dp1909
g7
I113
sg27
VC0022658
p1910
sg10
I15
sg11
Vdisease, kidney
p1911
sg13
I2
sa(dp1912
g7
I122
sg27
VC0151746
p1913
sg10
I18
sg11
Vkidney dysfunction
p1914
sg13
I2
sasa(dp1915
g2
S'In this study, we investigated whether fumarylacetoacetate hydrolase deficient (FAH-/-) pigs, a novel large-animal model of HT1, develop fibrosis and cirrhosis characteristic of the human disease.\n'
p1916
sg4
(lp1917
(dp1918
g7
I39
sg8
VP16930
p1919
sg10
I29
sg11
Vfumarylacetoacetate hydrolase
p1920
sg13
I2
sasg24
(lp1921
(dp1922
g7
I150
sg27
VC0023890
p1923
sg10
I9
sg11
Vcirrhosis
p1924
sg13
I1
sa(dp1925
g7
I137
sg27
VC0016059
p1926
sg10
I8
sg11
Vfibrosis
p1927
sg13
I1
sasa(dp1928
g2
S'Under conditions of low-dose NTBC, FAH-/- pigs developed liver fibrosis and portal hypertension, and thus may serve as a large-animal model of chronic liver disease.\n'
p1929
sg4
(lp1930
sg24
(lp1931
(dp1932
g7
I57
sg27
VC0239946
p1933
sg10
I14
sg11
Vliver fibrosis
p1934
sg13
I2
sa(dp1935
g7
I76
sg27
VC0020541
p1936
sg10
I19
sg11
Vportal hypertension
p1937
sg13
I2
sa(dp1938
g7
I143
sg27
VC0341439
p1939
sg10
I21
sg11
Vchronic liver disease
p1940
sg13
I3
sasa(dp1941
g2
S'Fah-deficient mice and pigs are phenotypically analogous to human HT1, but do not recapitulate all the chronic features of the human disorder, especially liver fibrosis and cirrhosis.\n'
p1942
sg4
(lp1943
(dp1944
g7
I0
sg8
VP16930
p1945
sg10
I3
sg11
VFah
p1946
sg13
I1
sasg24
(lp1947
(dp1948
g7
I154
sg27
VC0239946
p1949
sg10
I14
sg11
Vliver fibrosis
p1950
sg13
I2
sa(dp1951
g7
I173
sg27
VC0023890
p1952
sg10
I9
sg11
Vcirrhosis
p1953
sg13
I1
sasa(dp1954
g2
S'More importantly, the Fah(-/-) rats developed remarkable liver fibrosis and cirrhosis, which have not been observed in Fah mutant mice or pigs.\n'
p1955
sg4
(lp1956
(dp1957
g7
I22
sg8
VP16930
p1958
sg10
I8
sg11
VFah(-/-)
p1959
sg13
I1
sa(dp1960
g7
I119
sg8
VP16930
p1961
sg10
I10
sg11
VFah mutant
p1962
sg13
I2
sasg24
(lp1963
(dp1964
g7
I57
sg27
VC0239946
p1965
sg10
I14
sg11
Vliver fibrosis
p1966
sg13
I2
sa(dp1967
g7
I76
sg27
VC0023890
p1968
sg10
I9
sg11
Vcirrhosis
p1969
sg13
I1
sa(dp1970
g7
I123
sg27
VC0596988
p1971
sg10
I6
sg11
Vmutant
p1972
sg13
I1
sasa(dp1973
g2
S'Moreover, the highly efficient repopulation of hepatocytes in Fah(-/-) livers prevented the progression of liver fibrosis to cirrhosis and in turn restored liver architecture.\n'
p1974
sg4
(lp1975
(dp1976
g7
I62
sg8
VP16930
p1977
sg10
I8
sg11
VFah(-/-)
p1978
sg13
I1
sasg24
(lp1979
(dp1980
g7
I125
sg27
VC0023890
p1981
sg10
I9
sg11
Vcirrhosis
p1982
sg13
I1
sa(dp1983
g7
I107
sg27
VC0239946
p1984
sg10
I14
sg11
Vliver fibrosis
p1985
sg13
I2
sasa(dp1986
g2
S'These results indicate that Fah(-/-) rats may be used as an animal model of HT1 with liver cirrhosis.\n'
p1987
sg4
(lp1988
(dp1989
g7
I28
sg8
VP16930
p1990
sg10
I3
sg11
VFah
p1991
sg13
I1
sasg24
(lp1992
(dp1993
g7
I85
sg27
VC0023890
p1994
sg10
I15
sg11
Vliver cirrhosis
p1995
sg13
I2
sasa(dp1996
g2
S'Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).\n'
p1997
sg4
(lp1998
(dp1999
g7
I178
sg8
g9
sg10
I8
sg11
VARHGEF12
p2000
sg13
I1
sa(dp2001
g7
I268
sg8
g9
sg10
I5
sg11
VGLIS3
p2002
sg13
I1
sa(dp2003
g7
I201
sg8
g9
sg10
I5
sg11
VATXN2
p2004
sg13
I1
sa(dp2005
g7
I150
sg8
g9
sg10
I4
sg11
VGMDS
p2006
sg13
I1
sa(dp2007
g7
I255
sg8
g9
sg10
I5
sg11
VEPDR1
p2008
sg13
I1
sa(dp2009
g7
I194
sg8
g9
sg10
I5
sg11
VFOXC1
p2010
sg13
I1
sa(dp2011
g7
I162
sg8
g9
sg10
I6
sg11
VTGFBR3
p2012
sg13
I1
sa(dp2013
g7
I283
sg8
g9
sg10
I11
sg11
VDPM2-FAM102
p2014
sg13
I1
sa(dp2015
g7
I275
sg8
g9
sg10
I6
sg11
VFERMT2
p2016
sg13
I1
sa(dp2017
g7
I156
sg8
g9
sg10
I4
sg11
VPMM2
p2018
sg13
I1
sa(dp2019
g7
I188
sg8
g9
sg10
I4
sg11
VGAS7
p2020
sg13
I1
sa(dp2021
g7
I262
sg8
VP28329
p2022
sg10
I4
sg11
VCHAT
p2023
sg13
I1
sa(dp2024
g7
I143
sg8
g9
sg10
I5
sg11
VAFAP1
p2025
sg13
I1
sasg24
(lp2026
(dp2027
g7
I60
sg27
VC0017601
p2028
sg10
I8
sg11
Vglaucoma
p2029
sg13
I1
sa(dp2030
g7
I114
sg27
VC0017612
p2031
sg10
I19
sg11
Vopen-angle glaucoma
p2032
sg13
I2
sa(dp2033
g7
I323
sg27
VC0206368
p2034
sg10
I3
sg11
VXFS
p2035
sg13
I1
sa(dp2036
g7
I100
sg27
VC0339573
p2037
sg10
I4
sg11
VPOAG
p2038
sg13
I1
sa(dp2039
g7
I301
sg27
VC0206368
p2040
sg10
I20
sg11
Vexfoliation syndrome
p2041
sg13
I2
sa(dp2042
g7
I223
sg27
VC0017606
p2043
sg10
I30
sg11
Vprimary angle-closure glaucoma
p2044
sg13
I3
sa(dp2045
g7
I60
sg27
VC0017601
p2046
sg10
I8
sg11
Vglaucoma
p2047
sg13
I1
sasa(dp2048
g2
S'Recently, a genome-wide association study identified genetic variations in ITGA4 and HLA-DRB1 that affect the LMR levels and were widely believed to be susceptibility genes for autoimmune diseases, including rheumatoid arthritis (RA).\n'
p2049
sg4
(lp2050
(dp2051
g7
I85
sg8
VP30486
p2052
sg10
I3
sg11
VHLA
p2053
sg13
I1
sa(dp2054
g7
I89
sg8
g9
sg10
I4
sg11
VDRB1
p2055
sg13
I1
sa(dp2056
g7
I75
sg8
VP13612
p2057
sg10
I5
sg11
VITGA4
p2058
sg13
I1
sasg24
(lp2059
(dp2060
g7
I208
sg27
VC0003873
p2061
sg10
I20
sg11
Vrheumatoid arthritis
p2062
sg13
I2
sa(dp2063
g7
I230
sg27
VC0003873
p2064
sg10
I2
sg11
VRA
p2065
sg13
I1
sa(dp2066
g7
I177
sg27
VC0004364
p2067
sg10
I19
sg11
Vautoimmune diseases
p2068
sg13
I2
sasa(dp2069
g2
S'To evaluate serum levels of fractalkine (FKN), a mediator of leukocyte transmigration, C-reactive protein (CRP) and expression of integrins CD11a and CD49d on peripheral blood lymphocytes in systemic sclerosis (SSc) and to investigate whether they are modulated by intravenous prostaglandin E1 (PGE1).\n'
p2070
sg4
(lp2071
(dp2072
g7
I140
sg8
VP20701
p2073
sg10
I5
sg11
VCD11a
p2074
sg13
I1
sa(dp2075
g7
I150
sg8
VP13612
p2076
sg10
I5
sg11
VCD49d
p2077
sg13
I1
sa(dp2078
g7
I107
sg8
VP02741
p2079
sg10
I3
sg11
VCRP
p2080
sg13
I1
sa(dp2081
g7
I87
sg8
VP02741
p2082
sg10
I18
sg11
VC-reactive protein
p2083
sg13
I2
sasg24
(lp2084
(dp2085
g7
I211
sg27
VC0036421
p2086
sg10
I3
sg11
VSSc
p2087
sg13
I1
sa(dp2088
g7
I191
sg27
VC0036421
p2089
sg10
I18
sg11
Vsystemic sclerosis
p2090
sg13
I2
sasa(dp2091
g2
S'Prostaglandin E1 down-regulates serum fractalkine level, as well as CD11a and CD49d expression on peripheral blood lymphocytes, which suggests additional mechanisms in which this vasodilatatory agent exerts its efficacy in systemic sclerosis.\n'
p2092
sg4
(lp2093
(dp2094
g7
I78
sg8
VP13612
p2095
sg10
I5
sg11
VCD49d
p2096
sg13
I1
sa(dp2097
g7
I68
sg8
VP20701
p2098
sg10
I5
sg11
VCD11a
p2099
sg13
I1
sasg24
(lp2100
(dp2101
g7
I223
sg27
VC0036421
p2102
sg10
I18
sg11
Vsystemic sclerosis
p2103
sg13
I2
sasa(dp2104
g2
S'MR-1S directly phosphorylates and activates the MEK-ERK-RSK pathway to accelerate cancer growth and facilitates metastasis by activating the MLC2-FAK-AKT pathway.\n'
p2105
sg4
(lp2106
(dp2107
g7
I141
sg8
VP24844
p2108
sg10
I4
sg11
VMLC2
p2109
sg13
I1
sa(dp2110
g7
I150
sg8
g9
sg10
I3
sg11
VAKT
p2111
sg13
I1
sa(dp2112
g7
I48
sg8
VP45985
p2113
sg10
I3
sg11
VMEK
p2114
sg13
I1
sa(dp2115
g7
I52
sg8
VP29323
p2116
sg10
I3
sg11
VERK
p2117
sg13
I1
sa(dp2118
g7
I146
sg8
g9
sg10
I3
sg11
VFAK
p2119
sg13
I1
sa(dp2120
g7
I0
sg8
VP08235
p2121
sg10
I5
sg11
VMR-1S
p2122
sg13
I1
sa(dp2123
g7
I56
sg8
VP51812
p2124
sg10
I3
sg11
VRSK
p2125
sg13
I1
sasg24
(lp2126
(dp2127
g7
I112
sg27
VC0027627
p2128
sg10
I10
sg11
Vmetastasis
p2129
sg13
I1
sa(dp2130
g7
I82
sg27
VC0006826
p2131
sg10
I6
sg11
Vcancer
p2132
sg13
I1
sasa(dp2133
g2
S'After overexpressing TMEM17, levels of p-ERK and its downstream molecules, p-P90RSK and Snail, were down-regulated, while levels of Occludin and Zo-1 were up-regulated, which result in the inhibition of invasion and migration ability of lung cancer cells.\n'
p2134
sg4
(lp2135
(dp2136
g7
I132
sg8
g9
sg10
I8
sg11
VOccludin
p2137
sg13
I1
sa(dp2138
g7
I41
sg8
VP29323
p2139
sg10
I3
sg11
VERK
p2140
sg13
I1
sa(dp2141
g7
I145
sg8
g9
sg10
I4
sg11
VZo-1
p2142
sg13
I1
sa(dp2143
g7
I21
sg8
g9
sg10
I6
sg11
VTMEM17
p2144
sg13
I1
sasg24
(lp2145
(dp2146
g7
I203
sg27
VC2699153
p2147
sg10
I8
sg11
Vinvasion
p2148
sg13
I1
sa(dp2149
g7
I237
sg27
VC0684249
p2150
sg10
I11
sg11
Vlung cancer
p2151
sg13
I2
sasa(dp2152
g2
S'Herein, to understand the underlying relationship between obesity and brain tumors, we investigated the effect of leptin, alone or in combination with sPLA2-IIA on astrocytoma cell functions.\n'
p2153
sg4
(lp2154
(dp2155
g7
I114
sg8
VP41159
p2156
sg10
I6
sg11
Vleptin
p2157
sg13
I1
sa(dp2158
g7
I151
sg8
VP14555
p2159
sg10
I9
sg11
VsPLA2-IIA
p2160
sg13
I1
sasg24
(lp2161
(dp2162
g7
I164
sg27
VC0004114
p2163
sg10
I11
sg11
Vastrocytoma
p2164
sg13
I1
sa(dp2165
g7
I70
sg27
VC0006118
p2166
sg10
I12
sg11
Vbrain tumors
p2167
sg13
I2
sa(dp2168
g7
I58
sg27
VC0028754
p2169
sg10
I7
sg11
Vobesity
p2170
sg13
I1
sasa(dp2171
g2
S'PLA2g2a was elevated with hypothyroidism and high fat diets which may contribute to the low grade inflammation associated with hypothyroidism and diet induced obesity.\n'
p2172
sg4
(lp2173
(dp2174
g7
I0
sg8
VP14555
p2175
sg10
I7
sg11
VPLA2g2a
p2176
sg13
I1
sasg24
(lp2177
(dp2178
g7
I26
sg27
VC0020676
p2179
sg10
I14
sg11
Vhypothyroidism
p2180
sg13
I1
sa(dp2181
g7
I26
sg27
VC0020676
p2182
sg10
I14
sg11
Vhypothyroidism
p2183
sg13
I1
sa(dp2184
g7
I98
sg27
VC0021368
p2185
sg10
I12
sg11
Vinflammation
p2186
sg13
I1
sa(dp2187
g7
I159
sg27
VC0028754
p2188
sg10
I7
sg11
Vobesity
p2189
sg13
I1
sasa(dp2190
g2
S'There were significant correlations between age, visceral obesity, MPO, sPLA2, and SAA (r = 0.43; p = 0.00; r = 0.30; p = 0.00; r = 0.28; p = 0.00 and r = 0.53; p = 0.00).\n'
p2191
sg4
(lp2192
(dp2193
g7
I67
sg8
VP05164
p2194
sg10
I3
sg11
VMPO
p2195
sg13
I1
sa(dp2196
g7
I72
sg8
VP14555
p2197
sg10
I5
sg11
VsPLA2
p2198
sg13
I1
sasg24
(lp2199
(dp2200
g7
I49
sg27
VC2936179
p2201
sg10
I16
sg11
Vvisceral obesity
p2202
sg13
I2
sasa(dp2203
g2
S'We suggest that pla2g2a may have a causal relationship with chronic adiposity and metabolic syndrome and that its inhibition in vivo may be a valuable new approach to treat obesity, type 2 diabetes, and metabolic dysfunction in humans.\n'
p2204
sg4
(lp2205
(dp2206
g7
I16
sg8
VP14555
p2207
sg10
I7
sg11
Vpla2g2a
p2208
sg13
I1
sasg24
(lp2209
(dp2210
g7
I182
sg27
VC0011860
p2211
sg10
I15
sg11
Vtype 2 diabetes
p2212
sg13
I3
sa(dp2213
g7
I68
sg27
VC0028754
p2214
sg10
I9
sg11
Vadiposity
p2215
sg13
I1
sa(dp2216
g7
I173
sg27
VC0028754
p2217
sg10
I7
sg11
Vobesity
p2218
sg13
I1
sa(dp2219
g7
I82
sg27
VC0524620
p2220
sg10
I18
sg11
Vmetabolic syndrome
p2221
sg13
I2
sasa(dp2222
g2
S'Trypanosoma brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and metabolism by ornithine decarboxylase (ODC) for survival.\n'
p2223
sg4
(lp2224
(dp2225
g7
I133
sg8
VP11926
p2226
sg10
I23
sg11
Vornithine decarboxylase
p2227
sg13
I2
sa(dp2228
g7
I158
sg8
VP11926
p2229
sg10
I3
sg11
VODC
p2230
sg13
I1
sa(dp2231
g7
I82
sg8
g9
sg10
I3
sg11
VHAT
p2232
sg13
I1
sa(dp2233
g7
I51
sg8
g9
sg10
I29
sg11
Vhuman African trypanosomiasis
p2234
sg13
I3
sasg24
(lp2235
(dp2236
g7
I57
sg27
VC0041228
p2237
sg10
I23
sg11
VAfrican trypanosomiasis
p2238
sg13
I2
sasa(dp2239
g2
S'Furthermore, the molecular dynamics simulation work reveals that ZINC67909154 could be a potent inhibitor and this compound can be used to combat VL disease Conclusion: This study concludes that ZINC67909154 has the great potential to inhibit L. donovani ODC and would add to the drug discovery process against visceral leishmaniasis.\n'
p2240
sg4
(lp2241
sg24
(lp2242
(dp2243
g7
I311
sg27
VC0023290
p2244
sg10
I22
sg11
Vvisceral leishmaniasis
p2245
sg13
I2
sa(dp2246
g7
I269
sg27
VC0004269
p2247
sg10
I3
sg11
Vadd
p2248
sg13
I1
sasa(dp2249
g2
S'arginase (ARG), ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (AdoMetDC), spermidine synthase (SpdS), trypanothione synthetase (TryS or TSA), trypanothione reductase (TryR or TR), tryparedoxin peroxidase (TXNPx), deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) are promising targets for the development of new drugs against leishmaniasis.\n'
p2250
sg4
(lp2251
(dp2252
g7
I0
sg8
VP11926
p2253
sg10
I39
sg11
Varginase (ARG), ornithine decarboxylase
p2254
sg13
I4
sa(dp2255
g7
I266
sg8
g9
sg10
I25
sg11
Vdeoxyhypusine hydroxylase
p2256
sg13
I2
sa(dp2257
g7
I115
sg8
VP35453
p2258
sg10
I4
sg11
VSpdS
p2259
sg13
I1
sa(dp2260
g7
I225
sg8
VP30041
p2261
sg10
I5
sg11
VTXNPx
p2262
sg13
I1
sa(dp2263
g7
I83
sg8
VP17707
p2264
sg10
I8
sg11
VAdoMetDC
p2265
sg13
I1
sa(dp2266
g7
I156
sg8
VP32119
p2267
sg10
I3
sg11
VTSA
p2268
sg13
I1
sa(dp2269
g7
I94
sg8
VP19623
p2270
sg10
I19
sg11
Vspermidine synthase
p2271
sg13
I2
sa(dp2272
g7
I257
sg8
VP49366
p2273
sg10
I3
sg11
VDHS
p2274
sg13
I1
sa(dp2275
g7
I41
sg8
VP11926
p2276
sg10
I3
sg11
VODC
p2277
sg13
I1
sa(dp2278
g7
I162
sg8
g9
sg10
I23
sg11
Vtrypanothione reductase
p2279
sg13
I2
sa(dp2280
g7
I200
sg8
VP30041
p2281
sg10
I23
sg11
Vtryparedoxin peroxidase
p2282
sg13
I2
sa(dp2283
g7
I293
sg8
g9
sg10
I4
sg11
VDOHH
p2284
sg13
I1
sa(dp2285
g7
I47
sg8
VP17707
p2286
sg10
I34
sg11
VS-adenosylmethionine decarboxylase
p2287
sg13
I2
sa(dp2288
g7
I233
sg8
VP49366
p2289
sg10
I22
sg11
Vdeoxyhypusine synthase
p2290
sg13
I2
sasg24
(lp2291
(dp2292
g7
I257
sg27
VC0272051
p2293
sg10
I3
sg11
VDHS
p2294
sg13
I1
sa(dp2295
g7
I362
sg27
VC0023281
p2296
sg10
I13
sg11
Vleishmaniasis
p2297
sg13
I1
sasa(dp2298
g2
S'The plasma levels of arginase I, ornithine decarboxylase (ODC), transforming growth factor Beta (TGF-Beta), and prostaglandin E2 (PGE2) were higher in patients with DCL, compared with patients with localized cutaneous leishmaniasis (LCL) or with controls from an area of endemicity.\n'
p2299
sg4
(lp2300
(dp2301
g7
I33
sg8
VP11926
p2302
sg10
I23
sg11
Vornithine decarboxylase
p2303
sg13
I2
sa(dp2304
g7
I21
sg8
VP05089
p2305
sg10
I10
sg11
Varginase I
p2306
sg13
I2
sa(dp2307
g7
I64
sg8
VP18075
p2308
sg10
I31
sg11
Vtransforming growth factor Beta
p2309
sg13
I4
sa(dp2310
g7
I58
sg8
VP11926
p2311
sg10
I3
sg11
VODC
p2312
sg13
I1
sa(dp2313
g7
I97
sg8
VP18075
p2314
sg10
I8
sg11
VTGF-Beta
p2315
sg13
I1
sasg24
(lp2316
(dp2317
g7
I208
sg27
VC0023283
p2318
sg10
I23
sg11
Vcutaneous leishmaniasis
p2319
sg13
I2
sasa(dp2320
g2
S'Immunohistochemistry confirmed that arginase I, ODC, and cyclooxygenase2 expression was higher in lesion biopsy specimens from patients with DCL than in those from patients with LCL.\n'
p2321
sg4
(lp2322
(dp2323
g7
I48
sg8
VP11926
p2324
sg10
I3
sg11
VODC
p2325
sg13
I1
sa(dp2326
g7
I36
sg8
VP05089
p2327
sg10
I10
sg11
Varginase I
p2328
sg13
I2
sasg24
(lp2329
sa(dp2330
g2
S'Our data implicate arginase I, ODC, PGE2, and TGF-Beta in the failure to mount an efficient immune response and suggest perspectives in the development of new strategies for therapeutic intervention for patients with DCL.\n'
p2331
sg4
(lp2332
(dp2333
g7
I31
sg8
VP11926
p2334
sg10
I3
sg11
VODC
p2335
sg13
I1
sa(dp2336
g7
I19
sg8
VP05089
p2337
sg10
I10
sg11
Varginase I
p2338
sg13
I2
sa(dp2339
g7
I46
sg8
VP18075
p2340
sg10
I8
sg11
VTGF-Beta
p2341
sg13
I1
sasg24
(lp2342
sa(dp2343
g2
S'The active form of vitamin B6, pyridoxal 5-phosphate, is, besides its antioxidative properties, a cofactor for a variety of essential enzymes present in the malaria parasite which includes the ornithine decarboxylase (ODC, synthesis of polyamines), the aspartate aminotransferase (AspAT, involved in the protein biosynthesis), and the serine hydroxymethyltransferase (SHMT, a key enzyme within the folate metabolism).\n'
p2344
sg4
(lp2345
(dp2346
g7
I335
sg8
VP34896
p2347
sg10
I31
sg11
Vserine hydroxymethyltransferase
p2348
sg13
I2
sa(dp2349
g7
I281
sg8
VP17174
p2350
sg10
I5
sg11
VAspAT
p2351
sg13
I1
sa(dp2352
g7
I218
sg8
VP11926
p2353
sg10
I3
sg11
VODC
p2354
sg13
I1
sa(dp2355
g7
I193
sg8
VP11926
p2356
sg10
I23
sg11
Vornithine decarboxylase
p2357
sg13
I2
sa(dp2358
g7
I253
sg8
VP17174
p2359
sg10
I26
sg11
Vaspartate aminotransferase
p2360
sg13
I2
sa(dp2361
g7
I368
sg8
VP34896
p2362
sg10
I4
sg11
VSHMT
p2363
sg13
I1
sasg24
(lp2364
(dp2365
g7
I157
sg27
VC0024530
p2366
sg10
I7
sg11
Vmalaria
p2367
sg13
I1
sasa(dp2368
g2
S'Alfa-Difluoromethylornithine (DFMO), a potent drug used for the treatment of African sleeping sickness is an irreversible inhibitor of ornithine decarboxylase (ODC), the first rate limiting enzyme of polyamine biosynthesis.\n'
p2369
sg4
(lp2370
(dp2371
g7
I135
sg8
VP11926
p2372
sg10
I23
sg11
Vornithine decarboxylase
p2373
sg13
I2
sa(dp2374
g7
I160
sg8
VP11926
p2375
sg10
I3
sg11
VODC
p2376
sg13
I1
sasg24
(lp2377
(dp2378
g7
I77
sg27
VC0041228
p2379
sg10
I25
sg11
VAfrican sleeping sickness
p2380
sg13
I3
sasa(dp2381
g2
S'This is the first study from north India reporting CYP1B1 mutations in Axenfeld-Rieger syndrome with bilateral buphthalmos and early onset glaucoma.\n'
p2382
sg4
(lp2383
(dp2384
g7
I35
sg8
g9
sg10
I22
sg11
VIndia reporting CYP1B1
p2385
sg13
I3
sasg24
(lp2386
(dp2387
g7
I71
sg27
VC0265341
p2388
sg10
I24
sg11
VAxenfeld-Rieger syndrome
p2389
sg13
I2
sa(dp2390
g7
I139
sg27
VC0017601
p2391
sg10
I8
sg11
Vglaucoma
p2392
sg13
I1
sa(dp2393
g7
I111
sg27
VC0020302
p2394
sg10
I11
sg11
Vbuphthalmos
p2395
sg13
I1
sasa(dp2396
g2
S'Purported BS2 cases may be divided into: (1) Bardet-Biedl syndrome with fortuitous coloboma or aniridia, (2) BS2 sensu stricto, a recessively inherited syndrome of sexual infantilism, short stature, coloboma, and preaxial polydactyly without obesity, only known from the original report, (3) a "new" dominantly inherited form of colobomatous microphthalmia occasionally associated with obesity, hypogonadism, and mental retardation, to which our observations belong.\n'
p2397
sg4
(lp2398
sg24
(lp2399
(dp2400
g7
I58
sg27
VC0039082
p2401
sg10
I8
sg11
Vsyndrome
p2402
sg13
I1
sa(dp2403
g7
I213
sg27
VC0345354
p2404
sg10
I20
sg11
Vpreaxial polydactyly
p2405
sg13
I2
sa(dp2406
g7
I184
sg27
VC0013336
p2407
sg10
I13
sg11
Vshort stature
p2408
sg13
I2
sa(dp2409
g7
I164
sg27
VC0242341
p2410
sg10
I18
sg11
Vsexual infantilism
p2411
sg13
I2
sa(dp2412
g7
I45
sg27
VC0752166
p2413
sg10
I21
sg11
VBardet-Biedl syndrome
p2414
sg13
I2
sa(dp2415
g7
I95
sg27
VC0003076
p2416
sg10
I8
sg11
Vaniridia
p2417
sg13
I1
sa(dp2418
g7
I413
sg27
VC0025362
p2419
sg10
I18
sg11
Vmental retardation
p2420
sg13
I2
sa(dp2421
g7
I83
sg27
VC0009363
p2422
sg10
I8
sg11
Vcoloboma
p2423
sg13
I1
sa(dp2424
g7
I83
sg27
VC0009363
p2425
sg10
I8
sg11
Vcoloboma
p2426
sg13
I1
sa(dp2427
g7
I242
sg27
VC0028754
p2428
sg10
I7
sg11
Vobesity
p2429
sg13
I1
sa(dp2430
g7
I329
sg27
VC2931500
p2431
sg10
I27
sg11
Vcolobomatous microphthalmia
p2432
sg13
I2
sa(dp2433
g7
I395
sg27
VC0020619
p2434
sg10
I12
sg11
Vhypogonadism
p2435
sg13
I1
sa(dp2436
g7
I242
sg27
VC0028754
p2437
sg10
I7
sg11
Vobesity
p2438
sg13
I1
sasa(dp2439
g2
S'Ganglioneuromas (GNs) are benign tumors resulting from neural crest tissue.\n'
p2440
sg4
(lp2441
sg24
(lp2442
(dp2443
g7
I17
sg27
VC0017075
p2444
sg10
I3
sg11
VGNs
p2445
sg13
I1
sa(dp2446
g7
I26
sg27
VC0086692
p2447
sg10
I13
sg11
Vbenign tumors
p2448
sg13
I2
sa(dp2449
g7
I0
sg27
VC0017075
p2450
sg10
I15
sg11
VGanglioneuromas
p2451
sg13
I1
sa(dp2452
g7
I62
sg27
VC0206138
p2453
sg10
I5
sg11
Vcrest
p2454
sg13
I1
sasa(dp2455
g2
S'Adrenal ganglioneuromas (GNs) constitute rare, differentiated tumors which originate from neural crest cells.\n'
p2456
sg4
(lp2457
sg24
(lp2458
(dp2459
g7
I62
sg27
VC0027651
p2460
sg10
I6
sg11
Vtumors
p2461
sg13
I1
sa(dp2462
g7
I97
sg27
VC0206138
p2463
sg10
I5
sg11
Vcrest
p2464
sg13
I1
sa(dp2465
g7
I8
sg27
VC0017075
p2466
sg10
I15
sg11
Vganglioneuromas
p2467
sg13
I1
sa(dp2468
g7
I25
sg27
VC0017075
p2469
sg10
I3
sg11
VGNs
p2470
sg13
I1
sasa(dp2471
g2
S'Ganglioneuromas (GNs) are hamartomatous tumors derived from the autonomic nervous system.\n'
p2472
sg4
(lp2473
sg24
(lp2474
(dp2475
g7
I74
sg27
VC0027769
p2476
sg10
I7
sg11
Vnervous
p2477
sg13
I1
sa(dp2478
g7
I17
sg27
VC0017075
p2479
sg10
I3
sg11
VGNs
p2480
sg13
I1
sa(dp2481
g7
I0
sg27
VC0017075
p2482
sg10
I15
sg11
VGanglioneuromas
p2483
sg13
I1
sa(dp2484
g7
I40
sg27
VC0027651
p2485
sg10
I6
sg11
Vtumors
p2486
sg13
I1
sa(dp2487
g7
I26
sg27
VC0018552
p2488
sg10
I13
sg11
Vhamartomatous
p2489
sg13
I1
sasa(dp2490
g2
S'GNs are categorized into three different morphological subtypes, namely, polypoid GN, ganglioneuromatous polyposis, and diffuse ganglioneuromatosis.\n'
p2491
sg4
(lp2492
(dp2493
g7
I0
sg8
VP15586
p2494
sg10
I3
sg11
VGNs
p2495
sg13
I1
sasg24
(lp2496
(dp2497
g7
I105
sg27
VC0334108
p2498
sg10
I9
sg11
Vpolyposis
p2499
sg13
I1
sa(dp2500
g7
I128
sg27
VC0334595
p2501
sg10
I19
sg11
Vganglioneuromatosis
p2502
sg13
I1
sasa(dp2503
g2
S'Ganglioneuromas (GNs) arising from neural crest sympathogonia are rare benign neurogenic tumors.\n'
p2504
sg4
(lp2505
sg24
(lp2506
(dp2507
g7
I89
sg27
VC0027651
p2508
sg10
I6
sg11
Vtumors
p2509
sg13
I1
sa(dp2510
g7
I17
sg27
VC0017075
p2511
sg10
I3
sg11
VGNs
p2512
sg13
I1
sa(dp2513
g7
I0
sg27
VC0017075
p2514
sg10
I15
sg11
VGanglioneuromas
p2515
sg13
I1
sa(dp2516
g7
I42
sg27
VC0206138
p2517
sg10
I5
sg11
Vcrest
p2518
sg13
I1
sasa(dp2519
g2
S'Ganglioneuromas (GNs) are neural crest cell-derived tumors and rarely occur in the adrenal gland.\n'
p2520
sg4
(lp2521
sg24
(lp2522
(dp2523
g7
I17
sg27
VC0017075
p2524
sg10
I3
sg11
VGNs
p2525
sg13
I1
sa(dp2526
g7
I0
sg27
VC0017075
p2527
sg10
I15
sg11
VGanglioneuromas
p2528
sg13
I1
sa(dp2529
g7
I52
sg27
VC0027651
p2530
sg10
I6
sg11
Vtumors
p2531
sg13
I1
sa(dp2532
g7
I33
sg27
VC0206138
p2533
sg10
I5
sg11
Vcrest
p2534
sg13
I1
sasa(dp2535
g2
S'Ganglioneuromas (GNs) are the rarest and most benign of the neuroblastic tumors.\n'
p2536
sg4
(lp2537
sg24
(lp2538
(dp2539
g7
I17
sg27
VC0017075
p2540
sg10
I3
sg11
VGNs
p2541
sg13
I1
sa(dp2542
g7
I0
sg27
VC0017075
p2543
sg10
I15
sg11
VGanglioneuromas
p2544
sg13
I1
sa(dp2545
g7
I73
sg27
VC0027651
p2546
sg10
I6
sg11
Vtumors
p2547
sg13
I1
sasa(dp2548
g2
S'Ganglioneuromas (GNs) are rare benign tumors and their association with neurofibromatosis type 1 (NF-1) is especially uncommon.\n'
p2549
sg4
(lp2550
(dp2551
g7
I72
sg8
VP21359
p2552
sg10
I24
sg11
Vneurofibromatosis type 1
p2553
sg13
I3
sa(dp2554
g7
I98
sg8
VP21359
p2555
sg10
I4
sg11
VNF-1
p2556
sg13
I1
sasg24
(lp2557
(dp2558
g7
I72
sg27
VC0027831
p2559
sg10
I24
sg11
Vneurofibromatosis type 1
p2560
sg13
I3
sa(dp2561
g7
I17
sg27
VC0017075
p2562
sg10
I3
sg11
VGNs
p2563
sg13
I1
sa(dp2564
g7
I98
sg27
VC0027831
p2565
sg10
I4
sg11
VNF-1
p2566
sg13
I1
sa(dp2567
g7
I31
sg27
VC0086692
p2568
sg10
I13
sg11
Vbenign tumors
p2569
sg13
I2
sa(dp2570
g7
I0
sg27
VC0017075
p2571
sg10
I15
sg11
VGanglioneuromas
p2572
sg13
I1
sasa(dp2573
g2
S'Four of eight T1D-specific regions contained known type 2 diabetes (T2D) candidate genes (COBL, GLIS3, RNLS and BCAR1), suggesting a shared cellular etiology.\n'
p2574
sg4
(lp2575
(dp2576
g7
I103
sg8
g9
sg10
I4
sg11
VRNLS
p2577
sg13
I1
sa(dp2578
g7
I90
sg8
g9
sg10
I4
sg11
VCOBL
p2579
sg13
I1
sa(dp2580
g7
I96
sg8
g9
sg10
I5
sg11
VGLIS3
p2581
sg13
I1
sa(dp2582
g7
I112
sg8
VP56945
p2583
sg10
I5
sg11
VBCAR1
p2584
sg13
I1
sasg24
(lp2585
(dp2586
g7
I68
sg27
VC0011860
p2587
sg10
I3
sg11
VT2D
p2588
sg13
I1
sa(dp2589
g7
I51
sg27
VC0011860
p2590
sg10
I15
sg11
Vtype 2 diabetes
p2591
sg13
I3
sasa(dp2592
g2
S'Autoantibodies to insulin (IAA), GAD (GADA), insulinoma-associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured in follow-up sera, and genotyping for type 1 diabetes susceptibility genes (HLA-DR/HLA-DQ, INS variable number of tandem repeats [VNTR] and single nucleotide polymorphisms at PTPN22, PTPN2, ERBB3, IL2, SH2B3, CTLA4, IFIH1, KIAA0350 [also known as CLEC16A], CD25, IL18RAP, IL10, COBL) was performed on the DNA samples of children born to a parent with type 1 diabetes and prospectively followed from birth for up to 22 years.\n'
p2593
sg4
(lp2594
(dp2595
g7
I353
sg8
g9
sg10
I8
sg11
VKIAA0350
p2596
sg13
I1
sa(dp2597
g7
I206
sg8
VP30486
p2598
sg10
I6
sg11
VHLA-DR
p2599
sg13
I1
sa(dp2600
g7
I393
sg8
g9
sg10
I7
sg11
VIL18RAP
p2601
sg13
I1
sa(dp2602
g7
I320
sg8
VP21860
p2603
sg10
I5
sg11
VERBB3
p2604
sg13
I1
sa(dp2605
g7
I89
sg8
g9
sg10
I18
sg11
Vzinc transporter 8
p2606
sg13
I3
sa(dp2607
g7
I305
sg8
VP17706
p2608
sg10
I5
sg11
VPTPN2
p2609
sg13
I1
sa(dp2610
g7
I206
sg8
VP30486
p2611
sg10
I3
sg11
VHLA
p2612
sg13
I1
sa(dp2613
g7
I305
sg8
g9
sg10
I6
sg11
VPTPN22
p2614
sg13
I1
sa(dp2615
g7
I377
sg8
g9
sg10
I7
sg11
VCLEC16A
p2616
sg13
I1
sa(dp2617
g7
I339
sg8
VP16410
p2618
sg10
I5
sg11
VCTLA4
p2619
sg13
I1
sa(dp2620
g7
I402
sg8
VP22301
p2621
sg10
I4
sg11
VIL10
p2622
sg13
I1
sa(dp2623
g7
I408
sg8
g9
sg10
I4
sg11
VCOBL
p2624
sg13
I1
sa(dp2625
g7
I332
sg8
g9
sg10
I5
sg11
VSH2B3
p2626
sg13
I1
sa(dp2627
g7
I346
sg8
g9
sg10
I5
sg11
VIFIH1
p2628
sg13
I1
sa(dp2629
g7
I387
sg8
VP01589
p2630
sg10
I4
sg11
VCD25
p2631
sg13
I1
sa(dp2632
g7
I327
sg8
VP60568
p2633
sg10
I3
sg11
VIL2
p2634
sg13
I1
sa(dp2635
g7
I18
sg8
VP01308
p2636
sg10
I7
sg11
Vinsulin
p2637
sg13
I1
sasg24
(lp2638
(dp2639
g7
I33
sg27
VC0270549
p2640
sg10
I3
sg11
VGAD
p2641
sg13
I1
sa(dp2642
g7
I45
sg27
VC0021670
p2643
sg10
I10
sg11
Vinsulinoma
p2644
sg13
I1
sa(dp2645
g7
I221
sg27
VC1533172
p2646
sg10
I3
sg11
VINS
p2647
sg13
I1
sa(dp2648
g7
I168
sg27
VC0011854
p2649
sg10
I15
sg11
Vtype 1 diabetes
p2650
sg13
I3
sa(dp2651
g7
I168
sg27
VC0011854
p2652
sg10
I15
sg11
Vtype 1 diabetes
p2653
sg13
I3
sasa(dp2654
g2
S'Children of parents with type 1 diabetes and prospectively followed from birth for the development of islet autoantibodies and diabetes were genotyped for single-nucleotide polymorphisms at 12 type 1 diabetes susceptibility genes (ERBB3, PTPN2, IFIH1, PTPN22, KIAA0350, CD25, CTLA4, SH2B3, IL2, IL18RAP, IL10 and COBL).\n'
p2655
sg4
(lp2656
(dp2657
g7
I290
sg8
VP60568
p2658
sg10
I3
sg11
VIL2
p2659
sg13
I1
sa(dp2660
g7
I260
sg8
g9
sg10
I8
sg11
VKIAA0350
p2661
sg13
I1
sa(dp2662
g7
I231
sg8
VP21860
p2663
sg10
I5
sg11
VERBB3
p2664
sg13
I1
sa(dp2665
g7
I313
sg8
g9
sg10
I4
sg11
VCOBL
p2666
sg13
I1
sa(dp2667
g7
I276
sg8
VP16410
p2668
sg10
I5
sg11
VCTLA4
p2669
sg13
I1
sa(dp2670
g7
I295
sg8
g9
sg10
I7
sg11
VIL18RAP
p2671
sg13
I1
sa(dp2672
g7
I252
sg8
g9
sg10
I6
sg11
VPTPN22
p2673
sg13
I1
sa(dp2674
g7
I245
sg8
g9
sg10
I5
sg11
VIFIH1
p2675
sg13
I1
sa(dp2676
g7
I283
sg8
g9
sg10
I5
sg11
VSH2B3
p2677
sg13
I1
sa(dp2678
g7
I238
sg8
VP17706
p2679
sg10
I5
sg11
VPTPN2
p2680
sg13
I1
sa(dp2681
g7
I270
sg8
VP01589
p2682
sg10
I4
sg11
VCD25
p2683
sg13
I1
sa(dp2684
g7
I304
sg8
VP22301
p2685
sg10
I4
sg11
VIL10
p2686
sg13
I1
sasg24
(lp2687
(dp2688
g7
I25
sg27
VC0011854
p2689
sg10
I15
sg11
Vtype 1 diabetes
p2690
sg13
I3
sa(dp2691
g7
I25
sg27
VC0011854
p2692
sg10
I15
sg11
Vtype 1 diabetes
p2693
sg13
I3
sa(dp2694
g7
I32
sg27
VC0011849
p2695
sg10
I8
sg11
Vdiabetes
p2696
sg13
I1
sasa(dp2697
g2
S'The greatest diabetes discrimination was obtained by the sum of risk alleles for eight genes (IFIH1, CTLA4, PTPN22, IL18RAP, SH2B3, KIAA0350, COBL and ERBB3) in the HLA-risk children.\n'
p2698
sg4
(lp2699
(dp2700
g7
I165
sg8
VP30486
p2701
sg10
I3
sg11
VHLA
p2702
sg13
I1
sa(dp2703
g7
I101
sg8
VP16410
p2704
sg10
I5
sg11
VCTLA4
p2705
sg13
I1
sa(dp2706
g7
I116
sg8
g9
sg10
I7
sg11
VIL18RAP
p2707
sg13
I1
sa(dp2708
g7
I108
sg8
g9
sg10
I6
sg11
VPTPN22
p2709
sg13
I1
sa(dp2710
g7
I142
sg8
g9
sg10
I4
sg11
VCOBL
p2711
sg13
I1
sa(dp2712
g7
I94
sg8
g9
sg10
I5
sg11
VIFIH1
p2713
sg13
I1
sa(dp2714
g7
I125
sg8
g9
sg10
I5
sg11
VSH2B3
p2715
sg13
I1
sa(dp2716
g7
I132
sg8
g9
sg10
I8
sg11
VKIAA0350
p2717
sg13
I1
sa(dp2718
g7
I151
sg8
VP21860
p2719
sg10
I5
sg11
VERBB3
p2720
sg13
I1
sasg24
(lp2721
(dp2722
g7
I13
sg27
VC0011849
p2723
sg10
I8
sg11
Vdiabetes
p2724
sg13
I1
sasa(dp2725
g2
S'However, all of the eosinophil-activating cytokines, such as IL-5, IL-3, and GM-CSF, are typically present in atopic diseases, including allergic asthma.\n'
p2726
sg4
(lp2727
(dp2728
g7
I61
sg8
VP05113
p2729
sg10
I4
sg11
VIL-5
p2730
sg13
I1
sa(dp2731
g7
I67
sg8
VP08700
p2732
sg10
I4
sg11
VIL-3
p2733
sg13
I1
sa(dp2734
g7
I77
sg8
VP04141
p2735
sg10
I6
sg11
VGM-CSF
p2736
sg13
I1
sasg24
(lp2737
(dp2738
g7
I137
sg27
VC0155877
p2739
sg10
I15
sg11
Vallergic asthma
p2740
sg13
I2
sa(dp2741
g7
I110
sg27
VC0392707
p2742
sg10
I6
sg11
Vatopic
p2743
sg13
I1
sasa(dp2744
g2
S'In a murine model of allergic asthma, we found that Tyk-2((-/-)) asthmatic mice have induced peribronchial collagen deposition, mucosal type mast cells in the lung, IRF4 and hyperproliferative lung Th2 CD4(+) effector T cells over-expressing IL-3, IL-4, IL-5, IL-10 and IL-13.\n'
p2745
sg4
(lp2746
(dp2747
g7
I254
sg8
VP05113
p2748
sg10
I4
sg11
VIL-5
p2749
sg13
I1
sa(dp2750
g7
I165
sg8
g9
sg10
I4
sg11
VIRF4
p2751
sg13
I1
sa(dp2752
g7
I242
sg8
VP08700
p2753
sg10
I4
sg11
VIL-3
p2754
sg13
I1
sa(dp2755
g7
I248
sg8
VP05112
p2756
sg10
I4
sg11
VIL-4
p2757
sg13
I1
sa(dp2758
g7
I174
sg8
VP01730
p2759
sg10
I31
sg11
Vhyperproliferative lung Th2 CD4
p2760
sg13
I4
sa(dp2761
g7
I270
sg8
VP35225
p2762
sg10
I5
sg11
VIL-13
p2763
sg13
I1
sasg24
(lp2764
(dp2765
g7
I21
sg27
VC0155877
p2766
sg10
I15
sg11
Vallergic asthma
p2767
sg13
I2
sa(dp2768
g7
I65
sg27
VC0004096
p2769
sg10
I9
sg11
Vasthmatic
p2770
sg13
I1
sasa(dp2771
g2
S'Heterologous or homologous Nrf2 deletion (Nrf2+/- or Nrf2-/-) rescued the pancreatic phenotypes, weight loss and hypoglycemia in KC::Keap1 mice, suggesting that Nrf2 is a major downstream target of Keap1.\n'
p2772
sg4
(lp2773
(dp2774
g7
I27
sg8
g9
sg10
I4
sg11
VNrf2
p2775
sg13
I1
sa(dp2776
g7
I27
sg8
g9
sg10
I4
sg11
VNrf2
p2777
sg13
I1
sa(dp2778
g7
I133
sg8
g9
sg10
I5
sg11
VKeap1
p2779
sg13
I1
sa(dp2780
g7
I133
sg8
g9
sg10
I5
sg11
VKeap1
p2781
sg13
I1
sasg24
(lp2782
(dp2783
g7
I113
sg27
VC0020615
p2784
sg10
I12
sg11
Vhypoglycemia
p2785
sg13
I1
sasa(dp2786
g2
S"Disrupting the Keap1-Nrf2 pathway enhances Nrf2 activity, which has been identified as an important approach for the prevention of different chronic diseases in which oxidative stress and inflammation are present, such as cancer, diabetes, Alzheimer's and Parkinson's.\n"
p2787
sg4
(lp2788
(dp2789
g7
I21
sg8
g9
sg10
I4
sg11
VNrf2
p2790
sg13
I1
sa(dp2791
g7
I21
sg8
g9
sg10
I4
sg11
VNrf2
p2792
sg13
I1
sa(dp2793
g7
I15
sg8
g9
sg10
I5
sg11
VKeap1
p2794
sg13
I1
sasg24
(lp2795
(dp2796
g7
I222
sg27
VC0006826
p2797
sg10
I6
sg11
Vcancer
p2798
sg13
I1
sa(dp2799
g7
I230
sg27
VC0011849
p2800
sg10
I8
sg11
Vdiabetes
p2801
sg13
I1
sa(dp2802
g7
I167
sg27
VC0242606
p2803
sg10
I16
sg11
Voxidative stress
p2804
sg13
I2
sa(dp2805
g7
I188
sg27
VC0021368
p2806
sg10
I12
sg11
Vinflammation
p2807
sg13
I1
sa(dp2808
g7
I141
sg27
VC0008679
p2809
sg10
I16
sg11
Vchronic diseases
p2810
sg13
I2
sasa(dp2811
g2
S'This study investigates the role of ACSVL3 in the maintenance of glioblastoma multiforme (GBM) stem cell self-renewal and the capacity of GBM stem cells to initiate tumor xenograft formation.\n'
p2812
sg4
(lp2813
sg24
(lp2814
(dp2815
g7
I90
sg27
VC1621958
p2816
sg10
I3
sg11
VGBM
p2817
sg13
I1
sa(dp2818
g7
I90
sg27
VC1621958
p2819
sg10
I3
sg11
VGBM
p2820
sg13
I1
sa(dp2821
g7
I65
sg27
VC1621958
p2822
sg10
I23
sg11
Vglioblastoma multiforme
p2823
sg13
I2
sa(dp2824
g7
I165
sg27
VC0027651
p2825
sg10
I5
sg11
Vtumor
p2826
sg13
I1
sasa(dp2827
g2
S'We examined ACSVL3 expression during differentiation of several GBM stem cell enriched neurosphere cultures.\n'
p2828
sg4
(lp2829
sg24
(lp2830
(dp2831
g7
I64
sg27
VC0017636
p2832
sg10
I3
sg11
VGBM
p2833
sg13
I1
sasa(dp2834
g2
S'ACSVL3 expression levels were substantially increased in GBM stem cell enriched neurosphere cultures and decreased after differentiation of the neurospheres.\n'
p2835
sg4
(lp2836
sg24
(lp2837
(dp2838
g7
I57
sg27
VC0017636
p2839
sg10
I3
sg11
VGBM
p2840
sg13
I1
sasa(dp2841
g2
S'Furthermore, ACSVL3 knockdown reduced anchorage-independent neurosphere cell growth, neurosphere-forming capacity as well as self-renewal of these GBM stem cell enriched neurosphere cultures.\n'
p2842
sg4
(lp2843
sg24
(lp2844
(dp2845
g7
I147
sg27
VC0017636
p2846
sg10
I3
sg11
VGBM
p2847
sg13
I1
sasa(dp2848
g2
S'A link between ACSVL3 and cancer stem cell phenotype was further established by the findings that ACSVL3 expression was regulated by receptor tyrosine kinase pathways that support GBM stem cell self-renewal and tumor initiation, including EGFR and HGF/c-Met pathways.\n'
p2849
sg4
(lp2850
(dp2851
g7
I133
sg8
VP29401
p2852
sg10
I24
sg11
Vreceptor tyrosine kinase
p2853
sg13
I3
sa(dp2854
g7
I252
sg8
VP08581
p2855
sg10
I5
sg11
Vc-Met
p2856
sg13
I1
sa(dp2857
g7
I248
sg8
VP05231
p2858
sg10
I3
sg11
VHGF
p2859
sg13
I1
sasg24
(lp2860
(dp2861
g7
I180
sg27
VC0017636
p2862
sg10
I3
sg11
VGBM
p2863
sg13
I1
sa(dp2864
g7
I26
sg27
VC0006826
p2865
sg10
I6
sg11
Vcancer
p2866
sg13
I1
sa(dp2867
g7
I248
sg27
VC0399440
p2868
sg10
I3
sg11
VHGF
p2869
sg13
I1
sa(dp2870
g7
I211
sg27
VC0598935
p2871
sg10
I16
sg11
Vtumor initiation
p2872
sg13
I2
sasa(dp2873
g2
S'Our findings indicate that the lipid metabolism enzyme ACSVL3 is involved in GBM stem cell maintenance and the tumor-initiating capacity of GBM stem cell enriched-neurospheres in animals.\n'
p2874
sg4
(lp2875
sg24
(lp2876
(dp2877
g7
I77
sg27
VC0017636
p2878
sg10
I3
sg11
VGBM
p2879
sg13
I1
sa(dp2880
g7
I111
sg27
VC0027651
p2881
sg10
I5
sg11
Vtumor
p2882
sg13
I1
sa(dp2883
g7
I77
sg27
VC0017636
p2884
sg10
I3
sg11
VGBM
p2885
sg13
I1
sasa(dp2886
g2
S'A significant association was detected between TLR9 genotypes and some of the disease manifestations as myositis (p = 0.032), psychosis (p = 0.014), photosensitivity (p = 0.002), and pleurisy (p = &lt;0.001).\n'
p2887
sg4
(lp2888
(dp2889
g7
I47
sg8
g9
sg10
I14
sg11
VTLR9 genotypes
p2890
sg13
I2
sasg24
(lp2891
(dp2892
g7
I149
sg27
VC0393720
p2893
sg10
I16
sg11
Vphotosensitivity
p2894
sg13
I1
sa(dp2895
g7
I183
sg27
VC0497354
p2896
sg10
I8
sg11
Vpleurisy
p2897
sg13
I1
sa(dp2898
g7
I104
sg27
VC0027121
p2899
sg10
I8
sg11
Vmyositis
p2900
sg13
I1
sa(dp2901
g7
I126
sg27
VC0349204
p2902
sg10
I9
sg11
Vpsychosis
p2903
sg13
I1
sasa(dp2904
g2
S'In addition, rLj-HMGB2 could induce the generation of proinflammatory mediators in the activated human acute monocytic leukemia cell line (THP1), which suggested that Lj-HMGB2 may participate in the immune response of the lampreys.\n'
p2905
sg4
(lp2906
(dp2907
g7
I139
sg8
VP10070
p2908
sg10
I4
sg11
VTHP1
p2909
sg13
I1
sa(dp2910
g7
I13
sg8
VP26583
p2911
sg10
I9
sg11
VrLj-HMGB2
p2912
sg13
I1
sa(dp2913
g7
I14
sg8
VP26583
p2914
sg10
I8
sg11
VLj-HMGB2
p2915
sg13
I1
sasg24
(lp2916
(dp2917
g7
I103
sg27
VC1318544
p2918
sg10
I24
sg11
Vacute monocytic leukemia
p2919
sg13
I3
sasa(dp2920
g2
S'Nut consumption was independently associated with a decreased risk of overall and vascular-disease mortality, particularly in women.\n'
p2921
sg4
(lp2922
(dp2923
g7
I0
sg8
g9
sg10
I3
sg11
VNut
p2924
sg13
I1
sasg24
(lp2925
sa(dp2926
g2
S'Nut consumption has been inconsistently associated with risk of stroke.\n'
p2927
sg4
(lp2928
(dp2929
g7
I0
sg8
g9
sg10
I3
sg11
VNut
p2930
sg13
I1
sasg24
(lp2931
(dp2932
g7
I64
sg27
VC0038454
p2933
sg10
I6
sg11
Vstroke
p2934
sg13
I1
sasa(dp2935
g2
S'Ulcerative colitis patients display increased numbers of circulating pro-inflammatory monocyte human leukocyte antigen-DR [HLA-DRhi] monocytes expressing high levels of the gut-homing C-C chemokine receptor 9 [CCR9] and tumour necrosis factor [TNF]-Alfa.\n'
p2936
sg4
(lp2937
(dp2938
g7
I86
sg8
VP05534
p2939
sg10
I35
sg11
Vmonocyte human leukocyte antigen-DR
p2940
sg13
I4
sa(dp2941
g7
I123
sg8
VP30486
p2942
sg10
I3
sg11
VHLA
p2943
sg13
I1
sa(dp2944
g7
I220
sg8
VP01375
p2945
sg10
I33
sg11
Vtumour necrosis factor [TNF]-Alfa
p2946
sg13
I4
sa(dp2947
g7
I173
sg8
g9
sg10
I42
sg11
Vgut-homing C-C chemokine receptor 9 [CCR9]
p2948
sg13
I6
sasg24
(lp2949
(dp2950
g7
I0
sg27
VC0009324
p2951
sg10
I18
sg11
VUlcerative colitis
p2952
sg13
I2
sa(dp2953
g7
I220
sg27
VC0333516
p2954
sg10
I15
sg11
Vtumour necrosis
p2955
sg13
I2
sasa(dp2956
g2
S'The aim of this first-in-human, double-blind, randomised, placebo-controlled trial was to evaluate selective removal of circulating CCR9-expressing monocytes by leukapheresis in patients with moderate to severe ulcerative colitis, with regards to safety, tolerability, and immunological response.\n'
p2957
sg4
(lp2958
(dp2959
g7
I132
sg8
VP51686
p2960
sg10
I4
sg11
VCCR9
p2961
sg13
I1
sasg24
(lp2962
(dp2963
g7
I211
sg27
VC0009324
p2964
sg10
I18
sg11
Vulcerative colitis
p2965
sg13
I2
sa(dp2966
g7
I39
sg27
VC0456909
p2967
sg10
I5
sg11
Vblind
p2968
sg13
I1
sasa(dp2969
g2
S'Patients with ulcerative colitis were treated every second day with leukapheresis during five sessions with a C-C chemokine ligand 25 [CCL25; CCR9 ligand] column or a placebo column.\n'
p2970
sg4
(lp2971
(dp2972
g7
I110
sg8
VP55773
p2973
sg10
I23
sg11
VC-C chemokine ligand 25
p2974
sg13
I4
sa(dp2975
g7
I142
sg8
VP51686
p2976
sg10
I4
sg11
VCCR9
p2977
sg13
I1
sa(dp2978
g7
I135
sg8
g9
sg10
I5
sg11
VCCL25
p2979
sg13
I1
sasg24
(lp2980
(dp2981
g7
I14
sg27
VC0009324
p2982
sg10
I18
sg11
Vulcerative colitis
p2983
sg13
I2
sasa(dp2984
g2
S'CC chemokine receptor type 9 (CCR9) activation by CCL25 plays a key role in leukocyte recruitment to the gut and represents a therapeutic target in inflammatory bowel disease.\n'
p2985
sg4
(lp2986
(dp2987
g7
I0
sg8
g9
sg10
I28
sg11
VCC chemokine receptor type 9
p2988
sg13
I5
sa(dp2989
g7
I30
sg8
VP51686
p2990
sg10
I4
sg11
VCCR9
p2991
sg13
I1
sa(dp2992
g7
I50
sg8
g9
sg10
I5
sg11
VCCL25
p2993
sg13
I1
sasg24
(lp2994
(dp2995
g7
I148
sg27
VC0021390
p2996
sg10
I26
sg11
Vinflammatory bowel disease
p2997
sg13
I3
sa(dp2998
g7
I86
sg27
VC0271510
p2999
sg10
I11
sg11
Vrecruitment
p3000
sg13
I1
sasa(dp3001
g2
S"The selective CCR9 antagonist vercirnon progressed to phase 3 clinical trials in Crohn's disease but efficacy was limited, with the need for very high doses to block receptor activation.\n"
p3002
sg4
(lp3003
(dp3004
g7
I14
sg8
VP51686
p3005
sg10
I4
sg11
VCCR9
p3006
sg13
I1
sasg24
(lp3007
(dp3008
g7
I81
sg27
VC0010346
p3009
sg10
I15
sg11
VCrohn's disease
p3010
sg13
I2
sasa(dp3011
g2
S'To investigate whether Imiquimod (IMQ) as TLR7 ligand protects mice from colonic inflammation and the mechanisms underlying in such immunoregulatory conditions.#METHODS: Murine colitis was induced to Balb/c mice by administration of trinitrobenzene sulfonic acid (TNBS) with or without daily intraperitoneal administration of IMQ.#Colitis was evaluated by body weight decreases and by histological score.#Also colonic mRNA expression was measured by RT-PCR.#To confirm the induction of Regulatory T cells (Tregs) by type-1 IFN from pDCs, we generated mouse bone marrow-derived pDCs and co-cultured these with CD4+ T cells isolated from mouse spleen with or without IMQ stimulation.#Cytokine production in the culture supernatant was measured by ELISA and the number of Tregs were analyzed by flow cytometry.#Spleen and mesenteric lymph nodes (MLN) from IMQ-treated mice were collected, and mRNA expressions of cytokine were measured by RT-PCR and cytokine productions were measured by ELISA.#Tregs and chemokine expressions were analyzed in colon of TNBS-induced colitis mouse by immunohistochemistry.#RESULTS: Administration of IMQ significantly suppressed colonic inflammation of TNBS-induced colitis.#In the colons of IMQ-treated mice, mRNA expression of TNF-Alfa was decreased, and strong expressions of IL-6, IFN-Beta and TGF-Beta were detected.#IL-10 and TGF-Beta productions were increased in the supernatant of co-cultured cells stimulated with IMQ, although we were unable to detect Treg differentiaton in IMQ-stimulated co-cultured cells.#In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-Beta, TGF-Beta and Foxp3 mRNA were detected.#IL-10 production from MLN cells was also increased in the IMQ-treated group.#Finally, Tregs in the inflamed colon and CCR9 in MLN of IMQ-treated mice were detected.#CONCLUSION: These results suggest that IMQ protects mice from TNBS colitis through induction of CCR9, which regulates accumulation of Tregs in the inflamed colon.\n'
p3012
sg4
(lp3013
(dp3014
g7
I1772
sg8
VP51686
p3015
sg10
I4
sg11
VCCR9
p3016
sg13
I1
sa(dp3017
g7
I609
sg8
VP01730
p3018
sg10
I4
sg11
VCD4+
p3019
sg13
I1
sa(dp3020
g7
I42
sg8
g9
sg10
I11
sg11
VTLR7 ligand
p3021
sg13
I2
sa(dp3022
g7
I1327
sg8
VP18075
p3023
sg10
I8
sg11
VTGF-Beta
p3024
sg13
I1
sa(dp3025
g7
I1772
sg8
VP51686
p3026
sg10
I4
sg11
VCCR9
p3027
sg13
I1
sa(dp3028
g7
I1258
sg8
VP01375
p3029
sg10
I8
sg11
VTNF-Alfa
p3030
sg13
I1
sa(dp3031
g7
I42
sg8
g9
sg10
I4
sg11
VTLR7
p3032
sg13
I1
sa(dp3033
g7
I1314
sg8
VP01574
p3034
sg10
I8
sg11
VIFN-Beta
p3035
sg13
I1
sa(dp3036
g7
I1314
sg8
VP01574
p3037
sg10
I8
sg11
VIFN-Beta
p3038
sg13
I1
sa(dp3039
g7
I843
sg8
VP12872
p3040
sg10
I3
sg11
VMLN
p3041
sg13
I1
sa(dp3042
g7
I516
sg8
VP01562
p3043
sg10
I10
sg11
Vtype-1 IFN
p3044
sg13
I2
sa(dp3045
g7
I1327
sg8
VP18075
p3046
sg10
I8
sg11
VTGF-Beta
p3047
sg13
I1
sa(dp3048
g7
I1308
sg8
VP05231
p3049
sg10
I4
sg11
VIL-6
p3050
sg13
I1
sa(dp3051
g7
I1327
sg8
VP18075
p3052
sg10
I8
sg11
VTGF-Beta
p3053
sg13
I1
sa(dp3054
g7
I1628
sg8
g9
sg10
I10
sg11
VFoxp3 mRNA
p3055
sg13
I2
sa(dp3056
g7
I819
sg8
VP12872
p3057
sg10
I22
sg11
Vmesenteric lymph nodes
p3058
sg13
I3
sasg24
(lp3059
(dp3060
g7
I177
sg27
VC0009319
p3061
sg10
I7
sg11
Vcolitis
p3062
sg13
I1
sa(dp3063
g7
I177
sg27
VC0009319
p3064
sg10
I7
sg11
Vcolitis
p3065
sg13
I1
sa(dp3066
g7
I81
sg27
VC0021368
p3067
sg10
I12
sg11
Vinflammation
p3068
sg13
I1
sa(dp3069
g7
I81
sg27
VC0021368
p3070
sg10
I12
sg11
Vinflammation
p3071
sg13
I1
sa(dp3072
g7
I177
sg27
VC0009319
p3073
sg10
I7
sg11
Vcolitis
p3074
sg13
I1
sa(dp3075
g7
I331
sg27
VC0009319
p3076
sg10
I7
sg11
VColitis
p3077
sg13
I1
sa(dp3078
g7
I177
sg27
VC0009319
p3079
sg10
I7
sg11
Vcolitis
p3080
sg13
I1
sasa(dp3081
g2
S'We here showed that CCR9+ CD11b+ macrophages play an important role during the course of Concanavalin A-induced murine acute liver injury as well as human acute hepatitis via the production of inflammatory cytokines and the Th1 induction.\n'
p3082
sg4
(lp3083
(dp3084
g7
I20
sg8
VP51686
p3085
sg10
I12
sg11
VCCR9+ CD11b+
p3086
sg13
I2
sasg24
(lp3087
(dp3088
g7
I155
sg27
VC0267797
p3089
sg10
I15
sg11
Vacute hepatitis
p3090
sg13
I2
sasa(dp3091
g2
S'We found 54 single-nucleotide polymorphisms (SNPs) in 5 genes associated with celiac disease (TAGAP, IL18R1, RGS21, PLEK, and CCR9) in time to celiac disease analyses (10-4&gt;P&gt;5.8x10-6).\n'
p3092
sg4
(lp3093
(dp3094
g7
I126
sg8
VP51686
p3095
sg10
I4
sg11
VCCR9
p3096
sg13
I1
sa(dp3097
g7
I109
sg8
g9
sg10
I5
sg11
VRGS21
p3098
sg13
I1
sa(dp3099
g7
I116
sg8
VP08567
p3100
sg10
I4
sg11
VPLEK
p3101
sg13
I1
sa(dp3102
g7
I101
sg8
g9
sg10
I6
sg11
VIL18R1
p3103
sg13
I1
sa(dp3104
g7
I94
sg8
g9
sg10
I5
sg11
VTAGAP
p3105
sg13
I1
sasg24
(lp3106
(dp3107
g7
I78
sg27
VC0007570
p3108
sg10
I14
sg11
Vceliac disease
p3109
sg13
I2
sa(dp3110
g7
I78
sg27
VC0007570
p3111
sg10
I14
sg11
Vceliac disease
p3112
sg13
I2
sasa(dp3113
g2
S'Including chemokines [C-C motif ligand (CCL) 19, CCL20, CCL21, C-X-C motif ligand (CXCL) 6, CXCL10, and CXCL11] and soluble cytokine and chemokine receptors [soluble (s) interleukin (IL) 6 receptor (R), soluble tumor necrosis factor receptor (sTNFR) 1, sTNFR2, and sIL-R2], ten inflammation-related markers, were nominally associated with diabetes (P&lt;0.05).\n'
p3114
sg4
(lp3115
(dp3116
g7
I56
sg8
g9
sg10
I5
sg11
VCCL21
p3117
sg13
I1
sa(dp3118
g7
I92
sg8
VP02778
p3119
sg10
I6
sg11
VCXCL10
p3120
sg13
I1
sa(dp3121
g7
I211
sg8
VP01375
p3122
sg10
I40
sg11
Vtumor necrosis factor receptor (sTNFR) 1
p3123
sg13
I6
sa(dp3124
g7
I265
sg8
VP40967
p3125
sg10
I6
sg11
VsIL-R2
p3126
sg13
I1
sa(dp3127
g7
I104
sg8
g9
sg10
I6
sg11
VCXCL11
p3128
sg13
I1
sa(dp3129
g7
I49
sg8
VP78556
p3130
sg10
I5
sg11
VCCL20
p3131
sg13
I1
sasg24
(lp3132
(dp3133
g7
I339
sg27
VC0011849
p3134
sg10
I8
sg11
Vdiabetes
p3135
sg13
I1
sa(dp3136
g7
I21
sg27
VC1852438
p3137
sg10
I17
sg11
V[C-C motif ligand
p3138
sg13
I3
sa(dp3139
g7
I40
sg27
VC1852438
p3140
sg10
I3
sg11
VCCL
p3141
sg13
I1
sa(dp3142
g7
I265
sg27
VC0333873
p3143
sg10
I3
sg11
VsIL
p3144
sg13
I1
sa(dp3145
g7
I278
sg27
VC0021368
p3146
sg10
I12
sg11
Vinflammation
p3147
sg13
I1
sa(dp3148
g7
I211
sg27
VC0333516
p3149
sg10
I14
sg11
Vtumor necrosis
p3150
sg13
I2
sasa(dp3151
g2
S'We identified mutations in melanoma-associated antigen D2 in all study participants and showed, in vivo and in vitro, reduced expression of the furosemide and thiazide sensitive transporters sodium-potassium-2-chloride cotransporter and sodium chloride cotransporter, respectively.\n'
p3152
sg4
(lp3153
(dp3154
g7
I27
sg8
g9
sg10
I30
sg11
Vmelanoma-associated antigen D2
p3155
sg13
I3
sasg24
(lp3156
(dp3157
g7
I27
sg27
VC0025202
p3158
sg10
I8
sg11
Vmelanoma
p3159
sg13
I1
sasa(dp3160
g2
S"MAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.We distinguish two types of hereditary NDI: a 'pure' type with loss of water only and a complex type with loss of water and ions.\n"
p3161
sg4
(lp3162
(dp3163
g7
I0
sg8
g9
sg10
I6
sg11
VMAGED2
p3164
sg13
I1
sasg24
(lp3165
(dp3166
g7
I33
sg27
VC0020224
p3167
sg10
I14
sg11
Vpolyhydramnios
p3168
sg13
I1
sa(dp3169
g7
I168
sg27
VC1563705
p3170
sg10
I3
sg11
VNDI
p3171
sg13
I1
sa(dp3172
g7
I110
sg27
VC0004775
p3173
sg10
I18
sg11
VBartter's syndrome
p3174
sg13
I2
sasa(dp3175
g2
S"A new variant of this was recently identified: seven families were described with transient antenatal Bartter's syndrome, polyhydramnios and MAGED2 mutations.Multiple compounds have been identified experimentally that may stimulate urinary concentration independently of the vasopressin V2 receptor.\n"
p3176
sg4
(lp3177
(dp3178
g7
I275
sg8
VP30518
p3179
sg10
I23
sg11
Vvasopressin V2 receptor
p3180
sg13
I3
sa(dp3181
g7
I141
sg8
g9
sg10
I6
sg11
VMAGED2
p3182
sg13
I1
sasg24
(lp3183
(dp3184
g7
I122
sg27
VC0020224
p3185
sg10
I14
sg11
Vpolyhydramnios
p3186
sg13
I1
sa(dp3187
g7
I102
sg27
VC0004775
p3188
sg10
I18
sg11
VBartter's syndrome
p3189
sg13
I2
sasa(dp3190
g2
S'Fluorescent and radio conjugates of 11B6, an antibody targeting free hK2, are internalized and noninvasively report AR pathway activity in metastatic and genetically engineered models of cancer development and treatment.\n'
p3191
sg4
(lp3192
(dp3193
g7
I69
sg8
VP20151
p3194
sg10
I3
sg11
VhK2
p3195
sg13
I1
sasg24
(lp3196
(dp3197
g7
I187
sg27
VC0006826
p3198
sg10
I6
sg11
Vcancer
p3199
sg13
I1
sasa(dp3200
g2
S'Humanized 11B6, which has undergone toxicological tests in nonhuman primates, has the potential to improve patient management in these cancers.\n'
p3201
sg4
(lp3202
(dp3203
g7
I0
sg8
g9
sg10
I14
sg11
VHumanized 11B6
p3204
sg13
I2
sasg24
(lp3205
(dp3206
g7
I135
sg27
VC0006826
p3207
sg10
I7
sg11
Vcancers
p3208
sg13
I1
sasa(dp3209
g2
S'MAGE-D2 is new gene found to cause severe polyhydramnios and transient postnatal Bartter-like syndrome.\n'
p3210
sg4
(lp3211
(dp3212
g7
I0
sg8
g9
sg10
I7
sg11
VMAGE-D2
p3213
sg13
I1
sasg24
(lp3214
(dp3215
g7
I42
sg27
VC0020224
p3216
sg10
I14
sg11
Vpolyhydramnios
p3217
sg13
I1
sa(dp3218
g7
I94
sg27
VC0039082
p3219
sg10
I8
sg11
Vsyndrome
p3220
sg13
I1
sasa(dp3221
g2
S'These women were divided into two after breast cancer groups (BCG1 and BCG2) and a control group (CG).\n'
p3222
sg4
(lp3223
(dp3224
g7
I62
sg8
g9
sg10
I4
sg11
VBCG1
p3225
sg13
I1
sasg24
(lp3226
(dp3227
g7
I40
sg27
VC0678222
p3228
sg10
I13
sg11
Vbreast cancer
p3229
sg13
I2
sasa(dp3230
g2
S'Group BCG1 consisted of women who had undergone breast cancer surgery within the last 18months and BCG2 those whose postoperative periods were more than 18months.\n'
p3231
sg4
(lp3232
sg24
(lp3233
(dp3234
g7
I48
sg27
VC0678222
p3235
sg10
I13
sg11
Vbreast cancer
p3236
sg13
I2
sasa(dp3237
g2
S'The indices in millisecond, RMSSD (BCG1=19.83; BCG2=14.99; CG=31.46), SD1 (BCG1=14.03; BCG2=10.61; CG=22.27), SD2 (BCG1=39.17; BCG2=35.28; CG=61.16), SDNN (BCG1=29.58; BCG2=26.12; CG=46.36) and HF in milliseconds squared (BCG1=194.2; BCG2=91.07; CG=449.4) showed statistically significant reductions in the breast cancer groups compared to the CG (p&lt;=0.0001).\n'
p3238
sg4
(lp3239
sg24
(lp3240
(dp3241
g7
I307
sg27
VC0678222
p3242
sg10
I13
sg11
Vbreast cancer
p3243
sg13
I2
sa(dp3244
g7
I70
sg27
VC1861380
p3245
sg10
I3
sg11
VSD1
p3246
sg13
I1
sasa(dp3247
g2
S"The discovery that mutations in MAGED2 cause a rare and transient form of antenatal Bartter's Syndrome may have implications beyond the very small number of affected families.\n"
p3248
sg4
(lp3249
(dp3250
g7
I32
sg8
g9
sg10
I6
sg11
VMAGED2
p3251
sg13
I1
sasg24
(lp3252
(dp3253
g7
I84
sg27
VC0004775
p3254
sg10
I18
sg11
VBartter's Syndrome
p3255
sg13
I2
sasa(dp3256
g2
S"We identified a mutation in MAGED2 in each of the 13 infants in our analysis who had transient antenatal Bartter's syndrome.\n"
p3257
sg4
(lp3258
(dp3259
g7
I28
sg8
g9
sg10
I6
sg11
VMAGED2
p3260
sg13
I1
sasg24
(lp3261
(dp3262
g7
I105
sg27
VC0004775
p3263
sg10
I18
sg11
VBartter's syndrome
p3264
sg13
I2
sasa(dp3265
g2
S'MAGED2 encodes melanoma-associated antigen D2 (MAGE-D2) and maps to the X chromosome.\n'
p3266
sg4
(lp3267
(dp3268
g7
I0
sg8
g9
sg10
I6
sg11
VMAGED2
p3269
sg13
I1
sa(dp3270
g7
I47
sg8
g9
sg10
I7
sg11
VMAGE-D2
p3271
sg13
I1
sa(dp3272
g7
I15
sg8
g9
sg10
I30
sg11
Vmelanoma-associated antigen D2
p3273
sg13
I3
sasg24
(lp3274
(dp3275
g7
I15
sg27
VC0025202
p3276
sg10
I8
sg11
Vmelanoma
p3277
sg13
I1
sasa(dp3278
g2
S'We also identified two different MAGED2 mutations in two families with idiopathic polyhydramnios.\n'
p3279
sg4
(lp3280
(dp3281
g7
I33
sg8
g9
sg10
I16
sg11
VMAGED2 mutations
p3282
sg13
I2
sasg24
(lp3283
(dp3284
g7
I82
sg27
VC0020224
p3285
sg10
I14
sg11
Vpolyhydramnios
p3286
sg13
I1
sasa(dp3287
g2
S"We found that MAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.\n"
p3288
sg4
(lp3289
(dp3290
g7
I14
sg8
g9
sg10
I6
sg11
VMAGED2
p3291
sg13
I1
sasg24
(lp3292
(dp3293
g7
I124
sg27
VC0004775
p3294
sg10
I18
sg11
VBartter's syndrome
p3295
sg13
I2
sa(dp3296
g7
I47
sg27
VC0020224
p3297
sg10
I14
sg11
Vpolyhydramnios
p3298
sg13
I1
sasa(dp3299
g2
S'Virulence factors profiling showed that most of MRSA isolates in our center carried the virulence factor pattern of cna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld (214/239, 89.54%).\n'
p3300
sg4
(lp3301
(dp3302
g7
I116
sg8
g9
sg10
I66
sg11
Vcna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld
p3303
sg13
I1
sasg24
(lp3304
(dp3305
g7
I48
sg27
VC0343401
p3306
sg10
I4
sg11
VMRSA
p3307
sg13
I1
sasa(dp3308
g2
S'The main virulence genes in these strains were hlg (33.3%), scn (23.3%), cna (20%), hlb (20%), and clfA (18.3%), others including icaA, fnbA, tst, seb, hld, eta and sea.\n'
p3309
sg4
(lp3310
(dp3311
g7
I152
sg8
VP35670
p3312
sg10
I3
sg11
Vhld
p3313
sg13
I1
sa(dp3314
g7
I142
sg8
g9
sg10
I3
sg11
Vtst
p3315
sg13
I1
sa(dp3316
g7
I157
sg8
VP25101
p3317
sg10
I3
sg11
Veta
p3318
sg13
I1
sa(dp3319
g7
I147
sg8
g9
sg10
I3
sg11
Vseb
p3320
sg13
I1
sasg24
(lp3321
sa(dp3322
g2
S'Other virulence genes detected were (number of strains): tsst-1 (6), hla (15), hlb (9), hld (15), hlg (6), hlgv (9), cna (2), aur (14), and egc-like cluster (3).\n'
p3323
sg4
(lp3324
sg24
(lp3325
sa(dp3326
g2
S'Search terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases: CENTRAL (2007, Issue 1); MEDLINE via PUBMED (1966 to March 2007); EMBASE (2005 to April 2007); CINAHL (1982 to March 2007); LILACS (1982 to March 2007); PsycINFO (1887 to March 2007); ERIC (1966 to March 2007); CCT (March 2007); Academic Search Elite (to March 2007), C2- SPECTR (to March 2007 ), NRR (2007 Issue 1), ClinicalTrials.gov (accessed March 2007) and within supplements of Medicine and Science in Sports and Exercise.\n'
p3327
sg4
(lp3328
sg24
(lp3329
(dp3330
g7
I322
sg27
VC2752078
p3331
sg10
I3
sg11
VCCT
p3332
sg13
I1
sa(dp3333
g7
I54
sg27
VC0013080
p3334
sg10
I13
sg11
VDown syndrome
p3335
sg13
I2
sasa(dp3336
g2
S'Search terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases:CENTRAL (2005, Issue 2); MEDLINE (1966 to March 2005); EMBASE (2005 to April 2005); CINAHL (1982 to March 2005); LILACS (1982 to March 2005); PsycINFO (1887 to March 2005); ERIC (1966 to March 2005); CCT (March 2005); Academic Search Elite (to March 2005), C2- SPECTR (to March 2005 ), NRR (2005 Issue 1), ClinicalTrials.gov (accessed March 2005)and within supplements of Medicine and Science in Sports and Exercise.\n'
p3337
sg4
(lp3338
sg24
(lp3339
(dp3340
g7
I54
sg27
VC0013080
p3341
sg10
I13
sg11
VDown syndrome
p3342
sg13
I2
sa(dp3343
g7
I310
sg27
VC2752078
p3344
sg10
I3
sg11
VCCT
p3345
sg13
I1
sasa(dp3346
g2
S'FMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings.\n'
p3347
sg4
(lp3348
(dp3349
g7
I0
sg8
g9
sg10
I3
sg11
VFMT
p3350
sg13
I1
sasg24
(lp3351
(dp3352
g7
I36
sg27
VC0021390
p3353
sg10
I3
sg11
VIBD
p3354
sg13
I1
sa(dp3355
g7
I68
sg27
VC0022104
p3356
sg10
I3
sg11
VIBS
p3357
sg13
I1
sa(dp3358
g7
I42
sg27
VC0022104
p3359
sg10
I24
sg11
Virritable bowel syndrome
p3360
sg13
I3
sa(dp3361
g7
I77
sg27
VC0524620
p3362
sg10
I18
sg11
Vmetabolic syndrome
p3363
sg13
I2
sa(dp3364
g7
I7
sg27
VC0021390
p3365
sg10
I27
sg11
Vinflammatory bowel diseases
p3366
sg13
I3
sasa(dp3367
g2
S'Blockade of CD69-Myl9/12 interaction ameliorates allergic airway inflammation in ovalbumin-induced and house dust mite-induced mouse models of asthma.\n'
p3368
sg4
(lp3369
(dp3370
g7
I12
sg8
g9
sg10
I4
sg11
VCD69
p3371
sg13
I1
sa(dp3372
g7
I17
sg8
VP24844
p3373
sg10
I4
sg11
VMyl9
p3374
sg13
I1
sasg24
(lp3375
(dp3376
g7
I143
sg27
VC0004096
p3377
sg10
I6
sg11
Vasthma
p3378
sg13
I1
sa(dp3379
g7
I65
sg27
VC0021368
p3380
sg10
I12
sg11
Vinflammation
p3381
sg13
I1
sasa(dp3382
g2
S'A greater activation of myosin, via increased phosphorylation of its regulatory light chain (LC20) by myosin light chain kinase, correlates with an increased Vmax in models of AH and in human asthmatic bronchial SM cells.\n'
p3383
sg4
(lp3384
(dp3385
g7
I24
sg8
VP13535
p3386
sg10
I6
sg11
Vmyosin
p3387
sg13
I1
sa(dp3388
g7
I102
sg8
g9
sg10
I25
sg11
Vmyosin light chain kinase
p3389
sg13
I4
sasg24
(lp3390
(dp3391
g7
I192
sg27
VC0004096
p3392
sg10
I9
sg11
Vasthmatic
p3393
sg13
I1
sasa(dp3394
g2
S'Some of the differentially expressed lncRNAs that were upregulated, such as AK124776, lincRNA-RAB12-1, KRT8P25, RP11-474J18.4, AC000110.1, KRT8P13, KRT8P10, BC072678, and downregulated, such as nc-HOXB9-206, RP11-160A10.2, nc-HOXA11-86, nc-HOXD10-7, nc-HOXB9-205, CES4, nc-HOXD12-3, systematic research on these lncRNAs will help clarify the mechanisms of urothelial carcinoma of the bladder and guide the early diagnosis and treatment of this cancer in the future.\n'
p3395
sg4
(lp3396
(dp3397
g7
I223
sg8
VP31270
p3398
sg10
I12
sg11
Vnc-HOXA11-86
p3399
sg13
I1
sa(dp3400
g7
I112
sg8
g9
sg10
I25
sg11
VRP11-474J18.4, AC000110.1
p3401
sg13
I2
sa(dp3402
g7
I250
sg8
VP17482
p3403
sg10
I12
sg11
Vnc-HOXB9-205
p3404
sg13
I1
sa(dp3405
g7
I197
sg8
VP17482
p3406
sg10
I9
sg11
VHOXB9-206
p3407
sg13
I1
sa(dp3408
g7
I86
sg8
g9
sg10
I15
sg11
VlincRNA-RAB12-1
p3409
sg13
I1
sa(dp3410
g7
I208
sg8
g9
sg10
I13
sg11
VRP11-160A10.2
p3411
sg13
I1
sa(dp3412
g7
I237
sg8
VP28358
p3413
sg10
I11
sg11
Vnc-HOXD10-7
p3414
sg13
I1
sa(dp3415
g7
I270
sg8
VP35452
p3416
sg10
I11
sg11
Vnc-HOXD12-3
p3417
sg13
I1
sa(dp3418
g7
I264
sg8
g9
sg10
I4
sg11
VCES4
p3419
sg13
I1
sasg24
(lp3420
(dp3421
g7
I112
sg27
VC1838601
p3422
sg10
I4
sg11
VRP11
p3423
sg13
I1
sa(dp3424
g7
I367
sg27
VC0699885
p3425
sg10
I24
sg11
Vcarcinoma of the bladder
p3426
sg13
I4
sa(dp3427
g7
I444
sg27
VC0006826
p3428
sg10
I6
sg11
Vcancer
p3429
sg13
I1
sa(dp3430
g7
I112
sg27
VC1838601
p3431
sg10
I4
sg11
VRP11
p3432
sg13
I1
sasa(dp3433
g2
S'Proteins labeled with LCA were Rab-3, Rab-12, Rab-16, and M-Ras.\n'
p3434
sg4
(lp3435
(dp3436
g7
I46
sg8
VP52594
p3437
sg10
I6
sg11
VRab-16
p3438
sg13
I1
sa(dp3439
g7
I38
sg8
VP52594
p3440
sg10
I6
sg11
VRab-12
p3441
sg13
I1
sa(dp3442
g7
I31
sg8
VP52594
p3443
sg10
I5
sg11
VRab-3
p3444
sg13
I1
sa(dp3445
g7
I58
sg8
g9
sg10
I5
sg11
VM-Ras
p3446
sg13
I1
sasg24
(lp3447
(dp3448
g7
I22
sg27
VC0339527
p3449
sg10
I3
sg11
VLCA
p3450
sg13
I1
sasa(dp3451
g2
S'Moreover, the ANT2 precursors were observed to change in oncocytomas.\n'
p3452
sg4
(lp3453
(dp3454
g7
I14
sg8
VP05141
p3455
sg10
I15
sg11
VANT2 precursors
p3456
sg13
I2
sasg24
(lp3457
(dp3458
g7
I57
sg27
VC0949541
p3459
sg10
I11
sg11
Voncocytomas
p3460
sg13
I1
sasa(dp3461
g2
S'In particular, a high transcript level for the adenine nucleotide translocator isoform 2(ANT2) gene, which is usually not expressed in differentiated cells, was observed in oncocytoma and malignant urothelial renal tumor.\n'
p3462
sg4
(lp3463
(dp3464
g7
I89
sg8
VP05141
p3465
sg10
I4
sg11
VANT2
p3466
sg13
I1
sa(dp3467
g7
I47
sg8
g9
sg10
I41
sg11
Vadenine nucleotide translocator isoform 2
p3468
sg13
I5
sasg24
(lp3469
(dp3470
g7
I173
sg27
VC0949541
p3471
sg10
I10
sg11
Voncocytoma
p3472
sg13
I1
sa(dp3473
g7
I209
sg27
VC0022665
p3474
sg10
I11
sg11
Vrenal tumor
p3475
sg13
I2
sasa(dp3476
g2
S'Ruxolitinib was found to fully inhibit IL-6-mediated repression of CYP (CYP1A2, CYP2B6 and CYP3A4) and transporter (NTCP, OATP1B1 and OCT1) mRNA levels in primary human hepatocytes and differentiated hepatoma HepaRG cells.\n'
p3477
sg4
(lp3478
(dp3479
g7
I116
sg8
g9
sg10
I4
sg11
VNTCP
p3480
sg13
I1
sa(dp3481
g7
I39
sg8
VP05231
p3482
sg10
I4
sg11
VIL-6
p3483
sg13
I1
sa(dp3484
g7
I72
sg8
VP05177
p3485
sg10
I6
sg11
VCYP1A2
p3486
sg13
I1
sa(dp3487
g7
I122
sg8
g9
sg10
I7
sg11
VOATP1B1
p3488
sg13
I1
sa(dp3489
g7
I67
sg8
g9
sg10
I3
sg11
VCYP
p3490
sg13
I1
sa(dp3491
g7
I134
sg8
VP14859
p3492
sg10
I4
sg11
VOCT1
p3493
sg13
I1
sasg24
(lp3494
(dp3495
g7
I200
sg27
VC0023903
p3496
sg10
I8
sg11
Vhepatoma
p3497
sg13
I1
sasa(dp3498
g2
S'This study aimed to assess inflammatory, cardiac, renal and hematological markers in 56 breast cancer patients (BCP) before, during and after termination of chemotherapy with CYP and DOX.\n'
p3499
sg4
(lp3500
sg24
(lp3501
(dp3502
g7
I88
sg27
VC0678222
p3503
sg10
I13
sg11
Vbreast cancer
p3504
sg13
I2
sasa(dp3505
g2
S'Based on the results, we conclude that breast cancer and co-treatment of CYP and DOX interfere with various biological markers, thereby, showing the physiological imbalance.\n'
p3506
sg4
(lp3507
sg24
(lp3508
(dp3509
g7
I39
sg27
VC0678222
p3510
sg10
I13
sg11
Vbreast cancer
p3511
sg13
I2
sa(dp3512
g7
I163
sg27
VC1397014
p3513
sg10
I9
sg11
Vimbalance
p3514
sg13
I1
sasa(dp3515
g2
S'Epoxyeicosatrienoic acid (EET) production via cytochrome P450 (CYP) epoxygenases closely correlates with the progression of breast cancer.\n'
p3516
sg4
(lp3517
(dp3518
g7
I46
sg8
VP20853
p3519
sg10
I15
sg11
Vcytochrome P450
p3520
sg13
I2
sa(dp3521
g7
I63
sg8
VP20853
p3522
sg10
I3
sg11
VCYP
p3523
sg13
I1
sasg24
(lp3524
(dp3525
g7
I124
sg27
VC0678222
p3526
sg10
I13
sg11
Vbreast cancer
p3527
sg13
I2
sasa(dp3528
g2
S'Here, we found that CYP3A4 expression and its epoxy-product, 11,12-epoxyeicosatrienoic acid (11,12-EET) was enhanced in tamoxifen (TAM)-resistant MCF-7 (TAMR-MCF-7) breast cancer cells compared to control MCF-7 cells.\n'
p3529
sg4
(lp3530
(dp3531
g7
I20
sg8
VP08684
p3532
sg10
I6
sg11
VCYP3A4
p3533
sg13
I1
sasg24
(lp3534
(dp3535
g7
I165
sg27
VC0678222
p3536
sg10
I13
sg11
Vbreast cancer
p3537
sg13
I2
sa(dp3538
g7
I131
sg27
VC1834582
p3539
sg10
I3
sg11
VTAM
p3540
sg13
I1
sa(dp3541
g7
I120
sg27
VC1834582
p3542
sg10
I9
sg11
Vtamoxifen
p3543
sg13
I1
sasa(dp3544
g2
S'Our findings suggest that the CYP3A4-mediated EET pathway represents a potential therapeutic target for the treatment of tamoxifen-resistant breast cancer.\n'
p3545
sg4
(lp3546
(dp3547
g7
I30
sg8
VP08684
p3548
sg10
I6
sg11
VCYP3A4
p3549
sg13
I1
sasg24
(lp3550
(dp3551
g7
I141
sg27
VC0678222
p3552
sg10
I13
sg11
Vbreast cancer
p3553
sg13
I2
sasa(dp3554
g2
S'CYP3A4 was unexpectedly associated with breast cancer mitochondria and synthesized arachidonic acid (AA)-derived epoxyeicosatrienoic acids (EETs), which promoted the electron transport chain/respiration and inhibited AMPKAlfa.\n'
p3555
sg4
(lp3556
(dp3557
g7
I0
sg8
VP08684
p3558
sg10
I6
sg11
VCYP3A4
p3559
sg13
I1
sasg24
(lp3560
(dp3561
g7
I40
sg27
VC0678222
p3562
sg10
I13
sg11
Vbreast cancer
p3563
sg13
I2
sasa(dp3564
g2
S'CYP3A4 knockdown activated AMPKAlfa, promoted autophagy, and prevented mammary tumor formation.\n'
p3565
sg4
(lp3566
(dp3567
g7
I0
sg8
VP08684
p3568
sg10
I6
sg11
VCYP3A4
p3569
sg13
I1
sasg24
(lp3570
(dp3571
g7
I71
sg27
VC1458155
p3572
sg10
I13
sg11
Vmammary tumor
p3573
sg13
I2
sasa(dp3574
g2
S'Comprehensive genotyping of CYP enzymes and transporters was performed using the iPLEX ADME PGx Pro Panel in 302 tamoxifen-treated breast cancer patients.\n'
p3575
sg4
(lp3576
(dp3577
g7
I28
sg8
g9
sg10
I11
sg11
VCYP enzymes
p3578
sg13
I2
sasg24
(lp3579
(dp3580
g7
I131
sg27
VC0678222
p3581
sg10
I13
sg11
Vbreast cancer
p3582
sg13
I2
sasa(dp3583
g2
S'It has been recently reported that CD38 was highly expressed in adipose tissues from obese people and CD38-deficient mice were resistant to high-fat diet (HFD)-induced obesity.\n'
p3584
sg4
(lp3585
(dp3586
g7
I35
sg8
VP28907
p3587
sg10
I4
sg11
VCD38
p3588
sg13
I1
sa(dp3589
g7
I35
sg8
VP28907
p3590
sg10
I4
sg11
VCD38
p3591
sg13
I1
sasg24
(lp3592
(dp3593
g7
I168
sg27
VC0028754
p3594
sg10
I7
sg11
Vobesity
p3595
sg13
I1
sa(dp3596
g7
I85
sg27
VC0028754
p3597
sg10
I5
sg11
Vobese
p3598
sg13
I1
sasa(dp3599
g2
S'In this study, to explore the roles of CD38 in adipogenesis and lipogenesis in vivo and in vitro, obesity models were generated with male CD38-/- and WT mice fed with HFD.\n'
p3600
sg4
(lp3601
(dp3602
g7
I39
sg8
VP28907
p3603
sg10
I4
sg11
VCD38
p3604
sg13
I1
sa(dp3605
g7
I39
sg8
VP28907
p3606
sg10
I4
sg11
VCD38
p3607
sg13
I1
sasg24
(lp3608
(dp3609
g7
I98
sg27
VC0028754
p3610
sg10
I7
sg11
Vobesity
p3611
sg13
I1
sasa(dp3612
g2
S'The results showed that CD38-/- male mice were significantly resistant to HFD-induced obesity.\n'
p3613
sg4
(lp3614
(dp3615
g7
I24
sg8
VP28907
p3616
sg10
I4
sg11
VCD38
p3617
sg13
I1
sasg24
(lp3618
(dp3619
g7
I86
sg27
VC0028754
p3620
sg10
I7
sg11
Vobesity
p3621
sg13
I1
sasa(dp3622
g2
S'These results suggest that CD38 deficiency impairs adipogenesis and lipogenesis through activating Sirt1/PPARGamma-FASN signalling pathway during the development of obesity.\n'
p3623
sg4
(lp3624
(dp3625
g7
I27
sg8
VP28907
p3626
sg10
I4
sg11
VCD38
p3627
sg13
I1
sa(dp3628
g7
I99
sg8
g9
sg10
I5
sg11
VSirt1
p3629
sg13
I1
sasg24
(lp3630
(dp3631
g7
I165
sg27
VC0028754
p3632
sg10
I7
sg11
Vobesity
p3633
sg13
I1
sasa(dp3634
g2
S'We also found that obesity development was associated with an increase in the number of CD38+ adipose progenitors, this effect being more pronounced in intra-abdominal than in subcutaneous fat, suggesting a higher rate of adipocyte commitment in visceral depots.\n'
p3635
sg4
(lp3636
(dp3637
g7
I88
sg8
VP28907
p3638
sg10
I5
sg11
VCD38+
p3639
sg13
I1
sasg24
(lp3640
(dp3641
g7
I19
sg27
VC0028754
p3642
sg10
I7
sg11
Vobesity
p3643
sg13
I1
sasa(dp3644
g2
S'In this study, we show that CD45RO+CD38+ Beta cell Ag-specific CD4+ T cells were present at higher frequencies in type 1 diabetes subjects compared with those in healthy subjects.\n'
p3645
sg4
(lp3646
(dp3647
g7
I28
sg8
VP28907
p3648
sg10
I25
sg11
VCD45RO+CD38+ Beta cell Ag
p3649
sg13
I4
sa(dp3650
g7
I63
sg8
VP01730
p3651
sg10
I4
sg11
VCD4+
p3652
sg13
I1
sasg24
(lp3653
(dp3654
g7
I114
sg27
VC0011854
p3655
sg10
I15
sg11
Vtype 1 diabetes
p3656
sg13
I3
sasa(dp3657
g2
S'Regulation of the SIRT/NAD system was associated with early (SIRT4, SIRT7, NAPRT1 and NMNAT2) and late phases (NMNAT3, NMRK2, ABCA1 and CD38) of glucose intolerance.\n'
p3658
sg4
(lp3659
(dp3660
g7
I86
sg8
g9
sg10
I6
sg11
VNMNAT2
p3661
sg13
I1
sa(dp3662
g7
I68
sg8
g9
sg10
I5
sg11
VSIRT7
p3663
sg13
I1
sa(dp3664
g7
I136
sg8
VP28907
p3665
sg10
I4
sg11
VCD38
p3666
sg13
I1
sa(dp3667
g7
I61
sg8
g9
sg10
I5
sg11
VSIRT4
p3668
sg13
I1
sa(dp3669
g7
I111
sg8
g9
sg10
I6
sg11
VNMNAT3
p3670
sg13
I1
sa(dp3671
g7
I75
sg8
g9
sg10
I6
sg11
VNAPRT1
p3672
sg13
I1
sasg24
(lp3673
(dp3674
g7
I145
sg27
VC0271650
p3675
sg10
I19
sg11
Vglucose intolerance
p3676
sg13
I2
sa(dp3677
g7
I23
sg27
VC1850380
p3678
sg10
I3
sg11
VNAD
p3679
sg13
I1
sasa(dp3680
g2
S'A total of eleven of genes were differently expressed in celiac patients compared with disease controls of which CD36, CD38, FOXP1, SELL, PPARA, PPARG, AGT previously associated with type 2 diabetes and AKAP6, NTNG1 with anorexia nervosa remained significant after correction for multiple testing.\n'
p3681
sg4
(lp3682
(dp3683
g7
I152
sg8
VP21549
p3684
sg10
I3
sg11
VAGT
p3685
sg13
I1
sa(dp3686
g7
I119
sg8
VP28907
p3687
sg10
I4
sg11
VCD38
p3688
sg13
I1
sa(dp3689
g7
I145
sg8
g9
sg10
I5
sg11
VPPARG
p3690
sg13
I1
sa(dp3691
g7
I132
sg8
VP14151
p3692
sg10
I4
sg11
VSELL
p3693
sg13
I1
sa(dp3694
g7
I138
sg8
g9
sg10
I5
sg11
VPPARA
p3695
sg13
I1
sa(dp3696
g7
I210
sg8
g9
sg10
I5
sg11
VNTNG1
p3697
sg13
I1
sa(dp3698
g7
I125
sg8
g9
sg10
I5
sg11
VFOXP1
p3699
sg13
I1
sa(dp3700
g7
I203
sg8
g9
sg10
I5
sg11
VAKAP6
p3701
sg13
I1
sasg24
(lp3702
(dp3703
g7
I183
sg27
VC0011860
p3704
sg10
I15
sg11
Vtype 2 diabetes
p3705
sg13
I3
sa(dp3706
g7
I221
sg27
VC0003125
p3707
sg10
I16
sg11
Vanorexia nervosa
p3708
sg13
I2
sasa(dp3709
g2
S'PF significantly increased the expression of nuclear factor-YA (NF-YA), which strongly upregulated the molecules involved in the proteolytic machinery [molecular chaperones, carboxyl terminus of Hsc70-interacting protein and transcription factor EB], which thus mitigated the behavioral and pathological impairments in an SBMA mouse model through the upregulation of pathogenic androgen receptor protein clearance in motor neurons and muscles.\n'
p3710
sg4
(lp3711
(dp3712
g7
I195
sg8
VP50502
p3713
sg10
I25
sg11
VHsc70-interacting protein
p3714
sg13
I2
sa(dp3715
g7
I378
sg8
VP10275
p3716
sg10
I25
sg11
Vandrogen receptor protein
p3717
sg13
I3
sa(dp3718
g7
I45
sg8
VP01160
p3719
sg10
I17
sg11
Vnuclear factor-YA
p3720
sg13
I2
sa(dp3721
g7
I225
sg8
VP19484
p3722
sg10
I23
sg11
Vtranscription factor EB
p3723
sg13
I3
sa(dp3724
g7
I64
sg8
VP23511
p3725
sg10
I5
sg11
VNF-YA
p3726
sg13
I1
sasg24
(lp3727
(dp3728
g7
I322
sg27
VC1839259
p3729
sg10
I4
sg11
VSBMA
p3730
sg13
I1
sasa(dp3731
g2
S'One hundred and seven patients (49.3%) had no significant change in BP; 30.9% had intradialytic hypertension (IDHT) while 19.8% had intradialytic hypotension (IDH).\n'
p3732
sg4
(lp3733
sg24
(lp3734
(dp3735
g7
I96
sg27
VC0020538
p3736
sg10
I12
sg11
Vhypertension
p3737
sg13
I1
sasa(dp3738
g2
S"This week's articles describe ways to treat arthritis caused by chikungunya virus, IDH-mutant cancers, and hypertension.\n"
p3739
sg4
(lp3740
sg24
(lp3741
(dp3742
g7
I94
sg27
VC0006826
p3743
sg10
I7
sg11
Vcancers
p3744
sg13
I1
sa(dp3745
g7
I107
sg27
VC0020538
p3746
sg10
I12
sg11
Vhypertension
p3747
sg13
I1
sa(dp3748
g7
I64
sg27
VC0008055
p3749
sg10
I11
sg11
Vchikungunya
p3750
sg13
I1
sa(dp3751
g7
I87
sg27
VC0596988
p3752
sg10
I6
sg11
Vmutant
p3753
sg13
I1
sa(dp3754
g7
I44
sg27
VC0003864
p3755
sg10
I9
sg11
Varthritis
p3756
sg13
I1
sasa(dp3757
g2
S'On univariate analysis, diabetes mellitus, hypertension (HTN), cerebrovascular accident (CVA), left ventricular dysfunction (LVD), peripheral vascular disease (PVD), smoking, hepatitis C, inadequate dialysis, intradialytic hypotension (IDH), interdialytic weight gain, low serum creatinine &lt;4 mg/dL, and anemia (Hb &lt;10 g/dL) were found to be statistically significantly different between frail and nonfrail groups On multivariate regression analysis, only HTN, PVD, CVA, anemia, smoking, and IDH were found to be significant.\n'
p3758
sg4
(lp3759
(dp3760
g7
I57
sg8
VP24821
p3761
sg10
I3
sg11
VHTN
p3762
sg13
I1
sa(dp3763
g7
I209
sg8
VP48735
p3764
sg10
I25
sg11
Vintradialytic hypotension
p3765
sg13
I2
sa(dp3766
g7
I43
sg8
VP24821
p3767
sg10
I12
sg11
Vhypertension
p3768
sg13
I1
sa(dp3769
g7
I236
sg8
VP48735
p3770
sg10
I3
sg11
VIDH
p3771
sg13
I1
sasg24
(lp3772
(dp3773
g7
I160
sg27
VC0085096
p3774
sg10
I3
sg11
VPVD
p3775
sg13
I1
sa(dp3776
g7
I43
sg27
VC0020538
p3777
sg10
I12
sg11
Vhypertension
p3778
sg13
I1
sa(dp3779
g7
I89
sg27
VC0038454
p3780
sg10
I3
sg11
VCVA
p3781
sg13
I1
sa(dp3782
g7
I57
sg27
VC0020538
p3783
sg10
I3
sg11
VHTN
p3784
sg13
I1
sa(dp3785
g7
I125
sg27
VC0242698
p3786
sg10
I3
sg11
VLVD
p3787
sg13
I1
sa(dp3788
g7
I95
sg27
VC0242698
p3789
sg10
I28
sg11
Vleft ventricular dysfunction
p3790
sg13
I3
sa(dp3791
g7
I160
sg27
VC0085096
p3792
sg10
I3
sg11
VPVD
p3793
sg13
I1
sa(dp3794
g7
I307
sg27
VC0002871
p3795
sg10
I6
sg11
Vanemia
p3796
sg13
I1
sa(dp3797
g7
I63
sg27
VC0038454
p3798
sg10
I24
sg11
Vcerebrovascular accident
p3799
sg13
I2
sa(dp3800
g7
I307
sg27
VC0002871
p3801
sg10
I6
sg11
Vanemia
p3802
sg13
I1
sa(dp3803
g7
I57
sg27
VC0020538
p3804
sg10
I3
sg11
VHTN
p3805
sg13
I1
sa(dp3806
g7
I24
sg27
VC0011849
p3807
sg10
I17
sg11
Vdiabetes mellitus
p3808
sg13
I2
sa(dp3809
g7
I131
sg27
VC0085096
p3810
sg10
I27
sg11
Vperipheral vascular disease
p3811
sg13
I3
sa(dp3812
g7
I175
sg27
VC0019196
p3813
sg10
I11
sg11
Vhepatitis C
p3814
sg13
I2
sa(dp3815
g7
I89
sg27
VC0038454
p3816
sg10
I3
sg11
VCVA
p3817
sg13
I1
sasa(dp3818
g2
S'Factors predicting frailty include HTN, smoking, LVD, PVD, CVA, smoking, anemia, and IDH.\n'
p3819
sg4
(lp3820
(dp3821
g7
I85
sg8
VP48735
p3822
sg10
I3
sg11
VIDH
p3823
sg13
I1
sasg24
(lp3824
(dp3825
g7
I59
sg27
VC0038454
p3826
sg10
I3
sg11
VCVA
p3827
sg13
I1
sa(dp3828
g7
I73
sg27
VC0002871
p3829
sg10
I6
sg11
Vanemia
p3830
sg13
I1
sa(dp3831
g7
I35
sg27
VC0020538
p3832
sg10
I3
sg11
VHTN
p3833
sg13
I1
sa(dp3834
g7
I54
sg27
VC0085096
p3835
sg10
I3
sg11
VPVD
p3836
sg13
I1
sasa(dp3837
g2
S'Intradialytic hypertension (IDH) increases morbidity and mortality.\n'
p3838
sg4
(lp3839
sg24
(lp3840
(dp3841
g7
I14
sg27
VC0020538
p3842
sg10
I12
sg11
Vhypertension
p3843
sg13
I1
sasa(dp3844
g2
S'Intradialytic hypertension (ID-HTN) is an increasingly recognized phenomenon and although less common than IDH, portends poor cardiovascular prognosis as well as reflects higher hypertension burden in the dialysis population.\n'
p3845
sg4
(lp3846
sg24
(lp3847
(dp3848
g7
I31
sg27
VC0020538
p3849
sg10
I3
sg11
VHTN
p3850
sg13
I1
sa(dp3851
g7
I14
sg27
VC0020538
p3852
sg10
I12
sg11
Vhypertension
p3853
sg13
I1
sa(dp3854
g7
I14
sg27
VC0020538
p3855
sg10
I12
sg11
Vhypertension
p3856
sg13
I1
sasa(dp3857
g2
S'Dry weight, hypertension, and phosphorus levels are modifiable risk factors to possibly reduce the rate of IDH episodes.\n'
p3858
sg4
(lp3859
sg24
(lp3860
(dp3861
g7
I12
sg27
VC0020538
p3862
sg10
I12
sg11
Vhypertension
p3863
sg13
I1
sasa(dp3864
g2
S"We believe that all hypertension guidelines should follow the National Institute for Health and Excellence (NICE) and make IDP and CTD first choice 'thiazide-like diuretics.'"
p3865
sg4
(lp3866
sg24
(lp3867
(dp3868
g7
I20
sg27
VC0020538
p3869
sg10
I12
sg11
Vhypertension
p3870
sg13
I1
sasa(dp3871
g2
S'Immunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analyzed (14 glioblastomas, 14 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas, 5 diffuse astrocytomas, 1 oligodendroglioma, and 1 pilocytic astrocytoma) expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in nonneoplastic tissues from the cerebral cortex.\n'
p3872
sg4
(lp3873
(dp3874
g7
I43
sg8
VP35712
p3875
sg10
I4
sg11
VSOX6
p3876
sg13
I1
sa(dp3877
g7
I38
sg8
VP35712
p3878
sg10
I18
sg11
Vanti-SOX6 antibody
p3879
sg13
I2
sa(dp3880
g7
I43
sg8
VP35712
p3881
sg10
I4
sg11
VSOX6
p3882
sg13
I1
sasg24
(lp3883
(dp3884
g7
I134
sg27
VC0004114
p3885
sg10
I12
sg11
Vastrocytomas
p3886
sg13
I1
sa(dp3887
g7
I77
sg27
VC0017638
p3888
sg10
I6
sg11
Vglioma
p3889
sg13
I1
sa(dp3890
g7
I272
sg27
VC0027651
p3891
sg10
I5
sg11
Vtumor
p3892
sg13
I1
sa(dp3893
g7
I105
sg27
VC0017636
p3894
sg10
I13
sg11
Vglioblastomas
p3895
sg13
I1
sa(dp3896
g7
I231
sg27
VC0334583
p3897
sg10
I21
sg11
Vpilocytic astrocytoma
p3898
sg13
I2
sa(dp3899
g7
I206
sg27
VC0028945
p3900
sg10
I17
sg11
Voligodendroglioma
p3901
sg13
I1
sa(dp3902
g7
I123
sg27
VC0334579
p3903
sg10
I23
sg11
Vanaplastic astrocytomas
p3904
sg13
I2
sasa(dp3905
g2
S'To address these issues, we analyzed the production of proinflammatory mediators in mouse thyroid organs and demonstrate consistency with in vitro studies performed previously that Il1alpha, Il1beta, Il6, and Tnfalpha and the enzyme Cox2 are produced by RP3-transgenic thyroid tissue, but absent from nontransgenic thyroids.\n'
p3906
sg4
(lp3907
(dp3908
g7
I200
sg8
VP05231
p3909
sg10
I3
sg11
VIl6
p3910
sg13
I1
sa(dp3911
g7
I233
sg8
VP35354
p3912
sg10
I4
sg11
VCox2
p3913
sg13
I1
sa(dp3914
g7
I209
sg8
VP01375
p3915
sg10
I8
sg11
VTnfalpha
p3916
sg13
I1
sa(dp3917
g7
I181
sg8
VP01583
p3918
sg10
I8
sg11
VIl1alpha
p3919
sg13
I1
sa(dp3920
g7
I254
sg8
VP51808
p3921
sg10
I3
sg11
VRP3
p3922
sg13
I1
sa(dp3923
g7
I191
sg8
VP01584
p3924
sg10
I7
sg11
VIl1beta
p3925
sg13
I1
sasg24
(lp3926
(dp3927
g7
I254
sg27
VC1845667
p3928
sg10
I3
sg11
VRP3
p3929
sg13
I1
sasa(dp3930
g2
S'With a few exceptions, higher circulating levels of endostatin seem to reflect vascular and myocardial damage, and a worsened prognosis for cardiovascular events or mortality in individuals with hypertension, diabetes, kidney disease, cardiovascular disease, as well as in the general population.\n'
p3931
sg4
(lp3932
sg24
(lp3933
(dp3934
g7
I226
sg27
VC0007222
p3935
sg10
I23
sg11
Vdisease, cardiovascular
p3936
sg13
I2
sa(dp3937
g7
I209
sg27
VC0011849
p3938
sg10
I8
sg11
Vdiabetes
p3939
sg13
I1
sa(dp3940
g7
I195
sg27
VC0020538
p3941
sg10
I12
sg11
Vhypertension
p3942
sg13
I1
sasa(dp3943
g2
S'Endostatin is one of the main angiostatic mediators, and inhibits angiogenesis and prevents progression of atherosclerosis.\n'
p3944
sg4
(lp3945
sg24
(lp3946
(dp3947
g7
I107
sg27
VC0004153
p3948
sg10
I15
sg11
Vatherosclerosis
p3949
sg13
I1
sasa(dp3950
g2
S'For ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) &gt;4.9 (odds ratio, 2.40; 95% confidence interval, 1.55-3.71; P&lt;0.0001) and endostatin &gt;4.7 (odds ratio, 2.02; 95% confidence interval, 1.19-3.45; P=0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model.\n'
p3951
sg4
(lp3952
sg24
(lp3953
(dp3954
g7
I20
sg27
VC0553692
p3955
sg10
I19
sg11
Vhemorrhagic strokes
p3956
sg13
I2
sa(dp3957
g7
I32
sg27
VC0038454
p3958
sg10
I6
sg11
Vstroke
p3959
sg13
I1
sa(dp3960
g7
I352
sg27
VC0020538
p3961
sg10
I12
sg11
Vhypertension
p3962
sg13
I1
sa(dp3963
g7
I327
sg27
VC0004238
p3964
sg10
I19
sg11
Vatrial fibrillation
p3965
sg13
I2
sasa(dp3966
g2
S'In patients with coronary heart disease, the count of endothelial progenitor cells was lower by 4 times, the level of VEGF was higher by 52%, and the level of endostatin was lower by 13% than in healthy volunteers.\n'
p3967
sg4
(lp3968
sg24
(lp3969
(dp3970
g7
I17
sg27
VC0010054
p3971
sg10
I22
sg11
Vcoronary heart disease
p3972
sg13
I3
sasa(dp3973
g2
S'To examine the association between the serum endostatin levels and subclinical atherosclerosis independent of traditional risk factors in a healthy Japanese population.\n'
p3974
sg4
(lp3975
(dp3976
g7
I39
sg8
VP39059
p3977
sg10
I16
sg11
Vserum endostatin
p3978
sg13
I2
sasg24
(lp3979
(dp3980
g7
I79
sg27
VC0004153
p3981
sg10
I15
sg11
Vatherosclerosis
p3982
sg13
I1
sasa(dp3983
g2
S'A higher serum endostatin level reflected subclinical atherosclerosis in this Japanese population.\n'
p3984
sg4
(lp3985
sg24
(lp3986
(dp3987
g7
I54
sg27
VC0004153
p3988
sg10
I15
sg11
Vatherosclerosis
p3989
sg13
I1
sasa(dp3990
g2
S'The most common diseases among humanitarian cases were benign tumors (29%, 5/17), cranioplasty (23%, 4/17), obstructive hydrocephalus (11%, 2/17), nonobstructive hydrocephalus (11%, 2/17), hemifacial spasm (11%, 2/17), and cerebral angiography (11%, 2/17).\n'
p3991
sg4
(lp3992
sg24
(lp3993
(dp3994
g7
I200
sg27
VC0037763
p3995
sg10
I5
sg11
Vspasm
p3996
sg13
I1
sa(dp3997
g7
I108
sg27
VC0549423
p3998
sg10
I25
sg11
Vobstructive hydrocephalus
p3999
sg13
I2
sa(dp4000
g7
I55
sg27
VC0086692
p4001
sg10
I13
sg11
Vbenign tumors
p4002
sg13
I2
sa(dp4003
g7
I120
sg27
VC0020255
p4004
sg10
I13
sg11
Vhydrocephalus
p4005
sg13
I1
sasa(dp4006
g2
S'Twenty-seven (33.8%) patients developed ARE, 5 (6%) developed hydrocephalus, 10 (12.5%) reported new ataxia, 17 (21%) developed trigeminal dysfunction, 3 (3.75%) had facial weakness, and 1 patient developed hemifacial spasm.\n'
p4007
sg4
(lp4008
sg24
(lp4009
(dp4010
g7
I101
sg27
VC0004134
p4011
sg10
I6
sg11
Vataxia
p4012
sg13
I1
sa(dp4013
g7
I166
sg27
VC0427055
p4014
sg10
I15
sg11
Vfacial weakness
p4015
sg13
I2
sa(dp4016
g7
I62
sg27
VC0020255
p4017
sg10
I13
sg11
Vhydrocephalus
p4018
sg13
I1
sa(dp4019
g7
I218
sg27
VC0037763
p4020
sg10
I5
sg11
Vspasm
p4021
sg13
I1
sasa(dp4022
g2
S'Twelve factors, including gender, hypertension, intracranial aneurysm, cerebral vascular spasm, hydrocephalus and conscious disturbance during hospitalization, smoking, age, WFNS (World Federation of Neurological Surgeons) scale, Fisher grade, white blood cell count and blood glucose level at admission, were analyzed by using Chi-square test, t test, and Logistic multiple regression analysis.\n'
p4023
sg4
(lp4024
sg24
(lp4025
(dp4026
g7
I61
sg27
VC0917996
p4027
sg10
I18
sg11
Vaneurysm, cerebral
p4028
sg13
I2
sa(dp4029
g7
I34
sg27
VC0151740
p4030
sg10
I26
sg11
Vhypertension, intracranial
p4031
sg13
I2
sa(dp4032
g7
I96
sg27
VC0020255
p4033
sg10
I13
sg11
Vhydrocephalus
p4034
sg13
I1
sa(dp4035
g7
I80
sg27
VC0085616
p4036
sg10
I14
sg11
Vvascular spasm
p4037
sg13
I2
sasa(dp4038
g2
S'We studied 37 patients with spasm, trisomy 21, prematurity, epilepsy, psychomotor retardation, and/or hydrocephalus (study group) and 67 control patients, all between 14 months and 14 years of age.\n'
p4039
sg4
(lp4040
sg24
(lp4041
(dp4042
g7
I60
sg27
VC0085417
p4043
sg10
I21
sg11
Vepilepsy, psychomotor
p4044
sg13
I2
sa(dp4045
g7
I102
sg27
VC0020255
p4046
sg10
I13
sg11
Vhydrocephalus
p4047
sg13
I1
sa(dp4048
g7
I28
sg27
VC0037763
p4049
sg10
I5
sg11
Vspasm
p4050
sg13
I1
sa(dp4051
g7
I35
sg27
VC0013080
p4052
sg10
I10
sg11
Vtrisomy 21
p4053
sg13
I2
sasa(dp4054
g2
S'Surgical treatment after radiosurgery or radiotherapy may be necessary for tumors that continue to grow, or for patients who develop brainstem compressive symptoms, disabling hemifacial spasm, or hydrocephalus.\n'
p4055
sg4
(lp4056
sg24
(lp4057
(dp4058
g7
I186
sg27
VC0037763
p4059
sg10
I5
sg11
Vspasm
p4060
sg13
I1
sa(dp4061
g7
I75
sg27
VC0027651
p4062
sg10
I6
sg11
Vtumors
p4063
sg13
I1
sa(dp4064
g7
I196
sg27
VC0020255
p4065
sg10
I13
sg11
Vhydrocephalus
p4066
sg13
I1
sasa(dp4067
g2
S'Among these, 236 differentially expressed genes (DEGs) were statistically significant, including many DEGs that were novel in cervical cancer, including gastrulation brain homeobox 2,5-hydroxytryptamine receptor 1D and endothelin 3.\n'
p4068
sg4
(lp4069
(dp4070
g7
I49
sg8
g9
sg10
I4
sg11
VDEGs
p4071
sg13
I1
sa(dp4072
g7
I219
sg8
VP14138
p4073
sg10
I12
sg11
Vendothelin 3
p4074
sg13
I2
sa(dp4075
g7
I166
sg8
VP52954
p4076
sg10
I48
sg11
Vbrain homeobox 2,5-hydroxytryptamine receptor 1D
p4077
sg13
I5
sa(dp4078
g7
I17
sg8
g9
sg10
I30
sg11
Vdifferentially expressed genes
p4079
sg13
I3
sasg24
(lp4080
(dp4081
g7
I126
sg27
VC0302592
p4082
sg10
I15
sg11
Vcervical cancer
p4083
sg13
I2
sasa(dp4084
g2
S'A total of 5 overlapping genes [dipeptidyl peptidase 4 (DPP4); endothelin 3 (EDN3); fibroblast growth factor 14 (FGF14); tachykinin, precursor 1 (TAC1); and wingless-type MMTV integration site family, member 16 (WNT16)] between the 561 overlapping differentially methylated genes and the 242 DEGs were identified, which were downregulated and hypermethylated simultaneously in cervical cancer samples.\n'
p4085
sg4
(lp4086
(dp4087
g7
I121
sg8
VP29401
p4088
sg10
I23
sg11
Vtachykinin, precursor 1
p4089
sg13
I3
sa(dp4090
g7
I157
sg8
g9
sg10
I53
sg11
Vwingless-type MMTV integration site family, member 16
p4091
sg13
I7
sa(dp4092
g7
I31
sg8
VP27487
p4093
sg10
I23
sg11
V[dipeptidyl peptidase 4
p4094
sg13
I3
sa(dp4095
g7
I56
sg8
VP27487
p4096
sg10
I4
sg11
VDPP4
p4097
sg13
I1
sa(dp4098
g7
I84
sg8
g9
sg10
I27
sg11
Vfibroblast growth factor 14
p4099
sg13
I4
sa(dp4100
g7
I212
sg8
g9
sg10
I5
sg11
VWNT16
p4101
sg13
I1
sa(dp4102
g7
I113
sg8
g9
sg10
I5
sg11
VFGF14
p4103
sg13
I1
sa(dp4104
g7
I63
sg8
VP14138
p4105
sg10
I12
sg11
Vendothelin 3
p4106
sg13
I2
sa(dp4107
g7
I77
sg8
VP14138
p4108
sg10
I4
sg11
VEDN3
p4109
sg13
I1
sasg24
(lp4110
(dp4111
g7
I377
sg27
VC0302592
p4112
sg10
I15
sg11
Vcervical cancer
p4113
sg13
I2
sasa(dp4114
g2
S'Employing functions of several bioinformatics tools, we selected 143 differentially expressed genes (DEGs) associated with the cervical cancer.\n'
p4115
sg4
(lp4116
(dp4117
g7
I101
sg8
g9
sg10
I4
sg11
VDEGs
p4118
sg13
I1
sa(dp4119
g7
I69
sg8
g9
sg10
I30
sg11
Vdifferentially expressed genes
p4120
sg13
I3
sasg24
(lp4121
(dp4122
g7
I127
sg27
VC0302592
p4123
sg10
I15
sg11
Vcervical cancer
p4124
sg13
I2
sasa(dp4125
g2
S'The results of bioinformatics analysis show that these DEGs play important roles in the development of cervical cancer.\n'
p4126
sg4
(lp4127
(dp4128
g7
I55
sg8
g9
sg10
I4
sg11
VDEGs
p4129
sg13
I1
sasg24
(lp4130
(dp4131
g7
I103
sg27
VC0302592
p4132
sg10
I15
sg11
Vcervical cancer
p4133
sg13
I2
sasa(dp4134
g2
S'A total of 1,160 and 756 DEGs were identified in the pre-invasive and invasive stages of cervical cancer, respectively.\n'
p4135
sg4
(lp4136
sg24
(lp4137
(dp4138
g7
I89
sg27
VC0302592
p4139
sg10
I15
sg11
Vcervical cancer
p4140
sg13
I2
sasa(dp4141
g2
S'Survival analysis then revealed a five-PcG gene signature one protective gene (enhancer of zeste homolog 1) and four risky genes (EZH2, PHD finger protein 19, DNMT3A and DNMT3B), which may identify patients with high risk of poor prognosis of glioma.\n'
p4142
sg4
(lp4143
(dp4144
g7
I170
sg8
g9
sg10
I6
sg11
VDNMT3B
p4145
sg13
I1
sa(dp4146
g7
I91
sg8
g9
sg10
I15
sg11
Vzeste homolog 1
p4147
sg13
I3
sa(dp4148
g7
I159
sg8
g9
sg10
I6
sg11
VDNMT3A
p4149
sg13
I1
sa(dp4150
g7
I136
sg8
g9
sg10
I21
sg11
VPHD finger protein 19
p4151
sg13
I4
sa(dp4152
g7
I130
sg8
g9
sg10
I4
sg11
VEZH2
p4153
sg13
I1
sasg24
(lp4154
(dp4155
g7
I243
sg27
VC0017638
p4156
sg10
I6
sg11
Vglioma
p4157
sg13
I1
sasa(dp4158
g2
S'In this study, we exploited this platform to evaluate the behavior of two biodegradable formulations, poly-Epsilon-caprolactone (PCL3) and poly lactic-acid (PLA8), respectively, in cellular and animal models of triple-negative breast cancer (TNBC).\n'
p4159
sg4
(lp4160
(dp4161
g7
I129
sg8
g9
sg10
I4
sg11
VPCL3
p4162
sg13
I1
sa(dp4163
g7
I102
sg8
g9
sg10
I25
sg11
Vpoly-Epsilon-caprolactone
p4164
sg13
I1
sasg24
(lp4165
(dp4166
g7
I227
sg27
VC0678222
p4167
sg10
I13
sg11
Vbreast cancer
p4168
sg13
I2
sasa(dp4169
g2
S'Interestingly, changes in EZH2, PHF19, CBX7, CBX6 and EZH1 occurred progressively as astrocytoma grade increased.\n'
p4170
sg4
(lp4171
(dp4172
g7
I26
sg8
g9
sg10
I4
sg11
VEZH2
p4173
sg13
I1
sa(dp4174
g7
I39
sg8
g9
sg10
I4
sg11
VCBX7
p4175
sg13
I1
sa(dp4176
g7
I54
sg8
g9
sg10
I4
sg11
VEZH1
p4177
sg13
I1
sa(dp4178
g7
I45
sg8
g9
sg10
I4
sg11
VCBX6
p4179
sg13
I1
sa(dp4180
g7
I32
sg8
g9
sg10
I5
sg11
VPHF19
p4181
sg13
I1
sasg24
(lp4182
(dp4183
g7
I85
sg27
VC0004114
p4184
sg10
I11
sg11
Vastrocytoma
p4185
sg13
I1
sasa(dp4186
g2
S'In this report, we show that PHF19 silencing reduces the cell proliferation rate and increases the transendothelial migration capacities of melanoma cell lines.\n'
p4187
sg4
(lp4188
(dp4189
g7
I29
sg8
g9
sg10
I5
sg11
VPHF19
p4190
sg13
I1
sasg24
(lp4191
(dp4192
g7
I140
sg27
VC0025202
p4193
sg10
I8
sg11
Vmelanoma
p4194
sg13
I1
sa(dp4195
g7
I62
sg27
VC0334094
p4196
sg10
I13
sg11
Vproliferation
p4197
sg13
I1
sasa(dp4198
g2
S'Our data therefore indicate the role of PHF19 and its upstream regulator, Akt, in the phenotype switch of melanoma cells from proliferative to invasive states.\n'
p4199
sg4
(lp4200
(dp4201
g7
I40
sg8
g9
sg10
I5
sg11
VPHF19
p4202
sg13
I1
sa(dp4203
g7
I74
sg8
g9
sg10
I3
sg11
VAkt
p4204
sg13
I1
sasg24
(lp4205
(dp4206
g7
I106
sg27
VC0025202
p4207
sg10
I8
sg11
Vmelanoma
p4208
sg13
I1
sa(dp4209
g7
I126
sg27
VC0334094
p4210
sg10
I13
sg11
Vproliferative
p4211
sg13
I1
sasa(dp4212
g2
S'Interestingly, the products of the hPCL3 gene, particularly the short form, hPCL3S, are markedly overexpressed in many types of cancers, including colon, skin, lung, rectal, cervical, uterus, and liver cancers.\n'
p4213
sg4
(lp4214
(dp4215
g7
I76
sg8
g9
sg10
I6
sg11
VhPCL3S
p4216
sg13
I1
sa(dp4217
g7
I35
sg8
g9
sg10
I10
sg11
VhPCL3 gene
p4218
sg13
I2
sasg24
(lp4219
(dp4220
g7
I128
sg27
VC0006826
p4221
sg10
I7
sg11
Vcancers
p4222
sg13
I1
sa(dp4223
g7
I196
sg27
VC0345904
p4224
sg10
I13
sg11
Vliver cancers
p4225
sg13
I2
sasa(dp4226
g2
S'Both hPCL3S and hPCL3L messages were increased dramatically in most cell lines derived from various stages of melanoma and glioma tumor progression.\n'
p4227
sg4
(lp4228
(dp4229
g7
I5
sg8
g9
sg10
I6
sg11
VhPCL3S
p4230
sg13
I1
sasg24
(lp4231
(dp4232
g7
I123
sg27
VC0017638
p4233
sg10
I6
sg11
Vglioma
p4234
sg13
I1
sa(dp4235
g7
I110
sg27
VC0025202
p4236
sg10
I8
sg11
Vmelanoma
p4237
sg13
I1
sa(dp4238
g7
I130
sg27
VC0178874
p4239
sg10
I17
sg11
Vtumor progression
p4240
sg13
I2
sasa(dp4241
g2
S'Fifty patients (19 males and 31 females, mean age 52.4 y) showed sagging posterior layer TLF, and 32 of them developed &gt;=1 junctional problems, such as retrolistheses (n=25), compression fractures (n=5), spondylolistheses (n=4), progressive scoliosis (n=4), and segmental instability with bone marrow change (n=2).\n'
p4242
sg4
(lp4243
sg24
(lp4244
(dp4245
g7
I244
sg27
VC0700208
p4246
sg10
I9
sg11
Vscoliosis
p4247
sg13
I1
sa(dp4248
g7
I178
sg27
VC0521169
p4249
sg10
I21
sg11
Vcompression fractures
p4250
sg13
I2
sa(dp4251
g7
I207
sg27
VC0038016
p4252
sg10
I17
sg11
Vspondylolistheses
p4253
sg13
I1
sasa(dp4254
g2
S'However, the patients with thoracolumbar fracture (TLF) had significantly more MSCs than those with degenerative disc disease (DDD), but not for NCs.\n'
p4255
sg4
(lp4256
sg24
(lp4257
(dp4258
g7
I127
sg27
VC0406811
p4259
sg10
I3
sg11
VDDD
p4260
sg13
I1
sa(dp4261
g7
I100
sg27
VC0158266
p4262
sg10
I25
sg11
Vdegenerative disc disease
p4263
sg13
I3
sasa(dp4264
g2
S'Common physiological pathways are involved in several ARCA, such as DNA repair deficiency (AOA1, ataxia telangiectasia [AT]...), RNA termination disorder (AOA2), mitochondrial defect (FRDA, sensory ataxic neuropathy with dysarthria and ophthalmoplegia [Sando]...), lipoprotein assembly defects (AVED, abetalipoproteinemia [ABL]), chaperon protein disorders (ARSACS, Marinesco-Sjoegren syndrome [MSS]) or peroxysomal diseases (Refsum disease [RD]).\n'
p4265
sg4
(lp4266
(dp4267
g7
I184
sg8
g9
sg10
I4
sg11
VFRDA
p4268
sg13
I1
sasg24
(lp4269
(dp4270
g7
I236
sg27
VC0029089
p4271
sg10
I15
sg11
Vophthalmoplegia
p4272
sg13
I1
sa(dp4273
g7
I323
sg27
VC0000744
p4274
sg10
I3
sg11
VABL
p4275
sg13
I1
sa(dp4276
g7
I385
sg27
VC0039082
p4277
sg10
I8
sg11
Vsyndrome
p4278
sg13
I1
sa(dp4279
g7
I301
sg27
VC0000744
p4280
sg10
I20
sg11
Vabetalipoproteinemia
p4281
sg13
I1
sa(dp4282
g7
I184
sg27
VC1856689
p4283
sg10
I4
sg11
VFRDA
p4284
sg13
I1
sa(dp4285
g7
I221
sg27
VC0013362
p4286
sg10
I10
sg11
Vdysarthria
p4287
sg13
I1
sa(dp4288
g7
I155
sg27
VC1853761
p4289
sg10
I4
sg11
VAOA2
p4290
sg13
I1
sa(dp4291
g7
I253
sg27
VC1843851
p4292
sg10
I5
sg11
VSando
p4293
sg13
I1
sa(dp4294
g7
I205
sg27
VC0442874
p4295
sg10
I10
sg11
Vneuropathy
p4296
sg13
I1
sa(dp4297
g7
I358
sg27
VC1849140
p4298
sg10
I6
sg11
VARSACS
p4299
sg13
I1
sa(dp4300
g7
I97
sg27
VC0004135
p4301
sg10
I21
sg11
Vataxia telangiectasia
p4302
sg13
I2
sa(dp4303
g7
I198
sg27
VC0234366
p4304
sg10
I6
sg11
Vataxic
p4305
sg13
I1
sa(dp4306
g7
I91
sg27
VC1859598
p4307
sg10
I4
sg11
VAOA1
p4308
sg13
I1
sa(dp4309
g7
I426
sg27
VC0034960
p4310
sg10
I14
sg11
VRefsum disease
p4311
sg13
I2
sa(dp4312
g7
I68
sg27
VC0268134
p4313
sg10
I21
sg11
VDNA repair deficiency
p4314
sg13
I3
sa(dp4315
g7
I295
sg27
VC1848533
p4316
sg10
I4
sg11
VAVED
p4317
sg13
I1
sa(dp4318
g7
I395
sg27
VC0024814
p4319
sg10
I3
sg11
VMSS
p4320
sg13
I1
sasa(dp4321
g2
S"While Friedreich's ataxia (FRDA) and ataxia telangiectasia (AT) are known to be the two most frequent forms of autosomal recessive cerebellar ataxia (ARCA), knowledge on the other forms of ARCA has been obtained only recently, and they appear to be rarer.\n"
p4322
sg4
(lp4323
sg24
(lp4324
(dp4325
g7
I60
sg27
VC0004135
p4326
sg10
I2
sg11
VAT
p4327
sg13
I1
sa(dp4328
g7
I37
sg27
VC0004135
p4329
sg10
I21
sg11
Vataxia telangiectasia
p4330
sg13
I2
sa(dp4331
g7
I6
sg27
VC0016719
p4332
sg10
I19
sg11
VFriedreich's ataxia
p4333
sg13
I2
sa(dp4334
g7
I111
sg27
VC0007758
p4335
sg10
I37
sg11
Vautosomal recessive cerebellar ataxia
p4336
sg13
I4
sa(dp4337
g7
I27
sg27
VC1856689
p4338
sg10
I4
sg11
VFRDA
p4339
sg13
I1
sa(dp4340
g7
I150
sg27
VC0007758
p4341
sg10
I4
sg11
VARCA
p4342
sg13
I1
sa(dp4343
g7
I150
sg27
VC0007758
p4344
sg10
I4
sg11
VARCA
p4345
sg13
I1
sasa(dp4346
g2
S'Transcription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy.\n'
p4347
sg4
(lp4348
(dp4349
g7
I0
sg8
VP35398
p4350
sg10
I26
sg11
VTranscription factor MEF2C
p4351
sg13
I3
sa(dp4352
g7
I98
sg8
g9
sg10
I11
sg11
Vhuman MEF2C
p4353
sg13
I2
sasg24
(lp4354
(dp4355
g7
I174
sg27
VC0014544
p4356
sg10
I8
sg11
Vepilepsy
p4357
sg13
I1
sa(dp4358
g7
I88
sg27
VC1510586
p4359
sg10
I3
sg11
VASD
p4360
sg13
I1
sa(dp4361
g7
I145
sg27
VC0025362
p4362
sg10
I23
sg11
Vintellectual disability
p4363
sg13
I2
sa(dp4364
g7
I88
sg27
VC1510586
p4365
sg10
I3
sg11
VASD
p4366
sg13
I1
sa(dp4367
g7
I62
sg27
VC1510586
p4368
sg10
I24
sg11
Vautism spectrum disorder
p4369
sg13
I3
sasa(dp4370
g2
S'The microRNAs target a group of genes enriched for synaptic signaling and epilepsy risk, including SLC12A5, SYT1, GRIN2A, GRIN2B, KCNB1, SCN2A, TSC1, and MEF2C.\n'
p4371
sg4
(lp4372
(dp4373
g7
I108
sg8
VP21579
p4374
sg10
I4
sg11
VSYT1
p4375
sg13
I1
sa(dp4376
g7
I122
sg8
g9
sg10
I6
sg11
VGRIN2B
p4377
sg13
I1
sa(dp4378
g7
I99
sg8
g9
sg10
I7
sg11
VSLC12A5
p4379
sg13
I1
sa(dp4380
g7
I137
sg8
g9
sg10
I5
sg11
VSCN2A
p4381
sg13
I1
sa(dp4382
g7
I154
sg8
g9
sg10
I5
sg11
VMEF2C
p4383
sg13
I1
sa(dp4384
g7
I114
sg8
g9
sg10
I6
sg11
VGRIN2A
p4385
sg13
I1
sa(dp4386
g7
I130
sg8
g9
sg10
I5
sg11
VKCNB1
p4387
sg13
I1
sa(dp4388
g7
I144
sg8
g9
sg10
I4
sg11
VTSC1
p4389
sg13
I1
sasg24
(lp4390
(dp4391
g7
I144
sg27
VC1854465
p4392
sg10
I4
sg11
VTSC1
p4393
sg13
I1
sa(dp4394
g7
I74
sg27
VC0014544
p4395
sg10
I8
sg11
Vepilepsy
p4396
sg13
I1
sasa(dp4397
g2
S"Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.\n"
p4398
sg4
(lp4399
(dp4400
g7
I292
sg8
g9
sg10
I6
sg11
VPICALM
p4401
sg13
I1
sa(dp4402
g7
I176
sg8
g9
sg10
I5
sg11
VCD2AP
p4403
sg13
I1
sa(dp4404
g7
I270
sg8
g9
sg10
I6
sg11
VMS4A4E
p4405
sg13
I1
sa(dp4406
g7
I255
sg8
g9
sg10
I5
sg11
VMEF2C
p4407
sg13
I1
sa(dp4408
g7
I227
sg8
VP30486
p4409
sg10
I3
sg11
VHLA
p4410
sg13
I1
sa(dp4411
g7
I206
sg8
g9
sg10
I4
sg11
VDSG2
p4412
sg13
I1
sa(dp4413
g7
I189
sg8
g9
sg10
I5
sg11
VCELF1
p4414
sg13
I1
sa(dp4415
g7
I157
sg8
VP02649
p4416
sg10
I4
sg11
VAPOE
p4417
sg13
I1
sa(dp4418
g7
I150
sg8
g9
sg10
I5
sg11
VABCA7
p4419
sg13
I1
sa(dp4420
g7
I313
sg8
g9
sg10
I4
sg11
VRIN3
p4421
sg13
I1
sa(dp4422
g7
I328
sg8
g9
sg10
I5
sg11
VSORL1
p4423
sg13
I1
sa(dp4424
g7
I319
sg8
g9
sg10
I7
sg11
VSLC24A4
p4425
sg13
I1
sa(dp4426
g7
I247
sg8
g9
sg10
I6
sg11
VINPP5D
p4427
sg13
I1
sa(dp4428
g7
I262
sg8
g9
sg10
I6
sg11
VMS4A4A
p4429
sg13
I1
sa(dp4430
g7
I183
sg8
VP20138
p4431
sg10
I4
sg11
VCD33
p4432
sg13
I1
sa(dp4433
g7
I300
sg8
g9
sg10
I4
sg11
VPLD3
p4434
sg13
I1
sa(dp4435
g7
I219
sg8
g9
sg10
I6
sg11
VFERMT2
p4436
sg13
I1
sa(dp4437
g7
I169
sg8
g9
sg10
I5
sg11
VCASS4
p4438
sg13
I1
sa(dp4439
g7
I196
sg8
VP10909
p4440
sg10
I3
sg11
VCLU
p4441
sg13
I1
sa(dp4442
g7
I306
sg8
g9
sg10
I5
sg11
VPTK2B
p4443
sg13
I1
sa(dp4444
g7
I212
sg8
VP21709
p4445
sg10
I5
sg11
VEPHA1
p4446
sg13
I1
sa(dp4447
g7
I278
sg8
g9
sg10
I6
sg11
VMS4A6E
p4448
sg13
I1
sa(dp4449
g7
I227
sg8
VP30486
p4450
sg10
I3
sg11
VHLA
p4451
sg13
I1
sa(dp4452
g7
I201
sg8
VP17927
p4453
sg10
I3
sg11
VCR1
p4454
sg13
I1
sa(dp4455
g7
I339
sg8
g9
sg10
I12
sg11
VZCWPW1 genes
p4456
sg13
I2
sa(dp4457
g7
I286
sg8
g9
sg10
I4
sg11
VNME8
p4458
sg13
I1
sa(dp4459
g7
I231
sg8
g9
sg10
I4
sg11
VDRB1
p4460
sg13
I1
sasg24
(lp4461
(dp4462
g7
I95
sg27
VC0002395
p4463
sg10
I20
sg11
VAlzheimer's diseases
p4464
sg13
I2
sa(dp4465
g7
I117
sg27
VC0002395
p4466
sg10
I2
sg11
VAD
p4467
sg13
I1
sasa(dp4468
g2
S'Epilepsy-causing SIK1 sequence variations resulted in abnormalities in the MEF2C-ARC pathway of neuronal development and synapse activity response.\n'
p4469
sg4
(lp4470
(dp4471
g7
I17
sg8
VP57059
p4472
sg10
I13
sg11
VSIK1 sequence
p4473
sg13
I2
sa(dp4474
g7
I81
sg8
g9
sg10
I3
sg11
VARC
p4475
sg13
I1
sa(dp4476
g7
I75
sg8
g9
sg10
I5
sg11
VMEF2C
p4477
sg13
I1
sasg24
(lp4478
(dp4479
g7
I81
sg27
VC0001857
p4480
sg10
I3
sg11
VARC
p4481
sg13
I1
sa(dp4482
g7
I0
sg27
VC0014544
p4483
sg10
I8
sg11
VEpilepsy
p4484
sg13
I1
sasa(dp4485
g2
S'This work provides the first insights into the mechanisms of pathogenesis in SIK1 syndrome, and extends the ARX-MEF2C pathway in the pathogenesis of developmental epilepsy.\n'
p4486
sg4
(lp4487
(dp4488
g7
I112
sg8
g9
sg10
I5
sg11
VMEF2C
p4489
sg13
I1
sa(dp4490
g7
I108
sg8
g9
sg10
I3
sg11
VARX
p4491
sg13
I1
sasg24
(lp4492
(dp4493
g7
I61
sg27
VC0699748
p4494
sg10
I12
sg11
Vpathogenesis
p4495
sg13
I1
sa(dp4496
g7
I82
sg27
VC0039082
p4497
sg10
I8
sg11
Vsyndrome
p4498
sg13
I1
sa(dp4499
g7
I163
sg27
VC0014544
p4500
sg10
I8
sg11
Vepilepsy
p4501
sg13
I1
sa(dp4502
g7
I61
sg27
VC0699748
p4503
sg10
I12
sg11
Vpathogenesis
p4504
sg13
I1
sasa(dp4505
g2
S"A common single nucleotide polymorphism (SNP, rs190982) in MEF2C gene was identified to be related to late-onset Alzheimer's disease (LOAD) in Caucasians in a large meta-analysis of genome-wide association studies (GWAS).\n"
p4506
sg4
(lp4507
(dp4508
g7
I59
sg8
g9
sg10
I10
sg11
VMEF2C gene
p4509
sg13
I2
sasg24
(lp4510
(dp4511
g7
I113
sg27
VC1521724
p4512
sg10
I19
sg11
VAlzheimer's disease
p4513
sg13
I2
sasa(dp4514
g2
S'A key factor protecting from oxidative stress in gestational diabetes mellitus (GDM) and in type 2 diabetes (T2D) is paraoxonase-1 (PON1).\n'
p4515
sg4
(lp4516
(dp4517
g7
I132
sg8
VP27169
p4518
sg10
I4
sg11
VPON1
p4519
sg13
I1
sa(dp4520
g7
I117
sg8
VP14222
p4521
sg10
I13
sg11
Vparaoxonase-1
p4522
sg13
I1
sasg24
(lp4523
(dp4524
g7
I49
sg27
VC0085207
p4525
sg10
I29
sg11
Vgestational diabetes mellitus
p4526
sg13
I3
sa(dp4527
g7
I80
sg27
VC0085207
p4528
sg10
I3
sg11
VGDM
p4529
sg13
I1
sa(dp4530
g7
I109
sg27
VC0011860
p4531
sg10
I3
sg11
VT2D
p4532
sg13
I1
sa(dp4533
g7
I29
sg27
VC0242606
p4534
sg10
I16
sg11
Voxidative stress
p4535
sg13
I2
sa(dp4536
g7
I92
sg27
VC0011860
p4537
sg10
I15
sg11
Vtype 2 diabetes
p4538
sg13
I3
sasa(dp4539
g2
S'In this study our aim was to evaluate paraoxonase (PON1) activity and free sulfhydryl groups (-SH) as antioxidative parameters and lipid hydroperoxide (LOOH) as oxidative parameter in the serum of women with gestational diabetes mellitus (GDM) and determine their relation with the degree of subclinical atherosclerosis.\n'
p4540
sg4
(lp4541
(dp4542
g7
I38
sg8
VP14222
p4543
sg10
I11
sg11
Vparaoxonase
p4544
sg13
I1
sa(dp4545
g7
I51
sg8
VP27169
p4546
sg10
I4
sg11
VPON1
p4547
sg13
I1
sasg24
(lp4548
(dp4549
g7
I304
sg27
VC0004153
p4550
sg10
I15
sg11
Vatherosclerosis
p4551
sg13
I1
sa(dp4552
g7
I208
sg27
VC0085207
p4553
sg10
I29
sg11
Vgestational diabetes mellitus
p4554
sg13
I3
sa(dp4555
g7
I239
sg27
VC0085207
p4556
sg10
I3
sg11
VGDM
p4557
sg13
I1
sasa(dp4558
g2
S'To clarify the levels of protein oxidation markers such as protein carbonyl (PCO), protein hydroperoxides (P-OOH), advanced oxidation protein products (AOPP) and nitrotyrosine (NT), as well as antioxidative enzymes such as paraoxonase (PON-1) in women with and without gestational diabetes mellitus (GDM).\n'
p4559
sg4
(lp4560
(dp4561
g7
I223
sg8
VP14222
p4562
sg10
I11
sg11
Vparaoxonase
p4563
sg13
I1
sa(dp4564
g7
I236
sg8
VP27169
p4565
sg10
I5
sg11
VPON-1
p4566
sg13
I1
sasg24
(lp4567
(dp4568
g7
I269
sg27
VC0085207
p4569
sg10
I29
sg11
Vgestational diabetes mellitus
p4570
sg13
I3
sa(dp4571
g7
I59
sg27
VC0032460
p4572
sg10
I16
sg11
Vprotein carbonyl
p4573
sg13
I2
sa(dp4574
g7
I300
sg27
VC0085207
p4575
sg10
I3
sg11
VGDM
p4576
sg13
I1
sa(dp4577
g7
I77
sg27
VC0032460
p4578
sg10
I3
sg11
VPCO
p4579
sg13
I1
sasa(dp4580
g2
S'Recently, numerous new antibodies defining the characteristic clinical phenotype have been described as anti-MDA5 antibodies associated with interstitial lung disease and amyopathic dermatomyositis or anti-TIF1Gamma antibodies as markers for paraneoplastic dermatomyositis.\n'
p4581
sg4
(lp4582
(dp4583
g7
I104
sg8
g9
sg10
I20
sg11
Vanti-MDA5 antibodies
p4584
sg13
I2
sa(dp4585
g7
I201
sg8
g9
sg10
I25
sg11
Vanti-TIF1Gamma antibodies
p4586
sg13
I2
sasg24
(lp4587
(dp4588
g7
I242
sg27
VC1735598
p4589
sg10
I30
sg11
Vparaneoplastic dermatomyositis
p4590
sg13
I2
sa(dp4591
g7
I171
sg27
VC0406645
p4592
sg10
I26
sg11
Vamyopathic dermatomyositis
p4593
sg13
I2
sa(dp4594
g7
I141
sg27
VC0206062
p4595
sg10
I25
sg11
Vinterstitial lung disease
p4596
sg13
I3
sasa(dp4597
g2
S'PM is associated with anti-synthetase antibodies (anti-Jo-1, PL-7, PL-12, OJ, and EJ) and DM with anti-Mi-2, anti-SAE, anti-TIF-1-Gamma and anti-NXP2 (both associated with cancer) or anti-MDA5 antibodies (associated with interstitial lung disease).\n'
p4598
sg4
(lp4599
(dp4600
g7
I98
sg8
g9
sg10
I9
sg11
Vanti-Mi-2
p4601
sg13
I1
sa(dp4602
g7
I140
sg8
g9
sg10
I9
sg11
Vanti-NXP2
p4603
sg13
I1
sa(dp4604
g7
I183
sg8
g9
sg10
I20
sg11
Vanti-MDA5 antibodies
p4605
sg13
I2
sa(dp4606
g7
I119
sg8
g9
sg10
I16
sg11
Vanti-TIF-1-Gamma
p4607
sg13
I1
sasg24
(lp4608
(dp4609
g7
I172
sg27
VC0006826
p4610
sg10
I6
sg11
Vcancer
p4611
sg13
I1
sa(dp4612
g7
I221
sg27
VC0206062
p4613
sg10
I25
sg11
Vinterstitial lung disease
p4614
sg13
I3
sasa(dp4615
g2
S'Twenty-six (43.3%) PM/DM-ILD patients were anti-aminoacyl tRNA-synthetase antibody-positive (anti-ARS-positive), 15 (25.0%) were anti-melanoma differentiation-associated gene 5 antibody-positive (anti-MDA5-positive), 3 (5%) were anti-signal recognition particle antibody-positive, 1 (1.7%) was anti-transcriptional intermediary factor 1-gamma antibody-positive, and 15 (25%) were MSA-negative.\n'
p4616
sg4
(lp4617
(dp4618
g7
I196
sg8
g9
sg10
I9
sg11
Vanti-MDA5
p4619
sg13
I1
sa(dp4620
g7
I129
sg8
g9
sg10
I56
sg11
Vanti-melanoma differentiation-associated gene 5 antibody
p4621
sg13
I5
sa(dp4622
g7
I229
sg8
VP61011
p4623
sg10
I41
sg11
Vanti-signal recognition particle antibody
p4624
sg13
I4
sa(dp4625
g7
I294
sg8
g9
sg10
I57
sg11
Vanti-transcriptional intermediary factor 1-gamma antibody
p4626
sg13
I5
sasg24
(lp4627
(dp4628
g7
I134
sg27
VC0025202
p4629
sg10
I8
sg11
Vmelanoma
p4630
sg13
I1
sa(dp4631
g7
I380
sg27
VC0393571
p4632
sg10
I3
sg11
VMSA
p4633
sg13
I1
sasa(dp4634
g2
S'Antibodies to transcription intermediary factor 1Gamma/Alfa (TIF1Gamma/Alfa, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD.\n'
p4635
sg4
(lp4636
(dp4637
g7
I61
sg8
g9
sg10
I9
sg11
VTIF1Gamma
p4638
sg13
I1
sa(dp4639
g7
I147
sg8
g9
sg10
I47
sg11
Vanti-melanoma differentiation-associated gene 5
p4640
sg13
I4
sa(dp4641
g7
I14
sg8
g9
sg10
I40
sg11
Vtranscription intermediary factor 1Gamma
p4642
sg13
I4
sa(dp4643
g7
I77
sg8
g9
sg10
I8
sg11
Vp155/140
p4644
sg13
I1
sa(dp4645
g7
I196
sg8
g9
sg10
I4
sg11
VMDA5
p4646
sg13
I1
sasg24
(lp4647
(dp4648
g7
I130
sg27
VC0006826
p4649
sg10
I10
sg11
Vmalignancy
p4650
sg13
I1
sa(dp4651
g7
I152
sg27
VC0025202
p4652
sg10
I8
sg11
Vmelanoma
p4653
sg13
I1
sasa(dp4654
g2
S'Anti-TIF-1Gamma positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia.\n'
p4655
sg4
(lp4656
(dp4657
g7
I0
sg8
g9
sg10
I15
sg11
VAnti-TIF-1Gamma
p4658
sg13
I1
sasg24
(lp4659
(dp4660
g7
I114
sg27
VC0034735
p4661
sg10
I18
sg11
VRaynaud phenomenon
p4662
sg13
I2
sa(dp4663
g7
I148
sg27
VC0003862
p4664
sg10
I10
sg11
Varthralgia
p4665
sg13
I1
sa(dp4666
g7
I138
sg27
VC0003864
p4667
sg10
I9
sg11
Varthritis
p4668
sg13
I1
sa(dp4669
g7
I87
sg27
VC0206062
p4670
sg10
I25
sg11
Vinterstitial lung disease
p4671
sg13
I3
sasa(dp4672
g2
S'The frequency of pulmonary fibrosis during the disease progression was 2/12, 1/4 and 1/4 in anti-TIF1Gamma, anti-NXP2 and anti-SAE, respectively.\n'
p4673
sg4
(lp4674
(dp4675
g7
I108
sg8
g9
sg10
I9
sg11
Vanti-NXP2
p4676
sg13
I1
sa(dp4677
g7
I92
sg8
g9
sg10
I14
sg11
Vanti-TIF1Gamma
p4678
sg13
I1
sasg24
(lp4679
(dp4680
g7
I47
sg27
VC0242656
p4681
sg10
I19
sg11
Vdisease progression
p4682
sg13
I2
sa(dp4683
g7
I17
sg27
VC0034069
p4684
sg10
I18
sg11
Vpulmonary fibrosis
p4685
sg13
I2
sasa(dp4686
g2
S'Each of the identified mutations altered the equilibrium between alternative GR conformations distinctively, indicating that the Hsp90 dependence of SRs may correlate with differences in the conformational dynamics of these receptors.\n'
p4687
sg4
(lp4688
(dp4689
g7
I129
sg8
VP07900
p4690
sg10
I5
sg11
VHsp90
p4691
sg13
I1
sa(dp4692
g7
I149
sg8
VP35270
p4693
sg10
I3
sg11
VSRs
p4694
sg13
I1
sa(dp4695
g7
I77
sg8
VP00390
p4696
sg10
I2
sg11
VGR
p4697
sg13
I1
sasg24
(lp4698
(dp4699
g7
I135
sg27
VC0439857
p4700
sg10
I10
sg11
Vdependence
p4701
sg13
I1
sa(dp4702
g7
I149
sg27
VC0175693
p4703
sg10
I3
sg11
VSRs
p4704
sg13
I1
sasa(dp4705
g2
S'The ubiquitous heat shock protein 90 (hsp90) has been shown to participate directly in the function of a wide variety of cellular signal transduction components, including steroid receptors (SRs).\n'
p4706
sg4
(lp4707
(dp4708
g7
I172
sg8
VP52788
p4709
sg10
I17
sg11
Vsteroid receptors
p4710
sg13
I2
sa(dp4711
g7
I15
sg8
VP07900
p4712
sg10
I21
sg11
Vheat shock protein 90
p4713
sg13
I4
sa(dp4714
g7
I38
sg8
VP07900
p4715
sg10
I5
sg11
Vhsp90
p4716
sg13
I1
sa(dp4717
g7
I191
sg8
VP35270
p4718
sg10
I3
sg11
VSRs
p4719
sg13
I1
sasg24
(lp4720
(dp4721
g7
I172
sg27
VC0175693
p4722
sg10
I17
sg11
Vsteroid receptors
p4723
sg13
I2
sa(dp4724
g7
I191
sg27
VC0175693
p4725
sg10
I3
sg11
VSRs
p4726
sg13
I1
sasa(dp4727
g2
S'However, there is still no direct evidence for an in vivo association of SRs with hsp90.\n'
p4728
sg4
(lp4729
(dp4730
g7
I82
sg8
VP07900
p4731
sg10
I5
sg11
Vhsp90
p4732
sg13
I1
sa(dp4733
g7
I73
sg8
VP35270
p4734
sg10
I3
sg11
VSRs
p4735
sg13
I1
sasg24
(lp4736
(dp4737
g7
I73
sg27
VC0175693
p4738
sg10
I3
sg11
VSRs
p4739
sg13
I1
sasa(dp4740
g2
S'The results suggest that the interaction of SRs with the hsp90 is minimal when compared to a bona fide type of interaction with the co-factors.\n'
p4741
sg4
(lp4742
(dp4743
g7
I57
sg8
VP07900
p4744
sg10
I5
sg11
Vhsp90
p4745
sg13
I1
sa(dp4746
g7
I44
sg8
VP35270
p4747
sg10
I3
sg11
VSRs
p4748
sg13
I1
sasg24
(lp4749
(dp4750
g7
I44
sg27
VC0175693
p4751
sg10
I3
sg11
VSRs
p4752
sg13
I1
sasa(dp4753
g2
S'To address the role of endothelial Cx43 in this process, we analyzed Cx43 regulation in human umbilical vein endothelial cells in the proximity of Cx43high (DU-145 and MAT-LyLu) and Cx43low prostate cancer cells (PC-3 and AT-2).\n'
p4754
sg4
(lp4755
(dp4756
g7
I168
sg8
VP24752
p4757
sg10
I8
sg11
VMAT-LyLu
p4758
sg13
I1
sa(dp4759
g7
I35
sg8
VP17302
p4760
sg10
I4
sg11
VCx43
p4761
sg13
I1
sa(dp4762
g7
I35
sg8
VP17302
p4763
sg10
I4
sg11
VCx43
p4764
sg13
I1
sa(dp4765
g7
I213
sg8
g9
sg10
I4
sg11
VPC-3
p4766
sg13
I1
sasg24
(lp4767
(dp4768
g7
I190
sg27
VC0600139
p4769
sg10
I15
sg11
Vprostate cancer
p4770
sg13
I2
sasa(dp4771
g2
S'The data on the nature of AT2-R expression in prostate tissue of prostate cancer patients may be considered as a tool for predicting biochemical recurrence after combined hormone and radiation therapy.\n'
p4772
sg4
(lp4773
(dp4774
g7
I26
sg8
VP50052
p4775
sg10
I5
sg11
VAT2-R
p4776
sg13
I1
sasg24
(lp4777
(dp4778
g7
I145
sg27
VC1458156
p4779
sg10
I10
sg11
Vrecurrence
p4780
sg13
I1
sa(dp4781
g7
I65
sg27
VC0600139
p4782
sg10
I15
sg11
Vprostate cancer
p4783
sg13
I2
sasa(dp4784
g2
S'The present study found that, similarly to 5-fluorouracil, low concentrations (1-10 myM) of 9-aminoacridine (9-AAA) inhibited the growth of the two rat prostate cancer AT-2 and Mat-LyLu cell lines and the human melanoma A375 cell line.\n'
p4785
sg4
(lp4786
(dp4787
g7
I177
sg8
VP24752
p4788
sg10
I3
sg11
VMat
p4789
sg13
I1
sa(dp4790
g7
I148
sg8
g9
sg10
I24
sg11
Vrat prostate cancer AT-2
p4791
sg13
I4
sasg24
(lp4792
(dp4793
g7
I211
sg27
VC0025202
p4794
sg10
I8
sg11
Vmelanoma
p4795
sg13
I1
sa(dp4796
g7
I111
sg27
VC0162871
p4797
sg10
I3
sg11
VAAA
p4798
sg13
I1
sa(dp4799
g7
I152
sg27
VC0600139
p4800
sg10
I15
sg11
Vprostate cancer
p4801
sg13
I2
sasa(dp4802
g2
S'Furthermore, our previous studies indicate that increased expression of Ang II type 2 receptor (AT2R) alone induced apoptosis in human prostate cancer lines, an effect that did not require Ang II.\n'
p4803
sg4
(lp4804
(dp4805
g7
I72
sg8
VP01019
p4806
sg10
I22
sg11
VAng II type 2 receptor
p4807
sg13
I5
sa(dp4808
g7
I72
sg8
VP01019
p4809
sg10
I6
sg11
VAng II
p4810
sg13
I2
sa(dp4811
g7
I96
sg8
VP50052
p4812
sg10
I4
sg11
VAT2R
p4813
sg13
I1
sasg24
(lp4814
(dp4815
g7
I135
sg27
VC0600139
p4816
sg10
I15
sg11
Vprostate cancer
p4817
sg13
I2
sasa(dp4818
g2
S'Human prostate cancer DU145 xenograft mouse model was used to assess the effect of AT2R on tumor growth in vivo.\n'
p4819
sg4
(lp4820
(dp4821
g7
I83
sg8
VP50052
p4822
sg10
I4
sg11
VAT2R
p4823
sg13
I1
sasg24
(lp4824
(dp4825
g7
I91
sg27
VC0598934
p4826
sg10
I12
sg11
Vtumor growth
p4827
sg13
I2
sa(dp4828
g7
I6
sg27
VC0600139
p4829
sg10
I15
sg11
Vprostate cancer
p4830
sg13
I2
sasa(dp4831
g2
S'The results showed that AT2R overexpression can inhibit tumor growth of prostate cancer in vivo by inhibiting proliferation and inducing apoptosis of tumor cells.\n'
p4832
sg4
(lp4833
(dp4834
g7
I24
sg8
VP50052
p4835
sg10
I4
sg11
VAT2R
p4836
sg13
I1
sasg24
(lp4837
(dp4838
g7
I56
sg27
VC0598934
p4839
sg10
I12
sg11
Vtumor growth
p4840
sg13
I2
sa(dp4841
g7
I110
sg27
VC0334094
p4842
sg10
I13
sg11
Vproliferation
p4843
sg13
I1
sa(dp4844
g7
I72
sg27
VC0600139
p4845
sg10
I15
sg11
Vprostate cancer
p4846
sg13
I2
sa(dp4847
g7
I56
sg27
VC0027651
p4848
sg10
I5
sg11
Vtumor
p4849
sg13
I1
sasa(dp4850
g2
S'The aim of the present study was the evaluation of AT1 and AT2 expressions in human prostate cancers.\n'
p4851
sg4
(lp4852
(dp4853
g7
I51
sg8
VP30556
p4854
sg10
I3
sg11
VAT1
p4855
sg13
I1
sa(dp4856
g7
I59
sg8
VP50052
p4857
sg10
I3
sg11
VAT2
p4858
sg13
I1
sasg24
(lp4859
(dp4860
g7
I51
sg27
VC0004135
p4861
sg10
I3
sg11
VAT1
p4862
sg13
I1
sa(dp4863
g7
I84
sg27
VC0376358
p4864
sg10
I16
sg11
Vprostate cancers
p4865
sg13
I2
sasa(dp4866
g2
S'The data on AT1 and AT2 receptor expressions may suggest the involvement of RAS in prostate cancerogenesis.\n'
p4867
sg4
(lp4868
(dp4869
g7
I76
sg8
VP01116
p4870
sg10
I3
sg11
VRAS
p4871
sg13
I1
sa(dp4872
g7
I20
sg8
VP50052
p4873
sg10
I12
sg11
VAT2 receptor
p4874
sg13
I2
sa(dp4875
g7
I12
sg8
VP30556
p4876
sg10
I3
sg11
VAT1
p4877
sg13
I1
sasg24
(lp4878
(dp4879
g7
I12
sg27
VC0004135
p4880
sg10
I3
sg11
VAT1
p4881
sg13
I1
sasa(dp4882
g2
S'sartanes) and/or AT2 agonists in prostate cancer prophylaxis and/or treatment.\n'
p4883
sg4
(lp4884
sg24
(lp4885
(dp4886
g7
I33
sg27
VC0600139
p4887
sg10
I15
sg11
Vprostate cancer
p4888
sg13
I2
sasa(dp4889
g2
S'The results indicate that CEGA using the new circular stapling device in surgery of the esophageal carcinoma is a very effective procedure to improve the anastomotic technique from a traditional hand-sewn anastomosis to a stapled anastomosis and can reduce the incidence of complications.\n'
p4890
sg4
(lp4891
sg24
(lp4892
(dp4893
g7
I205
sg27
VC0332853
p4894
sg10
I11
sg11
Vanastomosis
p4895
sg13
I1
sa(dp4896
g7
I88
sg27
VC0152018
p4897
sg10
I20
sg11
Vesophageal carcinoma
p4898
sg13
I2
sa(dp4899
g7
I205
sg27
VC0332853
p4900
sg10
I11
sg11
Vanastomosis
p4901
sg13
I1
sasa(dp4902
g2
S'An unusual retinal pigment epitheliopathy resembling ophthalmomyiasis interna posterior (OMI) is endemic to Guam.\n'
p4903
sg4
(lp4904
sg24
(lp4905
(dp4906
g7
I11
sg27
VC0860552
p4907
sg10
I30
sg11
Vretinal pigment epitheliopathy
p4908
sg13
I3
sa(dp4909
g7
I53
sg27
VC0027034
p4910
sg10
I16
sg11
Vophthalmomyiasis
p4911
sg13
I1
sasa(dp4912
g2
S'Toxicity, such as mucositis, leukocytopenia and neutropenia, was higher in ConcCRTx than in CTx followed by RTx.\n'
p4913
sg4
(lp4914
sg24
(lp4915
(dp4916
g7
I92
sg27
VC0238052
p4917
sg10
I3
sg11
VCTx
p4918
sg13
I1
sa(dp4919
g7
I29
sg27
VC0023530
p4920
sg10
I14
sg11
Vleukocytopenia
p4921
sg13
I1
sa(dp4922
g7
I18
sg27
VC0333355
p4923
sg10
I9
sg11
Vmucositis
p4924
sg13
I1
sasa(dp4925
g2
S'At the 4th dose level (Ctx 1400 mg/m2, Epidx 100 mg/m2, 5-Fu 600 mg/m2), two patients had dose-limiting mucositis and one patient developed dose-limiting neutropenia.\n'
p4926
sg4
(lp4927
sg24
(lp4928
(dp4929
g7
I104
sg27
VC0333355
p4930
sg10
I9
sg11
Vmucositis
p4931
sg13
I1
sa(dp4932
g7
I23
sg27
VC0238052
p4933
sg10
I3
sg11
VCtx
p4934
sg13
I1
sasa(dp4935
g2
S'Therefore, the effect of CKD on the disposition of CYP1A2-metabolized, CYP2C8-metabolized, CYP2C9-metabolized, CYP2C19-metabolized, and organic anion-transporting polypeptide (OATP)-transported drugs was investigated.\n'
p4936
sg4
(lp4937
(dp4938
g7
I91
sg8
VP11712
p4939
sg10
I6
sg11
VCYP2C9
p4940
sg13
I1
sa(dp4941
g7
I111
sg8
VP33261
p4942
sg10
I7
sg11
VCYP2C19
p4943
sg13
I1
sa(dp4944
g7
I71
sg8
VP10632
p4945
sg10
I6
sg11
VCYP2C8
p4946
sg13
I1
sa(dp4947
g7
I51
sg8
VP05177
p4948
sg10
I6
sg11
VCYP1A2
p4949
sg13
I1
sasg24
(lp4950
sa(dp4951
g2
S'We identified dedicated CKD studies with 6, 5, 6, 4, and 12 "model" substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP, respectively.\n'
p4952
sg4
(lp4953
(dp4954
g7
I99
sg8
VP11712
p4955
sg10
I6
sg11
VCYP2C9
p4956
sg13
I1
sa(dp4957
g7
I83
sg8
VP05177
p4958
sg10
I6
sg11
VCYP1A2
p4959
sg13
I1
sa(dp4960
g7
I107
sg8
VP33261
p4961
sg10
I7
sg11
VCYP2C19
p4962
sg13
I1
sa(dp4963
g7
I91
sg8
VP10632
p4964
sg10
I6
sg11
VCYP2C8
p4965
sg13
I1
sasg24
(lp4966
sa(dp4967
g2
S'In contrast, the effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.\n'
p4968
sg4
(lp4969
(dp4970
g7
I54
sg8
VP33261
p4971
sg10
I7
sg11
VCYP2C19
p4972
sg13
I1
sa(dp4973
g7
I42
sg8
VP11712
p4974
sg10
I6
sg11
VCYP2C9
p4975
sg13
I1
sa(dp4976
g7
I109
sg8
VP46721
p4977
sg10
I4
sg11
VOATP
p4978
sg13
I1
sa(dp4979
g7
I34
sg8
VP05177
p4980
sg10
I6
sg11
VCYP1A2
p4981
sg13
I1
sa(dp4982
g7
I98
sg8
VP10632
p4983
sg10
I6
sg11
VCYP2C8
p4984
sg13
I1
sasg24
(lp4985
sa(dp4986
g2
S'To investigate the impact of genetic variants in CYP2C9, CYP2C19, CYP3A4, GSTT1, GSTM1 and GSTP1 on the efficacy of cyclophosphamide (CYC) therapy in patients with lupus nephritis.\n'
p4987
sg4
(lp4988
(dp4989
g7
I74
sg8
VP30711
p4990
sg10
I5
sg11
VGSTT1
p4991
sg13
I1
sa(dp4992
g7
I81
sg8
VP09488
p4993
sg10
I5
sg11
VGSTM1
p4994
sg13
I1
sa(dp4995
g7
I49
sg8
VP11712
p4996
sg10
I6
sg11
VCYP2C9
p4997
sg13
I1
sa(dp4998
g7
I91
sg8
VP09211
p4999
sg10
I5
sg11
VGSTP1
p5000
sg13
I1
sa(dp5001
g7
I57
sg8
VP33261
p5002
sg10
I7
sg11
VCYP2C19
p5003
sg13
I1
sa(dp5004
g7
I66
sg8
VP08684
p5005
sg10
I6
sg11
VCYP3A4
p5006
sg13
I1
sasg24
(lp5007
(dp5008
g7
I164
sg27
VC0024143
p5009
sg10
I15
sg11
Vlupus nephritis
p5010
sg13
I2
sasa(dp5011
g2
S'Chronic kidney disease (CKD) complicates warfarin anticoagulation partially through its effect on CYP2C9 activity.\n'
p5012
sg4
(lp5013
(dp5014
g7
I98
sg8
VP11712
p5015
sg10
I6
sg11
VCYP2C9
p5016
sg13
I1
sasg24
(lp5017
(dp5018
g7
I0
sg27
VC1561643
p5019
sg10
I22
sg11
VChronic kidney disease
p5020
sg13
I3
sa(dp5021
g7
I24
sg27
VC1561643
p5022
sg10
I3
sg11
VCKD
p5023
sg13
I1
sasa(dp5024
g2
S'CKD increased the effect of CYP2C9 genetic variation on (S)-warfarin and (R,S)-warfarin metabolism.\n'
p5025
sg4
(lp5026
(dp5027
g7
I28
sg8
VP11712
p5028
sg10
I6
sg11
VCYP2C9
p5029
sg13
I1
sasg24
(lp5030
sa(dp5031
g2
S'Tecarfarin exposure was similar between the HVs and the CKD subjects regardless of CYP2C9 genotype.\n'
p5032
sg4
(lp5033
(dp5034
g7
I83
sg8
VP11712
p5035
sg10
I15
sg11
VCYP2C9 genotype
p5036
sg13
I2
sasg24
(lp5037
sa(dp5038
g2
S'The CYP2C9 pathway (4-hydroxyflurbiprofen formation clearance) was similar in all the patients with CKD and was concordant with previous reports of patients with end-stage renal disease (ESRD) and healthy controls.\n'
p5039
sg4
(lp5040
(dp5041
g7
I4
sg8
VP11712
p5042
sg10
I6
sg11
VCYP2C9
p5043
sg13
I1
sasg24
(lp5044
(dp5045
g7
I187
sg27
VC0022661
p5046
sg10
I4
sg11
VESRD
p5047
sg13
I1
sa(dp5048
g7
I162
sg27
VC0022661
p5049
sg10
I23
sg11
Vend-stage renal disease
p5050
sg13
I3
sasa(dp5051
g2
S'For flurbiprofen, patients with glomerulonephritis had higher oral clearance than those with nonglomerular CKD, suggesting higher unbound fraction and enhanced metabolism through other (non-CYP2C9) routes.\n'
p5052
sg4
(lp5053
(dp5054
g7
I190
sg8
VP11712
p5055
sg10
I6
sg11
VCYP2C9
p5056
sg13
I1
sasg24
(lp5057
(dp5058
g7
I32
sg27
VC0017658
p5059
sg10
I18
sg11
Vglomerulonephritis
p5060
sg13
I1
sasa(dp5061
g2
S'The current study suggests no statistically significant differences in the in vivo activity of CYP2C9 and CYP3A4 in patients with either glomerulonephritis or nonglomerular CKD.\n'
p5062
sg4
(lp5063
(dp5064
g7
I95
sg8
VP08684
p5065
sg10
I17
sg11
VCYP2C9 and CYP3A4
p5066
sg13
I3
sasg24
(lp5067
(dp5068
g7
I137
sg27
VC0017658
p5069
sg10
I18
sg11
Vglomerulonephritis
p5070
sg13
I1
sasa(dp5071
g2
S'We examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy.\n'
p5072
sg4
(lp5073
(dp5074
g7
I24
sg8
VP00797
p5075
sg10
I5
sg11
Vrenin
p5076
sg13
I1
sa(dp5077
g7
I96
sg8
VP12821
p5078
sg10
I3
sg11
VACE
p5079
sg13
I1
sasg24
(lp5080
(dp5081
g7
I182
sg27
VC0027686
p5082
sg10
I15
sg11
Vneoangiogenesis
p5083
sg13
I1
sa(dp5084
g7
I143
sg27
VC0035309
p5085
sg10
I11
sg11
Vretinopathy
p5086
sg13
I1
sa(dp5087
g7
I120
sg27
VC0334094
p5088
sg10
I13
sg11
Vproliferative
p5089
sg13
I1
sa(dp5090
g7
I116
sg27
VC0004606
p5091
sg10
I38
sg11
Vnon-proliferative diabetic retinopathy
p5092
sg13
I3
sasa(dp5093
g2
S'To assess angiotensin-converting enzyme (ACE) levels in aqueous humor and plasma of patients with nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) as another potent ischemia-induced angiogenic factor.\n'
p5094
sg4
(lp5095
(dp5096
g7
I41
sg8
VP12821
p5097
sg10
I3
sg11
VACE
p5098
sg13
I1
sa(dp5099
g7
I223
sg8
g9
sg10
I17
sg11
Vangiogenic factor
p5100
sg13
I2
sa(dp5101
g7
I10
sg8
VP12821
p5102
sg10
I29
sg11
Vangiotensin-converting enzyme
p5103
sg13
I2
sasg24
(lp5104
(dp5105
g7
I98
sg27
VC0004606
p5106
sg10
I37
sg11
Vnonproliferative diabetic retinopathy
p5107
sg13
I3
sa(dp5108
g7
I56
sg27
VC0595936
p5109
sg10
I13
sg11
Vaqueous humor
p5110
sg13
I2
sa(dp5111
g7
I137
sg27
VC0004606
p5112
sg10
I4
sg11
VNPDR
p5113
sg13
I1
sa(dp5114
g7
I138
sg27
VC0154830
p5115
sg10
I3
sg11
VPDR
p5116
sg13
I1
sa(dp5117
g7
I206
sg27
VC0022116
p5118
sg10
I8
sg11
Vischemia
p5119
sg13
I1
sa(dp5120
g7
I101
sg27
VC0154830
p5121
sg10
I34
sg11
Vproliferative diabetic retinopathy
p5122
sg13
I3
sasa(dp5123
g2
S'We observed significantly elevated ACE level in aqueous humor of patients with PDR compared with the patients with NPDR and normal subjects (P = 0.023), but no significant difference was detected between nonproliferative diabetics and control group (P = 0.239).\n'
p5124
sg4
(lp5125
(dp5126
g7
I35
sg8
VP12821
p5127
sg10
I3
sg11
VACE
p5128
sg13
I1
sasg24
(lp5129
(dp5130
g7
I79
sg27
VC1845050
p5131
sg10
I3
sg11
VPDR
p5132
sg13
I1
sa(dp5133
g7
I48
sg27
VC0595936
p5134
sg10
I13
sg11
Vaqueous humor
p5135
sg13
I2
sasa(dp5136
g2
S'Studies exploring the association between ACE I/D polymorphism and BDR or PDR may help us better understand the genetics of DR.\n'
p5137
sg4
(lp5138
(dp5139
g7
I42
sg8
VP12821
p5140
sg10
I7
sg11
VACE I/D
p5141
sg13
I2
sasg24
(lp5142
(dp5143
g7
I74
sg27
VC1845050
p5144
sg10
I3
sg11
VPDR
p5145
sg13
I1
sasa(dp5146
g2
S'To evaluate the effects of angiotensin-converting enzyme inhibitors (ACE-I) in retarding progression of severe non-proliferative diabetic retinopathy (NPDR) in normotensive type 2 diabetic patients.\n'
p5147
sg4
(lp5148
(dp5149
g7
I69
sg8
VP12821
p5150
sg10
I5
sg11
VACE-I
p5151
sg13
I1
sa(dp5152
g7
I27
sg8
VP12821
p5153
sg10
I40
sg11
Vangiotensin-converting enzyme inhibitors
p5154
sg13
I3
sasg24
(lp5155
(dp5156
g7
I111
sg27
VC0004606
p5157
sg10
I38
sg11
Vnon-proliferative diabetic retinopathy
p5158
sg13
I3
sa(dp5159
g7
I151
sg27
VC0004606
p5160
sg10
I4
sg11
VNPDR
p5161
sg13
I1
sasa(dp5162
g2
S'This was a retrospective case control study of 128 patients with normotensive type 2 diabetes with lower than +1 dipstick proteinuria and severe NPDR who were classified into either an ACE-I treated group (Enalapril maleate 10 mg, n=12 , Ramipril 5 mg, n=17) or an ACE-I untreated group (n=99).\n'
p5163
sg4
(lp5164
(dp5165
g7
I185
sg8
VP12821
p5166
sg10
I5
sg11
VACE-I
p5167
sg13
I1
sa(dp5168
g7
I185
sg8
VP12821
p5169
sg10
I5
sg11
VACE-I
p5170
sg13
I1
sasg24
(lp5171
(dp5172
g7
I78
sg27
VC0011860
p5173
sg10
I15
sg11
Vtype 2 diabetes
p5174
sg13
I3
sa(dp5175
g7
I138
sg27
VC0730278
p5176
sg10
I11
sg11
Vsevere NPDR
p5177
sg13
I2
sasa(dp5178
g2
S'Small doses of ACE-I did not yield any beneficial effects in retarding the progression of severe NPDR.\n'
p5179
sg4
(lp5180
(dp5181
g7
I15
sg8
VP12821
p5182
sg10
I5
sg11
VACE-I
p5183
sg13
I1
sasg24
(lp5184
(dp5185
g7
I90
sg27
VC0730278
p5186
sg10
I11
sg11
Vsevere NPDR
p5187
sg13
I2
sasa(dp5188
g2
S'A7730C variant which showed a high mutation frequency in cervical cancer was predicted to be a binding site for the cellular transcription factor PHOX2A.\n'
p5189
sg4
(lp5190
(dp5191
g7
I146
sg8
g9
sg10
I6
sg11
VPHOX2A
p5192
sg13
I1
sasg24
(lp5193
(dp5194
g7
I57
sg27
VC0302592
p5195
sg10
I15
sg11
Vcervical cancer
p5196
sg13
I2
sasa(dp5197
g2
S'miR-326 regulates cell proliferation and migration in lung cancer by targeting Phox2a and is regulated by HOTAIR.\n'
p5198
sg4
(lp5199
(dp5200
g7
I0
sg8
g9
sg10
I3
sg11
VmiR
p5201
sg13
I1
sa(dp5202
g7
I79
sg8
g9
sg10
I6
sg11
VPhox2a
p5203
sg13
I1
sasg24
(lp5204
(dp5205
g7
I54
sg27
VC0684249
p5206
sg10
I11
sg11
Vlung cancer
p5207
sg13
I2
sa(dp5208
g7
I23
sg27
VC0334094
p5209
sg10
I13
sg11
Vproliferation
p5210
sg13
I1
sasa(dp5211
g2
S'PHOX2B and its paralogue gene PHOX2A are two homeodomain proteins in the network regulating the development of autonomic ganglia that have been associated with the pathogenesis of neuroblastoma (NB), because of their over-expression in different NB cell lines and tumour samples.\n'
p5212
sg4
(lp5213
(dp5214
g7
I0
sg8
g9
sg10
I6
sg11
VPHOX2B
p5215
sg13
I1
sa(dp5216
g7
I30
sg8
g9
sg10
I6
sg11
VPHOX2A
p5217
sg13
I1
sa(dp5218
g7
I45
sg8
g9
sg10
I20
sg11
Vhomeodomain proteins
p5219
sg13
I2
sasg24
(lp5220
(dp5221
g7
I195
sg27
VC0027819
p5222
sg10
I2
sg11
VNB
p5223
sg13
I1
sa(dp5224
g7
I195
sg27
VC0027819
p5225
sg10
I2
sg11
VNB
p5226
sg13
I1
sa(dp5227
g7
I264
sg27
VC0027651
p5228
sg10
I6
sg11
Vtumour
p5229
sg13
I1
sa(dp5230
g7
I164
sg27
VC0699748
p5231
sg10
I12
sg11
Vpathogenesis
p5232
sg13
I1
sa(dp5233
g7
I180
sg27
VC0027819
p5234
sg10
I13
sg11
Vneuroblastoma
p5235
sg13
I1
sasa(dp5236
g2
S'To identify novel abnormally methylated genes in early stage non-small cell lung cancer (NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1, MYF6, OC2, PDGFRA, PHOX2A, PITX2, RARB, SIX6, SMPD3 and SOX1) in cancer tissues from 101 cases of stage I NSCLC patients and lung tissues from 30 cases of non-cancerous lung disease controls, using methylation-specific PCR (MSP).\n'
p5237
sg4
(lp5238
(dp5239
g7
I189
sg8
g9
sg10
I6
sg11
VPHOX2A
p5240
sg13
I1
sa(dp5241
g7
I176
sg8
VP43235
p5242
sg10
I3
sg11
VOC2
p5243
sg13
I1
sa(dp5244
g7
I197
sg8
g9
sg10
I5
sg11
VPITX2
p5245
sg13
I1
sa(dp5246
g7
I170
sg8
VP23409
p5247
sg10
I4
sg11
VMYF6
p5248
sg13
I1
sa(dp5249
g7
I181
sg8
VP16234
p5250
sg10
I6
sg11
VPDGFRA
p5251
sg13
I1
sa(dp5252
g7
I226
sg8
g9
sg10
I4
sg11
VSOX1
p5253
sg13
I1
sa(dp5254
g7
I216
sg8
g9
sg10
I5
sg11
VSMPD3
p5255
sg13
I1
sa(dp5256
g7
I204
sg8
VP10826
p5257
sg10
I4
sg11
VRARB
p5258
sg13
I1
sa(dp5259
g7
I164
sg8
g9
sg10
I4
sg11
VHPP1
p5260
sg13
I1
sa(dp5261
g7
I145
sg8
g9
sg10
I4
sg11
VALX1
p5262
sg13
I1
sa(dp5263
g7
I210
sg8
g9
sg10
I4
sg11
VSIX6
p5264
sg13
I1
sa(dp5265
g7
I151
sg8
VP10415
p5266
sg10
I4
sg11
VBCL2
p5267
sg13
I1
sa(dp5268
g7
I157
sg8
VP58012
p5269
sg10
I5
sg11
VFOXL2
p5270
sg13
I1
sasg24
(lp5271
(dp5272
g7
I89
sg27
VC0007131
p5273
sg10
I5
sg11
VNSCLC
p5274
sg13
I1
sa(dp5275
g7
I81
sg27
VC0006826
p5276
sg10
I6
sg11
Vcancer
p5277
sg13
I1
sa(dp5278
g7
I61
sg27
VC0007131
p5279
sg10
I26
sg11
Vnon-small cell lung cancer
p5280
sg13
I4
sa(dp5281
g7
I339
sg27
VC0024115
p5282
sg10
I12
sg11
Vlung disease
p5283
sg13
I2
sa(dp5284
g7
I268
sg27
VC0278504
p5285
sg10
I13
sg11
Vstage I NSCLC
p5286
sg13
I3
sasa(dp5287
g2
S'The methylation frequencies (29.70-64.36%) of 7 genes (MYF6, SIX6, SOX1, RARB, BCL2, PHOX2A and FOLX2) in stage I NSCLC were significantly higher compared with those in non-cancerous lung disease controls (P&lt;0.05).\n'
p5288
sg4
(lp5289
(dp5290
g7
I85
sg8
g9
sg10
I6
sg11
VPHOX2A
p5291
sg13
I1
sa(dp5292
g7
I55
sg8
VP23409
p5293
sg10
I4
sg11
VMYF6
p5294
sg13
I1
sa(dp5295
g7
I61
sg8
g9
sg10
I4
sg11
VSIX6
p5296
sg13
I1
sa(dp5297
g7
I79
sg8
VP10415
p5298
sg10
I4
sg11
VBCL2
p5299
sg13
I1
sa(dp5300
g7
I67
sg8
g9
sg10
I4
sg11
VSOX1
p5301
sg13
I1
sa(dp5302
g7
I73
sg8
VP10826
p5303
sg10
I4
sg11
VRARB
p5304
sg13
I1
sasg24
(lp5305
(dp5306
g7
I106
sg27
VC0278504
p5307
sg10
I13
sg11
Vstage I NSCLC
p5308
sg13
I3
sa(dp5309
g7
I183
sg27
VC0024115
p5310
sg10
I12
sg11
Vlung disease
p5311
sg13
I2
sasa(dp5312
g2
S'Furthermore, we also detected the expression of 8 pathological markers (VEGF, HER-2, P53, P21, EGFR, CHGA, SYN and EMA) in cancer tissues of stage I NSCLC by immunohistochemistry, and found that high expression levels of p53 and CHGA were associated with the methylation of BCL2 (P=0.025) and PHOX2A (P=0.023), respectively.\n'
p5313
sg4
(lp5314
(dp5315
g7
I90
sg8
VP42857
p5316
sg10
I3
sg11
VP21
p5317
sg13
I1
sa(dp5318
g7
I101
sg8
VP10645
p5319
sg10
I4
sg11
VCHGA
p5320
sg13
I1
sa(dp5321
g7
I274
sg8
VP10415
p5322
sg10
I4
sg11
VBCL2
p5323
sg13
I1
sa(dp5324
g7
I101
sg8
VP10645
p5325
sg10
I4
sg11
VCHGA
p5326
sg13
I1
sa(dp5327
g7
I107
sg8
VP17600
p5328
sg10
I3
sg11
VSYN
p5329
sg13
I1
sa(dp5330
g7
I293
sg8
g9
sg10
I6
sg11
VPHOX2A
p5331
sg13
I1
sa(dp5332
g7
I221
sg8
VP42771
p5333
sg10
I3
sg11
Vp53
p5334
sg13
I1
sa(dp5335
g7
I85
sg8
VP42771
p5336
sg10
I3
sg11
VP53
p5337
sg13
I1
sa(dp5338
g7
I78
sg8
VP04626
p5339
sg10
I5
sg11
VHER-2
p5340
sg13
I1
sa(dp5341
g7
I115
sg8
VP13804
p5342
sg10
I3
sg11
VEMA
p5343
sg13
I1
sasg24
(lp5344
(dp5345
g7
I141
sg27
VC0278504
p5346
sg10
I13
sg11
Vstage I NSCLC
p5347
sg13
I3
sa(dp5348
g7
I123
sg27
VC0006826
p5349
sg10
I6
sg11
Vcancer
p5350
sg13
I1
sa(dp5351
g7
I115
sg27
VC0268596
p5352
sg10
I3
sg11
VEMA
p5353
sg13
I1
sasa(dp5354
g2
S'In this study, among the 7 genes which demonstrated hypermethylation in stage I NSCLC compared with non-cancerous lung diseases, 5 genes (MYF6, SIX6, PHOX2A, FOLX2 and SOX1) were found for the first time to be abonormally methylated in NSCLC.\n'
p5355
sg4
(lp5356
(dp5357
g7
I168
sg8
g9
sg10
I4
sg11
VSOX1
p5358
sg13
I1
sa(dp5359
g7
I138
sg8
VP23409
p5360
sg10
I4
sg11
VMYF6
p5361
sg13
I1
sa(dp5362
g7
I144
sg8
g9
sg10
I4
sg11
VSIX6
p5363
sg13
I1
sa(dp5364
g7
I150
sg8
g9
sg10
I6
sg11
VPHOX2A
p5365
sg13
I1
sasg24
(lp5366
(dp5367
g7
I72
sg27
VC0278504
p5368
sg10
I13
sg11
Vstage I NSCLC
p5369
sg13
I3
sa(dp5370
g7
I114
sg27
VC0024115
p5371
sg10
I13
sg11
Vlung diseases
p5372
sg13
I2
sa(dp5373
g7
I80
sg27
VC0007131
p5374
sg10
I5
sg11
VNSCLC
p5375
sg13
I1
sasa(dp5376
g2
S"Heteroplasmic m.3697G&gt;A has been reported in patients with Leber's hereditary optic neuropathy, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes and Stuve-Wiedemann syndrome.\n"
p5377
sg4
(lp5378
sg24
(lp5379
(dp5380
g7
I132
sg27
VC0001125
p5381
sg10
I15
sg11
Vlactic acidosis
p5382
sg13
I2
sa(dp5383
g7
I177
sg27
VC0796176
p5384
sg10
I24
sg11
VStuve-Wiedemann syndrome
p5385
sg13
I2
sa(dp5386
g7
I99
sg27
VC0162666
p5387
sg10
I31
sg11
Vmitochondrial encephalomyopathy
p5388
sg13
I2
sa(dp5389
g7
I152
sg27
VC0038454
p5390
sg10
I6
sg11
Vstroke
p5391
sg13
I1
sa(dp5392
g7
I62
sg27
VC0917796
p5393
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p5394
sg13
I4
sasa(dp5395
g2
S"These can be grouped into disorders with reduced papillae (Machado-Joseph disease, Stuve-Wiedemann syndrome, familial dysautonomia, dystonia musculorum, and Behcet's disease) and those with taste defects only (Alzheimer's disease, Huntington's disease, hereditary sensory and autonomic neuropathy type IV, and diabetes mellitus).\n"
p5396
sg4
(lp5397
sg24
(lp5398
(dp5399
g7
I310
sg27
VC0011849
p5400
sg10
I17
sg11
Vdiabetes mellitus
p5401
sg13
I2
sa(dp5402
g7
I132
sg27
VC0393593
p5403
sg10
I8
sg11
Vdystonia
p5404
sg13
I1
sa(dp5405
g7
I210
sg27
VC1521724
p5406
sg10
I19
sg11
VAlzheimer's disease
p5407
sg13
I2
sa(dp5408
g7
I253
sg27
VC0020074
p5409
sg10
I51
sg11
Vhereditary sensory and autonomic neuropathy type IV
p5410
sg13
I7
sa(dp5411
g7
I109
sg27
VC0013364
p5412
sg10
I21
sg11
Vfamilial dysautonomia
p5413
sg13
I2
sa(dp5414
g7
I59
sg27
VC0024408
p5415
sg10
I22
sg11
VMachado-Joseph disease
p5416
sg13
I2
sa(dp5417
g7
I231
sg27
VC0020179
p5418
sg10
I20
sg11
VHuntington's disease
p5419
sg13
I2
sa(dp5420
g7
I83
sg27
VC0796176
p5421
sg10
I24
sg11
VStuve-Wiedemann syndrome
p5422
sg13
I2
sa(dp5423
g7
I157
sg27
VC0004943
p5424
sg10
I16
sg11
VBehcet's disease
p5425
sg13
I2
sasa(dp5426
g2
S'We used in-situ hybridization to analyze the expression patterns of three known members (a, b and c) of the RGM ("repulsive guidance molecule") gene family and of the RGMa receptor neogenin in a glaucoma mouse model (DBA/2J strain) and the C57BL/6J strain, which served as a control.\n'
p5427
sg4
(lp5428
(dp5429
g7
I167
sg8
g9
sg10
I22
sg11
VRGMa receptor neogenin
p5430
sg13
I3
sasg24
(lp5431
(dp5432
g7
I195
sg27
VC0017601
p5433
sg10
I8
sg11
Vglaucoma
p5434
sg13
I1
sa(dp5435
g7
I217
sg27
VC0398550
p5436
sg10
I3
sg11
VDBA
p5437
sg13
I1
sasa(dp5438
g2
S'In order to understand the role of the RGMs and neogenin in glaucoma, we characterized their expression patterns in the developing and mature mouse retina and in the optic nerve.\n'
p5439
sg4
(lp5440
(dp5441
g7
I39
sg8
g9
sg10
I17
sg11
VRGMs and neogenin
p5442
sg13
I3
sasg24
(lp5443
(dp5444
g7
I60
sg27
VC0017601
p5445
sg10
I8
sg11
Vglaucoma
p5446
sg13
I1
sasa(dp5447
g2
S'Interestingly, we found a higher expression of RGMa, RGMb and neogenin in the retinas of all glaucoma-affected mice than in the age-matched control strain.\n'
p5448
sg4
(lp5449
(dp5450
g7
I53
sg8
g9
sg10
I17
sg11
VRGMb and neogenin
p5451
sg13
I3
sa(dp5452
g7
I47
sg8
g9
sg10
I4
sg11
VRGMa
p5453
sg13
I1
sasg24
(lp5454
(dp5455
g7
I93
sg27
VC0017601
p5456
sg10
I8
sg11
Vglaucoma
p5457
sg13
I1
sasa(dp5458
g2
S"A tool developed for their use--DeAR GP (Dementia Assessment Referral to GP)--empowers care home staff, makes more efficient use of GPs' and specialist memory nurses' time, and improves diagnosis of dementia.\n"
p5459
sg4
(lp5460
(dp5461
g7
I132
sg8
g9
sg10
I3
sg11
VGPs
p5462
sg13
I1
sasg24
(lp5463
(dp5464
g7
I41
sg27
VC0497327
p5465
sg10
I8
sg11
VDementia
p5466
sg13
I1
sa(dp5467
g7
I199
sg27
VC0497327
p5468
sg10
I8
sg11
Vdementia
p5469
sg13
I1
sa(dp5470
g7
I132
sg27
VC0272302
p5471
sg10
I3
sg11
VGPs
p5472
sg13
I1
sasa(dp5473
g2
S'Using homozygous mice for an autosomal dominant hypophosphatemic rickets-FGF23 mutation or animals treated with a furin inhibitor, we showed that cFGF23 and iFGF23 levels increased equivalently after PTH injection.\n'
p5474
sg4
(lp5475
(dp5476
g7
I114
sg8
VP09958
p5477
sg10
I5
sg11
Vfurin
p5478
sg13
I1
sa(dp5479
g7
I73
sg8
g9
sg10
I5
sg11
VFGF23
p5480
sg13
I1
sa(dp5481
g7
I200
sg8
VP01270
p5482
sg10
I3
sg11
VPTH
p5483
sg13
I1
sasg24
(lp5484
(dp5485
g7
I29
sg27
VC0342642
p5486
sg10
I43
sg11
Vautosomal dominant hypophosphatemic rickets
p5487
sg13
I4
sasa(dp5488
g2
S"We discuss in this review the current implications of GRx and/or glutathionylation in the inflammatory response and in diseases associated with chronic inflammation, namely diabetes, atherosclerosis, inflammatory lung disease, cancer, and Alzheimer's disease, and in viral infections.\n"
p5489
sg4
(lp5490
sg24
(lp5491
(dp5492
g7
I239
sg27
VC1521724
p5493
sg10
I19
sg11
VAlzheimer's disease
p5494
sg13
I2
sa(dp5495
g7
I90
sg27
VC1155266
p5496
sg10
I21
sg11
Vinflammatory response
p5497
sg13
I2
sa(dp5498
g7
I144
sg27
VC0021376
p5499
sg10
I20
sg11
Vchronic inflammation
p5500
sg13
I2
sa(dp5501
g7
I183
sg27
VC0004153
p5502
sg10
I15
sg11
Vatherosclerosis
p5503
sg13
I1
sa(dp5504
g7
I213
sg27
VC0024115
p5505
sg10
I12
sg11
Vlung disease
p5506
sg13
I2
sa(dp5507
g7
I267
sg27
VC0042769
p5508
sg10
I16
sg11
Vviral infections
p5509
sg13
I2
sa(dp5510
g7
I173
sg27
VC0011849
p5511
sg10
I8
sg11
Vdiabetes
p5512
sg13
I1
sa(dp5513
g7
I227
sg27
VC0006826
p5514
sg10
I6
sg11
Vcancer
p5515
sg13
I1
sasa(dp5516
g2
S'In addition to arising from the procedure per se, a genetic or cytogenetic abnormality in offspring of an ICSI pregnancy could arise as result of offspring inheriting the mutant gene or chromosomal abnormality conferring paternal infertility: Y deletions (DAZ) in oligospermia males, cystic fibrosis in offspring of males with congenital bilateral absence vas deferens (CBAVD), and sex chromosomal abnormalities in offspring of Klinefelter syndrome (47,XXY) males.\n'
p5517
sg4
(lp5518
sg24
(lp5519
(dp5520
g7
I284
sg27
VC0010674
p5521
sg10
I15
sg11
Vcystic fibrosis
p5522
sg13
I2
sa(dp5523
g7
I186
sg27
VC0008625
p5524
sg10
I23
sg11
Vchromosomal abnormality
p5525
sg13
I2
sa(dp5526
g7
I428
sg27
VC0022735
p5527
sg10
I20
sg11
VKlinefelter syndrome
p5528
sg13
I2
sa(dp5529
g7
I382
sg27
VC0036868
p5530
sg10
I29
sg11
Vsex chromosomal abnormalities
p5531
sg13
I3
sa(dp5532
g7
I370
sg27
VC0403814
p5533
sg10
I5
sg11
VCBAVD
p5534
sg13
I1
sa(dp5535
g7
I230
sg27
VC0021359
p5536
sg10
I11
sg11
Vinfertility
p5537
sg13
I1
sa(dp5538
g7
I171
sg27
VC0596988
p5539
sg10
I6
sg11
Vmutant
p5540
sg13
I1
sa(dp5541
g7
I327
sg27
VC0403814
p5542
sg10
I41
sg11
Vcongenital bilateral absence vas deferens
p5543
sg13
I5
sa(dp5544
g7
I264
sg27
VC0028960
p5545
sg10
I12
sg11
Voligospermia
p5546
sg13
I1
sa(dp5547
g7
I63
sg27
VC0008625
p5548
sg10
I23
sg11
Vcytogenetic abnormality
p5549
sg13
I2
sasa(dp5550
g2
S'Two recent candidate genes, ErbB3 and Fgfr1, are growth factors whose mRNA levels have been found to be altered in the leukocytes of patients that are affected by bipolar disorder in a depressive state.\n'
p5551
sg4
(lp5552
(dp5553
g7
I28
sg8
VP21860
p5554
sg10
I5
sg11
VErbB3
p5555
sg13
I1
sa(dp5556
g7
I38
sg8
VP20930
p5557
sg10
I5
sg11
VFgfr1
p5558
sg13
I1
sasg24
(lp5559
(dp5560
g7
I163
sg27
VC0005586
p5561
sg10
I16
sg11
Vbipolar disorder
p5562
sg13
I2
sa(dp5563
g7
I185
sg27
VC0011570
p5564
sg10
I16
sg11
Vdepressive state
p5565
sg13
I2
sasa(dp5566
g2
S"Molecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.\n"
p5567
sg4
(lp5568
(dp5569
g7
I94
sg8
g9
sg10
I8
sg11
VARHGEF10
p5570
sg13
I1
sa(dp5571
g7
I186
sg8
VP07197
p5572
sg10
I4
sg11
VNEF3
p5573
sg13
I1
sa(dp5574
g7
I210
sg8
VP48454
p5575
sg10
I6
sg11
VPPP3CC
p5576
sg13
I1
sa(dp5577
g7
I142
sg8
g9
sg10
I4
sg11
VEGR3
p5578
sg13
I1
sa(dp5579
g7
I120
sg8
g9
sg10
I6
sg11
VCHRNB3
p5580
sg13
I1
sa(dp5581
g7
I86
sg8
VP25100
p5582
sg10
I6
sg11
VADRA1A
p5583
sg13
I1
sa(dp5584
g7
I234
sg8
VP54219
p5585
sg10
I7
sg11
VSLC18A1
p5586
sg13
I1
sa(dp5587
g7
I228
sg8
VP54219
p5588
sg10
I5
sg11
VVMAT1
p5589
sg13
I1
sa(dp5590
g7
I180
sg8
VP18440
p5591
sg10
I4
sg11
VNAT2
p5592
sg13
I1
sa(dp5593
g7
I128
sg8
g9
sg10
I4
sg11
VDKK4
p5594
sg13
I1
sa(dp5595
g7
I162
sg8
VP20930
p5596
sg10
I5
sg11
VFGFR1
p5597
sg13
I1
sa(dp5598
g7
I104
sg8
g9
sg10
I6
sg11
VCHRNA2
p5599
sg13
I1
sa(dp5600
g7
I134
sg8
g9
sg10
I6
sg11
VDPYSL2
p5601
sg13
I1
sa(dp5602
g7
I169
sg8
g9
sg10
I4
sg11
VFZD3
p5603
sg13
I1
sa(dp5604
g7
I148
sg8
g9
sg10
I5
sg11
VFGF17
p5605
sg13
I1
sa(dp5606
g7
I155
sg8
g9
sg10
I5
sg11
VFGF20
p5607
sg13
I1
sa(dp5608
g7
I218
sg8
g9
sg10
I5
sg11
VSFRP1
p5609
sg13
I1
sa(dp5610
g7
I198
sg8
g9
sg10
I4
sg11
VPCM1
p5611
sg13
I1
sa(dp5612
g7
I112
sg8
g9
sg10
I6
sg11
VCHRNA6
p5613
sg13
I1
sasg24
(lp5614
(dp5615
g7
I436
sg27
VC0006826
p5616
sg10
I6
sg11
Vcancer
p5617
sg13
I1
sa(dp5618
g7
I309
sg27
VC0036341
p5619
sg10
I13
sg11
Vschizophrenia
p5620
sg13
I1
sa(dp5621
g7
I332
sg27
VC0005586
p5622
sg10
I16
sg11
Vbipolar disorder
p5623
sg13
I2
sa(dp5624
g7
I324
sg27
VC0004352
p5625
sg10
I6
sg11
Vautism
p5626
sg13
I1
sa(dp5627
g7
I366
sg27
VC0524851
p5628
sg10
I27
sg11
Vneurodegenerative disorders
p5629
sg13
I2
sa(dp5630
g7
I353
sg27
VC0011581
p5631
sg10
I10
sg11
Vdepression
p5632
sg13
I1
sa(dp5633
g7
I411
sg27
VC1521724
p5634
sg10
I19
sg11
VAlzheimer's disease
p5635
sg13
I2
sasa(dp5636
g2
S'The region on chromosome 3p13-p14 known to contain several chromosomal translocation breakpoints in families with "pure familial renal cell carcinoma" is quite proximal to the VHL locus in 3p25-p26 we have identified.\n'
p5637
sg4
(lp5638
(dp5639
g7
I176
sg8
VP40337
p5640
sg10
I9
sg11
VVHL locus
p5641
sg13
I2
sa(dp5642
g7
I30
sg8
VP03971
p5643
sg10
I3
sg11
Vp14
p5644
sg13
I1
sasg24
(lp5645
(dp5646
g7
I176
sg27
VC0019562
p5647
sg10
I3
sg11
VVHL
p5648
sg13
I1
sa(dp5649
g7
I120
sg27
VC2931352
p5650
sg10
I29
sg11
Vfamilial renal cell carcinoma
p5651
sg13
I4
sa(dp5652
g7
I59
sg27
VC0040715
p5653
sg10
I25
sg11
Vchromosomal translocation
p5654
sg13
I2
sasa(dp5655
g2
S'Immunohistochemical studies and TCR gamma gene rearrangement analysis using a polymerase chain reaction with primers specific for V gamma 1-8 and V gamma 9 gene segments in combination with denaturing gradient gel electrophoresis (PCR/ DGGE) were performed on frozen material of 11 pseudo-T-cell lymphomas and 17 CTCLs, including 9 cases of mycosis fungoides (MF) and 8 pleomorphic CTCLs.\n'
p5656
sg4
(lp5657
(dp5658
g7
I130
sg8
g9
sg10
I39
sg11
VV gamma 1-8 and V gamma 9 gene segments
p5659
sg13
I9
sasg24
(lp5660
(dp5661
g7
I341
sg27
VC0026948
p5662
sg10
I17
sg11
Vmycosis fungoides
p5663
sg13
I2
sa(dp5664
g7
I289
sg27
VC0079772
p5665
sg10
I16
sg11
VT-cell lymphomas
p5666
sg13
I2
sa(dp5667
g7
I360
sg27
VC0026948
p5668
sg10
I2
sg11
VMF
p5669
sg13
I1
sasa(dp5670
g2
S'Unclassifiable cutaneous T-cell lymphoma was also diagnosed in the second patient: it was associated with a monoclonal proliferation of T-cell receptor V gamma 9, delta + large granular T lymphocytes and finally developed into frank, acute pre-T lymphatic leukemia.\n'
p5671
sg4
(lp5672
(dp5673
g7
I136
sg8
g9
sg10
I32
sg11
VT-cell receptor V gamma 9, delta
p5674
sg13
I6
sasg24
(lp5675
(dp5676
g7
I119
sg27
VC0334094
p5677
sg10
I13
sg11
Vproliferation
p5678
sg13
I1
sa(dp5679
g7
I15
sg27
VC0079773
p5680
sg10
I25
sg11
Vcutaneous T-cell lymphoma
p5681
sg13
I3
sa(dp5682
g7
I246
sg27
VC0023448
p5683
sg10
I18
sg11
Vlymphatic leukemia
p5684
sg13
I2
sasa(dp5685
g2
S'In addition to providing insight into Pol I transcription and ES control, Pol I transcription inhibitors potentially also provide new approaches to treat trypanosomiasis.\n'
p5686
sg4
(lp5687
(dp5688
g7
I38
sg8
VP10266
p5689
sg10
I5
sg11
VPol I
p5690
sg13
I2
sa(dp5691
g7
I38
sg8
VP10266
p5692
sg10
I5
sg11
VPol I
p5693
sg13
I2
sasg24
(lp5694
(dp5695
g7
I154
sg27
VC0041227
p5696
sg10
I15
sg11
Vtrypanosomiasis
p5697
sg13
I1
sasa(dp5698
g2
S'In the unicellular parasite Trypanosoma brucei, which causes African sleeping sickness, TbISWI down-regulates RNA polymerase I (Pol I)-transcribed variant surface glycoprotein (VSG) gene expression sites (ESs), which are monoallelically expressed.\n'
p5699
sg4
(lp5700
(dp5701
g7
I110
sg8
VP24928
p5702
sg10
I16
sg11
VRNA polymerase I
p5703
sg13
I3
sa(dp5704
g7
I128
sg8
VP10266
p5705
sg10
I5
sg11
VPol I
p5706
sg13
I2
sasg24
(lp5707
(dp5708
g7
I61
sg27
VC0041228
p5709
sg10
I25
sg11
VAfrican sleeping sickness
p5710
sg13
I3
sasa(dp5711
g2
S'Furthermore, miR-130b-DEX significantly reduced expression of PPAR-Gamma downstream factor perilipin 1 as well as adipogenesis genes fatty acid synthase, acetyl coenzyme A carboxylase, 11Beta hydroxysteroid dehydrogenase type 1 and fat mass and obesity-associated gene, whereas expression as well as enzyme activity of adipose triglyceride lipase and hormone-sensitive lipase were greatly increased.\n'
p5712
sg4
(lp5713
(dp5714
g7
I340
sg8
VP04118
p5715
sg10
I6
sg11
Vlipase
p5716
sg13
I1
sa(dp5717
g7
I154
sg8
g9
sg10
I29
sg11
Vacetyl coenzyme A carboxylase
p5718
sg13
I4
sa(dp5719
g7
I185
sg8
VP49366
p5720
sg10
I42
sg11
V11Beta hydroxysteroid dehydrogenase type 1
p5721
sg13
I5
sa(dp5722
g7
I319
sg8
VP04118
p5723
sg10
I27
sg11
Vadipose triglyceride lipase
p5724
sg13
I3
sa(dp5725
g7
I133
sg8
VP48023
p5726
sg10
I19
sg11
Vfatty acid synthase
p5727
sg13
I3
sa(dp5728
g7
I13
sg8
g9
sg10
I8
sg11
VmiR-130b
p5729
sg13
I1
sa(dp5730
g7
I91
sg8
g9
sg10
I11
sg11
Vperilipin 1
p5731
sg13
I2
sa(dp5732
g7
I62
sg8
g9
sg10
I10
sg11
VPPAR-Gamma
p5733
sg13
I1
sasg24
(lp5734
(dp5735
g7
I245
sg27
VC0028754
p5736
sg10
I7
sg11
Vobesity
p5737
sg13
I1
sasa(dp5738
g2
S'A significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.\n'
p5739
sg4
(lp5740
(dp5741
g7
I48
sg8
g9
sg10
I19
sg11
Vperilipin rs1052700
p5742
sg13
I2
sasg24
(lp5743
(dp5744
g7
I85
sg27
VC0011860
p5745
sg10
I3
sg11
VT2D
p5746
sg13
I1
sa(dp5747
g7
I85
sg27
VC0011860
p5748
sg10
I3
sg11
VT2D
p5749
sg13
I1
sa(dp5750
g7
I137
sg27
VC0028754
p5751
sg10
I7
sg11
Vobesity
p5752
sg13
I1
sasa(dp5753
g2
S'The perilipin rs1052700 polymorphism is related to T2D but not obesity.\n'
p5754
sg4
(lp5755
(dp5756
g7
I51
sg8
g9
sg10
I3
sg11
VT2D
p5757
sg13
I1
sa(dp5758
g7
I4
sg8
g9
sg10
I19
sg11
Vperilipin rs1052700
p5759
sg13
I2
sasg24
(lp5760
(dp5761
g7
I51
sg27
VC0011860
p5762
sg10
I3
sg11
VT2D
p5763
sg13
I1
sa(dp5764
g7
I63
sg27
VC0028754
p5765
sg10
I7
sg11
Vobesity
p5766
sg13
I1
sasa(dp5767
g2
S'This prospective study recruited 22 patients with ESRD who underwent a first living kidney allograft transplantation, comprising 12 patients with CYP3A5*1 allele (CYP3A5*1/*1 or *1/*3) and 10 patients without CYP3A5*1 allele (CYP3A5*3/*3).\n'
p5768
sg4
(lp5769
(dp5770
g7
I146
sg8
VP20815
p5771
sg10
I8
sg11
VCYP3A5*1
p5772
sg13
I1
sa(dp5773
g7
I226
sg8
VP20815
p5774
sg10
I11
sg11
VCYP3A5*3/*3
p5775
sg13
I1
sa(dp5776
g7
I146
sg8
VP20815
p5777
sg10
I15
sg11
VCYP3A5*1 allele
p5778
sg13
I2
sa(dp5779
g7
I146
sg8
VP20815
p5780
sg10
I15
sg11
VCYP3A5*1 allele
p5781
sg13
I2
sasg24
(lp5782
(dp5783
g7
I50
sg27
VC0022661
p5784
sg10
I4
sg11
VESRD
p5785
sg13
I1
sasa(dp5786
g2
S'Nineteen SNPs in the ABCB1, NR1I2, UGT1A1, SLCO1B1 and CYP3A5 genes were examined in case patients with atazanavir/ritonavir-induced nephrolithiasis (n = 31) and controls (n = 47).\n'
p5787
sg4
(lp5788
(dp5789
g7
I35
sg8
VP35504
p5790
sg10
I6
sg11
VUGT1A1
p5791
sg13
I1
sa(dp5792
g7
I55
sg8
VP20815
p5793
sg10
I12
sg11
VCYP3A5 genes
p5794
sg13
I2
sa(dp5795
g7
I21
sg8
VP08183
p5796
sg10
I5
sg11
VABCB1
p5797
sg13
I1
sa(dp5798
g7
I43
sg8
g9
sg10
I7
sg11
VSLCO1B1
p5799
sg13
I1
sasg24
(lp5800
(dp5801
g7
I133
sg27
VC0392525
p5802
sg10
I15
sg11
Vnephrolithiasis
p5803
sg13
I1
sasa(dp5804
g2
S'Calcineurin inhibitor (CNI) use is considered to play a major role in the development of CKD after LT. We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT. Tacrolimus (Tac) predose concentrations at different time-points after transplantation and the CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T SNPs were determined in 125 LT recipients and their respective donors to study the influence of Tac predose levels and genetics on the development of CKD.\n'
p5805
sg4
(lp5806
(dp5807
g7
I425
sg8
VP08183
p5808
sg10
I11
sg11
VABCB1 3435C
p5809
sg13
I2
sa(dp5810
g7
I249
sg8
g9
sg10
I22
sg11
VCNI-transporting ABCB1
p5811
sg13
I2
sa(dp5812
g7
I210
sg8
g9
sg10
I30
sg11
VCNI-metabolizing enzyme CYP3A5
p5813
sg13
I3
sa(dp5814
g7
I23
sg8
g9
sg10
I3
sg11
VCNI
p5815
sg13
I1
sa(dp5816
g7
I0
sg8
g9
sg10
I21
sg11
VCalcineurin inhibitor
p5817
sg13
I2
sa(dp5818
g7
I440
sg8
g9
sg10
I6
sg11
VT SNPs
p5819
sg13
I2
sa(dp5820
g7
I403
sg8
VP20815
p5821
sg10
I12
sg11
VCYP3A5 6986A
p5822
sg13
I2
sasg24
(lp5823
sa(dp5824
g2
S'Neither did we find a correlation between the investigated SNPs in either donor or recipient ABCB1 and CYP3A5 genes (or combinations thereof) and the development of CKD.\n'
p5825
sg4
(lp5826
(dp5827
g7
I93
sg8
VP08183
p5828
sg10
I5
sg11
VABCB1
p5829
sg13
I1
sa(dp5830
g7
I103
sg8
VP20815
p5831
sg10
I12
sg11
VCYP3A5 genes
p5832
sg13
I2
sasg24
(lp5833
sa(dp5834
g2
S"An individual's risk of developing CKD after LT is not associated with genetic variation in either recipient or donor CYP3A5 or ABCB1 genotype status.\n"
p5835
sg4
(lp5836
(dp5837
g7
I118
sg8
VP20815
p5838
sg10
I6
sg11
VCYP3A5
p5839
sg13
I1
sa(dp5840
g7
I128
sg8
VP08183
p5841
sg10
I14
sg11
VABCB1 genotype
p5842
sg13
I2
sasg24
(lp5843
sa(dp5844
g2
S'In conclusion, these results suggest that CYP3A5 polymorphism and plasma concentration of 3-INDS may account for the interindividual variability of CYP3A activity, and that plasma concentration of 3-INDS may partially explain the gap in CYP3A activity that cannot be explained by genetic contribution in patients with renal failure.\n'
p5845
sg4
(lp5846
(dp5847
g7
I42
sg8
VP08684
p5848
sg10
I5
sg11
VCYP3A
p5849
sg13
I1
sa(dp5850
g7
I42
sg8
VP20815
p5851
sg10
I6
sg11
VCYP3A5
p5852
sg13
I1
sa(dp5853
g7
I42
sg8
VP08684
p5854
sg10
I5
sg11
VCYP3A
p5855
sg13
I1
sasg24
(lp5856
(dp5857
g7
I318
sg27
VC0035078
p5858
sg10
I13
sg11
Vrenal failure
p5859
sg13
I2
sasa(dp5860
g2
S'### ##FGD6  (faciogenital dysplasia) ############### ### ##FGD6#######, ##AdEasy#########, ############pSES-FGD6-siRNA, ##HP14.5###########FGD6###HP14.5########, ######PCR##FGD6##### (AFP) #### (Alb) #mRNA##, Western blot##FGD6#AFP#Alb###############pSES-Ad-RFP####################+/-### (x+/-s) ##, ########## ### FGD6#######HP14.5###############pSES-FGD6-siRNA###FGD6###HP14.5######, ###AFP#mRNA######, ###Alb#mRNA###### (P&lt;0.01) # ### ##FGD6###HP14.5######, ##HP14.5##########, ##, FGD6####################.\n'
p5861
sg4
(lp5862
(dp5863
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5864
sg13
I1
sa(dp5865
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5866
sg13
I1
sa(dp5867
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5868
sg13
I1
sa(dp5869
g7
I103
sg8
g9
sg10
I15
sg11
VpSES-FGD6-siRNA
p5870
sg13
I1
sa(dp5871
g7
I195
sg8
g9
sg10
I3
sg11
VAlb
p5872
sg13
I1
sa(dp5873
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5874
sg13
I1
sa(dp5875
g7
I258
sg8
VP25090
p5876
sg10
I3
sg11
VRFP
p5877
sg13
I1
sa(dp5878
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5879
sg13
I1
sa(dp5880
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5881
sg13
I1
sa(dp5882
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5883
sg13
I1
sa(dp5884
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5885
sg13
I1
sa(dp5886
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5887
sg13
I1
sa(dp5888
g7
I184
sg8
VP02771
p5889
sg10
I3
sg11
VAFP
p5890
sg13
I1
sa(dp5891
g7
I6
sg8
g9
sg10
I4
sg11
VFGD6
p5892
sg13
I1
sasg24
(lp5893
(dp5894
g7
I13
sg27
VC0175701
p5895
sg10
I22
sg11
Vfaciogenital dysplasia
p5896
sg13
I2
sasa(dp5897
g2
S'Filtered albumin has been suggested to be a cause of the glomerular and tubular injuries observed at advanced stages of Alport syndrome.\n'
p5898
sg4
(lp5899
(dp5900
g7
I9
sg8
VP00441
p5901
sg10
I7
sg11
Valbumin
p5902
sg13
I1
sasg24
(lp5903
(dp5904
g7
I120
sg27
VC1567741
p5905
sg10
I15
sg11
VAlport syndrome
p5906
sg13
I2
sasa(dp5907
g2
S'To directly investigate the role that albumin plays in the progression of disease in Alport syndrome, we generated albumin knockout (Alb(-/-)) mice to use as a tool for removing albuminuria as a component of kidney disease.\n'
p5908
sg4
(lp5909
(dp5910
g7
I38
sg8
VP00441
p5911
sg10
I7
sg11
Valbumin
p5912
sg13
I1
sa(dp5913
g7
I38
sg8
VP00441
p5914
sg10
I7
sg11
Valbumin
p5915
sg13
I1
sa(dp5916
g7
I133
sg8
g9
sg10
I3
sg11
VAlb
p5917
sg13
I1
sasg24
(lp5918
(dp5919
g7
I85
sg27
VC1567741
p5920
sg10
I15
sg11
VAlport syndrome
p5921
sg13
I2
sa(dp5922
g7
I208
sg27
VC0022658
p5923
sg10
I14
sg11
Vkidney disease
p5924
sg13
I2
sasa(dp5925
g2
S'Alb mutant mice were bred to collagen-Alfa3(IV) knockout (Col4a3(-/-)) mice, which are a model for human Alport syndrome.\n'
p5926
sg4
(lp5927
(dp5928
g7
I0
sg8
g9
sg10
I3
sg11
VAlb
p5929
sg13
I1
sasg24
(lp5930
(dp5931
g7
I105
sg27
VC1567741
p5932
sg10
I15
sg11
VAlport syndrome
p5933
sg13
I2
sa(dp5934
g7
I4
sg27
VC0596988
p5935
sg10
I6
sg11
Vmutant
p5936
sg13
I1
sasa(dp5937
g2
S'We conclude that filtered albumin is injurious to kidney cells in Alport syndrome and perhaps in other proteinuric kidney diseases, including diabetic nephropathy.\n'
p5938
sg4
(lp5939
(dp5940
g7
I26
sg8
VP00441
p5941
sg10
I7
sg11
Valbumin
p5942
sg13
I1
sasg24
(lp5943
(dp5944
g7
I142
sg27
VC0011881
p5945
sg10
I20
sg11
Vdiabetic nephropathy
p5946
sg13
I2
sa(dp5947
g7
I115
sg27
VC0022658
p5948
sg10
I15
sg11
Vkidney diseases
p5949
sg13
I2
sa(dp5950
g7
I66
sg27
VC1567741
p5951
sg10
I15
sg11
VAlport syndrome
p5952
sg13
I2
sasa(dp5953
g2
S'On the other hand, we believe that tumor depth of invasion (&gt;=4 mm), POI, and VEGF-C expression all need to be considered in the preoperative and postoperative planning stages for tongue cancer treatment.\n'
p5954
sg4
(lp5955
(dp5956
g7
I81
sg8
VP49767
p5957
sg10
I6
sg11
VVEGF-C
p5958
sg13
I1
sasg24
(lp5959
(dp5960
g7
I183
sg27
VC0558353
p5961
sg10
I13
sg11
Vtongue cancer
p5962
sg13
I2
sa(dp5963
g7
I35
sg27
VC0027651
p5964
sg10
I5
sg11
Vtumor
p5965
sg13
I1
sa(dp5966
g7
I50
sg27
VC2699153
p5967
sg10
I8
sg11
Vinvasion
p5968
sg13
I1
sasa(dp5969
g2
S'The use of a therapeutic approach which blocks lymphangiogenic factors, such as VEGF-C and VEGF-D, may be beneficial in suppressing the lymphatic spread of tongue cancer with intense intranodal lymphangiogenesis.\n'
p5970
sg4
(lp5971
(dp5972
g7
I80
sg8
VP49767
p5973
sg10
I6
sg11
VVEGF-C
p5974
sg13
I1
sa(dp5975
g7
I91
sg8
g9
sg10
I6
sg11
VVEGF-D
p5976
sg13
I1
sasg24
(lp5977
(dp5978
g7
I156
sg27
VC0558353
p5979
sg10
I13
sg11
Vtongue cancer
p5980
sg13
I2
sasa(dp5981
g2
S'VEGF, VEGF-C, VEGF-D and MIA expression levels of metastatic tongue cancer HSC-3 cells were higher than those with no metastatic HSC-4 cells, and VEGF, VEGF-C and VEGF-D expression levels were decreased by MIA siRNA treatment in both cells.\n'
p5982
sg4
(lp5983
(dp5984
g7
I14
sg8
g9
sg10
I6
sg11
VVEGF-D
p5985
sg13
I1
sa(dp5986
g7
I6
sg8
VP49767
p5987
sg10
I6
sg11
VVEGF-C
p5988
sg13
I1
sa(dp5989
g7
I206
sg8
g9
sg10
I9
sg11
VMIA siRNA
p5990
sg13
I2
sa(dp5991
g7
I25
sg8
g9
sg10
I3
sg11
VMIA
p5992
sg13
I1
sa(dp5993
g7
I14
sg8
g9
sg10
I6
sg11
VVEGF-D
p5994
sg13
I1
sa(dp5995
g7
I6
sg8
VP49767
p5996
sg10
I6
sg11
VVEGF-C
p5997
sg13
I1
sasg24
(lp5998
(dp5999
g7
I61
sg27
VC0558353
p6000
sg10
I13
sg11
Vtongue cancer
p6001
sg13
I2
sasa(dp6002
g2
S'Vascular endothelial growth factor and Notch1 expression are significantly related to cervical lymph node metastasis and depth of invasion in tongue cancer patients.\n'
p6003
sg4
(lp6004
(dp6005
g7
I0
sg8
g9
sg10
I34
sg11
VVascular endothelial growth factor
p6006
sg13
I4
sa(dp6007
g7
I39
sg8
VP46531
p6008
sg10
I6
sg11
VNotch1
p6009
sg13
I1
sasg24
(lp6010
(dp6011
g7
I130
sg27
VC2699153
p6012
sg10
I8
sg11
Vinvasion
p6013
sg13
I1
sa(dp6014
g7
I95
sg27
VC0686619
p6015
sg10
I21
sg11
Vlymph node metastasis
p6016
sg13
I3
sa(dp6017
g7
I142
sg27
VC0558353
p6018
sg10
I13
sg11
Vtongue cancer
p6019
sg13
I2
sasa(dp6020
g2
S'Mutant-type p53 and VEGF are known to be related to angiogenesis, and maspin is a potent angiogenic inhibitor but its role in tongue cancer has scarcely been examined.\n'
p6021
sg4
(lp6022
(dp6023
g7
I12
sg8
VP42771
p6024
sg10
I3
sg11
Vp53
p6025
sg13
I1
sasg24
(lp6026
(dp6027
g7
I0
sg27
VC0596988
p6028
sg10
I6
sg11
VMutant
p6029
sg13
I1
sa(dp6030
g7
I126
sg27
VC0558353
p6031
sg10
I13
sg11
Vtongue cancer
p6032
sg13
I2
sasa(dp6033
g2
S'We observed the expression of maspin, mutant-type p53 and VEGF by immunohistochemistry in 33 patients with stages I and II oral tongue cancer.\n'
p6034
sg4
(lp6035
(dp6036
g7
I30
sg8
VP36952
p6037
sg10
I6
sg11
Vmaspin
p6038
sg13
I1
sa(dp6039
g7
I38
sg8
VP42771
p6040
sg10
I15
sg11
Vmutant-type p53
p6041
sg13
I2
sasg24
(lp6042
(dp6043
g7
I128
sg27
VC0558353
p6044
sg10
I13
sg11
Vtongue cancer
p6045
sg13
I2
sa(dp6046
g7
I38
sg27
VC0596988
p6047
sg10
I6
sg11
Vmutant
p6048
sg13
I1
sasa(dp6049
g2
S'In an experimental autoimmune encephalomyelitis model of CNS autoimmunity, we found activation-induced cytidine deaminase, a GC-defining enzyme, in meningeal ELT (mELT) densely populated by B and T cells.\n'
p6050
sg4
(lp6051
(dp6052
g7
I103
sg8
VP32320
p6053
sg10
I18
sg11
Vcytidine deaminase
p6054
sg13
I2
sasg24
(lp6055
(dp6056
g7
I30
sg27
VC0014070
p6057
sg10
I17
sg11
Vencephalomyelitis
p6058
sg13
I1
sa(dp6059
g7
I61
sg27
VC0004368
p6060
sg10
I12
sg11
Vautoimmunity
p6061
sg13
I1
sa(dp6062
g7
I19
sg27
VC0443146
p6063
sg10
I10
sg11
Vautoimmune
p6064
sg13
I1
sasa(dp6065
g2
S'A prospective randomized survey of 113 abortions carried out by 1 operator using a single technique among women in the 7th-10th week of amenorrhea was undertaken to test the effectiveness of systemically administered oxytocins to reduce bleeding during therapeutic abortion by suction.\n'
p6066
sg4
(lp6067
sg24
(lp6068
(dp6069
g7
I136
sg27
VC0002453
p6070
sg10
I10
sg11
Vamenorrhea
p6071
sg13
I1
sa(dp6072
g7
I237
sg27
VC0019080
p6073
sg10
I8
sg11
Vbleeding
p6074
sg13
I1
sasa(dp6075
g2
S'This cross-sectional study includes 304 patients with type 2 diabetes treated with oral antidiabetic drugs (ADOs) and a glomerular filtration rate (estimated GFR) &amp;lt;60ml/min/1.73m2.\n'
p6076
sg4
(lp6077
sg24
(lp6078
(dp6079
g7
I54
sg27
VC0011860
p6080
sg10
I15
sg11
Vtype 2 diabetes
p6081
sg13
I3
sasa(dp6082
g2
S'The purpose of this study was to evaluate the hypothesis that acute hyperglycaemia in hearts of rats without diabetes alters coronary vascular responses to nitric oxide (NO), adenosine (ADO) and phenylephrine (PHE).\n'
p6083
sg4
(lp6084
sg24
(lp6085
(dp6086
g7
I62
sg27
VC0342301
p6087
sg10
I20
sg11
Vacute hyperglycaemia
p6088
sg13
I2
sa(dp6089
g7
I109
sg27
VC0011849
p6090
sg10
I8
sg11
Vdiabetes
p6091
sg13
I1
sasa(dp6092
g2
S'In conclusion, STZ-diabetes mellitus enhances the antiphosphaturic effect of ADO by mechanisms unrelated to ADO A1 receptor stimulation.\n'
p6093
sg4
(lp6094
(dp6095
g7
I108
sg8
g9
sg10
I15
sg11
VADO A1 receptor
p6096
sg13
I3
sasg24
(lp6097
(dp6098
g7
I19
sg27
VC0011849
p6099
sg10
I17
sg11
Vdiabetes mellitus
p6100
sg13
I2
sasa(dp6101
g2
S'Bradykinin type 1 receptor antagonism could represent a promising therapeutic tool in combination with TZD for the treatment of T2D, obesity and insulin resistance.\n'
p6102
sg4
(lp6103
(dp6104
g7
I0
sg8
VP01042
p6105
sg10
I26
sg11
VBradykinin type 1 receptor
p6106
sg13
I4
sa(dp6107
g7
I145
sg8
VP01308
p6108
sg10
I7
sg11
Vinsulin
p6109
sg13
I1
sasg24
(lp6110
(dp6111
g7
I133
sg27
VC0028754
p6112
sg10
I7
sg11
Vobesity
p6113
sg13
I1
sa(dp6114
g7
I145
sg27
VC0021655
p6115
sg10
I18
sg11
Vinsulin resistance
p6116
sg13
I2
sa(dp6117
g7
I128
sg27
VC0011860
p6118
sg10
I3
sg11
VT2D
p6119
sg13
I1
sasa(dp6120
g2
S'The aim of this study was to analyze the acute responses of bradykinin, insulin, and glycemia to exercise performed above and below lactate threshold (LT) in individuals with type 2 diabetes mellitus (T2D).\n'
p6121
sg4
(lp6122
(dp6123
g7
I60
sg8
VP01042
p6124
sg10
I10
sg11
Vbradykinin
p6125
sg13
I1
sa(dp6126
g7
I72
sg8
VP01308
p6127
sg10
I7
sg11
Vinsulin
p6128
sg13
I1
sasg24
(lp6129
(dp6130
g7
I175
sg27
VC0011860
p6131
sg10
I24
sg11
Vtype 2 diabetes mellitus
p6132
sg13
I4
sa(dp6133
g7
I201
sg27
VC0011860
p6134
sg10
I3
sg11
VT2D
p6135
sg13
I1
sasa(dp6136
g2
S'To examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).\n'
p6137
sg4
(lp6138
(dp6139
g7
I30
sg8
VP01042
p6140
sg10
I10
sg11
Vbradykinin
p6141
sg13
I1
sa(dp6142
g7
I171
sg8
VP00797
p6143
sg10
I5
sg11
VRenin
p6144
sg13
I1
sa(dp6145
g7
I177
sg8
VP21549
p6146
sg10
I11
sg11
VAngiotensin
p6147
sg13
I1
sasg24
(lp6148
(dp6149
g7
I86
sg27
VC0011881
p6150
sg10
I20
sg11
Vdiabetic nephropathy
p6151
sg13
I2
sa(dp6152
g7
I157
sg27
VC0011854
p6153
sg10
I3
sg11
VT1D
p6154
sg13
I1
sa(dp6155
g7
I140
sg27
VC0011854
p6156
sg10
I15
sg11
Vtype 1 diabetes
p6157
sg13
I3
sasa(dp6158
g2
S'Heterozygosity for missense mutations in Seipin, namely N88S and S90L, leads to a broad spectrum of motor neuropathy, while a number of loss-of-function mutations in Seipin are associated with the Berardinelli-Seip congenital generalized lipodystrophy type 2 (CGL2, BSCL2), a condition that is characterized by severe lipoatrophy, insulin resistance, and intellectual impairment.\n'
p6159
sg4
(lp6160
(dp6161
g7
I331
sg8
VP01308
p6162
sg10
I7
sg11
Vinsulin
p6163
sg13
I1
sa(dp6164
g7
I266
sg8
g9
sg10
I5
sg11
VBSCL2
p6165
sg13
I1
sa(dp6166
g7
I260
sg8
VP20718
p6167
sg10
I4
sg11
VCGL2
p6168
sg13
I1
sa(dp6169
g7
I41
sg8
g9
sg10
I6
sg11
VSeipin
p6170
sg13
I1
sa(dp6171
g7
I215
sg8
VP20718
p6172
sg10
I43
sg11
Vcongenital generalized lipodystrophy type 2
p6173
sg13
I5
sa(dp6174
g7
I41
sg8
g9
sg10
I6
sg11
VSeipin
p6175
sg13
I1
sasg24
(lp6176
(dp6177
g7
I318
sg27
VC1280433
p6178
sg10
I11
sg11
Vlipoatrophy
p6179
sg13
I1
sa(dp6180
g7
I331
sg27
VC0021655
p6181
sg10
I18
sg11
Vinsulin resistance
p6182
sg13
I2
sa(dp6183
g7
I276
sg27
VC0012634
p6184
sg10
I9
sg11
Vcondition
p6185
sg13
I1
sa(dp6186
g7
I100
sg27
VC0235025
p6187
sg10
I16
sg11
Vmotor neuropathy
p6188
sg13
I2
sa(dp6189
g7
I260
sg27
VC1720863
p6190
sg10
I4
sg11
VCGL2
p6191
sg13
I1
sa(dp6192
g7
I215
sg27
VC1720863
p6193
sg10
I43
sg11
Vcongenital generalized lipodystrophy type 2
p6194
sg13
I5
sa(dp6195
g7
I355
sg27
VC0683322
p6196
sg10
I23
sg11
Vintellectual impairment
p6197
sg13
I2
sasa(dp6198
g2
S'In comparison to liver biopsies of patients with non-viral liver disease, liver biopsies of patients with HCV showed significantly increased mRNA expression of IL-28A and IL-29.\n'
p6199
sg4
(lp6200
(dp6201
g7
I171
sg8
g9
sg10
I5
sg11
VIL-29
p6202
sg13
I1
sasg24
(lp6203
(dp6204
g7
I65
sg27
VC0023895
p6205
sg10
I14
sg11
Vdisease, liver
p6206
sg13
I2
sasa(dp6207
g2
S'Here, we demonstrate a key regulatory role of IL-28A in T-cell-mediated hepatitis.\n'
p6208
sg4
(lp6209
sg24
(lp6210
(dp6211
g7
I72
sg27
VC0019159
p6212
sg10
I9
sg11
Vhepatitis
p6213
sg13
I1
sasa(dp6214
g2
S'IL-28A induced TH1 cytokine production by CD4+ T lymphocytes in a T-bet-dependent manner and was up-regulated in a murine model of T-cell-mediated hepatitis upon Con A administration.\n'
p6215
sg4
(lp6216
(dp6217
g7
I42
sg8
VP01730
p6218
sg10
I4
sg11
VCD4+
p6219
sg13
I1
sa(dp6220
g7
I15
sg8
VP13236
p6221
sg10
I12
sg11
VTH1 cytokine
p6222
sg13
I2
sasg24
(lp6223
(dp6224
g7
I147
sg27
VC0019159
p6225
sg10
I9
sg11
Vhepatitis
p6226
sg13
I1
sasa(dp6227
g2
S'In addition, IL-28A-transgenic mice showed markedly augmented Con A-induced hepatitis with up-regulated interferon-gamma cytokine production, as compared with wild-type mice.\n'
p6228
sg4
(lp6229
(dp6230
g7
I104
sg8
VP01579
p6231
sg10
I16
sg11
Vinterferon-gamma
p6232
sg13
I1
sasg24
(lp6233
(dp6234
g7
I76
sg27
VC0019159
p6235
sg10
I9
sg11
Vhepatitis
p6236
sg13
I1
sasa(dp6237
g2
S'In addition, in vivo blockade of interferon-gamma but not IL-4 suppressed augmented liver inflammation in transgenic mice, suggesting that IL-28A induces the T-bet signaling pathway in T-cell-induced hepatitis.\n'
p6238
sg4
(lp6239
(dp6240
g7
I58
sg8
VP05112
p6241
sg10
I4
sg11
VIL-4
p6242
sg13
I1
sa(dp6243
g7
I158
sg8
g9
sg10
I5
sg11
VT-bet
p6244
sg13
I1
sa(dp6245
g7
I33
sg8
VP01579
p6246
sg10
I16
sg11
Vinterferon-gamma
p6247
sg13
I1
sasg24
(lp6248
(dp6249
g7
I90
sg27
VC0021368
p6250
sg10
I12
sg11
Vinflammation
p6251
sg13
I1
sa(dp6252
g7
I200
sg27
VC0019159
p6253
sg10
I9
sg11
Vhepatitis
p6254
sg13
I1
sasa(dp6255
g2
S'Thus, targeting of IL-28A represents a potential novel approach for therapy of Th1-mediated inflammatory diseases such as T-cell-mediated hepatitis.\n'
p6256
sg4
(lp6257
sg24
(lp6258
(dp6259
g7
I138
sg27
VC0019159
p6260
sg10
I9
sg11
Vhepatitis
p6261
sg13
I1
sasa(dp6262
g2
S'The present study therefore indicated that NOD receptor and TLR9 may modulate the inflammatory response and further impact upon intestinal injury of SAP, via the regulation of NF-KB expression and the oxidation/antioxidation balance, suggesting therapeutically targeting NOD receptor and TLR9 might be a useful approach for the treatment of severe acute pancreatitis.\n'
p6263
sg4
(lp6264
(dp6265
g7
I60
sg8
g9
sg10
I4
sg11
VTLR9
p6266
sg13
I1
sa(dp6267
g7
I60
sg8
g9
sg10
I4
sg11
VTLR9
p6268
sg13
I1
sa(dp6269
g7
I43
sg8
VP54259
p6270
sg10
I12
sg11
VNOD receptor
p6271
sg13
I2
sa(dp6272
g7
I43
sg8
VP54259
p6273
sg10
I12
sg11
VNOD receptor
p6274
sg13
I2
sasg24
(lp6275
(dp6276
g7
I82
sg27
VC1155266
p6277
sg10
I21
sg11
Vinflammatory response
p6278
sg13
I2
sa(dp6279
g7
I43
sg27
VC0751781
p6280
sg10
I3
sg11
VNOD
p6281
sg13
I1
sa(dp6282
g7
I348
sg27
VC0001339
p6283
sg10
I18
sg11
Vacute pancreatitis
p6284
sg13
I2
sa(dp6285
g7
I43
sg27
VC0751781
p6286
sg10
I3
sg11
VNOD
p6287
sg13
I1
sasa(dp6288
g2
S'It also has efficacy in limiting TLR9-mediated sterile inflammation in in vivo models of acute liver injury and acute pancreatitis.\n'
p6289
sg4
(lp6290
(dp6291
g7
I33
sg8
g9
sg10
I4
sg11
VTLR9
p6292
sg13
I1
sasg24
(lp6293
(dp6294
g7
I47
sg27
VC0678108
p6295
sg10
I7
sg11
Vsterile
p6296
sg13
I1
sa(dp6297
g7
I55
sg27
VC0021368
p6298
sg10
I12
sg11
Vinflammation
p6299
sg13
I1
sa(dp6300
g7
I112
sg27
VC0001339
p6301
sg10
I18
sg11
Vacute pancreatitis
p6302
sg13
I2
sasa(dp6303
g2
S'Genetic deletion and pharmacologic antagonism demonstrate that specific DAMP receptors, including Toll-like receptor (TLR) 4, TLR9, and P2X7, are also required for inflammation in experimental acute pancreatitis.\n'
p6304
sg4
(lp6305
(dp6306
g7
I63
sg8
g9
sg10
I23
sg11
Vspecific DAMP receptors
p6307
sg13
I3
sa(dp6308
g7
I98
sg8
g9
sg10
I26
sg11
VToll-like receptor (TLR) 4
p6309
sg13
I4
sa(dp6310
g7
I126
sg8
g9
sg10
I4
sg11
VTLR9
p6311
sg13
I1
sa(dp6312
g7
I136
sg8
g9
sg10
I4
sg11
VP2X7
p6313
sg13
I1
sasg24
(lp6314
(dp6315
g7
I164
sg27
VC0021368
p6316
sg10
I12
sg11
Vinflammation
p6317
sg13
I1
sa(dp6318
g7
I193
sg27
VC0001339
p6319
sg10
I18
sg11
Vacute pancreatitis
p6320
sg13
I2
sasa(dp6321
g2
S'Acute pancreatitis was induced by caerulein stimulation in wild-type mice and mice deficient in components of the inflammasome (apoptosis-associated speck-like protein containing a caspase recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor P2X(7).\n'
p6322
sg4
(lp6323
(dp6324
g7
I256
sg8
g9
sg10
I4
sg11
VTLR9
p6325
sg13
I1
sa(dp6326
g7
I270
sg8
VP51575
p6327
sg10
I26
sg11
Vpurinergic receptor P2X(7)
p6328
sg13
I3
sa(dp6329
g7
I234
sg8
g9
sg10
I20
sg11
VToll-like receptor 9
p6330
sg13
I3
sa(dp6331
g7
I181
sg8
VP39880
p6332
sg10
I7
sg11
Vcaspase
p6333
sg13
I1
sa(dp6334
g7
I222
sg8
VP29466
p6335
sg10
I9
sg11
Vcaspase-1
p6336
sg13
I1
sasg24
(lp6337
(dp6338
g7
I189
sg27
VC0271510
p6339
sg10
I11
sg11
Vrecruitment
p6340
sg13
I1
sa(dp6341
g7
I0
sg27
VC0001339
p6342
sg10
I18
sg11
VAcute pancreatitis
p6343
sg13
I2
sasa(dp6344
g2
S'Additionally, wild-type mice were pretreated with a TLR9 antagonist before induction of acute pancreatitis by caerulein or retrograde bile duct infusion of taurolithocholic acid 3-sulfate.\n'
p6345
sg4
(lp6346
(dp6347
g7
I52
sg8
g9
sg10
I4
sg11
VTLR9
p6348
sg13
I1
sasg24
(lp6349
(dp6350
g7
I88
sg27
VC0001339
p6351
sg10
I18
sg11
Vacute pancreatitis
p6352
sg13
I2
sasa(dp6353
g2
S'TLR9 and P2X(7) are important DAMP receptors upstream of inflammasome activation, and their antagonism could provide a new therapeutic strategy for treating acute pancreatitis.\n'
p6354
sg4
(lp6355
(dp6356
g7
I0
sg8
g9
sg10
I4
sg11
VTLR9
p6357
sg13
I1
sa(dp6358
g7
I9
sg8
VP51575
p6359
sg10
I6
sg11
VP2X(7)
p6360
sg13
I1
sasg24
(lp6361
(dp6362
g7
I157
sg27
VC0001339
p6363
sg10
I18
sg11
Vacute pancreatitis
p6364
sg13
I2
sasa(dp6365
g2
S'We are currently screening the 113 candidate DFNB79 genes for mutations and have excluded CACNA1B, EDF1, PTGDS, EHMT1, QSOX2, NOTCH1, MIR126 and MIR602.\n'
p6366
sg4
(lp6367
(dp6368
g7
I112
sg8
g9
sg10
I5
sg11
VEHMT1
p6369
sg13
I1
sa(dp6370
g7
I90
sg8
g9
sg10
I7
sg11
VCACNA1B
p6371
sg13
I1
sa(dp6372
g7
I119
sg8
g9
sg10
I5
sg11
VQSOX2
p6373
sg13
I1
sa(dp6374
g7
I99
sg8
g9
sg10
I4
sg11
VEDF1
p6375
sg13
I1
sa(dp6376
g7
I45
sg8
g9
sg10
I12
sg11
VDFNB79 genes
p6377
sg13
I2
sa(dp6378
g7
I126
sg8
VP46531
p6379
sg10
I6
sg11
VNOTCH1
p6380
sg13
I1
sa(dp6381
g7
I105
sg8
VP41222
p6382
sg10
I5
sg11
VPTGDS
p6383
sg13
I1
sasg24
(lp6384
(dp6385
g7
I45
sg27
VC2750082
p6386
sg10
I6
sg11
VDFNB79
p6387
sg13
I1
sasa(dp6388
g2
S'Exposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.\n'
p6389
sg4
(lp6390
(dp6391
g7
I79
sg8
VP22083
p6392
sg10
I4
sg11
VCD15
p6393
sg13
I1
sa(dp6394
g7
I194
sg8
VP04198
p6395
sg10
I12
sg11
VNMYC protein
p6396
sg13
I2
sa(dp6397
g7
I17
sg8
VP18075
p6398
sg10
I29
sg11
Vmorphogenetic protein (BMP)-4
p6399
sg13
I3
sa(dp6400
g7
I85
sg8
VP61073
p6401
sg10
I5
sg11
VCD184
p6402
sg13
I1
sasg24
(lp6403
(dp6404
g7
I92
sg27
VC0027819
p6405
sg10
I13
sg11
Vneuroblastoma
p6406
sg13
I1
sasa(dp6407
g2
S'Recent studies indicate that C-X-C motif chemokine receptor 4 (CXCR4) and its ligand, C-X-C motif chemokine ligand 12 (CXCL12), stimulate expression of the cell cycle regulatory protein Cyclin D1 in neurofibromatosis 1-associated malignant peripheral nerve sheath tumor (MPNST) cells and promote their proliferation.\n'
p6408
sg4
(lp6409
(dp6410
g7
I29
sg8
VP51679
p6411
sg10
I32
sg11
VC-X-C motif chemokine receptor 4
p6412
sg13
I5
sa(dp6413
g7
I119
sg8
VP48061
p6414
sg10
I6
sg11
VCXCL12
p6415
sg13
I1
sa(dp6416
g7
I63
sg8
VP61073
p6417
sg10
I5
sg11
VCXCR4
p6418
sg13
I1
sa(dp6419
g7
I86
sg8
VP55773
p6420
sg10
I31
sg11
VC-X-C motif chemokine ligand 12
p6421
sg13
I5
sa(dp6422
g7
I186
sg8
VP24385
p6423
sg10
I9
sg11
VCyclin D1
p6424
sg13
I2
sasg24
(lp6425
(dp6426
g7
I230
sg27
VC0751690
p6427
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p6428
sg13
I5
sa(dp6429
g7
I199
sg27
VC0027831
p6430
sg10
I19
sg11
Vneurofibromatosis 1
p6431
sg13
I2
sa(dp6432
g7
I302
sg27
VC0334094
p6433
sg10
I13
sg11
Vproliferation
p6434
sg13
I1
sa(dp6435
g7
I271
sg27
VC0751690
p6436
sg10
I5
sg11
VMPNST
p6437
sg13
I1
sasa(dp6438
g2
S'Western blot analysis revealed the expression of multiple CXCR4 isoforms in neuroblastoma cells.\n'
p6439
sg4
(lp6440
(dp6441
g7
I58
sg8
VP61073
p6442
sg10
I14
sg11
VCXCR4 isoforms
p6443
sg13
I2
sasg24
(lp6444
(dp6445
g7
I76
sg27
VC0027819
p6446
sg10
I13
sg11
Vneuroblastoma
p6447
sg13
I1
sasa(dp6448
g2
S'Our data suggest a modulatory role of the MSC secretome on the expression of the 47 kDa CXCR4 isoform and invasion potential of the neuroblastoma cells to the bone marrow.\n'
p6449
sg4
(lp6450
(dp6451
g7
I81
sg8
VP61073
p6452
sg10
I20
sg11
V47 kDa CXCR4 isoform
p6453
sg13
I4
sasg24
(lp6454
(dp6455
g7
I132
sg27
VC0027819
p6456
sg10
I13
sg11
Vneuroblastoma
p6457
sg13
I1
sa(dp6458
g7
I106
sg27
VC2699153
p6459
sg10
I8
sg11
Vinvasion
p6460
sg13
I1
sasa(dp6461
g2
S'In this study, we investigated the role of NF-KB signaling pathway in the regulation of CXC chemokine receptor-4 (CXCR4) in neuroblastoma metastasis.\n'
p6462
sg4
(lp6463
(dp6464
g7
I114
sg8
VP61073
p6465
sg10
I5
sg11
VCXCR4
p6466
sg13
I1
sa(dp6467
g7
I88
sg8
VP61073
p6468
sg10
I24
sg11
VCXC chemokine receptor-4
p6469
sg13
I3
sasg24
(lp6470
(dp6471
g7
I124
sg27
VC0027819
p6472
sg10
I13
sg11
Vneuroblastoma
p6473
sg13
I1
sa(dp6474
g7
I138
sg27
VC0027627
p6475
sg10
I10
sg11
Vmetastasis
p6476
sg13
I1
sasa(dp6477
g2
S'Targeting NF-KB signalling pathways and ultimately CXCR4 could be a strategy in neuroblastoma therapy.\n'
p6478
sg4
(lp6479
(dp6480
g7
I51
sg8
VP61073
p6481
sg10
I5
sg11
VCXCR4
p6482
sg13
I1
sasg24
(lp6483
(dp6484
g7
I80
sg27
VC0027819
p6485
sg10
I13
sg11
Vneuroblastoma
p6486
sg13
I1
sasa(dp6487
g2
S'The FAM3C interleukin-like epithelial-to-mesenchymal-transition (EMT) inducer (ILEI) has been shown to be strongly up-regulated in several cancers and to be essential for tumor formation and metastasis in epithelial cells, correlating with a significant decrease in overall survival in colon and breast cancer patients.\n'
p6488
sg4
(lp6489
(dp6490
g7
I79
sg8
g9
sg10
I4
sg11
VILEI
p6491
sg13
I1
sa(dp6492
g7
I4
sg8
g9
sg10
I5
sg11
VFAM3C
p6493
sg13
I1
sa(dp6494
g7
I10
sg8
VP60568
p6495
sg10
I16
sg11
Vinterleukin-like
p6496
sg13
I1
sasg24
(lp6497
(dp6498
g7
I139
sg27
VC0006826
p6499
sg10
I7
sg11
Vcancers
p6500
sg13
I1
sa(dp6501
g7
I296
sg27
VC0678222
p6502
sg10
I13
sg11
Vbreast cancer
p6503
sg13
I2
sa(dp6504
g7
I171
sg27
VC0027651
p6505
sg10
I5
sg11
Vtumor
p6506
sg13
I1
sa(dp6507
g7
I53
sg27
VC0599156
p6508
sg10
I10
sg11
Vtransition
p6509
sg13
I1
sa(dp6510
g7
I191
sg27
VC0027627
p6511
sg10
I10
sg11
Vmetastasis
p6512
sg13
I1
sasa(dp6513
g2
S'Interleukin-like epithelial-to-mesenchymal transition inducer (ILEI) is an essential cytokine in tumor progression that is upregulated in several cancers, and its altered subcellular localization is a predictor of poor survival in human breast cancer.\n'
p6514
sg4
(lp6515
(dp6516
g7
I0
sg8
VP60568
p6517
sg10
I16
sg11
VInterleukin-like
p6518
sg13
I1
sasg24
(lp6519
(dp6520
g7
I237
sg27
VC0678222
p6521
sg10
I13
sg11
Vbreast cancer
p6522
sg13
I2
sa(dp6523
g7
I97
sg27
VC0178874
p6524
sg10
I17
sg11
Vtumor progression
p6525
sg13
I2
sa(dp6526
g7
I43
sg27
VC0599156
p6527
sg10
I10
sg11
Vtransition
p6528
sg13
I1
sa(dp6529
g7
I146
sg27
VC0006826
p6530
sg10
I7
sg11
Vcancers
p6531
sg13
I1
sasa(dp6532
g2
S'Murine mammary tumor and metastasis models of EpC40 and 4T1 cells overexpressing different mutant forms of ILEI were used-extended with in vivo aprotinin treatment for the inhibition of ILEI-processing proteases-to test the in vivo relevance of proteolytic cleavage.\n'
p6533
sg4
(lp6534
(dp6535
g7
I107
sg8
g9
sg10
I4
sg11
VILEI
p6536
sg13
I1
sa(dp6537
g7
I107
sg8
g9
sg10
I4
sg11
VILEI
p6538
sg13
I1
sasg24
(lp6539
(dp6540
g7
I25
sg27
VC0027627
p6541
sg10
I10
sg11
Vmetastasis
p6542
sg13
I1
sa(dp6543
g7
I91
sg27
VC0596988
p6544
sg10
I6
sg11
Vmutant
p6545
sg13
I1
sa(dp6546
g7
I7
sg27
VC1458155
p6547
sg10
I13
sg11
Vmammary tumor
p6548
sg13
I2
sasa(dp6549
g2
S'Immunohistochemistry for ILEI localization and uPAR expression was performed on two human breast cancer arrays, and ILEI and uPAR scores were correlated with the metastasis-free survival of patients.\n'
p6550
sg4
(lp6551
(dp6552
g7
I25
sg8
g9
sg10
I4
sg11
VILEI
p6553
sg13
I1
sa(dp6554
g7
I25
sg8
g9
sg10
I4
sg11
VILEI
p6555
sg13
I1
sasg24
(lp6556
(dp6557
g7
I162
sg27
VC0027627
p6558
sg10
I10
sg11
Vmetastasis
p6559
sg13
I1
sa(dp6560
g7
I90
sg27
VC0678222
p6561
sg10
I13
sg11
Vbreast cancer
p6562
sg13
I2
sasa(dp6563
g2
S'Moreover, altered subcellular ILEI localization strongly correlates with high tumor cell-associated uPAR protein expression, as well as with poor survival, in human breast cancer.\n'
p6564
sg4
(lp6565
sg24
(lp6566
(dp6567
g7
I78
sg27
VC0027651
p6568
sg10
I5
sg11
Vtumor
p6569
sg13
I1
sa(dp6570
g7
I165
sg27
VC0678222
p6571
sg10
I13
sg11
Vbreast cancer
p6572
sg13
I2
sasa(dp6573
g2
S'Our findings point out extracellular serine proteases, in particular plasmin, and uPAR as valuable therapeutic targets against ILEI-driven tumor progression and emphasize the prognostic relevance of ILEI localization and a combined ILEI-uPAR marker analysis in human breast cancer.\n'
p6574
sg4
(lp6575
(dp6576
g7
I127
sg8
g9
sg10
I4
sg11
VILEI
p6577
sg13
I1
sa(dp6578
g7
I23
sg8
VP30740
p6579
sg10
I30
sg11
Vextracellular serine proteases
p6580
sg13
I3
sa(dp6581
g7
I69
sg8
VP00747
p6582
sg10
I7
sg11
Vplasmin
p6583
sg13
I1
sa(dp6584
g7
I127
sg8
g9
sg10
I4
sg11
VILEI
p6585
sg13
I1
sa(dp6586
g7
I127
sg8
g9
sg10
I4
sg11
VILEI
p6587
sg13
I1
sasg24
(lp6588
(dp6589
g7
I139
sg27
VC0178874
p6590
sg10
I17
sg11
Vtumor progression
p6591
sg13
I2
sa(dp6592
g7
I267
sg27
VC0678222
p6593
sg10
I13
sg11
Vbreast cancer
p6594
sg13
I2
sasa(dp6595
g2
S'ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.\n'
p6596
sg4
(lp6597
(dp6598
g7
I134
sg8
g9
sg10
I3
sg11
VEMT
p6599
sg13
I1
sa(dp6600
g7
I0
sg8
g9
sg10
I4
sg11
VILEI
p6601
sg13
I1
sasg24
(lp6602
(dp6603
g7
I139
sg27
VC0027627
p6604
sg10
I10
sg11
Vmetastasis
p6605
sg13
I1
sa(dp6606
g7
I125
sg27
VC2699153
p6607
sg10
I8
sg11
Vinvasion
p6608
sg13
I1
sa(dp6609
g7
I85
sg27
VC0027651
p6610
sg10
I6
sg11
Vtumors
p6611
sg13
I1
sa(dp6612
g7
I193
sg27
VC0678222
p6613
sg10
I13
sg11
Vbreast cancer
p6614
sg13
I2
sasa(dp6615
g2
S"Keeping in view the fact that molecular basis of Burkitt's lymphoma (BL) is poorly understood, we attempted to explore the small interfering RNA (siRNA) mediated c-myc gene regulation using BL-derived EB-3 cell line as archetype cellular model.\n"
p6616
sg4
(lp6617
(dp6618
g7
I162
sg8
VP12524
p6619
sg10
I10
sg11
Vc-myc gene
p6620
sg13
I2
sasg24
(lp6621
(dp6622
g7
I49
sg27
VC0006413
p6623
sg10
I18
sg11
VBurkitt's lymphoma
p6624
sg13
I2
sa(dp6625
g7
I69
sg27
VC0006413
p6626
sg10
I2
sg11
VBL
p6627
sg13
I1
sa(dp6628
g7
I69
sg27
VC0006413
p6629
sg10
I2
sg11
VBL
p6630
sg13
I1
sasa(dp6631
g2
S'With other procedures, as anti-complement immunoperoxidase (ACIP) and anti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen (EBNA) was detected precisely in EB3, Jijoye and Raji lymphocytes using anti-EBNA antibodies from patients with nasopharyngeal carcinoma or Burkitt lymphoma, in dilution 1:10-1:5120.\n'
p6632
sg4
(lp6633
(dp6634
g7
I169
sg8
g9
sg10
I3
sg11
VEB3
p6635
sg13
I1
sa(dp6636
g7
I60
sg8
g9
sg10
I4
sg11
VACIP
p6637
sg13
I1
sa(dp6638
g7
I26
sg8
g9
sg10
I32
sg11
Vanti-complement immunoperoxidase
p6639
sg13
I2
sa(dp6640
g7
I70
sg8
VP14209
p6641
sg10
I65
sg11
Vanti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen
p6642
sg13
I7
sasg24
(lp6643
(dp6644
g7
I248
sg27
VC2931822
p6645
sg10
I24
sg11
Vnasopharyngeal carcinoma
p6646
sg13
I2
sa(dp6647
g7
I276
sg27
VC0006413
p6648
sg10
I16
sg11
VBurkitt lymphoma
p6649
sg13
I2
sasa(dp6650
g2
S'The virus in the EB-3 cell line derived from a Burkitt lymphoma was partially purified by digestion with proteolytic enzyme and by density-gradient centrifugation on potassium tartrate.\n'
p6651
sg4
(lp6652
sg24
(lp6653
(dp6654
g7
I47
sg27
VC0006413
p6655
sg10
I16
sg11
VBurkitt lymphoma
p6656
sg13
I2
sasa(dp6657
g2
S'This conjugate proved to be a potent cytotoxin for surface Ig positive Burkitt lymphoma EB-3 cells, growing in vitro and produced 50% inhibition of protein synthesis at level of 1.4 x 10(-9) M. When tested for cytotoxic action on target cells, the composite conjugate molecule was at least 100 times more effective than antibodies alone, ricin A-chain alone or a conjugate ricin A-chain--normal rabbit IgG.\n'
p6658
sg4
(lp6659
(dp6660
g7
I395
sg8
g9
sg10
I10
sg11
Vrabbit IgG
p6661
sg13
I2
sa(dp6662
g7
I338
sg8
g9
sg10
I13
sg11
Vricin A-chain
p6663
sg13
I2
sasg24
(lp6664
(dp6665
g7
I71
sg27
VC0006413
p6666
sg10
I16
sg11
VBurkitt lymphoma
p6667
sg13
I2
sasa(dp6668
g2
S'The interaction of poly- and monoclonal antibodies against the L-chain of human Ig with Burkitt lymphoma EB-3 cells was studied using a fluorescent lipid probe, anthrylvinyl-labelled sphingomyelin, incorporated into the cell plasma membrane.\n'
p6669
sg4
(lp6670
sg24
(lp6671
(dp6672
g7
I88
sg27
VC0006413
p6673
sg10
I16
sg11
VBurkitt lymphoma
p6674
sg13
I2
sasa(dp6675
g2
S"The only gangliosides in Burkitt's lymphoma EB-3 cells is GM3.\n"
p6676
sg4
(lp6677
sg24
(lp6678
(dp6679
g7
I25
sg27
VC0006413
p6680
sg10
I18
sg11
VBurkitt's lymphoma
p6681
sg13
I2
sasa(dp6682
g2
S"Treatment of Burkitt's lymphoma EB-3 cells with gangliosides GM1 or GM3 results in their binding to and partial incorporation into the cell membrane.\n"
p6683
sg4
(lp6684
sg24
(lp6685
(dp6686
g7
I13
sg27
VC0006413
p6687
sg10
I18
sg11
VBurkitt's lymphoma
p6688
sg13
I2
sasa(dp6689
g2
S'We sought to investigate the renoprotection of CIRP in a rat model of deep hypothermic circulatory arrest.\n'
p6690
sg4
(lp6691
(dp6692
g7
I47
sg8
g9
sg10
I4
sg11
VCIRP
p6693
sg13
I1
sasg24
(lp6694
(dp6695
g7
I87
sg27
VC0444720
p6696
sg10
I18
sg11
Vcirculatory arrest
p6697
sg13
I2
sasa(dp6698
g2
S'Overexpression and knockdown of CIRP were achieved in vivo by directly injecting lentivirus vectors containing packaging lentivirus (pL)/internal ribosome entry site (IRES)/green fluorescent protein (GFP)-CIRP or pL/short hairpin RNA (shRNA)/F-cold inducible RNA binding protein (F-CIRP)-A into the renal parenchyma of rats 7 days before deep hypothermic circulatory arrest under the ultrasound guidance.\n'
p6699
sg4
(lp6700
(dp6701
g7
I173
sg8
g9
sg10
I25
sg11
Vgreen fluorescent protein
p6702
sg13
I3
sa(dp6703
g7
I241
sg8
g9
sg10
I37
sg11
V/F-cold inducible RNA binding protein
p6704
sg13
I5
sa(dp6705
g7
I280
sg8
g9
sg10
I6
sg11
VF-CIRP
p6706
sg13
I1
sa(dp6707
g7
I32
sg8
g9
sg10
I4
sg11
VCIRP
p6708
sg13
I1
sasg24
(lp6709
(dp6710
g7
I244
sg27
VC0024117
p6711
sg10
I4
sg11
Vcold
p6712
sg13
I1
sa(dp6713
g7
I355
sg27
VC0444720
p6714
sg10
I18
sg11
Vcirculatory arrest
p6715
sg13
I2
sasa(dp6716
g2
S'Our findings suggest that the CIRP exerts a robust renoprotective effect by inhibiting apoptosis in the rat model of deep hypothermic circulatory arrest.\n'
p6717
sg4
(lp6718
(dp6719
g7
I30
sg8
g9
sg10
I4
sg11
VCIRP
p6720
sg13
I1
sasg24
(lp6721
(dp6722
g7
I134
sg27
VC0444720
p6723
sg10
I18
sg11
Vcirculatory arrest
p6724
sg13
I2
sasa(dp6725
g2
S'Compared with baseline, rats resuscitated from cardiac arrest showed increased expression of CIRP, Bax, Caspase 9, and Caspase 3 and decreased expression of Bcl-2 in hippocampus (P &lt; 0.05).\n'
p6726
sg4
(lp6727
(dp6728
g7
I157
sg8
VP10415
p6729
sg10
I5
sg11
VBcl-2
p6730
sg13
I1
sa(dp6731
g7
I119
sg8
VP42574
p6732
sg10
I9
sg11
VCaspase 3
p6733
sg13
I2
sa(dp6734
g7
I93
sg8
g9
sg10
I4
sg11
VCIRP
p6735
sg13
I1
sa(dp6736
g7
I104
sg8
VP55211
p6737
sg10
I9
sg11
VCaspase 9
p6738
sg13
I2
sasg24
(lp6739
(dp6740
g7
I47
sg27
VC0018790
p6741
sg10
I14
sg11
Vcardiac arrest
p6742
sg13
I2
sasa(dp6743
g2
S'Our findings suggest that 32 C therapeutic hypothermia exerts an important neuroprotective effects by up-regulating CIRP expression and inhibiting mitochondrial apoptosis factor production in the cardiac arrest rat model.\n'
p6744
sg4
(lp6745
(dp6746
g7
I116
sg8
g9
sg10
I4
sg11
VCIRP
p6747
sg13
I1
sasg24
(lp6748
(dp6749
g7
I196
sg27
VC0018790
p6750
sg10
I14
sg11
Vcardiac arrest
p6751
sg13
I2
sasa(dp6752
g2
S'A previously reported expression signature of three genes (IGFBP3, F3 and VGLL3) was shown to have potential prognostic value in estimating overall and cancer-specific survivals at diagnosis of prostate cancer in a pilot cohort study using freshly frozen Fine Needle Aspiration (FNA) samples.\n'
p6753
sg4
(lp6754
(dp6755
g7
I74
sg8
g9
sg10
I5
sg11
VVGLL3
p6756
sg13
I1
sa(dp6757
g7
I59
sg8
VP17936
p6758
sg10
I6
sg11
VIGFBP3
p6759
sg13
I1
sasg24
(lp6760
(dp6761
g7
I194
sg27
VC0600139
p6762
sg10
I15
sg11
Vprostate cancer
p6763
sg13
I2
sa(dp6764
g7
I267
sg27
VC0700198
p6765
sg10
I10
sg11
VAspiration
p6766
sg13
I1
sa(dp6767
g7
I152
sg27
VC0006826
p6768
sg10
I6
sg11
Vcancer
p6769
sg13
I1
sasa(dp6770
g2
S'Multiple biopsy samples from 43 patients were evaluated using a previously reported gene signature of IGFBP3, F3 and VGLL3 with potential prognostic value in estimating overall survival at diagnosis of prostate cancer.\n'
p6771
sg4
(lp6772
(dp6773
g7
I117
sg8
g9
sg10
I5
sg11
VVGLL3
p6774
sg13
I1
sa(dp6775
g7
I102
sg8
VP17936
p6776
sg10
I6
sg11
VIGFBP3
p6777
sg13
I1
sasg24
(lp6778
(dp6779
g7
I202
sg27
VC0600139
p6780
sg10
I15
sg11
Vprostate cancer
p6781
sg13
I2
sasa(dp6782
g2
S'The gene expression levels of IGFBP3 and F3 in prostate cancer epithelial cell-containing tissue representing the primary and secondary Gleason patterns were high and consistent, while the low expressed VGLL3 showed more variation in its expression levels.\n'
p6783
sg4
(lp6784
(dp6785
g7
I203
sg8
g9
sg10
I5
sg11
VVGLL3
p6786
sg13
I1
sa(dp6787
g7
I30
sg8
VP17936
p6788
sg10
I6
sg11
VIGFBP3
p6789
sg13
I1
sasg24
(lp6790
(dp6791
g7
I47
sg27
VC0600139
p6792
sg10
I15
sg11
Vprostate cancer
p6793
sg13
I2
sasa(dp6794
g2
S'Previous studies have implicated vestigial like 3 (VGLL3), a chromosome 3p12.3 gene that encodes a putative transcription co-factor, as a candidate tumor suppressor gene (TSG) in high-grade serous ovarian carcinomas (HGSC), the most common type of epithelial ovarian cancer.\n'
p6795
sg4
(lp6796
(dp6797
g7
I171
sg8
g9
sg10
I3
sg11
VTSG
p6798
sg13
I1
sa(dp6799
g7
I33
sg8
g9
sg10
I16
sg11
Vvestigial like 3
p6800
sg13
I3
sa(dp6801
g7
I148
sg8
VP25054
p6802
sg10
I21
sg11
Vtumor suppressor gene
p6803
sg13
I3
sa(dp6804
g7
I51
sg8
g9
sg10
I5
sg11
VVGLL3
p6805
sg13
I1
sasg24
(lp6806
(dp6807
g7
I248
sg27
VC0677886
p6808
sg10
I25
sg11
Vepithelial ovarian cancer
p6809
sg13
I3
sa(dp6810
g7
I148
sg27
VC0027651
p6811
sg10
I5
sg11
Vtumor
p6812
sg13
I1
sa(dp6813
g7
I197
sg27
VC0029925
p6814
sg10
I18
sg11
Vovarian carcinomas
p6815
sg13
I2
sasa(dp6816
g2
S'A complementation analysis based on microcell-mediated chromosome transfer (MMCT) using a centric fragment of chromosome 3 (der3p12-q12.1) into the OV-90 ovarian cancer cell line haploinsufficient for 3p and lacking VGLL3 expression was performed to assess the effect on tumorigenic potential and growth characteristics.\n'
p6817
sg4
(lp6818
(dp6819
g7
I216
sg8
g9
sg10
I5
sg11
VVGLL3
p6820
sg13
I1
sasg24
(lp6821
(dp6822
g7
I154
sg27
VC1140680
p6823
sg10
I14
sg11
Vovarian cancer
p6824
sg13
I2
sasa(dp6825
g2
S'Interestingly, underexpression of VGLL3 and ZNF654 were observed in malignant ovarian tumor samples as compared with primary cultures of normal ovarian surface epithelial cells or benign ovarian tumors, and this occurred regardless of allelic content of 3p12.3-pcen.\n'
p6826
sg4
(lp6827
(dp6828
g7
I44
sg8
g9
sg10
I6
sg11
VZNF654
p6829
sg13
I1
sa(dp6830
g7
I34
sg8
g9
sg10
I5
sg11
VVGLL3
p6831
sg13
I1
sasg24
(lp6832
(dp6833
g7
I68
sg27
VC1140680
p6834
sg10
I23
sg11
Vmalignant ovarian tumor
p6835
sg13
I3
sa(dp6836
g7
I180
sg27
VC0004997
p6837
sg10
I21
sg11
Vbenign ovarian tumors
p6838
sg13
I3
sasa(dp6839
g2
S'We tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers.\n'
p6840
sg4
(lp6841
(dp6842
g7
I90
sg8
VP56524
p6843
sg10
I4
sg11
VHDAC
p6844
sg13
I1
sa(dp6845
g7
I29
sg8
VP45985
p6846
sg10
I3
sg11
VMEK
p6847
sg13
I1
sa(dp6848
g7
I56
sg8
g9
sg10
I3
sg11
VAkt
p6849
sg13
I1
sasg24
(lp6850
(dp6851
g7
I206
sg27
VC0699791
p6852
sg10
I17
sg11
Vgastric carcinoma
p6853
sg13
I2
sa(dp6854
g7
I187
sg27
VC2239176
p6855
sg10
I17
sg11
Vhepatic carcinoma
p6856
sg13
I2
sa(dp6857
g7
I146
sg27
VC0006826
p6858
sg10
I6
sg11
Vcancer
p6859
sg13
I1
sa(dp6860
g7
I225
sg27
VC0699790
p6861
sg10
I15
sg11
Vcolon carcinoma
p6862
sg13
I2
sa(dp6863
g7
I177
sg27
VC0025202
p6864
sg10
I8
sg11
Vmelanoma
p6865
sg13
I1
sa(dp6866
g7
I264
sg27
VC0153633
p6867
sg10
I13
sg11
Vbrain cancers
p6868
sg13
I2
sa(dp6869
g7
I242
sg27
VC0678222
p6870
sg10
I16
sg11
Vbreast carcinoma
p6871
sg13
I2
sasa(dp6872
g2
S'Here, we report that escape of human T-cell acute lymphoblastic leukemia (T-ALL) cells or colorectal cancer cells from dormancy is associated with Dll4 expression in the tumor microenvironment and increased Notch3 signaling in tumor cells.\n'
p6873
sg4
(lp6874
(dp6875
g7
I207
sg8
g9
sg10
I6
sg11
VNotch3
p6876
sg13
I1
sa(dp6877
g7
I147
sg8
g9
sg10
I4
sg11
VDll4
p6878
sg13
I1
sasg24
(lp6879
(dp6880
g7
I170
sg27
VC0027651
p6881
sg10
I5
sg11
Vtumor
p6882
sg13
I1
sa(dp6883
g7
I37
sg27
VC1961099
p6884
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p6885
sg13
I4
sa(dp6886
g7
I170
sg27
VC0027651
p6887
sg10
I5
sg11
Vtumor
p6888
sg13
I1
sa(dp6889
g7
I90
sg27
VC1527249
p6890
sg10
I17
sg11
Vcolorectal cancer
p6891
sg13
I2
sa(dp6892
g7
I74
sg27
VC1961099
p6893
sg10
I5
sg11
VT-ALL
p6894
sg13
I1
sasa(dp6895
g2
S"APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.\n"
p6896
sg4
(lp6897
(dp6898
g7
I0
sg8
VP41238
p6899
sg10
I7
sg11
VAPOBEC1
p6900
sg13
I1
sasg24
(lp6901
(dp6902
g7
I142
sg27
VC0012634
p6903
sg10
I9
sg11
Vcondition
p6904
sg13
I1
sa(dp6905
g7
I74
sg27
VC0596263
p6906
sg10
I14
sg11
Vcarcinogenesis
p6907
sg13
I1
sa(dp6908
g7
I29
sg27
VC0006826
p6909
sg10
I6
sg11
Vcancer
p6910
sg13
I1
sa(dp6911
g7
I174
sg27
VC0279628
p6912
sg10
I25
sg11
Vesophageal adenocarcinoma
p6913
sg13
I2
sa(dp6914
g7
I119
sg27
VC0004763
p6915
sg10
I19
sg11
VBarrett's esophagus
p6916
sg13
I2
sasa(dp6917
g2
S'The differential diagnosis includes Klippel-Trenaunay-Weber syndrome, neurofibromatosis, Milroy disease, and Proteus syndrome.\n'
p6918
sg4
(lp6919
sg24
(lp6920
(dp6921
g7
I109
sg27
VC0085261
p6922
sg10
I16
sg11
VProteus syndrome
p6923
sg13
I2
sa(dp6924
g7
I60
sg27
VC0162678
p6925
sg10
I27
sg11
Vsyndrome, neurofibromatosis
p6926
sg13
I2
sa(dp6927
g7
I89
sg27
VC1704423
p6928
sg10
I14
sg11
VMilroy disease
p6929
sg13
I2
sa(dp6930
g7
I36
sg27
VC0022739
p6931
sg10
I32
sg11
VKlippel-Trenaunay-Weber syndrome
p6932
sg13
I2
sasa(dp6933
g2
S"Notably, new experimental data have shown protective immune responses of bee venom group III sPLA2 against a wide range of diseases including asthma, Parkinson's disease, and drug-induced organ inflammation.\n"
p6934
sg4
(lp6935
sg24
(lp6936
(dp6937
g7
I194
sg27
VC0021368
p6938
sg10
I12
sg11
Vinflammation
p6939
sg13
I1
sa(dp6940
g7
I142
sg27
VC0004096
p6941
sg10
I6
sg11
Vasthma
p6942
sg13
I1
sa(dp6943
g7
I150
sg27
VC0030567
p6944
sg10
I19
sg11
VParkinson's disease
p6945
sg13
I2
sasa(dp6946
g2
S'Snake venom are known containing PLA2s (svPLA2s) which exhibit a wide variety of pharmacological effects including neurotoxicity, cardiotoxicity, myotoxicity and hemorrhage.\n'
p6947
sg4
(lp6948
(dp6949
g7
I33
sg8
VP04054
p6950
sg10
I5
sg11
VPLA2s
p6951
sg13
I1
sasg24
(lp6952
(dp6953
g7
I162
sg27
VC0019080
p6954
sg10
I10
sg11
Vhemorrhage
p6955
sg13
I1
sasa(dp6956
g2
S'This study was aimed to assess regulation of surface-membrane enzymes such as Delta-6-desaturase (FADS2), secretory Phospholipase A2(sPLA2) by hemp seed and evening primrose oils as well as Hot-natured dietary intervention in relapsing remitting multiple sclerosis (RRMS) patients.\n'
p6957
sg4
(lp6958
(dp6959
g7
I78
sg8
g9
sg10
I18
sg11
VDelta-6-desaturase
p6960
sg13
I1
sa(dp6961
g7
I116
sg8
VP04054
p6962
sg10
I16
sg11
VPhospholipase A2
p6963
sg13
I2
sa(dp6964
g7
I133
sg8
VP14555
p6965
sg10
I5
sg11
VsPLA2
p6966
sg13
I1
sa(dp6967
g7
I98
sg8
g9
sg10
I5
sg11
VFADS2
p6968
sg13
I1
sasg24
(lp6969
(dp6970
g7
I266
sg27
VC0751967
p6971
sg10
I4
sg11
VRRMS
p6972
sg13
I1
sa(dp6973
g7
I226
sg27
VC0751967
p6974
sg10
I38
sg11
Vrelapsing remitting multiple sclerosis
p6975
sg13
I4
sasa(dp6976
g2
S'Phospholipases A2 (PLA2s) are enzymes responsible for inflammatory effects, edema formation, myotoxicity, neurotoxicity and other manifestations from envenoming.\n'
p6977
sg4
(lp6978
(dp6979
g7
I0
sg8
VP04054
p6980
sg10
I17
sg11
VPhospholipases A2
p6981
sg13
I2
sa(dp6982
g7
I19
sg8
VP04054
p6983
sg10
I5
sg11
VPLA2s
p6984
sg13
I1
sasg24
(lp6985
(dp6986
g7
I76
sg27
VC0013604
p6987
sg10
I5
sg11
Vedema
p6988
sg13
I1
sasa(dp6989
g2
S'Defects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.\n'
p6990
sg4
(lp6991
(dp6992
g7
I30
sg8
g9
sg10
I26
sg11
Vintegrin-binding protein 2
p6993
sg13
I3
sa(dp6994
g7
I11
sg8
g9
sg10
I4
sg11
VCIB2
p6995
sg13
I1
sasg24
(lp6996
(dp6997
g7
I116
sg27
VC0271097
p6998
sg10
I14
sg11
VUsher syndrome
p6999
sg13
I2
sa(dp7000
g7
I207
sg27
VC0456909
p7001
sg10
I9
sg11
Vblindness
p7002
sg13
I1
sa(dp7003
g7
I95
sg27
VC0011053
p7004
sg10
I8
sg11
Vdeafness
p7005
sg13
I1
sa(dp7006
g7
I105
sg27
VC1836199
p7007
sg10
I6
sg11
VDFNB48
p7008
sg13
I1
sa(dp7009
g7
I95
sg27
VC0011053
p7010
sg10
I8
sg11
Vdeafness
p7011
sg13
I1
sasa(dp7012
g2
S'Here, we report that mutations in CIB2, which encodes a calcium- and integrin-binding protein, are associated with nonsyndromic deafness (DFNB48) and Usher syndrome type 1J (USH1J).\n'
p7013
sg4
(lp7014
(dp7015
g7
I34
sg8
g9
sg10
I4
sg11
VCIB2
p7016
sg13
I1
sa(dp7017
g7
I69
sg8
g9
sg10
I24
sg11
Vintegrin-binding protein
p7018
sg13
I2
sasg24
(lp7019
(dp7020
g7
I150
sg27
VC0271097
p7021
sg10
I14
sg11
VUsher syndrome
p7022
sg13
I2
sa(dp7023
g7
I138
sg27
VC1836199
p7024
sg10
I6
sg11
VDFNB48
p7025
sg13
I1
sa(dp7026
g7
I128
sg27
VC0011053
p7027
sg10
I8
sg11
Vdeafness
p7028
sg13
I1
sasa(dp7029
g2
S'In polymyositis and inclusion body myositis, KIF4 cells were mainly located around individual muscle fibers, whereas in dermatomyositis, they were also near blood vessels.\n'
p7030
sg4
(lp7031
(dp7032
g7
I45
sg8
g9
sg10
I4
sg11
VKIF4
p7033
sg13
I1
sasg24
(lp7034
(dp7035
g7
I3
sg27
VC0085655
p7036
sg10
I12
sg11
Vpolymyositis
p7037
sg13
I1
sa(dp7038
g7
I120
sg27
VC0221056
p7039
sg10
I15
sg11
Vdermatomyositis
p7040
sg13
I1
sa(dp7041
g7
I20
sg27
VC0238190
p7042
sg10
I23
sg11
Vinclusion body myositis
p7043
sg13
I3
sasa(dp7044
g2
S"CD9 expression obviously increased bortezomib sensitivity through inducing apoptosis, significantly inhibiting U266 cells' adhesion to HS-5 and primary bone marrow stromal cells, but increasing U266 cells' adhesion to fibronectin.\n"
p7045
sg4
(lp7046
(dp7047
g7
I0
sg8
VP21926
p7048
sg10
I3
sg11
VCD9
p7049
sg13
I1
sasg24
(lp7050
(dp7051
g7
I123
sg27
VC0001511
p7052
sg10
I8
sg11
Vadhesion
p7053
sg13
I1
sa(dp7054
g7
I123
sg27
VC0001511
p7055
sg10
I8
sg11
Vadhesion
p7056
sg13
I1
sasa(dp7057
g2
S'The immunoprofiles of MOLP-6 and MOLP-7 correspond to that seen typically in primary MM cells: positive for cytoplasmic immunoglobulin (Ig) chains, a heavy and kappa light chains, CD9, CD28, CD40, CD44, CD45, CD56, and PCA-1; the cells were negative for surface Igs and various other B-cell, T-cell and myelomonocyte associated markers.\n'
p7058
sg4
(lp7059
(dp7060
g7
I203
sg8
VP08575
p7061
sg10
I4
sg11
VCD45
p7062
sg13
I1
sa(dp7063
g7
I219
sg8
g9
sg10
I5
sg11
VPCA-1
p7064
sg13
I1
sa(dp7065
g7
I180
sg8
VP21926
p7066
sg10
I3
sg11
VCD9
p7067
sg13
I1
sa(dp7068
g7
I191
sg8
VP25942
p7069
sg10
I4
sg11
VCD40
p7070
sg13
I1
sa(dp7071
g7
I150
sg8
g9
sg10
I28
sg11
Vheavy and kappa light chains
p7072
sg13
I5
sa(dp7073
g7
I185
sg8
VP33681
p7074
sg10
I4
sg11
VCD28
p7075
sg13
I1
sa(dp7076
g7
I262
sg8
g9
sg10
I3
sg11
VIgs
p7077
sg13
I1
sa(dp7078
g7
I108
sg8
g9
sg10
I38
sg11
Vcytoplasmic immunoglobulin (Ig) chains
p7079
sg13
I4
sasg24
(lp7080
(dp7081
g7
I262
sg27
VC1306856
p7082
sg10
I3
sg11
VIgs
p7083
sg13
I1
sa(dp7084
g7
I219
sg27
VC0268398
p7085
sg10
I3
sg11
VPCA
p7086
sg13
I1
sasa(dp7087
g2
S'The univariate analysis showed that five parameters had an adverse effect on both complete remission (CR) and survival: advanced age (greater than 60 years), anemia (hemoglobin concentration (Hb) less than 10g/dl), the expression of the antigens detected by the anti-megakaryocytic antibodies (CDw41/CDw42), the monocytic antibodies (CD14), and the CD9 (FMC56, FMC8) antigen.\n'
p7088
sg4
(lp7089
(dp7090
g7
I166
sg8
g9
sg10
I10
sg11
Vhemoglobin
p7091
sg13
I1
sa(dp7092
g7
I349
sg8
VP21926
p7093
sg10
I3
sg11
VCD9
p7094
sg13
I1
sa(dp7095
g7
I334
sg8
VP08571
p7096
sg10
I4
sg11
VCD14
p7097
sg13
I1
sasg24
(lp7098
(dp7099
g7
I59
sg27
VC0879626
p7100
sg10
I14
sg11
Vadverse effect
p7101
sg13
I2
sa(dp7102
g7
I158
sg27
VC0002871
p7103
sg10
I6
sg11
Vanemia
p7104
sg13
I1
sa(dp7105
g7
I91
sg27
VC0687702
p7106
sg10
I9
sg11
Vremission
p7107
sg13
I1
sasa(dp7108
g2
S"In this review, we consider the following paraneoplastic hormonal syndromes: malign hypercalcaemia, hyponatraemia (inappropiate secretion of the antidiuretic hormone), ectopic Cushing's syndrome, ectopic acromegaly, hypoglycaemia due to tumours different from those of the islet cells and paraneoplastic gynaecomastia; we make a brief final reference to other hormones (calcitonin, somatostatin, and VIP).\n"
p7109
sg4
(lp7110
(dp7111
g7
I382
sg8
VP61278
p7112
sg10
I12
sg11
Vsomatostatin
p7113
sg13
I1
sa(dp7114
g7
I370
sg8
VP06881
p7115
sg10
I10
sg11
Vcalcitonin
p7116
sg13
I1
sa(dp7117
g7
I400
sg8
VP01282
p7118
sg10
I3
sg11
VVIP
p7119
sg13
I1
sasg24
(lp7120
(dp7121
g7
I216
sg27
VC0020615
p7122
sg10
I13
sg11
Vhypoglycaemia
p7123
sg13
I1
sa(dp7124
g7
I176
sg27
VC0010481
p7125
sg10
I18
sg11
VCushing's syndrome
p7126
sg13
I2
sa(dp7127
g7
I204
sg27
VC0001206
p7128
sg10
I10
sg11
Vacromegaly
p7129
sg13
I1
sa(dp7130
g7
I84
sg27
VC0020437
p7131
sg10
I14
sg11
Vhypercalcaemia
p7132
sg13
I1
sa(dp7133
g7
I66
sg27
VC0039082
p7134
sg10
I9
sg11
Vsyndromes
p7135
sg13
I1
sa(dp7136
g7
I237
sg27
VC0027651
p7137
sg10
I7
sg11
Vtumours
p7138
sg13
I1
sa(dp7139
g7
I304
sg27
VC0018418
p7140
sg10
I13
sg11
Vgynaecomastia
p7141
sg13
I1
sasa(dp7142
g2
S'Protrudin was found to interact with other HSP-related proteins including myelin proteolipid protein 1 (SPG2), atlastin-1 (SPG3A), REEP1 (SPG31), REEP5 (similar to REEP1), Kif5A (SPG10), Kif5B, Kif5C, and reticulon 1, 3, and 4 (similar to reticulon 2, SPG12).\n'
p7143
sg4
(lp7144
(dp7145
g7
I138
sg8
g9
sg10
I5
sg11
VSPG31
p7146
sg13
I1
sa(dp7147
g7
I187
sg8
VP33176
p7148
sg10
I5
sg11
VKif5B
p7149
sg13
I1
sa(dp7150
g7
I146
sg8
g9
sg10
I5
sg11
VREEP5
p7151
sg13
I1
sa(dp7152
g7
I111
sg8
g9
sg10
I10
sg11
Vatlastin-1
p7153
sg13
I1
sa(dp7154
g7
I74
sg8
VP60201
p7155
sg10
I28
sg11
Vmyelin proteolipid protein 1
p7156
sg13
I4
sa(dp7157
g7
I43
sg8
g9
sg10
I20
sg11
VHSP-related proteins
p7158
sg13
I2
sa(dp7159
g7
I131
sg8
g9
sg10
I5
sg11
VREEP1
p7160
sg13
I1
sa(dp7161
g7
I179
sg8
g9
sg10
I5
sg11
VSPG10
p7162
sg13
I1
sa(dp7163
g7
I172
sg8
g9
sg10
I5
sg11
VKif5A
p7164
sg13
I1
sa(dp7165
g7
I123
sg8
g9
sg10
I5
sg11
VSPG3A
p7166
sg13
I1
sa(dp7167
g7
I131
sg8
g9
sg10
I5
sg11
VREEP1
p7168
sg13
I1
sa(dp7169
g7
I194
sg8
g9
sg10
I5
sg11
VKif5C
p7170
sg13
I1
sa(dp7171
g7
I104
sg8
VP60201
p7172
sg10
I4
sg11
VSPG2
p7173
sg13
I1
sasg24
(lp7174
(dp7175
g7
I138
sg27
VC1853247
p7176
sg10
I5
sg11
VSPG31
p7177
sg13
I1
sa(dp7178
g7
I179
sg27
VC1858712
p7179
sg10
I5
sg11
VSPG10
p7180
sg13
I1
sa(dp7181
g7
I123
sg27
VC2931355
p7182
sg10
I5
sg11
VSPG3A
p7183
sg13
I1
sa(dp7184
g7
I104
sg27
VC1839264
p7185
sg10
I4
sg11
VSPG2
p7186
sg13
I1
sa(dp7187
g7
I43
sg27
VC0034152
p7188
sg10
I3
sg11
VHSP
p7189
sg13
I1
sa(dp7190
g7
I252
sg27
VC1858106
p7191
sg10
I5
sg11
VSPG12
p7192
sg13
I1
sasa(dp7193
g2
S'Downregulation of ACE2 is always associated with the ALI or ARDS induced by avian influenza virus, severe acute respiratory syndrome-coronavirus, respiratory syncytial virus and sepsis.\n'
p7194
sg4
(lp7195
(dp7196
g7
I18
sg8
g9
sg10
I4
sg11
VACE2
p7197
sg13
I1
sasg24
(lp7198
(dp7199
g7
I178
sg27
VC0243026
p7200
sg10
I6
sg11
Vsepsis
p7201
sg13
I1
sa(dp7202
g7
I60
sg27
VC0035222
p7203
sg10
I4
sg11
VARDS
p7204
sg13
I1
sa(dp7205
g7
I99
sg27
VC1175175
p7206
sg10
I33
sg11
Vsevere acute respiratory syndrome
p7207
sg13
I4
sa(dp7208
g7
I76
sg27
VC0016627
p7209
sg10
I15
sg11
Vavian influenza
p7210
sg13
I2
sasa(dp7211
g2
S'A virus infection assay showed that rWIV1-DeltaX replicated as efficiently as rWIV1 in Vero E6, Calu-3, and HeLa-hACE2 cells.\n'
p7212
sg4
(lp7213
(dp7214
g7
I96
sg8
g9
sg10
I6
sg11
VCalu-3
p7215
sg13
I1
sasg24
(lp7216
(dp7217
g7
I2
sg27
VC0042769
p7218
sg10
I15
sg11
Vvirus infection
p7219
sg13
I2
sasa(dp7220
g2
S'Results show that 106 cases of tetanus occurred in Aceh, with a case fatality ratio (CFR) of 18.9%; 71 cases occurred in Yogyakarta, with CFR of 36.6%.\n'
p7221
sg4
(lp7222
sg24
(lp7223
(dp7224
g7
I31
sg27
VC0039614
p7225
sg10
I7
sg11
Vtetanus
p7226
sg13
I1
sasa(dp7227
g2
S'Treatment of (DR-BB x WF)F1 x WF animals (all lyp+/+) using a standard induction protocol caused type 1 diabetes in 58% of progeny.\n'
p7228
sg4
(lp7229
sg24
(lp7230
(dp7231
g7
I97
sg27
VC0011854
p7232
sg10
I15
sg11
Vtype 1 diabetes
p7233
sg13
I3
sasa(dp7234
g2
S'All genetic analyses of BB rat diabetes to date have backcrossed to the DP-BB strain or used (DP-BB x non-BB)F2 animals to ensure that a fraction of progeny are homozygous for lyp.\n'
p7235
sg4
(lp7236
(dp7237
g7
I176
sg8
g9
sg10
I3
sg11
Vlyp
p7238
sg13
I1
sasg24
(lp7239
(dp7240
g7
I31
sg27
VC0011849
p7241
sg10
I8
sg11
Vdiabetes
p7242
sg13
I1
sa(dp7243
g7
I176
sg27
VC1868674
p7244
sg10
I3
sg11
Vlyp
p7245
sg13
I1
sasa(dp7246
g2
S'Since, type 1 diabetes is characterised by hyperglycaemia we analysed 22 diabetic and 43 non-diabetic [(BB x SHR)FI x BB] backcross hybrids (28M:37F) which were already homozygous for Iddml and Iddm2 to search for quantitative trait loci (QTLs) affecting blood glucose in BB/OK rats.\n'
p7247
sg4
(lp7248
(dp7249
g7
I194
sg8
VP01308
p7250
sg10
I5
sg11
VIddm2
p7251
sg13
I1
sasg24
(lp7252
(dp7253
g7
I43
sg27
VC0020456
p7254
sg10
I14
sg11
Vhyperglycaemia
p7255
sg13
I1
sa(dp7256
g7
I7
sg27
VC0011854
p7257
sg10
I15
sg11
Vtype 1 diabetes
p7258
sg13
I3
sa(dp7259
g7
I194
sg27
VC1852092
p7260
sg10
I5
sg11
VIddm2
p7261
sg13
I1
sasa(dp7262
g2
S'This prompted us to investigate the inheritance of IDDM in two subpopulations of BB rats (BB/OK and BB/PhiK) by crossing studies with the production of (diabetic BB x LEW 1.A) F1, F2 generations and of first backcross hybrids onto BB (B1BB) and LEW.1A (B1A) rats respectively.\n'
p7263
sg4
(lp7264
sg24
(lp7265
(dp7266
g7
I51
sg27
VC0011854
p7267
sg10
I4
sg11
VIDDM
p7268
sg13
I1
sasa(dp7269
g2
S'LRRK2 selectively interacts with three Beta-tubulin isoforms: TUBB, TUBB4, and TUBB6, one of which (TUBB4) is mutated in the movement disorder dystonia type 4 (DYT4).\n'
p7270
sg4
(lp7271
(dp7272
g7
I79
sg8
g9
sg10
I5
sg11
VTUBB6
p7273
sg13
I1
sa(dp7274
g7
I0
sg8
g9
sg10
I5
sg11
VLRRK2
p7275
sg13
I1
sa(dp7276
g7
I39
sg8
VP68371
p7277
sg10
I21
sg11
VBeta-tubulin isoforms
p7278
sg13
I2
sa(dp7279
g7
I68
sg8
VP04350
p7280
sg10
I5
sg11
VTUBB4
p7281
sg13
I1
sa(dp7282
g7
I62
sg8
VP04350
p7283
sg10
I4
sg11
VTUBB
p7284
sg13
I1
sa(dp7285
g7
I68
sg8
VP04350
p7286
sg10
I5
sg11
VTUBB4
p7287
sg13
I1
sasg24
(lp7288
(dp7289
g7
I125
sg27
VC0026650
p7290
sg10
I17
sg11
Vmovement disorder
p7291
sg13
I2
sa(dp7292
g7
I160
sg27
VC1851943
p7293
sg10
I4
sg11
VDYT4
p7294
sg13
I1
sa(dp7295
g7
I143
sg27
VC1851943
p7296
sg10
I15
sg11
Vdystonia type 4
p7297
sg13
I3
sasa(dp7298
g2
S'In this study, we aimed to analyze pairwise interactions that are associated with Body Mass Index (BMI) between SNPs from twelve genes robustly associated with obesity (BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2B1, and TMEM18).\n'
p7299
sg4
(lp7300
(dp7301
g7
I209
sg8
VP32245
p7302
sg10
I4
sg11
VMC4R
p7303
sg13
I1
sa(dp7304
g7
I188
sg8
g9
sg10
I3
sg11
VFTO
p7305
sg13
I1
sa(dp7306
g7
I222
sg8
g9
sg10
I5
sg11
VNEGR1
p7307
sg13
I1
sa(dp7308
g7
I175
sg8
VP41161
p7309
sg10
I4
sg11
VETV5
p7310
sg13
I1
sa(dp7311
g7
I229
sg8
g9
sg10
I6
sg11
VSEC16B
p7312
sg13
I1
sa(dp7313
g7
I181
sg8
g9
sg10
I5
sg11
VFAIM2
p7314
sg13
I1
sa(dp7315
g7
I193
sg8
g9
sg10
I6
sg11
VGNPDA2
p7316
sg13
I1
sa(dp7317
g7
I237
sg8
g9
sg10
I5
sg11
VSH2B1
p7318
sg13
I1
sa(dp7319
g7
I248
sg8
g9
sg10
I6
sg11
VTMEM18
p7320
sg13
I1
sa(dp7321
g7
I201
sg8
g9
sg10
I6
sg11
VKCTD15
p7322
sg13
I1
sa(dp7323
g7
I215
sg8
g9
sg10
I5
sg11
VMTCH2
p7324
sg13
I1
sasg24
(lp7325
(dp7326
g7
I160
sg27
VC0028754
p7327
sg10
I7
sg11
Vobesity
p7328
sg13
I1
sasa(dp7329
g2
S'In total, 15 loci reached genome-wide significance (P-value &lt; 5 x 10(-8)) in the joint discovery and replication analysis, of which 12 are previously identified loci in or close to ADCY3, GNPDA2, TMEM18, SEC16B, FAIM2, FTO, TFAP2B, TNNI3K, MC4R, GPR61, LMX1B and OLFM4 associated with adult body mass index or childhood obesity.\n'
p7330
sg4
(lp7331
(dp7332
g7
I256
sg8
g9
sg10
I5
sg11
VLMX1B
p7333
sg13
I1
sa(dp7334
g7
I222
sg8
g9
sg10
I3
sg11
VFTO
p7335
sg13
I1
sa(dp7336
g7
I199
sg8
g9
sg10
I6
sg11
VTMEM18
p7337
sg13
I1
sa(dp7338
g7
I215
sg8
g9
sg10
I5
sg11
VFAIM2
p7339
sg13
I1
sa(dp7340
g7
I266
sg8
g9
sg10
I5
sg11
VOLFM4
p7341
sg13
I1
sa(dp7342
g7
I227
sg8
g9
sg10
I6
sg11
VTFAP2B
p7343
sg13
I1
sa(dp7344
g7
I243
sg8
VP32245
p7345
sg10
I4
sg11
VMC4R
p7346
sg13
I1
sa(dp7347
g7
I191
sg8
g9
sg10
I6
sg11
VGNPDA2
p7348
sg13
I1
sa(dp7349
g7
I207
sg8
g9
sg10
I6
sg11
VSEC16B
p7350
sg13
I1
sa(dp7351
g7
I184
sg8
VP40145
p7352
sg10
I5
sg11
VADCY3
p7353
sg13
I1
sa(dp7354
g7
I249
sg8
g9
sg10
I5
sg11
VGPR61
p7355
sg13
I1
sa(dp7356
g7
I235
sg8
g9
sg10
I6
sg11
VTNNI3K
p7357
sg13
I1
sasg24
(lp7358
(dp7359
g7
I313
sg27
VC2362324
p7360
sg10
I17
sg11
Vchildhood obesity
p7361
sg13
I2
sasa(dp7362
g2
S'An obesity-related gene, Fas apoptotic inhibitory molecule 2 (FAIM2), is regulated by nutritional state and the methylation levels of the FAIM2 promoter are significantly associated with obesity.\n'
p7363
sg4
(lp7364
(dp7365
g7
I25
sg8
g9
sg10
I35
sg11
VFas apoptotic inhibitory molecule 2
p7366
sg13
I5
sa(dp7367
g7
I138
sg8
g9
sg10
I14
sg11
VFAIM2 promoter
p7368
sg13
I2
sa(dp7369
g7
I62
sg8
g9
sg10
I5
sg11
VFAIM2
p7370
sg13
I1
sasg24
(lp7371
(dp7372
g7
I3
sg27
VC0028754
p7373
sg10
I7
sg11
Vobesity
p7374
sg13
I1
sa(dp7375
g7
I3
sg27
VC0028754
p7376
sg10
I7
sg11
Vobesity
p7377
sg13
I1
sa(dp7378
g7
I25
sg27
VC0015923
p7379
sg10
I3
sg11
VFas
p7380
sg13
I1
sasa(dp7381
g2
S'Whether the molecular mechanisms by which FAIM2 affects obesity are involved in lifestyle is unclear.\n'
p7382
sg4
(lp7383
(dp7384
g7
I42
sg8
g9
sg10
I5
sg11
VFAIM2
p7385
sg13
I1
sasg24
(lp7386
(dp7387
g7
I56
sg27
VC0028754
p7388
sg10
I7
sg11
Vobesity
p7389
sg13
I1
sasa(dp7390
g2
S'Our results suggest that lifestyle may possibly be mediating the process of the FAIM2 involved in obesity.\n'
p7391
sg4
(lp7392
(dp7393
g7
I80
sg8
g9
sg10
I5
sg11
VFAIM2
p7394
sg13
I1
sasg24
(lp7395
(dp7396
g7
I98
sg27
VC0028754
p7397
sg10
I7
sg11
Vobesity
p7398
sg13
I1
sasa(dp7399
g2
S'Fas apoptotic inhibitory molecule 2 (FAIM2) is an obesity-related gene, but the mechanisms by which FAIM2 is involved in obesity are not understood.\n'
p7400
sg4
(lp7401
(dp7402
g7
I37
sg8
g9
sg10
I5
sg11
VFAIM2
p7403
sg13
I1
sa(dp7404
g7
I37
sg8
g9
sg10
I5
sg11
VFAIM2
p7405
sg13
I1
sa(dp7406
g7
I0
sg8
g9
sg10
I35
sg11
VFas apoptotic inhibitory molecule 2
p7407
sg13
I5
sasg24
(lp7408
(dp7409
g7
I0
sg27
VC0015923
p7410
sg10
I3
sg11
VFas
p7411
sg13
I1
sa(dp7412
g7
I50
sg27
VC0028754
p7413
sg10
I7
sg11
Vobesity
p7414
sg13
I1
sa(dp7415
g7
I50
sg27
VC0028754
p7416
sg10
I7
sg11
Vobesity
p7417
sg13
I1
sasa(dp7418
g2
S'The purpose of this study was to investigate the potential associations of FAIM2 promoter methylation with obesity and components of dyslipidaemia in Chinese children.\n'
p7419
sg4
(lp7420
(dp7421
g7
I75
sg8
g9
sg10
I14
sg11
VFAIM2 promoter
p7422
sg13
I2
sasg24
(lp7423
(dp7424
g7
I107
sg27
VC0028754
p7425
sg10
I7
sg11
Vobesity
p7426
sg13
I1
sa(dp7427
g7
I133
sg27
VC0242339
p7428
sg10
I13
sg11
Vdyslipidaemia
p7429
sg13
I1
sasa(dp7430
g2
S'This study provides the first evidence that the methylation levels of the FAIM2 promoter are significantly associated with obesity and are independently associated with dyslipidaemia and its components in Chinese children.\n'
p7431
sg4
(lp7432
(dp7433
g7
I74
sg8
g9
sg10
I14
sg11
VFAIM2 promoter
p7434
sg13
I2
sasg24
(lp7435
(dp7436
g7
I169
sg27
VC0242339
p7437
sg10
I13
sg11
Vdyslipidaemia
p7438
sg13
I1
sa(dp7439
g7
I123
sg27
VC0028754
p7440
sg10
I7
sg11
Vobesity
p7441
sg13
I1
sasa(dp7442
g2
S'The association of FTO rs9939609-A, MC4R rs17782313-C, GNPDA2 rs10938397-G, and FAIM2 rs7138803-A with higher BMI, fat mass percentage, waist circumference, and waist-to height ratio and risk of obesity, and BDNF rs6265-G allele may increase BMI and obesity risk in Chinese children.\n'
p7443
sg4
(lp7444
(dp7445
g7
I80
sg8
g9
sg10
I17
sg11
VFAIM2 rs7138803-A
p7446
sg13
I2
sa(dp7447
g7
I36
sg8
VP32245
p7448
sg10
I17
sg11
VMC4R rs17782313-C
p7449
sg13
I2
sa(dp7450
g7
I55
sg8
g9
sg10
I19
sg11
VGNPDA2 rs10938397-G
p7451
sg13
I2
sa(dp7452
g7
I19
sg8
g9
sg10
I15
sg11
VFTO rs9939609-A
p7453
sg13
I2
sasg24
(lp7454
(dp7455
g7
I195
sg27
VC0028754
p7456
sg10
I7
sg11
Vobesity
p7457
sg13
I1
sa(dp7458
g7
I195
sg27
VC0028754
p7459
sg10
I7
sg11
Vobesity
p7460
sg13
I1
sasa(dp7461
g2
S'Here we aim to see whether variants in obesity-associated genes--NEGR1, FTO, MTCH2, MC4R, LRRN6C, MAP2K5, FAIM2, SEC16B, ETV5, BDNF-AS, ATXN2L, ATP2A1, KCTD15, and TNN13K--are associated with white matter microstructural properties, assessed by high angular resolution diffusion imaging (HARDI) in young healthy adults between 20 and 30 years of age from the Queensland Twin Imaging study (QTIM).\n'
p7462
sg4
(lp7463
(dp7464
g7
I65
sg8
g9
sg10
I5
sg11
VNEGR1
p7465
sg13
I1
sa(dp7466
g7
I144
sg8
g9
sg10
I6
sg11
VATP2A1
p7467
sg13
I1
sa(dp7468
g7
I72
sg8
g9
sg10
I3
sg11
VFTO
p7469
sg13
I1
sa(dp7470
g7
I98
sg8
g9
sg10
I6
sg11
VMAP2K5
p7471
sg13
I1
sa(dp7472
g7
I106
sg8
g9
sg10
I5
sg11
VFAIM2
p7473
sg13
I1
sa(dp7474
g7
I113
sg8
g9
sg10
I6
sg11
VSEC16B
p7475
sg13
I1
sa(dp7476
g7
I152
sg8
g9
sg10
I6
sg11
VKCTD15
p7477
sg13
I1
sa(dp7478
g7
I121
sg8
VP41161
p7479
sg10
I4
sg11
VETV5
p7480
sg13
I1
sa(dp7481
g7
I77
sg8
g9
sg10
I5
sg11
VMTCH2
p7482
sg13
I1
sa(dp7483
g7
I84
sg8
VP32245
p7484
sg10
I4
sg11
VMC4R
p7485
sg13
I1
sa(dp7486
g7
I90
sg8
g9
sg10
I6
sg11
VLRRN6C
p7487
sg13
I1
sasg24
(lp7488
(dp7489
g7
I39
sg27
VC0028754
p7490
sg10
I7
sg11
Vobesity
p7491
sg13
I1
sasa(dp7492
g2
S'Our results reflect an epigenetic regulation of Rbl2/p130 expression in breast cancer.\n'
p7493
sg4
(lp7494
(dp7495
g7
I48
sg8
g9
sg10
I4
sg11
VRbl2
p7496
sg13
I1
sa(dp7497
g7
I53
sg8
g9
sg10
I4
sg11
Vp130
p7498
sg13
I1
sasg24
(lp7499
(dp7500
g7
I72
sg27
VC0678222
p7501
sg10
I13
sg11
Vbreast cancer
p7502
sg13
I2
sasa(dp7503
g2
S'This highlights the importance of Rbl2/p130 promoter methylation in breast cancer pathogenesis.\n'
p7504
sg4
(lp7505
(dp7506
g7
I39
sg8
g9
sg10
I4
sg11
Vp130
p7507
sg13
I1
sa(dp7508
g7
I34
sg8
g9
sg10
I4
sg11
VRbl2
p7509
sg13
I1
sasg24
(lp7510
(dp7511
g7
I68
sg27
VC0678222
p7512
sg10
I13
sg11
Vbreast cancer
p7513
sg13
I2
sa(dp7514
g7
I82
sg27
VC0699748
p7515
sg10
I12
sg11
Vpathogenesis
p7516
sg13
I1
sasa(dp7517
g2
S'Here, we report that ER-beta and pRb2/p130 proteins co-immunoprecipitate in both nucleus and cytoplasm of MCF-7 breast cancer cells.\n'
p7518
sg4
(lp7519
(dp7520
g7
I38
sg8
g9
sg10
I4
sg11
Vp130
p7521
sg13
I1
sa(dp7522
g7
I33
sg8
VP02812
p7523
sg10
I4
sg11
VpRb2
p7524
sg13
I1
sasg24
(lp7525
(dp7526
g7
I112
sg27
VC0678222
p7527
sg10
I13
sg11
Vbreast cancer
p7528
sg13
I2
sasa(dp7529
g2
S'Here we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells.\n'
p7530
sg4
(lp7531
(dp7532
g7
I81
sg8
VP02812
p7533
sg10
I4
sg11
VpRb2
p7534
sg13
I1
sa(dp7535
g7
I42
sg8
g9
sg10
I13
sg11
VER-alpha gene
p7536
sg13
I2
sa(dp7537
g7
I86
sg8
g9
sg10
I4
sg11
Vp130
p7538
sg13
I1
sasg24
(lp7539
(dp7540
g7
I106
sg27
VC0678222
p7541
sg10
I13
sg11
Vbreast cancer
p7542
sg13
I2
sa(dp7543
g7
I56
sg27
VC0544461
p7544
sg10
I12
sg11
Vinactivation
p7545
sg13
I1
sasa(dp7546
g2
S'These findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.\n'
p7547
sg4
(lp7548
(dp7549
g7
I33
sg8
g9
sg10
I4
sg11
Vp130
p7550
sg13
I1
sa(dp7551
g7
I104
sg8
g9
sg10
I13
sg11
VER-alpha gene
p7552
sg13
I2
sa(dp7553
g7
I28
sg8
VP02812
p7554
sg10
I4
sg11
VpRb2
p7555
sg13
I1
sasg24
(lp7556
(dp7557
g7
I240
sg27
VC0678222
p7558
sg10
I13
sg11
Vbreast cancer
p7559
sg13
I2
sa(dp7560
g7
I276
sg27
VC0027651
p7561
sg10
I6
sg11
Vtumors
p7562
sg13
I1
sasa(dp7563
g2
S'In order to further analyze the role of CEACAM1 in the development of breast cancer, we performed Western-blot analysis and immunohistochemistry with highly specific monoclonal antibodies in a cohort of 68 mammary carcinomas which had also been analyzed for expression of cell-cycle regulatory proteins cyclin D1, cyclin E, p16, p21, p27, Rb, and Rb2, as well as for steroid hormone receptor status, Ki67, and HER2/neu immunoreactivity.\n'
p7564
sg4
(lp7565
(dp7566
g7
I347
sg8
g9
sg10
I3
sg11
VRb2
p7567
sg13
I1
sa(dp7568
g7
I324
sg8
VP42771
p7569
sg10
I3
sg11
Vp16
p7570
sg13
I1
sa(dp7571
g7
I334
sg8
VP40305
p7572
sg10
I3
sg11
Vp27
p7573
sg13
I1
sa(dp7574
g7
I415
sg8
VP04626
p7575
sg10
I3
sg11
Vneu
p7576
sg13
I1
sa(dp7577
g7
I40
sg8
VP13688
p7578
sg10
I7
sg11
VCEACAM1
p7579
sg13
I1
sa(dp7580
g7
I329
sg8
VP42857
p7581
sg10
I3
sg11
Vp21
p7582
sg13
I1
sa(dp7583
g7
I314
sg8
VP24864
p7584
sg10
I8
sg11
Vcyclin E
p7585
sg13
I2
sa(dp7586
g7
I410
sg8
VP04626
p7587
sg10
I4
sg11
VHER2
p7588
sg13
I1
sa(dp7589
g7
I303
sg8
VP24385
p7590
sg10
I9
sg11
Vcyclin D1
p7591
sg13
I2
sa(dp7592
g7
I367
sg8
VP22736
p7593
sg10
I24
sg11
Vsteroid hormone receptor
p7594
sg13
I3
sasg24
(lp7595
(dp7596
g7
I70
sg27
VC0678222
p7597
sg10
I13
sg11
Vbreast cancer
p7598
sg13
I2
sa(dp7599
g7
I214
sg27
VC0007097
p7600
sg10
I10
sg11
Vcarcinomas
p7601
sg13
I1
sasa(dp7602
g2
S'Weak or absent Rb2 expression was more often found in endometrial (59%) than in mammary carcinomas (24%).\n'
p7603
sg4
(lp7604
(dp7605
g7
I15
sg8
g9
sg10
I3
sg11
VRb2
p7606
sg13
I1
sasg24
(lp7607
(dp7608
g7
I88
sg27
VC0007097
p7609
sg10
I10
sg11
Vcarcinomas
p7610
sg13
I1
sasa(dp7611
g2
S'We found significant positive correlations of Rb2 expression with Rb, ER, and PR-B in breast cancer samples, and of Rb2 with Rb, PR-A, PR-B, and younger age in endometrial carcinomas.\n'
p7612
sg4
(lp7613
(dp7614
g7
I46
sg8
g9
sg10
I3
sg11
VRb2
p7615
sg13
I1
sa(dp7616
g7
I46
sg8
g9
sg10
I3
sg11
VRb2
p7617
sg13
I1
sasg24
(lp7618
(dp7619
g7
I86
sg27
VC0678222
p7620
sg10
I13
sg11
Vbreast cancer
p7621
sg13
I2
sa(dp7622
g7
I160
sg27
VC0476089
p7623
sg10
I22
sg11
Vendometrial carcinomas
p7624
sg13
I2
sasa(dp7625
g2
S'Our results indicate that loss of Rb2 expression, mostly by transcriptional down-regulation, may be associated with the development and dedifferentiation of most endometrial and a subset of mammary carcinomas.\n'
p7626
sg4
(lp7627
(dp7628
g7
I34
sg8
g9
sg10
I3
sg11
VRb2
p7629
sg13
I1
sasg24
(lp7630
(dp7631
g7
I198
sg27
VC0007097
p7632
sg10
I10
sg11
Vcarcinomas
p7633
sg13
I1
sa(dp7634
g7
I136
sg27
VC0002793
p7635
sg10
I17
sg11
Vdedifferentiation
p7636
sg13
I1
sasa(dp7637
g2
S'We have developed a novel glycocancer biomarker, fucosylated haptoglobin (Fuc-Hpt), and have investigated its usefulness for the diagnosis of pancreatic cancer over approximately 10 years.\n'
p7638
sg4
(lp7639
(dp7640
g7
I74
sg8
VP00738
p7641
sg10
I7
sg11
VFuc-Hpt
p7642
sg13
I1
sa(dp7643
g7
I49
sg8
VP00738
p7644
sg10
I23
sg11
Vfucosylated haptoglobin
p7645
sg13
I2
sasg24
(lp7646
(dp7647
g7
I142
sg27
VC0235974
p7648
sg10
I17
sg11
Vpancreatic cancer
p7649
sg13
I2
sasa(dp7650
g2
S'In this review, we provide a historical summary of our research on Fuc-Hpt as a cancer biomarker, and discuss a potential early detection system for pancreatic cancer.\n'
p7651
sg4
(lp7652
(dp7653
g7
I67
sg8
VP00738
p7654
sg10
I7
sg11
VFuc-Hpt
p7655
sg13
I1
sasg24
(lp7656
(dp7657
g7
I80
sg27
VC0006826
p7658
sg10
I6
sg11
Vcancer
p7659
sg13
I1
sa(dp7660
g7
I149
sg27
VC0235974
p7661
sg10
I17
sg11
Vpancreatic cancer
p7662
sg13
I2
sasa(dp7663
g2
S'We developed a lectin-antibody ELISA kit using PhoSL to determine core-Fuc-Hpt levels in sera from colorectal or pancreatic cancer patients.\n'
p7664
sg4
(lp7665
(dp7666
g7
I66
sg8
VP00738
p7667
sg10
I12
sg11
Vcore-Fuc-Hpt
p7668
sg13
I1
sa(dp7669
g7
I15
sg8
g9
sg10
I15
sg11
Vlectin-antibody
p7670
sg13
I1
sasg24
(lp7671
(dp7672
g7
I113
sg27
VC0235974
p7673
sg10
I17
sg11
Vpancreatic cancer
p7674
sg13
I2
sasa(dp7675
g2
S'Serum levels of AAL-reactive Hpt are higher in pancreatic cancer patients, whereas those of PhoSL-reactive Hpt are higher in colorectal cancer patients.\n'
p7676
sg4
(lp7677
(dp7678
g7
I92
sg8
VP00738
p7679
sg10
I18
sg11
VPhoSL-reactive Hpt
p7680
sg13
I2
sa(dp7681
g7
I16
sg8
VP00738
p7682
sg10
I16
sg11
VAAL-reactive Hpt
p7683
sg13
I2
sasg24
(lp7684
(dp7685
g7
I47
sg27
VC0235974
p7686
sg10
I17
sg11
Vpancreatic cancer
p7687
sg13
I2
sa(dp7688
g7
I125
sg27
VC1527249
p7689
sg10
I17
sg11
Vcolorectal cancer
p7690
sg13
I2
sasa(dp7691
g2
S'Fucosylated haptoglobin (Fuc-Hpt) has been identified as a novel biomarker for pancreatic cancer.\n'
p7692
sg4
(lp7693
(dp7694
g7
I25
sg8
VP00738
p7695
sg10
I7
sg11
VFuc-Hpt
p7696
sg13
I1
sa(dp7697
g7
I0
sg8
VP00738
p7698
sg10
I23
sg11
VFucosylated haptoglobin
p7699
sg13
I2
sasg24
(lp7700
(dp7701
g7
I79
sg27
VC0235974
p7702
sg10
I17
sg11
Vpancreatic cancer
p7703
sg13
I2
sasa(dp7704
g2
S'We previously found that the level of Fuc-Hpt is increased in the sera of patients with pancreatic cancer, and established a lectin antibody ELISA using Aleuria aurantia lectin, which specifically binds to fucosylated residues on oligosaccharides.\n'
p7705
sg4
(lp7706
(dp7707
g7
I38
sg8
VP00738
p7708
sg10
I7
sg11
VFuc-Hpt
p7709
sg13
I1
sa(dp7710
g7
I153
sg8
g9
sg10
I23
sg11
VAleuria aurantia lectin
p7711
sg13
I3
sa(dp7712
g7
I125
sg8
g9
sg10
I15
sg11
Vlectin antibody
p7713
sg13
I2
sasg24
(lp7714
(dp7715
g7
I88
sg27
VC0235974
p7716
sg10
I17
sg11
Vpancreatic cancer
p7717
sg13
I2
sasa(dp7718
g2
S"Using the model checking method, we verified several Alzheimer's disease and cancer-related properties, and also identified important proteins (NFKB, ATF4, ASK1 and TRAF2) in the ER-Golgi network, which might be responsible for the pathogenesis of cancer and AD.\n"
p7719
sg4
(lp7720
(dp7721
g7
I156
sg8
g9
sg10
I4
sg11
VASK1
p7722
sg13
I1
sa(dp7723
g7
I144
sg8
g9
sg10
I4
sg11
VNFKB
p7724
sg13
I1
sa(dp7725
g7
I165
sg8
g9
sg10
I5
sg11
VTRAF2
p7726
sg13
I1
sa(dp7727
g7
I150
sg8
VP18848
p7728
sg10
I4
sg11
VATF4
p7729
sg13
I1
sasg24
(lp7730
(dp7731
g7
I77
sg27
VC0006826
p7732
sg10
I6
sg11
Vcancer
p7733
sg13
I1
sa(dp7734
g7
I53
sg27
VC1521724
p7735
sg10
I19
sg11
VAlzheimer's disease
p7736
sg13
I2
sa(dp7737
g7
I232
sg27
VC0699748
p7738
sg10
I12
sg11
Vpathogenesis
p7739
sg13
I1
sa(dp7740
g7
I77
sg27
VC0006826
p7741
sg10
I6
sg11
Vcancer
p7742
sg13
I1
sasa(dp7743
g2
S'We genotyped 107 AIH-1 children and up to 326 healthy subjects for TNFA G-308A, TNFA G-238A, LTA A+252G, LTA A+80C, NFKBIL1 T-63A, BAT1 C-348T, BAT1 G-22C, MICA, and HLA-B polymorphisms.\n'
p7744
sg4
(lp7745
(dp7746
g7
I105
sg8
VP10515
p7747
sg10
I9
sg11
VLTA A+80C
p7748
sg13
I2
sa(dp7749
g7
I166
sg8
VP30461
p7750
sg10
I5
sg11
VHLA-B
p7751
sg13
I1
sa(dp7752
g7
I131
sg8
VP82251
p7753
sg10
I11
sg11
VBAT1 C-348T
p7754
sg13
I2
sa(dp7755
g7
I144
sg8
VP82251
p7756
sg10
I10
sg11
VBAT1 G-22C
p7757
sg13
I2
sa(dp7758
g7
I93
sg8
VP10515
p7759
sg10
I10
sg11
VLTA A+252G
p7760
sg13
I2
sa(dp7761
g7
I67
sg8
VP01375
p7762
sg10
I11
sg11
VTNFA G-308A
p7763
sg13
I2
sa(dp7764
g7
I116
sg8
g9
sg10
I13
sg11
VNFKBIL1 T-63A
p7765
sg13
I2
sa(dp7766
g7
I80
sg8
VP01375
p7767
sg10
I11
sg11
VTNFA G-238A
p7768
sg13
I2
sasg24
(lp7769
(dp7770
g7
I156
sg27
VC0700319
p7771
sg10
I4
sg11
VMICA
p7772
sg13
I1
sasa(dp7773
g2
S'Tandem repeats of a novel, putative, zinc-binding motif (MYM) have been described within the products of two, highly homologous genes: ZNF198/RAMP/FIM and ZNF261/DXS6673E.\n'
p7774
sg4
(lp7775
(dp7776
g7
I155
sg8
g9
sg10
I6
sg11
VZNF261
p7777
sg13
I1
sa(dp7778
g7
I142
sg8
g9
sg10
I4
sg11
VRAMP
p7779
sg13
I1
sa(dp7780
g7
I147
sg8
VP28329
p7781
sg10
I3
sg11
VFIM
p7782
sg13
I1
sa(dp7783
g7
I162
sg8
g9
sg10
I8
sg11
VDXS6673E
p7784
sg13
I1
sasg24
(lp7785
(dp7786
g7
I147
sg27
VC0393929
p7787
sg10
I3
sg11
VFIM
p7788
sg13
I1
sasa(dp7789
g2
S"From 2005 to 2010, our unit performed testing for IL2RG, JAK3, IL7R, RAG1, RAG2, DCLRE1C, LIG4, AK2, and ZAP70 mutations in 42 Chinese and Southeast Asian infants with SCID adopting a candidate gene approach, based on patient's gender, immune phenotype, and inheritance pattern.\n"
p7790
sg4
(lp7791
(dp7792
g7
I50
sg8
VP31785
p7793
sg10
I5
sg11
VIL2RG
p7794
sg13
I1
sa(dp7795
g7
I96
sg8
g9
sg10
I3
sg11
VAK2
p7796
sg13
I1
sa(dp7797
g7
I105
sg8
VP43403
p7798
sg10
I15
sg11
VZAP70 mutations
p7799
sg13
I2
sa(dp7800
g7
I69
sg8
VP15918
p7801
sg10
I4
sg11
VRAG1
p7802
sg13
I1
sa(dp7803
g7
I75
sg8
VP55895
p7804
sg10
I4
sg11
VRAG2
p7805
sg13
I1
sa(dp7806
g7
I57
sg8
VP52333
p7807
sg10
I4
sg11
VJAK3
p7808
sg13
I1
sa(dp7809
g7
I90
sg8
VP49917
p7810
sg10
I4
sg11
VLIG4
p7811
sg13
I1
sasg24
(lp7812
(dp7813
g7
I168
sg27
VC0085110
p7814
sg10
I4
sg11
VSCID
p7815
sg13
I1
sasa(dp7816
g2
S'Mutations were identified in 26 patients, including IL2RG (n = 19), IL7R (n = 2), JAK3 (n = 2), RAG1 (n = 1), RAG2 (n = 1), and DCLRE1C (n = 1).\n'
p7817
sg4
(lp7818
(dp7819
g7
I82
sg8
VP52333
p7820
sg10
I4
sg11
VJAK3
p7821
sg13
I1
sa(dp7822
g7
I52
sg8
VP31785
p7823
sg10
I5
sg11
VIL2RG
p7824
sg13
I1
sa(dp7825
g7
I110
sg8
VP55895
p7826
sg10
I4
sg11
VRAG2
p7827
sg13
I1
sa(dp7828
g7
I96
sg8
VP15918
p7829
sg10
I4
sg11
VRAG1
p7830
sg13
I1
sasg24
(lp7831
sa(dp7832
g2
S'Mutations in any of eight known genes: IL2RG, ARTEMIS, RAG1, RAG2, ADA, CD45, JAK3, and IL7R cause SCID.\n'
p7833
sg4
(lp7834
(dp7835
g7
I39
sg8
VP31785
p7836
sg10
I5
sg11
VIL2RG
p7837
sg13
I1
sa(dp7838
g7
I78
sg8
VP52333
p7839
sg10
I4
sg11
VJAK3
p7840
sg13
I1
sa(dp7841
g7
I55
sg8
VP15918
p7842
sg10
I4
sg11
VRAG1
p7843
sg13
I1
sa(dp7844
g7
I72
sg8
VP08575
p7845
sg10
I4
sg11
VCD45
p7846
sg13
I1
sa(dp7847
g7
I67
sg8
VP00813
p7848
sg10
I3
sg11
VADA
p7849
sg13
I1
sa(dp7850
g7
I61
sg8
VP55895
p7851
sg10
I4
sg11
VRAG2
p7852
sg13
I1
sasg24
(lp7853
(dp7854
g7
I99
sg27
VC0085110
p7855
sg10
I4
sg11
VSCID
p7856
sg13
I1
sasa(dp7857
g2
S'Previous studies have reported that Nit2, a member of the nitrilase superfamily, is a potential tumor suppressor, although its function remains elusive in colon cancer.\n'
p7858
sg4
(lp7859
(dp7860
g7
I36
sg8
g9
sg10
I4
sg11
VNit2
p7861
sg13
I1
sasg24
(lp7862
(dp7863
g7
I155
sg27
VC0699790
p7864
sg10
I12
sg11
Vcolon cancer
p7865
sg13
I2
sa(dp7866
g7
I96
sg27
VC0027651
p7867
sg10
I5
sg11
Vtumor
p7868
sg13
I1
sasa(dp7869
g2
S'In the present study, we employed an RNA interference lentivirus system to silence endogenous NIT2 expression in the colon cancer cell line, HCT116.\n'
p7870
sg4
(lp7871
(dp7872
g7
I94
sg8
g9
sg10
I4
sg11
VNIT2
p7873
sg13
I1
sasg24
(lp7874
(dp7875
g7
I75
sg27
VC0858952
p7876
sg10
I7
sg11
Vsilence
p7877
sg13
I1
sa(dp7878
g7
I117
sg27
VC0699790
p7879
sg10
I12
sg11
Vcolon cancer
p7880
sg13
I2
sasa(dp7881
g2
S'The depletion of NIT2 markedly inhibited colon cancer cell proliferation and colony formation and induced cell cycle arrest in the G0/G1 phase, as shown by MTT assay, colony formation assay and flow cytometric analysis, respectively.\n'
p7882
sg4
(lp7883
(dp7884
g7
I17
sg8
g9
sg10
I4
sg11
VNIT2
p7885
sg13
I1
sasg24
(lp7886
(dp7887
g7
I59
sg27
VC0334094
p7888
sg10
I13
sg11
Vproliferation
p7889
sg13
I1
sa(dp7890
g7
I41
sg27
VC0699790
p7891
sg10
I12
sg11
Vcolon cancer
p7892
sg13
I2
sasa(dp7893
g2
S'Further investigation with an intracellular signaling array demonstrated that the depletion of NIT2 triggered the apoptosis of colon cancer cells through the caspase-3 and poly(ADP-ribose) polymerase (PARP) pathways.\n'
p7894
sg4
(lp7895
(dp7896
g7
I95
sg8
g9
sg10
I4
sg11
VNIT2
p7897
sg13
I1
sa(dp7898
g7
I201
sg8
VP09874
p7899
sg10
I4
sg11
VPARP
p7900
sg13
I1
sa(dp7901
g7
I158
sg8
VP42574
p7902
sg10
I9
sg11
Vcaspase-3
p7903
sg13
I1
sa(dp7904
g7
I172
sg8
VP09874
p7905
sg10
I27
sg11
Vpoly(ADP-ribose) polymerase
p7906
sg13
I2
sasg24
(lp7907
(dp7908
g7
I127
sg27
VC0699790
p7909
sg10
I12
sg11
Vcolon cancer
p7910
sg13
I2
sasa(dp7911
g2
S'Our findings suggest that NIT2 may be an oncogene in human colon cancer and may thus serve as a promising therapeutic target for the treatment of colon cancer.\n'
p7912
sg4
(lp7913
(dp7914
g7
I26
sg8
g9
sg10
I4
sg11
VNIT2
p7915
sg13
I1
sasg24
(lp7916
(dp7917
g7
I59
sg27
VC0699790
p7918
sg10
I12
sg11
Vcolon cancer
p7919
sg13
I2
sa(dp7920
g7
I59
sg27
VC0699790
p7921
sg10
I12
sg11
Vcolon cancer
p7922
sg13
I2
sasa(dp7923
g2
S'Our report may provide clues regarding the nature of the biological amidase substrate(s) of Nit1 (another member of the Nit family), which is a well-established tumor suppressor protein), and emphasizes a) the crucial role of Nit2 in nitrogen and sulfur metabolism, and b) the possible link of Nit2 to cancer biology.\n'
p7924
sg4
(lp7925
(dp7926
g7
I226
sg8
g9
sg10
I4
sg11
VNit2
p7927
sg13
I1
sa(dp7928
g7
I92
sg8
g9
sg10
I4
sg11
VNit1
p7929
sg13
I1
sa(dp7930
g7
I226
sg8
g9
sg10
I4
sg11
VNit2
p7931
sg13
I1
sasg24
(lp7932
(dp7933
g7
I161
sg27
VC0027651
p7934
sg10
I5
sg11
Vtumor
p7935
sg13
I1
sa(dp7936
g7
I302
sg27
VC0006826
p7937
sg10
I6
sg11
Vcancer
p7938
sg13
I1
sasa(dp7939
g2
S'The purpose of this study was to retrospectively characterize benign and malignant prostate peripheral zone tissue by using endorectal MRI and 3D 1H MRS. Fifty-two men with untreated biopsy-proven prostate cancer underwent combined endorectal MRI and MRSI.\n'
p7940
sg4
(lp7941
sg24
(lp7942
(dp7943
g7
I197
sg27
VC0600139
p7944
sg10
I15
sg11
Vprostate cancer
p7945
sg13
I2
sa(dp7946
g7
I149
sg27
VC0025235
p7947
sg10
I3
sg11
VMRS
p7948
sg13
I1
sasa(dp7949
g2
S'The addition of 3D1H MRSI to MRI can improve diagnosis of prostate cancer contributing indirectly to improve local staging.\n'
p7950
sg4
(lp7951
sg24
(lp7952
(dp7953
g7
I58
sg27
VC0600139
p7954
sg10
I15
sg11
Vprostate cancer
p7955
sg13
I2
sasa(dp7956
g2
S'In addition, the correlation between metabolic 3D1H MRSI data with pathological Gleason grade may offer a non-invasive means to better predict prostate cancer aggressiveness.\n'
p7957
sg4
(lp7958
sg24
(lp7959
(dp7960
g7
I143
sg27
VC1853195
p7961
sg10
I30
sg11
Vprostate cancer aggressiveness
p7962
sg13
I3
sasa(dp7963
g2
S'The objective of our study was to establish the sensitivity and specificity for prostate cancer detection using a combined 1H MR spectroscopy and diffusion-weighted MRI approach.\n'
p7964
sg4
(lp7965
sg24
(lp7966
(dp7967
g7
I80
sg27
VC0600139
p7968
sg10
I15
sg11
Vprostate cancer
p7969
sg13
I2
sasa(dp7970
g2
S'MRI, dynamic MRI, and 1H-MR spectroscopic imaging were performed in 10 patients with prostate cancer on 1.5T and 3T whole-body scanners.\n'
p7971
sg4
(lp7972
sg24
(lp7973
(dp7974
g7
I85
sg27
VC0600139
p7975
sg10
I15
sg11
Vprostate cancer
p7976
sg13
I2
sasa(dp7977
g2
S'Initial results of endorectal 3T 1H-MR spectroscopic imaging in prostate cancer patients showed potential advantages: the increase in spatial, temporal, and spectral resolution at higher field strength may result in an improved accuracy in delineating and staging prostate cancer.\n'
p7978
sg4
(lp7979
sg24
(lp7980
(dp7981
g7
I64
sg27
VC0600139
p7982
sg10
I15
sg11
Vprostate cancer
p7983
sg13
I2
sa(dp7984
g7
I64
sg27
VC0600139
p7985
sg10
I15
sg11
Vprostate cancer
p7986
sg13
I2
sasa(dp7987
g2
S'To establish an experimental setting for monitoring perfusion and metabolism in orthotopic prostate cancer at 1.5 T using dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) and 1H-MR spectroscopy (MRS).\n'
p7988
sg4
(lp7989
sg24
(lp7990
(dp7991
g7
I91
sg27
VC0600139
p7992
sg10
I15
sg11
Vprostate cancer
p7993
sg13
I2
sa(dp7994
g7
I209
sg27
VC0025235
p7995
sg10
I3
sg11
VMRS
p7996
sg13
I1
sa(dp7997
g7
I189
sg27
VC0025235
p7998
sg10
I18
sg11
V1H-MR spectroscopy
p7999
sg13
I2
sasa(dp8000
g2
S'DCE MRI and 1H-MRS has potential to characterize orthotopic Dunning prostate cancer in rats, which is a promising model similar to human prostate carcinomas.\n'
p8001
sg4
(lp8002
sg24
(lp8003
(dp8004
g7
I15
sg27
VC0025235
p8005
sg10
I3
sg11
VMRS
p8006
sg13
I1
sa(dp8007
g7
I68
sg27
VC0600139
p8008
sg10
I15
sg11
Vprostate cancer
p8009
sg13
I2
sa(dp8010
g7
I146
sg27
VC0007097
p8011
sg10
I10
sg11
Vcarcinomas
p8012
sg13
I1
sasa(dp8013
g2
S'We recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).\n'
p8014
sg4
(lp8015
(dp8016
g7
I117
sg8
g9
sg10
I7
sg11
VFam107A
p8017
sg13
I1
sa(dp8018
g7
I111
sg8
g9
sg10
I4
sg11
VDRR1
p8019
sg13
I1
sa(dp8020
g7
I39
sg8
VP48506
p8021
sg10
I29
sg11
Vglucocorticoid-regulated gene
p8022
sg13
I2
sasg24
(lp8023
(dp8024
g7
I88
sg27
VC0007134
p8025
sg10
I20
sg11
Vrenal cell carcinoma
p8026
sg13
I3
sasa(dp8027
g2
S'TU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).\n'
p8028
sg4
(lp8029
(dp8030
g7
I0
sg8
g9
sg10
I4
sg11
VTU3A
p8031
sg13
I1
sasg24
(lp8032
(dp8033
g7
I91
sg27
VC0007134
p8034
sg10
I20
sg11
Vrenal cell carcinoma
p8035
sg13
I3
sa(dp8036
g7
I66
sg27
VC0027651
p8037
sg10
I5
sg11
Vtumor
p8038
sg13
I1
sa(dp8039
g7
I113
sg27
VC0007134
p8040
sg10
I3
sg11
VRCC
p8041
sg13
I1
sasa(dp8042
g2
S'In our search for tumor suppressor genes from this region, we have cloned a gene that we have called DRR 1 (downregulated in renal cell carcinoma).\n'
p8043
sg4
(lp8044
(dp8045
g7
I101
sg8
g9
sg10
I5
sg11
VDRR 1
p8046
sg13
I2
sasg24
(lp8047
(dp8048
g7
I18
sg27
VC0027651
p8049
sg10
I5
sg11
Vtumor
p8050
sg13
I1
sa(dp8051
g7
I125
sg27
VC0007134
p8052
sg10
I20
sg11
Vrenal cell carcinoma
p8053
sg13
I3
sasa(dp8054
g2
S'Our results suggest that loss of expression of the DRR 1 gene may play an important role in the development of renal cell carcinoma and possibly other tumors.\n'
p8055
sg4
(lp8056
(dp8057
g7
I51
sg8
g9
sg10
I10
sg11
VDRR 1 gene
p8058
sg13
I3
sasg24
(lp8059
(dp8060
g7
I151
sg27
VC0027651
p8061
sg10
I6
sg11
Vtumors
p8062
sg13
I1
sa(dp8063
g7
I111
sg27
VC0007134
p8064
sg10
I20
sg11
Vrenal cell carcinoma
p8065
sg13
I3
sasa(dp8066
g2
S'E2F5 was identified as one of the most deregulated genes in prostate cancer tissues, predominantly in samples with Gleason-score 6.\n'
p8067
sg4
(lp8068
(dp8069
g7
I0
sg8
g9
sg10
I4
sg11
VE2F5
p8070
sg13
I1
sasg24
(lp8071
(dp8072
g7
I60
sg27
VC0600139
p8073
sg10
I15
sg11
Vprostate cancer
p8074
sg13
I2
sasa(dp8075
g2
S'Function of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.\n'
p8076
sg4
(lp8077
(dp8078
g7
I21
sg8
VP46108
p8079
sg10
I3
sg11
Vp38
p8080
sg13
I1
sa(dp8081
g7
I12
sg8
g9
sg10
I4
sg11
VE2F5
p8082
sg13
I1
sasg24
(lp8083
(dp8084
g7
I28
sg27
VC0600139
p8085
sg10
I15
sg11
Vprostate cancer
p8086
sg13
I2
sasa(dp8087
g2
S'Our findings unearthed that E2F5/p38 axis played a cardinal role in uncontrolled cellular proliferation in prostate cancer through pSMAD3L activation.\n'
p8088
sg4
(lp8089
(dp8090
g7
I33
sg8
VP46108
p8091
sg10
I3
sg11
Vp38
p8092
sg13
I1
sa(dp8093
g7
I28
sg8
g9
sg10
I4
sg11
VE2F5
p8094
sg13
I1
sasg24
(lp8095
(dp8096
g7
I81
sg27
VC0020507
p8097
sg10
I22
sg11
Vcellular proliferation
p8098
sg13
I2
sa(dp8099
g7
I107
sg27
VC0600139
p8100
sg10
I15
sg11
Vprostate cancer
p8101
sg13
I2
sasa(dp8102
g2
S'It also underscores a strong potential for E2F5 to be incorporated as a tool in early detection of prostate cancer.\n'
p8103
sg4
(lp8104
(dp8105
g7
I43
sg8
g9
sg10
I4
sg11
VE2F5
p8106
sg13
I1
sasg24
(lp8107
(dp8108
g7
I99
sg27
VC0600139
p8109
sg10
I15
sg11
Vprostate cancer
p8110
sg13
I2
sasa(dp8111
g2
S'We report the coexistence of otitis media and epididymo-orchitis owing to Hemophilus influenzae, type b in 2 children.\n'
p8112
sg4
(lp8113
sg24
(lp8114
(dp8115
g7
I29
sg27
VC0029882
p8116
sg10
I12
sg11
Votitis media
p8117
sg13
I2
sa(dp8118
g7
I46
sg27
VC0149881
p8119
sg10
I18
sg11
Vepididymo-orchitis
p8120
sg13
I1
sasa(dp8121
g2
S'Overexpression of tau rescued the Nogo-66-induced inhibition of neurite outgrowth in neuroblastoma 2a (N2a) cells and primary cortical neurons.\n'
p8122
sg4
(lp8123
sg24
(lp8124
(dp8125
g7
I85
sg27
VC0027819
p8126
sg10
I13
sg11
Vneuroblastoma
p8127
sg13
I1
sasa(dp8128
g2
S'Taken together, we suggest that Nogo-A is closely involved in the neuronal response to hypoxic and oxidative stress, an observation that may be of relevance not only in stroke-induced ischaemia, but also in neuroblastoma formation.\n'
p8129
sg4
(lp8130
sg24
(lp8131
(dp8132
g7
I99
sg27
VC0242606
p8133
sg10
I16
sg11
Voxidative stress
p8134
sg13
I2
sa(dp8135
g7
I184
sg27
VC0022116
p8136
sg10
I9
sg11
Vischaemia
p8137
sg13
I1
sa(dp8138
g7
I87
sg27
VC0242184
p8139
sg10
I7
sg11
Vhypoxic
p8140
sg13
I1
sa(dp8141
g7
I169
sg27
VC0038454
p8142
sg10
I6
sg11
Vstroke
p8143
sg13
I1
sa(dp8144
g7
I207
sg27
VC0027819
p8145
sg10
I13
sg11
Vneuroblastoma
p8146
sg13
I1
sasa(dp8147
g2
S'In the present study, we report on the role of GSK-3Beta signaling on Nogo-66-treated mouse neuroblastoma N2a cells.\n'
p8148
sg4
(lp8149
(dp8150
g7
I47
sg8
VP49841
p8151
sg10
I9
sg11
VGSK-3Beta
p8152
sg13
I1
sasg24
(lp8153
(dp8154
g7
I86
sg27
VC1524043
p8155
sg10
I19
sg11
Vmouse neuroblastoma
p8156
sg13
I2
sasa(dp8157
g2
S'Brain-derived neurotrophic factor stimulates the phosphorylation, suppressing Nogo-dependent inhibition of neurite outgrowth from neuroblastoma-derived neural cells.\n'
p8158
sg4
(lp8159
(dp8160
g7
I0
sg8
g9
sg10
I33
sg11
VBrain-derived neurotrophic factor
p8161
sg13
I3
sasg24
(lp8162
(dp8163
g7
I130
sg27
VC0027819
p8164
sg10
I13
sg11
Vneuroblastoma
p8165
sg13
I1
sasa(dp8166
g2
S'In our per-SNP analysis, eight myopia gene associations were replicated successfully: GJD2, RASGRF1, BICC1, KCNQ5, CD55, CYP26A1, LRRC4C, and B4GALNT2.Seven additional gene associations were replicated in our gene-based analyses: GRIA4, BMP2, QKI, BMP4, SFRP1, SH3GL2, and EHBP1L1.\n'
p8167
sg4
(lp8168
(dp8169
g7
I254
sg8
g9
sg10
I5
sg11
VSFRP1
p8170
sg13
I1
sa(dp8171
g7
I261
sg8
g9
sg10
I6
sg11
VSH3GL2
p8172
sg13
I1
sa(dp8173
g7
I130
sg8
g9
sg10
I6
sg11
VLRRC4C
p8174
sg13
I1
sa(dp8175
g7
I237
sg8
VP12643
p8176
sg10
I4
sg11
VBMP2
p8177
sg13
I1
sa(dp8178
g7
I86
sg8
g9
sg10
I4
sg11
VGJD2
p8179
sg13
I1
sa(dp8180
g7
I121
sg8
g9
sg10
I7
sg11
VCYP26A1
p8181
sg13
I1
sa(dp8182
g7
I273
sg8
g9
sg10
I7
sg11
VEHBP1L1
p8183
sg13
I1
sa(dp8184
g7
I108
sg8
g9
sg10
I5
sg11
VKCNQ5
p8185
sg13
I1
sa(dp8186
g7
I101
sg8
g9
sg10
I5
sg11
VBICC1
p8187
sg13
I1
sa(dp8188
g7
I115
sg8
VP08174
p8189
sg10
I4
sg11
VCD55
p8190
sg13
I1
sa(dp8191
g7
I230
sg8
VP48058
p8192
sg10
I5
sg11
VGRIA4
p8193
sg13
I1
sa(dp8194
g7
I248
sg8
VP12644
p8195
sg10
I4
sg11
VBMP4
p8196
sg13
I1
sa(dp8197
g7
I142
sg8
g9
sg10
I8
sg11
VB4GALNT2
p8198
sg13
I1
sa(dp8199
g7
I92
sg8
g9
sg10
I7
sg11
VRASGRF1
p8200
sg13
I1
sasg24
(lp8201
(dp8202
g7
I31
sg27
VC0027092
p8203
sg10
I6
sg11
Vmyopia
p8204
sg13
I1
sasa(dp8205
g2
S'The aims of the present study were to immunohistochemically examine S100A10 expression in surgically resected lung adenocarcinomas, and evaluate any relationships with clinicopathological parameters and prognosis of patients.\n'
p8206
sg4
(lp8207
(dp8208
g7
I68
sg8
VP60903
p8209
sg10
I7
sg11
VS100A10
p8210
sg13
I1
sasg24
(lp8211
(dp8212
g7
I115
sg27
VC0001418
p8213
sg10
I15
sg11
Vadenocarcinomas
p8214
sg13
I1
sasa(dp8215
g2
S'S100A10 expression was immunohistochemically studied in 202 consecutive resected lung adenocarcinomas, and its associations with clinicopathological parameters were evaluated.\n'
p8216
sg4
(lp8217
(dp8218
g7
I0
sg8
VP60903
p8219
sg10
I7
sg11
VS100A10
p8220
sg13
I1
sasg24
(lp8221
(dp8222
g7
I86
sg27
VC0001418
p8223
sg10
I15
sg11
Vadenocarcinomas
p8224
sg13
I1
sasa(dp8225
g2
S'S100A10 expression was detected in 65 of the 202 (32.2%) lung adenocarcinomas, being significantly correlated with poorer differentiation (P =0.015), a higher pathological TNM stage (stages II and III) (P=0.004), more frequent and severe intratumoral vascular invasion (P=0.001), and a poorer prognosis (P=0.030).\n'
p8226
sg4
(lp8227
(dp8228
g7
I0
sg8
VP60903
p8229
sg10
I7
sg11
VS100A10
p8230
sg13
I1
sasg24
(lp8231
(dp8232
g7
I62
sg27
VC0001418
p8233
sg10
I15
sg11
Vadenocarcinomas
p8234
sg13
I1
sa(dp8235
g7
I260
sg27
VC2699153
p8236
sg10
I8
sg11
Vinvasion
p8237
sg13
I1
sasa(dp8238
g2
S'The present study reveals that S100A10 is expressed in a subset of lung adenocarcinomas, and this is related to some clinicopathological parameters, although further studies are required to confirm the correlation between S100A10 expression and prognosis of lung adenocarcinoma patients.\n'
p8239
sg4
(lp8240
(dp8241
g7
I31
sg8
VP60903
p8242
sg10
I7
sg11
VS100A10
p8243
sg13
I1
sa(dp8244
g7
I31
sg8
VP60903
p8245
sg10
I7
sg11
VS100A10
p8246
sg13
I1
sasg24
(lp8247
(dp8248
g7
I72
sg27
VC0001418
p8249
sg10
I15
sg11
Vadenocarcinomas
p8250
sg13
I1
sa(dp8251
g7
I67
sg27
VC0152013
p8252
sg10
I19
sg11
Vlung adenocarcinoma
p8253
sg13
I2
sasa(dp8254
g2
S"Using mass spectrometry for protein identification and validating the results by immunohistochemistry on an independent validation set, we could identify two of 60 differentially expressed m/z species between Barrett's adenocarcinoma and the precursor lesion: COX7A2 and S100-A10.\n"
p8255
sg4
(lp8256
(dp8257
g7
I260
sg8
VP14406
p8258
sg10
I6
sg11
VCOX7A2
p8259
sg13
I1
sa(dp8260
g7
I271
sg8
VP04271
p8261
sg10
I4
sg11
VS100
p8262
sg13
I1
sasg24
(lp8263
(dp8264
g7
I209
sg27
VC1332460
p8265
sg10
I24
sg11
VBarrett's adenocarcinoma
p8266
sg13
I2
sasa(dp8267
g2
S"In the validation set, we found a correlation of the expression levels of COX7A2 and TAGLN2 with a poor prognosis while S100-A10 was confirmed by multivariate analysis as a novel independent prognostic factor in Barrett's adenocarcinoma.\n"
p8268
sg4
(lp8269
(dp8270
g7
I74
sg8
VP14406
p8271
sg10
I6
sg11
VCOX7A2
p8272
sg13
I1
sa(dp8273
g7
I85
sg8
VP37802
p8274
sg10
I6
sg11
VTAGLN2
p8275
sg13
I1
sasg24
(lp8276
(dp8277
g7
I212
sg27
VC1332460
p8278
sg10
I24
sg11
VBarrett's adenocarcinoma
p8279
sg13
I2
sasa(dp8280
g2
S'S100A10, a member of the S100 family, forms a heterotetramer with annexin IIH and promotes carcinoma invasion and metastasis by plasminogen activation.\n'
p8281
sg4
(lp8282
(dp8283
g7
I25
sg8
VP04271
p8284
sg10
I11
sg11
VS100 family
p8285
sg13
I2
sa(dp8286
g7
I0
sg8
VP60903
p8287
sg10
I7
sg11
VS100A10
p8288
sg13
I1
sa(dp8289
g7
I128
sg8
VP00747
p8290
sg10
I11
sg11
Vplasminogen
p8291
sg13
I1
sasg24
(lp8292
(dp8293
g7
I101
sg27
VC2699153
p8294
sg10
I8
sg11
Vinvasion
p8295
sg13
I1
sa(dp8296
g7
I114
sg27
VC0027627
p8297
sg10
I10
sg11
Vmetastasis
p8298
sg13
I1
sa(dp8299
g7
I91
sg27
VC0007097
p8300
sg10
I9
sg11
Vcarcinoma
p8301
sg13
I1
sasa(dp8302
g2
S'Cells stained positively in 14.6% and 20.8% of follicular carcinomas for S100A10 and annexin II, respectively, but their expression levels were always low.\n'
p8303
sg4
(lp8304
(dp8305
g7
I85
sg8
VP07355
p8306
sg10
I10
sg11
Vannexin II
p8307
sg13
I2
sa(dp8308
g7
I73
sg8
VP60903
p8309
sg10
I7
sg11
VS100A10
p8310
sg13
I1
sasg24
(lp8311
(dp8312
g7
I58
sg27
VC0007097
p8313
sg10
I10
sg11
Vcarcinomas
p8314
sg13
I1
sasa(dp8315
g2
S'S100A10 and annexin II were expressed in all papillary carcinomas, but 88.2% and 82.8% ofpapillary carcinomas were classified in the low group.\n'
p8316
sg4
(lp8317
(dp8318
g7
I12
sg8
VP07355
p8319
sg10
I10
sg11
Vannexin II
p8320
sg13
I2
sa(dp8321
g7
I0
sg8
VP60903
p8322
sg10
I7
sg11
VS100A10
p8323
sg13
I1
sasg24
(lp8324
(dp8325
g7
I45
sg27
VC0007133
p8326
sg10
I20
sg11
Vpapillary carcinomas
p8327
sg13
I2
sa(dp8328
g7
I55
sg27
VC0007097
p8329
sg10
I10
sg11
Vcarcinomas
p8330
sg13
I1
sasa(dp8331
g2
S'These findings suggest that S100A10 and annexin II contribute to the aggressive characteristics of anaplastic carcinoma, while playing a constitutive role in papillary carcinoma.\n'
p8332
sg4
(lp8333
(dp8334
g7
I40
sg8
VP07355
p8335
sg10
I10
sg11
Vannexin II
p8336
sg13
I2
sa(dp8337
g7
I28
sg8
VP60903
p8338
sg10
I7
sg11
VS100A10
p8339
sg13
I1
sasg24
(lp8340
(dp8341
g7
I69
sg27
VC0001807
p8342
sg10
I10
sg11
Vaggressive
p8343
sg13
I1
sa(dp8344
g7
I99
sg27
VC0205698
p8345
sg10
I20
sg11
Vanaplastic carcinoma
p8346
sg13
I2
sa(dp8347
g7
I158
sg27
VC0007133
p8348
sg10
I19
sg11
Vpapillary carcinoma
p8349
sg13
I2
sasa(dp8350
g2
S"The spin-labeled derivative of podophyllotoxin, N'-podophyllic acid-N-[3-(2,2,5,5-tetramethyl pyrrolinenyloxy)] semicarbazide (GP-11), was synthesized and tested for its antitumor activity against mouse transplantable tumors, Sarcoma-180, Hepatoma-A, P388 leukemia and Ehrlich ascites carcinoma.\n"
p8351
sg4
(lp8352
sg24
(lp8353
(dp8354
g7
I239
sg27
VC0023903
p8355
sg10
I8
sg11
VHepatoma
p8356
sg13
I1
sa(dp8357
g7
I285
sg27
VC0007097
p8358
sg10
I9
sg11
Vcarcinoma
p8359
sg13
I1
sa(dp8360
g7
I226
sg27
VC1261473
p8361
sg10
I7
sg11
VSarcoma
p8362
sg13
I1
sa(dp8363
g7
I256
sg27
VC0023418
p8364
sg10
I8
sg11
Vleukemia
p8365
sg13
I1
sa(dp8366
g7
I218
sg27
VC0027651
p8367
sg10
I6
sg11
Vtumors
p8368
sg13
I1
sasa(dp8369
g2
S'Remote parenchymal hemorrhage (rPH) after intravenous thrombolysis with recombinant tissue-type plasminogen activator may be associated with cerebral amyloid angiopathy, although supportive data are limited.\n'
p8370
sg4
(lp8371
(dp8372
g7
I84
sg8
VP00747
p8373
sg10
I33
sg11
Vtissue-type plasminogen activator
p8374
sg13
I3
sasg24
(lp8375
(dp8376
g7
I141
sg27
VC0085220
p8377
sg10
I27
sg11
Vcerebral amyloid angiopathy
p8378
sg13
I3
sa(dp8379
g7
I7
sg27
VC0747264
p8380
sg10
I22
sg11
Vparenchymal hemorrhage
p8381
sg13
I2
sasa(dp8382
g2
S"We here review the data with respect to the activation of tPA by fibrin and its multiple other cofactors, in relation to tPA's role in pathophysiology, notably fibrinolysis and amyloidosis, with emphasis on Alzheimer's disease.\n"
p8383
sg4
(lp8384
(dp8385
g7
I65
sg8
VP22087
p8386
sg10
I6
sg11
Vfibrin
p8387
sg13
I1
sasg24
(lp8388
(dp8389
g7
I177
sg27
VC0002726
p8390
sg10
I11
sg11
Vamyloidosis
p8391
sg13
I1
sa(dp8392
g7
I207
sg27
VC1521724
p8393
sg10
I19
sg11
VAlzheimer's disease
p8394
sg13
I2
sasa(dp8395
g2
S'Cerebral amyloid angiopathy (CAA) may be an important predisposing factor for the hemorrhagic complications of recombinant tissue-type plasminogen activator (rt-PA) therapy.\n'
p8396
sg4
(lp8397
(dp8398
g7
I158
sg8
VP00747
p8399
sg10
I5
sg11
Vrt-PA
p8400
sg13
I1
sa(dp8401
g7
I111
sg8
VP00747
p8402
sg10
I45
sg11
Vrecombinant tissue-type plasminogen activator
p8403
sg13
I4
sasg24
(lp8404
(dp8405
g7
I29
sg27
VC1842937
p8406
sg10
I3
sg11
VCAA
p8407
sg13
I1
sa(dp8408
g7
I0
sg27
VC0085220
p8409
sg10
I27
sg11
VCerebral amyloid angiopathy
p8410
sg13
I3
sasa(dp8411
g2
S'The purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice.\n'
p8412
sg4
(lp8413
(dp8414
g7
I180
sg8
VP36222
p8415
sg10
I14
sg11
Vglycoprotein B
p8416
sg13
I2
sa(dp8417
g7
I196
sg8
g9
sg10
I3
sg11
VgBs
p8418
sg13
I1
sasg24
(lp8419
(dp8420
g7
I196
sg27
VC1841700
p8421
sg10
I3
sg11
VgBs
p8422
sg13
I1
sa(dp8423
g7
I112
sg27
VC0333262
p8424
sg10
I8
sg11
Vvesicles
p8425
sg13
I1
sa(dp8426
g7
I330
sg27
VC0019372
p8427
sg10
I16
sg11
Vherpes infection
p8428
sg13
I2
sa(dp8429
g7
I204
sg27
VC0019348
p8430
sg10
I14
sg11
Vherpes simplex
p8431
sg13
I2
sasa(dp8432
g2
S'Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.\n'
p8433
sg4
(lp8434
(dp8435
g7
I57
sg8
VP35398
p8436
sg10
I36
sg11
VT-cell-specific transcription factor
p8437
sg13
I3
sa(dp8438
g7
I276
sg8
VP11473
p8439
sg10
I18
sg11
Vvitamin D receptor
p8440
sg13
I3
sa(dp8441
g7
I109
sg8
VP00519
p8442
sg10
I39
sg11
V"proto-oncogene tyrosine-protein kinase
p8443
sg13
I3
sa(dp8444
g7
I399
sg8
g9
sg10
I31
sg11
VPR domain zinc finger protein 1
p8445
sg13
I6
sa(dp8446
g7
I322
sg8
VP29323
p8447
sg10
I3
sg11
VERK
p8448
sg13
I1
sa(dp8449
g7
I362
sg8
VP20823
p8450
sg10
I35
sg11
Vrunt-related transcription factor 1
p8451
sg13
I4
sa(dp8452
g7
I477
sg8
VP01584
p8453
sg10
I13
sg11
Vinterleukin 1
p8454
sg13
I2
sa(dp8455
g7
I152
sg8
VP12931
p8456
sg10
I8
sg11
Vsarcoma"
p8457
sg13
I1
sa(dp8458
g7
I163
sg8
VP10914
p8459
sg10
I30
sg11
Vinterferon regulatory factor 1
p8460
sg13
I4
sa(dp8461
g7
I227
sg8
VP49336
p8462
sg10
I31
sg11
Vcyclin-dependent kinase (CDK) 4
p8463
sg13
I4
sa(dp8464
g7
I296
sg8
VP56524
p8465
sg10
I19
sg11
Vhistone deacetylase
p8466
sg13
I2
sa(dp8467
g7
I95
sg8
VP12931
p8468
sg10
I3
sg11
VSrc
p8469
sg13
I1
sa(dp8470
g7
I217
sg8
VP14635
p8471
sg10
I8
sg11
Vcyclin B
p8472
sg13
I2
sa(dp8473
g7
I334
sg8
VP10415
p8474
sg10
I26
sg11
Vbcl-2-associated X protein
p8475
sg13
I3
sa(dp8476
g7
I317
sg8
VP53779
p8477
sg10
I4
sg11
VMAPK
p8478
sg13
I1
sa(dp8479
g7
I432
sg8
VP09619
p8480
sg10
I39
sg11
Vplatelet-derived growth factor receptor
p8481
sg13
I4
sa(dp8482
g7
I265
sg8
VP29466
p8483
sg10
I9
sg11
Vcaspase-1
p8484
sg13
I1
sa(dp8485
g7
I195
sg8
VP04818
p8486
sg10
I20
sg11
Vthymidylate synthase
p8487
sg13
I2
sa(dp8488
g7
I252
sg8
VP24941
p8489
sg10
I3
sg11
VCDK
p8490
sg13
I1
sasg24
(lp8491
(dp8492
g7
I152
sg27
VC1261473
p8493
sg10
I7
sg11
Vsarcoma
p8494
sg13
I1
sa(dp8495
g7
I362
sg27
VC0013336
p8496
sg10
I4
sg11
Vrunt
p8497
sg13
I1
sasa(dp8498
g2
S'The IRF-1 priming of TEXs enhances antitumour immune response.British Journal of Cancer advance online publication, 7 November 2017; doi:10.1038/bjc.2017.389 www.bjcancer.com.\n'
p8499
sg4
(lp8500
(dp8501
g7
I4
sg8
VP10914
p8502
sg10
I5
sg11
VIRF-1
p8503
sg13
I1
sasg24
(lp8504
(dp8505
g7
I81
sg27
VC0006826
p8506
sg10
I6
sg11
VCancer
p8507
sg13
I1
sasa(dp8508
g2
S'Interferon regulatory factor 1 (IRF1) has been suggested to act as a tumor suppressor in human cancers.\n'
p8509
sg4
(lp8510
(dp8511
g7
I0
sg8
VP10914
p8512
sg10
I30
sg11
VInterferon regulatory factor 1
p8513
sg13
I4
sa(dp8514
g7
I32
sg8
VP10914
p8515
sg10
I4
sg11
VIRF1
p8516
sg13
I1
sasg24
(lp8517
(dp8518
g7
I69
sg27
VC0027651
p8519
sg10
I5
sg11
Vtumor
p8520
sg13
I1
sa(dp8521
g7
I95
sg27
VC0006826
p8522
sg10
I7
sg11
Vcancers
p8523
sg13
I1
sasa(dp8524
g2
S'However, the clinical significance and biological function of IRF1 in cholangiocarcinoma is poorly understood.\n'
p8525
sg4
(lp8526
(dp8527
g7
I62
sg8
VP10914
p8528
sg10
I4
sg11
VIRF1
p8529
sg13
I1
sasg24
(lp8530
(dp8531
g7
I70
sg27
VC0206698
p8532
sg10
I18
sg11
Vcholangiocarcinoma
p8533
sg13
I1
sasa(dp8534
g2
S'In our results, IRF1 mRNA and protein expressions were decreased in cholangiocarcinoma tissues and cell lines compared with paired normal hepatic tissues and intrahepatic bile duct epithelial cell line.\n'
p8535
sg4
(lp8536
(dp8537
g7
I16
sg8
VP10914
p8538
sg10
I9
sg11
VIRF1 mRNA
p8539
sg13
I2
sasg24
(lp8540
(dp8541
g7
I68
sg27
VC0206698
p8542
sg10
I18
sg11
Vcholangiocarcinoma
p8543
sg13
I1
sasa(dp8544
g2
S'IRF1 protein low-expression was associated with tumor stage, tumor size, vascular invasion and metastasis and served as a poor independent prognostic parameter in cholangiocarcinoma patients.\n'
p8545
sg4
(lp8546
(dp8547
g7
I0
sg8
VP10914
p8548
sg10
I4
sg11
VIRF1
p8549
sg13
I1
sasg24
(lp8550
(dp8551
g7
I95
sg27
VC0027627
p8552
sg10
I10
sg11
Vmetastasis
p8553
sg13
I1
sa(dp8554
g7
I163
sg27
VC0206698
p8555
sg10
I18
sg11
Vcholangiocarcinoma
p8556
sg13
I1
sa(dp8557
g7
I48
sg27
VC0027651
p8558
sg10
I5
sg11
Vtumor
p8559
sg13
I1
sa(dp8560
g7
I82
sg27
VC2699153
p8561
sg10
I8
sg11
Vinvasion
p8562
sg13
I1
sa(dp8563
g7
I48
sg27
VC0027651
p8564
sg10
I5
sg11
Vtumor
p8565
sg13
I1
sasa(dp8566
g2
S'Up-regulation of IRF1 expression suppressed cholangiocarcinoma cells proliferation, migration and invasion, and blocked cell cycle progression, but has no effect on apoptosis.\n'
p8567
sg4
(lp8568
(dp8569
g7
I17
sg8
VP10914
p8570
sg10
I4
sg11
VIRF1
p8571
sg13
I1
sasg24
(lp8572
(dp8573
g7
I44
sg27
VC0206698
p8574
sg10
I18
sg11
Vcholangiocarcinoma
p8575
sg13
I1
sa(dp8576
g7
I69
sg27
VC0334094
p8577
sg10
I13
sg11
Vproliferation
p8578
sg13
I1
sa(dp8579
g7
I98
sg27
VC2699153
p8580
sg10
I8
sg11
Vinvasion
p8581
sg13
I1
sasa(dp8582
g2
S'In conclusion, IRF1 is low-expressed in cholangiocarcinoma tissues and cell lines, and correlated with malignant status and prognosis in cholangiocarcinoma patients.\n'
p8583
sg4
(lp8584
(dp8585
g7
I15
sg8
VP10914
p8586
sg10
I4
sg11
VIRF1
p8587
sg13
I1
sasg24
(lp8588
(dp8589
g7
I40
sg27
VC0206698
p8590
sg10
I18
sg11
Vcholangiocarcinoma
p8591
sg13
I1
sa(dp8592
g7
I40
sg27
VC0206698
p8593
sg10
I18
sg11
Vcholangiocarcinoma
p8594
sg13
I1
sasa(dp8595
g2
S'IRF1 served as tumor suppressor in the regulation of cholangiocarcinoma cells proliferation, cell cycle, migration and invasion.\n'
p8596
sg4
(lp8597
(dp8598
g7
I0
sg8
VP10914
p8599
sg10
I4
sg11
VIRF1
p8600
sg13
I1
sasg24
(lp8601
(dp8602
g7
I119
sg27
VC2699153
p8603
sg10
I8
sg11
Vinvasion
p8604
sg13
I1
sa(dp8605
g7
I15
sg27
VC0027651
p8606
sg10
I5
sg11
Vtumor
p8607
sg13
I1
sa(dp8608
g7
I53
sg27
VC0206698
p8609
sg10
I18
sg11
Vcholangiocarcinoma
p8610
sg13
I1
sa(dp8611
g7
I78
sg27
VC0334094
p8612
sg10
I13
sg11
Vproliferation
p8613
sg13
I1
sasa(dp8614
g2
S'To examine genetic defects of the IFNGamma-IRF1 pathway in non-small cell lung cancer (NSCLC), we analyzed The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LuAd) and lung squamous cell carcinoma (LuSc) data.\n'
p8615
sg4
(lp8616
(dp8617
g7
I43
sg8
VP10914
p8618
sg10
I4
sg11
VIRF1
p8619
sg13
I1
sasg24
(lp8620
(dp8621
g7
I111
sg27
VC0006826
p8622
sg10
I6
sg11
VCancer
p8623
sg13
I1
sa(dp8624
g7
I59
sg27
VC0007131
p8625
sg10
I26
sg11
Vnon-small cell lung cancer
p8626
sg13
I4
sa(dp8627
g7
I169
sg27
VC0149782
p8628
sg10
I28
sg11
Vlung squamous cell carcinoma
p8629
sg13
I4
sa(dp8630
g7
I199
sg27
VC0149782
p8631
sg10
I4
sg11
VLuSc
p8632
sg13
I1
sa(dp8633
g7
I138
sg27
VC0152013
p8634
sg10
I19
sg11
Vlung adenocarcinoma
p8635
sg13
I2
sa(dp8636
g7
I87
sg27
VC0007131
p8637
sg10
I5
sg11
VNSCLC
p8638
sg13
I1
sa(dp8639
g7
I159
sg27
VC0152013
p8640
sg10
I4
sg11
VLuAd
p8641
sg13
I1
sasa(dp8642
g2
S'IRF1 expression was correlated with immune cytolytic activity markers GZMA and PRF1 in NSCLC.\n'
p8643
sg4
(lp8644
(dp8645
g7
I79
sg8
VP14222
p8646
sg10
I4
sg11
VPRF1
p8647
sg13
I1
sa(dp8648
g7
I70
sg8
VP12544
p8649
sg10
I4
sg11
VGZMA
p8650
sg13
I1
sa(dp8651
g7
I0
sg8
VP10914
p8652
sg10
I4
sg11
VIRF1
p8653
sg13
I1
sasg24
(lp8654
(dp8655
g7
I87
sg27
VC0007131
p8656
sg10
I5
sg11
VNSCLC
p8657
sg13
I1
sasa(dp8658
g2
S'Deletion of JAK2 or inhibition of the JAK2 kinase activity resulted in loss of IFNGamma-induced IRF1 and cell surface HLA-ABC in JAK2 wildtype NSCLC cells, whereas expression of exogenous JAK2 in H1573 cells restored the IFNGamma responses.\n'
p8659
sg4
(lp8660
(dp8661
g7
I12
sg8
g9
sg10
I4
sg11
VJAK2
p8662
sg13
I1
sa(dp8663
g7
I96
sg8
VP10914
p8664
sg10
I4
sg11
VIRF1
p8665
sg13
I1
sa(dp8666
g7
I12
sg8
g9
sg10
I4
sg11
VJAK2
p8667
sg13
I1
sa(dp8668
g7
I118
sg8
VP30486
p8669
sg10
I7
sg11
VHLA-ABC
p8670
sg13
I1
sa(dp8671
g7
I12
sg8
g9
sg10
I4
sg11
VJAK2
p8672
sg13
I1
sa(dp8673
g7
I38
sg8
g9
sg10
I11
sg11
VJAK2 kinase
p8674
sg13
I2
sasg24
(lp8675
(dp8676
g7
I143
sg27
VC0007131
p8677
sg10
I5
sg11
VNSCLC
p8678
sg13
I1
sasa(dp8679
g2
S'These findings show that JAK2 deficiency is the major mechanism of genetic defects of the IFNGamma-IRF1 pathway in NSCLC and reveal a previously unrecognized significance of chromosome 9p deletion in NSCLC.\n'
p8680
sg4
(lp8681
(dp8682
g7
I25
sg8
g9
sg10
I4
sg11
VJAK2
p8683
sg13
I1
sa(dp8684
g7
I90
sg8
VP10914
p8685
sg10
I13
sg11
VIFNGamma-IRF1
p8686
sg13
I1
sasg24
(lp8687
(dp8688
g7
I115
sg27
VC0007131
p8689
sg10
I5
sg11
VNSCLC
p8690
sg13
I1
sa(dp8691
g7
I115
sg27
VC0007131
p8692
sg10
I5
sg11
VNSCLC
p8693
sg13
I1
sasa(dp8694
g2
S'The performance of the GeneXpert(R) Bladder Cancer Assay, an assay labeled for investigational use only to detect the 5 mRNAs ABL1, CRH, IGF2, ANXA10 and UPK1B, was evaluated in an independent test cohort of 450 participants.\n'
p8695
sg4
(lp8696
(dp8697
g7
I132
sg8
VP06850
p8698
sg10
I3
sg11
VCRH
p8699
sg13
I1
sa(dp8700
g7
I154
sg8
g9
sg10
I5
sg11
VUPK1B
p8701
sg13
I1
sa(dp8702
g7
I143
sg8
g9
sg10
I6
sg11
VANXA10
p8703
sg13
I1
sa(dp8704
g7
I118
sg8
VP00519
p8705
sg10
I12
sg11
V5 mRNAs ABL1
p8706
sg13
I3
sa(dp8707
g7
I137
sg8
VP01344
p8708
sg10
I4
sg11
VIGF2
p8709
sg13
I1
sasg24
(lp8710
(dp8711
g7
I36
sg27
VC0699885
p8712
sg10
I14
sg11
VBladder Cancer
p8713
sg13
I2
sasa(dp8714
g2
S'Our previous mass spectrometry-based proteomics study revealed that annexin A10 (ANXA10) was uniquely overexpressed in pancreatic CD24+ adenocarcinoma cells that were dissected from clinical PDAC tissues but was absent in CD24- adjacent normal cells.\n'
p8715
sg4
(lp8716
(dp8717
g7
I81
sg8
g9
sg10
I6
sg11
VANXA10
p8718
sg13
I1
sa(dp8719
g7
I68
sg8
g9
sg10
I11
sg11
Vannexin A10
p8720
sg13
I2
sa(dp8721
g7
I130
sg8
VP25063
p8722
sg10
I4
sg11
VCD24
p8723
sg13
I1
sasg24
(lp8724
(dp8725
g7
I136
sg27
VC0001418
p8726
sg10
I14
sg11
Vadenocarcinoma
p8727
sg13
I1
sasa(dp8728
g2
S'The correlation between ANXA10 expression and the progression of pancreatic cancer remains unknown.\n'
p8729
sg4
(lp8730
(dp8731
g7
I24
sg8
g9
sg10
I6
sg11
VANXA10
p8732
sg13
I1
sasg24
(lp8733
(dp8734
g7
I65
sg27
VC0235974
p8735
sg10
I17
sg11
Vpancreatic cancer
p8736
sg13
I2
sasa(dp8737
g2
S'In this study, we performed an immunostaining assay to evaluate ANXA10 expression in 155 primary human tissue specimens, including normal pancreas, chronic pancreatitis (CP), pancreatic adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN, the most important precursor of PDAC), and intraductal papillary mucinous neoplasm (IPMN).\n'
p8738
sg4
(lp8739
(dp8740
g7
I64
sg8
g9
sg10
I6
sg11
VANXA10
p8741
sg13
I1
sasg24
(lp8742
(dp8743
g7
I209
sg27
VC1301034
p8744
sg10
I36
sg11
Vpancreatic intraepithelial neoplasia
p8745
sg13
I3
sa(dp8746
g7
I297
sg27
VC3160815
p8747
sg10
I39
sg11
Vintraductal papillary mucinous neoplasm
p8748
sg13
I4
sa(dp8749
g7
I175
sg27
VC0281361
p8750
sg10
I25
sg11
Vpancreatic adenocarcinoma
p8751
sg13
I2
sa(dp8752
g7
I148
sg27
VC0149521
p8753
sg10
I20
sg11
Vchronic pancreatitis
p8754
sg13
I2
sa(dp8755
g7
I202
sg27
VC0281361
p8756
sg10
I4
sg11
VPDAC
p8757
sg13
I1
sa(dp8758
g7
I202
sg27
VC0281361
p8759
sg10
I4
sg11
VPDAC
p8760
sg13
I1
sa(dp8761
g7
I170
sg27
VC0149521
p8762
sg10
I2
sg11
VCP
p8763
sg13
I1
sa(dp8764
g7
I247
sg27
VC1301034
p8765
sg10
I5
sg11
VPanIN
p8766
sg13
I1
sa(dp8767
g7
I338
sg27
VC3160815
p8768
sg10
I4
sg11
VIPMN
p8769
sg13
I1
sasa(dp8770
g2
S'Since PDAC develops through a series of PanINs which in turn arise from pancreatic ducts, the consistent overexpression of ANXA10 in ductal epithelial cells in PanINs and PDACs but negative in normal pancreatic ducts suggests that ANXA10 could serve as a potential marker indicating the presence of PDAC at its earliest precancerous stages.\n'
p8771
sg4
(lp8772
(dp8773
g7
I123
sg8
g9
sg10
I6
sg11
VANXA10
p8774
sg13
I1
sa(dp8775
g7
I123
sg8
g9
sg10
I6
sg11
VANXA10
p8776
sg13
I1
sasg24
(lp8777
sa(dp8778
g2
S'In this study, we evaluated the effects of simvastatin on ANXA10 signaling in androgen-independent prostate cancer cells.\n'
p8779
sg4
(lp8780
(dp8781
g7
I58
sg8
g9
sg10
I6
sg11
VANXA10
p8782
sg13
I1
sa(dp8783
g7
I43
sg8
g9
sg10
I11
sg11
Vsimvastatin
p8784
sg13
I1
sasg24
(lp8785
(dp8786
g7
I99
sg27
VC0600139
p8787
sg10
I15
sg11
Vprostate cancer
p8788
sg13
I2
sasa(dp8789
g2
S'In human prostate biopsy samples, ANXA10 mRNA expression was significantly lower in the prostate cancer group than in the BPH group.\n'
p8790
sg4
(lp8791
(dp8792
g7
I34
sg8
g9
sg10
I11
sg11
VANXA10 mRNA
p8793
sg13
I2
sasg24
(lp8794
(dp8795
g7
I122
sg27
VC0005001
p8796
sg10
I3
sg11
VBPH
p8797
sg13
I1
sa(dp8798
g7
I88
sg27
VC0600139
p8799
sg10
I15
sg11
Vprostate cancer
p8800
sg13
I2
sasa(dp8801
g2
S'Next, we found that up-regulation of ANXA10 in PC-3 resulted in down-regulation of S100 calcium binding protein A4 (S100A4), which is reportedly correlated with aggressiveness and a worse prognosis for patients with different types of carcinomas.\n'
p8802
sg4
(lp8803
(dp8804
g7
I116
sg8
VP26447
p8805
sg10
I6
sg11
VS100A4
p8806
sg13
I1
sa(dp8807
g7
I83
sg8
VP26447
p8808
sg10
I31
sg11
VS100 calcium binding protein A4
p8809
sg13
I5
sa(dp8810
g7
I47
sg8
g9
sg10
I4
sg11
VPC-3
p8811
sg13
I1
sa(dp8812
g7
I37
sg8
g9
sg10
I6
sg11
VANXA10
p8813
sg13
I1
sasg24
(lp8814
(dp8815
g7
I235
sg27
VC0007097
p8816
sg10
I10
sg11
Vcarcinomas
p8817
sg13
I1
sa(dp8818
g7
I161
sg27
VC0001807
p8819
sg10
I14
sg11
Vaggressiveness
p8820
sg13
I1
sasa(dp8821
g2
S'Our results suggest that statins inhibit the proliferation, migration, and invasion of androgen-independent prostate cancer cells by up-regulation of ANXA10.\n'
p8822
sg4
(lp8823
(dp8824
g7
I150
sg8
g9
sg10
I6
sg11
VANXA10
p8825
sg13
I1
sasg24
(lp8826
(dp8827
g7
I75
sg27
VC2699153
p8828
sg10
I8
sg11
Vinvasion
p8829
sg13
I1
sa(dp8830
g7
I108
sg27
VC0600139
p8831
sg10
I15
sg11
Vprostate cancer
p8832
sg13
I2
sa(dp8833
g7
I45
sg27
VC0334094
p8834
sg10
I13
sg11
Vproliferation
p8835
sg13
I1
sasa(dp8836
g2
S'Immunohistochemistry for 7 gastric-type markers (ANXA10, VSIG1, CLDN18, CTSE, TFF2, MUC5AC, and MUC6) and 2 intestinal-type markers (CDX2 and CK20) was performed in 36 normal gastric/colorectal mucosa tissues, 163 colorectal polyps, and 175 microsatellite-unstable colorectal carcinomas (MSI-H CRCs).\n'
p8837
sg4
(lp8838
(dp8839
g7
I133
sg8
g9
sg10
I4
sg11
VCDX2
p8840
sg13
I1
sa(dp8841
g7
I57
sg8
g9
sg10
I5
sg11
VVSIG1
p8842
sg13
I1
sa(dp8843
g7
I64
sg8
VP56856
p8844
sg10
I6
sg11
VCLDN18
p8845
sg13
I1
sa(dp8846
g7
I142
sg8
VP35900
p8847
sg10
I4
sg11
VCK20
p8848
sg13
I1
sa(dp8849
g7
I78
sg8
g9
sg10
I4
sg11
VTFF2
p8850
sg13
I1
sa(dp8851
g7
I72
sg8
VP14091
p8852
sg10
I4
sg11
VCTSE
p8853
sg13
I1
sa(dp8854
g7
I96
sg8
g9
sg10
I4
sg11
VMUC6
p8855
sg13
I1
sa(dp8856
g7
I49
sg8
g9
sg10
I6
sg11
VANXA10
p8857
sg13
I1
sasg24
(lp8858
(dp8859
g7
I265
sg27
VC0009402
p8860
sg10
I21
sg11
Vcolorectal carcinomas
p8861
sg13
I2
sa(dp8862
g7
I214
sg27
VC0949059
p8863
sg10
I17
sg11
Vcolorectal polyps
p8864
sg13
I2
sa(dp8865
g7
I288
sg27
VC0920269
p8866
sg10
I3
sg11
VMSI
p8867
sg13
I1
sasa(dp8868
g2
S'Two decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue.\n'
p8869
sg4
(lp8870
(dp8871
g7
I17
sg8
VP09382
p8872
sg10
I10
sg11
VGalectin-8
p8873
sg13
I1
sasg24
(lp8874
(dp8875
g7
I47
sg27
VC0600139
p8876
sg10
I18
sg11
Vprostate carcinoma
p8877
sg13
I2
sasa(dp8878
g2
S'In this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages.\n'
p8879
sg4
(lp8880
(dp8881
g7
I26
sg8
VP09382
p8882
sg10
I10
sg11
VGalectin-8
p8883
sg13
I1
sa(dp8884
g7
I78
sg8
VP42025
p8885
sg10
I3
sg11
VPC3
p8886
sg13
I1
sa(dp8887
g7
I86
sg8
g9
sg10
I8
sg11
VIGR-CaP1
p8888
sg13
I1
sasg24
(lp8889
(dp8890
g7
I170
sg27
VC0677042
p8891
sg10
I9
sg11
Vpathology
p8892
sg13
I1
sa(dp8893
g7
I50
sg27
VC0600139
p8894
sg10
I15
sg11
Vprostate cancer
p8895
sg13
I2
sasa(dp8896
g2
S'We show for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer.\n'
p8897
sg4
(lp8898
(dp8899
g7
I72
sg8
VP16278
p8900
sg10
I5
sg11
VGal-8
p8901
sg13
I1
sasg24
(lp8902
(dp8903
g7
I81
sg27
VC0027651
p8904
sg10
I6
sg11
Vtumour
p8905
sg13
I1
sa(dp8906
g7
I141
sg27
VC0600139
p8907
sg10
I15
sg11
Vprostate cancer
p8908
sg13
I2
sasa(dp8909
g2
S'Collectively, our results highlight Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer.\n'
p8910
sg4
(lp8911
(dp8912
g7
I36
sg8
VP09382
p8913
sg10
I10
sg11
VGalectin-8
p8914
sg13
I1
sasg24
(lp8915
(dp8916
g7
I105
sg27
VC0600139
p8917
sg10
I15
sg11
Vprostate cancer
p8918
sg13
I2
sasa(dp8919
g2
S'Immunocytochemistry for prostate carcinoma tumour antigen (PCTA-1) was performed for culture purity evaluation.\n'
p8920
sg4
(lp8921
(dp8922
g7
I24
sg8
VP49221
p8923
sg10
I33
sg11
Vprostate carcinoma tumour antigen
p8924
sg13
I4
sasg24
(lp8925
(dp8926
g7
I24
sg27
VC0600139
p8927
sg10
I18
sg11
Vprostate carcinoma
p8928
sg13
I2
sa(dp8929
g7
I43
sg27
VC0027651
p8930
sg10
I6
sg11
Vtumour
p8931
sg13
I1
sasa(dp8932
g2
S'Galectin-8 levels of expression positively correlate with certain human neoplasms, prostate cancer being the best example studied thus far.\n'
p8933
sg4
(lp8934
(dp8935
g7
I0
sg8
VP09382
p8936
sg10
I10
sg11
VGalectin-8
p8937
sg13
I1
sasg24
(lp8938
(dp8939
g7
I72
sg27
VC0033578
p8940
sg10
I19
sg11
Vneoplasms, prostate
p8941
sg13
I2
sa(dp8942
g7
I92
sg27
VC0006826
p8943
sg10
I6
sg11
Vcancer
p8944
sg13
I1
sasa(dp8945
g2
S'The Prostate Carcinoma Tumor Antigen-1 (PCTA-1) is located at the prostate cancer susceptibility locus on chromosome 1q42.2-43 (PCaP).\n'
p8946
sg4
(lp8947
(dp8948
g7
I13
sg8
VP14209
p8949
sg10
I25
sg11
VCarcinoma Tumor Antigen-1
p8950
sg13
I3
sa(dp8951
g7
I66
sg8
g9
sg10
I30
sg11
Vprostate cancer susceptibility
p8952
sg13
I3
sasg24
(lp8953
(dp8954
g7
I66
sg27
VC1864472
p8955
sg10
I60
sg11
Vprostate cancer susceptibility locus on chromosome 1q42.2-43
p8956
sg13
I7
sa(dp8957
g7
I23
sg27
VC0027651
p8958
sg10
I5
sg11
VTumor
p8959
sg13
I1
sa(dp8960
g7
I4
sg27
VC0600139
p8961
sg10
I18
sg11
VProstate Carcinoma
p8962
sg13
I2
sa(dp8963
g7
I128
sg27
VC1864472
p8964
sg10
I4
sg11
VPCaP
p8965
sg13
I1
sasa(dp8966
g2
S'Seventy-seven familial prostate cancer cases from 36 German and French pedigrees were screened for germline mutations in the PCTA-1 gene using enzymatic mutation detection (EMD).\n'
p8967
sg4
(lp8968
sg24
(lp8969
(dp8970
g7
I143
sg27
VC0340861
p8971
sg10
I28
sg11
Venzymatic mutation detection
p8972
sg13
I3
sa(dp8973
g7
I173
sg27
VC0340861
p8974
sg10
I3
sg11
VEMD
p8975
sg13
I1
sa(dp8976
g7
I23
sg27
VC0600139
p8977
sg10
I15
sg11
Vprostate cancer
p8978
sg13
I2
sasa(dp8979
g2
S'PCTA-1 is not a classical high risk gene with deleterious mutations predisposing to hereditary prostate cancer.\n'
p8980
sg4
(lp8981
sg24
(lp8982
(dp8983
g7
I84
sg27
VC2931456
p8984
sg10
I26
sg11
Vhereditary prostate cancer
p8985
sg13
I3
sasa(dp8986
g2
S'The isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination with expression screening.\n'
p8987
sg4
(lp8988
(dp8989
g7
I26
sg8
VP14209
p8990
sg10
I25
sg11
VCarcinoma Tumor Antigen-1
p8991
sg13
I3
sa(dp8992
g7
I102
sg8
VP09382
p8993
sg10
I10
sg11
VGalectin-8
p8994
sg13
I1
sasg24
(lp8995
(dp8996
g7
I36
sg27
VC0027651
p8997
sg10
I5
sg11
VTumor
p8998
sg13
I1
sa(dp8999
g7
I150
sg27
VC0600139
p9000
sg10
I15
sg11
Vprostate cancer
p9001
sg13
I2
sa(dp9002
g7
I244
sg27
VC0432222
p9003
sg10
I23
sg11
VSurface Epitope Masking
p9004
sg13
I3
sa(dp9005
g7
I17
sg27
VC0600139
p9006
sg10
I18
sg11
VProstate Carcinoma
p9007
sg13
I2
sa(dp9008
g7
I269
sg27
VC0432222
p9009
sg10
I3
sg11
VSEM
p9010
sg13
I1
sasa(dp9011
g2
S'PCTA-1 maps to 1q42-43, a locus associated with predisposition to prostate cancer.\n'
p9012
sg4
(lp9013
sg24
(lp9014
(dp9015
g7
I66
sg27
VC0600139
p9016
sg10
I15
sg11
Vprostate cancer
p9017
sg13
I2
sasa(dp9018
g2
S'Screening a human LNCaP prostate cancer cDNA expression library with the Pro 1.5 mAb identifies a gene, prostate carcinoma tumor antigen-1 (PCTA-1).\n'
p9019
sg4
(lp9020
(dp9021
g7
I73
sg8
VP63125
p9022
sg10
I11
sg11
VPro 1.5 mAb
p9023
sg13
I3
sa(dp9024
g7
I104
sg8
VP49221
p9025
sg10
I34
sg11
Vprostate carcinoma tumor antigen-1
p9026
sg13
I4
sa(dp9027
g7
I140
sg8
VP49221
p9028
sg10
I6
sg11
VPCTA-1
p9029
sg13
I1
sasg24
(lp9030
(dp9031
g7
I24
sg27
VC0600139
p9032
sg10
I15
sg11
Vprostate cancer
p9033
sg13
I2
sa(dp9034
g7
I123
sg27
VC0027651
p9035
sg10
I5
sg11
Vtumor
p9036
sg13
I1
sa(dp9037
g7
I104
sg27
VC0600139
p9038
sg10
I18
sg11
Vprostate carcinoma
p9039
sg13
I2
sasa(dp9040
g2
S"Primer pairs within the 3' untranslated region of PCTA-1 and reverse transcription-PCR demonstrate selective expression of PCTA-1 by prostate carcinomas versus normal prostate and benign prostatic hypertrophy.\n"
p9041
sg4
(lp9042
sg24
(lp9043
(dp9044
g7
I142
sg27
VC0007097
p9045
sg10
I10
sg11
Vcarcinomas
p9046
sg13
I1
sa(dp9047
g7
I180
sg27
VC0005001
p9048
sg10
I28
sg11
Vbenign prostatic hypertrophy
p9049
sg13
I3
sasa(dp9050
g2
S'Moreover, Foxp3 could interact with LMO2 and affect the expression level of TAL1, which was in accordance with the findings in T-cell acute lymphoblastic leukemia.\n'
p9051
sg4
(lp9052
(dp9053
g7
I76
sg8
VP17542
p9054
sg10
I4
sg11
VTAL1
p9055
sg13
I1
sa(dp9056
g7
I36
sg8
VP25791
p9057
sg10
I4
sg11
VLMO2
p9058
sg13
I1
sa(dp9059
g7
I10
sg8
g9
sg10
I5
sg11
VFoxp3
p9060
sg13
I1
sasg24
(lp9061
(dp9062
g7
I127
sg27
VC1961099
p9063
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p9064
sg13
I4
sasa(dp9065
g2
S'Overexpression of LMO2 is known to be one of the causes of T-cell acute lymphoblastic leukemia (T-ALL) development; however, the mechanisms behind its oncogenic activity are incompletely understood.\n'
p9066
sg4
(lp9067
(dp9068
g7
I18
sg8
VP25791
p9069
sg10
I4
sg11
VLMO2
p9070
sg13
I1
sasg24
(lp9071
(dp9072
g7
I96
sg27
VC1961099
p9073
sg10
I5
sg11
VT-ALL
p9074
sg13
I1
sa(dp9075
g7
I59
sg27
VC1961099
p9076
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p9077
sg13
I4
sasa(dp9078
g2
S'Expression of LMO2 has been evaluated in B-cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia; however, information concerning its role in breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) negative B-cell acute lymphoblastic leukemia (B-ALL) remains limited.\n'
p9079
sg4
(lp9080
(dp9081
g7
I14
sg8
VP25791
p9082
sg10
I4
sg11
VLMO2
p9083
sg13
I1
sa(dp9084
g7
I246
sg8
VP55157
p9085
sg10
I3
sg11
VABL
p9086
sg13
I1
sa(dp9087
g7
I242
sg8
VP11274
p9088
sg10
I3
sg11
VBCR
p9089
sg13
I1
sa(dp9090
g7
I207
sg8
VP35125
p9091
sg10
I33
sg11
Vleukemia viral oncogene homolog 1
p9092
sg13
I5
sasg24
(lp9093
(dp9094
g7
I98
sg27
VC0023467
p9095
sg10
I22
sg11
Vacute myeloid leukemia
p9096
sg13
I3
sa(dp9097
g7
I85
sg27
VC0023418
p9098
sg10
I8
sg11
Vleukemia
p9099
sg13
I1
sa(dp9100
g7
I246
sg27
VC0000744
p9101
sg10
I3
sg11
VABL
p9102
sg13
I1
sa(dp9103
g7
I297
sg27
VC0006413
p9104
sg10
I5
sg11
VB-ALL
p9105
sg13
I1
sa(dp9106
g7
I260
sg27
VC1292769
p9107
sg10
I35
sg11
VB-cell acute lymphoblastic leukemia
p9108
sg13
I4
sa(dp9109
g7
I58
sg27
VC1961099
p9110
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p9111
sg13
I4
sasa(dp9112
g2
S'Oncogenic transcription factors are commonly activated in acute leukemias and subvert normal gene expression networks to reprogram hematopoietic progenitors into preleukemic stem cells, as exemplified by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL).\n'
p9113
sg4
(lp9114
(dp9115
g7
I216
sg8
VP25791
p9116
sg10
I4
sg11
VLMO2
p9117
sg13
I1
sa(dp9118
g7
I204
sg8
g9
sg10
I10
sg11
VLIM-only 2
p9119
sg13
I2
sasg24
(lp9120
(dp9121
g7
I58
sg27
VC0085669
p9122
sg10
I15
sg11
Vacute leukemias
p9123
sg13
I2
sa(dp9124
g7
I262
sg27
VC1961099
p9125
sg10
I5
sg11
VT-ALL
p9126
sg13
I1
sa(dp9127
g7
I225
sg27
VC1961099
p9128
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p9129
sg13
I4
sasa(dp9130
g2
S'T-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex.\n'
p9131
sg4
(lp9132
(dp9133
g7
I93
sg8
VP17542
p9134
sg10
I35
sg11
VT-cell acute lymphocytic leukemia 1
p9135
sg13
I5
sa(dp9136
g7
I134
sg8
VP25791
p9137
sg10
I4
sg11
VLMO2
p9138
sg13
I1
sa(dp9139
g7
I0
sg8
g9
sg10
I12
sg11
VT-cell acute
p9140
sg13
I2
sa(dp9141
g7
I87
sg8
VP17542
p9142
sg10
I4
sg11
VTAL1
p9143
sg13
I1
sa(dp9144
g7
I165
sg8
VP17542
p9145
sg10
I28
sg11
VTAL1 transcriptional complex
p9146
sg13
I3
sasg24
(lp9147
(dp9148
g7
I0
sg27
VC1961099
p9149
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p9150
sg13
I4
sa(dp9151
g7
I37
sg27
VC1961099
p9152
sg10
I5
sg11
VT-ALL
p9153
sg13
I1
sa(dp9154
g7
I93
sg27
VC1961099
p9155
sg10
I33
sg11
VT-cell acute lymphocytic leukemia
p9156
sg13
I4
sasa(dp9157
g2
S'Lmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL).\n'
p9158
sg4
(lp9159
(dp9160
g7
I160
sg8
g9
sg10
I3
sg11
VETP
p9161
sg13
I1
sa(dp9162
g7
I137
sg8
VP01275
p9163
sg10
I21
sg11
VT-cell precursor-like
p9164
sg13
I2
sa(dp9165
g7
I0
sg8
VP25791
p9166
sg10
I4
sg11
VLmo2
p9167
sg13
I1
sasg24
(lp9168
(dp9169
g7
I85
sg27
VC0085669
p9170
sg10
I15
sg11
Vacute leukemias
p9171
sg13
I2
sa(dp9172
g7
I196
sg27
VC1961102
p9173
sg10
I3
sg11
VALL
p9174
sg13
I1
sa(dp9175
g7
I166
sg27
VC1961102
p9176
sg10
I28
sg11
Vacute lymphoblastic leukemia
p9177
sg13
I3
sasa(dp9178
g2
S'Participants (N = 4,901) were from Look AHEAD, a randomized controlled trial that compared ILI to diabetes support and education (DSE).\n'
p9179
sg4
(lp9180
sg24
(lp9181
(dp9182
g7
I98
sg27
VC0011849
p9183
sg10
I8
sg11
Vdiabetes
p9184
sg13
I1
sasa(dp9185
g2
S'A multidomain intensive lifestyle intervention (ILI) to induce weight loss and increase physical activity for 8 to 11 years or diabetes support and education (DSE), a control condition.\n'
p9186
sg4
(lp9187
sg24
(lp9188
(dp9189
g7
I175
sg27
VC0012634
p9190
sg10
I9
sg11
Vcondition
p9191
sg13
I1
sa(dp9192
g7
I127
sg27
VC0011849
p9193
sg10
I8
sg11
Vdiabetes
p9194
sg13
I1
sasa(dp9195
g2
S'Overweight and obese (BMI &gt;=25 kg/m 2) middle-aged and older adults (aged 45-76 years at enrollment) with type 2 diabetes enrolled in Look AHEAD, a trial evaluating an intensive lifestyle intervention (ILI) designed to achieve weight loss through caloric restriction and increased physical activity compared to diabetes support and education (DSE), underwent standardized assessments of performance-based physical function including a 4- and 400-m walk, lower extremity physical performance (expanded Short Physical Performance Battery, SPPBexp), and grip strength approximately 11 years post-randomization and 1.5 years after the intervention was stopped (n=3,783).\n'
p9196
sg4
(lp9197
sg24
(lp9198
(dp9199
g7
I116
sg27
VC0011849
p9200
sg10
I8
sg11
Vdiabetes
p9201
sg13
I1
sa(dp9202
g7
I15
sg27
VC0028754
p9203
sg10
I5
sg11
Vobese
p9204
sg13
I1
sa(dp9205
g7
I0
sg27
VC0497406
p9206
sg10
I10
sg11
VOverweight
p9207
sg13
I1
sa(dp9208
g7
I109
sg27
VC0011860
p9209
sg10
I15
sg11
Vtype 2 diabetes
p9210
sg13
I3
sasa(dp9211
g2
S'To address the unique nature of prions, our group targets epitopes, termed disease specific epitopes (DSEs), whose exposure for antibody binding depends on disease-associated misfolding of PrPC into PrPSc.\n'
p9212
sg4
(lp9213
(dp9214
g7
I189
sg8
VP48637
p9215
sg10
I4
sg11
VPrPC
p9216
sg13
I1
sasg24
(lp9217
sa(dp9218
g2
S'During 5 years spanning the end of intervention and post-intervention follow-up, repeated cognitive assessments were obtained in 1,091 individuals who had been assigned to ILI or a control condition of diabetes support and education (DSE).\n'
p9219
sg4
(lp9220
sg24
(lp9221
(dp9222
g7
I189
sg27
VC0012634
p9223
sg10
I9
sg11
Vcondition
p9224
sg13
I1
sa(dp9225
g7
I202
sg27
VC0011849
p9226
sg10
I8
sg11
Vdiabetes
p9227
sg13
I1
sasa(dp9228
g2
S'A total of 5145 persons aged 45 to 76 years with DM were randomized to either an intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain &gt;=7% weight loss or to diabetes support and education intervention (DSE).\n'
p9229
sg4
(lp9230
sg24
(lp9231
(dp9232
g7
I244
sg27
VC0011849
p9233
sg10
I8
sg11
Vdiabetes
p9234
sg13
I1
sasa(dp9235
g2
S'The purpose of this study was to assess range of motion (ROM), pain, and incidence of radiographic degenerative joint disease (DJD) after volar radioscapholunate (RSL) arthrodesis and distal scaphoidectomy (DSE) following malunited distal radius fractures (DRF).\n'
p9236
sg4
(lp9237
sg24
(lp9238
(dp9239
g7
I127
sg27
VC0029408
p9240
sg10
I3
sg11
VDJD
p9241
sg13
I1
sa(dp9242
g7
I99
sg27
VC0029408
p9243
sg10
I26
sg11
Vdegenerative joint disease
p9244
sg13
I3
sasa(dp9245
g2
S'Fourteen patients with malunited DRF and DJD limited to the radiocarpal joint underwent RSL arthrodesis and DSE between 2006 and 2014.\n'
p9246
sg4
(lp9247
sg24
(lp9248
sa(dp9249
g2
S"The impact of a static electric field (EF) on amyloid peptide aggregation has been much less studied, although EFs may have some applications to treat Parkinson's disease symptoms.\n"
p9250
sg4
(lp9251
sg24
(lp9252
(dp9253
g7
I46
sg27
VC0011560
p9254
sg10
I7
sg11
Vamyloid
p9255
sg13
I1
sa(dp9256
g7
I151
sg27
VC0030567
p9257
sg10
I19
sg11
VParkinson's disease
p9258
sg13
I2
sasa(dp9259
g2
S'Cognitive impairments occur frequently and early in multiple sclerosis (MS) and contribute significantly to a reduced quality of life of patients with MS. Executive functions (EFs) play a pivotal role for the behavioral adaption to the environment and are also crucial for compensatory processes of cognitive impairments.\n'
p9260
sg4
(lp9261
sg24
(lp9262
(dp9263
g7
I299
sg27
VC0338656
p9264
sg10
I21
sg11
Vcognitive impairments
p9265
sg13
I2
sa(dp9266
g7
I72
sg27
VC0036429
p9267
sg10
I2
sg11
VMS
p9268
sg13
I1
sa(dp9269
g7
I72
sg27
VC0036429
p9270
sg10
I2
sg11
VMS
p9271
sg13
I1
sa(dp9272
g7
I0
sg27
VC0338656
p9273
sg10
I21
sg11
VCognitive impairments
p9274
sg13
I2
sa(dp9275
g7
I52
sg27
VC0026769
p9276
sg10
I18
sg11
Vmultiple sclerosis
p9277
sg13
I2
sasa(dp9278
g2
S"Several recent studies have pointed out that early impairment of executive functions (EFs) in Parkinson's Disease (PD) may be a crucial marker to detect patients at risk for developing dementia.\n"
p9279
sg4
(lp9280
sg24
(lp9281
(dp9282
g7
I51
sg27
VC0684336
p9283
sg10
I10
sg11
Vimpairment
p9284
sg13
I1
sa(dp9285
g7
I94
sg27
VC0030567
p9286
sg10
I19
sg11
VParkinson's Disease
p9287
sg13
I2
sa(dp9288
g7
I115
sg27
VC0030567
p9289
sg10
I2
sg11
VPD
p9290
sg13
I1
sa(dp9291
g7
I185
sg27
VC0497327
p9292
sg10
I8
sg11
Vdementia
p9293
sg13
I1
sasa(dp9294
g2
S'Importantly, analysis of circulating EVs from plasma of alcoholic hepatitis patients revealed increased numbers of EVs that contained high levels of miR-27a as compared with healthy controls.\n'
p9295
sg4
(lp9296
(dp9297
g7
I149
sg8
g9
sg10
I7
sg11
VmiR-27a
p9298
sg13
I1
sasg24
(lp9299
(dp9300
g7
I56
sg27
VC0019187
p9301
sg10
I19
sg11
Valcoholic hepatitis
p9302
sg13
I2
sasa(dp9303
g2
S"The following associations were found: auto-immune thyroid disease (4.3% of DH patients and 6.0% of CD patients), insulin dependent diabetes (1.0% DH and 5.5% CD), lupus erythematosus (1.3% DH and 0.3% CD), Sjoegren's syndrome (1.0% DH and 2.9% CD), sarcoidosis (1.3% DH and 1.8% CD), and vitiligo or alopecia areata (1.6% DH and 0% CD).\n"
p9304
sg4
(lp9305
(dp9306
g7
I114
sg8
VP01308
p9307
sg10
I7
sg11
Vinsulin
p9308
sg13
I1
sasg24
(lp9309
(dp9310
g7
I51
sg27
VC0040128
p9311
sg10
I15
sg11
Vthyroid disease
p9312
sg13
I2
sa(dp9313
g7
I114
sg27
VC0011854
p9314
sg10
I26
sg11
Vinsulin dependent diabetes
p9315
sg13
I3
sa(dp9316
g7
I164
sg27
VC0409974
p9317
sg10
I19
sg11
Vlupus erythematosus
p9318
sg13
I2
sa(dp9319
g7
I250
sg27
VC0036202
p9320
sg10
I11
sg11
Vsarcoidosis
p9321
sg13
I1
sa(dp9322
g7
I301
sg27
VC0002171
p9323
sg10
I15
sg11
Valopecia areata
p9324
sg13
I2
sa(dp9325
g7
I207
sg27
VC1527336
p9326
sg10
I19
sg11
VSjoegren's syndrome
p9327
sg13
I2
sa(dp9328
g7
I289
sg27
VC0042900
p9329
sg10
I8
sg11
Vvitiligo
p9330
sg13
I1
sasa(dp9331
g2
S'Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the Beta-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations.\n'
p9332
sg4
(lp9333
(dp9334
g7
I331
sg8
g9
sg10
I5
sg11
VATXN3
p9335
sg13
I1
sa(dp9336
g7
I511
sg8
VP04062
p9337
sg10
I3
sg11
VGBA
p9338
sg13
I1
sa(dp9339
g7
I486
sg8
VP02774
p9340
sg10
I23
sg11
VBeta-glucocerebrosidase
p9341
sg13
I1
sa(dp9342
g7
I557
sg8
g9
sg10
I9
sg11
VLYST gene
p9343
sg13
I2
sa(dp9344
g7
I388
sg8
g9
sg10
I12
sg11
VATP13A2 gene
p9345
sg13
I2
sa(dp9346
g7
I321
sg8
g9
sg10
I8
sg11
Vataxin-3
p9347
sg13
I1
sasg24
(lp9348
(dp9349
g7
I344
sg27
VC1847640
p9350
sg10
I20
sg11
VKufor-Rakeb syndrome
p9351
sg13
I2
sa(dp9352
g7
I75
sg27
VC0524851
p9353
sg10
I26
sg11
Vneurodegenerative diseases
p9354
sg13
I2
sa(dp9355
g7
I525
sg27
VC0007965
p9356
sg10
I24
sg11
VChediak-Higashi syndrome
p9357
sg13
I2
sa(dp9358
g7
I149
sg27
VC0039082
p9359
sg10
I8
sg11
Vsyndrome
p9360
sg13
I1
sa(dp9361
g7
I219
sg27
VC0025362
p9362
sg10
I18
sg11
Vmental retardation
p9363
sg13
I2
sa(dp9364
g7
I142
sg27
VC0004134
p9365
sg10
I6
sg11
Vataxia
p9366
sg13
I1
sa(dp9367
g7
I26
sg27
VC0242422
p9368
sg10
I12
sg11
Vparkinsonism
p9369
sg13
I1
sa(dp9370
g7
I131
sg27
VC0040822
p9371
sg10
I6
sg11
Vtremor
p9372
sg13
I1
sa(dp9373
g7
I251
sg27
VC0024408
p9374
sg10
I22
sg11
VMachado-Joseph disease
p9375
sg13
I2
sa(dp9376
g7
I446
sg27
VC0017205
p9377
sg10
I15
sg11
VGaucher disease
p9378
sg13
I2
sasa(dp9379
g2
S'We also identified the mutation of the LYST gene, that is causative gene for Chediak-Higashi syndrome, for the autosomal recessive complicated spastic paraplegia with cerebellar ataxia and neuropathy.\n'
p9380
sg4
(lp9381
(dp9382
g7
I39
sg8
g9
sg10
I9
sg11
VLYST gene
p9383
sg13
I2
sasg24
(lp9384
(dp9385
g7
I167
sg27
VC0007758
p9386
sg10
I17
sg11
Vcerebellar ataxia
p9387
sg13
I2
sa(dp9388
g7
I189
sg27
VC0442874
p9389
sg10
I10
sg11
Vneuropathy
p9390
sg13
I1
sa(dp9391
g7
I143
sg27
VC0037772
p9392
sg10
I18
sg11
Vspastic paraplegia
p9393
sg13
I2
sa(dp9394
g7
I77
sg27
VC0007965
p9395
sg10
I24
sg11
VChediak-Higashi syndrome
p9396
sg13
I2
sasa(dp9397
g2
S'To our knowledge, this is the first study on spina bifida to determine the nucleotide sequences of breakpoints for trisomy 2p24.3-pter and monosomy 5p14.3-pter.\n'
p9398
sg4
(lp9399
sg24
(lp9400
(dp9401
g7
I45
sg27
VC0080178
p9402
sg10
I12
sg11
Vspina bifida
p9403
sg13
I2
sa(dp9404
g7
I139
sg27
VC0026499
p9405
sg10
I8
sg11
Vmonosomy
p9406
sg13
I1
sa(dp9407
g7
I115
sg27
VC0041107
p9408
sg10
I7
sg11
Vtrisomy
p9409
sg13
I1
sasa(dp9410
g2
S'Our report serves to emphasize the consistency in the prenatal sonographic feature of spina bifida in consecutive pregnancies with fetuses associated with partial trisomy 3q (3q26.1-qter) and partial monosomy 5p (5p13.33-pter).\n'
p9411
sg4
(lp9412
sg24
(lp9413
(dp9414
g7
I155
sg27
VC1297882
p9415
sg10
I15
sg11
Vpartial trisomy
p9416
sg13
I2
sa(dp9417
g7
I163
sg27
VC0795809
p9418
sg10
I10
sg11
Vtrisomy 3q
p9419
sg13
I2
sa(dp9420
g7
I192
sg27
VC0008628
p9421
sg10
I16
sg11
Vpartial monosomy
p9422
sg13
I2
sa(dp9423
g7
I86
sg27
VC0080178
p9424
sg10
I12
sg11
Vspina bifida
p9425
sg13
I2
sasa(dp9426
g2
S'These are classified into ten different types (NDNC1-10), which are described in OMIM.1 The genes described for isolated nail disorders include PLCD1 (MIM 602142), RSPO4 (MIM 610573), FZD6 (MIM 603409), COL7A1 (MIM 120120), HPGD (MIM 601688) and SLCO2A1 (MIM 601460).\n'
p9427
sg4
(lp9428
(dp9429
g7
I151
sg8
g9
sg10
I10
sg11
VMIM 602142
p9430
sg13
I2
sa(dp9431
g7
I255
sg8
g9
sg10
I10
sg11
VMIM 601460
p9432
sg13
I2
sa(dp9433
g7
I203
sg8
g9
sg10
I6
sg11
VCOL7A1
p9434
sg13
I1
sa(dp9435
g7
I190
sg8
g9
sg10
I10
sg11
VMIM 603409
p9436
sg13
I2
sa(dp9437
g7
I184
sg8
g9
sg10
I4
sg11
VFZD6
p9438
sg13
I1
sa(dp9439
g7
I211
sg8
g9
sg10
I10
sg11
VMIM 120120
p9440
sg13
I2
sa(dp9441
g7
I144
sg8
VP51178
p9442
sg10
I5
sg11
VPLCD1
p9443
sg13
I1
sa(dp9444
g7
I171
sg8
g9
sg10
I10
sg11
VMIM 610573
p9445
sg13
I2
sa(dp9446
g7
I164
sg8
g9
sg10
I5
sg11
VRSPO4
p9447
sg13
I1
sa(dp9448
g7
I246
sg8
g9
sg10
I7
sg11
VSLCO2A1
p9449
sg13
I1
sasg24
(lp9450
(dp9451
g7
I121
sg27
VC0027339
p9452
sg10
I14
sg11
Vnail disorders
p9453
sg13
I2
sa(dp9454
g7
I47
sg27
VC0406443
p9455
sg10
I5
sg11
VNDNC1
p9456
sg13
I1
sasa(dp9457
g2
S'Anonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence (anonychia) or hypoplasia (hyponuchia) of finger- and/or toenails frequently caused by mutations in the R-spondin 4 (RSPO4) gene.\n'
p9458
sg4
(lp9459
(dp9460
g7
I217
sg8
g9
sg10
I11
sg11
VR-spondin 4
p9461
sg13
I2
sa(dp9462
g7
I230
sg8
g9
sg10
I5
sg11
VRSPO4
p9463
sg13
I1
sasg24
(lp9464
(dp9465
g7
I128
sg27
VC0243069
p9466
sg10
I10
sg11
Vhypoplasia
p9467
sg13
I1
sa(dp9468
g7
I0
sg27
VC0265998
p9469
sg10
I112
sg11
VAnonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence
p9470
sg13
I13
sa(dp9471
g7
I114
sg27
VC0265998
p9472
sg10
I9
sg11
Vanonychia
p9473
sg13
I1
sasa(dp9474
g2
S'Because there were no other congenital abnormalities, this was considered to be anonychia congenita; probably caused by a recessive defect of the R-spondin 4-coding gene.\n'
p9475
sg4
(lp9476
(dp9477
g7
I146
sg8
g9
sg10
I23
sg11
VR-spondin 4-coding gene
p9478
sg13
I3
sasg24
(lp9479
(dp9480
g7
I80
sg27
VC0265998
p9481
sg10
I19
sg11
Vanonychia congenita
p9482
sg13
I2
sa(dp9483
g7
I28
sg27
VC0000768
p9484
sg10
I24
sg11
Vcongenital abnormalities
p9485
sg13
I2
sasa(dp9486
g2
S'To investigate whether receipt of any antithrombin concentrate improves laboratory and clinical outcomes in children undergoing extracorporeal membrane oxygenation for respiratory failure during their hospitalization compared with those who did not receive antithrombin.\n'
p9487
sg4
(lp9488
(dp9489
g7
I38
sg8
VP05546
p9490
sg10
I12
sg11
Vantithrombin
p9491
sg13
I1
sa(dp9492
g7
I38
sg8
VP05546
p9493
sg10
I12
sg11
Vantithrombin
p9494
sg13
I1
sasg24
(lp9495
(dp9496
g7
I168
sg27
VC1145670
p9497
sg10
I19
sg11
Vrespiratory failure
p9498
sg13
I2
sasa(dp9499
g2
S'Intermittent, on-demand dosing of antithrombin concentrate in pediatric patients on extracorporeal membrane oxygenation for respiratory failure increased antithrombin levels, but not typically to the targeted level.\n'
p9500
sg4
(lp9501
(dp9502
g7
I34
sg8
VP05546
p9503
sg10
I12
sg11
Vantithrombin
p9504
sg13
I1
sa(dp9505
g7
I34
sg8
VP05546
p9506
sg10
I12
sg11
Vantithrombin
p9507
sg13
I1
sasg24
(lp9508
(dp9509
g7
I124
sg27
VC1145670
p9510
sg10
I19
sg11
Vrespiratory failure
p9511
sg13
I2
sasa(dp9512
g2
S'We hypothesized that combining intravenous recombinant human antithrombin (rhAT), nebulized heparin, and nebulized tissue plasminogen activator (TPA) more effectively improves pulmonary gas exchange compared with a single rhAT infusion, while maintaining the anti-inflammatory properties of rhAT in ARDS.\n'
p9513
sg4
(lp9514
(dp9515
g7
I75
sg8
VP05546
p9516
sg10
I4
sg11
VrhAT
p9517
sg13
I1
sa(dp9518
g7
I75
sg8
VP05546
p9519
sg10
I4
sg11
VrhAT
p9520
sg13
I1
sa(dp9521
g7
I43
sg8
VP05546
p9522
sg10
I30
sg11
Vrecombinant human antithrombin
p9523
sg13
I3
sa(dp9524
g7
I145
sg8
VP00747
p9525
sg10
I3
sg11
VTPA
p9526
sg13
I1
sa(dp9527
g7
I75
sg8
VP05546
p9528
sg10
I4
sg11
VrhAT
p9529
sg13
I1
sa(dp9530
g7
I115
sg8
VP00747
p9531
sg10
I28
sg11
Vtissue plasminogen activator
p9532
sg13
I3
sasg24
(lp9533
(dp9534
g7
I299
sg27
VC0035222
p9535
sg10
I4
sg11
VARDS
p9536
sg13
I1
sasa(dp9537
g2
S'After 12 months, bonds fell from 43.9 +/- 9.5 MPa to 20.1 +/- 5.4 MPa and from 39.6 +/- 9.4 MPa to 14.2 +/- 5.0 MPa in control specimens for SB1 and XPB respectively, while bond fell only from 41.9 +/- 9.6MPa to 33.2 +/- 8.3 MPa and 38.3 +/- 8.9 MPa to 26.5 +/- 10.9 (for SB1 and XPB, respectively) when 0.2% CHX was previously used.\n'
p9538
sg4
(lp9539
(dp9540
g7
I141
sg8
g9
sg10
I3
sg11
VSB1
p9541
sg13
I1
sa(dp9542
g7
I149
sg8
VP19447
p9543
sg10
I3
sg11
VXPB
p9544
sg13
I1
sasg24
(lp9545
(dp9546
g7
I149
sg27
VC0268136
p9547
sg10
I3
sg11
VXPB
p9548
sg13
I1
sa(dp9549
g7
I149
sg27
VC0268136
p9550
sg10
I3
sg11
VXPB
p9551
sg13
I1
sasa(dp9552
g2
S'Primary SFs from patients with rheumatoid arthritis (RA) were treated with recombinant human bone morphogenetic protein-2 or transduced with a constitutively active mutant of the ALK3 gene (ALK3CA) with or without TNF-Alfa, and then cultured in pellets.\n'
p9553
sg4
(lp9554
(dp9555
g7
I179
sg8
VP36894
p9556
sg10
I9
sg11
VALK3 gene
p9557
sg13
I2
sa(dp9558
g7
I214
sg8
VP01375
p9559
sg10
I8
sg11
VTNF-Alfa
p9560
sg13
I1
sasg24
(lp9561
(dp9562
g7
I53
sg27
VC0003873
p9563
sg10
I2
sg11
VRA
p9564
sg13
I1
sa(dp9565
g7
I165
sg27
VC0596988
p9566
sg10
I6
sg11
Vmutant
p9567
sg13
I1
sa(dp9568
g7
I31
sg27
VC0003873
p9569
sg10
I20
sg11
Vrheumatoid arthritis
p9570
sg13
I2
sasa(dp9571
g2
S'We describe a patient with ALK-negative ALCL presenting with clinical and radiographic findings suggesting osteomyelitis 6 months after left rotator cuff repair surgery.\n'
p9572
sg4
(lp9573
sg24
(lp9574
(dp9575
g7
I40
sg27
VC0206180
p9576
sg10
I4
sg11
VALCL
p9577
sg13
I1
sa(dp9578
g7
I107
sg27
VC0029443
p9579
sg10
I13
sg11
Vosteomyelitis
p9580
sg13
I1
sasa(dp9581
g2
S"We compared levels of GABA(B) receptor subunits GABA(B) receptor 1 (GABBR1) and GABA(B) receptor 2 (GABBR2) in cerebellum, Brodmann's area 9 (BA9), and BA40 of subjects with autism and matched controls.\n"
p9582
sg4
(lp9583
(dp9584
g7
I80
sg8
g9
sg10
I18
sg11
VGABA(B) receptor 2
p9585
sg13
I3
sa(dp9586
g7
I100
sg8
g9
sg10
I6
sg11
VGABBR2
p9587
sg13
I1
sa(dp9588
g7
I48
sg8
g9
sg10
I18
sg11
VGABA(B) receptor 1
p9589
sg13
I3
sa(dp9590
g7
I22
sg8
g9
sg10
I16
sg11
VGABA(B) receptor
p9591
sg13
I2
sa(dp9592
g7
I68
sg8
g9
sg10
I6
sg11
VGABBR1
p9593
sg13
I1
sasg24
(lp9594
(dp9595
g7
I174
sg27
VC0004352
p9596
sg10
I6
sg11
Vautism
p9597
sg13
I1
sasa(dp9598
g2
S'Sclerosteosis is caused by loss-of-function mutations in the SOST gene which encodes a secreted glycoprotein, sclerostin.\n'
p9599
sg4
(lp9600
(dp9601
g7
I61
sg8
g9
sg10
I9
sg11
VSOST gene
p9602
sg13
I2
sasg24
(lp9603
(dp9604
g7
I0
sg27
VC0265301
p9605
sg10
I13
sg11
VSclerosteosis
p9606
sg13
I1
sa(dp9607
g7
I61
sg27
VC0265301
p9608
sg10
I4
sg11
VSOST
p9609
sg13
I1
sasa(dp9610
g2
S'VBD is caused by a noncoding deletion that removes a SOST-specific regulatory element in bone.\n'
p9611
sg4
(lp9612
sg24
(lp9613
(dp9614
g7
I53
sg27
VC0265301
p9615
sg10
I4
sg11
VSOST
p9616
sg13
I1
sasa(dp9617
g2
S'Here we describe how human genetics studies in sclerosteosis and VBD patients, in combination with the generation of transgenic and knockout mice, has led to a better understanding of the role of sclerostin in bone metabolism.\n'
p9618
sg4
(lp9619
(dp9620
g7
I196
sg8
g9
sg10
I10
sg11
Vsclerostin
p9621
sg13
I1
sasg24
(lp9622
(dp9623
g7
I47
sg27
VC0265301
p9624
sg10
I13
sg11
Vsclerosteosis
p9625
sg13
I1
sasa(dp9626
g2
S'In addition, expression of SOST is delayed or suppressed; resulting in active WNT signaling and enhanced periosteal bone formation, and the combined outcome is generalized hyperostosis.\n'
p9627
sg4
(lp9628
(dp9629
g7
I27
sg8
g9
sg10
I4
sg11
VSOST
p9630
sg13
I1
sasg24
(lp9631
(dp9632
g7
I27
sg27
VC0265301
p9633
sg10
I4
sg11
VSOST
p9634
sg13
I1
sa(dp9635
g7
I172
sg27
VC0020492
p9636
sg10
I12
sg11
Vhyperostosis
p9637
sg13
I1
sasa(dp9638
g2
S'Initially, we and others reported that sclerosteosis was caused by loss-of-function mutations in SOST, encoding sclerostin.\n'
p9639
sg4
(lp9640
(dp9641
g7
I97
sg8
g9
sg10
I4
sg11
VSOST
p9642
sg13
I1
sasg24
(lp9643
(dp9644
g7
I97
sg27
VC0265301
p9645
sg10
I4
sg11
VSOST
p9646
sg13
I1
sa(dp9647
g7
I39
sg27
VC0265301
p9648
sg10
I13
sg11
Vsclerosteosis
p9649
sg13
I1
sasa(dp9650
g2
S'More recently, we identified disease-causing mutations in LRP4, a binding partner of sclerostin, in three sclerosteosis patients.\n'
p9651
sg4
(lp9652
(dp9653
g7
I85
sg8
g9
sg10
I10
sg11
Vsclerostin
p9654
sg13
I1
sa(dp9655
g7
I58
sg8
g9
sg10
I4
sg11
VLRP4
p9656
sg13
I1
sasg24
(lp9657
(dp9658
g7
I106
sg27
VC0265301
p9659
sg10
I13
sg11
Vsclerosteosis
p9660
sg13
I1
sasa(dp9661
g2
S'The positive correlation we found between sclerostin and age in Paget disease of bone patients indicates that in comparative studies, sclerostin serum levels must be adjusted for age.\n'
p9662
sg4
(lp9663
sg24
(lp9664
(dp9665
g7
I64
sg27
VC0029401
p9666
sg10
I21
sg11
VPaget disease of bone
p9667
sg13
I4
sasa(dp9668
g2
S'Sclerosteosis and van Buchem disease are two rare bone sclerosing dysplasias caused by genetic defects in the synthesis of sclerostin.\n'
p9669
sg4
(lp9670
sg24
(lp9671
(dp9672
g7
I0
sg27
VC0265301
p9673
sg10
I13
sg11
VSclerosteosis
p9674
sg13
I1
sa(dp9675
g7
I18
sg27
VC0432272
p9676
sg10
I18
sg11
Vvan Buchem disease
p9677
sg13
I3
sa(dp9678
g7
I66
sg27
VC0334044
p9679
sg10
I10
sg11
Vdysplasias
p9680
sg13
I1
sasa(dp9681
g2
S'In this article we review the demographic, clinical, biochemical, radiological, and histological characteristics of patients with sclerosteosis and van Buchem disease that led to a better understanding of the role of sclerostin in bone metabolism in humans and we discuss the relevance of these findings for the development of new therapeutics for the treatment of patients with osteoporosis.\n'
p9682
sg4
(lp9683
(dp9684
g7
I217
sg8
g9
sg10
I10
sg11
Vsclerostin
p9685
sg13
I1
sasg24
(lp9686
(dp9687
g7
I148
sg27
VC0432272
p9688
sg10
I18
sg11
Vvan Buchem disease
p9689
sg13
I3
sa(dp9690
g7
I379
sg27
VC0029456
p9691
sg10
I12
sg11
Vosteoporosis
p9692
sg13
I1
sa(dp9693
g7
I130
sg27
VC0265301
p9694
sg10
I13
sg11
Vsclerosteosis
p9695
sg13
I1
sasa(dp9696
g2
S'After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation.\n'
p9697
sg4
(lp9698
(dp9699
g7
I36
sg8
g9
sg10
I10
sg11
Vsclerostin
p9700
sg13
I1
sa(dp9701
g7
I31
sg8
g9
sg10
I4
sg11
VSost
p9702
sg13
I1
sasg24
(lp9703
(dp9704
g7
I132
sg27
VC0265301
p9705
sg10
I13
sg11
Vsclerosteosis
p9706
sg13
I1
sa(dp9707
g7
I99
sg27
VC0039082
p9708
sg10
I9
sg11
Vsyndromes
p9709
sg13
I1
sa(dp9710
g7
I31
sg27
VC0265301
p9711
sg10
I4
sg11
VSost
p9712
sg13
I1
sa(dp9713
g7
I109
sg27
VC0432272
p9714
sg10
I18
sg11
VVan Buchem disease
p9715
sg13
I3
sasa(dp9716
g2
S'Loss-of-function mutations of the sclerostin gene (SOST) cause sclerosteosis and Van Buchem disease characterized by bone overgrowth.\n'
p9717
sg4
(lp9718
(dp9719
g7
I34
sg8
g9
sg10
I15
sg11
Vsclerostin gene
p9720
sg13
I2
sa(dp9721
g7
I51
sg8
g9
sg10
I4
sg11
VSOST
p9722
sg13
I1
sasg24
(lp9723
(dp9724
g7
I34
sg27
VC0265301
p9725
sg10
I15
sg11
Vsclerostin gene
p9726
sg13
I2
sa(dp9727
g7
I63
sg27
VC0265301
p9728
sg10
I13
sg11
Vsclerosteosis
p9729
sg13
I1
sa(dp9730
g7
I51
sg27
VC0265301
p9731
sg10
I4
sg11
VSOST
p9732
sg13
I1
sa(dp9733
g7
I81
sg27
VC0432272
p9734
sg10
I18
sg11
VVan Buchem disease
p9735
sg13
I3
sasa(dp9736
g2
S'Mutations in the human sclerostin gene (SOST) lead to sclerosteosis with progressive skeletal overgrowth, whereas sclerostin-deficient (Sost(-/-)) mice exhibit increased bone mass and strength.\n'
p9737
sg4
(lp9738
(dp9739
g7
I17
sg8
g9
sg10
I21
sg11
Vhuman sclerostin gene
p9740
sg13
I3
sa(dp9741
g7
I40
sg8
g9
sg10
I4
sg11
VSOST
p9742
sg13
I1
sasg24
(lp9743
(dp9744
g7
I23
sg27
VC0265301
p9745
sg10
I15
sg11
Vsclerostin gene
p9746
sg13
I2
sa(dp9747
g7
I136
sg27
VC0265301
p9748
sg10
I4
sg11
VSost
p9749
sg13
I1
sa(dp9750
g7
I40
sg27
VC0265301
p9751
sg10
I4
sg11
VSOST
p9752
sg13
I1
sa(dp9753
g7
I54
sg27
VC0265301
p9754
sg10
I13
sg11
Vsclerosteosis
p9755
sg13
I1
sasa(dp9756
g2
S"Therefore, this study provides additional support to develop OGA inhibitors as a treatment for Alzheimer's disease and other neurodegenerative tauopathies.\n"
p9757
sg4
(lp9758
(dp9759
g7
I61
sg8
g9
sg10
I3
sg11
VOGA
p9760
sg13
I1
sasg24
(lp9761
(dp9762
g7
I143
sg27
VC0949664
p9763
sg10
I11
sg11
Vtauopathies
p9764
sg13
I1
sa(dp9765
g7
I95
sg27
VC1521724
p9766
sg10
I19
sg11
VAlzheimer's disease
p9767
sg13
I2
sasa(dp9768
g2
S'To identify the association between gastrointestinal carcinomas (GIC) risk and UDP-glucuronosyltransferases (UGTs) 1A7 polymorphisms through a systematic review and network meta-analysis.\n'
p9769
sg4
(lp9770
(dp9771
g7
I79
sg8
g9
sg10
I28
sg11
VUDP-glucuronosyltransferases
p9772
sg13
I1
sa(dp9773
g7
I109
sg8
g9
sg10
I4
sg11
VUGTs
p9774
sg13
I1
sasg24
(lp9775
(dp9776
g7
I53
sg27
VC0007097
p9777
sg10
I10
sg11
Vcarcinomas
p9778
sg13
I1
sasa(dp9779
g2
S'In this study, the expression and regulation of two androgen-inactivating enzymes, the UDP-glucuronosyltransferases UGT2B15 and UGT2B17, was assessed in breast cancer.\n'
p9780
sg4
(lp9781
(dp9782
g7
I128
sg8
g9
sg10
I7
sg11
VUGT2B17
p9783
sg13
I1
sa(dp9784
g7
I87
sg8
VP54855
p9785
sg10
I36
sg11
VUDP-glucuronosyltransferases UGT2B15
p9786
sg13
I2
sasg24
(lp9787
(dp9788
g7
I153
sg27
VC0678222
p9789
sg10
I13
sg11
Vbreast cancer
p9790
sg13
I2
sasa(dp9791
g2
S'Global ablation of INSL3 hormone or its receptor RXFP2 in male mice results in cryptorchidism and infertility.\n'
p9792
sg4
(lp9793
(dp9794
g7
I49
sg8
g9
sg10
I5
sg11
VRXFP2
p9795
sg13
I1
sa(dp9796
g7
I19
sg8
VP51460
p9797
sg10
I13
sg11
VINSL3 hormone
p9798
sg13
I2
sasg24
(lp9799
(dp9800
g7
I98
sg27
VC0021359
p9801
sg10
I11
sg11
Vinfertility
p9802
sg13
I1
sa(dp9803
g7
I79
sg27
VC0010417
p9804
sg10
I14
sg11
Vcryptorchidism
p9805
sg13
I1
sasa(dp9806
g2
S'We have also produced shRNA transgenic mice with reduced RXFP2 expression Such males manifested various degree of uni- and bilateral cryptorchidism.\n'
p9807
sg4
(lp9808
(dp9809
g7
I57
sg8
g9
sg10
I5
sg11
VRXFP2
p9810
sg13
I1
sasg24
(lp9811
(dp9812
g7
I123
sg27
VC0431663
p9813
sg10
I24
sg11
Vbilateral cryptorchidism
p9814
sg13
I2
sasa(dp9815
g2
S'To study the consequences of an aberrant testicular environment in cryptorchidism we used a mouse model with a deletion of Rxfp2 gene resulting in a high intra-abdominal testicular position.\n'
p9816
sg4
(lp9817
(dp9818
g7
I123
sg8
g9
sg10
I10
sg11
VRxfp2 gene
p9819
sg13
I2
sasg24
(lp9820
(dp9821
g7
I67
sg27
VC0010417
p9822
sg10
I14
sg11
Vcryptorchidism
p9823
sg13
I1
sasa(dp9824
g2
S'Deletion of Insl3 or Rxfp2 genes in mice caused cryptorchidism resulting from a failure of gubernaculum development.\n'
p9825
sg4
(lp9826
(dp9827
g7
I12
sg8
VP51460
p9828
sg10
I5
sg11
VInsl3
p9829
sg13
I1
sa(dp9830
g7
I21
sg8
g9
sg10
I11
sg11
VRxfp2 genes
p9831
sg13
I2
sasg24
(lp9832
(dp9833
g7
I48
sg27
VC0010417
p9834
sg10
I14
sg11
Vcryptorchidism
p9835
sg13
I1
sasa(dp9836
g2
S'Using Cre transgene driven by retinoic acid receptor beta promoter, conditional gene targeting in gubernacular mesenchymal cells at early embryonic stages caused high intraabdominal cryptorchidism as in males with a global deletion of Rxfp2.\n'
p9837
sg4
(lp9838
(dp9839
g7
I30
sg8
VP10826
p9840
sg10
I36
sg11
Vretinoic acid receptor beta promoter
p9841
sg13
I5
sa(dp9842
g7
I6
sg8
g9
sg10
I13
sg11
VCre transgene
p9843
sg13
I2
sa(dp9844
g7
I235
sg8
g9
sg10
I5
sg11
VRxfp2
p9845
sg13
I1
sasg24
(lp9846
(dp9847
g7
I182
sg27
VC0010417
p9848
sg10
I14
sg11
Vcryptorchidism
p9849
sg13
I1
sasa(dp9850
g2
S'Prenatal exposure to diethylstilbestrol affected the expression of LGR8 mRNA in the mouse gubernaculum testis, which suggests that diethylstilbestrol may induce cryptorchidism by interfering with the INSL3-LGR8 signaling system and consequently the development of the gubernaculum testis.\n'
p9851
sg4
(lp9852
(dp9853
g7
I67
sg8
VP51460
p9854
sg10
I4
sg11
VLGR8
p9855
sg13
I1
sa(dp9856
g7
I200
sg8
VP51460
p9857
sg10
I5
sg11
VINSL3
p9858
sg13
I1
sa(dp9859
g7
I67
sg8
VP51460
p9860
sg10
I9
sg11
VLGR8 mRNA
p9861
sg13
I2
sasg24
(lp9862
(dp9863
g7
I161
sg27
VC0010417
p9864
sg10
I14
sg11
Vcryptorchidism
p9865
sg13
I1
sasa(dp9866
g2
S'Prospectively collected cremaster muscle and/or hernia sac tissues from boys with congenital (79) or acquired (66) nonsyndromic cryptorchidism and hernia/hydrocele (controls, 84) were analyzed for hormone receptor (RXFP2, AR, ESR1, ESR2) and myosin heavy chain specific (MYH1, MYH2, MYH7) mRNA expression using real-time reverse transcriptase polymerase chain reaction.\n'
p9867
sg4
(lp9868
(dp9869
g7
I226
sg8
VP03372
p9870
sg10
I4
sg11
VESR1
p9871
sg13
I1
sa(dp9872
g7
I277
sg8
g9
sg10
I4
sg11
VMYH2
p9873
sg13
I1
sa(dp9874
g7
I242
sg8
VP13535
p9875
sg10
I18
sg11
Vmyosin heavy chain
p9876
sg13
I3
sa(dp9877
g7
I193
sg8
VP22736
p9878
sg10
I20
sg11
Vfor hormone receptor
p9879
sg13
I3
sa(dp9880
g7
I271
sg8
VP12882
p9881
sg10
I4
sg11
VMYH1
p9882
sg13
I1
sa(dp9883
g7
I215
sg8
g9
sg10
I5
sg11
VRXFP2
p9884
sg13
I1
sasg24
(lp9885
(dp9886
g7
I48
sg27
VC0333062
p9887
sg10
I10
sg11
Vhernia sac
p9888
sg13
I2
sa(dp9889
g7
I128
sg27
VC0010417
p9890
sg10
I14
sg11
Vcryptorchidism
p9891
sg13
I1
sa(dp9892
g7
I48
sg27
VC0019270
p9893
sg10
I6
sg11
Vhernia
p9894
sg13
I1
sa(dp9895
g7
I154
sg27
VC1720771
p9896
sg10
I9
sg11
Vhydrocele
p9897
sg13
I1
sasa(dp9898
g2
S'Exon sequencing of candidate genes identified mutations in mice with cystic kidneys (Bicc1), cryptorchidism (Rxfp2), restricted germ cell deficiency (Plk4), and severe germ cell deficiency (Prdm9).\n'
p9899
sg4
(lp9900
(dp9901
g7
I150
sg8
g9
sg10
I4
sg11
VPlk4
p9902
sg13
I1
sa(dp9903
g7
I109
sg8
g9
sg10
I5
sg11
VRxfp2
p9904
sg13
I1
sa(dp9905
g7
I190
sg8
g9
sg10
I5
sg11
VPrdm9
p9906
sg13
I1
sa(dp9907
g7
I85
sg8
g9
sg10
I5
sg11
VBicc1
p9908
sg13
I1
sasg24
(lp9909
(dp9910
g7
I93
sg27
VC0010417
p9911
sg10
I14
sg11
Vcryptorchidism
p9912
sg13
I1
sa(dp9913
g7
I69
sg27
VC0022679
p9914
sg10
I14
sg11
Vcystic kidneys
p9915
sg13
I2
sasa(dp9916
g2
S'Patients with definite pneumonia at the time of admission, those with left-sided heart failure, pulmonary embolism and an identifiable cause of acute lung injury, and those whose albumin or C-reactive protein levels were not measured were excluded.\n'
p9917
sg4
(lp9918
(dp9919
g7
I190
sg8
VP02741
p9920
sg10
I18
sg11
VC-reactive protein
p9921
sg13
I2
sa(dp9922
g7
I179
sg8
VP00441
p9923
sg10
I7
sg11
Valbumin
p9924
sg13
I1
sasg24
(lp9925
(dp9926
g7
I96
sg27
VC0034065
p9927
sg10
I18
sg11
Vpulmonary embolism
p9928
sg13
I2
sa(dp9929
g7
I23
sg27
VC0032285
p9930
sg10
I9
sg11
Vpneumonia
p9931
sg13
I1
sa(dp9932
g7
I70
sg27
VC0023212
p9933
sg10
I24
sg11
Vleft-sided heart failure
p9934
sg13
I3
sasa(dp9935
g2
S'We have identified a hypoxia-induced pathway that utilizes the Hypoxia Inducible Factor 1Alfa (HIF-1Alfa) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 - Signal Transducer and Activator of Transcription 3) axis to enhance the self-renewal of glioma stem-like cells.\n'
p9936
sg4
(lp9937
(dp9938
g7
I95
sg8
g9
sg10
I9
sg11
VHIF-1Alfa
p9939
sg13
I1
sa(dp9940
g7
I142
sg8
VP40763
p9941
sg10
I5
sg11
VSTAT3
p9942
sg13
I1
sa(dp9943
g7
I168
sg8
VP40763
p9944
sg10
I50
sg11
VSignal Transducer and Activator of Transcription 3
p9945
sg13
I7
sa(dp9946
g7
I149
sg8
VP23458
p9947
sg10
I36
sg11
VJanus Kinase 1/2 - Signal Transducer
p9948
sg13
I6
sa(dp9949
g7
I135
sg8
VP23458
p9950
sg10
I6
sg11
VJAK1/2
p9951
sg13
I1
sa(dp9952
g7
I63
sg8
g9
sg10
I30
sg11
VHypoxia Inducible Factor 1Alfa
p9953
sg13
I4
sasg24
(lp9954
(dp9955
g7
I256
sg27
VC0017638
p9956
sg10
I6
sg11
Vglioma
p9957
sg13
I1
sa(dp9958
g7
I63
sg27
VC0242184
p9959
sg10
I7
sg11
VHypoxia
p9960
sg13
I1
sa(dp9961
g7
I21
sg27
VC0242184
p9962
sg10
I7
sg11
Vhypoxia
p9963
sg13
I1
sa(dp9964
g7
I149
sg27
VC0266700
p9965
sg10
I5
sg11
VJanus
p9966
sg13
I1
sasa(dp9967
g2
S'Analyzing gene expression signatures in endometrial and stomach adenocarcinomas revealed that tumors with a JAK1 frameshift exhibited reduced expression of interferon response signatures and multiple anti-tumor immune signatures.\n'
p9968
sg4
(lp9969
(dp9970
g7
I156
sg8
VP01563
p9971
sg10
I10
sg11
Vinterferon
p9972
sg13
I1
sa(dp9973
g7
I108
sg8
VP23458
p9974
sg10
I4
sg11
VJAK1
p9975
sg13
I1
sasg24
(lp9976
(dp9977
g7
I64
sg27
VC0001418
p9978
sg10
I15
sg11
Vadenocarcinomas
p9979
sg13
I1
sa(dp9980
g7
I113
sg27
VC0079380
p9981
sg10
I10
sg11
Vframeshift
p9982
sg13
I1
sa(dp9983
g7
I94
sg27
VC0027651
p9984
sg10
I6
sg11
Vtumors
p9985
sg13
I1
sa(dp9986
g7
I94
sg27
VC0027651
p9987
sg10
I5
sg11
Vtumor
p9988
sg13
I1
sasa(dp9989
g2
S'From these data, we derive two primary conclusions: 1) JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability; 2) The mechanism by which JAK1 loss of function contributes to tumor immune evasion is likely associated with loss of the JAK1-mediated interferon response.\n'
p9990
sg4
(lp9991
(dp9992
g7
I358
sg8
VP01563
p9993
sg10
I10
sg11
Vinterferon
p9994
sg13
I1
sa(dp9995
g7
I55
sg8
VP23458
p9996
sg10
I4
sg11
VJAK1
p9997
sg13
I1
sa(dp9998
g7
I55
sg8
VP23458
p9999
sg10
I4
sg11
VJAK1
p10000
sg13
I1
sa(dp10001
g7
I55
sg8
VP23458
p10002
sg10
I4
sg11
VJAK1
p10003
sg13
I1
sasg24
(lp10004
(dp10005
g7
I136
sg27
VC0006826
p10006
sg10
I6
sg11
Vcancer
p10007
sg13
I1
sa(dp10008
g7
I182
sg27
VC0027651
p10009
sg10
I6
sg11
Vtumors
p10010
sg13
I1
sa(dp10011
g7
I285
sg27
VC0282683
p10012
sg10
I20
sg11
Vtumor immune evasion
p10013
sg13
I3
sa(dp10014
g7
I194
sg27
VC0920269
p10015
sg10
I26
sg11
Vmicrosatellite instability
p10016
sg13
I2
sasa(dp10017
g2
S'MAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC.\n'
p10018
sg4
(lp10019
(dp10020
g7
I69
sg8
VP23458
p10021
sg10
I6
sg11
VJAK1/2
p10022
sg13
I1
sasg24
(lp10023
(dp10024
g7
I129
sg27
VC0032463
p10025
sg10
I17
sg11
Vpolycythemia vera
p10026
sg13
I2
sasa(dp10027
g2
S"Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder that is characterized by episodic yet cumulative heterotopic ossification (HO) in skeletal muscles, tendons, and ligaments over a patient's lifetime.\n"
p10028
sg4
(lp10029
sg24
(lp10030
(dp10031
g7
I157
sg27
VC0029396
p10032
sg10
I2
sg11
VHO
p10033
sg13
I1
sa(dp10034
g7
I0
sg27
VC0016037
p10035
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p10036
sg13
I3
sa(dp10037
g7
I131
sg27
VC0029396
p10038
sg10
I24
sg11
Vheterotopic ossification
p10039
sg13
I2
sa(dp10040
g7
I39
sg27
VC0016037
p10041
sg10
I3
sg11
VFOP
p10042
sg13
I1
sasa(dp10043
g2
S'Gain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor ACVR1 have been identified in two diseases: Fibrodysplasia Ossificans Progressiva (FOP), a rare autosomal dominant disorder characterized by genetically driven heterotopic ossification, and in 20-25% of Diffuse Intrinsic Pontine Gliomas (DIPGs), a pediatric brain tumor with no effective therapies and dismal median survival.\n'
p10044
sg4
(lp10045
(dp10046
g7
I34
sg8
VP29475
p10047
sg10
I31
sg11
VType I Bone Morphogenic Protein
p10048
sg13
I5
sasg24
(lp10049
(dp10050
g7
I329
sg27
VC0220603
p10051
sg10
I21
sg11
Vpediatric brain tumor
p10052
sg13
I3
sa(dp10053
g7
I310
sg27
VC0017638
p10054
sg10
I7
sg11
VGliomas
p10055
sg13
I1
sa(dp10056
g7
I241
sg27
VC0029396
p10057
sg10
I24
sg11
Vheterotopic ossification
p10058
sg13
I2
sa(dp10059
g7
I164
sg27
VC0016037
p10060
sg10
I3
sg11
VFOP
p10061
sg13
I1
sa(dp10062
g7
I125
sg27
VC0016037
p10063
sg10
I37
sg11
VFibrodysplasia Ossificans Progressiva
p10064
sg13
I3
sasa(dp10065
g2
S'Fibrodysplasia ossificans progressiva is an autosomal dominant disorder due to germline mutations of ACVR1/ALK2 causing progressive heterotopic endochondral ossifications.\n'
p10066
sg4
(lp10067
(dp10068
g7
I107
sg8
g9
sg10
I4
sg11
VALK2
p10069
sg13
I1
sa(dp10070
g7
I101
sg8
g9
sg10
I5
sg11
VACVR1
p10071
sg13
I1
sasg24
(lp10072
(dp10073
g7
I0
sg27
VC0016037
p10074
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p10075
sg13
I3
sasa(dp10076
g2
S'It is an autosomal dominant disease, usually caused by a new mutation in the ACVR1 receptor gene, which is in the signaling pathway for bone morphogenic protein.\n'
p10077
sg4
(lp10078
(dp10079
g7
I77
sg8
g9
sg10
I19
sg11
VACVR1 receptor gene
p10080
sg13
I3
sasg24
(lp10081
(dp10082
g7
I57
sg27
VC2985439
p10083
sg10
I12
sg11
Vnew mutation
p10084
sg13
I2
sasa(dp10085
g2
S'Fibrodysplasia ossificans progressiva (FOP), characterized by congenital malformation of bones, is an autosomal dominant disorder.\n'
p10086
sg4
(lp10087
sg24
(lp10088
(dp10089
g7
I0
sg27
VC0016037
p10090
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p10091
sg13
I3
sa(dp10092
g7
I62
sg27
VC1705254
p10093
sg10
I23
sg11
Vcongenital malformation
p10094
sg13
I2
sa(dp10095
g7
I39
sg27
VC0016037
p10096
sg10
I3
sg11
VFOP
p10097
sg13
I1
sasa(dp10098
g2
S'Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification in skeletal muscle tissue.\n'
p10099
sg4
(lp10100
sg24
(lp10101
(dp10102
g7
I0
sg27
VC0016037
p10103
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p10104
sg13
I3
sa(dp10105
g7
I111
sg27
VC0029396
p10106
sg10
I24
sg11
Vheterotopic ossification
p10107
sg13
I2
sa(dp10108
g7
I39
sg27
VC0016037
p10109
sg10
I3
sg11
VFOP
p10110
sg13
I1
sasa(dp10111
g2
S'Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification.\n'
p10112
sg4
(lp10113
sg24
(lp10114
(dp10115
g7
I0
sg27
VC0016037
p10116
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p10117
sg13
I3
sa(dp10118
g7
I111
sg27
VC0029396
p10119
sg10
I24
sg11
Vheterotopic ossification
p10120
sg13
I2
sa(dp10121
g7
I39
sg27
VC0016037
p10122
sg10
I3
sg11
VFOP
p10123
sg13
I1
sasa(dp10124
g2
S'Loss of ORAI1 function is linked with rheumatoid arthritis (RA) and hence pharmacological blockers of ORAI1 could be potential therapeutic agents for the treatment of RA.\n'
p10125
sg4
(lp10126
(dp10127
g7
I8
sg8
g9
sg10
I5
sg11
VORAI1
p10128
sg13
I1
sa(dp10129
g7
I8
sg8
g9
sg10
I5
sg11
VORAI1
p10130
sg13
I1
sasg24
(lp10131
(dp10132
g7
I9
sg27
VC0003873
p10133
sg10
I2
sg11
VRA
p10134
sg13
I1
sa(dp10135
g7
I9
sg27
VC0003873
p10136
sg10
I2
sg11
VRA
p10137
sg13
I1
sa(dp10138
g7
I38
sg27
VC0003873
p10139
sg10
I20
sg11
Vrheumatoid arthritis
p10140
sg13
I2
sasa(dp10141
g2
S'To determine whether Ca(2+) release-activated Ca(2+) (CRAC) channels contribute to the abnormal behaviour of T cells in patients with rheumatoid arthritis (RA), we performed a cross-sectional study to characterize the expression and functional status of CRACM1 channels in RA patients.\n'
p10142
sg4
(lp10143
sg24
(lp10144
(dp10145
g7
I87
sg27
VC0233514
p10146
sg10
I18
sg11
Vabnormal behaviour
p10147
sg13
I2
sa(dp10148
g7
I134
sg27
VC0003873
p10149
sg10
I20
sg11
Vrheumatoid arthritis
p10150
sg13
I2
sa(dp10151
g7
I55
sg27
VC0003873
p10152
sg10
I2
sg11
VRA
p10153
sg13
I1
sa(dp10154
g7
I55
sg27
VC0003873
p10155
sg10
I2
sg11
VRA
p10156
sg13
I1
sasa(dp10157
g2
S'Since autoreactive T cells play an important role in the development of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and organ transplantation, Orai1 becomes an attractive therapeutic target for ameliorating autoimmune disease.\n'
p10158
sg4
(lp10159
(dp10160
g7
I169
sg8
g9
sg10
I5
sg11
VOrai1
p10161
sg13
I1
sasg24
(lp10162
(dp10163
g7
I100
sg27
VC0003873
p10164
sg10
I20
sg11
Vrheumatoid arthritis
p10165
sg13
I2
sa(dp10166
g7
I72
sg27
VC0004364
p10167
sg10
I19
sg11
Vautoimmune diseases
p10168
sg13
I2
sa(dp10169
g7
I72
sg27
VC0004364
p10170
sg10
I18
sg11
Vautoimmune disease
p10171
sg13
I2
sa(dp10172
g7
I122
sg27
VC0026769
p10173
sg10
I18
sg11
Vmultiple sclerosis
p10174
sg13
I2
sasa(dp10175
g2
S'Our results demonstrate that a few point mutations in the Lol p 5 sequence yield mutants with reduced allergenic activity that represent potential vaccine candidates for immunotherapy of grass pollen allergy.\n'
p10176
sg4
(lp10177
(dp10178
g7
I58
sg8
g9
sg10
I30
sg11
VLol p 5 sequence yield mutants
p10179
sg13
I6
sasg24
(lp10180
(dp10181
g7
I187
sg27
VC0740919
p10182
sg10
I20
sg11
Vgrass pollen allergy
p10183
sg13
I3
sasa(dp10184
g2
S'Herein we present data relative to the effect of knocking down BCKDK gene on the real time oxygen consumption rate of fibroblasts obtained from a Maple Syrup Urine Disease (MSUD) patient.\n'
p10185
sg4
(lp10186
(dp10187
g7
I63
sg8
g9
sg10
I10
sg11
VBCKDK gene
p10188
sg13
I2
sasg24
(lp10189
(dp10190
g7
I173
sg27
VC0024776
p10191
sg10
I4
sg11
VMSUD
p10192
sg13
I1
sa(dp10193
g7
I146
sg27
VC0024776
p10194
sg10
I25
sg11
VMaple Syrup Urine Disease
p10195
sg13
I4
sasa(dp10196
g2
S'Data relative to the effectiveness of the knockdown together with the potentiality of the BCKDK-knockdown to increase the deficient branched-chain Alfa-ketoacid dehydrogenase activity detected in MSUD patients are also shown.\n'
p10197
sg4
(lp10198
(dp10199
g7
I90
sg8
g9
sg10
I5
sg11
VBCKDK
p10200
sg13
I1
sa(dp10201
g7
I147
sg8
VP49366
p10202
sg10
I27
sg11
VAlfa-ketoacid dehydrogenase
p10203
sg13
I2
sasg24
(lp10204
(dp10205
g7
I196
sg27
VC0024776
p10206
sg10
I4
sg11
VMSUD
p10207
sg13
I1
sasa(dp10208
g2
S'In the study, 800 patients with coronary artery disease, cerebrovascular disease, or peripheral artery disease (PAD) or multiple cardiovascular risk factors (MRF) were recruited.\n'
p10209
sg4
(lp10210
sg24
(lp10211
(dp10212
g7
I112
sg27
VC1704436
p10213
sg10
I3
sg11
VPAD
p10214
sg13
I1
sa(dp10215
g7
I32
sg27
VC1956346
p10216
sg10
I23
sg11
Vcoronary artery disease
p10217
sg13
I3
sa(dp10218
g7
I57
sg27
VC0007820
p10219
sg10
I23
sg11
Vcerebrovascular disease
p10220
sg13
I2
sa(dp10221
g7
I85
sg27
VC1704436
p10222
sg10
I25
sg11
Vperipheral artery disease
p10223
sg13
I3
sasa(dp10224
g2
S'To obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease (CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined vascular-related hospitalisation rates and associated costs in France and Germany.\n'
p10225
sg4
(lp10226
sg24
(lp10227
(dp10228
g7
I66
sg27
VC1963943
p10229
sg10
I16
sg11
Vatherothrombosis
p10230
sg13
I1
sa(dp10231
g7
I159
sg27
VC0007222
p10232
sg10
I3
sg11
VCVD
p10233
sg13
I1
sa(dp10234
g7
I275
sg27
VC1704436
p10235
sg10
I3
sg11
VPAD
p10236
sg13
I1
sa(dp10237
g7
I246
sg27
VC1704436
p10238
sg10
I27
sg11
Vperipheral arterial disease
p10239
sg13
I3
sa(dp10240
g7
I190
sg27
VC0010054
p10241
sg10
I3
sg11
VCAD
p10242
sg13
I1
sa(dp10243
g7
I134
sg27
VC0007820
p10244
sg10
I23
sg11
Vcerebrovascular disease
p10245
sg13
I2
sa(dp10246
g7
I165
sg27
VC0010054
p10247
sg10
I23
sg11
Vcoronary artery disease
p10248
sg13
I3
sasa(dp10249
g2
S'The stroke relationships of a Chinese character reflect its structure, which can be statistically represented by the neighborhood system and clique potentials within the MRF framework.\n'
p10250
sg4
(lp10251
sg24
(lp10252
(dp10253
g7
I4
sg27
VC0038454
p10254
sg10
I6
sg11
Vstroke
p10255
sg13
I1
sasa(dp10256
g2
S'We penalize the structurally mismatched stroke relationships with MRFs using the prior clique potentials, and derive the likelihood clique potentials from Gaussian mixture models, which encode the large variations of stroke relationships statistically.\n'
p10257
sg4
(lp10258
sg24
(lp10259
(dp10260
g7
I40
sg27
VC0038454
p10261
sg10
I6
sg11
Vstroke
p10262
sg13
I1
sa(dp10263
g7
I40
sg27
VC0038454
p10264
sg10
I6
sg11
Vstroke
p10265
sg13
I1
sasa(dp10266
g2
S'In the proposed HCCR system, we use the single-site likelihood clique potentials to extract many candidate strokes from character images, and use the pairsite clique potentials to determine the best structural match between the input candidate strokes and the MRF-based character models by relaxation labeling.\n'
p10267
sg4
(lp10268
sg24
(lp10269
(dp10270
g7
I107
sg27
VC0038454
p10271
sg10
I7
sg11
Vstrokes
p10272
sg13
I1
sa(dp10273
g7
I107
sg27
VC0038454
p10274
sg10
I7
sg11
Vstrokes
p10275
sg13
I1
sasa(dp10276
g2
S'Total left ventricular stroke volume (TSV), antegrade stroke volume (ASV), and mitral regurgitation volume (MRV) and fraction (MRF) were determined and compared between the two modalities.\n'
p10277
sg4
(lp10278
sg24
(lp10279
(dp10280
g7
I23
sg27
VC0038454
p10281
sg10
I6
sg11
Vstroke
p10282
sg13
I1
sa(dp10283
g7
I23
sg27
VC0038454
p10284
sg10
I6
sg11
Vstroke
p10285
sg13
I1
sa(dp10286
g7
I79
sg27
VC0026266
p10287
sg10
I20
sg11
Vmitral regurgitation
p10288
sg13
I2
sasa(dp10289
g2
S'The reliability of non-invasive quantification of mitral regurgitation (MR) was assessed in 76 patients with angiographically demonstrated MR by comparing the results of different echo-Doppler (ED) indices with angiographic grade and MR fraction (MRF).\n'
p10290
sg4
(lp10291
sg24
(lp10292
(dp10293
g7
I72
sg27
VC0026266
p10294
sg10
I2
sg11
VMR
p10295
sg13
I1
sa(dp10296
g7
I50
sg27
VC0026266
p10297
sg10
I20
sg11
Vmitral regurgitation
p10298
sg13
I2
sa(dp10299
g7
I72
sg27
VC0026266
p10300
sg10
I2
sg11
VMR
p10301
sg13
I1
sa(dp10302
g7
I72
sg27
VC0026266
p10303
sg10
I2
sg11
VMR
p10304
sg13
I1
sasa(dp10305
g2
S'Allergic asthma from mint is less well-recognized.\n'
p10306
sg4
(lp10307
sg24
(lp10308
(dp10309
g7
I0
sg27
VC0155877
p10310
sg10
I15
sg11
VAllergic asthma
p10311
sg13
I2
sasa(dp10312
g2
S'A case of a 54-year-old woman with dyspnea on exposure to the scent of peppermint is presented in whom mint exposure, as seemingly innocuous as the breath of others who had consumed Tic Tac candies, exacerbated her underlying asthma.\n'
p10313
sg4
(lp10314
(dp10315
g7
I182
sg8
g9
sg10
I7
sg11
VTic Tac
p10316
sg13
I2
sasg24
(lp10317
(dp10318
g7
I35
sg27
VC0013404
p10319
sg10
I7
sg11
Vdyspnea
p10320
sg13
I1
sa(dp10321
g7
I182
sg27
VC0278076
p10322
sg10
I3
sg11
VTic
p10323
sg13
I1
sa(dp10324
g7
I226
sg27
VC0004096
p10325
sg10
I6
sg11
Vasthma
p10326
sg13
I1
sasa(dp10327
g2
S'Additionally, this cases suggests that asthma can result from inhaling the scent of mint and gives consideration to obtaining confirmatory pre- and postexposure pulmonary function data by both impulse oscillometry and spirometry.\n'
p10328
sg4
(lp10329
sg24
(lp10330
(dp10331
g7
I39
sg27
VC0004096
p10332
sg10
I6
sg11
Vasthma
p10333
sg13
I1
sasa(dp10334
g2
S"We review the significance of elevated alpha-fetoprotein levels and discuss the clinical relevance of this unusual presentation of a possible primary Hodgkin's lymphoma.\n"
p10335
sg4
(lp10336
(dp10337
g7
I39
sg8
VP02771
p10338
sg10
I17
sg11
Valpha-fetoprotein
p10339
sg13
I1
sasg24
(lp10340
(dp10341
g7
I150
sg27
VC0019829
p10342
sg10
I18
sg11
VHodgkin's lymphoma
p10343
sg13
I2
sasa(dp10344
g2
S'However, we have found that exogenous 8-OHdG can paradoxically reduce ROS production, attenuate the nuclear factor-KB signaling pathway, and ameliorate the expression of proinflammatory mediators such as interleukin (IL)-1, IL-6, cyclo-oxygenase-2, and inducible nitric oxide synthase in addition to expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-1, NOX organizer-1 and NOX activator-1 in various conditions of inflammation-based gastrointestinal (GI) diseases including gastritis, inflammatory bowel disease, pancreatitis, and even colitis-associated carcinogenesis.\n'
p10345
sg4
(lp10346
(dp10347
g7
I230
sg8
VP00403
p10348
sg10
I17
sg11
Vcyclo-oxygenase-2
p10349
sg13
I1
sa(dp10350
g7
I395
sg8
VP05154
p10351
sg10
I15
sg11
VNOX activator-1
p10352
sg13
I2
sa(dp10353
g7
I263
sg8
VP29475
p10354
sg10
I21
sg11
Vnitric oxide synthase
p10355
sg13
I3
sa(dp10356
g7
I204
sg8
VP60568
p10357
sg10
I18
sg11
Vinterleukin (IL)-1
p10358
sg13
I2
sa(dp10359
g7
I224
sg8
VP05231
p10360
sg10
I4
sg11
VIL-6
p10361
sg13
I1
sa(dp10362
g7
I100
sg8
VP01160
p10363
sg10
I17
sg11
Vnuclear factor-KB
p10364
sg13
I2
sa(dp10365
g7
I314
sg8
g9
sg10
I59
sg11
Vnicotinamide adenine dinucleotide phosphate oxidase (NOX)-1
p10366
sg13
I6
sasg24
(lp10367
(dp10368
g7
I436
sg27
VC0021368
p10369
sg10
I12
sg11
Vinflammation
p10370
sg13
I1
sa(dp10371
g7
I535
sg27
VC0030305
p10372
sg10
I12
sg11
Vpancreatitis
p10373
sg13
I1
sa(dp10374
g7
I496
sg27
VC0017152
p10375
sg10
I9
sg11
Vgastritis
p10376
sg13
I1
sa(dp10377
g7
I577
sg27
VC0596263
p10378
sg10
I14
sg11
Vcarcinogenesis
p10379
sg13
I1
sa(dp10380
g7
I507
sg27
VC0021390
p10381
sg10
I26
sg11
Vinflammatory bowel disease
p10382
sg13
I3
sa(dp10383
g7
I558
sg27
VC0009319
p10384
sg10
I7
sg11
Vcolitis
p10385
sg13
I1
sasa(dp10386
g2
S'We studied nine patients (56 +/- 7 years) with complete AV-block and permanent dual-chamber pacemaker (DDD) under different pacing modes: ventricle pacing (VVI) 70 bpm, DDD 106 +/- 4 bpm, rate adaptive pacing (VVI-FA) 108 +/- 3 bpm.\n'
p10387
sg4
(lp10388
sg24
(lp10389
(dp10390
g7
I103
sg27
VC0406811
p10391
sg10
I3
sg11
VDDD
p10392
sg13
I1
sa(dp10393
g7
I103
sg27
VC0406811
p10394
sg10
I3
sg11
VDDD
p10395
sg13
I1
sasa(dp10396
g2
S'Recently, several reports have demonstrated that dysregulation of miR-4262 is in numerous cancers.\n'
p10397
sg4
(lp10398
(dp10399
g7
I66
sg8
g9
sg10
I8
sg11
VmiR-4262
p10400
sg13
I1
sasg24
(lp10401
(dp10402
g7
I90
sg27
VC0006826
p10403
sg10
I7
sg11
Vcancers
p10404
sg13
I1
sasa(dp10405
g2
S'Overexpression of miR-4262 was demonstrated to decrease GALNT4 mRNA and protein expression levels, and thereby suppressed cell viability, growth and cell-cycle progression in SW480 and SW620 colon cancer cells.\n'
p10406
sg4
(lp10407
(dp10408
g7
I18
sg8
g9
sg10
I8
sg11
VmiR-4262
p10409
sg13
I1
sa(dp10410
g7
I56
sg8
g9
sg10
I11
sg11
VGALNT4 mRNA
p10411
sg13
I2
sasg24
(lp10412
(dp10413
g7
I191
sg27
VC0699790
p10414
sg10
I12
sg11
Vcolon cancer
p10415
sg13
I2
sasa(dp10416
g2
S'The expression level of miR-4262 was observed to be downregulated as the expression of GALNT4 was upregulated in colon cancer tissues and cell lines.\n'
p10417
sg4
(lp10418
(dp10419
g7
I87
sg8
g9
sg10
I6
sg11
VGALNT4
p10420
sg13
I1
sa(dp10421
g7
I24
sg8
g9
sg10
I8
sg11
VmiR-4262
p10422
sg13
I1
sasg24
(lp10423
(dp10424
g7
I113
sg27
VC0699790
p10425
sg10
I12
sg11
Vcolon cancer
p10426
sg13
I2
sasa(dp10427
g2
S'In conclusion, the results demonstrated that miR-4262 may be involved in the development of colon cancer via targeting of GALNT4.\n'
p10428
sg4
(lp10429
(dp10430
g7
I122
sg8
g9
sg10
I6
sg11
VGALNT4
p10431
sg13
I1
sa(dp10432
g7
I45
sg8
g9
sg10
I8
sg11
VmiR-4262
p10433
sg13
I1
sasg24
(lp10434
(dp10435
g7
I92
sg27
VC0699790
p10436
sg10
I12
sg11
Vcolon cancer
p10437
sg13
I2
sasa(dp10438
g2
S'The miR-4262/GALNT4 axis may be a novel target for diagnosing and understanding the underlying molecular mechanism of colon cancer.\n'
p10439
sg4
(lp10440
(dp10441
g7
I13
sg8
g9
sg10
I6
sg11
VGALNT4
p10442
sg13
I1
sa(dp10443
g7
I4
sg8
g9
sg10
I8
sg11
VmiR-4262
p10444
sg13
I1
sasg24
(lp10445
(dp10446
g7
I118
sg27
VC0699790
p10447
sg10
I12
sg11
Vcolon cancer
p10448
sg13
I2
sasa(dp10449
g2
S'The aim of this study was to investigate whether miR-4262 was associated with the prognosis of acute myeloid leukemia (AML) patients.\n'
p10450
sg4
(lp10451
sg24
(lp10452
(dp10453
g7
I119
sg27
VC0023467
p10454
sg10
I3
sg11
VAML
p10455
sg13
I1
sa(dp10456
g7
I95
sg27
VC0023467
p10457
sg10
I22
sg11
Vacute myeloid leukemia
p10458
sg13
I3
sasa(dp10459
g2
S'In this study, we investigated the role and underlying mechanism of miR-4262 in the proliferation of human cutaneous malignant melanoma (CMM) cells.\n'
p10460
sg4
(lp10461
sg24
(lp10462
(dp10463
g7
I84
sg27
VC0334094
p10464
sg10
I13
sg11
Vproliferation
p10465
sg13
I1
sa(dp10466
g7
I107
sg27
VC0151779
p10467
sg10
I28
sg11
Vcutaneous malignant melanoma
p10468
sg13
I3
sa(dp10469
g7
I137
sg27
VC0151779
p10470
sg10
I3
sg11
VCMM
p10471
sg13
I1
sasa(dp10472
g2
S'The expression levels of miR-4262 were significantly upregulated in cancerous tissues compared with those in matched adjacent normal tissues from 110 CMM patients.\n'
p10473
sg4
(lp10474
sg24
(lp10475
sa(dp10476
g2
S'miR-4262 was also regulated in five types of CMM cell lines, displaying an opposite expression pattern to that of Kruppel-like 6 (KLF6), a proven tumor suppressor in several cancers other than CMM.\n'
p10477
sg4
(lp10478
(dp10479
g7
I0
sg8
g9
sg10
I8
sg11
VmiR-4262
p10480
sg13
I1
sa(dp10481
g7
I114
sg8
g9
sg10
I14
sg11
VKruppel-like 6
p10482
sg13
I2
sa(dp10483
g7
I130
sg8
g9
sg10
I4
sg11
VKLF6
p10484
sg13
I1
sasg24
(lp10485
(dp10486
g7
I174
sg27
VC0006826
p10487
sg10
I7
sg11
Vcancers
p10488
sg13
I1
sa(dp10489
g7
I146
sg27
VC0027651
p10490
sg10
I5
sg11
Vtumor
p10491
sg13
I1
sasa(dp10492
g2
S'miR-4262 is a potential tumor promoter in human cancers.\n'
p10493
sg4
(lp10494
(dp10495
g7
I0
sg8
g9
sg10
I8
sg11
VmiR-4262
p10496
sg13
I1
sasg24
(lp10497
(dp10498
g7
I48
sg27
VC0006826
p10499
sg10
I7
sg11
Vcancers
p10500
sg13
I1
sa(dp10501
g7
I24
sg27
VC0027651
p10502
sg10
I5
sg11
Vtumor
p10503
sg13
I1
sasa(dp10504
g2
S'In this study, we first investigated the role of miR-4262 in the proliferation and invasion of human breast cancer cells.\n'
p10505
sg4
(lp10506
sg24
(lp10507
(dp10508
g7
I65
sg27
VC0334094
p10509
sg10
I13
sg11
Vproliferation
p10510
sg13
I1
sa(dp10511
g7
I101
sg27
VC0678222
p10512
sg10
I13
sg11
Vbreast cancer
p10513
sg13
I2
sa(dp10514
g7
I83
sg27
VC2699153
p10515
sg10
I8
sg11
Vinvasion
p10516
sg13
I1
sasa(dp10517
g2
S'Our results showed that, compared with the adjacent tissues and MCF-10A normal breast epithelial cells, miR-4262 was markedly increased in the breast cancer tissues and five cell lines, including MDA-MB-231, MDA-MB-468, MDA-MB-435, SKBR3, and MCF-7.\n'
p10518
sg4
(lp10519
(dp10520
g7
I104
sg8
g9
sg10
I8
sg11
VmiR-4262
p10521
sg13
I1
sasg24
(lp10522
(dp10523
g7
I143
sg27
VC0678222
p10524
sg10
I13
sg11
Vbreast cancer
p10525
sg13
I2
sasa(dp10526
g2
S'Then the miR-4262 mimic or oligo anta-miR-4262 was transfected into MDA-MB-231 and MCF-7 breast cancer cell lines.\n'
p10527
sg4
(lp10528
sg24
(lp10529
(dp10530
g7
I89
sg27
VC0678222
p10531
sg10
I13
sg11
Vbreast cancer
p10532
sg13
I2
sasa(dp10533
g2
S'In conclusion, miR-4262 positively regulates proliferation and invasion of human breast cancer cells via suppression of KLF6 and KLF15.\n'
p10534
sg4
(lp10535
(dp10536
g7
I15
sg8
g9
sg10
I8
sg11
VmiR-4262
p10537
sg13
I1
sa(dp10538
g7
I129
sg8
g9
sg10
I5
sg11
VKLF15
p10539
sg13
I1
sa(dp10540
g7
I120
sg8
g9
sg10
I4
sg11
VKLF6
p10541
sg13
I1
sasg24
(lp10542
(dp10543
g7
I63
sg27
VC2699153
p10544
sg10
I8
sg11
Vinvasion
p10545
sg13
I1
sa(dp10546
g7
I105
sg27
VC0221103
p10547
sg10
I11
sg11
Vsuppression
p10548
sg13
I1
sa(dp10549
g7
I81
sg27
VC0678222
p10550
sg10
I13
sg11
Vbreast cancer
p10551
sg13
I2
sa(dp10552
g7
I45
sg27
VC0334094
p10553
sg10
I13
sg11
Vproliferation
p10554
sg13
I1
sasa(dp10555
g2
S'Together, our data suggest that suppression of miR-4262 in OS cells may promote OPN-mediated cancer invasion, highlighting miR-4262 as an intriguing therapeutic target to prevent OS metastases.\n'
p10556
sg4
(lp10557
(dp10558
g7
I80
sg8
VP10451
p10559
sg10
I3
sg11
VOPN
p10560
sg13
I1
sasg24
(lp10561
(dp10562
g7
I100
sg27
VC2699153
p10563
sg10
I8
sg11
Vinvasion
p10564
sg13
I1
sa(dp10565
g7
I32
sg27
VC0221103
p10566
sg10
I11
sg11
Vsuppression
p10567
sg13
I1
sa(dp10568
g7
I182
sg27
VC0027627
p10569
sg10
I10
sg11
Vmetastases
p10570
sg13
I1
sa(dp10571
g7
I93
sg27
VC0006826
p10572
sg10
I6
sg11
Vcancer
p10573
sg13
I1
sasa(dp10574
g2
S'Those can be classified into four groups: hypercalciuric hypomagnesemias (encompassing mutations in CLDN16, CLDN19, CASR, CLCNKB), Gitelman-like hypomagnesemias (CLCNKB, SLC12A3, BSND, KCNJ10, FYXD2, HNF1B, PCBD1), mitochondrial hypomagnesemias (SARS2, MT-TI, Kearns-Sayre syndrome) and other hypomagnesemias (TRPM6, CNMM2, EGF, EGFR, KCNA1, FAM111A).\n'
p10575
sg4
(lp10576
(dp10577
g7
I246
sg8
g9
sg10
I5
sg11
VSARS2
p10578
sg13
I1
sa(dp10579
g7
I324
sg8
VP01133
p10580
sg10
I3
sg11
VEGF
p10581
sg13
I1
sa(dp10582
g7
I108
sg8
g9
sg10
I6
sg11
VCLDN19
p10583
sg13
I1
sa(dp10584
g7
I310
sg8
g9
sg10
I5
sg11
VTRPM6
p10585
sg13
I1
sa(dp10586
g7
I122
sg8
VP51801
p10587
sg10
I6
sg11
VCLCNKB
p10588
sg13
I1
sa(dp10589
g7
I342
sg8
g9
sg10
I7
sg11
VFAM111A
p10590
sg13
I1
sa(dp10591
g7
I335
sg8
g9
sg10
I5
sg11
VKCNA1
p10592
sg13
I1
sa(dp10593
g7
I170
sg8
VP55017
p10594
sg10
I7
sg11
VSLC12A3
p10595
sg13
I1
sa(dp10596
g7
I207
sg8
VP61457
p10597
sg10
I5
sg11
VPCBD1
p10598
sg13
I1
sa(dp10599
g7
I200
sg8
VP35680
p10600
sg10
I5
sg11
VHNF1B
p10601
sg13
I1
sa(dp10602
g7
I179
sg8
g9
sg10
I4
sg11
VBSND
p10603
sg13
I1
sa(dp10604
g7
I185
sg8
VP78508
p10605
sg10
I6
sg11
VKCNJ10
p10606
sg13
I1
sa(dp10607
g7
I100
sg8
g9
sg10
I6
sg11
VCLDN16
p10608
sg13
I1
sa(dp10609
g7
I122
sg8
VP51801
p10610
sg10
I6
sg11
VCLCNKB
p10611
sg13
I1
sa(dp10612
g7
I116
sg8
VP41180
p10613
sg10
I4
sg11
VCASR
p10614
sg13
I1
sasg24
(lp10615
(dp10616
g7
I179
sg27
VC1865270
p10617
sg10
I4
sg11
VBSND
p10618
sg13
I1
sa(dp10619
g7
I260
sg27
VC0022541
p10620
sg10
I21
sg11
VKearns-Sayre syndrome
p10621
sg13
I2
sasa(dp10622
g2
S'For radiculopathy, epidural corticosteroids were associated with greater immediate-term reduction in pain (weighted mean difference on a scale of 0 to 100, -7.55 [95% CI, -11.4 to -3.74]; SOE, moderate), function (standardized mean difference after exclusion of an outlier trial, -0.33 [CI, -0.56 to -0.09]; SOE, low), and short-term surgery risk (relative risk, 0.62 [CI, 0.41 to 0.92]; SOE, low).\n'
p10623
sg4
(lp10624
sg24
(lp10625
(dp10626
g7
I4
sg27
VC0700594
p10627
sg10
I13
sg11
Vradiculopathy
p10628
sg13
I1
sasa(dp10629
g2
S'The final multilevel growth model revealed improvements in RMDQ scores in patients with radiculopathy at the 6-week (-8.1, 95 % CI -12.6 to -2.6; P = 0.006) and 6-month (-4.1, 95 % CI -7.4 to -0.7; P = 0.020) follow-up occasions compared to patients without radiculopathy.\n'
p10630
sg4
(lp10631
sg24
(lp10632
(dp10633
g7
I88
sg27
VC0700594
p10634
sg10
I13
sg11
Vradiculopathy
p10635
sg13
I1
sa(dp10636
g7
I88
sg27
VC0700594
p10637
sg10
I13
sg11
Vradiculopathy
p10638
sg13
I1
sasa(dp10639
g2
S'An interaction between electrodiagnostic status and time revealed faster weekly improvements in RMDQ scores in patients with radiculopathy at the 6-week (-0.72, 95 % CI -1.4 to -0.04; P = 0.040) through the 16-week (-0.30, 95 % CI, -0.57 to -0.04; P = 0.028) follow-up occasions compared to patients without radiculopathy.\n'
p10640
sg4
(lp10641
sg24
(lp10642
(dp10643
g7
I125
sg27
VC0700594
p10644
sg10
I13
sg11
Vradiculopathy
p10645
sg13
I1
sa(dp10646
g7
I125
sg27
VC0700594
p10647
sg10
I13
sg11
Vradiculopathy
p10648
sg13
I1
sasa(dp10649
g2
S'For patients with radiculopathy, a repeated-measures analysis of variance showed a significant decrease in the H reflex amplitude (from 0.81 +/- 0.4 to 0.69 +/- 0.39 mV), an increase in radicular symptoms after reading (from 4.2 +/- 1.3 to 5.6 +/- 1.4 on the visual analog scale), an increase in the H reflex amplitude (from 0.69 +/- 0.39 to 1.01 +/- 0.49 mV), and a decrease in pain intensity (from 5.6 +/- 1.4 to 1.5 +/- 1.3) after repeated neck retractions.\n'
p10650
sg4
(lp10651
sg24
(lp10652
(dp10653
g7
I18
sg27
VC0700594
p10654
sg10
I13
sg11
Vradiculopathy
p10655
sg13
I1
sasa(dp10656
g2
S'Although some autoinflammatory diseases are due to gain-of-function mutations for caspase-1 activity, common diseases such as gout, type 2 diabetes, heart failure, recurrent pericarditis, rheumatoid arthritis, and smoldering myeloma also are responsive to IL-1Beta neutralization.\n'
p10657
sg4
(lp10658
(dp10659
g7
I82
sg8
VP29466
p10660
sg10
I9
sg11
Vcaspase-1
p10661
sg13
I1
sa(dp10662
g7
I256
sg8
VP01584
p10663
sg10
I8
sg11
VIL-1Beta
p10664
sg13
I1
sasg24
(lp10665
(dp10666
g7
I126
sg27
VC0018099
p10667
sg10
I4
sg11
Vgout
p10668
sg13
I1
sa(dp10669
g7
I214
sg27
VC1531608
p10670
sg10
I18
sg11
Vsmoldering myeloma
p10671
sg13
I2
sa(dp10672
g7
I188
sg27
VC0003873
p10673
sg10
I20
sg11
Vrheumatoid arthritis
p10674
sg13
I2
sa(dp10675
g7
I174
sg27
VC0031046
p10676
sg10
I12
sg11
Vpericarditis
p10677
sg13
I1
sa(dp10678
g7
I132
sg27
VC0011860
p10679
sg10
I15
sg11
Vtype 2 diabetes
p10680
sg13
I3
sa(dp10681
g7
I149
sg27
VC0018802
p10682
sg10
I13
sg11
Vheart failure
p10683
sg13
I2
sasa(dp10684
g2
S'Inactivation of Ccl2 in an Lkb1-driven mouse model of endometrial cancer slowed tumor progression and increased survival.\n'
p10685
sg4
(lp10686
(dp10687
g7
I16
sg8
VP13500
p10688
sg10
I4
sg11
VCcl2
p10689
sg13
I1
sa(dp10690
g7
I27
sg8
g9
sg10
I4
sg11
VLkb1
p10691
sg13
I1
sasg24
(lp10692
(dp10693
g7
I80
sg27
VC0178874
p10694
sg10
I17
sg11
Vtumor progression
p10695
sg13
I2
sa(dp10696
g7
I54
sg27
VC0476089
p10697
sg10
I18
sg11
Vendometrial cancer
p10698
sg13
I2
sa(dp10699
g7
I0
sg27
VC0544461
p10700
sg10
I12
sg11
VInactivation
p10701
sg13
I1
sasa(dp10702
g2
S'In human primary endometrial cancers, loss of LKB1 protein was strongly associated with increased CCL2 expression by tumor cells as well as increased macrophage density in the tumor microenvironment.\n'
p10703
sg4
(lp10704
(dp10705
g7
I46
sg8
g9
sg10
I12
sg11
VLKB1 protein
p10706
sg13
I2
sa(dp10707
g7
I98
sg8
VP13500
p10708
sg10
I4
sg11
VCCL2
p10709
sg13
I1
sasg24
(lp10710
(dp10711
g7
I117
sg27
VC0027651
p10712
sg10
I5
sg11
Vtumor
p10713
sg13
I1
sa(dp10714
g7
I17
sg27
VC0476089
p10715
sg10
I19
sg11
Vendometrial cancers
p10716
sg13
I2
sa(dp10717
g7
I117
sg27
VC0027651
p10718
sg10
I5
sg11
Vtumor
p10719
sg13
I1
sasa(dp10720
g2
S'These data demonstrate that CCL2 is a potent effector of LKB1 loss in endometrial cancer, creating potential avenues for therapeutic opportunities.\n'
p10721
sg4
(lp10722
(dp10723
g7
I28
sg8
VP13500
p10724
sg10
I4
sg11
VCCL2
p10725
sg13
I1
sa(dp10726
g7
I57
sg8
g9
sg10
I4
sg11
VLKB1
p10727
sg13
I1
sasg24
(lp10728
(dp10729
g7
I70
sg27
VC0476089
p10730
sg10
I18
sg11
Vendometrial cancer
p10731
sg13
I2
sasa(dp10732
g2
S'Our results showed that in HEC-1-B (human endometrial cancer) cells, IL-17 stimulation induced mRNA level increases of CCL2, CCL5, CCL20, CXCL2, and IL-8.\n'
p10733
sg4
(lp10734
(dp10735
g7
I131
sg8
VP78556
p10736
sg10
I5
sg11
VCCL20
p10737
sg13
I1
sa(dp10738
g7
I27
sg8
g9
sg10
I7
sg11
VHEC-1-B
p10739
sg13
I1
sa(dp10740
g7
I138
sg8
VP19875
p10741
sg10
I5
sg11
VCXCL2
p10742
sg13
I1
sa(dp10743
g7
I125
sg8
VP13501
p10744
sg10
I4
sg11
VCCL5
p10745
sg13
I1
sa(dp10746
g7
I119
sg8
VP13500
p10747
sg10
I4
sg11
VCCL2
p10748
sg13
I1
sasg24
(lp10749
(dp10750
g7
I42
sg27
VC0476089
p10751
sg10
I18
sg11
Vendometrial cancer
p10752
sg13
I2
sasa(dp10753
g2
S'In this study of Turkish women, the association of CCL2 A2518G and CCR2 V64I polymorphisms with endometrial cancer was investigated using 50 endometrial cancer patients and 211 controls.\n'
p10754
sg4
(lp10755
(dp10756
g7
I67
sg8
VP41597
p10757
sg10
I4
sg11
VCCR2
p10758
sg13
I1
sa(dp10759
g7
I51
sg8
VP13500
p10760
sg10
I11
sg11
VCCL2 A2518G
p10761
sg13
I2
sasg24
(lp10762
(dp10763
g7
I96
sg27
VC0476089
p10764
sg10
I18
sg11
Vendometrial cancer
p10765
sg13
I2
sa(dp10766
g7
I96
sg27
VC0476089
p10767
sg10
I18
sg11
Vendometrial cancer
p10768
sg13
I2
sasa(dp10769
g2
S'In our study, individuals with CCL2 A2518G GG genotype showed a 6.7-fold increased risk for endometrial cancer (p&lt;0.0001) and individuals with CCL2 A2518G A allele had a 7.14-fold lower risk of endometrium cancer (p&lt;0.0001).\n'
p10770
sg4
(lp10771
(dp10772
g7
I31
sg8
VP13500
p10773
sg10
I23
sg11
VCCL2 A2518G GG genotype
p10774
sg13
I4
sa(dp10775
g7
I146
sg8
VP13500
p10776
sg10
I20
sg11
VCCL2 A2518G A allele
p10777
sg13
I4
sasg24
(lp10778
(dp10779
g7
I92
sg27
VC0476089
p10780
sg10
I18
sg11
Vendometrial cancer
p10781
sg13
I2
sa(dp10782
g7
I197
sg27
VC0476089
p10783
sg10
I18
sg11
Vendometrium cancer
p10784
sg13
I2
sasa(dp10785
g2
S'In conclusion, we state that there appears to be an association between polymorphism of CCL2 and its receptor CCR2 and endometrial cancer.\n'
p10786
sg4
(lp10787
(dp10788
g7
I110
sg8
VP41597
p10789
sg10
I4
sg11
VCCR2
p10790
sg13
I1
sa(dp10791
g7
I88
sg8
VP13500
p10792
sg10
I4
sg11
VCCL2
p10793
sg13
I1
sasg24
(lp10794
(dp10795
g7
I119
sg27
VC0476089
p10796
sg10
I18
sg11
Vendometrial cancer
p10797
sg13
I2
sasa(dp10798
g2
S'A total of 146 cryptorchid and 140 infertile patients without a history of cryptorchidism were screened with a sequence tagged site plus/minus method and further confirmed and characterized by CDY1/DAZ gene dosage and copy analysis.\n'
p10799
sg4
(lp10800
(dp10801
g7
I193
sg8
g9
sg10
I4
sg11
VCDY1
p10802
sg13
I1
sa(dp10803
g7
I198
sg8
g9
sg10
I3
sg11
VDAZ
p10804
sg13
I1
sasg24
(lp10805
(dp10806
g7
I35
sg27
VC0021359
p10807
sg10
I9
sg11
Vinfertile
p10808
sg13
I1
sa(dp10809
g7
I75
sg27
VC0010417
p10810
sg10
I14
sg11
Vcryptorchidism
p10811
sg13
I1
sasa(dp10812
g2
S'Downregulation of microRNA-497 (miR-497) has been observed in human colorectal cancer (CRC) tissues, but the function of miR-497 in CRC has not been well investigated.\n'
p10813
sg4
(lp10814
(dp10815
g7
I121
sg8
g9
sg10
I14
sg11
VmiR-497 in CRC
p10816
sg13
I3
sa(dp10817
g7
I62
sg8
VP31749
p10818
sg10
I29
sg11
Vhuman colorectal cancer (CRC)
p10819
sg13
I4
sasg24
(lp10820
(dp10821
g7
I87
sg27
VC1527249
p10822
sg10
I3
sg11
VCRC
p10823
sg13
I1
sa(dp10824
g7
I68
sg27
VC1527249
p10825
sg10
I17
sg11
Vcolorectal cancer
p10826
sg13
I2
sa(dp10827
g7
I87
sg27
VC1527249
p10828
sg10
I3
sg11
VCRC
p10829
sg13
I1
sasa(dp10830
g2
S'The aim of this study is to explore the various modes of action miR-497 has on human cervical cancer (CC) cell behavior.\n'
p10831
sg4
(lp10832
sg24
(lp10833
(dp10834
g7
I85
sg27
VC0302592
p10835
sg10
I15
sg11
Vcervical cancer
p10836
sg13
I2
sasa(dp10837
g2
S'In this study, the expression levels of PVT1 and miR-497 in NSCLC cells were determined by qRT-PCR.\n'
p10838
sg4
(lp10839
(dp10840
g7
I49
sg8
g9
sg10
I7
sg11
VmiR-497
p10841
sg13
I1
sasg24
(lp10842
(dp10843
g7
I60
sg27
VC0007131
p10844
sg10
I5
sg11
VNSCLC
p10845
sg13
I1
sasa(dp10846
g2
S'Our findings indicated that PVT1 was significantly upregulated and miR-497 was markedly downregulated in NSCLC cell lines.\n'
p10847
sg4
(lp10848
(dp10849
g7
I67
sg8
g9
sg10
I7
sg11
VmiR-497
p10850
sg13
I1
sasg24
(lp10851
(dp10852
g7
I105
sg27
VC0007131
p10853
sg10
I5
sg11
VNSCLC
p10854
sg13
I1
sasa(dp10855
g2
S'Moreover, PVT1 overexpression reversed the inhibitory effect of miR-497 on cell viability, invasion and promotion effect on apoptosis of NSCLC cells.\n'
p10856
sg4
(lp10857
sg24
(lp10858
(dp10859
g7
I137
sg27
VC0007131
p10860
sg10
I5
sg11
VNSCLC
p10861
sg13
I1
sa(dp10862
g7
I91
sg27
VC2699153
p10863
sg10
I8
sg11
Vinvasion
p10864
sg13
I1
sasa(dp10865
g2
S'In conclusion, knockdown of PVT1 inhibited cell viability, invasion and induced apoptosis in NSCLC by regulating miR-497 expression, elucidating the molecular mechanism of the oncogenic role of PVT1 in NSCLC and providing an lncRNA-directed target for NSCLC.\n'
p10866
sg4
(lp10867
sg24
(lp10868
(dp10869
g7
I93
sg27
VC0007131
p10870
sg10
I5
sg11
VNSCLC
p10871
sg13
I1
sa(dp10872
g7
I59
sg27
VC2699153
p10873
sg10
I8
sg11
Vinvasion
p10874
sg13
I1
sa(dp10875
g7
I93
sg27
VC0007131
p10876
sg10
I5
sg11
VNSCLC
p10877
sg13
I1
sa(dp10878
g7
I93
sg27
VC0007131
p10879
sg10
I5
sg11
VNSCLC
p10880
sg13
I1
sasa(dp10881
g2
S'Many prominent cancer-associated molecules have been identified over the recent years which include EGFR, CD44, TGFbRII, HER2, miR-497, NMP22, BTA, Fibrin/FDP etc.\n'
p10882
sg4
(lp10883
(dp10884
g7
I127
sg8
g9
sg10
I7
sg11
VmiR-497
p10885
sg13
I1
sa(dp10886
g7
I155
sg8
g9
sg10
I3
sg11
VFDP
p10887
sg13
I1
sa(dp10888
g7
I148
sg8
VP22087
p10889
sg10
I6
sg11
VFibrin
p10890
sg13
I1
sa(dp10891
g7
I121
sg8
VP04626
p10892
sg10
I4
sg11
VHER2
p10893
sg13
I1
sasg24
(lp10894
(dp10895
g7
I15
sg27
VC0006826
p10896
sg10
I6
sg11
Vcancer
p10897
sg13
I1
sasa(dp10898
g2
S'PHR patient portal users (34 percent of eligible persons) were older and more likely to be White, have private health insurance, and develop gestational diabetes than nonusers.\n'
p10899
sg4
(lp10900
sg24
(lp10901
(dp10902
g7
I141
sg27
VC0085207
p10903
sg10
I20
sg11
Vgestational diabetes
p10904
sg13
I2
sasa(dp10905
g2
S'We searched the Internet to review patient-held medical records (PHRs) of patients with diabetes and examine current levels of integration of diabetes and depression care in Japan.\n'
p10906
sg4
(lp10907
sg24
(lp10908
(dp10909
g7
I88
sg27
VC0011849
p10910
sg10
I8
sg11
Vdiabetes
p10911
sg13
I1
sa(dp10912
g7
I155
sg27
VC0011581
p10913
sg10
I10
sg11
Vdepression
p10914
sg13
I1
sa(dp10915
g7
I88
sg27
VC0011849
p10916
sg10
I8
sg11
Vdiabetes
p10917
sg13
I1
sasa(dp10918
g2
S'Eight sets of PHRs were found for people with diabetes.\n'
p10919
sg4
(lp10920
sg24
(lp10921
(dp10922
g7
I46
sg27
VC0011849
p10923
sg10
I8
sg11
Vdiabetes
p10924
sg13
I1
sasa(dp10925
g2
S'All PHRs included clinical follow-up of diabetes and multidisciplinary clinical pathways for diabetes care.\n'
p10926
sg4
(lp10927
sg24
(lp10928
(dp10929
g7
I40
sg27
VC0011849
p10930
sg10
I8
sg11
Vdiabetes
p10931
sg13
I1
sa(dp10932
g7
I40
sg27
VC0011849
p10933
sg10
I8
sg11
Vdiabetes
p10934
sg13
I1
sasa(dp10935
g2
S'In terms of an integrated PHR for a patient comorbid with diabetes and depression, necessary components include hopes/preferences, educational information on diabetes complications and treatment, medical history, stress and coping, resources, and monitoring diabetes and depression.\n'
p10936
sg4
(lp10937
sg24
(lp10938
(dp10939
g7
I58
sg27
VC0011849
p10940
sg10
I8
sg11
Vdiabetes
p10941
sg13
I1
sa(dp10942
g7
I71
sg27
VC0011581
p10943
sg10
I10
sg11
Vdepression
p10944
sg13
I1
sa(dp10945
g7
I58
sg27
VC0011849
p10946
sg10
I8
sg11
Vdiabetes
p10947
sg13
I1
sa(dp10948
g7
I158
sg27
VC0342257
p10949
sg10
I22
sg11
Vdiabetes complications
p10950
sg13
I2
sa(dp10951
g7
I71
sg27
VC0011581
p10952
sg10
I10
sg11
Vdepression
p10953
sg13
I1
sasa(dp10954
g2
S'A new PHR may be suitable for comorbid patients with diabetes and depression.\n'
p10955
sg4
(lp10956
sg24
(lp10957
(dp10958
g7
I66
sg27
VC0011581
p10959
sg10
I10
sg11
Vdepression
p10960
sg13
I1
sa(dp10961
g7
I53
sg27
VC0011849
p10962
sg10
I8
sg11
Vdiabetes
p10963
sg13
I1
sasa(dp10964
g2
S'to evaluate the attitude of patients with Type II diabetes towards using a PHR to manage their condition.\n'
p10965
sg4
(lp10966
sg24
(lp10967
(dp10968
g7
I42
sg27
VC0011860
p10969
sg10
I16
sg11
VType II diabetes
p10970
sg13
I3
sa(dp10971
g7
I95
sg27
VC0012634
p10972
sg10
I9
sg11
Vcondition
p10973
sg13
I1
sasa(dp10974
g2
S'The attitude of patients towards using PHR in management of their diabetes was positive.\n'
p10975
sg4
(lp10976
sg24
(lp10977
(dp10978
g7
I66
sg27
VC0011849
p10979
sg10
I8
sg11
Vdiabetes
p10980
sg13
I1
sasa(dp10981
g2
S'Personal health records (PHRs) have the potential to improve patient self-management for chronic conditions such as diabetes.\n'
p10982
sg4
(lp10983
sg24
(lp10984
(dp10985
g7
I116
sg27
VC0011849
p10986
sg10
I8
sg11
Vdiabetes
p10987
sg13
I1
sasa(dp10988
g2
S'The purpose of this qualitative study was to explore how patients with type 2 diabetes used a PHR to manage their diabetes-related health information for self-care.\n'
p10989
sg4
(lp10990
sg24
(lp10991
(dp10992
g7
I71
sg27
VC0011860
p10993
sg10
I15
sg11
Vtype 2 diabetes
p10994
sg13
I3
sa(dp10995
g7
I78
sg27
VC0011849
p10996
sg10
I8
sg11
Vdiabetes
p10997
sg13
I1
sasa(dp10998
g2
S'Fifty-nine patients with type 2 diabetes were interviewed 3-6 months after receiving initial training on a free-of-charge, Web-based PHR.\n'
p10999
sg4
(lp11000
sg24
(lp11001
(dp11002
g7
I123
sg27
VC0332875
p11003
sg10
I3
sg11
VWeb
p11004
sg13
I1
sa(dp11005
g7
I25
sg27
VC0011860
p11006
sg10
I15
sg11
Vtype 2 diabetes
p11007
sg13
I3
sasa(dp11008
g2
S'The objective of this paper is to describe the design and implementation of a Personal Health Record System (PHR-S) for supporting monitoring of blood glucose in diabetes mellitus type 2 patients.\n'
p11009
sg4
(lp11010
sg24
(lp11011
(dp11012
g7
I162
sg27
VC0011860
p11013
sg10
I24
sg11
Vdiabetes mellitus type 2
p11014
sg13
I4
sasa(dp11015
g2
S'In this study the different applications and functionalities of the program are demonstrated such as: exhaustive assembly (rDNA region and mitochondrial genome), extracting homologous regions or genes (IGS, RPB1, RPB2 and TEF1a), as well as extracting multiple regions within a single run.\n'
p11016
sg4
(lp11017
(dp11018
g7
I207
sg8
VP24928
p11019
sg10
I4
sg11
VRPB1
p11020
sg13
I1
sa(dp11021
g7
I213
sg8
VP30876
p11022
sg10
I4
sg11
VRPB2
p11023
sg13
I1
sa(dp11024
g7
I202
sg8
g9
sg10
I3
sg11
VIGS
p11025
sg13
I1
sasg24
(lp11026
(dp11027
g7
I202
sg27
VC1306856
p11028
sg10
I3
sg11
VIGS
p11029
sg13
I1
sasa(dp11030
g2
S'Sequences of the translation elongation factor 1Alfa (tef1Alfa), RNA polymerase II subunit B2 (rpb2), ATP citrate lyase subunit A (acla), and internal transcribed spacer (ITS) regions were monomorphic, while the intergenic spacer (IGS) region showed length polymorphisms at two minisatellites of 23 and 39 nucleotides (nt).\n'
p11031
sg4
(lp11032
(dp11033
g7
I102
sg8
g9
sg10
I27
sg11
VATP citrate lyase subunit A
p11034
sg13
I5
sa(dp11035
g7
I54
sg8
g9
sg10
I8
sg11
Vtef1Alfa
p11036
sg13
I1
sa(dp11037
g7
I95
sg8
VP30876
p11038
sg10
I4
sg11
Vrpb2
p11039
sg13
I1
sa(dp11040
g7
I131
sg8
g9
sg10
I4
sg11
Vacla
p11041
sg13
I1
sa(dp11042
g7
I65
sg8
VP30876
p11043
sg10
I28
sg11
VRNA polymerase II subunit B2
p11044
sg13
I5
sa(dp11045
g7
I17
sg8
g9
sg10
I35
sg11
Vtranslation elongation factor 1Alfa
p11046
sg13
I4
sasg24
(lp11047
(dp11048
g7
I212
sg27
VC1306856
p11049
sg10
I17
sg11
Vintergenic spacer
p11050
sg13
I2
sa(dp11051
g7
I231
sg27
VC1306856
p11052
sg10
I3
sg11
VIGS
p11053
sg13
I1
sasa(dp11054
g2
S'The phylogenetic relationships of these species were determined using sequences from the ITS and IGS region of the nuclear rRNA gene complex, two nuclear genes ( Beta -tubulin (benA) and RNA polymerase II second largest subunit (rpb2)) and two mitochondrial genes (small rRNA subunit (rns) and cytochrome oxidase subunit I (cox1)) and, where available, related sequences from databases.\n'
p11055
sg4
(lp11056
(dp11057
g7
I324
sg8
VP00395
p11058
sg10
I4
sg11
Vcox1
p11059
sg13
I1
sa(dp11060
g7
I294
sg8
VP00395
p11061
sg10
I28
sg11
Vcytochrome oxidase subunit I
p11062
sg13
I4
sa(dp11063
g7
I229
sg8
VP30876
p11064
sg10
I4
sg11
Vrpb2
p11065
sg13
I1
sa(dp11066
g7
I187
sg8
VP19388
p11067
sg10
I17
sg11
VRNA polymerase II
p11068
sg13
I3
sasg24
(lp11069
(dp11070
g7
I285
sg27
VC1850106
p11071
sg10
I3
sg11
Vrns
p11072
sg13
I1
sa(dp11073
g7
I97
sg27
VC1306856
p11074
sg10
I3
sg11
VIGS
p11075
sg13
I1
sasa(dp11076
g2
S'The combined use of the three commonly employed nuclear genes (benA, rpb2, and ITS), the IGS region, and two less often used mitochondrial gene sequences (rns and cox1) as a single unit resolved several taxonomic ambiguities.\n'
p11077
sg4
(lp11078
(dp11079
g7
I155
sg8
g9
sg10
I3
sg11
Vrns
p11080
sg13
I1
sa(dp11081
g7
I163
sg8
VP00395
p11082
sg10
I4
sg11
Vcox1
p11083
sg13
I1
sa(dp11084
g7
I69
sg8
VP30876
p11085
sg10
I4
sg11
Vrpb2
p11086
sg13
I1
sa(dp11087
g7
I89
sg8
g9
sg10
I10
sg11
VIGS region
p11088
sg13
I2
sasg24
(lp11089
(dp11090
g7
I89
sg27
VC1306856
p11091
sg10
I3
sg11
VIGS
p11092
sg13
I1
sa(dp11093
g7
I155
sg27
VC1850106
p11094
sg10
I3
sg11
Vrns
p11095
sg13
I1
sasa(dp11096
g2
S'In order to find other markers that, in combination with the ITS rDNA region can be used for species identification in Cladonia, we studied the loci IGS rDNA, ef1Alfa, rpb2 and cox1.\n'
p11097
sg4
(lp11098
(dp11099
g7
I149
sg8
g9
sg10
I8
sg11
VIGS rDNA
p11100
sg13
I2
sa(dp11101
g7
I168
sg8
VP30876
p11102
sg10
I4
sg11
Vrpb2
p11103
sg13
I1
sa(dp11104
g7
I177
sg8
VP00395
p11105
sg10
I4
sg11
Vcox1
p11106
sg13
I1
sasg24
(lp11107
(dp11108
g7
I149
sg27
VC1306856
p11109
sg10
I3
sg11
VIGS
p11110
sg13
I1
sasa(dp11111
g2
S"Three-gene combined analyses (ITS+IGS+rpb2) were performed and the results indicated that the Chinese 'G.\n"
p11112
sg4
(lp11113
sg24
(lp11114
sa(dp11115
g2
S'Seven loci were analyzed: the translation elongation factor 1 alpha gene (EF-1Alfa); the nuclear rRNA internal transcribed spacer (ITS), large subunit (LSU), and intergenic spacer (IGS) regions; the second largest subunit of the RNA polymerase gene (RPB2); the calmodulin gene (CAM); and the mitochondrial small subunit (mtSSU) rRNA gene.\n'
p11116
sg4
(lp11117
(dp11118
g7
I30
sg8
g9
sg10
I42
sg11
Vtranslation elongation factor 1 alpha gene
p11119
sg13
I6
sa(dp11120
g7
I250
sg8
VP30876
p11121
sg10
I4
sg11
VRPB2
p11122
sg13
I1
sa(dp11123
g7
I278
sg8
VP01768
p11124
sg10
I3
sg11
VCAM
p11125
sg13
I1
sa(dp11126
g7
I261
sg8
g9
sg10
I15
sg11
Vcalmodulin gene
p11127
sg13
I2
sasg24
(lp11128
(dp11129
g7
I162
sg27
VC1306856
p11130
sg10
I17
sg11
Vintergenic spacer
p11131
sg13
I2
sa(dp11132
g7
I261
sg27
VC1861821
p11133
sg10
I15
sg11
Vcalmodulin gene
p11134
sg13
I2
sa(dp11135
g7
I181
sg27
VC1306856
p11136
sg10
I3
sg11
VIGS
p11137
sg13
I1
sa(dp11138
g7
I278
sg27
VC1861821
p11139
sg10
I3
sg11
VCAM
p11140
sg13
I1
sasa(dp11141
g2
S'Twenty-nine IGS, 27 EF-1Alfa, 26 RPB2, 24 CAM, 18 ITS, 19 LSU, and 18 mtSSU haplotypes were identified; 29 were unique, and haplotypes for 24 clinical strains were novel.\n'
p11142
sg4
(lp11143
(dp11144
g7
I12
sg8
g9
sg10
I25
sg11
VIGS, 27 EF-1Alfa, 26 RPB2
p11145
sg13
I5
sasg24
(lp11146
(dp11147
g7
I12
sg27
VC1306856
p11148
sg10
I3
sg11
VIGS
p11149
sg13
I1
sa(dp11150
g7
I42
sg27
VC1861821
p11151
sg10
I3
sg11
VCAM
p11152
sg13
I1
sasa(dp11153
g2
S'Complete absence of STAT6 was most common in pleomorphic liposarcoma and alveolar soft part sarcoma (60% and 72% cases negative, respectively).\n'
p11154
sg4
(lp11155
(dp11156
g7
I20
sg8
VP42226
p11157
sg10
I5
sg11
VSTAT6
p11158
sg13
I1
sasg24
(lp11159
(dp11160
g7
I45
sg27
VC0205825
p11161
sg10
I23
sg11
Vpleomorphic liposarcoma
p11162
sg13
I2
sa(dp11163
g7
I73
sg27
VC0206657
p11164
sg10
I26
sg11
Valveolar soft part sarcoma
p11165
sg13
I4
sasa(dp11166
g2
S'Patients with ASC due to choledocholithiasis were allocated to two groups: Those who underwent EST immediately and those who underwent EBD followed by EST 1 wk later because they were under anticoagulant therapy, had a coagulopathy (international normalized ratio &gt; 1.3, partial thromboplastin time greater than twice that of control), or had a platelet count &lt; 50000 x 10(3)/myL.\n'
p11167
sg4
(lp11168
(dp11169
g7
I282
sg8
VP13726
p11170
sg10
I14
sg11
Vthromboplastin
p11171
sg13
I1
sa(dp11172
g7
I382
sg8
VP29590
p11173
sg10
I3
sg11
VmyL
p11174
sg13
I1
sasg24
(lp11175
(dp11176
g7
I25
sg27
VC0701818
p11177
sg10
I19
sg11
Vcholedocholithiasis
p11178
sg13
I1
sa(dp11179
g7
I219
sg27
VC0005779
p11180
sg10
I12
sg11
Vcoagulopathy
p11181
sg13
I1
sasa(dp11182
g2
S'A cross of the Asd-4 mutant with wild-type resulted in fruiting bodies that appeared to be normal macroscopically but which were complete devoid of asci and ascospores.\n'
p11183
sg4
(lp11184
(dp11185
g7
I15
sg8
VP51689
p11186
sg10
I12
sg11
VAsd-4 mutant
p11187
sg13
I2
sasg24
(lp11188
(dp11189
g7
I15
sg27
VC1510586
p11190
sg10
I3
sg11
VAsd
p11191
sg13
I1
sa(dp11192
g7
I21
sg27
VC0596988
p11193
sg10
I6
sg11
Vmutant
p11194
sg13
I1
sasa(dp11195
g2
S'A mutant strain (asd-1) with a recessive crossing defect (apparently caused by the RIP process) was isolated; in this strain, early development is normal and may asci are formed, but ascospores are never delineated.\n'
p11196
sg4
(lp11197
(dp11198
g7
I17
sg8
VP51689
p11199
sg10
I5
sg11
Vasd-1
p11200
sg13
I1
sasg24
(lp11201
(dp11202
g7
I17
sg27
VC1510586
p11203
sg10
I3
sg11
Vasd
p11204
sg13
I1
sa(dp11205
g7
I2
sg27
VC0596988
p11206
sg10
I6
sg11
Vmutant
p11207
sg13
I1
sasa(dp11208
g2
S'cPGES and mPGES-2 have been found expressed in normal gastric mucosa, with no change in expression levels seen in gastritis or gastric ulcer tissue.\n'
p11209
sg4
(lp11210
(dp11211
g7
I10
sg8
g9
sg10
I7
sg11
VmPGES-2
p11212
sg13
I1
sa(dp11213
g7
I0
sg8
g9
sg10
I5
sg11
VcPGES
p11214
sg13
I1
sasg24
(lp11215
(dp11216
g7
I114
sg27
VC0017152
p11217
sg10
I9
sg11
Vgastritis
p11218
sg13
I1
sa(dp11219
g7
I127
sg27
VC0038358
p11220
sg10
I13
sg11
Vgastric ulcer
p11221
sg13
I2
sasa(dp11222
g2
S'Herein we investigated the ATR-Chk1 and ATM-Chk2 signalings in male breast cancer (MBC).\n'
p11223
sg4
(lp11224
(dp11225
g7
I31
sg8
g9
sg10
I4
sg11
VChk1
p11226
sg13
I1
sa(dp11227
g7
I40
sg8
g9
sg10
I3
sg11
VATM
p11228
sg13
I1
sasg24
(lp11229
(dp11230
g7
I83
sg27
VC0242787
p11231
sg10
I3
sg11
VMBC
p11232
sg13
I1
sa(dp11233
g7
I63
sg27
VC0242787
p11234
sg10
I18
sg11
Vmale breast cancer
p11235
sg13
I3
sasa(dp11236
g2
S'We have previously shown that the1100delC variant of the cell-cycle-checkpoint kinase gene CHEK2, which is carried by approximately 1% of the population confers a two-fold increase in female breast cancer and a 10-fold increase in male breast cancer.\n'
p11237
sg4
(lp11238
sg24
(lp11239
(dp11240
g7
I184
sg27
VC0235653
p11241
sg10
I20
sg11
Vfemale breast cancer
p11242
sg13
I3
sa(dp11243
g7
I186
sg27
VC0242787
p11244
sg10
I18
sg11
Vmale breast cancer
p11245
sg13
I3
sasa(dp11246
g2
S'The purpose of present study was to investigate the relation of serum interleukin-19 (IL-19) levels with diabetic nephropathy (DN).\n'
p11247
sg4
(lp11248
(dp11249
g7
I70
sg8
g9
sg10
I14
sg11
Vinterleukin-19
p11250
sg13
I1
sa(dp11251
g7
I86
sg8
g9
sg10
I5
sg11
VIL-19
p11252
sg13
I1
sasg24
(lp11253
(dp11254
g7
I105
sg27
VC0011881
p11255
sg10
I20
sg11
Vdiabetic nephropathy
p11256
sg13
I2
sa(dp11257
g7
I127
sg27
VC0011881
p11258
sg10
I2
sg11
VDN
p11259
sg13
I1
sasa(dp11260
g2
S'IL-19 is significantly positive correlated with UAE and Cystatin C. IL-19 may play an important role that contributes to the progression of diabetic nephropathy.\n'
p11261
sg4
(lp11262
(dp11263
g7
I0
sg8
g9
sg10
I5
sg11
VIL-19
p11264
sg13
I1
sa(dp11265
g7
I0
sg8
g9
sg10
I5
sg11
VIL-19
p11266
sg13
I1
sa(dp11267
g7
I56
sg8
VP01034
p11268
sg10
I10
sg11
VCystatin C
p11269
sg13
I2
sasg24
(lp11270
(dp11271
g7
I140
sg27
VC0011881
p11272
sg10
I20
sg11
Vdiabetic nephropathy
p11273
sg13
I2
sasa(dp11274
g2
S'We also demonstrate a large increase in levels of IL-19 in urine of patients with chronic kidney disease, which significantly correlated with estimated glomerular filtration rate levels.\n'
p11275
sg4
(lp11276
(dp11277
g7
I50
sg8
g9
sg10
I5
sg11
VIL-19
p11278
sg13
I1
sasg24
(lp11279
(dp11280
g7
I82
sg27
VC1561643
p11281
sg10
I22
sg11
Vchronic kidney disease
p11282
sg13
I3
sasa(dp11283
g2
S'Non-clustered protocadherins (PCDHs) are calcium-dependent adhesion molecules which have attracted attention for their possible roles in the neuronal circuit formation during development and their implications in the neurological disorders such as autism and mental retardation.\n'
p11284
sg4
(lp11285
sg24
(lp11286
(dp11287
g7
I217
sg27
VC0027765
p11288
sg10
I22
sg11
Vneurological disorders
p11289
sg13
I2
sa(dp11290
g7
I59
sg27
VC0001511
p11291
sg10
I8
sg11
Vadhesion
p11292
sg13
I1
sa(dp11293
g7
I248
sg27
VC0004352
p11294
sg10
I6
sg11
Vautism
p11295
sg13
I1
sa(dp11296
g7
I259
sg27
VC0025362
p11297
sg10
I18
sg11
Vmental retardation
p11298
sg13
I2
sasa(dp11299
g2
S'Mutation screening of 30 individuals with autism identified two PCDH11Y polymorphic amino acid changes, F885V and K980N.\n'
p11300
sg4
(lp11301
sg24
(lp11302
(dp11303
g7
I42
sg27
VC0004352
p11304
sg10
I6
sg11
Vautism
p11305
sg13
I1
sasa(dp11306
g2
S'In the present study, we analyzed the expression levels of LETM1 in bladder cancer tissues and non-cancerous tissues as well as in four bladder cancer cell lines (T24, EJ, 5637 and J82) and a human bladder epithelial immortalized cell line SV-HUC-1.\n'
p11307
sg4
(lp11308
(dp11309
g7
I59
sg8
g9
sg10
I5
sg11
VLETM1
p11310
sg13
I1
sasg24
(lp11311
(dp11312
g7
I68
sg27
VC0699885
p11313
sg10
I14
sg11
Vbladder cancer
p11314
sg13
I2
sa(dp11315
g7
I68
sg27
VC0699885
p11316
sg10
I14
sg11
Vbladder cancer
p11317
sg13
I2
sasa(dp11318
g2
S'The PD-L1 mRNA and protein expression levels were measured in the bladder cancer T24 cell line and the human uroepithelial SV-HUC-1 cell line, following treatment with interleukin (IL)-2, interferon (IFN)-Alfa and IFN-Gamma, by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively.\n'
p11319
sg4
(lp11320
(dp11321
g7
I200
sg8
VP01562
p11322
sg10
I3
sg11
VIFN
p11323
sg13
I1
sa(dp11324
g7
I188
sg8
VP01563
p11325
sg10
I10
sg11
Vinterferon
p11326
sg13
I1
sa(dp11327
g7
I214
sg8
VP01579
p11328
sg10
I9
sg11
VIFN-Gamma
p11329
sg13
I1
sa(dp11330
g7
I168
sg8
VP60568
p11331
sg10
I18
sg11
Vinterleukin (IL)-2
p11332
sg13
I2
sasg24
(lp11333
(dp11334
g7
I66
sg27
VC0699885
p11335
sg10
I14
sg11
Vbladder cancer
p11336
sg13
I2
sasa(dp11337
g2
S'RT-qPCR and western blotting demonstrated that cytokines IL-2, IFN-Alfa and IFN-Gamma markedly upregulated PD-L1 mRNA expression rates and protein levels in bladder cancer T24 cells (P&lt;0.05), but had no significant effect in non-tumor SV-HUC-1 cells.\n'
p11338
sg4
(lp11339
(dp11340
g7
I63
sg8
VP01562
p11341
sg10
I8
sg11
VIFN-Alfa
p11342
sg13
I1
sa(dp11343
g7
I57
sg8
VP60568
p11344
sg10
I4
sg11
VIL-2
p11345
sg13
I1
sa(dp11346
g7
I76
sg8
VP01579
p11347
sg10
I9
sg11
VIFN-Gamma
p11348
sg13
I1
sasg24
(lp11349
(dp11350
g7
I157
sg27
VC0699885
p11351
sg10
I14
sg11
Vbladder cancer
p11352
sg13
I2
sa(dp11353
g7
I232
sg27
VC0027651
p11354
sg10
I5
sg11
Vtumor
p11355
sg13
I1
sasa(dp11356
g2
S'Our data showed that miR-6838 was sharply up-regulated in the bladder tissues from bladder cancer patients and 4 human bladder cancer cell lines, compared with the healthy volunteers and SU-HUC-1 human normal bladder epithelial cells.\n'
p11357
sg4
(lp11358
(dp11359
g7
I187
sg8
g9
sg10
I8
sg11
VSU-HUC-1
p11360
sg13
I1
sasg24
(lp11361
(dp11362
g7
I83
sg27
VC0699885
p11363
sg10
I14
sg11
Vbladder cancer
p11364
sg13
I2
sa(dp11365
g7
I83
sg27
VC0699885
p11366
sg10
I14
sg11
Vbladder cancer
p11367
sg13
I2
sasa(dp11368
g2
S'Treatment with dioscin decreased viability of BC 5637 and T24 cells, but not non-cancer bladder epithelial cell, SV-HUC-1.\n'
p11369
sg4
(lp11370
sg24
(lp11371
(dp11372
g7
I81
sg27
VC0006826
p11373
sg10
I6
sg11
Vcancer
p11374
sg13
I1
sasa(dp11375
g2
S'A primary deficiency of protein C or S is proposed which would produce cerebral thrombosis with exposure of phospholipids; this thrombosis then, like antigens, would generate antibodies acting on the thrombin-thrombomodulin complex, exacerbating the thrombotic process.\n'
p11376
sg4
(lp11377
(dp11378
g7
I24
sg8
VP02810
p11379
sg10
I9
sg11
Vprotein C
p11380
sg13
I2
sa(dp11381
g7
I200
sg8
VP00734
p11382
sg10
I8
sg11
Vthrombin
p11383
sg13
I1
sa(dp11384
g7
I209
sg8
VP07204
p11385
sg10
I14
sg11
Vthrombomodulin
p11386
sg13
I1
sasg24
(lp11387
(dp11388
g7
I71
sg27
VC0795687
p11389
sg10
I19
sg11
Vcerebral thrombosis
p11390
sg13
I2
sa(dp11391
g7
I80
sg27
VC0040053
p11392
sg10
I10
sg11
Vthrombosis
p11393
sg13
I1
sasa(dp11394
g2
S'To investigate whether defects in the SPATA17 gene are associated with azoospermia due to meiotic arrest, a mutational analysis was conducted, in which the SPATA17 coding regions of 18 Japanese patients with this condition were sequenced.\n'
p11395
sg4
(lp11396
(dp11397
g7
I38
sg8
g9
sg10
I12
sg11
VSPATA17 gene
p11398
sg13
I2
sa(dp11399
g7
I38
sg8
g9
sg10
I7
sg11
VSPATA17
p11400
sg13
I1
sasg24
(lp11401
(dp11402
g7
I213
sg27
VC0012634
p11403
sg10
I9
sg11
Vcondition
p11404
sg13
I1
sa(dp11405
g7
I71
sg27
VC1321542
p11406
sg10
I11
sg11
Vazoospermia
p11407
sg13
I1
sasa(dp11408
g2
S'The frequencies of erythrocyte MNSs antigens and certain histocompatibility leukocyte antigen (HLA) specificities (HLA-A, HLA-B, and HLA-DR) were determined in white patients with meningitis or epiglottitis due to Haemophilus influenzae type b and in controls.\n'
p11409
sg4
(lp11410
(dp11411
g7
I19
sg8
VP21333
p11412
sg10
I25
sg11
Verythrocyte MNSs antigens
p11413
sg13
I3
sa(dp11414
g7
I49
sg8
VP14209
p11415
sg10
I44
sg11
Vcertain histocompatibility leukocyte antigen
p11416
sg13
I4
sa(dp11417
g7
I122
sg8
VP30461
p11418
sg10
I5
sg11
VHLA-B
p11419
sg13
I1
sa(dp11420
g7
I133
sg8
VP30486
p11421
sg10
I6
sg11
VHLA-DR
p11422
sg13
I1
sa(dp11423
g7
I115
sg8
VP30447
p11424
sg10
I5
sg11
VHLA-A
p11425
sg13
I1
sa(dp11426
g7
I95
sg8
VP30486
p11427
sg10
I3
sg11
VHLA
p11428
sg13
I1
sasg24
(lp11429
(dp11430
g7
I194
sg27
VC0014541
p11431
sg10
I12
sg11
Vepiglottitis
p11432
sg13
I1
sa(dp11433
g7
I180
sg27
VC0025289
p11434
sg10
I10
sg11
Vmeningitis
p11435
sg13
I1
sasa(dp11436
g2
S'Analysis of antigen expression pattern, the presence or absence of T cell-associated antigen deletion, and the expression of CD10 and CD34 by 4-color flow cytometry can help differentiate thymoma from T-cell ALL/LBL.\n'
p11437
sg4
(lp11438
(dp11439
g7
I125
sg8
VP08473
p11440
sg10
I4
sg11
VCD10
p11441
sg13
I1
sa(dp11442
g7
I134
sg8
VP28906
p11443
sg10
I4
sg11
VCD34
p11444
sg13
I1
sa(dp11445
g7
I67
sg8
VP14209
p11446
sg10
I25
sg11
VT cell-associated antigen
p11447
sg13
I3
sasg24
(lp11448
(dp11449
g7
I188
sg27
VC0040100
p11450
sg10
I7
sg11
Vthymoma
p11451
sg13
I1
sasa(dp11452
g2
S'We found that CYC1 was upregulated in breast tumor tissues, especially in tissues with lymph node metastasis.\n'
p11453
sg4
(lp11454
(dp11455
g7
I14
sg8
VP08574
p11456
sg10
I4
sg11
VCYC1
p11457
sg13
I1
sasg24
(lp11458
(dp11459
g7
I38
sg27
VC1458155
p11460
sg10
I12
sg11
Vbreast tumor
p11461
sg13
I2
sa(dp11462
g7
I87
sg27
VC0686619
p11463
sg10
I21
sg11
Vlymph node metastasis
p11464
sg13
I3
sasa(dp11465
g2
S'And higher expression of CYC1 correlates with poor prognosis in breast cancer patients using online databases and tools.\n'
p11466
sg4
(lp11467
(dp11468
g7
I25
sg8
VP08574
p11469
sg10
I4
sg11
VCYC1
p11470
sg13
I1
sasg24
(lp11471
(dp11472
g7
I64
sg27
VC0678222
p11473
sg10
I13
sg11
Vbreast cancer
p11474
sg13
I2
sasa(dp11475
g2
S'Then we confirmed that CYC1 contributed to metastasis and proliferation in two highly metastatic human breast cancer cell lines.\n'
p11476
sg4
(lp11477
(dp11478
g7
I23
sg8
VP08574
p11479
sg10
I4
sg11
VCYC1
p11480
sg13
I1
sasg24
(lp11481
(dp11482
g7
I43
sg27
VC0027627
p11483
sg10
I10
sg11
Vmetastasis
p11484
sg13
I1
sa(dp11485
g7
I58
sg27
VC0334094
p11486
sg10
I13
sg11
Vproliferation
p11487
sg13
I1
sa(dp11488
g7
I103
sg27
VC0678222
p11489
sg10
I13
sg11
Vbreast cancer
p11490
sg13
I2
sasa(dp11491
g2
S'Our results indicated that CYC1 plays crucial roles in breast cancer progression and might be a predictive factor assisting future patient diagnosis.\n'
p11492
sg4
(lp11493
(dp11494
g7
I27
sg8
VP08574
p11495
sg10
I4
sg11
VCYC1
p11496
sg13
I1
sasg24
(lp11497
(dp11498
g7
I62
sg27
VC0178874
p11499
sg10
I18
sg11
Vcancer progression
p11500
sg13
I2
sasa(dp11501
g2
S'Ubiquinol-cytochrome c reductase hinge protein (UQCRH), as a connecter between cytochrome c1 with cytochrome c in complex III of respiratory chain, is top-ranked hypermethylated gene in clear cell renal cell carcinoma (ccRCC).\n'
p11502
sg4
(lp11503
(dp11504
g7
I48
sg8
VP07919
p11505
sg10
I5
sg11
VUQCRH
p11506
sg13
I1
sa(dp11507
g7
I79
sg8
VP08574
p11508
sg10
I13
sg11
Vcytochrome c1
p11509
sg13
I2
sa(dp11510
g7
I10
sg8
VP99999
p11511
sg10
I12
sg11
Vcytochrome c
p11512
sg13
I2
sa(dp11513
g7
I0
sg8
VP99999
p11514
sg10
I46
sg11
VUbiquinol-cytochrome c reductase hinge protein
p11515
sg13
I5
sasg24
(lp11516
(dp11517
g7
I219
sg27
VC0279702
p11518
sg10
I5
sg11
VccRCC
p11519
sg13
I1
sa(dp11520
g7
I186
sg27
VC0279702
p11521
sg10
I31
sg11
Vclear cell renal cell carcinoma
p11522
sg13
I5
sasa(dp11523
g2
S'This study aimed at testing a panel of nine reference genes [beta-2-microglobulin, cytochrome c-1 (CYC1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase, hypoxanthine guanine phosphoribosyl transferase 1, ribosomal protein L13a (RPL13A), succinate dehydrogenase, TATA-box binding protein and 14-3-3 protein zeta] to identify and validate the most suitable reference genes for expression studies in human glioma of different grades (World Health Organization grades II-IV).\n'
p11524
sg4
(lp11525
(dp11526
g7
I99
sg8
VP08574
p11527
sg10
I4
sg11
VCYC1
p11528
sg13
I1
sa(dp11529
g7
I61
sg8
VP61769
p11530
sg10
I20
sg11
Vbeta-2-microglobulin
p11531
sg13
I1
sa(dp11532
g7
I237
sg8
VP40429
p11533
sg10
I22
sg11
Vribosomal protein L13a
p11534
sg13
I3
sa(dp11535
g7
I295
sg8
VP20226
p11536
sg10
I24
sg11
VTATA-box binding protein
p11537
sg13
I3
sa(dp11538
g7
I83
sg8
VP99999
p11539
sg10
I14
sg11
Vcytochrome c-1
p11540
sg13
I2
sa(dp11541
g7
I261
sg8
VP40429
p11542
sg10
I6
sg11
VRPL13A
p11543
sg13
I1
sa(dp11544
g7
I106
sg8
VP04406
p11545
sg10
I40
sg11
Vglyceraldehyde-3-phosphate dehydrogenase
p11546
sg13
I2
sa(dp11547
g7
I186
sg8
VP00492
p11548
sg10
I49
sg11
Vhypoxanthine guanine phosphoribosyl transferase 1
p11549
sg13
I5
sa(dp11550
g7
I156
sg8
VP08397
p11551
sg10
I28
sg11
Vhydroxymethylbilane synthase
p11552
sg13
I2
sa(dp11553
g7
I148
sg8
VP04406
p11554
sg10
I5
sg11
VGAPDH
p11555
sg13
I1
sa(dp11556
g7
I270
sg8
VP49366
p11557
sg10
I23
sg11
Vsuccinate dehydrogenase
p11558
sg13
I2
sasg24
(lp11559
(dp11560
g7
I436
sg27
VC0017638
p11561
sg10
I6
sg11
Vglioma
p11562
sg13
I1
sasa(dp11563
g2
S'After analysis of the stability values calculated using geNorm, NormFinder, and BestKeeper algorithms, GAPDH, RPL13A, and CYC1 can be indicated as reference genes applicable for accurate normalization of gene expression in glioma compared with normal brain and anaplastic astrocytoma or glioblastoma alone within this experimental setting.\n'
p11564
sg4
(lp11565
(dp11566
g7
I110
sg8
VP40429
p11567
sg10
I6
sg11
VRPL13A
p11568
sg13
I1
sa(dp11569
g7
I122
sg8
VP08574
p11570
sg10
I4
sg11
VCYC1
p11571
sg13
I1
sa(dp11572
g7
I103
sg8
VP04406
p11573
sg10
I5
sg11
VGAPDH
p11574
sg13
I1
sasg24
(lp11575
(dp11576
g7
I287
sg27
VC0017636
p11577
sg10
I12
sg11
Vglioblastoma
p11578
sg13
I1
sa(dp11579
g7
I261
sg27
VC0334579
p11580
sg10
I22
sg11
Vanaplastic astrocytoma
p11581
sg13
I2
sa(dp11582
g7
I223
sg27
VC0017638
p11583
sg10
I6
sg11
Vglioma
p11584
sg13
I1
sasa(dp11585
g2
S'Kaplan-Meier plots identified correlations between individual or combined overexpression of E2F1, E2F3a, Mps1/TTK, Nek2, BubR1, or Hec1 and poor overall and relapse-free survival of breast cancer patients.\n'
p11586
sg4
(lp11587
(dp11588
g7
I131
sg8
g9
sg10
I4
sg11
VHec1
p11589
sg13
I1
sa(dp11590
g7
I105
sg8
VP33981
p11591
sg10
I4
sg11
VMps1
p11592
sg13
I1
sa(dp11593
g7
I115
sg8
VP51955
p11594
sg10
I4
sg11
VNek2
p11595
sg13
I1
sa(dp11596
g7
I92
sg8
g9
sg10
I4
sg11
VE2F1
p11597
sg13
I1
sa(dp11598
g7
I110
sg8
VP49841
p11599
sg10
I3
sg11
VTTK
p11600
sg13
I1
sa(dp11601
g7
I98
sg8
g9
sg10
I5
sg11
VE2F3a
p11602
sg13
I1
sasg24
(lp11603
(dp11604
g7
I157
sg27
VC0277556
p11605
sg10
I7
sg11
Vrelapse
p11606
sg13
I1
sa(dp11607
g7
I182
sg27
VC0678222
p11608
sg10
I13
sg11
Vbreast cancer
p11609
sg13
I2
sasa(dp11610
g2
S'By interrogating the METABRIC database, we observed a significant correlation between p53 expression and that of c-Abl and TTK in basal-like breast cancers.\n'
p11611
sg4
(lp11612
(dp11613
g7
I86
sg8
VP42771
p11614
sg10
I3
sg11
Vp53
p11615
sg13
I1
sa(dp11616
g7
I113
sg8
VP00519
p11617
sg10
I5
sg11
Vc-Abl
p11618
sg13
I1
sa(dp11619
g7
I123
sg8
VP49841
p11620
sg10
I3
sg11
VTTK
p11621
sg13
I1
sasg24
(lp11622
(dp11623
g7
I141
sg27
VC0006142
p11624
sg10
I14
sg11
Vbreast cancers
p11625
sg13
I2
sa(dp11626
g7
I115
sg27
VC0000744
p11627
sg10
I3
sg11
VAbl
p11628
sg13
I1
sasa(dp11629
g2
S'The protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a critical component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple negative breast cancer.\n'
p11630
sg4
(lp11631
(dp11632
g7
I46
sg8
VP49841
p11633
sg10
I3
sg11
VTTK
p11634
sg13
I1
sa(dp11635
g7
I4
sg8
VP29401
p11636
sg10
I40
sg11
Vprotein kinase threonine tyrosine kinase
p11637
sg13
I5
sa(dp11638
g7
I65
sg8
VP33981
p11639
sg10
I4
sg11
VMps1
p11640
sg13
I1
sasg24
(lp11641
(dp11642
g7
I190
sg27
VC0006826
p11643
sg10
I7
sg11
Vcancers
p11644
sg13
I1
sa(dp11645
g7
I223
sg27
VC0678222
p11646
sg10
I13
sg11
Vbreast cancer
p11647
sg13
I2
sa(dp11648
g7
I179
sg27
VC0001807
p11649
sg10
I10
sg11
Vaggressive
p11650
sg13
I1
sasa(dp11651
g2
S'High levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting a potential new therapeutic target for aggressive breast cancers (BC).\n'
p11652
sg4
(lp11653
(dp11654
g7
I50
sg8
VP49841
p11655
sg10
I3
sg11
VTTK
p11656
sg13
I1
sa(dp11657
g7
I45
sg8
VP33981
p11658
sg10
I4
sg11
VMps1
p11659
sg13
I1
sasg24
(lp11660
(dp11661
g7
I165
sg27
VC0001807
p11662
sg10
I10
sg11
Vaggressive
p11663
sg13
I1
sa(dp11664
g7
I176
sg27
VC0006142
p11665
sg10
I14
sg11
Vbreast cancers
p11666
sg13
I2
sa(dp11667
g7
I100
sg27
VC0006142
p11668
sg10
I13
sg11
Vbreast cancer
p11669
sg13
I2
sa(dp11670
g7
I192
sg27
VC0006142
p11671
sg10
I2
sg11
VBC
p11672
sg13
I1
sasa(dp11673
g2
S'These compounds were evaluated in anti-proliferative assays of a panel of 15 breast cancer cell lines and further examined for their ability to inhibit a variety of Mps1-dependent biological functions.\n'
p11674
sg4
(lp11675
(dp11676
g7
I165
sg8
VP33981
p11677
sg10
I4
sg11
VMps1
p11678
sg13
I1
sasg24
(lp11679
(dp11680
g7
I77
sg27
VC0678222
p11681
sg10
I13
sg11
Vbreast cancer
p11682
sg13
I2
sa(dp11683
g7
I39
sg27
VC0334094
p11684
sg10
I13
sg11
Vproliferative
p11685
sg13
I1
sasa(dp11686
g2
S'In addition, the lead compounds 1 and 13 inhibit Mps1 kinase enzymatic activity with IC50 values from 0.356myM to 0.809myM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells.\n'
p11687
sg4
(lp11688
(dp11689
g7
I49
sg8
VP33981
p11690
sg10
I4
sg11
VMps1
p11691
sg13
I1
sa(dp11692
g7
I49
sg8
VP33981
p11693
sg10
I11
sg11
VMps1 kinase
p11694
sg13
I2
sasg24
(lp11695
(dp11696
g7
I250
sg27
VC0678222
p11697
sg10
I13
sg11
Vbreast cancer
p11698
sg13
I2
sa(dp11699
g7
I192
sg27
VC1705960
p11700
sg10
I11
sg11
Vduplication
p11701
sg13
I1
sasa(dp11702
g2
S'Using drug discovery technologies, computational modeling, medicinal chemistry, cell culture and in vivo assays, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers.\n'
p11703
sg4
(lp11704
(dp11705
g7
I139
sg8
VP49841
p11706
sg10
I3
sg11
VTTK
p11707
sg13
I1
sa(dp11708
g7
I134
sg8
VP33981
p11709
sg10
I4
sg11
VMps1
p11710
sg13
I1
sasg24
(lp11711
(dp11712
g7
I211
sg27
VC0006142
p11713
sg10
I14
sg11
Vbreast cancers
p11714
sg13
I2
sasa(dp11715
g2
S'However, high levels of Mps1 are found in many types of human malignancies, including glioblastoma, thyroid carcinoma, breast cancer, and other cancers.\n'
p11716
sg4
(lp11717
(dp11718
g7
I24
sg8
VP33981
p11719
sg10
I4
sg11
VMps1
p11720
sg13
I1
sasg24
(lp11721
(dp11722
g7
I100
sg27
VC0549473
p11723
sg10
I17
sg11
Vthyroid carcinoma
p11724
sg13
I2
sa(dp11725
g7
I86
sg27
VC0017636
p11726
sg10
I12
sg11
Vglioblastoma
p11727
sg13
I1
sa(dp11728
g7
I62
sg27
VC0006826
p11729
sg10
I12
sg11
Vmalignancies
p11730
sg13
I1
sa(dp11731
g7
I144
sg27
VC0006826
p11732
sg10
I7
sg11
Vcancers
p11733
sg13
I1
sa(dp11734
g7
I119
sg27
VC0678222
p11735
sg10
I13
sg11
Vbreast cancer
p11736
sg13
I2
sasa(dp11737
g2
S'Here, we employed amphiphilic polymers and silenced the expression of two cell cycle proteins, TTK and CDC20, and the anti-apoptosis protein survivin to determine the efficacy of polymer-mediated siRNA treatment in breast cancer cells as well as side effects in nonmalignant cells in vitro.\n'
p11738
sg4
(lp11739
(dp11740
g7
I95
sg8
VP49841
p11741
sg10
I3
sg11
VTTK
p11742
sg13
I1
sa(dp11743
g7
I103
sg8
g9
sg10
I5
sg11
VCDC20
p11744
sg13
I1
sasg24
(lp11745
(dp11746
g7
I215
sg27
VC0678222
p11747
sg10
I13
sg11
Vbreast cancer
p11748
sg13
I2
sasa(dp11749
g2
S'To explore expressions of matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinases-1 (TIMP-1) and transforming growth factor-Beta1 (TGF-Beta1) in valve tissue of rheumatic heart disease (RHD), and to analyzed their roles in RHD.\n'
p11750
sg4
(lp11751
(dp11752
g7
I62
sg8
VP01033
p11753
sg10
I40
sg11
Vtissue inhibitor of metalloproteinases-1
p11754
sg13
I4
sa(dp11755
g7
I150
sg8
VP01137
p11756
sg10
I9
sg11
VTGF-Beta1
p11757
sg13
I1
sa(dp11758
g7
I116
sg8
VP01137
p11759
sg10
I32
sg11
Vtransforming growth factor-Beta1
p11760
sg13
I3
sa(dp11761
g7
I104
sg8
VP01033
p11762
sg10
I6
sg11
VTIMP-1
p11763
sg13
I1
sa(dp11764
g7
I54
sg8
VP03956
p11765
sg10
I5
sg11
VMMP-1
p11766
sg13
I1
sa(dp11767
g7
I26
sg8
VP03956
p11768
sg10
I26
sg11
Vmatrix metalloproteinase-1
p11769
sg13
I2
sasg24
(lp11770
(dp11771
g7
I205
sg27
VC0035439
p11772
sg10
I3
sg11
VRHD
p11773
sg13
I1
sa(dp11774
g7
I180
sg27
VC0035439
p11775
sg10
I23
sg11
Vrheumatic heart disease
p11776
sg13
I3
sa(dp11777
g7
I205
sg27
VC0035439
p11778
sg10
I3
sg11
VRHD
p11779
sg13
I1
sasa(dp11780
g2
S'Objectives The aim of this study was to investigate plasma ADAMTS-13 activity in patients with proliferative lupus nephritis and to evaluate the role of clinical, laboratory and pathological features, especially the vascular lesions in lupus nephritis.\n'
p11781
sg4
(lp11782
sg24
(lp11783
(dp11784
g7
I109
sg27
VC0024143
p11785
sg10
I15
sg11
Vlupus nephritis
p11786
sg13
I2
sa(dp11787
g7
I216
sg27
VC1402315
p11788
sg10
I16
sg11
Vvascular lesions
p11789
sg13
I2
sa(dp11790
g7
I95
sg27
VC0334094
p11791
sg10
I13
sg11
Vproliferative
p11792
sg13
I1
sa(dp11793
g7
I109
sg27
VC0024143
p11794
sg10
I15
sg11
Vlupus nephritis
p11795
sg13
I2
sasa(dp11796
g2
S'Results Plasma ADAMTS-13 activity in lupus nephritis patients was significantly lower than that in normal controls (84 +/- 21% vs. 90 +/- 13%, p = 0.005).\n'
p11797
sg4
(lp11798
sg24
(lp11799
(dp11800
g7
I37
sg27
VC0024143
p11801
sg10
I15
sg11
Vlupus nephritis
p11802
sg13
I2
sasa(dp11803
g2
S'Conclusions Decreased ADAMTS-13 activity was found in patients with proliferative lupus nephritis, and plasma ADAMTS-13 activity was closely associated with renal injury indices, especially pathological vascular scores.\n'
p11804
sg4
(lp11805
sg24
(lp11806
(dp11807
g7
I82
sg27
VC0024143
p11808
sg10
I15
sg11
Vlupus nephritis
p11809
sg13
I2
sa(dp11810
g7
I68
sg27
VC0334094
p11811
sg10
I13
sg11
Vproliferative
p11812
sg13
I1
sasa(dp11813
g2
S'The serum ADAMTS-13 activity was significantly lower in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (40% versus 69%, P = 0.012; 40% versus 81%, P &lt; 0.001, respectively).\n'
p11814
sg4
(lp11815
sg24
(lp11816
(dp11817
g7
I75
sg27
VC0024143
p11818
sg10
I15
sg11
Vlupus nephritis
p11819
sg13
I2
sa(dp11820
g7
I75
sg27
VC0024143
p11821
sg10
I15
sg11
Vlupus nephritis
p11822
sg13
I2
sa(dp11823
g7
I95
sg27
VC1268935
p11824
sg10
I3
sg11
VTTP
p11825
sg13
I1
sasa(dp11826
g2
S'The prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (6/7, 86% versus 10/55, 18%, P &lt; 0.001; 6/7, 86% versus 0, P &lt; 0.001, respectively).\n'
p11827
sg4
(lp11828
sg24
(lp11829
(dp11830
g7
I90
sg27
VC0024143
p11831
sg10
I15
sg11
Vlupus nephritis
p11832
sg13
I2
sa(dp11833
g7
I110
sg27
VC1268935
p11834
sg10
I3
sg11
VTTP
p11835
sg13
I1
sa(dp11836
g7
I90
sg27
VC0024143
p11837
sg10
I15
sg11
Vlupus nephritis
p11838
sg13
I2
sasa(dp11839
g2
S'ADAMTS-13 autoantibodies might play an important role in the pathogenesis of TTP-HUS associated with lupus nephritis.\n'
p11840
sg4
(lp11841
(dp11842
g7
I77
sg8
g9
sg10
I7
sg11
VTTP-HUS
p11843
sg13
I1
sasg24
(lp11844
(dp11845
g7
I77
sg27
VC1268935
p11846
sg10
I3
sg11
VTTP
p11847
sg13
I1
sa(dp11848
g7
I101
sg27
VC0024143
p11849
sg10
I15
sg11
Vlupus nephritis
p11850
sg13
I2
sa(dp11851
g7
I61
sg27
VC0699748
p11852
sg10
I12
sg11
Vpathogenesis
p11853
sg13
I1
sasa(dp11854
g2
S'Plasma vWF and vWF-CP activities were measured using enzyme-linked immunosorbent assay (ELISA) and residual collagen binding assay respectively in patients with lupus nephritis (n = 31), primary nephritic syndrome (n = 25), diabetic nephropathy (n = 45), chronic glomerulonephritis (n = 38) and 40 normal controls.\n'
p11855
sg4
(lp11856
(dp11857
g7
I15
sg8
VP04275
p11858
sg10
I6
sg11
VvWF-CP
p11859
sg13
I1
sa(dp11860
g7
I7
sg8
VP04275
p11861
sg10
I3
sg11
VvWF
p11862
sg13
I1
sasg24
(lp11863
(dp11864
g7
I195
sg27
VC0268732
p11865
sg10
I18
sg11
Vnephritic syndrome
p11866
sg13
I2
sa(dp11867
g7
I161
sg27
VC0024143
p11868
sg10
I15
sg11
Vlupus nephritis
p11869
sg13
I2
sa(dp11870
g7
I224
sg27
VC0011881
p11871
sg10
I20
sg11
Vdiabetic nephropathy
p11872
sg13
I2
sa(dp11873
g7
I255
sg27
VC0152451
p11874
sg10
I26
sg11
Vchronic glomerulonephritis
p11875
sg13
I2
sasa(dp11876
g2
S'Renal biopsy demonstrated that the vWF level in stage IV was higher than in stages II and III while vWF-CP activity was lower in patients with lupus nephritis.\n'
p11877
sg4
(lp11878
(dp11879
g7
I35
sg8
VP04275
p11880
sg10
I3
sg11
VvWF
p11881
sg13
I1
sa(dp11882
g7
I100
sg8
VP04275
p11883
sg10
I6
sg11
VvWF-CP
p11884
sg13
I1
sasg24
(lp11885
(dp11886
g7
I143
sg27
VC0024143
p11887
sg10
I15
sg11
Vlupus nephritis
p11888
sg13
I2
sasa(dp11889
g2
S'Furthermore the demonstration of a normal vWF-CP assay aided in the distinction between TTP and MAHA due to lupus nephritis.\n'
p11890
sg4
(lp11891
(dp11892
g7
I42
sg8
VP04275
p11893
sg10
I3
sg11
VvWF
p11894
sg13
I1
sasg24
(lp11895
(dp11896
g7
I108
sg27
VC0024143
p11897
sg10
I15
sg11
Vlupus nephritis
p11898
sg13
I2
sa(dp11899
g7
I88
sg27
VC1268935
p11900
sg10
I3
sg11
VTTP
p11901
sg13
I1
sasa(dp11902
g2
S"In this study we have investigated the distribution and the level of expression of kinesin light chains (KLCs) (responsible for binding of cargos during anterograde transport) and of dynein intermediate chain (DIC) (a component of the dynein complex during retrograde transport) in frontal cortex and cerebellar cortex of control subjects and Alzheimer's disease patients.\n"
p11903
sg4
(lp11904
(dp11905
g7
I83
sg8
g9
sg10
I20
sg11
Vkinesin light chains
p11906
sg13
I3
sa(dp11907
g7
I105
sg8
g9
sg10
I4
sg11
VKLCs
p11908
sg13
I1
sasg24
(lp11909
(dp11910
g7
I210
sg27
VC0012739
p11911
sg10
I3
sg11
VDIC
p11912
sg13
I1
sa(dp11913
g7
I343
sg27
VC1521724
p11914
sg10
I19
sg11
VAlzheimer's disease
p11915
sg13
I2
sa(dp11916
g7
I183
sg27
VC0012739
p11917
sg10
I25
sg11
Vdynein intermediate chain
p11918
sg13
I3
sasa(dp11919
g2
S"By immunoblotting, we found a significant decrease in the levels of expression of KLC1 and 2 and DIC in the frontal cortex, but not in the cerebellar cortex, of Alzheimer's disease patients.\n"
p11920
sg4
(lp11921
sg24
(lp11922
(dp11923
g7
I97
sg27
VC0012739
p11924
sg10
I3
sg11
VDIC
p11925
sg13
I1
sa(dp11926
g7
I161
sg27
VC1521724
p11927
sg10
I19
sg11
VAlzheimer's disease
p11928
sg13
I2
sasa(dp11929
g2
S"We suggest that reduction of KLCs and DIC proteins in AD cortex results from both reduced expression and neuronal loss, and that these reductions and GSK-3Beta-mediated phosphorylation of KLC1 contribute to disturbances of axoplasmic flows and synaptic integrity in Alzheimer's disease.\n"
p11930
sg4
(lp11931
(dp11932
g7
I150
sg8
VP49841
p11933
sg10
I9
sg11
VGSK-3Beta
p11934
sg13
I1
sasg24
(lp11935
(dp11936
g7
I266
sg27
VC1521724
p11937
sg10
I19
sg11
VAlzheimer's disease
p11938
sg13
I2
sa(dp11939
g7
I38
sg27
VC0012739
p11940
sg10
I3
sg11
VDIC
p11941
sg13
I1
sasa(dp11942
g2
S'Children with cystic fibrosis (CF) often have suboptimal adherence rates to nebulized medication.\n'
p11943
sg4
(lp11944
sg24
(lp11945
(dp11946
g7
I14
sg27
VC0010674
p11947
sg10
I15
sg11
Vcystic fibrosis
p11948
sg13
I2
sa(dp11949
g7
I31
sg27
VC0010674
p11950
sg10
I2
sg11
VCF
p11951
sg13
I1
sasa(dp11952
g2
S'A cocktail of three phages active against Pseudomonas aeruginosa isolates from cystic fibrosis patients was developed for a potential nebulized formulation.\n'
p11953
sg4
(lp11954
sg24
(lp11955
(dp11956
g7
I79
sg27
VC0010674
p11957
sg10
I15
sg11
Vcystic fibrosis
p11958
sg13
I2
sasa(dp11959
g2
S'Treatment regimen for families of children with cystic fibrosis (CF) is considerable, particularly when nebulised therapies for chronic Pseudomonas aeruginosa airway infection are prescribed.\n'
p11960
sg4
(lp11961
sg24
(lp11962
(dp11963
g7
I166
sg27
VC0009450
p11964
sg10
I9
sg11
Vinfection
p11965
sg13
I1
sa(dp11966
g7
I48
sg27
VC0010674
p11967
sg10
I15
sg11
Vcystic fibrosis
p11968
sg13
I2
sa(dp11969
g7
I65
sg27
VC0010674
p11970
sg10
I2
sg11
VCF
p11971
sg13
I1
sasa(dp11972
g2
S'The time requirements for multiple daily nebulizer treatments are important impediments to the quality of life for most patients with cystic fibrosis (CF).\n'
p11973
sg4
(lp11974
sg24
(lp11975
(dp11976
g7
I134
sg27
VC0010674
p11977
sg10
I15
sg11
Vcystic fibrosis
p11978
sg13
I2
sa(dp11979
g7
I151
sg27
VC0010674
p11980
sg10
I2
sg11
VCF
p11981
sg13
I1
sasa(dp11982
g2
S'Therefore, in this study, the author describes for the first time the common feature of oral clefts in patients carrying a microduplication of 15q13.3 encompassing the CHRNA7 gene, which sheds light on the correlation between CHRNA7 and cleft palate.\n'
p11983
sg4
(lp11984
(dp11985
g7
I168
sg8
VP36544
p11986
sg10
I11
sg11
VCHRNA7 gene
p11987
sg13
I2
sasg24
(lp11988
(dp11989
g7
I237
sg27
VC0008925
p11990
sg10
I12
sg11
Vcleft palate
p11991
sg13
I2
sasa(dp11992
g2
S'In contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).\n'
p11993
sg4
(lp11994
(dp11995
g7
I169
sg8
g9
sg10
I5
sg11
VMEIS2
p11996
sg13
I1
sa(dp11997
g7
I163
sg8
g9
sg10
I4
sg11
VCX36
p11998
sg13
I1
sa(dp11999
g7
I272
sg8
VP08912
p12000
sg10
I5
sg11
VCHRM5
p12001
sg13
I1
sa(dp12002
g7
I202
sg8
VP68032
p12003
sg10
I4
sg11
VACTC
p12004
sg13
I1
sa(dp12005
g7
I264
sg8
VP36544
p12006
sg10
I6
sg11
VCHRNA7
p12007
sg13
I1
sa(dp12008
g7
I169
sg8
g9
sg10
I5
sg11
VMEIS2
p12009
sg13
I1
sa(dp12010
g7
I156
sg8
g9
sg10
I5
sg11
VGREM1
p12011
sg13
I1
sa(dp12012
g7
I156
sg8
g9
sg10
I5
sg11
VGREM1
p12013
sg13
I1
sa(dp12014
g7
I163
sg8
g9
sg10
I4
sg11
VCX36
p12015
sg13
I1
sa(dp12016
g7
I253
sg8
g9
sg10
I9
sg11
VARHGAP11A
p12017
sg13
I1
sasg24
(lp12018
(dp12019
g7
I233
sg27
VC0025362
p12020
sg10
I18
sg11
Vmental retardation
p12021
sg13
I2
sa(dp12022
g7
I142
sg27
VC0008925
p12023
sg10
I12
sg11
Vcleft palate
p12024
sg13
I2
sa(dp12025
g7
I34
sg27
VC1855900
p12026
sg10
I3
sg11
VCGH
p12027
sg13
I1
sa(dp12028
g7
I177
sg27
VC0018798
p12029
sg10
I23
sg11
Vcongenital heart defect
p12030
sg13
I3
sasa(dp12031
g2
S'Comparative deletion mapping shows that this region can be dissected into five chromosomal segments containing at least six candidate genes (DAB1, HOOK1, NFIA, DOCK7, DNAJC6, and PDE4B) most likely responsible for syndromic intellectual disability, which was corroborated by their reduced transcript levels in RT-qPCR.\n'
p12032
sg4
(lp12033
(dp12034
g7
I154
sg8
g9
sg10
I4
sg11
VNFIA
p12035
sg13
I1
sa(dp12036
g7
I147
sg8
g9
sg10
I5
sg11
VHOOK1
p12037
sg13
I1
sa(dp12038
g7
I167
sg8
g9
sg10
I6
sg11
VDNAJC6
p12039
sg13
I1
sa(dp12040
g7
I179
sg8
g9
sg10
I5
sg11
VPDE4B
p12041
sg13
I1
sa(dp12042
g7
I141
sg8
g9
sg10
I4
sg11
VDAB1
p12043
sg13
I1
sasg24
(lp12044
(dp12045
g7
I224
sg27
VC0025362
p12046
sg10
I23
sg11
Vintellectual disability
p12047
sg13
I2
sasa(dp12048
g2
S'Importantly, one patient with an intragenic microdeletion within NFIA and an additional patient with a balanced translocation disrupting NFIA display intellectual disability coupled with macrocephaly.\n'
p12049
sg4
(lp12050
(dp12051
g7
I65
sg8
g9
sg10
I4
sg11
VNFIA
p12052
sg13
I1
sa(dp12053
g7
I65
sg8
g9
sg10
I4
sg11
VNFIA
p12054
sg13
I1
sasg24
(lp12055
(dp12056
g7
I150
sg27
VC0025362
p12057
sg10
I23
sg11
Vintellectual disability
p12058
sg13
I2
sa(dp12059
g7
I112
sg27
VC0040715
p12060
sg10
I13
sg11
Vtranslocation
p12061
sg13
I1
sa(dp12062
g7
I187
sg27
VC0221355
p12063
sg10
I12
sg11
Vmacrocephaly
p12064
sg13
I1
sasa(dp12065
g2
S'We propose NFIA is responsible for intellectual disability coupled with macrocephaly, and microdeletions at 1p31.3p32.2 constitute a contiguous gene syndrome with several genes contributing to syndromic intellectual disability.\n'
p12066
sg4
(lp12067
(dp12068
g7
I11
sg8
g9
sg10
I4
sg11
VNFIA
p12069
sg13
I1
sasg24
(lp12070
(dp12071
g7
I72
sg27
VC0221355
p12072
sg10
I12
sg11
Vmacrocephaly
p12073
sg13
I1
sa(dp12074
g7
I149
sg27
VC0039082
p12075
sg10
I8
sg11
Vsyndrome
p12076
sg13
I1
sa(dp12077
g7
I35
sg27
VC0025362
p12078
sg10
I23
sg11
Vintellectual disability
p12079
sg13
I2
sa(dp12080
g7
I35
sg27
VC0025362
p12081
sg10
I23
sg11
Vintellectual disability
p12082
sg13
I2
sasa(dp12083
g2
S'Non-progressive cerebellar ataxia with mental retardation (CANPMR, OMIM 614756) and chromosome 1p32-p31 deletion syndrome (OMIM 613735) are two very rare inherited disorders, which are caused by mono-allelic deficiency (haplo-insufficiency) of calmodulin-binding transcription activator 1 (CAMTA1) and, respectively, nuclear factor 1 A (NFIA) genes.\n'
p12084
sg4
(lp12085
(dp12086
g7
I244
sg8
g9
sg10
I44
sg11
Vcalmodulin-binding transcription activator 1
p12087
sg13
I4
sa(dp12088
g7
I317
sg8
VP01160
p12089
sg10
I18
sg11
Vnuclear factor 1 A
p12090
sg13
I4
sa(dp12091
g7
I290
sg8
g9
sg10
I6
sg11
VCAMTA1
p12092
sg13
I1
sa(dp12093
g7
I337
sg8
g9
sg10
I4
sg11
VNFIA
p12094
sg13
I1
sasg24
(lp12095
(dp12096
g7
I4
sg27
VC0393525
p12097
sg10
I29
sg11
Vprogressive cerebellar ataxia
p12098
sg13
I3
sa(dp12099
g7
I84
sg27
VC3151036
p12100
sg10
I37
sg11
Vchromosome 1p32-p31 deletion syndrome
p12101
sg13
I4
sa(dp12102
g7
I39
sg27
VC0025362
p12103
sg10
I18
sg11
Vmental retardation
p12104
sg13
I2
sa(dp12105
g7
I195
sg27
VC0021345
p12106
sg10
I4
sg11
Vmono
p12107
sg13
I1
sasa(dp12108
g2
S'Among these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis.\n'
p12109
sg4
(lp12110
(dp12111
g7
I49
sg8
g9
sg10
I5
sg11
VAuts2
p12112
sg13
I1
sa(dp12113
g7
I56
sg8
g9
sg10
I4
sg11
VNfia
p12114
sg13
I1
sa(dp12115
g7
I106
sg8
g9
sg10
I4
sg11
VTBR1
p12116
sg13
I1
sa(dp12117
g7
I62
sg8
VP43354
p12118
sg10
I5
sg11
VNr4a2
p12119
sg13
I1
sasg24
(lp12120
(dp12121
g7
I165
sg27
VC0699748
p12122
sg10
I12
sg11
Vpathogenesis
p12123
sg13
I1
sa(dp12124
g7
I158
sg27
VC0004352
p12125
sg10
I6
sg11
Vautism
p12126
sg13
I1
sasa(dp12127
g2
S'Some of these maternal and maternal-child associations were in or adjacent to autism candidate genes including: PCDH9, FOXP1, GABRB3, NRXN1, RELN, MACROD2, FHIT, RORA, CNTN4, CNTNAP2, FAM135B, LAMA1, NFIA, NLGN4X, RAPGEF4, and SDK1.\n'
p12128
sg4
(lp12129
(dp12130
g7
I200
sg8
g9
sg10
I4
sg11
VNFIA
p12131
sg13
I1
sa(dp12132
g7
I78
sg8
VP27635
p12133
sg10
I22
sg11
Vautism candidate genes
p12134
sg13
I3
sa(dp12135
g7
I162
sg8
VP35398
p12136
sg10
I4
sg11
VRORA
p12137
sg13
I1
sa(dp12138
g7
I227
sg8
g9
sg10
I4
sg11
VSDK1
p12139
sg13
I1
sa(dp12140
g7
I206
sg8
g9
sg10
I6
sg11
VNLGN4X
p12141
sg13
I1
sa(dp12142
g7
I112
sg8
g9
sg10
I5
sg11
VPCDH9
p12143
sg13
I1
sa(dp12144
g7
I156
sg8
VP49789
p12145
sg10
I4
sg11
VFHIT
p12146
sg13
I1
sa(dp12147
g7
I119
sg8
g9
sg10
I5
sg11
VFOXP1
p12148
sg13
I1
sa(dp12149
g7
I214
sg8
g9
sg10
I7
sg11
VRAPGEF4
p12150
sg13
I1
sa(dp12151
g7
I175
sg8
g9
sg10
I7
sg11
VCNTNAP2
p12152
sg13
I1
sa(dp12153
g7
I184
sg8
g9
sg10
I7
sg11
VFAM135B
p12154
sg13
I1
sa(dp12155
g7
I193
sg8
VP25391
p12156
sg10
I5
sg11
VLAMA1
p12157
sg13
I1
sa(dp12158
g7
I168
sg8
g9
sg10
I5
sg11
VCNTN4
p12159
sg13
I1
sa(dp12160
g7
I147
sg8
g9
sg10
I7
sg11
VMACROD2
p12161
sg13
I1
sa(dp12162
g7
I141
sg8
VP78509
p12163
sg10
I4
sg11
VRELN
p12164
sg13
I1
sa(dp12165
g7
I126
sg8
VP28472
p12166
sg10
I6
sg11
VGABRB3
p12167
sg13
I1
sa(dp12168
g7
I134
sg8
VP58400
p12169
sg10
I5
sg11
VNRXN1
p12170
sg13
I1
sasg24
(lp12171
(dp12172
g7
I78
sg27
VC0004352
p12173
sg10
I6
sg11
Vautism
p12174
sg13
I1
sasa(dp12175
g2
S'These results provided a mechanistic linking between TRPM2-mediated Ca2+ influx and p47 phox signaling to induce excess ROS production and TXNIP-mediated NLRP3 inflammasome activation under HG, and suggested that TRPM2 represented a potential target for alleviating NLRP3 inflammasome activation related to hyperglycemia-induced oxidative stress in Type 2 diabetes Mellitus (T2DM).\n'
p12176
sg4
(lp12177
(dp12178
g7
I53
sg8
VP10909
p12179
sg10
I5
sg11
VTRPM2
p12180
sg13
I1
sa(dp12181
g7
I139
sg8
g9
sg10
I5
sg11
VTXNIP
p12182
sg13
I1
sa(dp12183
g7
I88
sg8
VP19878
p12184
sg10
I4
sg11
Vphox
p12185
sg13
I1
sa(dp12186
g7
I53
sg8
VP10909
p12187
sg10
I5
sg11
VTRPM2
p12188
sg13
I1
sa(dp12189
g7
I84
sg8
VP08567
p12190
sg10
I3
sg11
Vp47
p12191
sg13
I1
sasg24
(lp12192
(dp12193
g7
I349
sg27
VC0011860
p12194
sg10
I24
sg11
VType 2 diabetes Mellitus
p12195
sg13
I4
sa(dp12196
g7
I375
sg27
VC0011860
p12197
sg10
I4
sg11
VT2DM
p12198
sg13
I1
sa(dp12199
g7
I307
sg27
VC0020456
p12200
sg10
I13
sg11
Vhyperglycemia
p12201
sg13
I1
sa(dp12202
g7
I329
sg27
VC0242606
p12203
sg10
I16
sg11
Voxidative stress
p12204
sg13
I2
sasa(dp12205
g2
S'SOX3 mutations have been associated with growth hormone deficiency, variable degrees of additional pituitary hormone deficiencies, and mental retardation.\n'
p12206
sg4
(lp12207
(dp12208
g7
I41
sg8
VP01242
p12209
sg10
I14
sg11
Vgrowth hormone
p12210
sg13
I2
sa(dp12211
g7
I99
sg8
VP18509
p12212
sg10
I17
sg11
Vpituitary hormone
p12213
sg13
I2
sa(dp12214
g7
I0
sg8
VP41225
p12215
sg10
I4
sg11
VSOX3
p12216
sg13
I1
sasg24
(lp12217
(dp12218
g7
I41
sg27
VC0271561
p12219
sg10
I25
sg11
Vgrowth hormone deficiency
p12220
sg13
I3
sa(dp12221
g7
I135
sg27
VC0025362
p12222
sg10
I18
sg11
Vmental retardation
p12223
sg13
I2
sasa(dp12224
g2
S'SOX3 involvement should be considered in a male with short stature due to GH deficiency associated with intellectual disability.\n'
p12225
sg4
(lp12226
(dp12227
g7
I0
sg8
VP41225
p12228
sg10
I4
sg11
VSOX3
p12229
sg13
I1
sasg24
(lp12230
(dp12231
g7
I104
sg27
VC0025362
p12232
sg10
I23
sg11
Vintellectual disability
p12233
sg13
I2
sa(dp12234
g7
I53
sg27
VC0013336
p12235
sg10
I13
sg11
Vshort stature
p12236
sg13
I2
sasa(dp12237
g2
S'A further XX male, ascertained because of intellectual disability, carried a de novo cryptic duplication at Xq27.1, involving SOX3.\n'
p12238
sg4
(lp12239
(dp12240
g7
I126
sg8
VP41225
p12241
sg10
I4
sg11
VSOX3
p12242
sg13
I1
sasg24
(lp12243
(dp12244
g7
I42
sg27
VC0025362
p12245
sg10
I23
sg11
Vintellectual disability
p12246
sg13
I2
sa(dp12247
g7
I93
sg27
VC1705960
p12248
sg10
I11
sg11
Vduplication
p12249
sg13
I1
sa(dp12250
g7
I10
sg27
VC0432475
p12251
sg10
I7
sg11
VXX male
p12252
sg13
I2
sasa(dp12253
g2
S'In humans, over- and underdosage of SOX3 is associated with X-linked hypopituitarism with variable phenotypes ranging from isolated GH deficiency (GHD) to panhypopituitarism, with or without mental retardation and, in most cases, with reported pituitary imaging, an ectopic/undescended posterior pituitary.\n'
p12254
sg4
(lp12255
(dp12256
g7
I36
sg8
VP41225
p12257
sg10
I4
sg11
VSOX3
p12258
sg13
I1
sasg24
(lp12259
(dp12260
g7
I191
sg27
VC0025362
p12261
sg10
I18
sg11
Vmental retardation
p12262
sg13
I2
sa(dp12263
g7
I147
sg27
VC0271561
p12264
sg10
I3
sg11
VGHD
p12265
sg13
I1
sa(dp12266
g7
I155
sg27
VC0242343
p12267
sg10
I18
sg11
Vpanhypopituitarism
p12268
sg13
I1
sa(dp12269
g7
I69
sg27
VC0020635
p12270
sg10
I15
sg11
Vhypopituitarism
p12271
sg13
I1
sa(dp12272
g7
I132
sg27
VC0271561
p12273
sg10
I13
sg11
VGH deficiency
p12274
sg13
I2
sasa(dp12275
g2
S'Screening for SOX3 should be advised not only for hypopituitary patients with an ectopic posterior pituitary, but also for those with a structurally normal pituitary and additional findings, including clefts and a persistent craniopharyngeal canal, with or without mental retardation.\n'
p12276
sg4
(lp12277
(dp12278
g7
I14
sg8
VP41225
p12279
sg10
I4
sg11
VSOX3
p12280
sg13
I1
sasg24
(lp12281
(dp12282
g7
I265
sg27
VC0025362
p12283
sg10
I18
sg11
Vmental retardation
p12284
sg13
I2
sasa(dp12285
g2
S'Both duplications encompassing SOX3 and loss-of function mutations in SOX3 have been reported in a minor portion of X-linked isolated growth hormone deficiency (GHD) or combined pituitary hormone deficiency (CPHD) patients with or without mental retardation.\n'
p12286
sg4
(lp12287
(dp12288
g7
I169
sg8
VP18509
p12289
sg10
I26
sg11
Vcombined pituitary hormone
p12290
sg13
I3
sa(dp12291
g7
I134
sg8
VP01242
p12292
sg10
I14
sg11
Vgrowth hormone
p12293
sg13
I2
sa(dp12294
g7
I31
sg8
VP41225
p12295
sg10
I4
sg11
VSOX3
p12296
sg13
I1
sasg24
(lp12297
(dp12298
g7
I239
sg27
VC0025362
p12299
sg10
I18
sg11
Vmental retardation
p12300
sg13
I2
sa(dp12301
g7
I161
sg27
VC0271561
p12302
sg10
I3
sg11
VGHD
p12303
sg13
I1
sa(dp12304
g7
I141
sg27
VC0599750
p12305
sg10
I18
sg11
Vhormone deficiency
p12306
sg13
I2
sa(dp12307
g7
I125
sg27
VC0271563
p12308
sg10
I34
sg11
Visolated growth hormone deficiency
p12309
sg13
I4
sasa(dp12310
g2
S'In humans, duplication of SOX3 and polyalanine expansions at its C-terminus may cause intellectual disability and hypopituitarism.\n'
p12311
sg4
(lp12312
(dp12313
g7
I26
sg8
VP41225
p12314
sg10
I4
sg11
VSOX3
p12315
sg13
I1
sasg24
(lp12316
(dp12317
g7
I11
sg27
VC1705960
p12318
sg10
I11
sg11
Vduplication
p12319
sg13
I1
sa(dp12320
g7
I114
sg27
VC0020635
p12321
sg10
I15
sg11
Vhypopituitarism
p12322
sg13
I1
sa(dp12323
g7
I86
sg27
VC0025362
p12324
sg10
I23
sg11
Vintellectual disability
p12325
sg13
I2
sasa(dp12326
g2
S'The UNH159 marker as well as RNA-binding motif protein, X-linked (rbmx), SRY-box containing gene 3 (sox3) and alpha-thalassemia/mental retardation syndrome X-linked (atrx) genes were mapped to linkage group 2.\n'
p12327
sg4
(lp12328
(dp12329
g7
I100
sg8
VP41225
p12330
sg10
I4
sg11
Vsox3
p12331
sg13
I1
sa(dp12332
g7
I73
sg8
VP41225
p12333
sg10
I25
sg11
VSRY-box containing gene 3
p12334
sg13
I4
sasg24
(lp12335
(dp12336
g7
I110
sg27
VC1845055
p12337
sg10
I54
sg11
Valpha-thalassemia/mental retardation syndrome X-linked
p12338
sg13
I4
sa(dp12339
g7
I166
sg27
VC1845055
p12340
sg10
I4
sg11
Vatrx
p12341
sg13
I1
sasa(dp12342
g2
S'Both overdosage of SOX3, as a result of gene duplication, and loss of function resulting from expansion of the first polyalanine (PA) tract are associated with variable degrees of hypopituitarism, with or without mental retardation.\n'
p12343
sg4
(lp12344
(dp12345
g7
I19
sg8
VP41225
p12346
sg10
I4
sg11
VSOX3
p12347
sg13
I1
sasg24
(lp12348
(dp12349
g7
I213
sg27
VC0025362
p12350
sg10
I18
sg11
Vmental retardation
p12351
sg13
I2
sa(dp12352
g7
I180
sg27
VC0020635
p12353
sg10
I15
sg11
Vhypopituitarism
p12354
sg13
I1
sa(dp12355
g7
I40
sg27
VC1705960
p12356
sg10
I16
sg11
Vgene duplication
p12357
sg13
I2
sasa(dp12358
g2
S'Duplications and polyalanine expansions within the transcription factor SOX3 have recently been described in association with infundibular hypoplasia, hypopituitarism and variable mental retardation, whilst mutations in SOX2 are associated with variable hypopituitarism in association with learning difficulties, oesophageal atresia and anophthalmia.\n'
p12359
sg4
(lp12360
(dp12361
g7
I220
sg8
VP48431
p12362
sg10
I4
sg11
VSOX2
p12363
sg13
I1
sa(dp12364
g7
I72
sg8
VP41225
p12365
sg10
I4
sg11
VSOX3
p12366
sg13
I1
sasg24
(lp12367
(dp12368
g7
I151
sg27
VC0020635
p12369
sg10
I15
sg11
Vhypopituitarism
p12370
sg13
I1
sa(dp12371
g7
I139
sg27
VC0243069
p12372
sg10
I10
sg11
Vhypoplasia
p12373
sg13
I1
sa(dp12374
g7
I337
sg27
VC0003119
p12375
sg10
I12
sg11
Vanophthalmia
p12376
sg13
I1
sa(dp12377
g7
I180
sg27
VC0025362
p12378
sg10
I18
sg11
Vmental retardation
p12379
sg13
I2
sa(dp12380
g7
I151
sg27
VC0020635
p12381
sg10
I15
sg11
Vhypopituitarism
p12382
sg13
I1
sa(dp12383
g7
I313
sg27
VC0014850
p12384
sg10
I19
sg11
Voesophageal atresia
p12385
sg13
I2
sasa(dp12386
g2
S'Using mouse P19 embryonal carcinoma cells, which divide rapidly, yet in retinoic acid adopt a neuronal phenotype, admixed with occasional (approximately 10%) fibroblast-like cells, together with a panel of peptide-specific antibodies raised to 7 of the 8 CCT subunits we show that; (1) adoption of a post mitotic phenotype is accompanied by reduced CCT protein expression, significantly more so for CCTbeta, CCTdelta, CCTepsilon, and CCTtheta than for CCTalpha (TCP-1), CCTgamma and CCTzeta; (2) CCTalpha is detected preferentially over other subunits in neurites of P19 neurons; (3) small amounts of CCTalpha and gamma are localised in nuclei (i.e.\n'
p12387
sg4
(lp12388
(dp12389
g7
I462
sg8
VP00995
p12390
sg10
I5
sg11
VTCP-1
p12391
sg13
I1
sa(dp12392
g7
I349
sg8
g9
sg10
I11
sg11
VCCT protein
p12393
sg13
I2
sasg24
(lp12394
(dp12395
g7
I16
sg27
VC0206659
p12396
sg10
I19
sg11
Vembryonal carcinoma
p12397
sg13
I2
sa(dp12398
g7
I255
sg27
VC2752078
p12399
sg10
I3
sg11
VCCT
p12400
sg13
I1
sa(dp12401
g7
I462
sg27
VC1842402
p12402
sg10
I3
sg11
VTCP
p12403
sg13
I1
sa(dp12404
g7
I255
sg27
VC2752078
p12405
sg10
I3
sg11
VCCT
p12406
sg13
I1
sasa(dp12407
g2
S'In line with these observations, in preclinical models, SIRT2 deficiency increases survival of mice with chronic staphylococcal infection, while having no effect on the course of toxic shock syndrome toxin-1, LPS or TNF-induced shock, fulminant Escherichia coli peritonitis, sub-lethal Klebsiella pneumoniae pneumonia, and chronic candidiasis.\n'
p12408
sg4
(lp12409
(dp12410
g7
I216
sg8
VP01375
p12411
sg10
I3
sg11
VTNF
p12412
sg13
I1
sa(dp12413
g7
I56
sg8
g9
sg10
I5
sg11
VSIRT2
p12414
sg13
I1
sasg24
(lp12415
(dp12416
g7
I179
sg27
VC0600327
p12417
sg10
I20
sg11
Vtoxic shock syndrome
p12418
sg13
I3
sa(dp12419
g7
I262
sg27
VC0031154
p12420
sg10
I11
sg11
Vperitonitis
p12421
sg13
I1
sa(dp12422
g7
I209
sg27
VC0175697
p12423
sg10
I3
sg11
VLPS
p12424
sg13
I1
sa(dp12425
g7
I286
sg27
VC0519030
p12426
sg10
I31
sg11
VKlebsiella pneumoniae pneumonia
p12427
sg13
I3
sa(dp12428
g7
I323
sg27
VC0857069
p12429
sg10
I19
sg11
Vchronic candidiasis
p12430
sg13
I2
sa(dp12431
g7
I113
sg27
VC0038160
p12432
sg10
I24
sg11
Vstaphylococcal infection
p12433
sg13
I2
sasa(dp12434
g2
S'Lung injury was studied by measuring: vascular permeability-related pulmonary edema; histopathologic scores, neutrophil infiltration and concentrations of inflammatory cytokines in bronchoalveolar fluid; expression of inflammatory enzymes and sirtuin (SIRT) 1 as well as nuclear factor-kappa B (NF-KB) activity in pulmonary tissues.\n'
p12435
sg4
(lp12436
(dp12437
g7
I295
sg8
VP01160
p12438
sg10
I5
sg11
VNF-KB
p12439
sg13
I1
sa(dp12440
g7
I271
sg8
VP01160
p12441
sg10
I22
sg11
Vnuclear factor-kappa B
p12442
sg13
I3
sasg24
(lp12443
(dp12444
g7
I120
sg27
VC0332448
p12445
sg10
I12
sg11
Vinfiltration
p12446
sg13
I1
sa(dp12447
g7
I68
sg27
VC0034063
p12448
sg10
I15
sg11
Vpulmonary edema
p12449
sg13
I2
sasa(dp12450
g2
S'The aim of our study was to compare the expression of sirtuin in large and small airways in nonsmokers, asymptomatic smokers, and smokers with chronic obstructive pulmonary disease.\n'
p12451
sg4
(lp12452
(dp12453
g7
I54
sg8
g9
sg10
I7
sg11
Vsirtuin
p12454
sg13
I1
sasg24
(lp12455
(dp12456
g7
I143
sg27
VC0024117
p12457
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12458
sg13
I4
sasa(dp12459
g2
S'Smokers both with and without chronic obstructive pulmonary disease had decreased sirtuin expression in large airways.\n'
p12460
sg4
(lp12461
(dp12462
g7
I82
sg8
g9
sg10
I7
sg11
Vsirtuin
p12463
sg13
I1
sasg24
(lp12464
(dp12465
g7
I30
sg27
VC0024117
p12466
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12467
sg13
I4
sasa(dp12468
g2
S'However, in small airways, sirtuin expression was decreased only in patients with chronic obstructive pulmonary disease.\n'
p12469
sg4
(lp12470
sg24
(lp12471
(dp12472
g7
I82
sg27
VC0024117
p12473
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12474
sg13
I4
sasa(dp12475
g2
S'Smoking is characterized by suppressed sirtuin expression in large airways, whereas chronic obstructive pulmonary disease is characterized by more severe suppression of sirtuin expression both in large and small airways.\n'
p12476
sg4
(lp12477
(dp12478
g7
I39
sg8
g9
sg10
I7
sg11
Vsirtuin
p12479
sg13
I1
sa(dp12480
g7
I39
sg8
g9
sg10
I7
sg11
Vsirtuin
p12481
sg13
I1
sasg24
(lp12482
(dp12483
g7
I154
sg27
VC0221103
p12484
sg10
I11
sg11
Vsuppression
p12485
sg13
I1
sa(dp12486
g7
I84
sg27
VC0024117
p12487
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12488
sg13
I4
sasa(dp12489
g2
S'These data demonstrate a new mechanism of CB plasticity and suggest P2X-TRPV1 dependent sensory LTF as a novel target for pharmacological intervention in some forms of neurogenic hypertension associated with recurrent apneas.\n'
p12490
sg4
(lp12491
(dp12492
g7
I96
sg8
g9
sg10
I3
sg11
VLTF
p12493
sg13
I1
sa(dp12494
g7
I68
sg8
VP51575
p12495
sg10
I3
sg11
VP2X
p12496
sg13
I1
sa(dp12497
g7
I72
sg8
g9
sg10
I5
sg11
VTRPV1
p12498
sg13
I1
sasg24
(lp12499
(dp12500
g7
I218
sg27
VC0003578
p12501
sg10
I6
sg11
Vapneas
p12502
sg13
I1
sa(dp12503
g7
I168
sg27
VC0597048
p12504
sg10
I23
sg11
Vneurogenic hypertension
p12505
sg13
I2
sasa(dp12506
g2
S'Human equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC).\n'
p12507
sg4
(lp12508
(dp12509
g7
I83
sg8
g9
sg10
I7
sg11
VSLC29A2
p12510
sg13
I1
sa(dp12511
g7
I71
sg8
g9
sg10
I7
sg11
VSLC29A1
p12512
sg13
I1
sa(dp12513
g7
I0
sg8
g9
sg10
I43
sg11
VHuman equilibrative nucleoside transporters
p12514
sg13
I4
sa(dp12515
g7
I45
sg8
g9
sg10
I4
sg11
VhENT
p12516
sg13
I1
sasg24
(lp12517
(dp12518
g7
I254
sg27
VC1527249
p12519
sg10
I3
sg11
VCRC
p12520
sg13
I1
sa(dp12521
g7
I235
sg27
VC1527249
p12522
sg10
I17
sg11
Vcolorectal cancer
p12523
sg13
I2
sasa(dp12524
g2
S'The purpose of this study was to evaluate the expression profiles of SLC29A1 and SLC29A2 in human cancer cell lines.\n'
p12525
sg4
(lp12526
(dp12527
g7
I81
sg8
g9
sg10
I7
sg11
VSLC29A2
p12528
sg13
I1
sa(dp12529
g7
I69
sg8
g9
sg10
I7
sg11
VSLC29A1
p12530
sg13
I1
sasg24
(lp12531
(dp12532
g7
I98
sg27
VC0006826
p12533
sg10
I6
sg11
Vcancer
p12534
sg13
I1
sasa(dp12535
g2
S'Using quantitative real-time polymerase chain reaction, we comprehensively profiled the transcription levels of SLC29A1 and SLC29A2 in 16 colon cancer cell lines.\n'
p12536
sg4
(lp12537
(dp12538
g7
I124
sg8
g9
sg10
I7
sg11
VSLC29A2
p12539
sg13
I1
sa(dp12540
g7
I112
sg8
g9
sg10
I7
sg11
VSLC29A1
p12541
sg13
I1
sasg24
(lp12542
(dp12543
g7
I138
sg27
VC0699790
p12544
sg10
I12
sg11
Vcolon cancer
p12545
sg13
I2
sasa(dp12546
g2
S'We validated the ubiquitous and heterogeneous distribution of SLC29A1 and SLC29A2 in human colon cancer cell lines and demonstrated that SLC29A1 was highly expressed in 25% of metastatic cell lines (Colo201 and Colo205) and 62.5% of primary cell lines (Caco2, Colo320, HCT116, RKO, and SW48).\n'
p12547
sg4
(lp12548
(dp12549
g7
I62
sg8
g9
sg10
I7
sg11
VSLC29A1
p12550
sg13
I1
sa(dp12551
g7
I74
sg8
g9
sg10
I7
sg11
VSLC29A2
p12552
sg13
I1
sa(dp12553
g7
I62
sg8
g9
sg10
I7
sg11
VSLC29A1
p12554
sg13
I1
sasg24
(lp12555
(dp12556
g7
I91
sg27
VC0699790
p12557
sg10
I12
sg11
Vcolon cancer
p12558
sg13
I2
sasa(dp12559
g2
S'For the first time, we showed that both SLC29A1 and SLC29A2 were expressed at lower levels in colon cancer cell lines originating from metastatic sites than from primary sites.\n'
p12560
sg4
(lp12561
(dp12562
g7
I40
sg8
g9
sg10
I7
sg11
VSLC29A1
p12563
sg13
I1
sa(dp12564
g7
I52
sg8
g9
sg10
I7
sg11
VSLC29A2
p12565
sg13
I1
sasg24
(lp12566
(dp12567
g7
I94
sg27
VC0699790
p12568
sg10
I12
sg11
Vcolon cancer
p12569
sg13
I2
sasa(dp12570
g2
S'As ENT inhibitors including dilazep have shown efficacy improving oHSV1 targeted oncolytic cancer therapy, a series of dilazep analogues was synthesized and biologically evaluated to examine both ENT1 and ENT2 inhibition.\n'
p12571
sg4
(lp12572
(dp12573
g7
I196
sg8
g9
sg10
I4
sg11
VENT1
p12574
sg13
I1
sa(dp12575
g7
I205
sg8
g9
sg10
I4
sg11
VENT2
p12576
sg13
I1
sasg24
(lp12577
(dp12578
g7
I91
sg27
VC0006826
p12579
sg10
I6
sg11
Vcancer
p12580
sg13
I1
sasa(dp12581
g2
S'The most significant changes common to HLHS-RV versus control-RV and control-LV sample groups is observed for Anti mullerian hormone receptor 2 (AMHR2) (+18.79 control-RV, +3.38 control-LV), and the BMP antagonist Inhibin alpha (INHA) (+11.47 control-RV, +5.73 control-LV).\n'
p12582
sg4
(lp12583
(dp12584
g7
I110
sg8
VP22736
p12585
sg10
I33
sg11
VAnti mullerian hormone receptor 2
p12586
sg13
I5
sa(dp12587
g7
I145
sg8
g9
sg10
I5
sg11
VAMHR2
p12588
sg13
I1
sa(dp12589
g7
I229
sg8
VP05111
p12590
sg10
I4
sg11
VINHA
p12591
sg13
I1
sa(dp12592
g7
I39
sg8
VP17302
p12593
sg10
I7
sg11
VHLHS-RV
p12594
sg13
I1
sa(dp12595
g7
I199
sg8
VP18075
p12596
sg10
I28
sg11
VBMP antagonist Inhibin alpha
p12597
sg13
I4
sasg24
(lp12598
(dp12599
g7
I39
sg27
VC0152101
p12600
sg10
I4
sg11
VHLHS
p12601
sg13
I1
sasa(dp12602
g2
S'We have described previously the Ets family member ERM/ETV5 specifically upregulated in endometrial endometrioid carcinoma (EEC) associated with myometrial infiltration.\n'
p12603
sg4
(lp12604
(dp12605
g7
I55
sg8
VP41161
p12606
sg10
I4
sg11
VETV5
p12607
sg13
I1
sa(dp12608
g7
I51
sg8
VP41161
p12609
sg10
I3
sg11
VERM
p12610
sg13
I1
sa(dp12611
g7
I33
sg8
VP20908
p12612
sg10
I17
sg11
VEts family member
p12613
sg13
I3
sasg24
(lp12614
(dp12615
g7
I156
sg27
VC0332448
p12616
sg10
I12
sg11
Vinfiltration
p12617
sg13
I1
sa(dp12618
g7
I124
sg27
VC1851841
p12619
sg10
I3
sg11
VEEC
p12620
sg13
I1
sa(dp12621
g7
I100
sg27
VC0206687
p12622
sg10
I22
sg11
Vendometrioid carcinoma
p12623
sg13
I2
sasa(dp12624
g2
S'We have described recently the Ets family transcription factor, ERM/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration.\n'
p12625
sg4
(lp12626
(dp12627
g7
I68
sg8
VP41161
p12628
sg10
I4
sg11
VETV5
p12629
sg13
I1
sa(dp12630
g7
I64
sg8
VP41161
p12631
sg10
I3
sg11
VERM
p12632
sg13
I1
sa(dp12633
g7
I31
sg8
VP35398
p12634
sg10
I31
sg11
VEts family transcription factor
p12635
sg13
I4
sasg24
(lp12636
(dp12637
g7
I175
sg27
VC0332448
p12638
sg10
I12
sg11
Vinfiltration
p12639
sg13
I1
sa(dp12640
g7
I116
sg27
VC0476089
p12641
sg10
I21
sg11
Vendometrial carcinoma
p12642
sg13
I2
sa(dp12643
g7
I139
sg27
VC1851841
p12644
sg10
I3
sg11
VEEC
p12645
sg13
I1
sasa(dp12646
g2
S'Finally, the specific localization of ERM/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM/ETV5 in the early steps of endometrial dissemination.\n'
p12647
sg4
(lp12648
(dp12649
g7
I42
sg8
VP41161
p12650
sg10
I4
sg11
VETV5
p12651
sg13
I1
sa(dp12652
g7
I38
sg8
VP41161
p12653
sg10
I3
sg11
VERM
p12654
sg13
I1
sa(dp12655
g7
I38
sg8
VP41161
p12656
sg10
I3
sg11
VERM
p12657
sg13
I1
sa(dp12658
g7
I51
sg8
VP08253
p12659
sg10
I5
sg11
VMMP-2
p12660
sg13
I1
sa(dp12661
g7
I42
sg8
VP41161
p12662
sg10
I4
sg11
VETV5
p12663
sg13
I1
sasg24
(lp12664
(dp12665
g7
I93
sg27
VC0332448
p12666
sg10
I12
sg11
Vinfiltrating
p12667
sg13
I1
sa(dp12668
g7
I112
sg27
VC0476089
p12669
sg10
I22
sg11
Vendometrial carcinomas
p12670
sg13
I2
sasa(dp12671
g2
S'Most importantly, the defects seen in Gfi1 deficient mice also point to roles of Gfi1 in diseases of the immune system that involve auto-immune responses and acute lymphoid leukemia and lymphoma.\n'
p12672
sg4
(lp12673
(dp12674
g7
I38
sg8
g9
sg10
I4
sg11
VGfi1
p12675
sg13
I1
sa(dp12676
g7
I38
sg8
g9
sg10
I4
sg11
VGfi1
p12677
sg13
I1
sasg24
(lp12678
(dp12679
g7
I186
sg27
VC0024299
p12680
sg10
I8
sg11
Vlymphoma
p12681
sg13
I1
sa(dp12682
g7
I158
sg27
VC1961102
p12683
sg10
I23
sg11
Vacute lymphoid leukemia
p12684
sg13
I3
sasa(dp12685
g2
S'The results showed that the gfi-1 expression level in all leukemia patients was significantly higher than that in normal group (p &lt; 0.05); the gfi-1 mRNA expression in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL) patients was significantly higher than that in normal group (p &lt; 0.05); but the difference of gfi-1 mRNA expression between AL and CML or ALL and AML was not significant.\n'
p12686
sg4
(lp12687
(dp12688
g7
I28
sg8
g9
sg10
I5
sg11
Vgfi-1
p12689
sg13
I1
sa(dp12690
g7
I146
sg8
g9
sg10
I10
sg11
Vgfi-1 mRNA
p12691
sg13
I2
sasg24
(lp12692
(dp12693
g7
I238
sg27
VC1961102
p12694
sg10
I23
sg11
Vacute lymphoid leukemia
p12695
sg13
I3
sa(dp12696
g7
I206
sg27
VC0023467
p12697
sg10
I22
sg11
Vacute myeloid leukemia
p12698
sg13
I3
sa(dp12699
g7
I171
sg27
VC0023473
p12700
sg10
I24
sg11
Vchronic myeloid leukemia
p12701
sg13
I3
sa(dp12702
g7
I263
sg27
VC1961102
p12703
sg10
I3
sg11
VALL
p12704
sg13
I1
sa(dp12705
g7
I230
sg27
VC0023467
p12706
sg10
I3
sg11
VAML
p12707
sg13
I1
sa(dp12708
g7
I197
sg27
VC0023473
p12709
sg10
I3
sg11
VCML
p12710
sg13
I1
sa(dp12711
g7
I197
sg27
VC0023473
p12712
sg10
I3
sg11
VCML
p12713
sg13
I1
sa(dp12714
g7
I58
sg27
VC0023418
p12715
sg10
I8
sg11
Vleukemia
p12716
sg13
I1
sa(dp12717
g7
I230
sg27
VC0023467
p12718
sg10
I3
sg11
VAML
p12719
sg13
I1
sa(dp12720
g7
I263
sg27
VC1961102
p12721
sg10
I3
sg11
VALL
p12722
sg13
I1
sasa(dp12723
g2
S'The MDM2 309GG genotype was linked to a higher risk of acute G3-4 dermatitis.\n'
p12724
sg4
(lp12725
sg24
(lp12726
(dp12727
g7
I66
sg27
VC0011603
p12728
sg10
I10
sg11
Vdermatitis
p12729
sg13
I1
sasa(dp12730
g2
S'In an antibody microarray chip analysis, MDM2 expression was increased in atopic dermatitis patients.\n'
p12731
sg4
(lp12732
sg24
(lp12733
(dp12734
g7
I74
sg27
VC0011615
p12735
sg10
I17
sg11
Vatopic dermatitis
p12736
sg13
I2
sasa(dp12737
g2
S'All doxorubicin (Dox)-resistant tumors expressed higher levels of cancer stem-like cell biomarkers, including CD44, Wnt and its receptor LRP5/6, relative to Dox-sensitive tumors.\n'
p12738
sg4
(lp12739
(dp12740
g7
I137
sg8
g9
sg10
I6
sg11
VLRP5/6
p12741
sg13
I1
sasg24
(lp12742
(dp12743
g7
I66
sg27
VC0006826
p12744
sg10
I6
sg11
Vcancer
p12745
sg13
I1
sa(dp12746
g7
I32
sg27
VC0027651
p12747
sg10
I6
sg11
Vtumors
p12748
sg13
I1
sa(dp12749
g7
I32
sg27
VC0027651
p12750
sg10
I6
sg11
Vtumors
p12751
sg13
I1
sasa(dp12752
g2
S'Our results showed that simultaneous binding to LRP5/6 and uPAR by the dual receptor targeted IONPs was required to inhibit breast cancer cell invasion.\n'
p12753
sg4
(lp12754
(dp12755
g7
I48
sg8
g9
sg10
I6
sg11
VLRP5/6
p12756
sg13
I1
sasg24
(lp12757
(dp12758
g7
I138
sg27
VC2699153
p12759
sg10
I13
sg11
Vcell invasion
p12760
sg13
I2
sa(dp12761
g7
I124
sg27
VC0678222
p12762
sg10
I13
sg11
Vbreast cancer
p12763
sg13
I2
sasa(dp12764
g2
S'STAT5 LKO caused hyperglycemia, hyperinsulinemia, hyperleptinemia and elevated free fatty acid and cholesterol concentrations under HFD feeding but induced only hyperglycemia on normal diet.\n'
p12765
sg4
(lp12766
(dp12767
g7
I0
sg8
VP42229
p12768
sg10
I5
sg11
VSTAT5
p12769
sg13
I1
sasg24
(lp12770
(dp12771
g7
I32
sg27
VC0020459
p12772
sg10
I16
sg11
Vhyperinsulinemia
p12773
sg13
I1
sa(dp12774
g7
I17
sg27
VC0020456
p12775
sg10
I13
sg11
Vhyperglycemia
p12776
sg13
I1
sa(dp12777
g7
I17
sg27
VC0020456
p12778
sg10
I13
sg11
Vhyperglycemia
p12779
sg13
I1
sasa(dp12780
g2
S'Prx2 is a key cytoprotector against IO that is induced either by iron supplementation or due to chronic hemolysis as in Beta-thalassemia.\n'
p12781
sg4
(lp12782
(dp12783
g7
I0
sg8
VP32119
p12784
sg10
I4
sg11
VPrx2
p12785
sg13
I1
sasg24
(lp12786
(dp12787
g7
I104
sg27
VC0019054
p12788
sg10
I9
sg11
Vhemolysis
p12789
sg13
I1
sa(dp12790
g7
I120
sg27
VC0005283
p12791
sg10
I16
sg11
VBeta-thalassemia
p12792
sg13
I1
sasa(dp12793
g2
S'Peroxiredoxin-2 (Prx2), a typical 2-cysteine peroxiredoxin, is upregulated during Beta-thalassemic erythropoiesis, but its contribution to stress erythropoiesis, a common feature of thalassemia, is yet to be fully defined.\n'
p12794
sg4
(lp12795
(dp12796
g7
I0
sg8
VP32119
p12797
sg10
I15
sg11
VPeroxiredoxin-2
p12798
sg13
I1
sa(dp12799
g7
I17
sg8
VP32119
p12800
sg10
I4
sg11
VPrx2
p12801
sg13
I1
sasg24
(lp12802
(dp12803
g7
I182
sg27
VC0039730
p12804
sg10
I11
sg11
Vthalassemia
p12805
sg13
I1
sasa(dp12806
g2
S'In the present study, we aimed to investigate plasma levels of peroxiredoxin 2 (Prx2) and thioredoxin 1 (Trx1), and the activity of thioredoxin reductase (TrxR), in thalassemia major (TM) patients living in the Antalya region, Turkey.\n'
p12807
sg4
(lp12808
(dp12809
g7
I80
sg8
VP32119
p12810
sg10
I4
sg11
VPrx2
p12811
sg13
I1
sa(dp12812
g7
I90
sg8
VP10599
p12813
sg10
I13
sg11
Vthioredoxin 1
p12814
sg13
I2
sa(dp12815
g7
I132
sg8
VP10599
p12816
sg10
I21
sg11
Vthioredoxin reductase
p12817
sg13
I2
sa(dp12818
g7
I105
sg8
VP60606
p12819
sg10
I4
sg11
VTrx1
p12820
sg13
I1
sa(dp12821
g7
I63
sg8
VP32119
p12822
sg10
I15
sg11
Vperoxiredoxin 2
p12823
sg13
I2
sa(dp12824
g7
I155
sg8
VP30044
p12825
sg10
I4
sg11
VTrxR
p12826
sg13
I1
sasg24
(lp12827
(dp12828
g7
I184
sg27
VC0002875
p12829
sg10
I2
sg11
VTM
p12830
sg13
I1
sa(dp12831
g7
I165
sg27
VC0002875
p12832
sg10
I17
sg11
Vthalassemia major
p12833
sg13
I2
sasa(dp12834
g2
S'Proteomic analysis of microparticles released from thalassemia intermedia erythrocytes indicated that, besides hemichromes and clustered band 3, the microparticles contain a characteristic set of proteins that includes catalase, heat shock protein 70, peroxiredoxin 2 and carbonic anhydrase.\n'
p12835
sg4
(lp12836
(dp12837
g7
I219
sg8
VP04040
p12838
sg10
I8
sg11
Vcatalase
p12839
sg13
I1
sa(dp12840
g7
I229
sg8
VP34932
p12841
sg10
I21
sg11
Vheat shock protein 70
p12842
sg13
I4
sa(dp12843
g7
I252
sg8
VP32119
p12844
sg10
I15
sg11
Vperoxiredoxin 2
p12845
sg13
I2
sa(dp12846
g7
I272
sg8
VP35218
p12847
sg10
I18
sg11
Vcarbonic anhydrase
p12848
sg13
I2
sasg24
(lp12849
(dp12850
g7
I51
sg27
VC0271979
p12851
sg10
I22
sg11
Vthalassemia intermedia
p12852
sg13
I2
sasa(dp12853
g2
S'Interestingly, Prx II interacted with Hb in mouse RBCs, and their interaction, in particular, was severely impaired in RBCs of patients with thalassemia (THAL) and sickle cell anemia (SCA).\n'
p12854
sg4
(lp12855
(dp12856
g7
I15
sg8
VP30041
p12857
sg10
I6
sg11
VPrx II
p12858
sg13
I2
sasg24
(lp12859
(dp12860
g7
I141
sg27
VC0039730
p12861
sg10
I11
sg11
Vthalassemia
p12862
sg13
I1
sa(dp12863
g7
I184
sg27
VC0002895
p12864
sg10
I3
sg11
VSCA
p12865
sg13
I1
sa(dp12866
g7
I164
sg27
VC0002895
p12867
sg10
I18
sg11
Vsickle cell anemia
p12868
sg13
I3
sa(dp12869
g7
I154
sg27
VC0039730
p12870
sg10
I4
sg11
VTHAL
p12871
sg13
I1
sa(dp12872
g7
I107
sg27
VC0684336
p12873
sg10
I8
sg11
Vimpaired
p12874
sg13
I1
sasa(dp12875
g2
S'The cover image, by Lihadh Al Gazali et al., is based on the Original Article A recessive syndrome of intellectual disability, moderate overgrowth, and renal dysplasia predisposing to Wilms tumor is caused by a mutation in FIBP gene, DOI:10.1002/ajmg.a.37741.\n'
p12876
sg4
(lp12877
(dp12878
g7
I223
sg8
g9
sg10
I9
sg11
VFIBP gene
p12879
sg13
I2
sasg24
(lp12880
(dp12881
g7
I102
sg27
VC0025362
p12882
sg10
I23
sg11
Vintellectual disability
p12883
sg13
I2
sa(dp12884
g7
I152
sg27
VC0266313
p12885
sg10
I15
sg11
Vrenal dysplasia
p12886
sg13
I2
sa(dp12887
g7
I90
sg27
VC0039082
p12888
sg10
I8
sg11
Vsyndrome
p12889
sg13
I1
sa(dp12890
g7
I184
sg27
VC0027708
p12891
sg10
I11
sg11
VWilms tumor
p12892
sg13
I2
sasa(dp12893
g2
S'Different observational clinical studies reported that circulating levels of ANGPTL2 increase significantly in various chronic inflammatory diseases and showed associations between ANGPTL2 levels and diagnosis and/or prognosis of cardiovascular diseases, diabetes, chronic kidney disease, and various types of cancers.\n'
p12894
sg4
(lp12895
(dp12896
g7
I77
sg8
g9
sg10
I7
sg11
VANGPTL2
p12897
sg13
I1
sa(dp12898
g7
I77
sg8
g9
sg10
I7
sg11
VANGPTL2
p12899
sg13
I1
sasg24
(lp12900
(dp12901
g7
I255
sg27
VC0011849
p12902
sg10
I8
sg11
Vdiabetes
p12903
sg13
I1
sa(dp12904
g7
I310
sg27
VC0006826
p12905
sg10
I7
sg11
Vcancers
p12906
sg13
I1
sa(dp12907
g7
I230
sg27
VC0007222
p12908
sg10
I23
sg11
Vcardiovascular diseases
p12909
sg13
I2
sa(dp12910
g7
I265
sg27
VC1561643
p12911
sg10
I22
sg11
Vchronic kidney disease
p12912
sg13
I3
sasa(dp12913
g2
S'Circulating ANGPTL2 is increased in chronic kidney disease (CKD), where the risk of CVD is amplified.\n'
p12914
sg4
(lp12915
(dp12916
g7
I12
sg8
g9
sg10
I7
sg11
VANGPTL2
p12917
sg13
I1
sasg24
(lp12918
(dp12919
g7
I60
sg27
VC1561643
p12920
sg10
I3
sg11
VCKD
p12921
sg13
I1
sa(dp12922
g7
I36
sg27
VC1561643
p12923
sg10
I22
sg11
Vchronic kidney disease
p12924
sg13
I3
sa(dp12925
g7
I84
sg27
VC0007222
p12926
sg10
I3
sg11
VCVD
p12927
sg13
I1
sasa(dp12928
g2
S'The positive association between post-KTx ANGPTL2, aortic stiffness and mortality, suggests that ANGPTL2 may play a biological role in CKD-related CVD.\n'
p12929
sg4
(lp12930
(dp12931
g7
I42
sg8
g9
sg10
I7
sg11
VANGPTL2
p12932
sg13
I1
sa(dp12933
g7
I42
sg8
g9
sg10
I7
sg11
VANGPTL2
p12934
sg13
I1
sasg24
(lp12935
(dp12936
g7
I147
sg27
VC0007222
p12937
sg10
I3
sg11
VCVD
p12938
sg13
I1
sa(dp12939
g7
I51
sg27
VC3178782
p12940
sg10
I16
sg11
Vaortic stiffness
p12941
sg13
I2
sasa(dp12942
g2
S'Histological analysis of human kidneys indicated abundant expression of angiopoietin-like protein 2 (ANGPTL2) in renal tubule epithelial cells during progression of renal fibrosis.\n'
p12943
sg4
(lp12944
(dp12945
g7
I72
sg8
g9
sg10
I27
sg11
Vangiopoietin-like protein 2
p12946
sg13
I3
sa(dp12947
g7
I101
sg8
g9
sg10
I7
sg11
VANGPTL2
p12948
sg13
I1
sasg24
(lp12949
(dp12950
g7
I165
sg27
VC0151650
p12951
sg10
I14
sg11
Vrenal fibrosis
p12952
sg13
I2
sasa(dp12953
g2
S'Furthermore, ANGPTL2 deficiency in a mouse unilateral ureteral obstruction model significantly reduced renal fibrosis by decreasing TGF-Beta1 signal amplification in kidney.\n'
p12954
sg4
(lp12955
(dp12956
g7
I132
sg8
VP01137
p12957
sg10
I9
sg11
VTGF-Beta1
p12958
sg13
I1
sa(dp12959
g7
I13
sg8
g9
sg10
I7
sg11
VANGPTL2
p12960
sg13
I1
sasg24
(lp12961
(dp12962
g7
I103
sg27
VC0151650
p12963
sg10
I14
sg11
Vrenal fibrosis
p12964
sg13
I2
sa(dp12965
g7
I54
sg27
VC0041956
p12966
sg10
I20
sg11
Vureteral obstruction
p12967
sg13
I2
sa(dp12968
g7
I149
sg27
VC1705759
p12969
sg10
I13
sg11
Vamplification
p12970
sg13
I1
sasa(dp12971
g2
S'Thus, ANGPTL2 and TGF-Beta1 positively regulate each other as renal fibrosis progresses.\n'
p12972
sg4
(lp12973
(dp12974
g7
I6
sg8
g9
sg10
I7
sg11
VANGPTL2
p12975
sg13
I1
sa(dp12976
g7
I18
sg8
VP01137
p12977
sg10
I9
sg11
VTGF-Beta1
p12978
sg13
I1
sasg24
(lp12979
(dp12980
g7
I62
sg27
VC0151650
p12981
sg10
I14
sg11
Vrenal fibrosis
p12982
sg13
I2
sasa(dp12983
g2
S'demonstrated that genetic depletion of Angptl2 confers amelioration of the mouse kidney fibrosis induced by a unilateral ureteral obstruction, implicating that ANGPTL2, predominantly in the renal tubular compartments, activates the transforming growth factor-Beta signaling and vice versa through miR-221.\n'
p12984
sg4
(lp12985
(dp12986
g7
I160
sg8
g9
sg10
I7
sg11
VANGPTL2
p12987
sg13
I1
sa(dp12988
g7
I39
sg8
g9
sg10
I7
sg11
VAngptl2
p12989
sg13
I1
sa(dp12990
g7
I232
sg8
VP18075
p12991
sg10
I31
sg11
Vtransforming growth factor-Beta
p12992
sg13
I3
sasg24
(lp12993
(dp12994
g7
I81
sg27
VC0151650
p12995
sg10
I15
sg11
Vkidney fibrosis
p12996
sg13
I2
sa(dp12997
g7
I121
sg27
VC0041956
p12998
sg10
I20
sg11
Vureteral obstruction
p12999
sg13
I2
sasa(dp13000
g2
S'In the present study, we tested whether there is a correlation between increased ANGPTL2 expression and inflammation in response to Staphylococcus aureus in murine mastitis and the mechanisms involved.\n'
p13001
sg4
(lp13002
(dp13003
g7
I81
sg8
g9
sg10
I7
sg11
VANGPTL2
p13004
sg13
I1
sasg24
(lp13005
(dp13006
g7
I104
sg27
VC0021368
p13007
sg10
I12
sg11
Vinflammation
p13008
sg13
I1
sa(dp13009
g7
I164
sg27
VC3251795
p13010
sg10
I8
sg11
Vmastitis
p13011
sg13
I1
sasa(dp13012
g2
S'The present findings indicate ANGPTL2 may mediate the inflammation in murine mastitis through the activation of IL-6 and TNF-Alfa.\n'
p13013
sg4
(lp13014
(dp13015
g7
I112
sg8
VP05231
p13016
sg10
I4
sg11
VIL-6
p13017
sg13
I1
sa(dp13018
g7
I121
sg8
VP01375
p13019
sg10
I8
sg11
VTNF-Alfa
p13020
sg13
I1
sa(dp13021
g7
I30
sg8
g9
sg10
I7
sg11
VANGPTL2
p13022
sg13
I1
sasg24
(lp13023
(dp13024
g7
I54
sg27
VC0021368
p13025
sg10
I12
sg11
Vinflammation
p13026
sg13
I1
sa(dp13027
g7
I77
sg27
VC3251795
p13028
sg10
I8
sg11
Vmastitis
p13029
sg13
I1
sasa(dp13030
g2
S'The aim of this study was to investigate the relationship between serum Angptl2 level and chronic kidney disease (CKD).\n'
p13031
sg4
(lp13032
(dp13033
g7
I72
sg8
g9
sg10
I7
sg11
VAngptl2
p13034
sg13
I1
sasg24
(lp13035
(dp13036
g7
I90
sg27
VC1561643
p13037
sg10
I22
sg11
Vchronic kidney disease
p13038
sg13
I3
sa(dp13039
g7
I114
sg27
VC1561643
p13040
sg10
I3
sg11
VCKD
p13041
sg13
I1
sasa(dp13042
g2
S'The age- and sex-adjusted ORs for the presence of CKD increased with higher serum Angptl2 level.\n'
p13043
sg4
(lp13044
(dp13045
g7
I82
sg8
g9
sg10
I7
sg11
VAngptl2
p13046
sg13
I1
sasg24
(lp13047
sa(dp13048
g2
S'Elevated serum Angptl2 is associated with the likelihood of CKD in the general population.\n'
p13049
sg4
(lp13050
(dp13051
g7
I9
sg8
g9
sg10
I13
sg11
Vserum Angptl2
p13052
sg13
I2
sasg24
(lp13053
sa(dp13054
g2
S'We investigated whether serum Angptl2 levels are associated with diabetic nephropathy in patients with type 2 diabetes.\n'
p13055
sg4
(lp13056
(dp13057
g7
I30
sg8
g9
sg10
I7
sg11
VAngptl2
p13058
sg13
I1
sasg24
(lp13059
(dp13060
g7
I103
sg27
VC0011860
p13061
sg10
I15
sg11
Vtype 2 diabetes
p13062
sg13
I3
sa(dp13063
g7
I65
sg27
VC0011881
p13064
sg10
I20
sg11
Vdiabetic nephropathy
p13065
sg13
I2
sasa(dp13066
g2
S'This suggests a possible role of Angptl2 in progressive nephropathy in patients with type 2 diabetes.\n'
p13067
sg4
(lp13068
(dp13069
g7
I33
sg8
g9
sg10
I7
sg11
VAngptl2
p13070
sg13
I1
sasg24
(lp13071
(dp13072
g7
I85
sg27
VC0011860
p13073
sg10
I15
sg11
Vtype 2 diabetes
p13074
sg13
I3
sa(dp13075
g7
I56
sg27
VC0022658
p13076
sg10
I11
sg11
Vnephropathy
p13077
sg13
I1
sasa(dp13078
g2
S'Improvements to restriction fragment length polymorphism (RFLP)-based genotyping assays currently used for detection of mutations responsible for bovine ferrochelatase and myophosphorylase deficiencies, and equine hyperkalemic periodic paralysis (HYPP) are described.\n'
p13079
sg4
(lp13080
(dp13081
g7
I146
sg8
VP22830
p13082
sg10
I21
sg11
Vbovine ferrochelatase
p13083
sg13
I2
sa(dp13084
g7
I172
sg8
VP11217
p13085
sg10
I16
sg11
Vmyophosphorylase
p13086
sg13
I1
sasg24
(lp13087
(dp13088
g7
I247
sg27
VC0238357
p13089
sg10
I4
sg11
VHYPP
p13090
sg13
I1
sa(dp13091
g7
I214
sg27
VC0238357
p13092
sg10
I31
sg11
Vhyperkalemic periodic paralysis
p13093
sg13
I3
sasa(dp13094
g2
S'Thus, peripheral changes of TOAG-1 and RHAMM expression can be used to predict clinical response to Alefacept treatment in psoriasis patients.\n'
p13095
sg4
(lp13096
(dp13097
g7
I39
sg8
g9
sg10
I5
sg11
VRHAMM
p13098
sg13
I1
sasg24
(lp13099
(dp13100
g7
I123
sg27
VC0033860
p13101
sg10
I9
sg11
Vpsoriasis
p13102
sg13
I1
sasa(dp13103
g2
S'In this study, we examined the pharmacological profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion.\n'
p13104
sg4
(lp13105
(dp13106
g7
I73
sg8
VP09874
p13107
sg10
I4
sg11
VPARP
p13108
sg13
I1
sasg24
(lp13109
(dp13110
g7
I220
sg27
VC0028778
p13111
sg10
I9
sg11
Vocclusion
p13112
sg13
I1
sa(dp13113
g7
I138
sg27
VC0038454
p13114
sg10
I19
sg11
Vcerebral infarction
p13115
sg13
I2
sasa(dp13116
g2
S'Our data thus suggest that the tested PARP polymorphisms do not principally contribute to cerebral infarction, although extensive searches would be required to clarify whether the PARP gene plays an important role in the pathogenesis of human stroke.\n'
p13117
sg4
(lp13118
(dp13119
g7
I180
sg8
VP09874
p13120
sg10
I9
sg11
VPARP gene
p13121
sg13
I2
sa(dp13122
g7
I38
sg8
VP09874
p13123
sg10
I4
sg11
VPARP
p13124
sg13
I1
sasg24
(lp13125
(dp13126
g7
I221
sg27
VC0699748
p13127
sg10
I12
sg11
Vpathogenesis
p13128
sg13
I1
sa(dp13129
g7
I90
sg27
VC0038454
p13130
sg10
I19
sg11
Vcerebral infarction
p13131
sg13
I2
sa(dp13132
g7
I243
sg27
VC0038454
p13133
sg10
I6
sg11
Vstroke
p13134
sg13
I1
sasa(dp13135
g2
S'The OR of breast cancer for the percentage BPE measure (BPE%) quantified from SUB1 was 3.5 (95% Confidence Interval: 1.3, 9.8; p = 0.015) for 20% increments.\n'
p13136
sg4
(lp13137
(dp13138
g7
I78
sg8
VP53999
p13139
sg10
I4
sg11
VSUB1
p13140
sg13
I1
sasg24
(lp13141
(dp13142
g7
I10
sg27
VC0678222
p13143
sg10
I13
sg11
Vbreast cancer
p13144
sg13
I2
sasa(dp13145
g2
S'In this study, we show elevated expression of SUB1 in aggressive prostate cancer.\n'
p13146
sg4
(lp13147
(dp13148
g7
I46
sg8
VP53999
p13149
sg10
I4
sg11
VSUB1
p13150
sg13
I1
sasg24
(lp13151
(dp13152
g7
I54
sg27
VC0001807
p13153
sg10
I10
sg11
Vaggressive
p13154
sg13
I1
sa(dp13155
g7
I65
sg27
VC0600139
p13156
sg10
I15
sg11
Vprostate cancer
p13157
sg13
I2
sasa(dp13158
g2
S'Knockdown of SUB1 in prostate cancer cells resulted in reduced cell proliferation, invasion and migration in vitro, and tumor growth and metastasis in vivo.\n'
p13159
sg4
(lp13160
(dp13161
g7
I13
sg8
VP53999
p13162
sg10
I4
sg11
VSUB1
p13163
sg13
I1
sasg24
(lp13164
(dp13165
g7
I120
sg27
VC0598934
p13166
sg10
I12
sg11
Vtumor growth
p13167
sg13
I2
sa(dp13168
g7
I137
sg27
VC0027627
p13169
sg10
I10
sg11
Vmetastasis
p13170
sg13
I1
sa(dp13171
g7
I68
sg27
VC0334094
p13172
sg10
I13
sg11
Vproliferation
p13173
sg13
I1
sa(dp13174
g7
I21
sg27
VC0600139
p13175
sg10
I15
sg11
Vprostate cancer
p13176
sg13
I2
sa(dp13177
g7
I83
sg27
VC2699153
p13178
sg10
I8
sg11
Vinvasion
p13179
sg13
I1
sasa(dp13180
g2
S'PLK1 knockdown or use of PLK1 inhibitor can mitigate oncogenic function of SUB1 in benign prostate cancer cells.\n'
p13181
sg4
(lp13182
(dp13183
g7
I75
sg8
VP53999
p13184
sg10
I4
sg11
VSUB1
p13185
sg13
I1
sa(dp13186
g7
I0
sg8
VP53350
p13187
sg10
I4
sg11
VPLK1
p13188
sg13
I1
sa(dp13189
g7
I0
sg8
VP53350
p13190
sg10
I4
sg11
VPLK1
p13191
sg13
I1
sasg24
(lp13192
(dp13193
g7
I90
sg27
VC0600139
p13194
sg10
I15
sg11
Vprostate cancer
p13195
sg13
I2
sasa(dp13196
g2
S'Thus, our study suggests that miR-101 loss results in increased SUB1 expression and subsequent activation of known oncogenes driving prostate cancer progression and metastasis.\n'
p13197
sg4
(lp13198
(dp13199
g7
I64
sg8
VP53999
p13200
sg10
I4
sg11
VSUB1
p13201
sg13
I1
sa(dp13202
g7
I30
sg8
g9
sg10
I12
sg11
VmiR-101 loss
p13203
sg13
I2
sasg24
(lp13204
(dp13205
g7
I142
sg27
VC0178874
p13206
sg10
I18
sg11
Vcancer progression
p13207
sg13
I2
sa(dp13208
g7
I165
sg27
VC0027627
p13209
sg10
I10
sg11
Vmetastasis
p13210
sg13
I1
sasa(dp13211
g2
S'This study therefore demonstrates functional role of SUB1 in prostate cancer, and identifies its regulation and potential downstream therapeutic targets of SUB1 in prostate cancer.\n'
p13212
sg4
(lp13213
(dp13214
g7
I53
sg8
VP53999
p13215
sg10
I4
sg11
VSUB1
p13216
sg13
I1
sa(dp13217
g7
I53
sg8
VP53999
p13218
sg10
I4
sg11
VSUB1
p13219
sg13
I1
sasg24
(lp13220
(dp13221
g7
I61
sg27
VC0600139
p13222
sg10
I15
sg11
Vprostate cancer
p13223
sg13
I2
sa(dp13224
g7
I61
sg27
VC0600139
p13225
sg10
I15
sg11
Vprostate cancer
p13226
sg13
I2
sasa(dp13227
g2
S'The proposed study aims to explore whether PC4 correlates with VEGF-C/VEGF-D/VEGFR-3 axis of lymphangiogenesis in the lymph node metastasis during lung adenocarcinoma.\n'
p13228
sg4
(lp13229
(dp13230
g7
I63
sg8
VP49767
p13231
sg10
I6
sg11
VVEGF-C
p13232
sg13
I1
sa(dp13233
g7
I77
sg8
VP35968
p13234
sg10
I5
sg11
VVEGFR
p13235
sg13
I1
sasg24
(lp13236
(dp13237
g7
I147
sg27
VC0152013
p13238
sg10
I19
sg11
Vlung adenocarcinoma
p13239
sg13
I2
sa(dp13240
g7
I118
sg27
VC0686619
p13241
sg10
I21
sg11
Vlymph node metastasis
p13242
sg13
I3
sasa(dp13243
g2
S'Here, small interfering RNA technique was employed to investigate the relationship of PC4 and the VEGF-C/VEGF-D/VEGFR-3 axis in lung adenocarcinoma cell lines as well as tumor xenografts of mice model.\n'
p13244
sg4
(lp13245
(dp13246
g7
I98
sg8
VP49767
p13247
sg10
I6
sg11
VVEGF-C
p13248
sg13
I1
sa(dp13249
g7
I86
sg8
VP53999
p13250
sg10
I3
sg11
VPC4
p13251
sg13
I1
sa(dp13252
g7
I112
sg8
VP35916
p13253
sg10
I7
sg11
VVEGFR-3
p13254
sg13
I1
sasg24
(lp13255
(dp13256
g7
I128
sg27
VC0152013
p13257
sg10
I19
sg11
Vlung adenocarcinoma
p13258
sg13
I2
sa(dp13259
g7
I170
sg27
VC0027651
p13260
sg10
I5
sg11
Vtumor
p13261
sg13
I1
sasa(dp13262
g2
S'PC4 expression correlated with the levels of VEGF-C, VEGF-D and VEGFR-3 during the development of lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma in vitro and in vivo, which may be a novel marker in the development of lymphangiogenesis and lymphatic metastasis of tumors.\n'
p13263
sg4
(lp13264
(dp13265
g7
I45
sg8
VP49767
p13266
sg10
I6
sg11
VVEGF-C
p13267
sg13
I1
sa(dp13268
g7
I53
sg8
g9
sg10
I6
sg11
VVEGF-D
p13269
sg13
I1
sa(dp13270
g7
I0
sg8
VP53999
p13271
sg10
I3
sg11
VPC4
p13272
sg13
I1
sa(dp13273
g7
I64
sg8
VP35916
p13274
sg10
I7
sg11
VVEGFR-3
p13275
sg13
I1
sasg24
(lp13276
(dp13277
g7
I144
sg27
VC0152013
p13278
sg10
I19
sg11
Vlung adenocarcinoma
p13279
sg13
I2
sa(dp13280
g7
I282
sg27
VC0027651
p13281
sg10
I6
sg11
Vtumors
p13282
sg13
I1
sa(dp13283
g7
I120
sg27
VC0024232
p13284
sg10
I20
sg11
Vlymphatic metastasis
p13285
sg13
I2
sa(dp13286
g7
I120
sg27
VC0024232
p13287
sg10
I20
sg11
Vlymphatic metastasis
p13288
sg13
I2
sasa(dp13289
g2
S'To test the hypothesis that elevated urinary levels of soluble E-cadherin (sE-cadherin) would aid in the detection of transitional cell carcinoma (TCC) of the urinary bladder.\n'
p13290
sg4
(lp13291
(dp13292
g7
I75
sg8
g9
sg10
I11
sg11
VsE-cadherin
p13293
sg13
I1
sa(dp13294
g7
I55
sg8
g9
sg10
I18
sg11
Vsoluble E-cadherin
p13295
sg13
I2
sasg24
(lp13296
(dp13297
g7
I118
sg27
VC0007138
p13298
sg10
I27
sg11
Vtransitional cell carcinoma
p13299
sg13
I3
sa(dp13300
g7
I147
sg27
VC1861305
p13301
sg10
I3
sg11
VTCC
p13302
sg13
I1
sasa(dp13303
g2
S'We propose potential pathogenic pathways for transitional cell carcinoma of the bladder in diabetic patients based on altered integrin and cadherin distribution in urothelial cells in diabetic patients.\n'
p13304
sg4
(lp13305
(dp13306
g7
I139
sg8
g9
sg10
I8
sg11
Vcadherin
p13307
sg13
I1
sasg24
(lp13308
(dp13309
g7
I45
sg27
VC0279680
p13310
sg10
I42
sg11
Vtransitional cell carcinoma of the bladder
p13311
sg13
I6
sasa(dp13312
g2
S'To evaluate soluble E-cadherin (sE-cadherin) as a potential tumour marker in patients with transitional cell carcinoma (TCC) of the bladder (previously shown to correlate with tumour grade, number of Ta/T1 tumours at presentation and a positive 3-month check cystoscopy) by assessing its serum concentration in relation to transurethral resection of bladder tumour (TURBT).\n'
p13313
sg4
(lp13314
(dp13315
g7
I12
sg8
VP35558
p13316
sg10
I18
sg11
Vsoluble E-cadherin
p13317
sg13
I2
sa(dp13318
g7
I32
sg8
g9
sg10
I11
sg11
VsE-cadherin
p13319
sg13
I1
sasg24
(lp13320
(dp13321
g7
I60
sg27
VC0027651
p13322
sg10
I6
sg11
Vtumour
p13323
sg13
I1
sa(dp13324
g7
I120
sg27
VC1861305
p13325
sg10
I3
sg11
VTCC
p13326
sg13
I1
sa(dp13327
g7
I60
sg27
VC0027651
p13328
sg10
I6
sg11
Vtumour
p13329
sg13
I1
sa(dp13330
g7
I91
sg27
VC0007138
p13331
sg10
I27
sg11
Vtransitional cell carcinoma
p13332
sg13
I3
sa(dp13333
g7
I60
sg27
VC0027651
p13334
sg10
I6
sg11
Vtumour
p13335
sg13
I1
sa(dp13336
g7
I206
sg27
VC0027651
p13337
sg10
I7
sg11
Vtumours
p13338
sg13
I1
sasa(dp13339
g2
S'Elevated mRNA expression of liver IL-6, IL-17A, IL-17F, TGF-Beta1, Alfa-SMA, TGR5, NTCP, OATP1a1, and ileum ASBT and decreased liver IL-10, FXR, CAR, VDR, BSEP, MRP2, MRP3, MRP4 was also observed in ANIT-induced cholestasis but were attenuated or normalized by YCHT.\n'
p13340
sg4
(lp13341
(dp13342
g7
I34
sg8
VP05231
p13343
sg10
I4
sg11
VIL-6
p13344
sg13
I1
sa(dp13345
g7
I67
sg8
g9
sg10
I8
sg11
VAlfa-SMA
p13346
sg13
I1
sa(dp13347
g7
I83
sg8
g9
sg10
I4
sg11
VNTCP
p13348
sg13
I1
sa(dp13349
g7
I140
sg8
VP23945
p13350
sg10
I3
sg11
VFXR
p13351
sg13
I1
sa(dp13352
g7
I155
sg8
g9
sg10
I4
sg11
VBSEP
p13353
sg13
I1
sa(dp13354
g7
I150
sg8
VP11473
p13355
sg10
I3
sg11
VVDR
p13356
sg13
I1
sa(dp13357
g7
I173
sg8
g9
sg10
I4
sg11
VMRP4
p13358
sg13
I1
sa(dp13359
g7
I56
sg8
VP01137
p13360
sg10
I9
sg11
VTGF-Beta1
p13361
sg13
I1
sa(dp13362
g7
I77
sg8
g9
sg10
I4
sg11
VTGR5
p13363
sg13
I1
sa(dp13364
g7
I161
sg8
g9
sg10
I4
sg11
VMRP2
p13365
sg13
I1
sasg24
(lp13366
(dp13367
g7
I145
sg27
VC2607929
p13368
sg10
I3
sg11
VCAR
p13369
sg13
I1
sa(dp13370
g7
I212
sg27
VC0008370
p13371
sg10
I11
sg11
Vcholestasis
p13372
sg13
I1
sa(dp13373
g7
I72
sg27
VC0026847
p13374
sg10
I3
sg11
VSMA
p13375
sg13
I1
sasa(dp13376
g2
S'The objective of the present study is to evaluate whether IL-6, TNF-Alfa, IL-10 are associated with nutritional status in patients with cirrhosis secondary to biliary atresia and compare to healthy controls.\n'
p13377
sg4
(lp13378
(dp13379
g7
I58
sg8
VP05231
p13380
sg10
I4
sg11
VIL-6
p13381
sg13
I1
sa(dp13382
g7
I64
sg8
VP01375
p13383
sg10
I8
sg11
VTNF-Alfa
p13384
sg13
I1
sasg24
(lp13385
(dp13386
g7
I136
sg27
VC0023890
p13387
sg10
I9
sg11
Vcirrhosis
p13388
sg13
I1
sa(dp13389
g7
I159
sg27
VC0005411
p13390
sg10
I15
sg11
Vbiliary atresia
p13391
sg13
I2
sasa(dp13392
g2
S'The authors suggest that, in patients with cirrhosis secondary to biliary atresia, IL-6 could be used as a possible supporting biomarker of deficient nutritional status and elevated IL-10 levels could be used as a possible early-stage supporting biomarker of deteriorating nutritional status.\n'
p13393
sg4
(lp13394
(dp13395
g7
I83
sg8
VP05231
p13396
sg10
I4
sg11
VIL-6
p13397
sg13
I1
sasg24
(lp13398
(dp13399
g7
I66
sg27
VC0005411
p13400
sg10
I15
sg11
Vbiliary atresia
p13401
sg13
I2
sa(dp13402
g7
I43
sg27
VC0023890
p13403
sg10
I9
sg11
Vcirrhosis
p13404
sg13
I1
sasa(dp13405
g2
S'In a prospective study, 47 patients with obstructive jaundice secondary to malignant lesions were evaluated before, at the fifth hour after, and on the fifth day after PTBD for neopterin, nitrate, tumor necrosis factor (TNF)-Alfa, interleukin (IL)-6, IL-10, CRP levels, and liver function.\n'
p13406
sg4
(lp13407
(dp13408
g7
I197
sg8
VP01375
p13409
sg10
I32
sg11
Vtumor necrosis factor (TNF)-Alfa
p13410
sg13
I4
sa(dp13411
g7
I231
sg8
VP60568
p13412
sg10
I18
sg11
Vinterleukin (IL)-6
p13413
sg13
I2
sa(dp13414
g7
I258
sg8
VP02741
p13415
sg10
I3
sg11
VCRP
p13416
sg13
I1
sasg24
(lp13417
(dp13418
g7
I41
sg27
VC0022354
p13419
sg10
I20
sg11
Vobstructive jaundice
p13420
sg13
I2
sa(dp13421
g7
I197
sg27
VC0333516
p13422
sg10
I14
sg11
Vtumor necrosis
p13423
sg13
I2
sasa(dp13424
g2
S'It has been reported that the hypermethylation of APAF-1, DAPK-1 and other tumor suppressive genes (TSGs) correlates with progression of renal cell carcinoma and exerts prognostic and diagnostic relevance in renal cell carcinoma.\n'
p13425
sg4
(lp13426
(dp13427
g7
I58
sg8
VP53355
p13428
sg10
I6
sg11
VDAPK-1
p13429
sg13
I1
sasg24
(lp13430
(dp13431
g7
I137
sg27
VC0007134
p13432
sg10
I20
sg11
Vrenal cell carcinoma
p13433
sg13
I3
sa(dp13434
g7
I137
sg27
VC0007134
p13435
sg10
I20
sg11
Vrenal cell carcinoma
p13436
sg13
I3
sa(dp13437
g7
I75
sg27
VC0027651
p13438
sg10
I5
sg11
Vtumor
p13439
sg13
I1
sasa(dp13440
g2
S'The present study confirmed that DAC demethylated the CpGs, particularly APAF-1 in renal carcinoma cells, and that the demethylation synergized the cytotoxity of CDDP in renal carcinoma cells via enhancing the CDDP-induced apoptosis.\n'
p13441
sg4
(lp13442
(dp13443
g7
I33
sg8
VP57775
p13444
sg10
I3
sg11
VDAC
p13445
sg13
I1
sasg24
(lp13446
(dp13447
g7
I83
sg27
VC0007134
p13448
sg10
I15
sg11
Vrenal carcinoma
p13449
sg13
I2
sa(dp13450
g7
I83
sg27
VC0007134
p13451
sg10
I15
sg11
Vrenal carcinoma
p13452
sg13
I2
sasa(dp13453
g2
S'The aim of this study was to investigate the occurrence and relevance of promoter methylation of the tumor suppressor DAPK-1, APAF-1 () and SPARC in relation to different pathological stages and histological grades of tumor progression that might act as possible independent prognostic factor in the susceptibility towards renal cell carcinoma (RCC) in North Indian population.\n'
p13454
sg4
(lp13455
(dp13456
g7
I118
sg8
VP53355
p13457
sg10
I6
sg11
VDAPK-1
p13458
sg13
I1
sa(dp13459
g7
I140
sg8
VP09486
p13460
sg10
I5
sg11
VSPARC
p13461
sg13
I1
sasg24
(lp13462
(dp13463
g7
I101
sg27
VC0027651
p13464
sg10
I5
sg11
Vtumor
p13465
sg13
I1
sa(dp13466
g7
I323
sg27
VC0007134
p13467
sg10
I20
sg11
Vrenal cell carcinoma
p13468
sg13
I3
sa(dp13469
g7
I218
sg27
VC0178874
p13470
sg10
I17
sg11
Vtumor progression
p13471
sg13
I2
sa(dp13472
g7
I345
sg27
VC0007134
p13473
sg10
I3
sg11
VRCC
p13474
sg13
I1
sasa(dp13475
g2
S'To examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.\n'
p13476
sg4
(lp13477
(dp13478
g7
I186
sg8
VP53355
p13479
sg10
I6
sg11
VDAPK-1
p13480
sg13
I1
sa(dp13481
g7
I60
sg8
g9
sg10
I77
sg11
Vp53 target and tumour suppressor genes apoptotic protease activating factor-1
p13482
sg13
I10
sa(dp13483
g7
I151
sg8
VP53355
p13484
sg10
I33
sg11
Vdeath-associated protein kinase-1
p13485
sg13
I3
sasg24
(lp13486
(dp13487
g7
I75
sg27
VC0027651
p13488
sg10
I6
sg11
Vtumour
p13489
sg13
I1
sa(dp13490
g7
I75
sg27
VC0027651
p13491
sg10
I6
sg11
Vtumour
p13492
sg13
I1
sa(dp13493
g7
I344
sg27
VC0007134
p13494
sg10
I3
sg11
VRCC
p13495
sg13
I1
sa(dp13496
g7
I264
sg27
VC1861305
p13497
sg10
I3
sg11
VTCC
p13498
sg13
I1
sa(dp13499
g7
I235
sg27
VC0007138
p13500
sg10
I27
sg11
Vtransitional cell carcinoma
p13501
sg13
I3
sa(dp13502
g7
I75
sg27
VC0027651
p13503
sg10
I6
sg11
Vtumour
p13504
sg13
I1
sa(dp13505
g7
I322
sg27
VC0007134
p13506
sg10
I20
sg11
Vrenal cell carcinoma
p13507
sg13
I3
sasa(dp13508
g2
S'Quantification of mRNA expression of HNF1B, six of its potential target genes (PKHD1, PKD1, PKD2, IFT88, TMEM27 and UMOD) and three genes involved in the Mg(2+) renal homeostasis (ATP1A1, FXYD2 and CLDN16) in the urinary sediment of 11 individuals with mutation of HNF1B and in 9 controls (non-invasive assessment of the renal transcriptome).\n'
p13509
sg4
(lp13510
(dp13511
g7
I105
sg8
g9
sg10
I6
sg11
VTMEM27
p13512
sg13
I1
sa(dp13513
g7
I188
sg8
VP54710
p13514
sg10
I5
sg11
VFXYD2
p13515
sg13
I1
sa(dp13516
g7
I37
sg8
VP35680
p13517
sg10
I5
sg11
VHNF1B
p13518
sg13
I1
sa(dp13519
g7
I92
sg8
g9
sg10
I4
sg11
VPKD2
p13520
sg13
I1
sa(dp13521
g7
I180
sg8
VP05023
p13522
sg10
I6
sg11
VATP1A1
p13523
sg13
I1
sa(dp13524
g7
I37
sg8
VP35680
p13525
sg10
I5
sg11
VHNF1B
p13526
sg13
I1
sa(dp13527
g7
I98
sg8
g9
sg10
I5
sg11
VIFT88
p13528
sg13
I1
sa(dp13529
g7
I116
sg8
VP07911
p13530
sg10
I4
sg11
VUMOD
p13531
sg13
I1
sa(dp13532
g7
I79
sg8
VP08F94
p13533
sg10
I5
sg11
VPKHD1
p13534
sg13
I1
sa(dp13535
g7
I198
sg8
g9
sg10
I6
sg11
VCLDN16
p13536
sg13
I1
sa(dp13537
g7
I86
sg8
VP98161
p13538
sg10
I4
sg11
VPKD1
p13539
sg13
I1
sasg24
(lp13540
(dp13541
g7
I79
sg27
VC0085548
p13542
sg10
I5
sg11
VPKHD1
p13543
sg13
I1
sa(dp13544
g7
I92
sg27
VC2751306
p13545
sg10
I4
sg11
VPKD2
p13546
sg13
I1
sa(dp13547
g7
I86
sg27
VC3149841
p13548
sg10
I4
sg11
VPKD1
p13549
sg13
I1
sasa(dp13550
g2
S'Collectrin is a downstream target of the transcription factor hepatocyte nuclear factor-1alpha (HNF-1alpha), which is mutated in maturity-onset diabetes of the young subtype 3 (MODY3).\n'
p13551
sg4
(lp13552
(dp13553
g7
I62
sg8
VP20823
p13554
sg10
I32
sg11
Vhepatocyte nuclear factor-1alpha
p13555
sg13
I3
sa(dp13556
g7
I177
sg8
VP20823
p13557
sg10
I5
sg11
VMODY3
p13558
sg13
I1
sa(dp13559
g7
I0
sg8
g9
sg10
I10
sg11
VCollectrin
p13560
sg13
I1
sa(dp13561
g7
I96
sg8
VP20823
p13562
sg10
I10
sg11
VHNF-1alpha
p13563
sg13
I1
sa(dp13564
g7
I129
sg8
VP20823
p13565
sg10
I46
sg11
Vmaturity-onset diabetes of the young subtype 3
p13566
sg13
I7
sasg24
(lp13567
(dp13568
g7
I177
sg27
VC1838100
p13569
sg10
I5
sg11
VMODY3
p13570
sg13
I1
sa(dp13571
g7
I129
sg27
VC1838100
p13572
sg10
I46
sg11
Vmaturity-onset diabetes of the young subtype 3
p13573
sg13
I7
sasa(dp13574
g2
S'Several forms of ichthyosis are associated with neurologic manifestations, including Sjoegren-Larsson syndrome, Refsum disease, and mental retardation-enteropathy-deafness-neuropathy-ichthyosis-keratoderma (MEDNIK) syndrome.\n'
p13575
sg4
(lp13576
sg24
(lp13577
(dp13578
g7
I194
sg27
VC0022579
p13579
sg10
I11
sg11
Vkeratoderma
p13580
sg13
I1
sa(dp13581
g7
I85
sg27
VC0037231
p13582
sg10
I25
sg11
VSjoegren-Larsson syndrome
p13583
sg13
I2
sa(dp13584
g7
I163
sg27
VC0011053
p13585
sg10
I8
sg11
Vdeafness
p13586
sg13
I1
sa(dp13587
g7
I17
sg27
VC0020758
p13588
sg10
I10
sg11
Vichthyosis
p13589
sg13
I1
sa(dp13590
g7
I112
sg27
VC0034960
p13591
sg10
I14
sg11
VRefsum disease
p13592
sg13
I2
sa(dp13593
g7
I17
sg27
VC0020758
p13594
sg10
I10
sg11
Vichthyosis
p13595
sg13
I1
sa(dp13596
g7
I102
sg27
VC0039082
p13597
sg10
I8
sg11
Vsyndrome
p13598
sg13
I1
sa(dp13599
g7
I132
sg27
VC0025362
p13600
sg10
I18
sg11
Vmental retardation
p13601
sg13
I2
sa(dp13602
g7
I151
sg27
VC0021831
p13603
sg10
I11
sg11
Venteropathy
p13604
sg13
I1
sa(dp13605
g7
I172
sg27
VC0442874
p13606
sg10
I10
sg11
Vneuropathy
p13607
sg13
I1
sasa(dp13608
g2
S'To determine the difference in thrombomodulin expression in the myometrium and in myoma; and to understand the correlation of anticoagulation/fibrinolytic function and the mechanism of uterine artery occlusion in the treatment of leiomyoma.\n'
p13609
sg4
(lp13610
(dp13611
g7
I31
sg8
VP07204
p13612
sg10
I14
sg11
Vthrombomodulin
p13613
sg13
I1
sasg24
(lp13614
(dp13615
g7
I230
sg27
VC0023267
p13616
sg10
I9
sg11
Vleiomyoma
p13617
sg13
I1
sa(dp13618
g7
I82
sg27
VC0027086
p13619
sg10
I5
sg11
Vmyoma
p13620
sg13
I1
sa(dp13621
g7
I193
sg27
VC0264995
p13622
sg10
I16
sg11
Vartery occlusion
p13623
sg13
I2
sasa(dp13624
g2
S'The relative transcription of thrombomodulin mRNA was 1.28 times higher in myometrial tissue than in myomal tissue (P &lt; 0.05).\n'
p13625
sg4
(lp13626
(dp13627
g7
I30
sg8
VP07204
p13628
sg10
I19
sg11
Vthrombomodulin mRNA
p13629
sg13
I2
sasg24
(lp13630
sa(dp13631
g2
S'Similarly, leiomyoma-associated endometrium expressed less PAI-1 and thrombomodulin in vivo.\n'
p13632
sg4
(lp13633
(dp13634
g7
I59
sg8
VP05121
p13635
sg10
I5
sg11
VPAI-1
p13636
sg13
I1
sa(dp13637
g7
I69
sg8
VP07204
p13638
sg10
I14
sg11
Vthrombomodulin
p13639
sg13
I1
sasg24
(lp13640
(dp13641
g7
I11
sg27
VC0023267
p13642
sg10
I9
sg11
Vleiomyoma
p13643
sg13
I1
sasa(dp13644
g2
S'Alfa-methylacyl coenzyme A racemase (AMACR) and insulin-like growth factor-II mRNA-binding protein 3 (IMP3) are 2 markers helpful in detecting difficult cases of dysplasia in Barrett esophagus (BE).\n'
p13645
sg4
(lp13646
(dp13647
g7
I48
sg8
VP01308
p13648
sg10
I52
sg11
Vinsulin-like growth factor-II mRNA-binding protein 3
p13649
sg13
I6
sa(dp13650
g7
I102
sg8
g9
sg10
I4
sg11
VIMP3
p13651
sg13
I1
sa(dp13652
g7
I37
sg8
g9
sg10
I5
sg11
VAMACR
p13653
sg13
I1
sa(dp13654
g7
I0
sg8
g9
sg10
I35
sg11
VAlfa-methylacyl coenzyme A racemase
p13655
sg13
I4
sasg24
(lp13656
(dp13657
g7
I194
sg27
VC0004763
p13658
sg10
I2
sg11
VBE
p13659
sg13
I1
sa(dp13660
g7
I162
sg27
VC0334044
p13661
sg10
I9
sg11
Vdysplasia
p13662
sg13
I1
sa(dp13663
g7
I175
sg27
VC0004763
p13664
sg10
I17
sg11
VBarrett esophagus
p13665
sg13
I2
sasa(dp13666
g2
S"To investigate the value of Alfa-methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO).\n"
p13667
sg4
(lp13668
(dp13669
g7
I28
sg8
g9
sg10
I28
sg11
VAlfa-methylacyl-CoA racemase
p13670
sg13
I2
sa(dp13671
g7
I58
sg8
g9
sg10
I5
sg11
VAMACR
p13672
sg13
I1
sasg24
(lp13673
(dp13674
g7
I44
sg27
VC2678439
p13675
sg10
I3
sg11
VCoA
p13676
sg13
I1
sa(dp13677
g7
I127
sg27
VC0004763
p13678
sg10
I20
sg11
VBarrett's oesophagus
p13679
sg13
I2
sa(dp13680
g7
I101
sg27
VC0178874
p13681
sg10
I22
sg11
Vneoplastic progression
p13682
sg13
I2
sa(dp13683
g7
I149
sg27
VC0004763
p13684
sg10
I2
sg11
VBO
p13685
sg13
I1
sasa(dp13686
g2
S"The aim of this study was to evaluate AMACR expression in the metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus (BE), ulcerative colitis (UC), and Crohn's disease (CD) and to determine whether its expression can be used to detect dysplastic epithelium in these conditions.\n"
p13687
sg4
(lp13688
sg24
(lp13689
(dp13690
g7
I160
sg27
VC0010346
p13691
sg10
I15
sg11
VCrohn's disease
p13692
sg13
I2
sa(dp13693
g7
I243
sg27
VC0334044
p13694
sg10
I10
sg11
Vdysplastic
p13695
sg13
I1
sa(dp13696
g7
I62
sg27
VC0025568
p13697
sg10
I10
sg11
Vmetaplasia
p13698
sg13
I1
sa(dp13699
g7
I73
sg27
VC0334044
p13700
sg10
I9
sg11
Vdysplasia
p13701
sg13
I1
sa(dp13702
g7
I83
sg27
VC0007097
p13703
sg10
I9
sg11
Vcarcinoma
p13704
sg13
I1
sa(dp13705
g7
I105
sg27
VC0004763
p13706
sg10
I19
sg11
VBarrett's esophagus
p13707
sg13
I2
sa(dp13708
g7
I126
sg27
VC0004763
p13709
sg10
I2
sg11
VBE
p13710
sg13
I1
sa(dp13711
g7
I177
sg27
VC0010346
p13712
sg10
I2
sg11
VCD
p13713
sg13
I1
sa(dp13714
g7
I131
sg27
VC0009324
p13715
sg10
I18
sg11
Vulcerative colitis
p13716
sg13
I2
sa(dp13717
g7
I151
sg27
VC0009324
p13718
sg10
I2
sg11
VUC
p13719
sg13
I1
sasa(dp13720
g2
S'These associations implicate genes related to apoptosis (HRK), development (WIF1), oxidative stress (MSR3B), ubiquitination (FBXW8) and neuronal migration (ASTN2), as well as enzymes targeted by new diabetes medications (DPP4), indicating new genetic influences on hippocampal size and possibly the risk of cognitive decline and dementia.\n'
p13721
sg4
(lp13722
(dp13723
g7
I221
sg8
VP27487
p13724
sg10
I4
sg11
VDPP4
p13725
sg13
I1
sa(dp13726
g7
I125
sg8
g9
sg10
I5
sg11
VFBXW8
p13727
sg13
I1
sa(dp13728
g7
I76
sg8
g9
sg10
I4
sg11
VWIF1
p13729
sg13
I1
sasg24
(lp13730
(dp13731
g7
I199
sg27
VC0011849
p13732
sg10
I8
sg11
Vdiabetes
p13733
sg13
I1
sa(dp13734
g7
I329
sg27
VC0497327
p13735
sg10
I8
sg11
Vdementia
p13736
sg13
I1
sa(dp13737
g7
I83
sg27
VC0242606
p13738
sg10
I16
sg11
Voxidative stress
p13739
sg13
I2
sa(dp13740
g7
I307
sg27
VC0338656
p13741
sg10
I17
sg11
Vcognitive decline
p13742
sg13
I2
sasa(dp13743
g2
S'Histomorphometrical analysis of experimental implants inserted in the femurs of CKD mice revealed a trend of decreased BIC ratio at 2-week healing.\n'
p13744
sg4
(lp13745
sg24
(lp13746
sa(dp13747
g2
S'A Cochrane Collaboration review (Roderick, Cochrane Data base of systemic reviews 2007, DOI 10.1002/14651858.CD0018.90.pub3) reported that there was no evidence for correction of acidosis by sodium bicarbonate in pre-end-stage renal disease (ESRD) patients, and concluded that randomized controlled trials (RCTs) are necessary to evaluate the benefits and harms of correcting metabolic acidosis in pre-ESRD patients.\n'
p13748
sg4
(lp13749
sg24
(lp13750
(dp13751
g7
I376
sg27
VC0220981
p13752
sg10
I18
sg11
Vmetabolic acidosis
p13753
sg13
I2
sa(dp13754
g7
I179
sg27
VC0001122
p13755
sg10
I8
sg11
Vacidosis
p13756
sg13
I1
sa(dp13757
g7
I213
sg27
VC0022661
p13758
sg10
I27
sg11
Vpre-end-stage renal disease
p13759
sg13
I3
sa(dp13760
g7
I242
sg27
VC0022661
p13761
sg10
I4
sg11
VESRD
p13762
sg13
I1
sa(dp13763
g7
I242
sg27
VC0022661
p13764
sg10
I4
sg11
VESRD
p13765
sg13
I1
sasa(dp13766
g2
S'We will randomize 600 patients with chronic kidney disease (CKD) stages 3b and 4; 300 of these patients will be included in the bicarbonate study group (Bic), in which levels of bicarbonate should be kept &gt;24 mEq/L; the other 300 patients will be included in the usual-treatment group (no-Bic).\n'
p13767
sg4
(lp13768
sg24
(lp13769
(dp13770
g7
I60
sg27
VC1561643
p13771
sg10
I3
sg11
VCKD
p13772
sg13
I1
sa(dp13773
g7
I36
sg27
VC1561643
p13774
sg10
I22
sg11
Vchronic kidney disease
p13775
sg13
I3
sasa(dp13776
g2
S'Acid-Base Disorders in CKD: Moderate metabolic acidosis (Bic 16-20) mEq/L is common with glomerular filtration rates below 20 ml/min, and favors bone demineralization due to the release of calcium and phosphate from the bone, chronic hyperventilation, and muscular weakness and atrophy.\n'
p13777
sg4
(lp13778
(dp13779
g7
I0
sg8
g9
sg10
I9
sg11
VAcid-Base
p13780
sg13
I1
sasg24
(lp13781
(dp13782
g7
I0
sg27
VC0740265
p13783
sg10
I19
sg11
VAcid-Base Disorders
p13784
sg13
I2
sa(dp13785
g7
I256
sg27
VC0151786
p13786
sg10
I17
sg11
Vmuscular weakness
p13787
sg13
I2
sa(dp13788
g7
I145
sg27
VC0242699
p13789
sg10
I21
sg11
Vbone demineralization
p13790
sg13
I2
sa(dp13791
g7
I226
sg27
VC0268054
p13792
sg10
I24
sg11
Vchronic hyperventilation
p13793
sg13
I2
sa(dp13794
g7
I37
sg27
VC0220981
p13795
sg10
I18
sg11
Vmetabolic acidosis
p13796
sg13
I2
sa(dp13797
g7
I278
sg27
VC0333641
p13798
sg10
I7
sg11
Vatrophy
p13799
sg13
I1
sasa(dp13800
g2
S'In a prospective randomized crossover trial, patients with acute renal failure received CRRT with either sodium bicarbonate (Bic) or sodium lactate (Lac) as a buffering agent over 2 consecutive 24-h periods.\n'
p13801
sg4
(lp13802
(dp13803
g7
I140
sg8
VP09848
p13804
sg10
I7
sg11
Vlactate
p13805
sg13
I1
sa(dp13806
g7
I149
sg8
VP09848
p13807
sg10
I3
sg11
VLac
p13808
sg13
I1
sasg24
(lp13809
(dp13810
g7
I59
sg27
VC0022660
p13811
sg10
I19
sg11
Vacute renal failure
p13812
sg13
I3
sasa(dp13813
g2
S'The combination of bicarbonate and mannitol (BIC/MAN) is commonly used to prevent renal failure (RF) in patients with rhabdomyolysis despite the absence of sufficient evidence validating its use.\n'
p13814
sg4
(lp13815
sg24
(lp13816
(dp13817
g7
I118
sg27
VC0035410
p13818
sg10
I14
sg11
Vrhabdomyolysis
p13819
sg13
I1
sa(dp13820
g7
I82
sg27
VC0035078
p13821
sg10
I13
sg11
Vrenal failure
p13822
sg13
I2
sa(dp13823
g7
I97
sg27
VC0035078
p13824
sg10
I2
sg11
VRF
p13825
sg13
I1
sasa(dp13826
g2
S'To unmask weak inputs from outside the conventional RF (CRF), cell excitability was raised by iontophoretic application of glutamate (GLU) and/or bicuculline methiodide (BIC) or by light stimulation of the CRF.\n'
p13827
sg4
(lp13828
(dp13829
g7
I56
sg8
VP06850
p13830
sg10
I3
sg11
VCRF
p13831
sg13
I1
sa(dp13832
g7
I39
sg8
VP06850
p13833
sg10
I15
sg11
Vconventional RF
p13834
sg13
I2
sasg24
(lp13835
(dp13836
g7
I56
sg27
VC0022661
p13837
sg10
I3
sg11
VCRF
p13838
sg13
I1
sa(dp13839
g7
I67
sg27
VC0235169
p13840
sg10
I12
sg11
Vexcitability
p13841
sg13
I1
sa(dp13842
g7
I56
sg27
VC0022661
p13843
sg10
I3
sg11
VCRF
p13844
sg13
I1
sa(dp13845
g7
I39
sg27
VC0022661
p13846
sg10
I15
sg11
Vconventional RF
p13847
sg13
I2
sasa(dp13848
g2
S'Bicarbonate-buffered replacement fluid (RF-bic) in continuous venovenous hemofiltration (CVVH) may be superior to lactate-buffered replacement fluid (RF-lac) in acute renal failure.\n'
p13849
sg4
(lp13850
sg24
(lp13851
(dp13852
g7
I161
sg27
VC0022660
p13853
sg10
I19
sg11
Vacute renal failure
p13854
sg13
I3
sasa(dp13855
g2
S'In an open, randomized, multicenter study, we investigated the effects of RF-bic and RF-lac on cardiovascular outcome in patients requiring CVVH following acute renal failure.\n'
p13856
sg4
(lp13857
(dp13858
g7
I85
sg8
VP09848
p13859
sg10
I6
sg11
VRF-lac
p13860
sg13
I1
sasg24
(lp13861
(dp13862
g7
I155
sg27
VC0022660
p13863
sg10
I19
sg11
Vacute renal failure
p13864
sg13
I3
sasa(dp13865
g2
S'The data also suggest that the use of RF-bic during CVVH reduces cardiovascular events in critically ill patients with acute renal failure, particularly those with previous cardiovascular disease or heart failure.\n'
p13866
sg4
(lp13867
sg24
(lp13868
(dp13869
g7
I119
sg27
VC0022660
p13870
sg10
I19
sg11
Vacute renal failure
p13871
sg13
I3
sa(dp13872
g7
I199
sg27
VC0018802
p13873
sg10
I13
sg11
Vheart failure
p13874
sg13
I2
sa(dp13875
g7
I173
sg27
VC0007222
p13876
sg10
I22
sg11
Vcardiovascular disease
p13877
sg13
I2
sa(dp13878
g7
I90
sg27
VC0010340
p13879
sg10
I14
sg11
Vcritically ill
p13880
sg13
I2
sasa(dp13881
g2
S'The effect of BIC on whisker-evoked responses was a preferential enhancement in the responses elicited by the whisker giving rise to the highest probability response (center receptive field whisker or CRF).\n'
p13882
sg4
(lp13883
sg24
(lp13884
(dp13885
g7
I201
sg27
VC0022661
p13886
sg10
I3
sg11
VCRF
p13887
sg13
I1
sasa(dp13888
g2
S'The primary influence of BIC and, to a lesser degree, 2-OH-S was to prolong the response duration of VPM neurons to CRF whisker stimulation.\n'
p13889
sg4
(lp13890
(dp13891
g7
I116
sg8
VP06850
p13892
sg10
I3
sg11
VCRF
p13893
sg13
I1
sasg24
(lp13894
(dp13895
g7
I116
sg27
VC0022661
p13896
sg10
I3
sg11
VCRF
p13897
sg13
I1
sasa(dp13898
g2
S'Selective PDE5 inhibitors have shown potential in treating kidney fibrosis in patients with chronic kidney disease (CKD), via their downstream signaling, and these inhibitors also have known activity as antithrombotic and anticancer agents.\n'
p13899
sg4
(lp13900
(dp13901
g7
I10
sg8
g9
sg10
I4
sg11
VPDE5
p13902
sg13
I1
sasg24
(lp13903
(dp13904
g7
I92
sg27
VC1561643
p13905
sg10
I22
sg11
Vchronic kidney disease
p13906
sg13
I3
sa(dp13907
g7
I116
sg27
VC1561643
p13908
sg10
I3
sg11
VCKD
p13909
sg13
I1
sa(dp13910
g7
I59
sg27
VC0151650
p13911
sg10
I15
sg11
Vkidney fibrosis
p13912
sg13
I2
sasa(dp13913
g2
S'The FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.\n'
p13914
sg4
(lp13915
(dp13916
g7
I4
sg8
VP31371
p13917
sg10
I14
sg11
VFGF9 subfamily
p13918
sg13
I2
sa(dp13919
g7
I4
sg8
VP31371
p13920
sg10
I4
sg11
VFGF9
p13921
sg13
I1
sa(dp13922
g7
I36
sg8
g9
sg10
I5
sg11
VFGF16
p13923
sg13
I1
sa(dp13924
g7
I47
sg8
g9
sg10
I5
sg11
VFGF20
p13925
sg13
I1
sasg24
(lp13926
(dp13927
g7
I169
sg27
VC2239176
p13928
sg10
I24
sg11
Vhepatocellular carcinoma
p13929
sg13
I2
sa(dp13930
g7
I195
sg27
VC2239176
p13931
sg10
I3
sg11
VHCC
p13932
sg13
I1
sa(dp13933
g7
I127
sg27
VC0334094
p13934
sg10
I13
sg11
Vproliferation
p13935
sg13
I1
sasa(dp13936
g2
S'Furthermore, the results indicate that exogenous rhFGF9- and rhFGF20-activated ERK/NF-KB signal transduction pathways play important roles in the regulation of HCC cell proliferation and migration, and this discovery helps to find the potential for new solutions of the treatment of liver cancer.\n'
p13937
sg4
(lp13938
(dp13939
g7
I79
sg8
VP29323
p13940
sg10
I3
sg11
VERK
p13941
sg13
I1
sasg24
(lp13942
(dp13943
g7
I169
sg27
VC0334094
p13944
sg10
I13
sg11
Vproliferation
p13945
sg13
I1
sa(dp13946
g7
I160
sg27
VC2239176
p13947
sg10
I3
sg11
VHCC
p13948
sg13
I1
sa(dp13949
g7
I283
sg27
VC0345904
p13950
sg10
I12
sg11
Vliver cancer
p13951
sg13
I2
sasa(dp13952
g2
S'These include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.\n'
p13953
sg4
(lp13954
(dp13955
g7
I120
sg8
g9
sg10
I5
sg11
VFGF10
p13956
sg13
I1
sa(dp13957
g7
I277
sg8
g9
sg10
I5
sg11
VFGF23
p13958
sg13
I1
sa(dp13959
g7
I38
sg8
VP55075
p13960
sg10
I4
sg11
VFGF8
p13961
sg13
I1
sa(dp13962
g7
I212
sg8
g9
sg10
I5
sg11
VFGF14
p13963
sg13
I1
sa(dp13964
g7
I101
sg8
VP31371
p13965
sg10
I4
sg11
VFGF9
p13966
sg13
I1
sa(dp13967
g7
I14
sg8
VP11487
p13968
sg10
I4
sg11
VFGF3
p13969
sg13
I1
sasg24
(lp13970
(dp13971
g7
I254
sg27
VC0030567
p13972
sg10
I17
sg11
VParkinson disease
p13973
sg13
I2
sa(dp13974
g7
I29
sg27
VC0243065
p13975
sg10
I7
sg11
Vaplasia
p13976
sg13
I1
sa(dp13977
g7
I171
sg27
VC0265269
p13978
sg10
I39
sg11
Vlacrimo-auriculo-dento-digital syndrome
p13979
sg13
I2
sa(dp13980
g7
I46
sg27
VC0158646
p13981
sg10
I16
sg11
Vcleft lip/palate
p13982
sg13
I2
sa(dp13983
g7
I309
sg27
VC1704375
p13984
sg10
I24
sg11
Vhypophosphatemic rickets
p13985
sg13
I2
sa(dp13986
g7
I286
sg27
VC0263628
p13987
sg10
I18
sg11
Vtumoral calcinosis
p13988
sg13
I2
sa(dp13989
g7
I109
sg27
VC0007097
p13990
sg10
I9
sg11
Vcarcinoma
p13991
sg13
I1
sa(dp13992
g7
I29
sg27
VC0243065
p13993
sg10
I7
sg11
Vaplasia
p13994
sg13
I1
sa(dp13995
g7
I70
sg27
VC0022735
p13996
sg10
I29
sg11
Vhypogonadotropic hypogonadism
p13997
sg13
I2
sa(dp13998
g7
I221
sg27
VC0087012
p13999
sg10
I22
sg11
Vspinocerebellar ataxia
p14000
sg13
I2
sasa(dp14001
g2
S"Molecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.\n"
p14002
sg4
(lp14003
(dp14004
g7
I94
sg8
g9
sg10
I8
sg11
VARHGEF10
p14005
sg13
I1
sa(dp14006
g7
I186
sg8
VP07197
p14007
sg10
I4
sg11
VNEF3
p14008
sg13
I1
sa(dp14009
g7
I210
sg8
VP48454
p14010
sg10
I6
sg11
VPPP3CC
p14011
sg13
I1
sa(dp14012
g7
I142
sg8
g9
sg10
I4
sg11
VEGR3
p14013
sg13
I1
sa(dp14014
g7
I120
sg8
g9
sg10
I6
sg11
VCHRNB3
p14015
sg13
I1
sa(dp14016
g7
I86
sg8
VP25100
p14017
sg10
I6
sg11
VADRA1A
p14018
sg13
I1
sa(dp14019
g7
I234
sg8
VP54219
p14020
sg10
I7
sg11
VSLC18A1
p14021
sg13
I1
sa(dp14022
g7
I228
sg8
VP54219
p14023
sg10
I5
sg11
VVMAT1
p14024
sg13
I1
sa(dp14025
g7
I180
sg8
VP18440
p14026
sg10
I4
sg11
VNAT2
p14027
sg13
I1
sa(dp14028
g7
I128
sg8
g9
sg10
I4
sg11
VDKK4
p14029
sg13
I1
sa(dp14030
g7
I162
sg8
VP20930
p14031
sg10
I5
sg11
VFGFR1
p14032
sg13
I1
sa(dp14033
g7
I104
sg8
g9
sg10
I6
sg11
VCHRNA2
p14034
sg13
I1
sa(dp14035
g7
I134
sg8
g9
sg10
I6
sg11
VDPYSL2
p14036
sg13
I1
sa(dp14037
g7
I169
sg8
g9
sg10
I4
sg11
VFZD3
p14038
sg13
I1
sa(dp14039
g7
I148
sg8
g9
sg10
I5
sg11
VFGF17
p14040
sg13
I1
sa(dp14041
g7
I155
sg8
g9
sg10
I5
sg11
VFGF20
p14042
sg13
I1
sa(dp14043
g7
I218
sg8
g9
sg10
I5
sg11
VSFRP1
p14044
sg13
I1
sa(dp14045
g7
I198
sg8
g9
sg10
I4
sg11
VPCM1
p14046
sg13
I1
sa(dp14047
g7
I112
sg8
g9
sg10
I6
sg11
VCHRNA6
p14048
sg13
I1
sasg24
(lp14049
(dp14050
g7
I436
sg27
VC0006826
p14051
sg10
I6
sg11
Vcancer
p14052
sg13
I1
sa(dp14053
g7
I309
sg27
VC0036341
p14054
sg10
I13
sg11
Vschizophrenia
p14055
sg13
I1
sa(dp14056
g7
I332
sg27
VC0005586
p14057
sg10
I16
sg11
Vbipolar disorder
p14058
sg13
I2
sa(dp14059
g7
I324
sg27
VC0004352
p14060
sg10
I6
sg11
Vautism
p14061
sg13
I1
sa(dp14062
g7
I366
sg27
VC0524851
p14063
sg10
I27
sg11
Vneurodegenerative disorders
p14064
sg13
I2
sa(dp14065
g7
I353
sg27
VC0011581
p14066
sg10
I10
sg11
Vdepression
p14067
sg13
I1
sa(dp14068
g7
I411
sg27
VC1521724
p14069
sg10
I19
sg11
VAlzheimer's disease
p14070
sg13
I2
sasa(dp14071
g2
S'EphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression.\n'
p14072
sg4
(lp14073
(dp14074
g7
I10
sg8
VP01588
p14075
sg10
I14
sg11
Verythropoietin
p14076
sg13
I1
sa(dp14077
g7
I0
sg8
VP52799
p14078
sg10
I8
sg11
VEphrinB2
p14079
sg13
I1
sasg24
(lp14080
(dp14081
g7
I35
sg27
VC0023903
p14082
sg10
I8
sg11
Vhepatoma
p14083
sg13
I1
sa(dp14084
g7
I188
sg27
VC0242656
p14085
sg10
I19
sg11
Vdisease progression
p14086
sg13
I2
sasa(dp14087
g2
S'The aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).\n'
p14088
sg4
(lp14089
(dp14090
g7
I128
sg8
g9
sg10
I14
sg11
Vangiopoietin 2
p14091
sg13
I2
sa(dp14092
g7
I85
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p14093
sg13
I4
sa(dp14094
g7
I151
sg8
VP52799
p14095
sg10
I8
sg11
VephrinB2
p14096
sg13
I1
sa(dp14097
g7
I224
sg8
VP58294
p14098
sg10
I7
sg11
VEG-VEGF
p14099
sg13
I1
sa(dp14100
g7
I164
sg8
VP58294
p14101
sg10
I58
sg11
Vendocrine gland-derived vascular endothelial growth factor
p14102
sg13
I6
sa(dp14103
g7
I144
sg8
g9
sg10
I4
sg11
VAng2
p14104
sg13
I1
sa(dp14105
g7
I121
sg8
g9
sg10
I4
sg11
VVEGF
p14106
sg13
I1
sasg24
(lp14107
(dp14108
g7
I334
sg27
VC2239176
p14109
sg10
I3
sg11
VHCC
p14110
sg13
I1
sa(dp14111
g7
I237
sg27
VC0596263
p14112
sg10
I14
sg11
Vcarcinogenesis
p14113
sg13
I1
sa(dp14114
g7
I267
sg27
VC3163918
p14115
sg10
I14
sg11
Vtumor thrombus
p14116
sg13
I2
sa(dp14117
g7
I308
sg27
VC2239176
p14118
sg10
I24
sg11
Vhepatocellular carcinoma
p14119
sg13
I2
sasa(dp14120
g2
S'We investigated whether the human MBX gene was associated with susceptibility to microphthalmia by analyzing four Korean families demonstrating microphthalmia with congenital cataract.\n'
p14121
sg4
(lp14122
(dp14123
g7
I28
sg8
g9
sg10
I14
sg11
Vhuman MBX gene
p14124
sg13
I3
sasg24
(lp14125
(dp14126
g7
I81
sg27
VC0026010
p14127
sg10
I14
sg11
Vmicrophthalmia
p14128
sg13
I1
sa(dp14129
g7
I81
sg27
VC0026010
p14130
sg10
I14
sg11
Vmicrophthalmia
p14131
sg13
I1
sa(dp14132
g7
I164
sg27
VC0009691
p14133
sg10
I19
sg11
Vcongenital cataract
p14134
sg13
I2
sasa(dp14135
g2
S'Therefore, no indications were found for an association between the MBX gene and microphthalmia with congenital cataract in humans.\n'
p14136
sg4
(lp14137
(dp14138
g7
I68
sg8
g9
sg10
I8
sg11
VMBX gene
p14139
sg13
I2
sasg24
(lp14140
(dp14141
g7
I81
sg27
VC0026010
p14142
sg10
I14
sg11
Vmicrophthalmia
p14143
sg13
I1
sa(dp14144
g7
I101
sg27
VC0009691
p14145
sg10
I19
sg11
Vcongenital cataract
p14146
sg13
I2
sasa(dp14147
g2
S'Sequence changes have been observed for both NCKX1 and NCKX2 in patients with retinal diseases, but a definitive association with retinal disease has not been shown.\n'
p14148
sg4
(lp14149
(dp14150
g7
I55
sg8
g9
sg10
I5
sg11
VNCKX2
p14151
sg13
I1
sa(dp14152
g7
I45
sg8
g9
sg10
I5
sg11
VNCKX1
p14153
sg13
I1
sasg24
(lp14154
(dp14155
g7
I78
sg27
VC0035309
p14156
sg10
I15
sg11
Vretinal disease
p14157
sg13
I2
sa(dp14158
g7
I78
sg27
VC0035309
p14159
sg10
I16
sg11
Vretinal diseases
p14160
sg13
I2
sasa(dp14161
g2
S'To study the possible involvement of the rod (SLC24A1) and cone (SLC24A2) Na-Ca+K exchanger (NCKX) genes in retinal diseases.\n'
p14162
sg4
(lp14163
(dp14164
g7
I74
sg8
g9
sg10
I30
sg11
VNa-Ca+K exchanger (NCKX) genes
p14165
sg13
I4
sa(dp14166
g7
I65
sg8
g9
sg10
I7
sg11
VSLC24A2
p14167
sg13
I1
sa(dp14168
g7
I41
sg8
VP50748
p14169
sg10
I3
sg11
Vrod
p14170
sg13
I1
sa(dp14171
g7
I46
sg8
g9
sg10
I7
sg11
VSLC24A1
p14172
sg13
I1
sasg24
(lp14173
(dp14174
g7
I108
sg27
VC0035309
p14175
sg10
I16
sg11
Vretinal diseases
p14176
sg13
I2
sasa(dp14177
g2
S'Approximately 23% of patients with metastatic castration-resistant prostate cancer exhibit somatic or germline aberrations in genes implicated in DNA repair, such as BRCA2, BRCA1, ATM, CHEK2, and PALB2, as well as mismatch repair genes.\n'
p14178
sg4
(lp14179
(dp14180
g7
I166
sg8
VP51587
p14181
sg10
I5
sg11
VBRCA2
p14182
sg13
I1
sa(dp14183
g7
I196
sg8
g9
sg10
I5
sg11
VPALB2
p14184
sg13
I1
sa(dp14185
g7
I180
sg8
g9
sg10
I3
sg11
VATM
p14186
sg13
I1
sa(dp14187
g7
I173
sg8
VP38398
p14188
sg10
I5
sg11
VBRCA1
p14189
sg13
I1
sasg24
(lp14190
(dp14191
g7
I67
sg27
VC0600139
p14192
sg10
I15
sg11
Vprostate cancer
p14193
sg13
I2
sasa(dp14194
g2
S'Men who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks.\n'
p14195
sg4
(lp14196
(dp14197
g7
I213
sg8
VP43246
p14198
sg10
I4
sg11
VMSH2
p14199
sg13
I1
sa(dp14200
g7
I197
sg8
g9
sg10
I3
sg11
VATM
p14201
sg13
I1
sa(dp14202
g7
I49
sg8
VP51587
p14203
sg10
I5
sg11
VBRCA2
p14204
sg13
I1
sa(dp14205
g7
I59
sg8
VP38398
p14206
sg10
I5
sg11
VBRCA1
p14207
sg13
I1
sa(dp14208
g7
I218
sg8
VP52701
p14209
sg10
I4
sg11
VMSH6
p14210
sg13
I1
sasg24
(lp14211
(dp14212
g7
I101
sg27
VC0001807
p14213
sg10
I10
sg11
Vaggressive
p14214
sg13
I1
sa(dp14215
g7
I112
sg27
VC0600139
p14216
sg10
I15
sg11
Vprostate cancer
p14217
sg13
I2
sasa(dp14218
g2
S'The CHEK2 gene del5395 is a founder mutation in the Latvian population, which, however, does not have a direct impact on genetic predisposition toward colorectal, breast, ovarian and prostate cancer.\n'
p14219
sg4
(lp14220
sg24
(lp14221
(dp14222
g7
I183
sg27
VC0600139
p14223
sg10
I15
sg11
Vprostate cancer
p14224
sg13
I2
sa(dp14225
g7
I28
sg27
VC2985435
p14226
sg10
I16
sg11
Vfounder mutation
p14227
sg13
I2
sasa(dp14228
g2
S'Human limbal neurospheres expressed the neural lineage markers, Nestin, sex determining region box-2 and N-cadherin, and the retinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2 and orthodentical homeobox-2.\n'
p14229
sg4
(lp14230
(dp14231
g7
I250
sg8
VP52954
p14232
sg10
I10
sg11
Vhomeobox-2
p14233
sg13
I1
sa(dp14234
g7
I64
sg8
VP48681
p14235
sg10
I36
sg11
VNestin, sex determining region box-2
p14236
sg13
I5
sa(dp14237
g7
I105
sg8
VP19022
p14238
sg10
I10
sg11
VN-cadherin
p14239
sg13
I1
sa(dp14240
g7
I125
sg8
g9
sg10
I106
sg11
Vretinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2
p14241
sg13
I10
sasg24
(lp14242
(dp14243
g7
I155
sg27
VC0026010
p14244
sg10
I14
sg11
Vmicrophthalmia
p14245
sg13
I1
sasa(dp14246
g2
S'Mutations of orthodentricle homeobox 2 (OTX2) in human and mice often cause retinal dystrophy and nyctalopia, suggesting a role of OTX2 in mature retina, in addition to its functions in the development of the eye and retina.\n'
p14247
sg4
(lp14248
(dp14249
g7
I40
sg8
VP32243
p14250
sg10
I4
sg11
VOTX2
p14251
sg13
I1
sa(dp14252
g7
I13
sg8
VP32243
p14253
sg10
I25
sg11
Vorthodentricle homeobox 2
p14254
sg13
I3
sa(dp14255
g7
I40
sg8
VP32243
p14256
sg10
I4
sg11
VOTX2
p14257
sg13
I1
sasg24
(lp14258
(dp14259
g7
I76
sg27
VC0854723
p14260
sg10
I17
sg11
Vretinal dystrophy
p14261
sg13
I2
sa(dp14262
g7
I98
sg27
VC0028077
p14263
sg10
I10
sg11
Vnyctalopia
p14264
sg13
I1
sasa(dp14265
g2
S'THE ROLE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: Angiotensin-converting enzyme inhibitors (ACE) affect the different mechanisms that lead to glomerulosclerosis: antihypertensive effect, with the normalisation of blood pressure having demonstrated its determining role in the production of nephrosis in various epidemiological studies; hemodynamic effect with a decrease in glomerular capillary pressure, in the filtration fraction, and inhibition of the bradykinin deterioration; antiproteinuric effect superior to that of other anti-hypertensive drugs (excepting angiotensin II-receptor antagonists).\n'
p14266
sg4
(lp14267
(dp14268
g7
I96
sg8
VP12821
p14269
sg10
I3
sg11
VACE
p14270
sg13
I1
sa(dp14271
g7
I569
sg8
VP01019
p14272
sg10
I23
sg11
Vangiotensin II-receptor
p14273
sg13
I2
sa(dp14274
g7
I54
sg8
VP12821
p14275
sg10
I40
sg11
VAngiotensin-converting enzyme inhibitors
p14276
sg13
I3
sa(dp14277
g7
I459
sg8
VP01042
p14278
sg10
I10
sg11
Vbradykinin
p14279
sg13
I1
sasg24
(lp14280
(dp14281
g7
I294
sg27
VC0027720
p14282
sg10
I9
sg11
Vnephrosis
p14283
sg13
I1
sa(dp14284
g7
I146
sg27
VC0178664
p14285
sg10
I18
sg11
Vglomerulosclerosis
p14286
sg13
I1
sasa(dp14287
g2
S'To investigate whether the reduction in proteinuria is due to decreased generation of angiotensin II (AngII) or to decreased degradation of bradykinin, four series of experiments in established adriamycin nephrosis were performed.\n'
p14288
sg4
(lp14289
(dp14290
g7
I140
sg8
VP01042
p14291
sg10
I10
sg11
Vbradykinin
p14292
sg13
I1
sa(dp14293
g7
I102
sg8
VP01019
p14294
sg10
I5
sg11
VAngII
p14295
sg13
I1
sa(dp14296
g7
I86
sg8
VP01019
p14297
sg10
I14
sg11
Vangiotensin II
p14298
sg13
I2
sasg24
(lp14299
(dp14300
g7
I205
sg27
VC0027720
p14301
sg10
I9
sg11
Vnephrosis
p14302
sg13
I1
sasa(dp14303
g2
S'There were few reports demonstrating behavior of kinin and kininogen in the nephrotic syndrome.\n'
p14304
sg4
(lp14305
(dp14306
g7
I49
sg8
VP01042
p14307
sg10
I19
sg11
Vkinin and kininogen
p14308
sg13
I3
sasg24
(lp14309
(dp14310
g7
I76
sg27
VC0027726
p14311
sg10
I18
sg11
Vnephrotic syndrome
p14312
sg13
I2
sasa(dp14313
g2
S'In this paper, coagulation factors related to contact activation, such as factor XII (FXII), factor XI (FXI), prekallikrein (PK), high molecular weight kininogen (HMWKG), and kinins were measured in 15 cases of nephrotic syndrome, and clinical significance of these results were discussed.\n'
p14314
sg4
(lp14315
(dp14316
g7
I74
sg8
VP00748
p14317
sg10
I28
sg11
Vfactor XII (FXII), factor XI
p14318
sg13
I5
sa(dp14319
g7
I86
sg8
g9
sg10
I3
sg11
VFXI
p14320
sg13
I1
sa(dp14321
g7
I110
sg8
VP03952
p14322
sg10
I51
sg11
Vprekallikrein (PK), high molecular weight kininogen
p14323
sg13
I6
sasg24
(lp14324
(dp14325
g7
I211
sg27
VC0027726
p14326
sg10
I18
sg11
Vnephrotic syndrome
p14327
sg13
I2
sasa(dp14328
g2
S'It was concluded that kinin formation in the nephrotic syndrome was not due to the activation of intrinsic coagulation system but due to release of kinin from low molecular weight kininogen.\n'
p14329
sg4
(lp14330
sg24
(lp14331
(dp14332
g7
I45
sg27
VC0027726
p14333
sg10
I18
sg11
Vnephrotic syndrome
p14334
sg13
I2
sasa(dp14335
g2
S'To investigate the role of anti-inflammatory TSG-6 in controlling MMP-1 and MMP-3, which have been shown to be upregulated in conjunctivochalasis (CCh).\n'
p14336
sg4
(lp14337
(dp14338
g7
I45
sg8
VP98066
p14339
sg10
I5
sg11
VTSG-6
p14340
sg13
I1
sa(dp14341
g7
I76
sg8
VP08254
p14342
sg10
I5
sg11
VMMP-3
p14343
sg13
I1
sa(dp14344
g7
I66
sg8
VP03956
p14345
sg10
I5
sg11
VMMP-1
p14346
sg13
I1
sasg24
(lp14347
(dp14348
g7
I126
sg27
VC0878693
p14349
sg10
I19
sg11
Vconjunctivochalasis
p14350
sg13
I1
sa(dp14351
g7
I147
sg27
VC0878693
p14352
sg10
I3
sg11
VCCh
p14353
sg13
I1
sasa(dp14354
g2
S'Direct sequencing analyses were performed in 19 genes, including ALS/frontotemporal lobar degeneration (FTLD)-related genes (SOD2, SOD3, ALS2/alsin, SMN1, PGRN, ANG, VEGF, VCP, VAPB, DCTN1, CHMP2B, and TARDBP or TDP-43), tauopathy-related gene (GSK3beta), and parkinsonism-related genes (alpha-synuclein, LRRK2, parkin, DJ-1, PINK1, and ATP13A2).\n'
p14355
sg4
(lp14356
(dp14357
g7
I305
sg8
g9
sg10
I5
sg11
VLRRK2
p14358
sg13
I1
sa(dp14359
g7
I260
sg8
VP01893
p14360
sg10
I26
sg11
Vparkinsonism-related genes
p14361
sg13
I2
sa(dp14362
g7
I202
sg8
g9
sg10
I6
sg11
VTARDBP
p14363
sg13
I1
sa(dp14364
g7
I183
sg8
g9
sg10
I5
sg11
VDCTN1
p14365
sg13
I1
sa(dp14366
g7
I125
sg8
VP04179
p14367
sg10
I4
sg11
VSOD2
p14368
sg13
I1
sa(dp14369
g7
I288
sg8
VP37840
p14370
sg10
I15
sg11
Valpha-synuclein
p14371
sg13
I1
sa(dp14372
g7
I190
sg8
g9
sg10
I6
sg11
VCHMP2B
p14373
sg13
I1
sa(dp14374
g7
I177
sg8
g9
sg10
I4
sg11
VVAPB
p14375
sg13
I1
sa(dp14376
g7
I149
sg8
g9
sg10
I4
sg11
VSMN1
p14377
sg13
I1
sa(dp14378
g7
I320
sg8
g9
sg10
I4
sg11
VDJ-1
p14379
sg13
I1
sa(dp14380
g7
I172
sg8
VP55072
p14381
sg10
I3
sg11
VVCP
p14382
sg13
I1
sa(dp14383
g7
I137
sg8
g9
sg10
I4
sg11
VALS2
p14384
sg13
I1
sa(dp14385
g7
I142
sg8
g9
sg10
I5
sg11
Valsin
p14386
sg13
I1
sa(dp14387
g7
I212
sg8
g9
sg10
I6
sg11
VTDP-43
p14388
sg13
I1
sa(dp14389
g7
I326
sg8
g9
sg10
I5
sg11
VPINK1
p14390
sg13
I1
sa(dp14391
g7
I337
sg8
g9
sg10
I7
sg11
VATP13A2
p14392
sg13
I1
sa(dp14393
g7
I131
sg8
VP08294
p14394
sg10
I4
sg11
VSOD3
p14395
sg13
I1
sa(dp14396
g7
I161
sg8
VP03950
p14397
sg10
I3
sg11
VANG
p14398
sg13
I1
sasg24
(lp14399
(dp14400
g7
I137
sg27
VC1859807
p14401
sg10
I4
sg11
VALS2
p14402
sg13
I1
sa(dp14403
g7
I104
sg27
VC0751072
p14404
sg10
I4
sg11
VFTLD
p14405
sg13
I1
sa(dp14406
g7
I260
sg27
VC0242422
p14407
sg10
I12
sg11
Vparkinsonism
p14408
sg13
I1
sa(dp14409
g7
I221
sg27
VC0949664
p14410
sg10
I9
sg11
Vtauopathy
p14411
sg13
I1
sa(dp14412
g7
I65
sg27
VC0751072
p14413
sg10
I37
sg11
VALS/frontotemporal lobar degeneration
p14414
sg13
I3
sasa(dp14415
g2
S'This patient broadens the phenotypic spectrum of the 22q11.2 microduplication syndrome and raises the possibility that TUBA8 and USP18 may play an important role in the pathogenesis of amyoplasia.\n'
p14416
sg4
(lp14417
(dp14418
g7
I119
sg8
g9
sg10
I5
sg11
VTUBA8
p14419
sg13
I1
sa(dp14420
g7
I129
sg8
g9
sg10
I5
sg11
VUSP18
p14421
sg13
I1
sasg24
(lp14422
(dp14423
g7
I169
sg27
VC0699748
p14424
sg10
I12
sg11
Vpathogenesis
p14425
sg13
I1
sa(dp14426
g7
I78
sg27
VC0039082
p14427
sg10
I8
sg11
Vsyndrome
p14428
sg13
I1
sasa(dp14429
g2
S'Despite the support for including patient-reported outcomes (PROs) and health-related quality of life in clinical trials, there have been deficiencies in how these have been assessed and reported in epithelial ovarian cancer (EOC) clinical trials.\n'
p14430
sg4
(lp14431
sg24
(lp14432
(dp14433
g7
I199
sg27
VC0677886
p14434
sg10
I25
sg11
Vepithelial ovarian cancer
p14435
sg13
I3
sa(dp14436
g7
I226
sg27
VC0677886
p14437
sg10
I3
sg11
VEOC
p14438
sg13
I1
sasa(dp14439
g2
S"To redress this, the 5th Ovarian Cancer Consensus Conference, included a plenary session entitled 'How to include PROs in clinical trials'.\n"
p14440
sg4
(lp14441
sg24
(lp14442
(dp14443
g7
I25
sg27
VC1140680
p14444
sg10
I14
sg11
VOvarian Cancer
p14445
sg13
I2
sasa(dp14446
g2
S'To test the hypothesis that ovarian cancer patients with worse PROs would drop out earlier, we examined how patients differed by time of dropout on health-related quality of life (HRQOL), anxiety, depression, optimism and insomnia.\n'
p14447
sg4
(lp14448
sg24
(lp14449
(dp14450
g7
I28
sg27
VC1140680
p14451
sg10
I14
sg11
Vovarian cancer
p14452
sg13
I2
sa(dp14453
g7
I222
sg27
VC0917801
p14454
sg10
I8
sg11
Vinsomnia
p14455
sg13
I1
sa(dp14456
g7
I197
sg27
VC0011581
p14457
sg10
I10
sg11
Vdepression
p14458
sg13
I1
sasa(dp14459
g2
S'Progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial.\n'
p14460
sg4
(lp14461
sg24
(lp14462
(dp14463
g7
I190
sg27
VC1140680
p14464
sg10
I14
sg11
Vovarian cancer
p14465
sg13
I2
sasa(dp14466
g2
S'Despite increased recognition of the value of including patient-reported outcomes (PROs) as important end points in phase III clinical trials, there has been a lack of pre-specified PRO hypotheses and shortcomings with the analyses and interpretation of PROs in many ovarian cancer trials.\n'
p14467
sg4
(lp14468
sg24
(lp14469
(dp14470
g7
I267
sg27
VC1140680
p14471
sg10
I14
sg11
Vovarian cancer
p14472
sg13
I2
sasa(dp14473
g2
S'Promoting the importance of hypothesis-driven PROs in ovarian cancer clinical trials will lead to improvements in the design of these trials and the interpretation of their results.\n'
p14474
sg4
(lp14475
sg24
(lp14476
(dp14477
g7
I54
sg27
VC1140680
p14478
sg10
I14
sg11
Vovarian cancer
p14479
sg13
I2
sasa(dp14480
g2
S'We conducted the Surgery in Ovarian Cancer Quality of life Evaluation Research study (SOCQER 1), a prospective study investigating the feasibility of collection of serial PROs in patients who had extensive surgery and standard surgery for ovarian cancer.\n'
p14481
sg4
(lp14482
sg24
(lp14483
(dp14484
g7
I28
sg27
VC1140680
p14485
sg10
I14
sg11
VOvarian Cancer
p14486
sg13
I2
sa(dp14487
g7
I239
sg27
VC1140680
p14488
sg10
I14
sg11
Vovarian cancer
p14489
sg13
I2
sasa(dp14490
g2
S'There is no consensus as to what symptoms or quality-of-life (QOL) domains should be measured as patient-reported outcomes (PROs) in ovarian cancer clinical trials.\n'
p14491
sg4
(lp14492
sg24
(lp14493
(dp14494
g7
I133
sg27
VC1140680
p14495
sg10
I14
sg11
Vovarian cancer
p14496
sg13
I2
sasa(dp14497
g2
S'The results were included in and combined with an expert consensus-building process to identify the most salient PROs for ovarian cancer clinical trials.\n'
p14498
sg4
(lp14499
sg24
(lp14500
(dp14501
g7
I122
sg27
VC1140680
p14502
sg10
I14
sg11
Vovarian cancer
p14503
sg13
I2
sasa(dp14504
g2
S'We identified a set of PROs specific to ovarian cancer: abdominal pain, bloating, cramping, fear of recurrence/disease progression, indigestion, sexual dysfunction, vomiting, weight gain, and weight loss.\n'
p14505
sg4
(lp14506
(dp14507
g7
I23
sg8
VP07225
p14508
sg10
I4
sg11
VPROs
p14509
sg13
I1
sasg24
(lp14510
(dp14511
g7
I132
sg27
VC0013395
p14512
sg10
I11
sg11
Vindigestion
p14513
sg13
I1
sa(dp14514
g7
I165
sg27
VC0042963
p14515
sg10
I8
sg11
Vvomiting
p14516
sg13
I1
sa(dp14517
g7
I72
sg27
VC1291077
p14518
sg10
I8
sg11
Vbloating
p14519
sg13
I1
sa(dp14520
g7
I56
sg27
VC0000737
p14521
sg10
I14
sg11
Vabdominal pain
p14522
sg13
I2
sa(dp14523
g7
I100
sg27
VC1458156
p14524
sg10
I10
sg11
Vrecurrence
p14525
sg13
I1
sa(dp14526
g7
I111
sg27
VC0242656
p14527
sg10
I19
sg11
Vdisease progression
p14528
sg13
I2
sa(dp14529
g7
I40
sg27
VC1140680
p14530
sg10
I14
sg11
Vovarian cancer
p14531
sg13
I2
sa(dp14532
g7
I145
sg27
VC0036877
p14533
sg10
I18
sg11
Vsexual dysfunction
p14534
sg13
I2
sa(dp14535
g7
I82
sg27
VC1446787
p14536
sg10
I8
sg11
Vcramping
p14537
sg13
I1
sasa(dp14538
g2
S'Findings of the review and consensus process provide good support for use of these ovarian cancer-specific PROs in ovarian cancer clinical trials.\n'
p14539
sg4
(lp14540
sg24
(lp14541
(dp14542
g7
I83
sg27
VC1140680
p14543
sg10
I14
sg11
Vovarian cancer
p14544
sg13
I2
sa(dp14545
g7
I83
sg27
VC1140680
p14546
sg10
I14
sg11
Vovarian cancer
p14547
sg13
I2
sasa(dp14548
g2
S'Mutations within this gene are responsible for kinesigenic paroxysmal dyskinesias (PKD) as well as for benign familial infantile epilepsy (BFIE), a disease associating infantile convulsions and choreoathetosis (ICCA), a form of familial hemiplegic migraine (FHM type 4), paroxysmal benign torticollis of childhood, and episodic ataxia.\n'
p14549
sg4
(lp14550
sg24
(lp14551
(dp14552
g7
I319
sg27
VC1720189
p14553
sg10
I15
sg11
Vepisodic ataxia
p14554
sg13
I2
sa(dp14555
g7
I83
sg27
VC1868682
p14556
sg10
I3
sg11
VPKD
p14557
sg13
I1
sa(dp14558
g7
I258
sg27
VC1832894
p14559
sg10
I3
sg11
VFHM
p14560
sg13
I1
sa(dp14561
g7
I59
sg27
VC0752210
p14562
sg10
I22
sg11
Vparoxysmal dyskinesias
p14563
sg13
I2
sa(dp14564
g7
I211
sg27
VC1865926
p14565
sg10
I4
sg11
VICCA
p14566
sg13
I1
sa(dp14567
g7
I289
sg27
VC0040485
p14568
sg10
I11
sg11
Vtorticollis
p14569
sg13
I1
sa(dp14570
g7
I228
sg27
VC0338484
p14571
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14572
sg13
I3
sa(dp14573
g7
I129
sg27
VC0014544
p14574
sg10
I8
sg11
Vepilepsy
p14575
sg13
I1
sa(dp14576
g7
I168
sg27
VC1865926
p14577
sg10
I41
sg11
Vinfantile convulsions and choreoathetosis
p14578
sg13
I4
sasa(dp14579
g2
S'FHM type 4 is attributed to mutations in the PRRT2 gene, which encodes a proline-rich transmembrane protein of as yet unknown function.\n'
p14580
sg4
(lp14581
(dp14582
g7
I45
sg8
g9
sg10
I10
sg11
VPRRT2 gene
p14583
sg13
I2
sasg24
(lp14584
(dp14585
g7
I0
sg27
VC1832894
p14586
sg10
I3
sg11
VFHM
p14587
sg13
I1
sasa(dp14588
g2
S'Two PRRT2 mutations were in familial hemiplegic migraine or episodic ataxia, one SLC2A1 family had episodic ataxia and one PNKD family had familial hemiplegic migraine alone.\n'
p14589
sg4
(lp14590
(dp14591
g7
I123
sg8
g9
sg10
I11
sg11
VPNKD family
p14592
sg13
I2
sa(dp14593
g7
I4
sg8
g9
sg10
I15
sg11
VPRRT2 mutations
p14594
sg13
I2
sa(dp14595
g7
I81
sg8
VP11166
p14596
sg10
I6
sg11
VSLC2A1
p14597
sg13
I1
sasg24
(lp14598
(dp14599
g7
I60
sg27
VC1720189
p14600
sg10
I15
sg11
Vepisodic ataxia
p14601
sg13
I2
sa(dp14602
g7
I28
sg27
VC0338484
p14603
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14604
sg13
I3
sa(dp14605
g7
I28
sg27
VC0338484
p14606
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14607
sg13
I3
sa(dp14608
g7
I60
sg27
VC1720189
p14609
sg10
I15
sg11
Vepisodic ataxia
p14610
sg13
I2
sasa(dp14611
g2
S'SLC2A1 mutations were associated with variable phenotypes including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, episodic ataxia and myotonia and we identified a novel PNKD gene deletion in familial hemiplegic migraine.\n'
p14612
sg4
(lp14613
(dp14614
g7
I197
sg8
g9
sg10
I9
sg11
VPNKD gene
p14615
sg13
I2
sa(dp14616
g7
I0
sg8
VP11166
p14617
sg10
I6
sg11
VSLC2A1
p14618
sg13
I1
sasg24
(lp14619
(dp14620
g7
I142
sg27
VC1720189
p14621
sg10
I15
sg11
Vepisodic ataxia
p14622
sg13
I2
sa(dp14623
g7
I68
sg27
VC1868682
p14624
sg10
I33
sg11
Vparoxysmal kinesigenic dyskinesia
p14625
sg13
I3
sa(dp14626
g7
I202
sg27
VC1442161
p14627
sg10
I13
sg11
Vgene deletion
p14628
sg13
I2
sa(dp14629
g7
I91
sg27
VC0013384
p14630
sg10
I10
sg11
Vdyskinesia
p14631
sg13
I1
sa(dp14632
g7
I219
sg27
VC0338484
p14633
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14634
sg13
I3
sasa(dp14635
g2
S'We assessed the clinical features of both FHM families and performed direct sequencing of all coding exons (and adjacent sequences) of the CACNA1A, ATP1A2, PRRT2 and SCN1A genes.\n'
p14636
sg4
(lp14637
(dp14638
g7
I148
sg8
VP50993
p14639
sg10
I6
sg11
VATP1A2
p14640
sg13
I1
sa(dp14641
g7
I166
sg8
VP35498
p14642
sg10
I11
sg11
VSCN1A genes
p14643
sg13
I2
sa(dp14644
g7
I42
sg8
VP19883
p14645
sg10
I12
sg11
VFHM families
p14646
sg13
I2
sa(dp14647
g7
I156
sg8
g9
sg10
I5
sg11
VPRRT2
p14648
sg13
I1
sasg24
(lp14649
(dp14650
g7
I42
sg27
VC1832894
p14651
sg10
I3
sg11
VFHM
p14652
sg13
I1
sasa(dp14653
g2
S'In 2012, PRRT2 has been identified as the fourth FHM gene, and encodes an axonal protein associated to the exocytosis complex.\n'
p14654
sg4
(lp14655
(dp14656
g7
I9
sg8
g9
sg10
I5
sg11
VPRRT2
p14657
sg13
I1
sasg24
(lp14658
(dp14659
g7
I49
sg27
VC1832894
p14660
sg10
I3
sg11
VFHM
p14661
sg13
I1
sasa(dp14662
g2
S'To characterise the phenotype of a family with paroxysmal exercise induced dystonia (PED) and migraine and establish whether it is linked to the paroxysmal non-kinesigenic dyskinesia (PNKD) locus on chromosome 2q33-35, the familial hemiplegic migraine (FHM) locus on chromosome 19p, or the familial infantile convulsions and paroxysmal choreoathetosis (ICCA syndrome) locus on chromosome 16.\n'
p14663
sg4
(lp14664
sg24
(lp14665
(dp14666
g7
I172
sg27
VC0013384
p14667
sg10
I10
sg11
Vdyskinesia
p14668
sg13
I1
sa(dp14669
g7
I253
sg27
VC1832894
p14670
sg10
I3
sg11
VFHM
p14671
sg13
I1
sa(dp14672
g7
I309
sg27
VC0009951
p14673
sg10
I11
sg11
Vconvulsions
p14674
sg13
I1
sa(dp14675
g7
I358
sg27
VC0039082
p14676
sg10
I8
sg11
Vsyndrome
p14677
sg13
I1
sa(dp14678
g7
I75
sg27
VC0393593
p14679
sg10
I8
sg11
Vdystonia
p14680
sg13
I1
sa(dp14681
g7
I223
sg27
VC0338484
p14682
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14683
sg13
I3
sa(dp14684
g7
I58
sg27
VC0239313
p14685
sg10
I16
sg11
Vexercise induced
p14686
sg13
I2
sa(dp14687
g7
I94
sg27
VC0149931
p14688
sg10
I8
sg11
Vmigraine
p14689
sg13
I1
sa(dp14690
g7
I353
sg27
VC1865926
p14691
sg10
I4
sg11
VICCA
p14692
sg13
I1
sa(dp14693
g7
I325
sg27
VC1868682
p14694
sg10
I26
sg11
Vparoxysmal choreoathetosis
p14695
sg13
I2
sasa(dp14696
g2
S'Haplotypes were reconstructed for all the available family members by typing several microsatellite markers spanning the PNKD, FHM, and ICCA loci.\n'
p14697
sg4
(lp14698
(dp14699
g7
I121
sg8
g9
sg10
I4
sg11
VPNKD
p14700
sg13
I1
sasg24
(lp14701
(dp14702
g7
I127
sg27
VC1832894
p14703
sg10
I3
sg11
VFHM
p14704
sg13
I1
sa(dp14705
g7
I136
sg27
VC1865926
p14706
sg10
I4
sg11
VICCA
p14707
sg13
I1
sasa(dp14708
g2
S'Linkage of the disease to the PNKD, FHM, or ICCA loci was excluded as no common haplotype was shared by all the affected members for each locus.\n'
p14709
sg4
(lp14710
(dp14711
g7
I30
sg8
g9
sg10
I4
sg11
VPNKD
p14712
sg13
I1
sasg24
(lp14713
(dp14714
g7
I44
sg27
VC1865926
p14715
sg10
I4
sg11
VICCA
p14716
sg13
I1
sa(dp14717
g7
I36
sg27
VC1832894
p14718
sg10
I3
sg11
VFHM
p14719
sg13
I1
sasa(dp14720
g2
S'This family presented with the classic phenotype of PED and is not linked to the PNKD, FHM, or ICCA loci.\n'
p14721
sg4
(lp14722
(dp14723
g7
I81
sg8
g9
sg10
I4
sg11
VPNKD
p14724
sg13
I1
sasg24
(lp14725
(dp14726
g7
I87
sg27
VC1832894
p14727
sg10
I3
sg11
VFHM
p14728
sg13
I1
sa(dp14729
g7
I95
sg27
VC1865926
p14730
sg10
I4
sg11
VICCA
p14731
sg13
I1
sasa(dp14732
g2
S'The (FZr-EUl/FZl-EUr) and (FZr-EUr)/(FZl-EUl) were used for the patients with unicoronal craniosynostosis.\n'
p14733
sg4
(lp14734
sg24
(lp14735
(dp14736
g7
I78
sg27
VC0432124
p14737
sg10
I27
sg11
Vunicoronal craniosynostosis
p14738
sg13
I2
sasa(dp14739
g2
S'Our findings indicated that all evaluated parameters (epididymal sperm profile, Johnsen score, Plzf, GfrAlfa-1, Scp-1, Tekt-1 expressions, and histopathological profile) were significantly decreased following testicular torsion (group 3) when compared to the control group (p &lt;= 0.05).\n'
p14740
sg4
(lp14741
(dp14742
g7
I112
sg8
g9
sg10
I5
sg11
VScp-1
p14743
sg13
I1
sasg24
(lp14744
(dp14745
g7
I209
sg27
VC0037856
p14746
sg10
I18
sg11
Vtesticular torsion
p14747
sg13
I2
sasa(dp14748
g2
S'Dyschromatosis symmetrica hereditaria (DSH) is a rare type of pigmentary genodermatosis, which is autosomal dominantly inherited with high penetrance.\n'
p14749
sg4
(lp14750
sg24
(lp14751
(dp14752
g7
I39
sg27
VC0406775
p14753
sg10
I3
sg11
VDSH
p14754
sg13
I1
sa(dp14755
g7
I73
sg27
VC0037277
p14756
sg10
I14
sg11
Vgenodermatosis
p14757
sg13
I1
sa(dp14758
g7
I0
sg27
VC0406775
p14759
sg10
I37
sg11
VDyschromatosis symmetrica hereditaria
p14760
sg13
I3
sasa(dp14761
g2
S'The onset of DSH is typically during infancy or childhood.\n'
p14762
sg4
(lp14763
(dp14764
g7
I13
sg8
VP55265
p14765
sg10
I3
sg11
VDSH
p14766
sg13
I1
sasg24
(lp14767
(dp14768
g7
I13
sg27
VC0406775
p14769
sg10
I3
sg11
VDSH
p14770
sg13
I1
sasa(dp14771
g2
S'Additionally, there have been few significant non-cutaneous complications reported with DSH.\n'
p14772
sg4
(lp14773
(dp14774
g7
I88
sg8
VP55265
p14775
sg10
I3
sg11
VDSH
p14776
sg13
I1
sasg24
(lp14777
(dp14778
g7
I88
sg27
VC0406775
p14779
sg10
I3
sg11
VDSH
p14780
sg13
I1
sasa(dp14781
g2
S'The present study reported two sporadic cases of patients born with DSH, confirmed by the identification of ADAR1 mutations.\n'
p14782
sg4
(lp14783
(dp14784
g7
I68
sg8
VP55265
p14785
sg10
I3
sg11
VDSH
p14786
sg13
I1
sa(dp14787
g7
I108
sg8
VP55265
p14788
sg10
I5
sg11
VADAR1
p14789
sg13
I1
sasg24
(lp14790
(dp14791
g7
I68
sg27
VC0406775
p14792
sg10
I3
sg11
VDSH
p14793
sg13
I1
sasa(dp14794
g2
S'Additionally, comorbidity of DSH, congenital heart disease (CHD) and hemangioma disease were first reported.\n'
p14795
sg4
(lp14796
(dp14797
g7
I29
sg8
VP55265
p14798
sg10
I3
sg11
VDSH
p14799
sg13
I1
sasg24
(lp14800
(dp14801
g7
I69
sg27
VC0018916
p14802
sg10
I10
sg11
Vhemangioma
p14803
sg13
I1
sa(dp14804
g7
I60
sg27
VC0152021
p14805
sg10
I3
sg11
VCHD
p14806
sg13
I1
sa(dp14807
g7
I34
sg27
VC0152021
p14808
sg10
I24
sg11
Vcongenital heart disease
p14809
sg13
I3
sa(dp14810
g7
I29
sg27
VC0406775
p14811
sg10
I3
sg11
VDSH
p14812
sg13
I1
sasa(dp14813
g2
S'In the patient with isolated DSH from birth, a nonsense mutation (p.Y1192X) was identified, whereas in the second patient with DSH, CHD and hemangioma from birth, a frameshift mutation (p.Glu673ValfsX652) in ADAR1 was identified.\n'
p14814
sg4
(lp14815
(dp14816
g7
I208
sg8
VP55265
p14817
sg10
I5
sg11
VADAR1
p14818
sg13
I1
sa(dp14819
g7
I29
sg8
VP55265
p14820
sg10
I3
sg11
VDSH
p14821
sg13
I1
sasg24
(lp14822
(dp14823
g7
I47
sg27
VC0544885
p14824
sg10
I17
sg11
Vnonsense mutation
p14825
sg13
I2
sa(dp14826
g7
I140
sg27
VC0018916
p14827
sg10
I10
sg11
Vhemangioma
p14828
sg13
I1
sa(dp14829
g7
I29
sg27
VC0406775
p14830
sg10
I3
sg11
VDSH
p14831
sg13
I1
sa(dp14832
g7
I29
sg27
VC0406775
p14833
sg10
I3
sg11
VDSH
p14834
sg13
I1
sa(dp14835
g7
I165
sg27
VC0079380
p14836
sg10
I19
sg11
Vframeshift mutation
p14837
sg13
I2
sasa(dp14838
g2
S"To the best of the authors' knowledge, &gt;120 mutations in ADAR1 have been reported to cause DSH; however, no previous studies have reported mutations in ADAR1 in DSH at birth, with CHD and hemangioma.\n"
p14839
sg4
(lp14840
(dp14841
g7
I60
sg8
VP55265
p14842
sg10
I5
sg11
VADAR1
p14843
sg13
I1
sa(dp14844
g7
I94
sg8
VP55265
p14845
sg10
I3
sg11
VDSH
p14846
sg13
I1
sa(dp14847
g7
I60
sg8
VP55265
p14848
sg10
I5
sg11
VADAR1
p14849
sg13
I1
sasg24
(lp14850
(dp14851
g7
I191
sg27
VC0018916
p14852
sg10
I10
sg11
Vhemangioma
p14853
sg13
I1
sa(dp14854
g7
I94
sg27
VC0406775
p14855
sg10
I3
sg11
VDSH
p14856
sg13
I1
sa(dp14857
g7
I94
sg27
VC0406775
p14858
sg10
I3
sg11
VDSH
p14859
sg13
I1
sasa(dp14860
g2
S'The novel variants described in the current study add to the current knowledge of ADAR1 mutations in DSH.\n'
p14861
sg4
(lp14862
(dp14863
g7
I101
sg8
VP55265
p14864
sg10
I3
sg11
VDSH
p14865
sg13
I1
sa(dp14866
g7
I82
sg8
VP55265
p14867
sg10
I5
sg11
VADAR1
p14868
sg13
I1
sasg24
(lp14869
(dp14870
g7
I101
sg27
VC0406775
p14871
sg10
I3
sg11
VDSH
p14872
sg13
I1
sa(dp14873
g7
I50
sg27
VC0004269
p14874
sg10
I3
sg11
Vadd
p14875
sg13
I1
sasa(dp14876
g2
S'Pathogenic molecular variants in the ADAR gene are a known cause of rare diseases, autosomal recessive Aicardi- Goutieres syndrome type 6, severe infantile encephalopathy with intracranial calcifications and dominant dyschromatosis symmetrica hereditaria, demonstrated mainly in Asian adults.\n'
p14877
sg4
(lp14878
(dp14879
g7
I37
sg8
VP55265
p14880
sg10
I9
sg11
VADAR gene
p14881
sg13
I2
sasg24
(lp14882
(dp14883
g7
I122
sg27
VC0039082
p14884
sg10
I8
sg11
Vsyndrome
p14885
sg13
I1
sa(dp14886
g7
I217
sg27
VC0406775
p14887
sg10
I37
sg11
Vdyschromatosis symmetrica hereditaria
p14888
sg13
I3
sa(dp14889
g7
I68
sg27
VC0678236
p14890
sg10
I13
sg11
Vrare diseases
p14891
sg13
I2
sa(dp14892
g7
I156
sg27
VC0085584
p14893
sg10
I14
sg11
Vencephalopathy
p14894
sg13
I1
sasa(dp14895
g2
S'To identify potential mutation of the ADAR1 gene in a Chinese family and a sporadic case affected with dyschromatosis symmetrica hereditaria(DSH).\n'
p14896
sg4
(lp14897
(dp14898
g7
I38
sg8
VP55265
p14899
sg10
I10
sg11
VADAR1 gene
p14900
sg13
I2
sasg24
(lp14901
(dp14902
g7
I141
sg27
VC0406775
p14903
sg10
I3
sg11
VDSH
p14904
sg13
I1
sa(dp14905
g7
I103
sg27
VC0406775
p14906
sg10
I37
sg11
Vdyschromatosis symmetrica hereditaria
p14907
sg13
I3
sasa(dp14908
g2
S'The frame-shift mutation c.2638delG (p.Asp880ThrfsX15) and the nonsense mutation c.2867C&gt;A (p.Ser956X) in the ADAR1 gene probably underlie the DSH in our patients.\n'
p14909
sg4
(lp14910
(dp14911
g7
I146
sg8
VP55265
p14912
sg10
I3
sg11
VDSH
p14913
sg13
I1
sa(dp14914
g7
I113
sg8
VP55265
p14915
sg10
I10
sg11
VADAR1 gene
p14916
sg13
I2
sasg24
(lp14917
(dp14918
g7
I146
sg27
VC0406775
p14919
sg10
I3
sg11
VDSH
p14920
sg13
I1
sa(dp14921
g7
I63
sg27
VC0544885
p14922
sg10
I17
sg11
Vnonsense mutation
p14923
sg13
I2
sasa(dp14924
g2
S'Dyschromatosis symmetrica hereditaria (DSH) is a rare autosomal dominant cutaneous disorder caused by the mutations of adenosine deaminase acting on RNA1 (ADAR1) gene.\n'
p14925
sg4
(lp14926
(dp14927
g7
I155
sg8
VP55265
p14928
sg10
I5
sg11
VADAR1
p14929
sg13
I1
sa(dp14930
g7
I119
sg8
VP55265
p14931
sg10
I34
sg11
Vadenosine deaminase acting on RNA1
p14932
sg13
I5
sasg24
(lp14933
(dp14934
g7
I39
sg27
VC0406775
p14935
sg10
I3
sg11
VDSH
p14936
sg13
I1
sa(dp14937
g7
I73
sg27
VC0037274
p14938
sg10
I18
sg11
Vcutaneous disorder
p14939
sg13
I2
sa(dp14940
g7
I0
sg27
VC0406775
p14941
sg10
I37
sg11
VDyschromatosis symmetrica hereditaria
p14942
sg13
I3
sasa(dp14943
g2
S'We present a clinical and genetic study of seven unrelated families and two sporadic cases with DSH for mutations in the full coding sequence of ADAR1 gene.\n'
p14944
sg4
(lp14945
(dp14946
g7
I96
sg8
VP55265
p14947
sg10
I3
sg11
VDSH
p14948
sg13
I1
sa(dp14949
g7
I145
sg8
VP55265
p14950
sg10
I10
sg11
VADAR1 gene
p14951
sg13
I2
sasg24
(lp14952
(dp14953
g7
I96
sg27
VC0406775
p14954
sg10
I3
sg11
VDSH
p14955
sg13
I1
sasa(dp14956
g2
S'ADAR1 gene was sequenced in seven unrelated families and two sporadic cases with DSH and 120 controls.\n'
p14957
sg4
(lp14958
(dp14959
g7
I0
sg8
VP55265
p14960
sg10
I10
sg11
VADAR1 gene
p14961
sg13
I2
sasg24
(lp14962
(dp14963
g7
I81
sg27
VC0406775
p14964
sg10
I3
sg11
VDSH
p14965
sg13
I1
sasa(dp14966
g2
S'We describe six novel mutations of the ADAR1 gene in Chinese patients with DSH including a nonstop mutation p.Stop1227R, which was firstly reported in ADAR1 gene.\n'
p14967
sg4
(lp14968
(dp14969
g7
I39
sg8
VP55265
p14970
sg10
I10
sg11
VADAR1 gene
p14971
sg13
I2
sa(dp14972
g7
I39
sg8
VP55265
p14973
sg10
I10
sg11
VADAR1 gene
p14974
sg13
I2
sasg24
(lp14975
(dp14976
g7
I75
sg27
VC0406775
p14977
sg10
I3
sg11
VDSH
p14978
sg13
I1
sasa(dp14979
g2
S'A three-generation family exhibiting phenotypic variability with a single germline ADAR1 mutation suggests that chilblain might aggravate the clinical phenotypes of DSH.\n'
p14980
sg4
(lp14981
(dp14982
g7
I165
sg8
VP55265
p14983
sg10
I3
sg11
VDSH
p14984
sg13
I1
sa(dp14985
g7
I83
sg8
VP55265
p14986
sg10
I5
sg11
VADAR1
p14987
sg13
I1
sasg24
(lp14988
(dp14989
g7
I165
sg27
VC0406775
p14990
sg10
I3
sg11
VDSH
p14991
sg13
I1
sa(dp14992
g7
I112
sg27
VC0008058
p14993
sg10
I9
sg11
Vchilblain
p14994
sg13
I1
sasa(dp14995
g2
S'All patients underwent upper endoscopy and subsequently liver CT. Three radiologists independently evaluated the presence of high-risk esophageal varices with transverse images alone and with three orthogonal multiplanar reformation (MPR) images, respectively.\n'
p14996
sg4
(lp14997
sg24
(lp14998
(dp14999
g7
I135
sg27
VC0014867
p15000
sg10
I18
sg11
Vesophageal varices
p15001
sg13
I2
sasa(dp15002
g2
S'To study the correlation between changes in portosystemic collaterals, evaluated by multidetector-row computed tomography imaging using multiplanar reconstruction (MDCT-MPR), and prognosis in patients with hemorrhagic esophageal varices (EV) after endoscopic treatment.\n'
p15003
sg4
(lp15004
(dp15005
g7
I164
sg8
g9
sg10
I8
sg11
VMDCT-MPR
p15006
sg13
I1
sa(dp15007
g7
I84
sg8
g9
sg10
I78
sg11
Vmultidetector-row computed tomography imaging using multiplanar reconstruction
p15008
sg13
I7
sasg24
(lp15009
(dp15010
g7
I238
sg27
VC0014867
p15011
sg10
I2
sg11
VEV
p15012
sg13
I1
sa(dp15013
g7
I218
sg27
VC0014867
p15014
sg10
I18
sg11
Vesophageal varices
p15015
sg13
I2
sasa(dp15016
g2
S'The purpose of our study was to assess the relationship between hemodynamic changes in portosystemic collaterals and the prognosis of patients with esophageal varices after endoscopic injection sclerotherapy using multiplanar reconstruction (MPR) MDCT images.\n'
p15017
sg4
(lp15018
sg24
(lp15019
(dp15020
g7
I148
sg27
VC0014867
p15021
sg10
I18
sg11
Vesophageal varices
p15022
sg13
I2
sasa(dp15023
g2
S'MPR MDCT images on portosystemic collaterals can accurately predict relapse of esophageal varices after endoscopic injection sclerotherapy.\n'
p15024
sg4
(lp15025
sg24
(lp15026
(dp15027
g7
I68
sg27
VC0277556
p15028
sg10
I7
sg11
Vrelapse
p15029
sg13
I1
sa(dp15030
g7
I79
sg27
VC0014867
p15031
sg10
I18
sg11
Vesophageal varices
p15032
sg13
I2
sasa(dp15033
g2
S'TTD is caused by mutations in DNA repair/transcription genes XPD, XPB or TTDA, and in TTDN1, a gene of unknown function.\n'
p15034
sg4
(lp15035
(dp15036
g7
I66
sg8
VP19447
p15037
sg10
I3
sg11
VXPB
p15038
sg13
I1
sa(dp15039
g7
I61
sg8
VP18074
p15040
sg10
I3
sg11
VXPD
p15041
sg13
I1
sa(dp15042
g7
I73
sg8
g9
sg10
I4
sg11
VTTDA
p15043
sg13
I1
sa(dp15044
g7
I86
sg8
g9
sg10
I5
sg11
VTTDN1
p15045
sg13
I1
sasg24
(lp15046
(dp15047
g7
I66
sg27
VC0268136
p15048
sg10
I3
sg11
VXPB
p15049
sg13
I1
sa(dp15050
g7
I61
sg27
VC0268138
p15051
sg10
I3
sg11
VXPD
p15052
sg13
I1
sa(dp15053
g7
I86
sg27
VC1961117
p15054
sg10
I5
sg11
VTTDN1
p15055
sg13
I1
sasa(dp15056
g2
S'To date, four genes have been identified as responsible for TTD: XPD, XPB, p8/TTDA, and TTDN1.\n'
p15057
sg4
(lp15058
(dp15059
g7
I65
sg8
VP18074
p15060
sg10
I3
sg11
VXPD
p15061
sg13
I1
sa(dp15062
g7
I70
sg8
VP19447
p15063
sg10
I3
sg11
VXPB
p15064
sg13
I1
sa(dp15065
g7
I88
sg8
g9
sg10
I5
sg11
VTTDN1
p15066
sg13
I1
sa(dp15067
g7
I78
sg8
g9
sg10
I4
sg11
VTTDA
p15068
sg13
I1
sasg24
(lp15069
(dp15070
g7
I65
sg27
VC0268138
p15071
sg10
I3
sg11
VXPD
p15072
sg13
I1
sa(dp15073
g7
I70
sg27
VC0268136
p15074
sg10
I3
sg11
VXPB
p15075
sg13
I1
sa(dp15076
g7
I88
sg27
VC1961117
p15077
sg10
I5
sg11
VTTDN1
p15078
sg13
I1
sasa(dp15079
g2
S'We analysed the gene expression and protein distribution of different members of the Hsp27, Hsp70, and Hsp90 families in the central nervous system of sheep naturally infected with scrapie.\n'
p15080
sg4
(lp15081
(dp15082
g7
I92
sg8
VP34932
p15083
sg10
I5
sg11
VHsp70
p15084
sg13
I1
sa(dp15085
g7
I103
sg8
VP19883
p15086
sg10
I14
sg11
VHsp90 families
p15087
sg13
I2
sa(dp15088
g7
I85
sg8
g9
sg10
I5
sg11
VHsp27
p15089
sg13
I1
sasg24
(lp15090
(dp15091
g7
I181
sg27
VC0036457
p15092
sg10
I7
sg11
Vscrapie
p15093
sg13
I1
sa(dp15094
g7
I133
sg27
VC0027769
p15095
sg10
I7
sg11
Vnervous
p15096
sg13
I1
sasa(dp15097
g2
S'We have previously shown that scrapie-infected mouse neuroblastoma (ScN2a) cells fail to induce the expression of Hsp72 and Hsp28 after various stress conditions.\n'
p15098
sg4
(lp15099
(dp15100
g7
I114
sg8
VP08107
p15101
sg10
I5
sg11
VHsp72
p15102
sg13
I1
sasg24
(lp15103
(dp15104
g7
I30
sg27
VC0036457
p15105
sg10
I7
sg11
Vscrapie
p15106
sg13
I1
sa(dp15107
g7
I47
sg27
VC1524043
p15108
sg10
I19
sg11
Vmouse neuroblastoma
p15109
sg13
I2
sasa(dp15110
g2
S'In scrapie-infected N2a (ScN2a) cells, Hsp72 and Hsp28 were not induced by heat shock, sodium arsenite, or an amino acid analog, in contrast to uninfected control N2a cells, while other inducible Hsps were increased by these treatments.\n'
p15111
sg4
(lp15112
(dp15113
g7
I39
sg8
VP08107
p15114
sg10
I5
sg11
VHsp72
p15115
sg13
I1
sa(dp15116
g7
I196
sg8
VP08107
p15117
sg10
I4
sg11
VHsps
p15118
sg13
I1
sa(dp15119
g7
I25
sg8
g9
sg10
I5
sg11
VScN2a
p15120
sg13
I1
sa(dp15121
g7
I3
sg8
g9
sg10
I20
sg11
Vscrapie-infected N2a
p15122
sg13
I2
sasg24
(lp15123
(dp15124
g7
I3
sg27
VC0036457
p15125
sg10
I7
sg11
Vscrapie
p15126
sg13
I1
sasa(dp15127
g2
S'We have identified Receptor-interacting serine/threonine protein kinase 4 (RIP4) as a regulator of tumor differentiation in lung adenocarcinoma (AC).\n'
p15128
sg4
(lp15129
(dp15130
g7
I75
sg8
VP57078
p15131
sg10
I4
sg11
VRIP4
p15132
sg13
I1
sa(dp15133
g7
I19
sg8
g9
sg10
I54
sg11
VReceptor-interacting serine/threonine protein kinase 4
p15134
sg13
I5
sasg24
(lp15135
(dp15136
g7
I99
sg27
VC0027651
p15137
sg10
I5
sg11
Vtumor
p15138
sg13
I1
sa(dp15139
g7
I124
sg27
VC0152013
p15140
sg10
I19
sg11
Vlung adenocarcinoma
p15141
sg13
I2
sasa(dp15142
g2
S'Altogether, our work has identified that loss of RIP4 enhances STAT3 signaling in lung cancer cells, promoting the expression of ECM remodeling genes and cancer dedifferentiation.\n'
p15143
sg4
(lp15144
(dp15145
g7
I129
sg8
g9
sg10
I20
sg11
VECM remodeling genes
p15146
sg13
I3
sa(dp15147
g7
I63
sg8
VP40763
p15148
sg10
I5
sg11
VSTAT3
p15149
sg13
I1
sa(dp15150
g7
I49
sg8
VP57078
p15151
sg10
I4
sg11
VRIP4
p15152
sg13
I1
sasg24
(lp15153
(dp15154
g7
I82
sg27
VC0684249
p15155
sg10
I11
sg11
Vlung cancer
p15156
sg13
I2
sa(dp15157
g7
I87
sg27
VC0006826
p15158
sg10
I6
sg11
Vcancer
p15159
sg13
I1
sa(dp15160
g7
I161
sg27
VC0002793
p15161
sg10
I17
sg11
Vdedifferentiation
p15162
sg13
I1
sasa(dp15163
g2
S'In conclusion, our data suggest that RIPK4/EZH2 markers might be used as potential predictors of prognosis in cervical cancer.\n'
p15164
sg4
(lp15165
(dp15166
g7
I43
sg8
g9
sg10
I4
sg11
VEZH2
p15167
sg13
I1
sa(dp15168
g7
I37
sg8
VP57078
p15169
sg10
I5
sg11
VRIPK4
p15170
sg13
I1
sasg24
(lp15171
(dp15172
g7
I110
sg27
VC0302592
p15173
sg10
I15
sg11
Vcervical cancer
p15174
sg13
I2
sasa(dp15175
g2
S'To investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.\n'
p15176
sg4
(lp15177
(dp15178
g7
I78
sg8
VP57078
p15179
sg10
I5
sg11
VRIPK4
p15180
sg13
I1
sa(dp15181
g7
I39
sg8
g9
sg10
I37
sg11
Vreceptor-interacting kinase protein 4
p15182
sg13
I4
sasg24
(lp15183
(dp15184
g7
I140
sg27
VC1527249
p15185
sg10
I17
sg11
Vcolorectal cancer
p15186
sg13
I2
sa(dp15187
g7
I159
sg27
VC1527249
p15188
sg10
I3
sg11
VCRC
p15189
sg13
I1
sasa(dp15190
g2
S'In colon cancer subgroup, high RIPK4 RCN was significantly associated with poor OS (median OS, 31.5 months vs. 56.6 months, P=0.015) but not with RFS (P=0.135).\n'
p15191
sg4
(lp15192
(dp15193
g7
I31
sg8
VP57078
p15194
sg10
I9
sg11
VRIPK4 RCN
p15195
sg13
I2
sasg24
(lp15196
(dp15197
g7
I3
sg27
VC0699790
p15198
sg10
I12
sg11
Vcolon cancer
p15199
sg13
I2
sa(dp15200
g7
I146
sg27
VC0015624
p15201
sg10
I3
sg11
VRFS
p15202
sg13
I1
sasa(dp15203
g2
S'In rectal cancer subgroup, RIPK4 RCN was not associated with both OS and RFS (P=0.981, P=0.738).\n'
p15204
sg4
(lp15205
(dp15206
g7
I27
sg8
VP57078
p15207
sg10
I9
sg11
VRIPK4 RCN
p15208
sg13
I2
sasg24
(lp15209
(dp15210
g7
I3
sg27
VC0007113
p15211
sg10
I13
sg11
Vrectal cancer
p15212
sg13
I2
sa(dp15213
g7
I73
sg27
VC0015624
p15214
sg10
I3
sg11
VRFS
p15215
sg13
I1
sasa(dp15216
g2
S'RIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.\n'
p15217
sg4
(lp15218
(dp15219
g7
I0
sg8
VP57078
p15220
sg10
I9
sg11
VRIPK4 RCN
p15221
sg13
I2
sasg24
(lp15222
(dp15223
g7
I60
sg27
VC0699790
p15224
sg10
I12
sg11
Vcolon cancer
p15225
sg13
I2
sa(dp15226
g7
I60
sg27
VC0699790
p15227
sg10
I12
sg11
Vcolon cancer
p15228
sg13
I2
sasa(dp15229
g2
S'Aberrant expression of receptor interacting protein kinase 4 (RIPK4), a crucial regulatory protein of Wnt/Beta-catenin signaling, has recently been reported to be involved in several cancers.\n'
p15230
sg4
(lp15231
(dp15232
g7
I62
sg8
VP57078
p15233
sg10
I5
sg11
VRIPK4
p15234
sg13
I1
sa(dp15235
g7
I23
sg8
g9
sg10
I37
sg11
Vreceptor interacting protein kinase 4
p15236
sg13
I5
sasg24
(lp15237
(dp15238
g7
I183
sg27
VC0006826
p15239
sg10
I7
sg11
Vcancers
p15240
sg13
I1
sasa(dp15241
g2
S'Here, we report the potential clinical implication and biological functions of RIPK4 in cervical squamous cell carcinoma (CSCC).\n'
p15242
sg4
(lp15243
(dp15244
g7
I79
sg8
VP57078
p15245
sg10
I5
sg11
VRIPK4
p15246
sg13
I1
sasg24
(lp15247
(dp15248
g7
I122
sg27
VC0279671
p15249
sg10
I4
sg11
VCSCC
p15250
sg13
I1
sa(dp15251
g7
I88
sg27
VC0279671
p15252
sg10
I32
sg11
Vcervical squamous cell carcinoma
p15253
sg13
I4
sasa(dp15254
g2
S'RIPK4 expression increased significantly with disease progression from 3.2% in chronic cervicitis, 19.3% in LSILs and 85.1% in HSILs to 94.4% in CSCCs (P &lt; 0.001).\n'
p15255
sg4
(lp15256
(dp15257
g7
I0
sg8
VP57078
p15258
sg10
I5
sg11
VRIPK4
p15259
sg13
I1
sasg24
(lp15260
(dp15261
g7
I79
sg27
VC0269062
p15262
sg10
I18
sg11
Vchronic cervicitis
p15263
sg13
I2
sa(dp15264
g7
I46
sg27
VC0242656
p15265
sg10
I19
sg11
Vdisease progression
p15266
sg13
I2
sasa(dp15267
g2
S'Knockdown of RIPK4 reduced cell migration and invasion via inhibition of Vimentin, MMP2 and Fibronectin expression in cervical cancer cells.\n'
p15268
sg4
(lp15269
(dp15270
g7
I83
sg8
VP08253
p15271
sg10
I4
sg11
VMMP2
p15272
sg13
I1
sa(dp15273
g7
I13
sg8
VP57078
p15274
sg10
I5
sg11
VRIPK4
p15275
sg13
I1
sasg24
(lp15276
(dp15277
g7
I118
sg27
VC0302592
p15278
sg10
I15
sg11
Vcervical cancer
p15279
sg13
I2
sa(dp15280
g7
I46
sg27
VC2699153
p15281
sg10
I8
sg11
Vinvasion
p15282
sg13
I1
sasa(dp15283
g2
S'RIPK4 might act as a potential diagnostic and independent prognostic biomarker for CSCC patients.\n'
p15284
sg4
(lp15285
(dp15286
g7
I0
sg8
VP57078
p15287
sg10
I5
sg11
VRIPK4
p15288
sg13
I1
sasg24
(lp15289
sa(dp15290
g2
S'We previously showed that protein kinase C-associated kinase (PKK, also known as DIK/RIP4), which belongs to the receptor-interacting protein (RIP) kinase family, mediates the B cell activating factor of the TNF family (BAFF)-induced NF-KB activation in diffuse large B cell lymphoma (DLBCL) cell lines.\n'
p15291
sg4
(lp15292
(dp15293
g7
I113
sg8
g9
sg10
I28
sg11
Vreceptor-interacting protein
p15294
sg13
I2
sa(dp15295
g7
I26
sg8
VP17252
p15296
sg10
I34
sg11
Vprotein kinase C-associated kinase
p15297
sg13
I4
sa(dp15298
g7
I176
sg8
g9
sg10
I42
sg11
VB cell activating factor of the TNF family
p15299
sg13
I8
sa(dp15300
g7
I85
sg8
VP52594
p15301
sg10
I3
sg11
VRIP
p15302
sg13
I1
sa(dp15303
g7
I81
sg8
VP57078
p15304
sg10
I3
sg11
VDIK
p15305
sg13
I1
sa(dp15306
g7
I62
sg8
VP57078
p15307
sg10
I3
sg11
VPKK
p15308
sg13
I1
sa(dp15309
g7
I85
sg8
VP57078
p15310
sg10
I4
sg11
VRIP4
p15311
sg13
I1
sa(dp15312
g7
I220
sg8
g9
sg10
I4
sg11
VBAFF
p15313
sg13
I1
sasg24
(lp15314
(dp15315
g7
I285
sg27
VC0079744
p15316
sg10
I5
sg11
VDLBCL
p15317
sg13
I1
sa(dp15318
g7
I254
sg27
VC0079744
p15319
sg10
I29
sg11
Vdiffuse large B cell lymphoma
p15320
sg13
I5
sasa(dp15321
g2
S'Suppression of PKK expression by RNA interference inhibits phosphorylation of IKKAlfa and IKKBeta as well as activation of NF-KB in human cancer cell lines.\n'
p15322
sg4
(lp15323
(dp15324
g7
I90
sg8
g9
sg10
I7
sg11
VIKKBeta
p15325
sg13
I1
sa(dp15326
g7
I15
sg8
VP57078
p15327
sg10
I3
sg11
VPKK
p15328
sg13
I1
sasg24
(lp15329
(dp15330
g7
I0
sg27
VC0221103
p15331
sg10
I11
sg11
VSuppression
p15332
sg13
I1
sa(dp15333
g7
I138
sg27
VC0006826
p15334
sg10
I6
sg11
Vcancer
p15335
sg13
I1
sasa(dp15336
g2
S'We propose that PKK may provide a critical link between IKK activation and various upstream signaling cascades, and may represent a potential target for inhibiting abnormal NF-KB activation in human cancers.\n'
p15337
sg4
(lp15338
(dp15339
g7
I16
sg8
VP57078
p15340
sg10
I3
sg11
VPKK
p15341
sg13
I1
sa(dp15342
g7
I56
sg8
g9
sg10
I3
sg11
VIKK
p15343
sg13
I1
sasg24
(lp15344
(dp15345
g7
I199
sg27
VC0006826
p15346
sg10
I7
sg11
Vcancers
p15347
sg13
I1
sasa(dp15348
g2
S'To assess RIPK4 expression in various differentiated TSCC and to determine its basic biological function.\n'
p15349
sg4
(lp15350
(dp15351
g7
I10
sg8
VP57078
p15352
sg10
I5
sg11
VRIPK4
p15353
sg13
I1
sasg24
(lp15354
sa(dp15355
g2
S'A significantly higher level of RIPK4 was found in well-differentiated TSCC samples than in the poorly differentiated ones (p&lt;0.01).\n'
p15356
sg4
(lp15357
(dp15358
g7
I32
sg8
VP57078
p15359
sg10
I5
sg11
VRIPK4
p15360
sg13
I1
sasg24
(lp15361
sa(dp15362
g2
S'In the present work we found a correlation between RIPK4 expression and TSCC degree of differentiation, age, and gender.\n'
p15363
sg4
(lp15364
(dp15365
g7
I51
sg8
VP57078
p15366
sg10
I5
sg11
VRIPK4
p15367
sg13
I1
sasg24
(lp15368
sa(dp15369
g2
S'The better understanding of the molecular mechanism of RIPK4 in TSCC may provide a promising biomarker for tongue cancer prognosis and treatment.\n'
p15370
sg4
(lp15371
(dp15372
g7
I55
sg8
VP57078
p15373
sg10
I5
sg11
VRIPK4
p15374
sg13
I1
sasg24
(lp15375
(dp15376
g7
I107
sg27
VC0558353
p15377
sg10
I13
sg11
Vtongue cancer
p15378
sg13
I2
sasa(dp15379
g2
S'Interestingly, maladaptive ECM remodeling was observed in early AVM without AVD and worsened with late AVD, as evidenced by increased MMP-2 and MMP-9 expression and activity, as well as abnormalities in ADAMTS-mediated versican processing.\n'
p15380
sg4
(lp15381
(dp15382
g7
I144
sg8
VP14780
p15383
sg10
I5
sg11
VMMP-9
p15384
sg13
I1
sa(dp15385
g7
I134
sg8
VP08253
p15386
sg10
I5
sg11
VMMP-2
p15387
sg13
I1
sasg24
(lp15388
(dp15389
g7
I64
sg27
VC0003857
p15390
sg10
I3
sg11
VAVM
p15391
sg13
I1
sasa(dp15392
g2
S'In patients with aortic stenosis or the hemolytic-uremic syndrome, abnormally high levels of shear stress across the stenotic valve or in the microcirculation inflicted with thrombosis may promote cleavage of vWF by ADAMTS13, contributing to the loss of large multimers commonly observed among these patients.\n'
p15393
sg4
(lp15394
(dp15395
g7
I209
sg8
VP04275
p15396
sg10
I3
sg11
VvWF
p15397
sg13
I1
sa(dp15398
g7
I216
sg8
g9
sg10
I8
sg11
VADAMTS13
p15399
sg13
I1
sasg24
(lp15400
(dp15401
g7
I174
sg27
VC0040053
p15402
sg10
I10
sg11
Vthrombosis
p15403
sg13
I1
sa(dp15404
g7
I40
sg27
VC0019061
p15405
sg10
I25
sg11
Vhemolytic-uremic syndrome
p15406
sg13
I2
sa(dp15407
g7
I17
sg27
VC0003507
p15408
sg10
I15
sg11
Vaortic stenosis
p15409
sg13
I2
sasa(dp15410
g2
S'The gene and protein expression profiles and protein distribution of six potential genetic biomarkers (i.e., CAPN6, COL1A2, COL3A1, GALA1, MT2A and MTNR1B) are presented here for both the early and terminal stages of scrapie in five different brain regions.\n'
p15411
sg4
(lp15412
(dp15413
g7
I109
sg8
g9
sg10
I5
sg11
VCAPN6
p15414
sg13
I1
sa(dp15415
g7
I139
sg8
VP02795
p15416
sg10
I4
sg11
VMT2A
p15417
sg13
I1
sa(dp15418
g7
I148
sg8
VP49286
p15419
sg10
I6
sg11
VMTNR1B
p15420
sg13
I1
sasg24
(lp15421
(dp15422
g7
I217
sg27
VC0036457
p15423
sg10
I7
sg11
Vscrapie
p15424
sg13
I1
sasa(dp15425
g2
S'The distribution of the GALA1 was identified in glial cells from the cerebellum of scrapie-infected animals, GALA1 protein expression was increased in clinical animals in the majority of regions, and the increase of MT2A was in agreement with previous reports.\n'
p15426
sg4
(lp15427
(dp15428
g7
I216
sg8
VP02795
p15429
sg10
I4
sg11
VMT2A
p15430
sg13
I1
sasg24
(lp15431
(dp15432
g7
I83
sg27
VC0036457
p15433
sg10
I7
sg11
Vscrapie
p15434
sg13
I1
sasa(dp15435
g2
S'In conclusion, this study of gene transcription and protein expression and distribution confirm CAPN6, GALA1, MTNR1B and MT2A as potential targets for further prion disease research.\n'
p15436
sg4
(lp15437
(dp15438
g7
I110
sg8
VP49286
p15439
sg10
I6
sg11
VMTNR1B
p15440
sg13
I1
sa(dp15441
g7
I96
sg8
g9
sg10
I5
sg11
VCAPN6
p15442
sg13
I1
sa(dp15443
g7
I121
sg8
VP02795
p15444
sg10
I4
sg11
VMT2A
p15445
sg13
I1
sasg24
(lp15446
(dp15447
g7
I159
sg27
VC0162534
p15448
sg10
I13
sg11
Vprion disease
p15449
sg13
I2
sasa(dp15450
g2
S'LincRNA-p21 could lead to pulmonary fibrosis in ARDS by inhibition of the expression of Thy-1.\n'
p15451
sg4
(lp15452
(dp15453
g7
I88
sg8
VP04216
p15454
sg10
I5
sg11
VThy-1
p15455
sg13
I1
sa(dp15456
g7
I8
sg8
VP42857
p15457
sg10
I3
sg11
Vp21
p15458
sg13
I1
sasg24
(lp15459
(dp15460
g7
I26
sg27
VC0034069
p15461
sg10
I18
sg11
Vpulmonary fibrosis
p15462
sg13
I2
sa(dp15463
g7
I48
sg27
VC0035222
p15464
sg10
I4
sg11
VARDS
p15465
sg13
I1
sasa(dp15466
g2
S'LPS-induced pulmonary fibrosis was related with activation of HDAC, deacetylation of histone H3 and H4 and Thy-1 gene silencing.\n'
p15467
sg4
(lp15468
(dp15469
g7
I107
sg8
VP04216
p15470
sg10
I10
sg11
VThy-1 gene
p15471
sg13
I2
sa(dp15472
g7
I85
sg8
g9
sg10
I10
sg11
Vhistone H3
p15473
sg13
I2
sa(dp15474
g7
I62
sg8
VP56524
p15475
sg10
I4
sg11
VHDAC
p15476
sg13
I1
sasg24
(lp15477
(dp15478
g7
I12
sg27
VC0034069
p15479
sg10
I18
sg11
Vpulmonary fibrosis
p15480
sg13
I2
sa(dp15481
g7
I0
sg27
VC0175697
p15482
sg10
I3
sg11
VLPS
p15483
sg13
I1
sasa(dp15484
g2
S'HDAC inhibitor BA could inhibit LPS-induced pulmonary fibrosis and Thy-1 gene silencing through inhibiting activation of HDAC and deacetylation of histone H4.\n'
p15485
sg4
(lp15486
(dp15487
g7
I0
sg8
VP56524
p15488
sg10
I4
sg11
VHDAC
p15489
sg13
I1
sa(dp15490
g7
I147
sg8
VP62805
p15491
sg10
I10
sg11
Vhistone H4
p15492
sg13
I2
sa(dp15493
g7
I0
sg8
VP56524
p15494
sg10
I4
sg11
VHDAC
p15495
sg13
I1
sasg24
(lp15496
(dp15497
g7
I44
sg27
VC0034069
p15498
sg10
I18
sg11
Vpulmonary fibrosis
p15499
sg13
I2
sa(dp15500
g7
I32
sg27
VC0175697
p15501
sg10
I3
sg11
VLPS
p15502
sg13
I1
sasa(dp15503
g2
S'SSc patients with pulmonary fibrosis (P = 0.006) and patients with PAH (P &lt; 0.001) had increased sCD90 serum concentrations compared to patients without the respective pulmonary manifestation of SSc.\n'
p15504
sg4
(lp15505
sg24
(lp15506
(dp15507
g7
I18
sg27
VC0034069
p15508
sg10
I18
sg11
Vpulmonary fibrosis
p15509
sg13
I2
sa(dp15510
g7
I67
sg27
VC0152171
p15511
sg10
I3
sg11
VPAH
p15512
sg13
I1
sasa(dp15513
g2
S'Osteoporosis pseudoglioma syndrome (OPPGS) is a rare autosomal recessive genetic disorder characterised by congenital blindness and osteoporosis, caused by biallelic mutations in the LRP5 gene.\n'
p15514
sg4
(lp15515
(dp15516
g7
I183
sg8
g9
sg10
I9
sg11
VLRP5 gene
p15517
sg13
I2
sasg24
(lp15518
(dp15519
g7
I73
sg27
VC0019247
p15520
sg10
I16
sg11
Vgenetic disorder
p15521
sg13
I2
sa(dp15522
g7
I107
sg27
VC0005754
p15523
sg10
I20
sg11
Vcongenital blindness
p15524
sg13
I2
sa(dp15525
g7
I26
sg27
VC0039082
p15526
sg10
I8
sg11
Vsyndrome
p15527
sg13
I1
sa(dp15528
g7
I132
sg27
VC0029456
p15529
sg10
I12
sg11
Vosteoporosis
p15530
sg13
I1
sa(dp15531
g7
I0
sg27
VC0432252
p15532
sg10
I25
sg11
VOsteoporosis pseudoglioma
p15533
sg13
I2
sasa(dp15534
g2
S'Molecular genetic examination detected the LRP5 gene for FEVR.\n'
p15535
sg4
(lp15536
(dp15537
g7
I43
sg8
g9
sg10
I9
sg11
VLRP5 gene
p15538
sg13
I2
sasg24
(lp15539
sa(dp15540
g2
S'The majority of mutations identified in FEVR are found within four genes that encode the receptor complex (FZD4, LRP5, and TSPAN12) and ligand (NDP) of a molecular pathway that controls angiogenesis, the Norrin-Beta-catenin signaling pathway.\n'
p15541
sg4
(lp15542
(dp15543
g7
I211
sg8
VP35222
p15544
sg10
I12
sg11
VBeta-catenin
p15545
sg13
I1
sa(dp15546
g7
I107
sg8
g9
sg10
I4
sg11
VFZD4
p15547
sg13
I1
sa(dp15548
g7
I113
sg8
g9
sg10
I4
sg11
VLRP5
p15549
sg13
I1
sa(dp15550
g7
I123
sg8
g9
sg10
I7
sg11
VTSPAN12
p15551
sg13
I1
sa(dp15552
g7
I204
sg8
g9
sg10
I6
sg11
VNorrin
p15553
sg13
I1
sa(dp15554
g7
I40
sg8
g9
sg10
I4
sg11
VFEVR
p15555
sg13
I1
sasg24
(lp15556
sa(dp15557
g2
S'Primers were designed to amplify the coding exons and adjacent intronic regions of the FEVR-causing genes FZD4, LRP5, NDP and TSPAN12.\n'
p15558
sg4
(lp15559
(dp15560
g7
I112
sg8
g9
sg10
I4
sg11
VLRP5
p15561
sg13
I1
sa(dp15562
g7
I126
sg8
g9
sg10
I7
sg11
VTSPAN12
p15563
sg13
I1
sa(dp15564
g7
I106
sg8
g9
sg10
I4
sg11
VFZD4
p15565
sg13
I1
sa(dp15566
g7
I118
sg8
g9
sg10
I3
sg11
VNDP
p15567
sg13
I1
sasg24
(lp15568
sa(dp15569
g2
S'We identified five LRP5 mutations: three novel heterozygous mutations-p.M181R, p.R399S and p.G503R and two known mutations that were never reported in FEVR patients: p.R494Q and p.G876S.\n'
p15570
sg4
(lp15571
(dp15572
g7
I19
sg8
g9
sg10
I14
sg11
VLRP5 mutations
p15573
sg13
I2
sasg24
(lp15574
sa(dp15575
g2
S'Surprisingly, we then found mutations in familial exudative vitreoretinopathy (FEVR) genes; low-density lipoprotein receptor-related protein 5 mutations (six families), tetraspanin 12 mutations (two families), and NDP mutations (two families).\n'
p15576
sg4
(lp15577
(dp15578
g7
I214
sg8
g9
sg10
I13
sg11
VNDP mutations
p15579
sg13
I2
sa(dp15580
g7
I92
sg8
g9
sg10
I60
sg11
Vlow-density lipoprotein receptor-related protein 5 mutations
p15581
sg13
I6
sa(dp15582
g7
I169
sg8
g9
sg10
I14
sg11
Vtetraspanin 12
p15583
sg13
I2
sasg24
(lp15584
(dp15585
g7
I79
sg27
VC0339539
p15586
sg10
I4
sg11
VFEVR
p15587
sg13
I1
sa(dp15588
g7
I41
sg27
VC0339539
p15589
sg10
I36
sg11
Vfamilial exudative vitreoretinopathy
p15590
sg13
I3
sasa(dp15591
g2
S'Therefore, this study aimed to determine the role of the Mdm2 SNIP 309 polymorphism in the gastric mucosal morphological patterns in patients with Helicobacter pylori associated gastritis.\n'
p15592
sg4
(lp15593
(dp15594
g7
I57
sg8
g9
sg10
I9
sg11
VMdm2 SNIP
p15595
sg13
I2
sasg24
(lp15596
(dp15597
g7
I178
sg27
VC0017152
p15598
sg10
I9
sg11
Vgastritis
p15599
sg13
I1
sasa(dp15600
g2
S'Therefore, this study aimed to determine the correlation between the patterns of Mdm2 SNIP 309 and the inflammation grading of Helicobacter pylori associated gastritis in a Thai population.\n'
p15601
sg4
(lp15602
(dp15603
g7
I81
sg8
g9
sg10
I13
sg11
VMdm2 SNIP 309
p15604
sg13
I3
sasg24
(lp15605
(dp15606
g7
I158
sg27
VC0017152
p15607
sg10
I9
sg11
Vgastritis
p15608
sg13
I1
sa(dp15609
g7
I103
sg27
VC0021368
p15610
sg10
I12
sg11
Vinflammation
p15611
sg13
I1
sasa(dp15612
g2
S'Gastric mucosa from 100 patients with Helicobacter pylori associated gastritis was analyzed for MDM2 SNP309 using real-time PCR hybridization (light-cycler) probes.\n'
p15613
sg4
(lp15614
sg24
(lp15615
(dp15616
g7
I69
sg27
VC0017152
p15617
sg10
I9
sg11
Vgastritis
p15618
sg13
I1
sasa(dp15619
g2
S'While planning genomics, we describe that 11 well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, KCNJ11, FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) showed similar associations compared to literature.\n'
p15620
sg4
(lp15621
(dp15622
g7
I168
sg8
g9
sg10
I6
sg11
VCDKAL1
p15623
sg13
I1
sa(dp15624
g7
I131
sg8
g9
sg10
I7
sg11
VIGF2BP2
p15625
sg13
I1
sa(dp15626
g7
I118
sg8
g9
sg10
I6
sg11
VKCNJ11
p15627
sg13
I1
sa(dp15628
g7
I176
sg8
VP51787
p15629
sg10
I5
sg11
VKCNQ1
p15630
sg13
I1
sa(dp15631
g7
I162
sg8
g9
sg10
I4
sg11
VHHEX
p15632
sg13
I1
sa(dp15633
g7
I112
sg8
g9
sg10
I4
sg11
VP12A
p15634
sg13
I1
sa(dp15635
g7
I106
sg8
g9
sg10
I5
sg11
VPPARG
p15636
sg13
I1
sa(dp15637
g7
I126
sg8
g9
sg10
I3
sg11
VFTO
p15638
sg13
I1
sa(dp15639
g7
I140
sg8
g9
sg10
I5
sg11
VDUSP9
p15640
sg13
I1
sasg24
(lp15641
(dp15642
g7
I56
sg27
VC0011860
p15643
sg10
I15
sg11
Vtype 2 diabetes
p15644
sg13
I3
sasa(dp15645
g2
S'Associations between insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs11705701, insulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene polymorphisms with prediabetes and type 2 diabetes (T2D) have not been evaluated in the Han Chinese population.\n'
p15646
sg4
(lp15647
(dp15648
g7
I74
sg8
g9
sg10
I7
sg11
VIGF2BP2
p15649
sg13
I1
sa(dp15650
g7
I21
sg8
VP01308
p15651
sg10
I51
sg11
Vinsulin-like growth factor 2 mRNA-binding protein 2
p15652
sg13
I7
sa(dp15653
g7
I95
sg8
VP35568
p15654
sg10
I140
sg11
Vinsulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene
p15655
sg13
I17
sasg24
(lp15656
(dp15657
g7
I271
sg27
VC0011860
p15658
sg10
I15
sg11
Vtype 2 diabetes
p15659
sg13
I3
sa(dp15660
g7
I255
sg27
VC0362046
p15661
sg10
I11
sg11
Vprediabetes
p15662
sg13
I1
sa(dp15663
g7
I288
sg27
VC0011860
p15664
sg10
I3
sg11
VT2D
p15665
sg13
I1
sasa(dp15666
g2
S'A breakdown analysis by gender revealed a significant association of IGF2BP2 rs11705701 with prediabetes under the dominant genetic model in females following application of the Bonferroni correction (odds ratio = 0.26; 95% confidence interval = 0.10-0.67; P=0.005).\n'
p15667
sg4
(lp15668
(dp15669
g7
I69
sg8
g9
sg10
I18
sg11
VIGF2BP2 rs11705701
p15670
sg13
I2
sasg24
(lp15671
(dp15672
g7
I2
sg27
VC1265875
p15673
sg10
I9
sg11
Vbreakdown
p15674
sg13
I1
sa(dp15675
g7
I93
sg27
VC0362046
p15676
sg10
I11
sg11
Vprediabetes
p15677
sg13
I1
sasa(dp15678
g2
S'The present case-control study reveals a significant association between IGF2BP2 rs11705701 and prediabetes in female patients.\n'
p15679
sg4
(lp15680
(dp15681
g7
I73
sg8
g9
sg10
I18
sg11
VIGF2BP2 rs11705701
p15682
sg13
I2
sasg24
(lp15683
(dp15684
g7
I96
sg27
VC0362046
p15685
sg10
I11
sg11
Vprediabetes
p15686
sg13
I1
sasa(dp15687
g2
S'Genome-wide association studies (GWAS) found that IGF2BP2 rs4402960 and rs1470579 polymorphisms were associated with type 2 diabetes mellitus (T2DM) risk.\n'
p15688
sg4
(lp15689
(dp15690
g7
I50
sg8
g9
sg10
I7
sg11
VIGF2BP2
p15691
sg13
I1
sasg24
(lp15692
(dp15693
g7
I117
sg27
VC0011860
p15694
sg10
I24
sg11
Vtype 2 diabetes mellitus
p15695
sg13
I4
sa(dp15696
g7
I143
sg27
VC0011860
p15697
sg10
I4
sg11
VT2DM
p15698
sg13
I1
sasa(dp15699
g2
S'Decreased expression of CHC1L is linked to pathogenesis and progression of both prostate cancer and multiple myeloma.\n'
p15700
sg4
(lp15701
(dp15702
g7
I24
sg8
g9
sg10
I5
sg11
VCHC1L
p15703
sg13
I1
sasg24
(lp15704
(dp15705
g7
I43
sg27
VC0699748
p15706
sg10
I12
sg11
Vpathogenesis
p15707
sg13
I1
sa(dp15708
g7
I80
sg27
VC0600139
p15709
sg10
I15
sg11
Vprostate cancer
p15710
sg13
I2
sa(dp15711
g7
I100
sg27
VC0026764
p15712
sg10
I16
sg11
Vmultiple myeloma
p15713
sg13
I2
sasa(dp15714
g2
S'Recent studies of the RAN (6p21), ZHX-2 (8q24.3), CHC1L (13q14.3) loci highlight the importance of these genes in multiple myeloma (MM) prognosis and therapeutic applications.\n'
p15715
sg4
(lp15716
(dp15717
g7
I34
sg8
g9
sg10
I36
sg11
VZHX-2 (8q24.3), CHC1L (13q14.3) loci
p15718
sg13
I5
sasg24
(lp15719
(dp15720
g7
I114
sg27
VC0026764
p15721
sg10
I16
sg11
Vmultiple myeloma
p15722
sg13
I2
sasa(dp15723
g2
S'Low expression levels of RAN, ZHX-2, and CHC1L were observed in myeloma patients, compared with peripheral blood lymphocytes and MOLP-8 cells.\n'
p15724
sg4
(lp15725
(dp15726
g7
I41
sg8
g9
sg10
I5
sg11
VCHC1L
p15727
sg13
I1
sasg24
(lp15728
(dp15729
g7
I64
sg27
VC0026764
p15730
sg10
I7
sg11
Vmyeloma
p15731
sg13
I1
sasa(dp15732
g2
S'RAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines.\n'
p15733
sg4
(lp15734
(dp15735
g7
I22
sg8
g9
sg10
I5
sg11
VCHC1L
p15736
sg13
I1
sa(dp15737
g7
I5
sg8
g9
sg10
I4
sg11
VZHX2
p15738
sg13
I1
sa(dp15739
g7
I14
sg8
g9
sg10
I6
sg11
VRCBTB2
p15740
sg13
I1
sasg24
(lp15741
(dp15742
g7
I271
sg27
VC0026470
p15743
sg10
I50
sg11
Vmonoclonal gammopathy of undetermined significance
p15744
sg13
I5
sa(dp15745
g7
I340
sg27
VC0023418
p15746
sg10
I10
sg11
Vleukaemias
p15747
sg13
I1
sa(dp15748
g7
I192
sg27
VC0026764
p15749
sg10
I16
sg11
Vmultiple myeloma
p15750
sg13
I2
sa(dp15751
g7
I152
sg27
VC1136085
p15752
sg10
I23
sg11
Vmonoclonal gammopathies
p15753
sg13
I2
sasa(dp15754
g2
S'BCCIP deficiency impaired embryonic and postnatal neural development, causing severe ataxia, cerebral and cerebellar defects, and microcephaly.\n'
p15755
sg4
(lp15756
sg24
(lp15757
(dp15758
g7
I17
sg27
VC0684336
p15759
sg10
I8
sg11
Vimpaired
p15760
sg13
I1
sa(dp15761
g7
I130
sg27
VC0025958
p15762
sg10
I12
sg11
Vmicrocephaly
p15763
sg13
I1
sa(dp15764
g7
I85
sg27
VC0004134
p15765
sg10
I6
sg11
Vataxia
p15766
sg13
I1
sasa(dp15767
g2
S'Phosphorylation also links HS1 to multiple signaling proteins, including Lck, PLCgamma1, and Vav1, and is essential for the stable recruitment of Vav1 to the IS.\n'
p15768
sg4
(lp15769
(dp15770
g7
I93
sg8
VP15498
p15771
sg10
I4
sg11
VVav1
p15772
sg13
I1
sa(dp15773
g7
I27
sg8
VP27348
p15774
sg10
I3
sg11
VHS1
p15775
sg13
I1
sa(dp15776
g7
I78
sg8
VP19174
p15777
sg10
I9
sg11
VPLCgamma1
p15778
sg13
I1
sa(dp15779
g7
I93
sg8
VP15498
p15780
sg10
I4
sg11
VVav1
p15781
sg13
I1
sasg24
(lp15782
(dp15783
g7
I27
sg27
VC2674218
p15784
sg10
I3
sg11
VHS1
p15785
sg13
I1
sa(dp15786
g7
I131
sg27
VC0271510
p15787
sg10
I11
sg11
Vrecruitment
p15788
sg13
I1
sasa(dp15789
g2
S'On the other hand, we confirmed previously mapped Lck SH3 binding sites in ADAM15, HS1, SLP76, and NS5A, and identified putative Lck SH3 binding sites of Sam68, FasL, c-Cbl, and Cbl-b.\n'
p15790
sg4
(lp15791
(dp15792
g7
I83
sg8
VP27348
p15793
sg10
I3
sg11
VHS1
p15794
sg13
I1
sa(dp15795
g7
I161
sg8
VP48023
p15796
sg10
I4
sg11
VFasL
p15797
sg13
I1
sa(dp15798
g7
I154
sg8
g9
sg10
I5
sg11
VSam68
p15799
sg13
I1
sa(dp15800
g7
I167
sg8
VP22681
p15801
sg10
I5
sg11
Vc-Cbl
p15802
sg13
I1
sa(dp15803
g7
I75
sg8
g9
sg10
I6
sg11
VADAM15
p15804
sg13
I1
sa(dp15805
g7
I54
sg8
VP63244
p15806
sg10
I17
sg11
VSH3 binding sites
p15807
sg13
I3
sa(dp15808
g7
I54
sg8
VP63244
p15809
sg10
I17
sg11
VSH3 binding sites
p15810
sg13
I3
sa(dp15811
g7
I88
sg8
g9
sg10
I5
sg11
VSLP76
p15812
sg13
I1
sa(dp15813
g7
I178
sg8
g9
sg10
I5
sg11
VCbl-b
p15814
sg13
I1
sasg24
(lp15815
(dp15816
g7
I83
sg27
VC2674218
p15817
sg10
I3
sg11
VHS1
p15818
sg13
I1
sasa(dp15819
g2
S'The SH2 domains of ZAP70, SHP-1 and PLC gamma 1 and the SH3 domains of lck, vav and HS1 did not bind to pp85--90.\n'
p15820
sg4
(lp15821
(dp15822
g7
I84
sg8
VP27348
p15823
sg10
I3
sg11
VHS1
p15824
sg13
I1
sa(dp15825
g7
I76
sg8
VP15498
p15826
sg10
I3
sg11
Vvav
p15827
sg13
I1
sa(dp15828
g7
I36
sg8
VP98160
p15829
sg10
I11
sg11
VPLC gamma 1
p15830
sg13
I3
sa(dp15831
g7
I19
sg8
VP43403
p15832
sg10
I5
sg11
VZAP70
p15833
sg13
I1
sa(dp15834
g7
I26
sg8
VP29350
p15835
sg10
I5
sg11
VSHP-1
p15836
sg13
I1
sasg24
(lp15837
(dp15838
g7
I84
sg27
VC2674218
p15839
sg10
I3
sg11
VHS1
p15840
sg13
I1
sasa(dp15841
g2
S'These analyses identified several cellular proteins inside HIV-1: elongation factor 1alpha, glyceraldehyde-3-phosphate dehydrogenase, HS-1, phosphatidylethanolamine-binding protein, Pin1, Lck, Nm23-H1, and the C-terminal tail of CD43.\n'
p15842
sg4
(lp15843
(dp15844
g7
I59
sg8
g9
sg10
I31
sg11
VHIV-1: elongation factor 1alpha
p15845
sg13
I4
sa(dp15846
g7
I140
sg8
VP30086
p15847
sg10
I40
sg11
Vphosphatidylethanolamine-binding protein
p15848
sg13
I2
sa(dp15849
g7
I182
sg8
g9
sg10
I4
sg11
VPin1
p15850
sg13
I1
sa(dp15851
g7
I193
sg8
VP22392
p15852
sg10
I7
sg11
VNm23-H1
p15853
sg13
I1
sa(dp15854
g7
I229
sg8
VP16150
p15855
sg10
I4
sg11
VCD43
p15856
sg13
I1
sa(dp15857
g7
I92
sg8
VP04406
p15858
sg10
I40
sg11
Vglyceraldehyde-3-phosphate dehydrogenase
p15859
sg13
I2
sasg24
(lp15860
(dp15861
g7
I59
sg27
VC0019693
p15862
sg10
I3
sg11
VHIV
p15863
sg13
I1
sasa(dp15864
g2
S'We find that the Src homology 3 domains of Grb2 directly associate, in vitro and in vivo, with murine hemopoietic specific protein 1 (HS1), a protein identical to Lck-binding protein 1.\n'
p15865
sg4
(lp15866
(dp15867
g7
I43
sg8
VP62993
p15868
sg10
I4
sg11
VGrb2
p15869
sg13
I1
sa(dp15870
g7
I163
sg8
VP14222
p15871
sg10
I21
sg11
VLck-binding protein 1
p15872
sg13
I3
sa(dp15873
g7
I95
sg8
VP14222
p15874
sg10
I37
sg11
Vmurine hemopoietic specific protein 1
p15875
sg13
I5
sa(dp15876
g7
I17
sg8
VP12931
p15877
sg10
I14
sg11
VSrc homology 3
p15878
sg13
I3
sa(dp15879
g7
I134
sg8
VP27348
p15880
sg10
I3
sg11
VHS1
p15881
sg13
I1
sasg24
(lp15882
(dp15883
g7
I102
sg27
VC2674218
p15884
sg10
I30
sg11
Vhemopoietic specific protein 1
p15885
sg13
I4
sa(dp15886
g7
I134
sg27
VC2674218
p15887
sg10
I3
sg11
VHS1
p15888
sg13
I1
sasa(dp15889
g2
S'Because HS1 associates with the p56(lck) and p59(lyn) tyrosine kinases in vitro and in vivo, and becomes tyrosine phosphorylated upon various receptor stimulations, our present data suggest that HS1 mediates linkage between Lck or Lyn and Grb2 in lymphoid lineage cells.\n'
p15890
sg4
(lp15891
(dp15892
g7
I8
sg8
VP27348
p15893
sg10
I3
sg11
VHS1
p15894
sg13
I1
sa(dp15895
g7
I49
sg8
VP07948
p15896
sg10
I3
sg11
Vlyn
p15897
sg13
I1
sa(dp15898
g7
I231
sg8
VP07948
p15899
sg10
I3
sg11
VLyn
p15900
sg13
I1
sa(dp15901
g7
I32
sg8
VP62191
p15902
sg10
I3
sg11
Vp56
p15903
sg13
I1
sa(dp15904
g7
I239
sg8
VP62993
p15905
sg10
I4
sg11
VGrb2
p15906
sg13
I1
sa(dp15907
g7
I45
sg8
g9
sg10
I3
sg11
Vp59
p15908
sg13
I1
sa(dp15909
g7
I54
sg8
VP29401
p15910
sg10
I16
sg11
Vtyrosine kinases
p15911
sg13
I2
sasg24
(lp15912
(dp15913
g7
I8
sg27
VC2674218
p15914
sg10
I3
sg11
VHS1
p15915
sg13
I1
sa(dp15916
g7
I8
sg27
VC2674218
p15917
sg10
I3
sg11
VHS1
p15918
sg13
I1
sasa(dp15919
g2
S'With this method, we previously isolated an Lck tyrosine kinase-associated protein, LckBP1, which is identical to HS1 (Kitamura et al., 1989, 1995; Takemoto et al., 1995).\n'
p15920
sg4
(lp15921
(dp15922
g7
I84
sg8
VP14317
p15923
sg10
I6
sg11
VLckBP1
p15924
sg13
I1
sa(dp15925
g7
I48
sg8
VP29401
p15926
sg10
I34
sg11
Vtyrosine kinase-associated protein
p15927
sg13
I3
sasg24
(lp15928
(dp15929
g7
I114
sg27
VC2674218
p15930
sg10
I3
sg11
VHS1
p15931
sg13
I1
sasa(dp15932
g2
S'We have previously found that purine-rich element binding protein, PURalpha, was significantly repressed in androgen-independent prostate cancer cell lines in comparison to an androgen-dependent line.\n'
p15933
sg4
(lp15934
(dp15935
g7
I30
sg8
g9
sg10
I35
sg11
Vpurine-rich element binding protein
p15936
sg13
I4
sa(dp15937
g7
I67
sg8
g9
sg10
I8
sg11
VPURalpha
p15938
sg13
I1
sasg24
(lp15939
(dp15940
g7
I129
sg27
VC0600139
p15941
sg10
I15
sg11
Vprostate cancer
p15942
sg13
I2
sasa(dp15943
g2
S'Moreover, over-expressing PURalpha in androgen-independent prostate cancer cells attenuated their cell proliferation.\n'
p15944
sg4
(lp15945
(dp15946
g7
I26
sg8
g9
sg10
I8
sg11
VPURalpha
p15947
sg13
I1
sasg24
(lp15948
(dp15949
g7
I103
sg27
VC0334094
p15950
sg10
I13
sg11
Vproliferation
p15951
sg13
I1
sa(dp15952
g7
I59
sg27
VC0600139
p15953
sg10
I15
sg11
Vprostate cancer
p15954
sg13
I2
sasa(dp15955
g2
S'These findings suggest that regulation of PURalpha expression in prostate cancer cells may serve as a therapeutic target for hormone refractory prostate cancer.\n'
p15956
sg4
(lp15957
(dp15958
g7
I42
sg8
g9
sg10
I8
sg11
VPURalpha
p15959
sg13
I1
sasg24
(lp15960
(dp15961
g7
I125
sg27
VC1328504
p15962
sg10
I34
sg11
Vhormone refractory prostate cancer
p15963
sg13
I4
sa(dp15964
g7
I65
sg27
VC0600139
p15965
sg10
I15
sg11
Vprostate cancer
p15966
sg13
I2
sasa(dp15967
g2
S'We investigated the effects of the DNA damage-inducing cancer chemotherapeutic agent cisplatin on mouse embryo fibroblasts (MEFs) from PURA(-/-) knockout mice that lack Puralpha.\n'
p15968
sg4
(lp15969
(dp15970
g7
I169
sg8
g9
sg10
I8
sg11
VPuralpha
p15971
sg13
I1
sasg24
(lp15972
(dp15973
g7
I55
sg27
VC0006826
p15974
sg10
I6
sg11
Vcancer
p15975
sg13
I1
sa(dp15976
g7
I35
sg27
VC0012860
p15977
sg10
I10
sg11
VDNA damage
p15978
sg13
I2
sasa(dp15979
g2
S'Moreover, PURalpha was decreased in its expression both at the protein and mRNA levels in the androgen-independent prostate cancer cell lines, PC3 and DU145 in comparison to LNCaP cells.\n'
p15980
sg4
(lp15981
(dp15982
g7
I10
sg8
g9
sg10
I8
sg11
VPURalpha
p15983
sg13
I1
sasg24
(lp15984
(dp15985
g7
I115
sg27
VC0600139
p15986
sg10
I15
sg11
Vprostate cancer
p15987
sg13
I2
sasa(dp15988
g2
S'Frequent SIs were pneumonia (15.9%), cellulitis (9.9%), and sepsis (5.0%).\n'
p15989
sg4
(lp15990
sg24
(lp15991
(dp15992
g7
I18
sg27
VC0032285
p15993
sg10
I9
sg11
Vpneumonia
p15994
sg13
I1
sa(dp15995
g7
I60
sg27
VC0243026
p15996
sg10
I6
sg11
Vsepsis
p15997
sg13
I1
sa(dp15998
g7
I37
sg27
VC0007642
p15999
sg10
I10
sg11
Vcellulitis
p16000
sg13
I1
sasa(dp16001
g2
S'We additionally show that pulmonary fibrosis in MyD88-KO mice was associated with the accumulation of pro-fibrotic regulatory T lymphocytes (T regs) and pro-fibrotic cytokine expression (TGF-Beta, IL-10 and PDGF-B), not with T helper (Th) 17 cell influx.\n'
p16002
sg4
(lp16003
(dp16004
g7
I187
sg8
VP18075
p16005
sg10
I8
sg11
VTGF-Beta
p16006
sg13
I1
sa(dp16007
g7
I207
sg8
VP01127
p16008
sg10
I6
sg11
VPDGF-B
p16009
sg13
I1
sa(dp16010
g7
I48
sg8
g9
sg10
I8
sg11
VMyD88-KO
p16011
sg13
I1
sasg24
(lp16012
(dp16013
g7
I26
sg27
VC0034069
p16014
sg10
I18
sg11
Vpulmonary fibrosis
p16015
sg13
I2
sasa(dp16016
g2
S'The aim of our investigation was to analyze the pattern of interleukin-1 (IL-1) family compounds: IL-1 beta, IL-1 receptor accessory protein (Acp), IL-1 receptor antagonist (IL-1Ra) and IL-1 receptor type II (IL-1RII) in the serum and cerebrospinal fluid (CSF) from 67 multiple sclerosis (MS) patients and 31 controls.\n'
p16017
sg4
(lp16018
(dp16019
g7
I209
sg8
g9
sg10
I7
sg11
VIL-1RII
p16020
sg13
I1
sa(dp16021
g7
I109
sg8
g9
sg10
I31
sg11
VIL-1 receptor accessory protein
p16022
sg13
I4
sa(dp16023
g7
I59
sg8
VP60568
p16024
sg10
I13
sg11
Vinterleukin-1
p16025
sg13
I1
sa(dp16026
g7
I148
sg8
g9
sg10
I24
sg11
VIL-1 receptor antagonist
p16027
sg13
I3
sa(dp16028
g7
I174
sg8
VP18510
p16029
sg10
I6
sg11
VIL-1Ra
p16030
sg13
I1
sa(dp16031
g7
I235
sg8
VP04141
p16032
sg10
I25
sg11
Vcerebrospinal fluid (CSF)
p16033
sg13
I3
sa(dp16034
g7
I142
sg8
VP13686
p16035
sg10
I3
sg11
VAcp
p16036
sg13
I1
sa(dp16037
g7
I74
sg8
VP01584
p16038
sg10
I4
sg11
VIL-1
p16039
sg13
I1
sa(dp16040
g7
I98
sg8
VP01584
p16041
sg10
I9
sg11
VIL-1 beta
p16042
sg13
I2
sa(dp16043
g7
I186
sg8
g9
sg10
I21
sg11
VIL-1 receptor type II
p16044
sg13
I4
sasg24
(lp16045
(dp16046
g7
I123
sg27
VC0394005
p16047
sg10
I17
sg11
Vaccessory protein
p16048
sg13
I2
sa(dp16049
g7
I142
sg27
VC0394005
p16050
sg10
I3
sg11
VAcp
p16051
sg13
I1
sa(dp16052
g7
I289
sg27
VC0026769
p16053
sg10
I2
sg11
VMS
p16054
sg13
I1
sa(dp16055
g7
I269
sg27
VC0026769
p16056
sg10
I18
sg11
Vmultiple sclerosis
p16057
sg13
I2
sasa(dp16058
g2
S'Partial loss of IFT80 function leads Jeune asphyxiating thoracic dystrophy (JATD) or short-rib polydactyly (SRP) syndrome type III, displaying narrow thoracic cavity and multiple cartilage anomalies.\n'
p16059
sg4
(lp16060
(dp16061
g7
I16
sg8
g9
sg10
I5
sg11
VIFT80
p16062
sg13
I1
sasg24
(lp16063
(dp16064
g7
I56
sg27
VC0729233
p16065
sg10
I8
sg11
Vthoracic
p16066
sg13
I1
sa(dp16067
g7
I95
sg27
VC0152427
p16068
sg10
I11
sg11
Vpolydactyly
p16069
sg13
I1
sa(dp16070
g7
I43
sg27
VC0265275
p16071
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p16072
sg13
I3
sa(dp16073
g7
I113
sg27
VC0039082
p16074
sg10
I8
sg11
Vsyndrome
p16075
sg13
I1
sa(dp16076
g7
I159
sg27
VC0011334
p16077
sg10
I6
sg11
Vcavity
p16078
sg13
I1
sasa(dp16079
g2
S'Partial mutation of intraflagellar transport 80 (IFT80) in humans causes Jeune asphyxiating thoracic dystrophy (JATD) and short-rib polydactyly (SRP) syndrome type III.\n'
p16080
sg4
(lp16081
(dp16082
g7
I49
sg8
g9
sg10
I5
sg11
VIFT80
p16083
sg13
I1
sa(dp16084
g7
I20
sg8
g9
sg10
I27
sg11
Vintraflagellar transport 80
p16085
sg13
I3
sasg24
(lp16086
(dp16087
g7
I150
sg27
VC0039082
p16088
sg10
I8
sg11
Vsyndrome
p16089
sg13
I1
sa(dp16090
g7
I132
sg27
VC0152427
p16091
sg10
I11
sg11
Vpolydactyly
p16092
sg13
I1
sa(dp16093
g7
I79
sg27
VC0265275
p16094
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p16095
sg13
I3
sasa(dp16096
g2
S'Partial mutation of IFT80 in humans causes diseases such as Jeune asphyxiating thoracic dystrophy (JATD) and short rib polydactyly (SRP) type III with abnormal skeletal development.\n'
p16097
sg4
(lp16098
(dp16099
g7
I20
sg8
g9
sg10
I5
sg11
VIFT80
p16100
sg13
I1
sasg24
(lp16101
(dp16102
g7
I66
sg27
VC0265275
p16103
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p16104
sg13
I3
sa(dp16105
g7
I119
sg27
VC0152427
p16106
sg10
I11
sg11
Vpolydactyly
p16107
sg13
I1
sasa(dp16108
g2
S"Jeune's asphyxiating thoracic dystrophy (JATD) is an autosomal recessive disorder with symptoms of retinal degeneration, kidney cysts, and chondrodysplasia and results from mutations in the ift80 gene.\n"
p16109
sg4
(lp16110
(dp16111
g7
I190
sg8
g9
sg10
I10
sg11
Vift80 gene
p16112
sg13
I2
sasg24
(lp16113
(dp16114
g7
I99
sg27
VC0035304
p16115
sg10
I20
sg11
Vretinal degeneration
p16116
sg13
I2
sa(dp16117
g7
I121
sg27
VC0268800
p16118
sg10
I12
sg11
Vkidney cysts
p16119
sg13
I2
sa(dp16120
g7
I8
sg27
VC0265275
p16121
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p16122
sg13
I3
sa(dp16123
g7
I139
sg27
VC0343284
p16124
sg10
I16
sg11
Vchondrodysplasia
p16125
sg13
I1
sasa(dp16126
g2
S'IL-33 is associated with a variety of autoimmune diseases, such as sclerosis, inflammatory bowel disease, and rheumatoid arthritis.\n'
p16127
sg4
(lp16128
sg24
(lp16129
(dp16130
g7
I38
sg27
VC0004364
p16131
sg10
I19
sg11
Vautoimmune diseases
p16132
sg13
I2
sa(dp16133
g7
I78
sg27
VC0021390
p16134
sg10
I26
sg11
Vinflammatory bowel disease
p16135
sg13
I3
sa(dp16136
g7
I67
sg27
VC0036429
p16137
sg10
I9
sg11
Vsclerosis
p16138
sg13
I1
sa(dp16139
g7
I110
sg27
VC0003873
p16140
sg10
I20
sg11
Vrheumatoid arthritis
p16141
sg13
I2
sasa(dp16142
g2
S'IL-33 was significantly higher in BD patients (101.2+/-20.1pg/ml) as compared to healthy controls (31.5+/-10.5 pg/ml) but lower than rheumatoid arthritis patients (132.5+/-19.1 pg/ml).\n'
p16143
sg4
(lp16144
sg24
(lp16145
(dp16146
g7
I133
sg27
VC0003873
p16147
sg10
I20
sg11
Vrheumatoid arthritis
p16148
sg13
I2
sasa(dp16149
g2
S'It has been shown that the administration of interleukin-33 exacerbates collagen-induced arthritis in experimental models, and a positive correlation between cytokine concentrations in serum and synovial fluid of patients with rheumatoid arthritis and disease activity was found.\n'
p16150
sg4
(lp16151
(dp16152
g7
I45
sg8
g9
sg10
I14
sg11
Vinterleukin-33
p16153
sg13
I1
sasg24
(lp16154
(dp16155
g7
I227
sg27
VC0003873
p16156
sg10
I20
sg11
Vrheumatoid arthritis
p16157
sg13
I2
sa(dp16158
g7
I89
sg27
VC0003864
p16159
sg10
I9
sg11
Varthritis
p16160
sg13
I1
sasa(dp16161
g2
S'This review discusses evidence for the role of interleukin-33 with a focus on rheumatoid arthritis.\n'
p16162
sg4
(lp16163
(dp16164
g7
I47
sg8
g9
sg10
I14
sg11
Vinterleukin-33
p16165
sg13
I1
sasg24
(lp16166
(dp16167
g7
I78
sg27
VC0003873
p16168
sg10
I20
sg11
Vrheumatoid arthritis
p16169
sg13
I2
sasa(dp16170
g2
S'The antigenic protein spots reacted against sera from clonorchiasis patients and were identified as cysteine proteases, glutathione transferases, gelsolin, propionyl-CoA carboxylase (PCC), prohibitin and 14-3-3 protein (14-3-3) using LC-coupled ESI-MS/MS and an EST database for C. sinensis.\n'
p16171
sg4
(lp16172
(dp16173
g7
I183
sg8
VP07320
p16174
sg10
I3
sg11
VPCC
p16175
sg13
I1
sa(dp16176
g7
I120
sg8
VP48637
p16177
sg10
I24
sg11
Vglutathione transferases
p16178
sg13
I2
sa(dp16179
g7
I100
sg8
VP49662
p16180
sg10
I18
sg11
Vcysteine proteases
p16181
sg13
I2
sa(dp16182
g7
I146
sg8
VP06396
p16183
sg10
I35
sg11
Vgelsolin, propionyl-CoA carboxylase
p16184
sg13
I3
sa(dp16185
g7
I189
sg8
VP35232
p16186
sg10
I10
sg11
Vprohibitin
p16187
sg13
I1
sasg24
(lp16188
(dp16189
g7
I54
sg27
VC0009021
p16190
sg10
I13
sg11
Vclonorchiasis
p16191
sg13
I1
sa(dp16192
g7
I183
sg27
VC1832526
p16193
sg10
I3
sg11
VPCC
p16194
sg13
I1
sa(dp16195
g7
I22
sg27
VC0015230
p16196
sg10
I5
sg11
Vspots
p16197
sg13
I1
sa(dp16198
g7
I156
sg27
VC1832526
p16199
sg10
I25
sg11
Vpropionyl-CoA carboxylase
p16200
sg13
I2
sasa(dp16201
g2
S'To report the effect of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia (type 2 IMT).\n'
p16202
sg4
(lp16203
sg24
(lp16204
(dp16205
g7
I78
sg27
VC0039446
p16206
sg10
I14
sg11
Vtelangiectasia
p16207
sg13
I1
sasa(dp16208
g2
S'To identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-Beta (TGF-Beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.\n'
p16209
sg4
(lp16210
(dp16211
g7
I45
sg8
VP21781
p16212
sg10
I26
sg11
Vkeratinocyte growth factor
p16213
sg13
I3
sa(dp16214
g7
I112
sg8
VP29279
p16215
sg10
I4
sg11
VCTGF
p16216
sg13
I1
sa(dp16217
g7
I155
sg8
VP18075
p16218
sg10
I8
sg11
VTGF-Beta
p16219
sg13
I1
sa(dp16220
g7
I73
sg8
VP21781
p16221
sg10
I3
sg11
VKGF
p16222
sg13
I1
sa(dp16223
g7
I79
sg8
VP29279
p16224
sg10
I31
sg11
Vconnective tissue growth factor
p16225
sg13
I4
sa(dp16226
g7
I122
sg8
VP18075
p16227
sg10
I31
sg11
Vtransforming growth factor-Beta
p16228
sg13
I3
sasg24
(lp16229
(dp16230
g7
I184
sg27
VC0751039
p16231
sg10
I3
sg11
VCsA
p16232
sg13
I1
sa(dp16233
g7
I168
sg27
VC0751039
p16234
sg10
I14
sg11
Vcyclosporine-A
p16235
sg13
I1
sasa(dp16236
g2
S'Keratinocyte growth factor (KGF) and scatter factor (SF) are fibroblast-derived growth factors with potent mitogenic and motogenic effects on epithelial cells, and, therefore, could be involved in the pathogenesis of gingival overgrowth.\n'
p16237
sg4
(lp16238
(dp16239
g7
I0
sg8
VP21781
p16240
sg10
I26
sg11
VKeratinocyte growth factor
p16241
sg13
I3
sa(dp16242
g7
I28
sg8
VP21781
p16243
sg10
I3
sg11
VKGF
p16244
sg13
I1
sasg24
(lp16245
(dp16246
g7
I201
sg27
VC0699748
p16247
sg10
I12
sg11
Vpathogenesis
p16248
sg13
I1
sasa(dp16249
g2
S'These results suggest that KGF and SF may have an important role in cyclosporin-induced gingival overgrowth.\n'
p16250
sg4
(lp16251
(dp16252
g7
I27
sg8
VP21781
p16253
sg10
I3
sg11
VKGF
p16254
sg13
I1
sasg24
(lp16255
sa(dp16256
g2
S'On return to the district to calve, 54% of calves from herd 1 and 30% of calves from herd 2 were affected with congenital arthrogryposis or hydranencephaly caused by Akabane virus infection.\n'
p16257
sg4
(lp16258
sg24
(lp16259
(dp16260
g7
I122
sg27
VC0003886
p16261
sg10
I14
sg11
Varthrogryposis
p16262
sg13
I1
sa(dp16263
g7
I140
sg27
VC0020225
p16264
sg10
I15
sg11
Vhydranencephaly
p16265
sg13
I1
sa(dp16266
g7
I174
sg27
VC0042769
p16267
sg10
I15
sg11
Vvirus infection
p16268
sg13
I2
sasa(dp16269
g2
S'Twelve patients with classic radiologic and histologic features of MO, 6 with brown tumors, and 5 with cherubism diagnosed at our institution were studied for the presence of USP6 rearrangements using fluorescence in situ hybridization with probes flanking the USP6 locus on chromosome 17p13.\n'
p16270
sg4
(lp16271
(dp16272
g7
I175
sg8
VP35125
p16273
sg10
I19
sg11
VUSP6 rearrangements
p16274
sg13
I2
sa(dp16275
g7
I261
sg8
VP35125
p16276
sg10
I10
sg11
VUSP6 locus
p16277
sg13
I2
sasg24
(lp16278
(dp16279
g7
I103
sg27
VC0008029
p16280
sg10
I9
sg11
Vcherubism
p16281
sg13
I1
sa(dp16282
g7
I78
sg27
VC0029405
p16283
sg10
I12
sg11
Vbrown tumors
p16284
sg13
I2
sasa(dp16285
g2
S'None of the patients with brown tumor or cherubism demonstrated USP6 rearrangements.\n'
p16286
sg4
(lp16287
(dp16288
g7
I64
sg8
VP35125
p16289
sg10
I19
sg11
VUSP6 rearrangements
p16290
sg13
I2
sasg24
(lp16291
(dp16292
g7
I26
sg27
VC0029405
p16293
sg10
I11
sg11
Vbrown tumor
p16294
sg13
I2
sa(dp16295
g7
I41
sg27
VC0008029
p16296
sg10
I9
sg11
Vcherubism
p16297
sg13
I1
sasa(dp16298
g2
S'In contrast, no USP6 rearrangements were found in patients with cherubism or brown tumor, supporting the prevailing view that these lesions are distinct biologic entities.\n'
p16299
sg4
(lp16300
(dp16301
g7
I16
sg8
VP35125
p16302
sg10
I19
sg11
VUSP6 rearrangements
p16303
sg13
I2
sasg24
(lp16304
(dp16305
g7
I64
sg27
VC0008029
p16306
sg10
I9
sg11
Vcherubism
p16307
sg13
I1
sa(dp16308
g7
I77
sg27
VC0029405
p16309
sg10
I11
sg11
Vbrown tumor
p16310
sg13
I2
sasa(dp16311
g2
S"Consistent with findings in mice, marked alterations in nuclear envelope morphology, abnormal localization of RanGAP1, and nuclear accumulation of mRNA were found in cortex of Huntington's disease patients.\n"
p16312
sg4
(lp16313
(dp16314
g7
I110
sg8
VP46060
p16315
sg10
I7
sg11
VRanGAP1
p16316
sg13
I1
sasg24
(lp16317
(dp16318
g7
I176
sg27
VC0020179
p16319
sg10
I20
sg11
VHuntington's disease
p16320
sg13
I2
sasa(dp16321
g2
S'Double immunofluorescent analyses revealed nuclear retention and apparent colocalization of RanGap1 with Nup205, Gp210 with Nup205, and partial colocalization of Nup205 with Nup107; most of the ischemic changes above were similar to those observed in patients with C9orf72-genetic amyotrophic lateral sclerosis.\n'
p16322
sg4
(lp16323
(dp16324
g7
I105
sg8
g9
sg10
I6
sg11
VNup205
p16325
sg13
I1
sa(dp16326
g7
I92
sg8
VP46060
p16327
sg10
I7
sg11
VRanGap1
p16328
sg13
I1
sa(dp16329
g7
I174
sg8
VP57740
p16330
sg10
I6
sg11
VNup107
p16331
sg13
I1
sa(dp16332
g7
I105
sg8
g9
sg10
I6
sg11
VNup205
p16333
sg13
I1
sa(dp16334
g7
I105
sg8
g9
sg10
I6
sg11
VNup205
p16335
sg13
I1
sa(dp16336
g7
I113
sg8
g9
sg10
I5
sg11
VGp210
p16337
sg13
I1
sasg24
(lp16338
(dp16339
g7
I281
sg27
VC0002736
p16340
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p16341
sg13
I3
sasa(dp16342
g2
S'Detection of the expression of these proteins and genes encoding these proteins in human gastric cancer tissues by real-time PCR (RT-qPCR) and western blot revealed that the expression of Beta-ACTIN, LDH, DLD, PRPF19 and CaM genes were up-regulated and RanGAP was down-regulated in gastric cancer tissues and/or metastatic lymph nodes compared to peri-cancerous tissues.\n'
p16343
sg4
(lp16344
(dp16345
g7
I205
sg8
VP98173
p16346
sg10
I3
sg11
VDLD
p16347
sg13
I1
sa(dp16348
g7
I200
sg8
g9
sg10
I3
sg11
VLDH
p16349
sg13
I1
sa(dp16350
g7
I188
sg8
VP63261
p16351
sg10
I10
sg11
VBeta-ACTIN
p16352
sg13
I1
sa(dp16353
g7
I221
sg8
VP01768
p16354
sg10
I9
sg11
VCaM genes
p16355
sg13
I2
sa(dp16356
g7
I210
sg8
g9
sg10
I6
sg11
VPRPF19
p16357
sg13
I1
sasg24
(lp16358
(dp16359
g7
I89
sg27
VC0024623
p16360
sg10
I14
sg11
Vgastric cancer
p16361
sg13
I2
sa(dp16362
g7
I89
sg27
VC0024623
p16363
sg10
I14
sg11
Vgastric cancer
p16364
sg13
I2
sa(dp16365
g7
I221
sg27
VC1861821
p16366
sg10
I3
sg11
VCaM
p16367
sg13
I1
sasa(dp16368
g2
S'Stable coronary artery disease (SCAD) patients scheduled for PCI were randomized to one of the three study arms: 1) genotyping, 2) PFT, and 3) control and evaluated by the CYP2C19 allele genotyping and PFT with P2Y12 assay.\n'
p16369
sg4
(lp16370
(dp16371
g7
I172
sg8
VP33261
p16372
sg10
I14
sg11
VCYP2C19 allele
p16373
sg13
I2
sasg24
(lp16374
(dp16375
g7
I0
sg27
VC0342783
p16376
sg10
I30
sg11
VStable coronary artery disease
p16377
sg13
I4
sa(dp16378
g7
I107
sg27
VC0206655
p16379
sg10
I4
sg11
Varms
p16380
sg13
I1
sa(dp16381
g7
I32
sg27
VC0342783
p16382
sg10
I4
sg11
VSCAD
p16383
sg13
I1
sasa(dp16384
g2
S'To assess the association of CYP2C19 G681A, P2RY12 H1/H2, and ITGB3 T1565C polymorphisms with the extent of platelet aggregation in patients with coronary heart disease (CHD) during antiplatelet therapy.\n'
p16385
sg4
(lp16386
(dp16387
g7
I44
sg8
g9
sg10
I12
sg11
VP2RY12 H1/H2
p16388
sg13
I2
sa(dp16389
g7
I29
sg8
VP33261
p16390
sg10
I13
sg11
VCYP2C19 G681A
p16391
sg13
I2
sa(dp16392
g7
I62
sg8
VP05106
p16393
sg10
I12
sg11
VITGB3 T1565C
p16394
sg13
I2
sasg24
(lp16395
(dp16396
g7
I170
sg27
VC0010054
p16397
sg10
I3
sg11
VCHD
p16398
sg13
I1
sa(dp16399
g7
I146
sg27
VC0010054
p16400
sg10
I22
sg11
Vcoronary heart disease
p16401
sg13
I3
sasa(dp16402
g2
S"This shortening of the HuR mRNA 3'-UTR via alternative polyadenylation (APA) was observed to be dependent on cleavage stimulation factor subunit 2 (CSTF2/CstF-64), which is up-regulated in the TAMR breast cancer cells.\n"
p16403
sg4
(lp16404
(dp16405
g7
I148
sg8
VP33240
p16406
sg10
I5
sg11
VCSTF2
p16407
sg13
I1
sa(dp16408
g7
I23
sg8
g9
sg10
I15
sg11
VHuR mRNA 3'-UTR
p16409
sg13
I3
sa(dp16410
g7
I154
sg8
VP33240
p16411
sg10
I7
sg11
VCstF-64
p16412
sg13
I1
sa(dp16413
g7
I130
sg8
g9
sg10
I16
sg11
Vfactor subunit 2
p16414
sg13
I3
sasg24
(lp16415
(dp16416
g7
I198
sg27
VC0678222
p16417
sg10
I13
sg11
Vbreast cancer
p16418
sg13
I2
sasa.